SETTING - - O
: - - O
University - - O
hospital-based - - O
, - - O
tertiary - - O
care - - O
infertility - - O
center - - O
. - - O

Large - - O
T - - O
antigen - - O
was - - O
coimmunoprecipitated - - O
by - - O
antibodies - - O
to - - O
epitope-tagged - - O
TBP - - O
, - - O
endogenous - - O
TBP - - O
, - - O
hTAF - - O
( - - O
II - - O
) - - O
100 - - O
, - - O
hTAF - - O
( - - O
II - - O
) - - O
130 - - O
, - - O
and - - O
hTAF - - O
( - - O
II - - O
) - - O
250 - - O
, - - O
under - - O
conditions - - O
where - - O
holo-TFIID - - O
would - - O
be - - O
precipitated - - O
. - - O

CONCLUSIONS - - O
: - - O
This - - O
randomized - - O
study - - O
shows - - O
that - - O
Vivostat - - O
fibrin - - O
sealant - - O
is - - O
effective - - O
in - - O
preventing - - O
air - - O
leakage - - O
after - - O
small - - O
lung - - O
resections - - O
in - - O
pigs - - O
, - - O
even - - O
at - - O
high - - O
inspiratory - - O
pressures - - O
. - - O

We - - O
propose - - O
a - - O
model - - O
in - - O
which - - O
Sro7 - - O
function - - O
is - - O
involved - - O
in - - O
the - - O
targeting - - O
of - - O
the - - O
myosin - - O
proteins - - O
to - - O
their - - O
intrinsic - - O
pathways - - O
. - - O

The - - O
response - - O
properties - - O
of - - O
cat - - O
horizontal - - O
canal - - O
afferents - - O
( - - O
N - - O
= - - O
81 - - O
) - - O
were - - O
characterized - - O
by - - O
three - - O
parameters - - O
: - - O
their - - O
long - - O
time - - O
constants - - O
( - - O
tau - - O
) - - O
, - - O
low - - O
frequency - - O
gain - - O
constants - - O
( - - O
G1 - - O
) - - O
, - - O
and - - O
middle - - O
frequency - - O
gain - - O
constants - - O
( - - O
Gm - - O
) - - O
. - - O

Glycogen - - O
synthesis - - O
and - - O
catabolism - - O
, - - O
gluconeogenesis - - O
, - - O
glycolysis - - O
, - - O
motility - - O
, - - O
cell - - O
surface - - O
properties - - O
and - - O
adherence - - O
are - - O
modulated - - O
by - - O
csrA - - O
in - - O
Escherichia - - O
coli - - O
, - - O
while - - O
the - - O
production - - O
of - - O
several - - O
secreted - - O
virulence - - O
factors - - O
, - - O
the - - O
plant - - O
hypersensitive - - O
response - - O
elicitor - - O
HrpN - - O
( - - O
Ecc - - O
) - - O
and - - O
, - - O
potentially - - O
, - - O
other - - O
secondary - - O
metabolites - - O
are - - O
regulated - - O
by - - O
rsmA - - O
in - - O
Erwinia - - O
carotovora - - O
. - - O

We - - O
have - - O
applied - - O
the - - O
mRNA - - O
differential - - O
display - - O
method - - O
to - - O
compare - - O
and - - O
analyze - - O
mRNAs - - O
prepared - - O
from - - O
five - - O
normal - - O
nasopharyngeal - - O
epithelial - - O
cell - - O
cultures - - O
and - - O
five - - O
nasopharyngeal - - O
carcinoma - - O
cell - - O
lines - - O
. - - O

Lung - - O
and - - O
multi-system - - O
damage - - O
were - - O
early - - O
indicators - - O
of - - O
poor - - O
outcome - - O
in - - O
severe - - O
non-fatal - - O
disease - - O
. - - O

Histological - - O
slides - - O
of - - O
one - - O
biopsy - - O
of - - O
each - - O
patient - - O
( - - O
formalin-fixed - - O
and - - O
paraffin-embedded - - O
) - - O
were - - O
stained - - O
with - - O
a - - O
Modified - - O
Giemsa - - O
( - - O
MG - - O
) - - O
, - - O
the - - O
Warthin-Starry - - O
( - - O
WS - - O
) - - O
, - - O
and - - O
an - - O
immunohistochemical - - O
method - - O
( - - O
IMM - - O
) - - O
using - - O
purified - - O
polyclonal - - O
H - - O
. - - O
pylori - - O
antiserum - - O
( - - O
DAKO - - O
B471 - - O
) - - O
. - - O

BACKGROUND - - O
: - - O
Chemicals - - O
vary - - O
considerably - - O
in - - O
their - - O
intrinsic - - O
ability - - O
to - - O
cause - - O
allergic - - O
contact - - O
dermatitis - - O
. - - O

Demispan - - O
is - - O
a - - O
reliable - - O
and - - O
reproducible - - O
measure - - O
of - - O
stature - - O
in - - O
the - - O
elderly - - O
. - - O

In - - O
one - - O
acromegalic - - O
patient - - O
visual - - O
improvement - - O
was - - O
obtained - - O
while - - O
the - - O
abnormal - - O
GH - - O
secretion - - O
remained - - O
unaltered - - O
. - - O

When - - O
the - - O
blood - - O
pressure - - O
increase - - O
in - - O
response - - O
to - - O
smoking - - O
was - - O
blunted - - O
by - - O
nitroprusside - - O
infusion - - O
, - - O
there - - O
was - - O
a - - O
striking - - O
increase - - O
in - - O
muscle - - O
SNA - - O
. - - O

Multiple - - O
single-stranded - - O
cis - - O
elements - - O
are - - O
associated - - O
with - - O
activated - - O
chromatin - - O
of - - O
the - - O
human - - O
c-myc - - O
gene - - O
in - - O
vivo - - O
. - - O

Removal - - O
of - - O
thick - - O
, - - O
permanently - - O
altered - - O
mucoas - - O
is - - O
recommended - - O
even - - O
in - - O
the - - O
absence - - O
of - - O
squamous - - O
epithelium - - O
. - - O

The - - O
position - - O
, - - O
transcription - - O
orientation - - O
, - - O
and - - O
imprinted - - O
status - - O
of - - O
the - - O
genes - - O
immediately - - O
flanking - - O
Igf2r - - O
have - - O
been - - O
assessed - - O
. - - O

High-pressure - - O
effects - - O
on - - O
ultrafast-relaxation - - O
kinetics - - O
of - - O
excitons - - O
in - - O
polydiacetylene - - O
4BCMU - - O
. - - O

Interestingly - - O
, - - O
we - - O
find - - O
that - - O
the - - O
interaction - - O
between - - O
Tat - - O
and - - O
hCycT1 - - O
requires - - O
zinc - - O
as - - O
well - - O
as - - O
essential - - O
cysteine - - O
residues - - O
in - - O
both - - O
proteins - - O
. - - O

Treatment - - O
of - - O
2 - - O
patients - - O
with - - O
pseudohypoparathyroidism - - O
type - - O
I - - O
with - - O
vitamin-D-3 - - O
and - - O
1 - - O
alpha-Hydroxycholecalciferol - - O
consecutively - - O
resulted - - O
in - - O
a - - O
nonuniform - - O
response - - O
with - - O
regard - - O
to - - O
the - - O
normalisation - - O
of - - O
serum-calcium - - O
. - - O

Tumour - - O
necrosis - - O
factor - - O
and - - O
adult - - O
respiratory - - O
distress - - O
syndrome - - O
. - - O

Immunologic - - O
mechanisms - - O
in - - O
chronic - - O
brucellosis - - O
in - - O
humans - - O
. - - O

Biological - - O
evaluation - - O
of - - O
mibolerone - - O
in - - O
the - - O
female - - O
Beagle - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
Rho1p - - O
regulates - - O
cytoskeletal - - O
reorganization - - O
at - - O
least - - O
through - - O
Bni1p - - O
and - - O
Pkc1p - - O
. - - O

This - - O
protein-protein - - O
interaction - - O
does - - O
not - - O
require - - O
the - - O
simultaneous - - O
binding - - O
of - - O
Oct - - O
proteins - - O
to - - O
DNA - - O
, - - O
and - - O
high - - O
resolution - - O
footprinting - - O
of - - O
the - - O
Oct-DNA - - O
interaction - - O
reveals - - O
that - - O
binding - - O
of - - O
BOB - - O
. - - O
1 - - O
OBF - - O
. - - O
1 - - O
to - - O
Oct1 - - O
or - - O
Oct2 - - O
does - - O
not - - O
alter - - O
the - - O
interaction - - O
with - - O
DNA - - O
. - - O

The - - O
lytic - - O
cycle - - O
of - - O
KSHV - - O
, - - O
probably - - O
under - - O
the - - O
initial - - O
control - - O
of - - O
the - - O
KSHV - - O
Rta - - O
gene - - O
, - - O
may - - O
directly - - O
contribute - - O
to - - O
tumor - - O
pathogenesis - - O
. - - O

In - - O
about - - O
770 - - O
bp - - O
upstream - - O
region - - O
of - - O
Spam1 - - O
that - - O
has - - O
been - - O
cloned - - O
and - - O
sequenced - - O
, - - O
multiple - - O
transcription - - O
factor - - O
binding - - O
sites - - O
including - - O
a - - O
CRE - - O
( - - O
cAMP-responsive - - O
element - - O
) - - O
were - - O
found - - O
. - - O

Perfusion - - O
washout - - O
: - - O
increasing - - O
a - - O
microvascular - - O
free - - O
flap - - O
tolerance - - O
to - - O
ischemia - - O
. - - O

A - - O
case - - O
of - - O
M - - O
hemoglobinosis - - O
. - - O

The - - O
location - - O
and - - O
approximate - - O
length - - O
of - - O
the - - O
intron - - O
are - - O
conserved - - O
in - - O
both - - O
the - - O
tomato - - O
and - - O
Arabidopsis - - O
genes - - O
, - - O
with - - O
the - - O
intron - - O
separating - - O
the - - O
'nose' - - O
region - - O
( - - O
encoded - - O
by - - O
exon - - O
1 - - O
) - - O
from - - O
the - - O
central - - O
globular - - O
domain - - O
( - - O
exon - - O
2 - - O
) - - O
. - - O

Thus - - O
, - - O
the - - O
bovine - - O
PEDF - - O
cDNA - - O
isolated - - O
here - - O
codes - - O
for - - O
a - - O
functional - - O
soluble - - O
secreted - - O
PEDF - - O
glycoprotein - - O
. - - O

Using - - O
16 - - O
strains - - O
of - - O
C - - O
. - - O
trachomatis - - O
in - - O
triplicate - - O
assays - - O
, - - O
we - - O
found - - O
the - - O
RT-PCR - - O
method - - O
consistently - - O
more - - O
sensitive - - O
than - - O
the - - O
conventional - - O
technique - - O
for - - O
all - - O
eight - - O
antimicrobials - - O
tested - - O
, - - O
with - - O
resultant - - O
MICs - - O
determined - - O
by - - O
RT-PCR - - O
ranging - - O
from - - O
1 - - O
. - - O
6-fold - - O
higher - - O
( - - O
erythromycin - - O
) - - O
to - - O
> - - O
= - - O
195-fold - - O
higher - - O
( - - O
amoxicillin - - O
) - - O
. - - O

However - - O
, - - O
the - - O
element - - O
proximal - - O
to - - O
the - - O
transcription - - O
start - - O
site - - O
is - - O
dependent - - O
on - - O
the - - O
SRE-1 - - O
. - - O

Klebsiella - - O
oxytoca - - O
can - - O
assimilate - - O
nitrate - - O
and - - O
nitrite - - O
by - - O
using - - O
enzymes - - O
encoded - - O
by - - O
the - - O
nasFEDCBA - - O
operon - - O
. - - O

Use - - O
of - - O
the - - O
immunofluorescence - - O
method - - O
for - - O
identification - - O
of - - O
enteroviruses - - O
in - - O
cell - - O
cultures - - O
. - - O

Atcys1 - - O
, - - O
Athyp1 - - O
, - - O
AKin10 - - O
and - - O
the - - O
ORF - - O
are - - O
very - - O
close - - O
to - - O
each - - O
other - - O
and - - O
organized - - O
in - - O
the - - O
same - - O
polarity - - O
; - - O
hence - - O
, - - O
the - - O
intergenic - - O
regions - - O
probably - - O
contain - - O
, - - O
within - - O
less - - O
than - - O
0 - - O
. - - O
5 - - O
kb - - O
, - - O
all - - O
the - - O
regulatory - - O
elements - - O
necessary - - O
to - - O
govern - - O
initiation - - O
and - - O
termination - - O
of - - O
transcription - - O
. - - O

The - - O
increase - - O
in - - O
amplitudes - - O
of - - O
the - - O
b-wave - - O
during - - O
the - - O
adaptation - - O
period - - O
was - - O
more - - O
prominent - - O
in - - O
lead-exposed - - O
subjects - - O
than - - O
in - - O
controls - - O
. - - O

( - - O
ii - - O
) - - O
An - - O
AF - - O
G-CSF - - O
level - - O
> - - O
2000 - - O
pg - - O
ml - - O
is - - O
a - - O
strong - - O
positive - - O
predictor - - O
of - - O
CAM - - O
. - - O

I - - O
report - - O
here - - O
that - - O
induction - - O
of - - O
HSP82 - - O
is - - O
regulated - - O
by - - O
the - - O
early - - O
meiotic - - O
IME1-IME2 - - O
transcriptional - - O
cascade - - O
. - - O

We - - O
now - - O
report - - O
the - - O
isolation - - O
and - - O
expression - - O
of - - O
cDNAs - - O
encoding - - O
PTF - - O
gamma - - O
and - - O
PTF - - O
delta - - O
, - - O
as - - O
well - - O
as - - O
functional - - O
studies - - O
with - - O
cognate - - O
antibodies - - O
that - - O
recognize - - O
the - - O
native - - O
PTF - - O
complex - - O
in - - O
HeLa - - O
extracts - - O
. - - O

Primers - - O
for - - O
subsequent - - O
rounds - - O
of - - O
RACE - - O
were - - O
designed - - O
from - - O
the - - O
5'-ends - - O
of - - O
amplified - - O
RACE - - O
products - - O
. - - O

Current - - O
status - - O
of - - O
zinc - - O
deficiency - - O
in - - O
the - - O
pathogenesis - - O
of - - O
neurological - - O
, - - O
dermatological - - O
and - - O
musculoskeletal - - O
disorders - - O
. - - O

Several - - O
free - - O
2nd-generation - - O
schizonts - - O
, - - O
which - - O
varied - - O
in - - O
diameter - - O
from - - O
11 - - O
to - - O
21 - - O
. - - O
6 - - O
micrometer - - O
, - - O
were - - O
found - - O
on - - O
the - - O
epithelial - - O
surface - - O
of - - O
the - - O
cecum - - O
. - - O

Active - - O
lambda - - O
and - - O
kappa - - O
antibody - - O
gene - - O
rearrangement - - O
in - - O
Abelson - - O
murine - - O
leukemia - - O
virus-transformed - - O
pre-B - - O
cell - - O
lines - - O
. - - O

Brainstem - - O
auditory - - O
evoked - - O
responses - - O
( - - O
BAERs - - O
) - - O
and - - O
quantitative - - O
saccadic - - O
eye - - O
movement - - O
studies - - O
provide - - O
information - - O
on - - O
the - - O
integrity - - O
of - - O
pathways - - O
traversing - - O
the - - O
brainstem - - O
. - - O

Spinal - - O
cord - - O
representation - - O
of - - O
the - - O
micturition - - O
reflex - - O
. - - O

The - - O
patients - - O
were - - O
divided - - O
into - - O
ischaemia - - O
and - - O
non-ischaemia - - O
groups - - O
on - - O
the - - O
basis - - O
of - - O
the - - O
change - - O
in - - O
lactate - - O
extraction - - O
ratio - - O
during - - O
balloon - - O
inflation - - O
. - - O

Glycemic - - O
response - - O
to - - O
malted - - O
, - - O
popped - - O
and - - O
roller - - O
dried - - O
wheat-legume - - O
based - - O
foods - - O
in - - O
normal - - O
subjects - - O
. - - O

Sterol-mediated - - O
suppression - - O
of - - O
cleavage - - O
of - - O
SREBP-1 - - O
was - - O
found - - O
to - - O
be - - O
dependent - - O
on - - O
the - - O
extreme - - O
COOH-terminal - - O
region - - O
( - - O
residue - - O
1034 - - O
to - - O
the - - O
COOH - - O
terminus - - O
) - - O
, - - O
which - - O
exists - - O
in - - O
two - - O
forms - - O
as - - O
a - - O
result - - O
of - - O
alternative - - O
splicing - - O
. - - O

The - - O
difference - - O
between - - O
the - - O
patients - - O
and - - O
the - - O
controls - - O
was - - O
statistically - - O
significant - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
03 - - O
) - - O
. - - O

The - - O
coefficient - - O
of - - O
determination - - O
, - - O
r2 - - O
, - - O
of - - O
the - - O
other - - O
scores - - O
ranged - - O
from - - O
0 - - O
. - - O
56 - - O
to - - O
0 - - O
. - - O
61 - - O
. - - O

The - - O
androgen - - O
receptor - - O
( - - O
AR - - O
) - - O
amino-terminus - - O
imposes - - O
androgen-specific - - O
regulation - - O
of - - O
AR - - O
gene - - O
expression - - O
via - - O
an - - O
exonic - - O
enhancer - - O
. - - O

A - - O
yeast - - O
DNA - - O
fragment - - O
carrying - - O
the - - O
gene - - O
CP - - O
A1 - - O
encoding - - O
the - - O
small - - O
subunit - - O
of - - O
the - - O
arginine - - O
pathway - - O
carbamoyl-phosphate - - O
synthetase - - O
has - - O
been - - O
sequenced - - O
. - - O

In - - O
an - - O
effort - - O
to - - O
identify - - O
the - - O
USH1C - - O
disease - - O
gene - - O
we - - O
have - - O
isolated - - O
the - - O
region - - O
between - - O
these - - O
markers - - O
in - - O
yeast - - O
artificial - - O
chromosomes - - O
( - - O
YACs - - O
) - - O
using - - O
a - - O
combination - - O
of - - O
STS - - O
content - - O
mapping - - O
and - - O
Alu-PCR - - O
hybridization - - O
. - - O

Critical - - O
residues - - O
required - - O
for - - O
repression - - O
are - - O
located - - O
within - - O
the - - O
C-terminal - - O
27 - - O
amino - - O
acids - - O
of - - O
c-Fos - - O
, - - O
since - - O
v-Fos - - O
and - - O
C-terminal - - O
truncations - - O
of - - O
c-Fos - - O
did - - O
not - - O
down - - O
regulate - - O
. - - O

Altogether - - O
these - - O
results - - O
indicate - - O
that - - O
the - - O
Syn - - O
5 - - O
locus - - O
segregates - - O
from - - O
the - - O
gene - - O
specifying - - O
gH - - O
, - - O
to - - O
a - - O
region - - O
encompassing - - O
portions - - O
of - - O
the - - O
TK - - O
and - - O
UL - - O
24 - - O
genes - - O
, - - O
and - - O
that - - O
the - - O
syn - - O
mutation - - O
does - - O
not - - O
affect - - O
the - - O
expression - - O
or - - O
activity - - O
of - - O
TK - - O
. - - O

To - - O
identify - - O
factors - - O
that - - O
may - - O
modify - - O
the - - O
heterosexual - - O
transmission - - O
of - - O
human - - O
T - - O
cell - - O
leukemia - - O
lymphoma - - O
virus - - O
type - - O
I - - O
( - - O
HTLV-I - - O
) - - O
, - - O
534 - - O
married - - O
couples - - O
enrolled - - O
in - - O
the - - O
Miyazaki - - O
Cohort - - O
Study - - O
between - - O
November - - O
1984 - - O
and - - O
April - - O
1989 - - O
were - - O
studied - - O
: - - O
95 - - O
husband - - O
HTLV-I-seropositive - - O
( - - O
H+ - - O
) - - O
wife - - O
seropositive - - O
( - - O
W+ - - O
) - - O
, - - O
33 - - O
H+ - - O
W- - - O
, - - O
64 - - O
H- - - O
W+ - - O
, - - O
and - - O
342 - - O
H- - - O
W- - - O
. - - O

2 - - O
. - - O

Upon - - O
analysis - - O
of - - O
various - - O
deletion - - O
and - - O
point-mutated - - O
variants - - O
of - - O
the - - O
human - - O
IL-6 - - O
gene - - O
promoter - - O
coupled - - O
to - - O
a - - O
reporter - - O
gene - - O
, - - O
we - - O
screened - - O
for - - O
possible - - O
cooperating - - O
transcription - - O
factors - - O
. - - O

Characterization - - O
of - - O
the - - O
5' - - O
end - - O
of - - O
the - - O
growth-regulated - - O
Syrian - - O
hamster - - O
CAD - - O
gene - - O
. - - O

Horvath - - O
, - - O
I - - O
. - - O

Switching - - O
FDC-P1 - - O
MAC - - O
cells - - O
from - - O
growth - - O
in - - O
M-CSF - - O
to - - O
GM-CSF - - O
caused - - O
the - - O
selective - - O
degradation - - O
of - - O
c-fms - - O
mRNA - - O
within - - O
6 - - O
h - - O
after - - O
factor - - O
switching - - O
. - - O

Analysis - - O
of - - O
the - - O
gag - - O
and - - O
rev - - O
proteins - - O
in - - O
the - - O
transfected - - O
cells - - O
demonstrated - - O
that - - O
these - - O
proteins - - O
were - - O
not - - O
detectable - - O
in - - O
cells - - O
transfected - - O
with - - O
the - - O
tat - - O
mutants - - O
but - - O
could - - O
be - - O
readily - - O
detected - - O
when - - O
the - - O
mutations - - O
were - - O
complemented - - O
in - - O
trans - - O
with - - O
a - - O
tat - - O
expression - - O
vector - - O
. - - O

However - - O
, - - O
the - - O
BCH - - O
group - - O
showed - - O
inferior - - O
gross - - O
motor - - O
performance - - O
on - - O
the - - O
Bruininks-Oseretsky - - O
Test - - O
of - - O
Motor - - O
Proficiency - - O
( - - O
Bruininks - - O
1978 - - O
) - - O
. - - O

Repression - - O
is - - O
alleviated - - O
when - - O
the - - O
two - - O
( - - O
for - - O
E2 - - O
) - - O
or - - O
three - - O
( - - O
for - - O
E2-C - - O
) - - O
promoter-proximal - - O
copies - - O
of - - O
E2-RS - - O
are - - O
mutated - - O
. - - O

Our - - O
findings - - O
suggest - - O
that - - O
striatal - - O
FDG - - O
and - - O
particularly - - O
RACLO - - O
are - - O
sensitive - - O
and - - O
effective - - O
measures - - O
of - - O
striatal - - O
function - - O
and - - O
may - - O
help - - O
characterizing - - O
patients - - O
with - - O
multiple - - O
system - - O
atrophy - - O
. - - O

A - - O
prospective - - O
trail - - O
comparing - - O
hysterectomy - - O
, - - O
hysterectomy - - O
plus - - O
vaginal - - O
radium - - O
, - - O
and - - O
uterine - - O
radium - - O
plus - - O
hysterectomy - - O
in - - O
stage - - O
I - - O
endometrial - - O
carcinoma - - O
. - - O

Serum - - O
Fibrin - - O
Degradation - - O
Products - - O
( - - O
FDP - - O
) - - O
were - - O
determined - - O
in - - O
50 - - O
oral - - O
cancer - - O
patients - - O
and - - O
50 - - O
normal - - O
individuals - - O
prior - - O
to - - O
any - - O
kind - - O
of - - O
treatment - - O
. - - O

Among - - O
these - - O
360 - - O
ZFPs - - O
, - - O
a - - O
novel - - O
ZFP - - O
cDNA - - O
named - - O
HFHZ - - O
( - - O
human - - O
fetal - - O
heart - - O
ZFP - - O
) - - O
with - - O
sequence - - O
homology - - O
to - - O
a - - O
Kruppel-associated - - O
box - - O
( - - O
KRAB - - O
) - - O
was - - O
identified - - O
. - - O

Such - - O
a - - O
mechanism - - O
may - - O
allow - - O
acceleration - - O
of - - O
degenerative - - O
joint - - O
conditions - - O
, - - O
and - - O
may - - O
account - - O
for - - O
the - - O
increased - - O
prevalence - - O
of - - O
such - - O
conditions - - O
seen - - O
with - - O
HMS - - O
subjects - - O
. - - O

Furthermore - - O
, - - O
stable - - O
expression - - O
of - - O
a - - O
constitutively - - O
active - - O
form - - O
of - - O
chicken - - O
Notch1 - - O
or - - O
Notch2 - - O
in - - O
a - - O
B - - O
cell - - O
line - - O
results - - O
in - - O
a - - O
down-regulation - - O
of - - O
surface - - O
IgM - - O
expression - - O
, - - O
which - - O
is - - O
accompanied - - O
by - - O
the - - O
reduction - - O
of - - O
IgH - - O
gene - - O
transcripts - - O
. - - O

Cochlear - - O
microphonic - - O
potentials - - O
in - - O
patients - - O
with - - O
vestibular - - O
schwannomas - - O
. - - O

A - - O
case - - O
of - - O
chronic - - O
hepatitis - - O
C - - O
with - - O
primary - - O
hypothyroidism - - O
manifested - - O
during - - O
interferon - - O
treatment - - O
. - - O

For - - O
this - - O
purpose - - O
, - - O
a - - O
segment - - O
of - - O
dxr - - O
was - - O
amplified - - O
from - - O
Synechococcus - - O
leopoliensis - - O
SAUG - - O
1402-1 - - O
DNA - - O
via - - O
PCR - - O
using - - O
oligonucleotides - - O
for - - O
conserved - - O
regions - - O
. - - O

This - - O
result - - O
indicates - - O
that - - O
separate - - O
complexes - - O
exist - - O
containing - - O
ankyrin - - O
and - - O
fodrin - - O
with - - O
either - - O
uvomorulin - - O
or - - O
Na+ - - O
, - - O
K+-ATPase - - O
. - - O

Nerve - - O
growth - - O
factor - - O
( - - O
NGF - - O
) - - O
and - - O
retinoic - - O
acid - - O
( - - O
RA - - O
) - - O
exert - - O
important - - O
actions - - O
on - - O
PC12 - - O
cells - - O
. - - O

Sustained - - O
ventricular - - O
tachycardia - - O
and - - O
its - - O
successful - - O
prophylaxis - - O
during - - O
high-dose - - O
bolus - - O
interleukin-2 - - O
therapy - - O
for - - O
metastatic - - O
renal - - O
cell - - O
carcinoma - - O
. - - O

Because - - O
of - - O
its - - O
wide - - O
spectrum - - O
of - - O
activity - - O
particularly - - O
against - - O
ampicillin - - O
resistant - - O
strains - - O
of - - O
H - - O
. - - O
influenzae - - O
and - - O
because - - O
of - - O
its - - O
good - - O
tolerance - - O
Cefaclor - - O
is - - O
very - - O
useful - - O
in - - O
treatment - - O
of - - O
respiratory - - O
tract - - O
infections - - O
in - - O
children - - O
. - - O

Using - - O
purified - - O
recombinant - - O
HMG - - O
I - - O
, - - O
we - - O
have - - O
identified - - O
several - - O
high-affinity - - O
binding - - O
sites - - O
which - - O
overlap - - O
important - - O
transcription - - O
factor - - O
binding - - O
sites - - O
. - - O

BCL6 - - O
encodes - - O
a - - O
POZ - - O
Zn - - O
finger - - O
protein - - O
, - - O
a - - O
structure - - O
similar - - O
to - - O
that - - O
of - - O
many - - O
Drosophila - - O
developmental - - O
regulators - - O
and - - O
to - - O
another - - O
protein - - O
involved - - O
in - - O
a - - O
human - - O
hematopoietic - - O
malignancy - - O
, - - O
PLZF - - O
. - - O

The - - O
level - - O
of - - O
contamination - - O
in - - O
the - - O
wound - - O
can - - O
be - - O
determined - - O
with - - O
the - - O
rapid - - O
biopsy - - O
fixation - - O
technique - - O
. - - O

A - - O
sequence - - O
homology - - O
analysis - - O
between - - O
human - - O
nm23-H1 - - O
and - - O
the - - O
homolog - - O
gene - - O
of - - O
the - - O
rat - - O
( - - O
NDP-K - - O
beta - - O
) - - O
shows - - O
that - - O
exon-intron - - O
boundaries - - O
are - - O
well - - O
conserved - - O
between - - O
these - - O
two - - O
species - - O
. - - O

The - - O
presence - - O
of - - O
PDZ - - O
and - - O
SAM - - O
domains - - O
in - - O
the - - O
KS5 - - O
protein - - O
suggests - - O
that - - O
it - - O
may - - O
act - - O
as - - O
a - - O
molecular - - O
adaptor - - O
, - - O
promoting - - O
and - - O
relaying - - O
information - - O
in - - O
a - - O
signal - - O
transduction - - O
pathway - - O
. - - O

An - - O
IgG - - O
monoclonal - - O
gammopathy - - O
was - - O
present - - O
in - - O
the - - O
serum - - O
of - - O
4 - - O
patients - - O
and - - O
Bence-Joanes - - O
proteinuria - - O
was - - O
found - - O
in - - O
1 - - O
patient - - O
. - - O

The - - O
eluting - - O
solvent - - O
was - - O
methanol-chloroform - - O
( - - O
10+90 - - O
) - - O
at - - O
a - - O
flow - - O
rate - - O
of - - O
2 - - O
. - - O
0 - - O
ml - - O
min - - O
. - - O

HLA-A - - O
and - - O
B - - O
phenotypes - - O
of - - O
105 - - O
patients - - O
suffering - - O
from - - O
malignant - - O
melanomas - - O
were - - O
determined - - O
, - - O
with - - O
special - - O
regard - - O
for - - O
metastatic - - O
form - - O
or - - O
relapse - - O
. - - O

PATIENTS - - O
OR - - O
OTHER - - O
PARTICIPANTS - - O
: - - O
Twenty - - O
children - - O
met - - O
the - - O
criteria - - O
for - - O
being - - O
learning - - O
disabled - - O
. - - O

Further - - O
investigation - - O
on - - O
the - - O
chemotactic - - O
influence - - O
of - - O
thymic - - O
hormone - - O
on - - O
lymphocytes - - O
. - - O

Tumor - - O
necrosis - - O
factor - - O
alpha - - O
, - - O
the - - O
cytokine - - O
that - - O
participates - - O
in - - O
the - - O
autocrine - - O
growth - - O
control - - O
of - - O
hairy - - O
cell - - O
leukemia - - O
has - - O
strong - - O
bone - - O
resorptive - - O
properties - - O
. - - O

This - - O
rapid - - O
and - - O
extensive - - O
penetration - - O
of - - O
intrathecally - - O
administered - - O
chemotherapy - - O
may - - O
offer - - O
insight - - O
into - - O
the - - O
myelopathy - - O
observed - - O
with - - O
these - - O
treatments - - O
. - - O

The - - O
'field - - O
of - - O
stress' - - O
of - - O
the - - O
supervisory - - O
nurse - - O
. - - O

Using - - O
transgenic - - O
Xenopus - - O
embryos - - O
, - - O
we - - O
demonstrate - - O
that - - O
the - - O
integrity - - O
of - - O
these - - O
two - - O
sequences - - O
is - - O
necessary - - O
for - - O
correct - - O
spatial - - O
expression - - O
of - - O
a - - O
Xbra2 - - O
promoter-driven - - O
reporter - - O
gene - - O
. - - O

Its - - O
role - - O
in - - O
these - - O
processes - - O
suggests - - O
that - - O
the - - O
function - - O
of - - O
c-Myb - - O
may - - O
be - - O
important - - O
early - - O
in - - O
the - - O
establishment - - O
of - - O
the - - O
hematopoietic - - O
lineage - - O
. - - O

The - - O
development - - O
and - - O
distribution - - O
of - - O
Trypanosoma - - O
congolense - - O
, - - O
T - - O
vivax - - O
and - - O
T - - O
brucei - - O
in - - O
the - - O
skin - - O
of - - O
goats - - O
was - - O
examined - - O
after - - O
the - - O
animals - - O
were - - O
bitten - - O
by - - O
infected - - O
Glossina - - O
morsitans - - O
centralis - - O
. - - O

The - - O
purpose - - O
of - - O
this - - O
study - - O
is - - O
twofold - - O
: - - O
( - - O
1 - - O
) - - O
to - - O
present - - O
a - - O
parallel - - O
form - - O
of - - O
the - - O
Gudjonsson - - O
Suggestibility - - O
Scale - - O
( - - O
GSS - - O
, - - O
Form - - O
1 - - O
) - - O
; - - O
( - - O
2 - - O
) - - O
to - - O
study - - O
test-retest - - O
reliabilities - - O
of - - O
interrogative - - O
suggestibility - - O
. - - O

Antimicrobial - - O
Susceptibility - - O
of - - O
Klebsiella - - O
pneumoniae - - O
Producing - - O
Extended-Spectrum - - O
beta-lactamase - - O
( - - O
ESBL - - O
) - - O
Isolated - - O
in - - O
Hospitals - - O
in - - O
Brazil - - O
. - - O

Coronary - - O
T1 - - O
and - - O
T2 - - O
weighted - - O
images - - O
were - - O
obtained - - O
. - - O

CONCLUSION - - O
: - - O
These - - O
findings - - O
imply - - O
that - - O
eotaxin - - O
either - - O
is - - O
mechanistically - - O
involved - - O
in - - O
acute - - O
asthma - - O
or - - O
serves - - O
as - - O
a - - O
biomarker - - O
for - - O
activity - - O
of - - O
the - - O
CCR3 - - O
receptor - - O
ligand - - O
system - - O
, - - O
which - - O
is - - O
functionally - - O
linked - - O
to - - O
asthma - - O
. - - O

GH - - O
failed - - O
to - - O
stimulate - - O
phosphorylation - - O
or - - O
activation - - O
of - - O
Jun - - O
N-terminal - - O
kinase - - O
under - - O
the - - O
conditions - - O
used - - O
. - - O

Surgical - - O
treatment - - O
of - - O
pulmonary - - O
metastases - - O
. - - O

We - - O
found - - O
that - - O
the - - O
expression - - O
of - - O
the - - O
protein - - O
was - - O
maximum - - O
in - - O
mitosis - - O
and - - O
minimum - - O
in - - O
G1 - - O
, - - O
which - - O
correlated - - O
with - - O
the - - O
expression - - O
of - - O
its - - O
messenger - - O
RNA - - O
. - - O

Three - - O
separate - - O
activation - - O
subdomains - - O
, - - O
and - - O
one - - O
negative-acting - - O
region - - O
, - - O
which - - O
function - - O
in - - O
yeast - - O
were - - O
located - - O
in - - O
the - - O
carboxyl-terminal - - O
region - - O
of - - O
NIT4 - - O
. - - O

The - - O
existence - - O
of - - O
threshold - - O
concentrations - - O
, - - O
above - - O
which - - O
certain - - O
phenomena - - O
may - - O
occur - - O
, - - O
strengthens - - O
the - - O
role - - O
of - - O
sentinels - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
Gab1 - - O
is - - O
involved - - O
in - - O
the - - O
control - - O
of - - O
egr-1 - - O
expression - - O
regulated - - O
by - - O
insulin - - O
. - - O

Object - - O
relations - - O
, - - O
affect - - O
management - - O
, - - O
and - - O
psychic - - O
structure - - O
formation - - O
. - - O

The - - O
molecular - - O
weight - - O
of - - O
in - - O
vivo-labeled - - O
proteins - - O
was - - O
increased - - O
relative - - O
to - - O
that - - O
of - - O
in - - O
vitro-translated - - O
proteins - - O
, - - O
indicating - - O
that - - O
a - - O
posttranslational - - O
modification - - O
had - - O
occurred - - O
. - - O

Cross-linking - - O
the - - O
B - - O
cell - - O
Ag - - O
receptor - - O
( - - O
BCR - - O
) - - O
to - - O
surface - - O
Fc - - O
receptors - - O
for - - O
IgG - - O
( - - O
Fc - - O
gamma - - O
R - - O
) - - O
inhibits - - O
G1-to-S - - O
progression - - O
; - - O
the - - O
mechanism - - O
by - - O
which - - O
this - - O
occurs - - O
is - - O
not - - O
completely - - O
known - - O
. - - O

We - - O
report - - O
here - - O
the - - O
identification - - O
of - - O
HSF - - O
in - - O
the - - O
fission - - O
yeast - - O
Schizosaccharomyces - - O
pombe - - O
. - - O

Role - - O
of - - O
secondary - - O
structure - - O
in - - O
discrimination - - O
between - - O
constitutive - - O
and - - O
inducible - - O
activators - - O
. - - O

A - - O
study - - O
of - - O
the - - O
E - - O
. - - O
O - - O
. - - O
R - - O
. - - O
T - - O
. - - O
C - - O
. - - O

METHODS - - O
: - - O
The - - O
most - - O
distal - - O
muscle - - O
fibres - - O
from - - O
the - - O
deep - - O
and - - O
superficial - - O
finger - - O
flexors - - O
were - - O
measured - - O
relative - - O
to - - O
the - - O
pisiform - - O
bone - - O
in - - O
18 - - O
cadaveric - - O
specimens - - O
. - - O

The - - O
microcirculatory - - O
dynamics - - O
of - - O
prostaglandin - - O
E1 - - O
and - - O
or - - O
nicardipine - - O
and - - O
their - - O
different - - O
reactions - - O
in - - O
the - - O
hyper- - - O
and - - O
hypodynamic - - O
state - - O
of - - O
septic - - O
shock - - O
in - - O
a - - O
rat - - O
model - - O
. - - O

A - - O
new - - O
, - - O
flexible - - O
fiberoptic - - O
ventriculoscope - - O
for - - O
observation - - O
of - - O
the - - O
ventricles - - O
and - - O
major - - O
cisterns - - O
is - - O
reported - - O
. - - O

The - - O
highly - - O
conserved - - O
ninth - - O
heptad - - O
, - - O
which - - O
is - - O
involved - - O
in - - O
heterodimerization - - O
, - - O
appears - - O
to - - O
participate - - O
in - - O
the - - O
receptor-inhibitor - - O
interaction - - O
, - - O
suggesting - - O
that - - O
the - - O
inhibitor - - O
is - - O
a - - O
related - - O
member - - O
of - - O
the - - O
receptor - - O
gene - - O
family - - O
. - - O

The - - O
human - - O
eps15 - - O
gene - - O
, - - O
encoding - - O
a - - O
tyrosine - - O
kinase - - O
substrate - - O
, - - O
is - - O
conserved - - O
in - - O
evolution - - O
and - - O
maps - - O
to - - O
1p31-p32 - - O
. - - O

The - - O
rate - - O
of - - O
decrement - - O
in - - O
DPOAE - - O
amplitude - - O
over - - O
a - - O
prescribed - - O
time - - O
period - - O
was - - O
utilized - - O
as - - O
a - - O
measure - - O
of - - O
susceptibility - - O
to - - O
the - - O
acoustic - - O
trauma - - O
. - - O

Its - - O
C-terminal - - O
catalytic - - O
domain - - O
was - - O
found - - O
to - - O
be - - O
highly - - O
conserved - - O
in - - O
the - - O
homologues - - O
p140 - - O
( - - O
ras-GRF - - O
) - - O
and - - O
Sos - - O
. - - O

Expression - - O
of - - O
six - - O
genes - - O
, - - O
ipaB - - O
, - - O
ipaC - - O
, - - O
invE - - O
, - - O
invG - - O
, - - O
invJ - - O
, - - O
and - - O
invK - - O
, - - O
was - - O
apparently - - O
regulated - - O
by - - O
the - - O
positive - - O
regulator - - O
virF - - O
. - - O

These - - O
combined - - O
observations - - O
define - - O
a - - O
promoter - - O
and - - O
an - - O
enhancer - - O
for - - O
the - - O
chicken - - O
L-CAM - - O
gene - - O
. - - O

METHODS - - O
: - - O
Fifty-one - - O
healthy - - O
eyes - - O
, - - O
169 - - O
ocular - - O
hypertensive - - O
eyes - - O
with - - O
normal - - O
visual - - O
fields - - O
, - - O
and - - O
132 - - O
glaucomatous - - O
eyes - - O
with - - O
early - - O
visual - - O
field - - O
defects - - O
were - - O
evaluated - - O
with - - O
qualitative - - O
and - - O
quantitative - - O
measures - - O
of - - O
structural - - O
damage - - O
to - - O
the - - O
optic - - O
nerve - - O
and - - O
nerve - - O
fiber - - O
layer - - O
. - - O

From - - O
these - - O
results - - O
, - - O
CBF-A - - O
is - - O
a - - O
novel - - O
CArG - - O
box- - - O
, - - O
ssDNA- - - O
and - - O
RNA-binding - - O
protein - - O
, - - O
as - - O
well - - O
as - - O
a - - O
repressive - - O
transcriptional - - O
factor - - O
. - - O

We - - O
have - - O
tested - - O
the - - O
function - - O
of - - O
two - - O
potential - - O
NF-kappaB-like - - O
sites - - O
present - - O
in - - O
the - - O
PAI-2 - - O
proximal - - O
promoter - - O
for - - O
responsiveness - - O
to - - O
TNFalpha - - O
using - - O
chloramphenicol - - O
acetyl - - O
transferase - - O
reporter - - O
gene - - O
deletion - - O
and - - O
mutation - - O
analyses - - O
. - - O

Overexpression - - O
of - - O
wild-type - - O
p53 - - O
also - - O
induces - - O
apoptosis - - O
in - - O
an - - O
LCL - - O
. - - O

RESULTS - - O
: - - O
The - - O
medians - - O
of - - O
average - - O
daily - - O
CD34+ - - O
cell - - O
yields - - O
for - - O
patients - - O
who - - O
received - - O
paclitaxel - - O
plus - - O
CY - - O
, - - O
CE - - O
, - - O
and - - O
CEP - - O
with - - O
G-CSF - - O
were - - O
12 - - O
. - - O
9 - - O
, - - O
11 - - O
. - - O
03 - - O
, - - O
and - - O
5 - - O
. - - O
37 - - O
x - - O
10 - - O
( - - O
6 - - O
) - - O
kg - - O
, - - O
respectively - - O
, - - O
compared - - O
with - - O
2 - - O
. - - O
02 - - O
x - - O
10 - - O
( - - O
6 - - O
) - - O
kg - - O
in - - O
the - - O
reference - - O
group - - O
that - - O
received - - O
CY - - O
with - - O
G-CSF - - O
( - - O
P - - O
= - - O
< - - O
. - - O
0001 - - O
, - - O
. - - O
002 - - O
, - - O
and - - O
. - - O
09 - - O
, - - O
respectively - - O
) - - O
. - - O

The - - O
calculated - - O
pD2 - - O
values - - O
were - - O
8 - - O
. - - O
8 - - O
for - - O
E - - O
, - - O
8 - - O
. - - O
6 - - O
for - - O
DHE - - O
and - - O
6 - - O
. - - O
6 - - O
for - - O
M - - O
. - - O

Significant - - O
intergroup - - O
differences - - O
are - - O
highlighted - - O
for - - O
both - - O
selected - - O
dentoskeletal - - O
and - - O
soft - - O
tissue - - O
profile - - O
variables - - O
. - - O

Mutations - - O
in - - O
the - - O
VPS45 - - O
gene - - O
, - - O
a - - O
SEC1 - - O
homologue - - O
, - - O
result - - O
in - - O
vacuolar - - O
protein - - O
sorting - - O
defects - - O
and - - O
accumulation - - O
of - - O
membrane - - O
vesicles - - O
. - - O

B - - O
cell-specific - - O
mb-1 - - O
and - - O
B29 - - O
genes - - O
encode - - O
the - - O
alpha - - O
beta - - O
components - - O
of - - O
the - - O
BCR-associated - - O
complex - - O
in - - O
mature - - O
sIgM+ - - O
B - - O
cells - - O
. - - O

Comparative - - O
DNA - - O
sequence - - O
analysis - - O
showed - - O
the - - O
Genethon - - O
microsatellite - - O
D19S596 - - O
lies - - O
2 - - O
. - - O
2 - - O
kb - - O
downstream - - O
of - - O
the - - O
coding - - O
region - - O
of - - O
FUT1 - - O
, - - O
indicating - - O
that - - O
the - - O
cluster - - O
comprising - - O
the - - O
closely - - O
linked - - O
FUT1 - - O
and - - O
FUT2 - - O
genes - - O
is - - O
located - - O
4 - - O
cM - - O
distal - - O
to - - O
D19S412 - - O
( - - O
lod - - O
score - - O
13 - - O
. - - O
7 - - O
) - - O
and - - O
9 - - O
cM - - O
proximal - - O
to - - O
D19S571 - - O
( - - O
lod - - O
score - - O
11 - - O
. - - O
7 - - O
) - - O
. - - O

Only - - O
17% - - O
of - - O
all - - O
patients - - O
admitted - - O
it - - O
at - - O
all - - O
times - - O
. - - O

The - - O
c-myc - - O
gene - - O
is - - O
overexpressed - - O
in - - O
a - - O
variety - - O
of - - O
tumor - - O
types - - O
and - - O
appears - - O
to - - O
play - - O
an - - O
important - - O
role - - O
in - - O
the - - O
abnormal - - O
growth - - O
of - - O
a - - O
number - - O
of - - O
cell - - O
types - - O
. - - O

Inhibition - - O
of - - O
the - - O
apolipoprotein - - O
B - - O
mRNA - - O
editing - - O
enzyme-complex - - O
by - - O
hnRNP - - O
C1 - - O
protein - - O
and - - O
40S - - O
hnRNP - - O
complexes - - O
. - - O

Twenty-six - - O
( - - O
55% - - O
) - - O
( - - O
95% - - O
CI - - O
, - - O
41-69% - - O
) - - O
patients - - O
experienced - - O
> - - O
or - - O
= - - O
grade - - O
3 - - O
acute - - O
toxicity - - O
( - - O
RTOG - - O
) - - O
. - - O

To - - O
estimate - - O
the - - O
locations - - O
of - - O
sources - - O
with - - O
the - - O
TF-MUSIC - - O
algorithm - - O
, - - O
we - - O
first - - O
set - - O
the - - O
target - - O
region - - O
on - - O
the - - O
spectrogram - - O
of - - O
the - - O
somatosensory - - O
responses - - O
. - - O

A - - O
microsporidian - - O
, - - O
Nosema - - O
algerae - - O
Vavra - - O
and - - O
undeen - - O
, - - O
was - - O
found - - O
parasitizing - - O
larvae - - O
and - - O
adults - - O
of - - O
a - - O
laboratory - - O
colony - - O
of - - O
Culex - - O
pipiens - - O
L - - O
. - - O
originated - - O
from - - O
Gharbia - - O
Governorate - - O
. - - O

Serological - - O
studies - - O
of - - O
antibodies - - O
to - - O
Epstein-Barr - - O
virus - - O
in - - O
infectious - - O
mononucleosis - - O
. - - O

The - - O
mean - - O
transfer - - O
ratios - - O
of - - O
the - - O
drug - - O
into - - O
the - - O
genital - - O
tissues - - O
to - - O
the - - O
concentration - - O
in - - O
the - - O
uterine - - O
arterial - - O
blood - - O
were - - O
such - - O
that - - O
the - - O
transfer - - O
ratio - - O
into - - O
the - - O
portio - - O
vaginalis - - O
was - - O
the - - O
highest - - O
, - - O
followed - - O
by - - O
the - - O
uterine - - O
cervix - - O
and - - O
the - - O
myometrium - - O
, - - O
and - - O
that - - O
into - - O
the - - O
oviduct - - O
was - - O
the - - O
lowest - - O
with - - O
about - - O
1 - - O
2 - - O
that - - O
into - - O
the - - O
portio - - O
vaginalis - - O
. - - O

We - - O
have - - O
also - - O
isolated - - O
and - - O
analyzed - - O
the - - O
5' - - O
flanking - - O
region - - O
of - - O
the - - O
pea - - O
33RNP - - O
gene - - O
. - - O

We - - O
conclude - - O
that - - O
for - - O
mono-intronic - - O
precursors - - O
in - - O
which - - O
there - - O
is - - O
only - - O
one - - O
choice - - O
of - - O
splice - - O
sites - - O
, - - O
most - - O
of - - O
the - - O
exon - - O
sequences - - O
are - - O
not - - O
mechanistically - - O
involved - - O
in - - O
the - - O
splicing - - O
process - - O
. - - O

Identification - - O
and - - O
characterization - - O
of - - O
two - - O
putative - - O
human - - O
arginine - - O
methyltransferases - - O
( - - O
HRMT1L1 - - O
and - - O
HRMT1L2 - - O
) - - O
. - - O

The - - O
contraceptive - - O
pattern - - O
of - - O
157 - - O
women - - O
was - - O
analysed - - O
and - - O
13 - - O
. - - O
8 - - O
percent - - O
were - - O
using - - O
inefficient - - O
methods - - O
. - - O

In - - O
fus3 - - O
mutants - - O
, - - O
the - - O
levels - - O
of - - O
Ty1 - - O
RNA - - O
, - - O
protein - - O
synthesis - - O
, - - O
and - - O
proteolytic - - O
processing - - O
were - - O
not - - O
altered - - O
relative - - O
to - - O
those - - O
in - - O
FUS3 - - O
strains - - O
but - - O
steady-state - - O
levels - - O
of - - O
TyA - - O
, - - O
integrase - - O
, - - O
and - - O
reverse - - O
transcriptase - - O
proteins - - O
and - - O
Ty1 - - O
cDNA - - O
were - - O
all - - O
increased - - O
. - - O

Patients - - O
at - - O
risk - - O
of - - O
hypothyroidism - - O
. - - O

Thus - - O
, - - O
included - - O
in - - O
the - - O
KG1a - - O
EST - - O
dataset - - O
are - - O
candidates - - O
for - - O
new - - O
human - - O
genes - - O
that - - O
may - - O
play - - O
roles - - O
in - - O
hematopoietic - - O
differentiative - - O
progression - - O
and - - O
lineage - - O
commitment - - O
. - - O

Restoration - - O
of - - O
opponens - - O
function - - O
with - - O
transplantation - - O
of - - O
free - - O
composites - - O
dorsal - - O
pedal - - O
skin - - O
flap - - O
containing - - O
m - - O
. - - O
extensor - - O
hallucis - - O
brevis - - O
. - - O

They - - O
also - - O
interact - - O
with - - O
GTPase - - O
activating - - O
proteins - - O
encoded - - O
by - - O
IRA1 - - O
and - - O
IRA2 - - O
. - - O

Activation - - O
of - - O
T - - O
cells - - O
via - - O
the - - O
TCR - - O
and - - O
other - - O
costimulatory - - O
receptors - - O
triggers - - O
a - - O
number - - O
of - - O
signaling - - O
cascades - - O
. - - O

GLRaV-2 - - O
is - - O
the - - O
only - - O
closterovirus - - O
, - - O
so - - O
far - - O
, - - O
that - - O
matches - - O
the - - O
genome - - O
organization - - O
of - - O
the - - O
type - - O
member - - O
of - - O
the - - O
group - - O
, - - O
BYV - - O
, - - O
and - - O
thus - - O
can - - O
be - - O
unambiguously - - O
classified - - O
as - - O
a - - O
definitive - - O
member - - O
of - - O
the - - O
genus - - O
Closterovirus - - O
. - - O

Our - - O
results - - O
demonstrate - - O
that - - O
the - - O
promoter - - O
and - - O
enhancer - - O
regions - - O
identified - - O
here - - O
are - - O
essential - - O
for - - O
maintaining - - O
the - - O
efficient - - O
promoter - - O
activity - - O
of - - O
the - - O
human - - O
activin - - O
betaA - - O
subunit - - O
gene - - O
. - - O

CONCLUSIONS - - O
: - - O
Significant - - O
elevations - - O
of - - O
IL-1alpha - - O
and - - O
IL-1beta - - O
occur - - O
in - - O
patients - - O
with - - O
bacterial - - O
cystitis - - O
and - - O
microscopic - - O
hematuria - - O
. - - O

Recent - - O
work - - O
in - - O
this - - O
laboratory - - O
has - - O
shown - - O
that - - O
the - - O
gene - - O
coding - - O
for - - O
acetate - - O
kinase - - O
( - - O
ackA - - O
) - - O
in - - O
Sinorhizobium - - O
meliloti - - O
is - - O
up-regulated - - O
in - - O
response - - O
to - - O
phosphate - - O
limitation - - O
. - - O

Five - - O
additional - - O
copies - - O
of - - O
Lian - - O
elements - - O
were - - O
isolated - - O
, - - O
mapped - - O
by - - O
restriction - - O
digestion - - O
, - - O
and - - O
partially - - O
sequenced - - O
. - - O

Autoimmune - - O
neutropenia - - O
( - - O
AIN - - O
) - - O
is - - O
a - - O
frequent - - O
cause - - O
of - - O
chronic - - O
neutropenia - - O
especially - - O
in - - O
youngest - - O
children - - O
. - - O

Comparison - - O
of - - O
the - - O
amino - - O
acid - - O
sequences - - O
of - - O
the - - O
RPO1 - - O
polypeptides - - O
of - - O
IIV6 - - O
, - - O
LCDV - - O
, - - O
and - - O
MCV-1 - - O
with - - O
the - - O
corresponding - - O
prokaryotic - - O
, - - O
eukaryotic - - O
, - - O
and - - O
viral - - O
proteins - - O
revealed - - O
differences - - O
in - - O
amino - - O
acid - - O
similarity - - O
and - - O
phylogenetic - - O
relationships - - O
. - - O

Intravenous - - O
antibiotic - - O
therapy - - O
in - - O
cystic - - O
fibrosis - - O
: - - O
in - - O
hospital - - O
or - - O
at - - O
home - - O
? - - O

Concordantly - - O
, - - O
it - - O
was - - O
shown - - O
that - - O
the - - O
dnHLH - - O
protein - - O
Id1 - - O
inhibits - - O
differentiation - - O
of - - O
muscle - - O
and - - O
myeloid - - O
cells - - O
in - - O
vitro - - O
. - - O

Data - - O
from - - O
119 - - O
men - - O
and - - O
40 - - O
women - - O
undergoing - - O
coronary - - O
angiography - - O
provide - - O
an - - O
opportunity - - O
to - - O
compare - - O
these - - O
associations - - O
in - - O
relation - - O
to - - O
a - - O
direct - - O
and - - O
continuous - - O
measure - - O
of - - O
atherosclerosis - - O
while - - O
controlling - - O
for - - O
age - - O
, - - O
sex - - O
, - - O
income - - O
, - - O
hypertension - - O
, - - O
serum - - O
cholesterol - - O
, - - O
smoking - - O
, - - O
angina - - O
, - - O
diabetes - - O
, - - O
family - - O
history - - O
of - - O
heart - - O
disease - - O
, - - O
Type - - O
A - - O
behavior - - O
pattern - - O
, - - O
and - - O
hostility - - O
. - - O

The - - O
Drosophila - - O
melanogaster - - O
suppressor - - O
of - - O
sable - - O
gene - - O
, - - O
su - - O
( - - O
s - - O
) - - O
, - - O
encodes - - O
a - - O
novel - - O
, - - O
150-kDa - - O
nuclear - - O
RNA - - O
binding - - O
protein - - O
, - - O
SU - - O
( - - O
S - - O
) - - O
, - - O
that - - O
negatively - - O
regulates - - O
RNA - - O
accumulation - - O
from - - O
mutant - - O
alleles - - O
of - - O
other - - O
genes - - O
that - - O
have - - O
transposon - - O
insertions - - O
in - - O
the - - O
5' - - O
transcribed - - O
region - - O
. - - O

0 - - O
. - - O
61 - - O
+ - - O
- - - O
0 - - O
. - - O
04 - - O
) - - O
. - - O

In - - O
addition - - O
, - - O
both - - O
the - - O
exon - - O
1- - - O
and - - O
exon - - O
2-initiated - - O
forms - - O
of - - O
the - - O
c-Myc - - O
protein - - O
stimulated - - O
transcription - - O
of - - O
a - - O
Myc - - O
Max-responsive - - O
reporter - - O
construct - - O
to - - O
a - - O
similar - - O
level - - O
. - - O

Productive - - O
growth - - O
of - - O
phage - - O
P22 - - O
in - - O
wild-type - - O
Salmonella - - O
typhimurium - - O
correlates - - O
with - - O
the - - O
presence - - O
of - - O
Abc2 - - O
, - - O
but - - O
is - - O
independent - - O
of - - O
the - - O
absolute - - O
level - - O
of - - O
ATP-dependent - - O
nuclease - - O
activity - - O
, - - O
suggesting - - O
a - - O
qualitative - - O
change - - O
in - - O
the - - O
nature - - O
of - - O
Abc2-modified - - O
RecBCD - - O
nuclease - - O
activity - - O
relative - - O
to - - O
the - - O
native - - O
enzyme - - O
. - - O

These - - O
data - - O
may - - O
also - - O
aid - - O
in - - O
the - - O
localization - - O
of - - O
other - - O
disease - - O
loci - - O
mapped - - O
to - - O
this - - O
region - - O
, - - O
including - - O
the - - O
gene - - O
for - - O
tricho-dento-osseous - - O
syndrome - - O
and - - O
a - - O
murine - - O
locus - - O
for - - O
susceptibility - - O
to - - O
ozone-induced - - O
acute - - O
lung - - O
injury - - O
. - - O

Thus - - O
, - - O
endemic - - O
cumlations - - O
of - - O
hepatitis - - O
A - - O
diseases - - O
are - - O
possible - - O
. - - O

Systematic - - O
review - - O
of - - O
diagnostic - - O
tests - - O
for - - O
vaginal - - O
trichomoniasis - - O
. - - O

Modification - - O
by - - O
this - - O
latter - - O
compound - - O
was - - O
so - - O
extensive - - O
that - - O
the - - O
amount - - O
of - - O
membrane-associated - - O
N-myristoylated - - O
protein - - O
was - - O
decreased - - O
. - - O

Rearrangements - - O
of - - O
the - - O
NFKB2 - - O
gene - - O
are - - O
associated - - O
with - - O
lymphoid - - O
malignancies - - O
, - - O
but - - O
the - - O
functional - - O
significance - - O
of - - O
these - - O
alterations - - O
is - - O
not - - O
known - - O
. - - O

Using - - O
fluorescence - - O
in - - O
situ - - O
hybridization - - O
, - - O
we - - O
mapped - - O
the - - O
chromosome-17 - - O
breakpoint - - O
in - - O
a - - O
patient - - O
with - - O
acampomelic - - O
CMPD - - O
and - - O
sex - - O
reversal - - O
, - - O
who - - O
carries - - O
a - - O
de - - O
novo - - O
constitutional - - O
t - - O
( - - O
12 - - O
; - - O
17 - - O
) - - O
translocation - - O
, - - O
between - - O
two - - O
known - - O
cosmid - - O
markers - - O
in - - O
the - - O
17q24-q25 - - O
region - - O
. - - O

Thus - - O
, - - O
in - - O
the - - O
presence - - O
of - - O
active - - O
S-CDKs - - O
and - - O
Dbf4 - - O
Cdc7 - - O
, - - O
Mcms - - O
may - - O
open - - O
origins - - O
and - - O
thereby - - O
facilitate - - O
the - - O
loading - - O
of - - O
RPA - - O
. - - O

In - - O
canrenoate-treated - - O
rats - - O
, - - O
ANP - - O
infusion - - O
caused - - O
greater - - O
increases - - O
in - - O
sodium - - O
excretion - - O
( - - O
FENA - - O
from - - O
3 - - O
. - - O
05 - - O
+ - - O
- - - O
0 - - O
. - - O
71 - - O
to - - O
7 - - O
. - - O
21 - - O
+ - - O
- - - O
0 - - O
. - - O
45% - - O
; - - O
P - - O
< - - O
0 - - O
. - - O
05 - - O
; - - O
n - - O
= - - O
8 - - O
) - - O
than - - O
saline - - O
infusion - - O
( - - O
FENA - - O
from - - O
4 - - O
. - - O
16 - - O
+ - - O
- - - O
1 - - O
. - - O
11 - - O
to - - O
5 - - O
. - - O
47 - - O
+ - - O
- - - O
0 - - O
. - - O
66% - - O
; - - O
n - - O
= - - O
6 - - O
) - - O
, - - O
despite - - O
the - - O
hypocapnia - - O
. - - O

RT-PCR - - O
analysis - - O
showed - - O
that - - O
PLP-H - - O
as - - O
well - - O
as - - O
PLP-C - - O
and - - O
PLP-D - - O
are - - O
expressed - - O
in - - O
all - - O
rat - - O
strains - - O
examined - - O
, - - O
confirming - - O
that - - O
PLP - - O
diversity - - O
is - - O
not - - O
due - - O
to - - O
strain - - O
differences - - O
. - - O

In - - O
rats - - O
bearing - - O
Walker-256-carcinosarcoma - - O
4-EPI - - O
was - - O
effective - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Resultant - - O
activation - - O
of - - O
c-Jun - - O
N-terminal - - O
kinase - - O
stress-activated - - O
protein - - O
kinase - - O
( - - O
JNK - - O
SAPK - - O
) - - O
. - - O

This - - O
makes - - O
these - - O
compounds - - O
attractive - - O
as - - O
vehicles - - O
for - - O
these - - O
and - - O
other - - O
gases - - O
in-vivo - - O
and - - O
in-vitro - - O
. - - O

Chem - - O
. - - O

We - - O
now - - O
show - - O
that - - O
the - - O
BAT1 - - O
translation - - O
product - - O
is - - O
the - - O
homolog - - O
of - - O
the - - O
rat - - O
p47 - - O
nuclear - - O
protein - - O
, - - O
the - - O
WM6 - - O
Drosophila - - O
gene - - O
product - - O
, - - O
and - - O
probably - - O
also - - O
Ce08102 - - O
of - - O
Caenorhabditis - - O
elegans - - O
, - - O
all - - O
members - - O
of - - O
the - - O
DEAD - - O
protein - - O
family - - O
of - - O
ATP-dependent - - O
RNA - - O
helicases - - O
. - - O

In - - O
synchronized - - O
HeLa - - O
cells - - O
, - - O
expression - - O
of - - O
luciferase - - O
activity - - O
was - - O
induced - - O
at - - O
the - - O
beginning - - O
of - - O
DNA - - O
synthesis - - O
and - - O
was - - O
dependent - - O
on - - O
the - - O
presence - - O
of - - O
an - - O
E2F-binding - - O
site - - O
in - - O
the - - O
H2A - - O
. - - O
1 - - O
promoter - - O
. - - O

The - - O
DNA - - O
binding - - O
domain - - O
of - - O
NirA - - O
was - - O
expressed - - O
as - - O
a - - O
fusion - - O
protein - - O
with - - O
the - - O
glutathione - - O
S-transferase - - O
of - - O
Schistosoma - - O
japonicum - - O
. - - O

Seventy-one - - O
supplementary - - O
doses - - O
of - - O
vecuronium - - O
were - - O
used - - O
for - - O
muscle - - O
relaxation - - O
during - - O
a - - O
22-h-long - - O
NLA - - O
II - - O
anaesthesia - - O
. - - O

Strikingly - - O
, - - O
these - - O
cells - - O
contain - - O
a - - O
missense - - O
mutation - - O
of - - O
the - - O
p53 - - O
gene - - O
at - - O
codon - - O
242 - - O
( - - O
p53 - - O
( - - O
242 - - O
) - - O
) - - O
, - - O
which - - O
substitutes - - O
alanine - - O
for - - O
glycine - - O
. - - O

The - - O
mapping - - O
was - - O
completed - - O
with - - O
Southern - - O
blotting - - O
and - - O
restriction - - O
analysis - - O
. - - O

Together - - O
, - - O
the - - O
data - - O
suggest - - O
that - - O
cAMP-dependent - - O
control - - O
of - - O
the - - O
amounts - - O
of - - O
the - - O
activator - - O
SF-1 - - O
vs - - O
. - - O
the - - O
repressor - - O
COUP-TF - - O
could - - O
influence - - O
CRS2-dependent - - O
transcription - - O
. - - O

Altogether - - O
these - - O
results - - O
suggest - - O
that - - O
, - - O
in - - O
KG1a - - O
cells - - O
, - - O
TNFalpha - - O
can - - O
stimulate - - O
in - - O
parallel - - O
PC-PLC - - O
and - - O
PLD - - O
, - - O
whose - - O
lipid - - O
products - - O
activate - - O
in - - O
turn - - O
mitogen-activated - - O
protein - - O
kinase - - O
( - - O
MAP - - O
kinase - - O
) - - O
and - - O
NF-kappaB - - O
signalling - - O
respectively - - O
. - - O

The - - O
findings - - O
are - - O
discussed - - O
in - - O
the - - O
context - - O
of - - O
known - - O
properties - - O
of - - O
cortical-bar - - O
detectors - - O
. - - O

Human - - O
alpha-galactosidase - - O
A - - O
: - - O
nucleotide - - O
sequence - - O
of - - O
a - - O
cDNA - - O
clone - - O
encoding - - O
the - - O
mature - - O
enzyme - - O
. - - O

In - - O
the - - O
absence - - O
of - - O
MHC - - O
class - - O
II - - O
, - - O
purified - - O
soluble - - O
D10 - - O
TCR - - O
bound - - O
to - - O
Staphylococcus - - O
aureus - - O
enterotoxin - - O
C2 - - O
with - - O
an - - O
association - - O
rate - - O
of - - O
1 - - O
. - - O
69+ - - O
-0 - - O
. - - O
12 - - O
x - - O
10 - - O
( - - O
4 - - O
) - - O
M - - O
( - - O
-1 - - O
) - - O
sec - - O
( - - O
-1 - - O
) - - O
and - - O
a - - O
dissociation - - O
rate - - O
of - - O
1 - - O
. - - O
9+ - - O
-0 - - O
. - - O
47 - - O
x - - O
10 - - O
( - - O
-2 - - O
) - - O
sec - - O
( - - O
-1 - - O
) - - O
, - - O
giving - - O
a - - O
dissociation - - O
constant - - O
of - - O
1 - - O
. - - O
1 - - O
microM - - O
. - - O

The - - O
case - - O
for - - O
completing - - O
the - - O
lymphadenectomy - - O
when - - O
positive - - O
lymph - - O
nodes - - O
are - - O
found - - O
during - - O
radical - - O
hysterectomy - - O
for - - O
cervical - - O
carcinoma - - O
. - - O

To - - O
further - - O
characterize - - O
the - - O
structure - - O
and - - O
evolutionary - - O
synthesis - - O
of - - O
the - - O
CMT1A-REP - - O
repeat - - O
, - - O
fluorescent - - O
in - - O
situ - - O
hybridization - - O
( - - O
FISH - - O
) - - O
analysis - - O
and - - O
heterologous - - O
PCR-based - - O
assays - - O
were - - O
carried - - O
out - - O
for - - O
a - - O
series - - O
of - - O
primates - - O
. - - O

When - - O
expressed - - O
per - - O
kilogram - - O
body - - O
weight - - O
, - - O
mean - - O
GIT - - O
increased - - O
in - - O
the - - O
dF - - O
group - - O
from - - O
0 - - O
. - - O
14% - - O
to - - O
0 - - O
. - - O
16% - - O
above - - O
RMR - - O
, - - O
with - - O
a - - O
significant - - O
decrease - - O
from - - O
0 - - O
. - - O
15% - - O
to - - O
0 - - O
. - - O
13% - - O
in - - O
the - - O
P - - O
group - - O
. - - O

The - - O
mature - - O
chromosome - - O
4 - - O
FRG1 - - O
transcript - - O
is - - O
1042 - - O
bp - - O
in - - O
length - - O
and - - O
contains - - O
nine - - O
exons - - O
which - - O
encode - - O
a - - O
putative - - O
protein - - O
of - - O
258 - - O
amino - - O
acid - - O
residues - - O
. - - O

Various - - O
transcripts - - O
are - - O
generated - - O
from - - O
the - - O
VCSA1 - - O
gene - - O
by - - O
alternative - - O
splicing - - O
and - - O
poly - - O
( - - O
A - - O
) - - O
processing - - O
in - - O
the - - O
rat - - O
submandibular - - O
gland - - O
. - - O

A - - O
stochastic - - O
version - - O
of - - O
Kernell's - - O
( - - O
1968 - - O
, - - O
1972 - - O
) - - O
model - - O
with - - O
cumulative - - O
afterhyperpolarization - - O
( - - O
AHP - - O
) - - O
was - - O
simulated - - O
. - - O

The - - O
data - - O
indicate - - O
that - - O
etr-1 - - O
is - - O
essential - - O
for - - O
muscle - - O
development - - O
in - - O
C - - O
. - - O
elegans - - O
, - - O
perhaps - - O
by - - O
playing - - O
a - - O
role - - O
in - - O
post-transcriptional - - O
processing - - O
of - - O
some - - O
muscle - - O
component - - O
, - - O
and - - O
thus - - O
suggesting - - O
a - - O
possible - - O
conservation - - O
of - - O
gene - - O
function - - O
with - - O
human - - O
CUG-bp - - O
. - - O

This - - O
hypothesis - - O
was - - O
tested - - O
by - - O
introducing - - O
mutations - - O
at - - O
each - - O
of - - O
the - - O
three - - O
histidine - - O
pairs - - O
, - - O
the - - O
H382-X2-H385 - - O
pair - - O
, - - O
the - - O
H411-X2-H414 - - O
pair - - O
and - - O
the - - O
H430-X5-H436 - - O
pair - - O
, - - O
which - - O
constitute - - O
the - - O
histidine-rich - - O
region - - O
near - - O
the - - O
C - - O
terminus - - O
of - - O
gp17 - - O
. - - O

The - - O
isolated - - O
plasmin - - O
fragments - - O
of - - O
VEGF - - O
were - - O
compared - - O
with - - O
respect - - O
to - - O
heparin - - O
binding - - O
, - - O
interaction - - O
with - - O
soluble - - O
VEGF - - O
receptors - - O
, - - O
and - - O
ability - - O
to - - O
promote - - O
endothelial - - O
cell - - O
mitogenesis - - O
. - - O

Hepatitis - - O
A - - O
infected - - O
food - - O
handler - - O
at - - O
an - - O
Edmonton - - O
, - - O
Alberta - - O
retail - - O
food - - O
facility - - O
: - - O
public - - O
health - - O
protection - - O
strategies - - O
. - - O

METHODS - - O
: - - O
126 - - O
patients - - O
with - - O
histologically - - O
confirmed - - O
MFH - - O
were - - O
analyzed - - O
. - - O

A - - O
recently - - O
reported - - O
new - - O
member - - O
of - - O
the - - O
Vav - - O
family - - O
proteins - - O
, - - O
Vav3 - - O
has - - O
been - - O
identified - - O
as - - O
a - - O
Ros - - O
receptor - - O
protein - - O
tyrosine - - O
kinase - - O
( - - O
RPTK - - O
) - - O
interacting - - O
protein - - O
by - - O
yeast - - O
two-hybrid - - O
screening - - O
. - - O

Our - - O
purpose - - O
was - - O
to - - O
determine - - O
if - - O
intact - - O
perianal - - O
( - - O
S4-5 - - O
) - - O
pin - - O
sensation - - O
( - - O
PPS - - O
) - - O
and - - O
bulbocavernosus - - O
( - - O
S2-4 - - O
) - - O
reflex - - O
( - - O
BCR - - O
) - - O
shortly - - O
after - - O
spinal - - O
cord - - O
injury - - O
( - - O
SCI - - O
) - - O
are - - O
predictive - - O
of - - O
bladder - - O
function - - O
recovery - - O
. - - O

Further - - O
studies - - O
demonstrated - - O
that - - O
the - - O
PPARalpha - - O
ligand - - O
8 - - O
( - - O
S - - O
) - - O
-hydroxyeicosatetraenoic - - O
acid - - O
strongly - - O
promotes - - O
the - - O
interaction - - O
of - - O
PPARalpha - - O
with - - O
the - - O
co-activator - - O
RIP-140 - - O
but - - O
decreases - - O
the - - O
interaction - - O
of - - O
PPARalpha - - O
with - - O
the - - O
co-repressor - - O
SMRT - - O
. - - O

When - - O
O2 - - O
therapy - - O
was - - O
controlled - - O
for - - O
, - - O
the - - O
association - - O
between - - O
RBT - - O
and - - O
RLF - - O
did - - O
not - - O
achieve - - O
statistical - - O
significance - - O
( - - O
P - - O
= - - O
. - - O
07 - - O
) - - O
. - - O

In - - O
the - - O
brain - - O
, - - O
muscarinic - - O
receptors - - O
mediate - - O
motor - - O
and - - O
memory - - O
function - - O
by - - O
interaction - - O
with - - O
their - - O
ligand - - O
acetylcholine - - O
. - - O

Batch - - O
cultures - - O
of - - O
S - - O
. - - O
mutans - - O
serotype - - O
a - - O
demonstrated - - O
no - - O
growth - - O
on - - O
MSB - - O
agar - - O
. - - O

Management - - O
often - - O
involves - - O
beta- - - O
and - - O
calcium - - O
channel - - O
blocking - - O
drugs - - O
or - - O
type - - O
IC - - O
antiarrhythmic - - O
drugs - - O
. - - O

Sensitivity - - O
and - - O
specificity - - O
was - - O
established - - O
for - - O
the - - O
Pharmacia - - O
CAP - - O
System - - O
and - - O
the - - O
DPC - - O
AlaSTAT - - O
System - - O
by - - O
comparison - - O
with - - O
results - - O
of - - O
the - - O
skin - - O
prick - - O
test - - O
. - - O

The - - O
interferon-inducible - - O
protein - - O
kinase - - O
PKR - - O
modulates - - O
the - - O
transcriptional - - O
activation - - O
of - - O
immunoglobulin - - O
kappa - - O
gene - - O
. - - O

We - - O
report - - O
a - - O
case - - O
of - - O
vasculitis - - O
( - - O
cutaneous - - O
and - - O
neurologic - - O
) - - O
which - - O
led - - O
to - - O
the - - O
discovery - - O
of - - O
a - - O
selective - - O
immunodeficit - - O
towards - - O
EBV - - O
, - - O
similar - - O
to - - O
Purtilo's - - O
syndrome - - O
. - - O

A - - O
stretch - - O
of - - O
16 - - O
nucleotides - - O
just - - O
upstream - - O
of - - O
the - - O
IL-4RE - - O
contributed - - O
to - - O
IL-4 - - O
inducibility - - O
and - - O
formed - - O
nucleoprotein - - O
complexes - - O
with - - O
constitutive - - O
factors - - O
. - - O

Inhibition - - O
appears - - O
to - - O
result - - O
from - - O
titration - - O
of - - O
general - - O
transcription - - O
factors - - O
because - - O
MDM2 - - O
overexpression - - O
inhibits - - O
c-fos - - O
as - - O
well - - O
as - - O
other - - O
promoters - - O
in - - O
vivo - - O
and - - O
basal - - O
transcription - - O
in - - O
vitro - - O
. - - O

A - - O
13-bp - - O
cis-regulatory - - O
element - - O
in - - O
the - - O
LTR - - O
promoter - - O
of - - O
the - - O
tobacco - - O
retrotransposon - - O
Tto1 - - O
is - - O
involved - - O
in - - O
responsiveness - - O
to - - O
tissue - - O
culture - - O
, - - O
wounding - - O
, - - O
methyl - - O
jasmonate - - O
and - - O
fungal - - O
elicitors - - O
. - - O

Serum - - O
leptin - - O
concentrations - - O
in - - O
women - - O
during - - O
gonadotropin - - O
stimulation - - O
cycles - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
purified - - O
and - - O
characterized - - O
the - - O
recombinant - - O
furin - - O
from - - O
the - - O
conditioned - - O
medium - - O
of - - O
these - - O
cells - - O
. - - O

The - - O
presence - - O
of - - O
regulatory - - O
sequences - - O
for - - O
the - - O
binding - - O
of - - O
transcription - - O
factors - - O
such - - O
as - - O
NF-kappa - - O
B - - O
and - - O
AP-2 - - O
, - - O
whose - - O
activation - - O
is - - O
associated - - O
with - - O
the - - O
immediate - - O
response - - O
of - - O
the - - O
cell - - O
to - - O
an - - O
injury - - O
, - - O
may - - O
be - - O
an - - O
indication - - O
of - - O
the - - O
important - - O
role - - O
which - - O
HO-1 - - O
may - - O
play - - O
in - - O
defense - - O
mechanisms - - O
against - - O
tissue - - O
injury - - O
. - - O

Moreover - - O
, - - O
the - - O
effect - - O
exerted - - O
by - - O
TIS1 - - O
appeared - - O
to - - O
be - - O
selective - - O
for - - O
the - - O
MCK - - O
promoter - - O
. - - O

CD7+ - - O
CD3- - - O
T-cell - - O
precursors - - O
exhibit - - O
V - - O
delta - - O
2D - - O
delta - - O
3 - - O
rearrangements - - O
. - - O

GCR1 - - O
gene - - O
function - - O
is - - O
required - - O
for - - O
high-level - - O
glycolytic - - O
gene - - O
expression - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
. - - O

Crohn's - - O
disease - - O
in - - O
prolonged - - O
remission - - O
: - - O
should - - O
one - - O
augment - - O
protein-calorie - - O
intake - - O
as - - O
compared - - O
to - - O
healthy - - O
subjects - - O
? - - O
The - - O
aim - - O
of - - O
our - - O
two - - O
year - - O
prospective - - O
study - - O
was - - O
to - - O
evaluate - - O
whether - - O
adult - - O
Crohn's - - O
disease - - O
patients - - O
in - - O
prolonged - - O
remission - - O
( - - O
CDAI - - O
< - - O
150 - - O
) - - O
, - - O
in - - O
order - - O
to - - O
maintain - - O
their - - O
body - - O
weight - - O
as - - O
close - - O
as - - O
possible - - O
to - - O
the - - O
ideal - - O
one - - O
, - - O
need - - O
a - - O
protein-calorie - - O
intake - - O
higher - - O
than - - O
the - - O
predicted - - O
one - - O
and - - O
that - - O
of - - O
healthy - - O
controls - - O
. - - O

We - - O
are - - O
reporting - - O
an - - O
autopsy - - O
case - - O
of - - O
so-called - - O
"acute - - O
multiple - - O
sclerosis" - - O
that - - O
was - - O
difficult - - O
to - - O
differentiate - - O
from - - O
a - - O
brain - - O
tumor - - O
on - - O
MRI - - O
findings - - O
. - - O

Thus - - O
, - - O
this - - O
study - - O
provides - - O
evidence - - O
that - - O
a - - O
novel - - O
, - - O
ubiquitous - - O
factor - - O
( - - O
HF-1a - - O
) - - O
and - - O
a - - O
muscle - - O
factor - - O
( - - O
HF-1b - - O
MEF-2 - - O
) - - O
can - - O
form - - O
a - - O
novel - - O
, - - O
E-box-independent - - O
pathway - - O
for - - O
muscle-specific - - O
expression - - O
in - - O
ventricular - - O
cardiac - - O
muscle - - O
cells - - O
. - - O

Thyroid - - O
function - - O
tests - - O
were - - O
performed - - O
on - - O
300 - - O
admissions - - O
, - - O
leaving - - O
707 - - O
untested - - O
. - - O

Molecular - - O
cloning - - O
and - - O
expression - - O
of - - O
RPE65 - - O
, - - O
a - - O
novel - - O
retinal - - O
pigment - - O
epithelium-specific - - O
microsomal - - O
protein - - O
that - - O
is - - O
post-transcriptionally - - O
regulated - - O
in - - O
vitro - - O
. - - O

The - - O
concentrations - - O
of - - O
apo - - O
A-I - - O
and - - O
apo - - O
A-II - - O
of - - O
abstainers - - O
decreased - - O
significantly - - O
compared - - O
with - - O
the - - O
corresponding - - O
changes - - O
in - - O
controls - - O
. - - O

Inclusion - - O
of - - O
the - - O
extended - - O
N - - O
terminus - - O
into - - O
the - - O
originally - - O
reported - - O
protein - - O
resulted - - O
in - - O
a - - O
striking - - O
similarity - - O
to - - O
the - - O
lymphoid - - O
factor - - O
Lef-1 - - O
. - - O

These - - O
results - - O
provide - - O
the - - O
first - - O
demonstration - - O
that - - O
an - - O
SR - - O
protein - - O
can - - O
influence - - O
splicing - - O
of - - O
specific - - O
pre-mRNAs - - O
in - - O
vivo - - O
. - - O

Yeast - - O
mutants - - O
assigned - - O
to - - O
the - - O
pet - - O
complementation - - O
group - - O
G104 - - O
were - - O
found - - O
to - - O
lack - - O
alpha-ketoglutarate - - O
dehydrogenase - - O
activity - - O
as - - O
a - - O
result - - O
of - - O
mutations - - O
in - - O
the - - O
dihydrolipoyl - - O
transsuccinylase - - O
( - - O
KE2 - - O
) - - O
component - - O
of - - O
the - - O
complex - - O
. - - O

We - - O
show - - O
, - - O
by - - O
injection - - O
of - - O
synthetic - - O
mRNAs - - O
, - - O
that - - O
the - - O
cis-acting - - O
sequences - - O
responsible - - O
for - - O
repression - - O
of - - O
cyclin - - O
B1 - - O
mRNA - - O
reside - - O
within - - O
its - - O
3'UTR - - O
. - - O

The - - O
present - - O
study - - O
was - - O
designed - - O
to - - O
evaluate - - O
the - - O
sensitivity - - O
and - - O
specificity - - O
of - - O
AMP - - O
CT - - O
( - - O
Gen-Probe - - O
Incorporated - - O
, - - O
San - - O
Diego - - O
, - - O
CA - - O
, - - O
USA - - O
) - - O
on - - O
urogenital - - O
specimens - - O
taken - - O
from - - O
symptomatic - - O
patients - - O
and - - O
on - - O
first - - O
void - - O
urine - - O
( - - O
FVU - - O
) - - O
specimens - - O
from - - O
asymptomatic - - O
patients - - O
. - - O

The - - O
range - - O
of - - O
eosinophils - - O
was - - O
22-56% - - O
of - - O
the - - O
number - - O
of - - O
peripheral - - O
white - - O
blood - - O
cells - - O
( - - O
mean - - O
nadir - - O
33% - - O
) - - O
. - - O

There - - O
were - - O
35 - - O
boys - - O
and - - O
15 - - O
girls - - O
, - - O
with - - O
a - - O
mean - - O
age - - O
of - - O
five - - O
and - - O
a - - O
half - - O
years - - O
. - - O

Analysis - - O
of - - O
mig - - O
CAT - - O
chimeric - - O
constructs - - O
transiently - - O
transfected - - O
into - - O
the - - O
RAW - - O
264 - - O
. - - O
7 - - O
mouse - - O
monocytic - - O
cell - - O
line - - O
revealed - - O
a - - O
unique - - O
IFN-gamma-responsive - - O
element - - O
( - - O
gamma - - O
RE-1 - - O
) - - O
. - - O

In - - O
most - - O
cases - - O
, - - O
DR4-homozygous - - O
, - - O
DRB1-heterozygous - - O
individuals - - O
could - - O
be - - O
genotyped - - O
with - - O
the - - O
panel - - O
of - - O
probes - - O
. - - O

In - - O
study - - O
2 - - O
, - - O
the - - O
correlation - - O
coefficients - - O
between - - O
the - - O
ISO2 - - O
measurements - - O
obtained - - O
at - - O
the - - O
ulcer - - O
margin - - O
and - - O
at - - O
the - - O
adjacent - - O
normal - - O
mucosa - - O
, - - O
and - - O
delta - - O
ISO2 - - O
obtained - - O
by - - O
the - - O
experienced - - O
observer - - O
and - - O
one - - O
of - - O
the - - O
three - - O
learners - - O
were - - O
0 - - O
. - - O
94 - - O
, - - O
0 - - O
. - - O
97 - - O
, - - O
and - - O
0 - - O
. - - O
94 - - O
, - - O
respectively - - O
. - - O

More - - O
specific - - O
adverse - - O
events - - O
, - - O
also - - O
frequently - - O
considered - - O
as - - O
dose-limiting - - O
toxicities - - O
, - - O
include - - O
hypotension - - O
with - - O
IL-1 - - O
, - - O
severe - - O
headache - - O
or - - O
skin - - O
rash - - O
with - - O
IL-3 - - O
, - - O
and - - O
nasal - - O
congestion - - O
and - - O
gastroduodenal - - O
lesions - - O
with - - O
IL-4 - - O
. - - O

Much - - O
evidence - - O
indicates - - O
that - - O
p38 - - O
is - - O
an - - O
activator - - O
of - - O
MyoD - - O
: - - O
( - - O
i - - O
) - - O
p38 - - O
kinase - - O
activity - - O
is - - O
required - - O
for - - O
the - - O
expression - - O
of - - O
MyoD-responsive - - O
genes - - O
, - - O
( - - O
ii - - O
) - - O
enforced - - O
induction - - O
of - - O
p38 - - O
stimulates - - O
the - - O
transcriptional - - O
activity - - O
of - - O
a - - O
Gal4-MyoD - - O
fusion - - O
protein - - O
and - - O
allows - - O
efficient - - O
activation - - O
of - - O
chromatin-integrated - - O
reporters - - O
by - - O
MyoD - - O
, - - O
and - - O
( - - O
iii - - O
) - - O
MyoD-dependent - - O
myogenic - - O
conversion - - O
is - - O
reduced - - O
in - - O
mouse - - O
embryonic - - O
fibroblasts - - O
derived - - O
from - - O
p38alpha - - O
( - - O
- - - O
- - - O
) - - O
embryos - - O
. - - O

Magnetic - - O
storm - - O
indicators - - O
could - - O
be - - O
used - - O
in - - O
medicine - - O
, - - O
in - - O
geophysics - - O
and - - O
for - - O
special - - O
purposes - - O
. - - O

However - - O
, - - O
a - - O
strongly - - O
increased - - O
frequency - - O
of - - O
CpG - - O
dinucleotides - - O
was - - O
found - - O
. - - O

Thus - - O
, - - O
as - - O
expected - - O
, - - O
trans-splicing - - O
depends - - O
on - - O
the - - O
integrity - - O
of - - O
U2 - - O
, - - O
U4 - - O
, - - O
and - - O
U6 - - O
snRNAs - - O
. - - O

An - - O
exaggerated - - O
tissue - - O
response - - O
adjacent - - O
to - - O
the - - O
cyanoacrylate - - O
site - - O
suggested - - O
a - - O
potential - - O
toxic - - O
chemical - - O
or - - O
thermal - - O
reaction - - O
, - - O
or - - O
both - - O
, - - O
to - - O
the - - O
tissue - - O
adhesive - - O
, - - O
but - - O
there - - O
was - - O
no - - O
evidence - - O
of - - O
any - - O
distant - - O
ocular - - O
effects - - O
. - - O

The - - O
protein - - O
folds - - O
correctly - - O
with - - O
two - - O
disulfide - - O
bonds - - O
and - - O
a - - O
free - - O
thiol - - O
group - - O
at - - O
Cys25 - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
used - - O
footprinting - - O
and - - O
gel - - O
mobility - - O
retardation - - O
assays - - O
to - - O
reveal - - O
that - - O
bacterially - - O
synthesized - - O
Zta - - O
fusion - - O
proteins - - O
bound - - O
directly - - O
to - - O
six - - O
TGTGCAA-like - - O
motifs - - O
within - - O
DSL - - O
. - - O

Dsh - - O
is - - O
required - - O
for - - O
two - - O
different - - O
pathways - - O
, - - O
the - - O
Wnt - - O
pathway - - O
and - - O
planar - - O
polarity - - O
pathway - - O
in - - O
Drosophila - - O
. - - O

The - - O
C2C-Prx - - O
is - - O
encoded - - O
as - - O
a - - O
preprotein - - O
of - - O
273 - - O
amino - - O
acids - - O
containing - - O
a - - O
putative - - O
chloroplast-targeting - - O
signal - - O
of - - O
65 - - O
amino - - O
acids - - O
at - - O
its - - O
N-terminus - - O
. - - O

In - - O
throttling - - O
valves - - O
, - - O
the - - O
aim - - O
is - - O
to - - O
correlate - - O
the - - O
effect - - O
of - - O
shear - - O
to - - O
a - - O
parameter - - O
related - - O
to - - O
the - - O
inner - - O
geometry - - O
of - - O
the - - O
valve - - O
and - - O
to - - O
operating - - O
conditions - - O
. - - O

Here - - O
we - - O
show - - O
in - - O
mouse - - O
fibroblasts - - O
stably - - O
transformed - - O
by - - O
v-Src - - O
that - - O
mRNA - - O
and - - O
protein - - O
levels - - O
of - - O
p21 - - O
( - - O
WAF1 - - O
CIP1 - - O
) - - O
, - - O
cyclin - - O
D1 - - O
, - - O
and - - O
cyclin - - O
E - - O
are - - O
elevated - - O
. - - O

These - - O
experiments - - O
confirm - - O
that - - O
the - - O
6-S - - O
liganded - - O
form - - O
of - - O
the - - O
receptor - - O
identified - - O
in - - O
nuclear - - O
extracts - - O
of - - O
cells - - O
treated - - O
with - - O
2 - - O
, - - O
3 - - O
, - - O
7 - - O
, - - O
8-tetrachlorodibenzo-p-dioxin - - O
( - - O
TCDD - - O
) - - O
contains - - O
the - - O
Ah - - O
receptor - - O
protein - - O
and - - O
ARNT - - O
but - - O
not - - O
the - - O
90-kDa - - O
heat - - O
shock - - O
protein - - O
. - - O

These - - O
children - - O
were - - O
grouped - - O
into - - O
four - - O
diagnostic - - O
categories - - O
: - - O
1 - - O
) - - O
idiopathic - - O
GH - - O
deficiency - - O
( - - O
n - - O
= - - O
10 - - O
) - - O
; - - O
2 - - O
) - - O
organic - - O
hypopituitarism - - O
( - - O
n - - O
= - - O
7 - - O
) - - O
; - - O
3 - - O
) - - O
intrauterine - - O
growth - - O
retardation - - O
( - - O
n - - O
= - - O
5 - - O
) - - O
; - - O
and - - O
4 - - O
) - - O
constitutional - - O
delay - - O
of - - O
growth - - O
and - - O
or - - O
familial - - O
short - - O
stature - - O
( - - O
n - - O
= - - O
18 - - O
) - - O
, - - O
by - - O
standard - - O
clinical - - O
criteria - - O
and - - O
physiological - - O
and - - O
pharmacological - - O
tests - - O
of - - O
GH - - O
reserve - - O
. - - O

A - - O
total - - O
of - - O
125 - - O
acute - - O
leukemia - - O
adult - - O
patients - - O
were - - O
autografted - - O
with - - O
bone - - O
marrow - - O
( - - O
BM - - O
) - - O
purged - - O
by - - O
mafosfamide - - O
( - - O
ASTA - - O
Z - - O
) - - O
during - - O
the - - O
period - - O
of - - O
January - - O
1983 - - O
to - - O
January - - O
1993 - - O
. - - O

Members - - O
of - - O
the - - O
meis1 - - O
and - - O
pbx - - O
homeodomain - - O
protein - - O
families - - O
cooperatively - - O
bind - - O
a - - O
cAMP-responsive - - O
sequence - - O
( - - O
CRS1 - - O
) - - O
from - - O
bovine - - O
CYP17 - - O
. - - O

We - - O
have - - O
investigated - - O
the - - O
contribution - - O
of - - O
specific - - O
TATA-binding - - O
protein - - O
( - - O
TBP - - O
) - - O
-TATA - - O
interactions - - O
to - - O
the - - O
promoter - - O
activity - - O
of - - O
a - - O
constitutively - - O
expressed - - O
silkworm - - O
tRNA - - O
( - - O
C - - O
) - - O
( - - O
Ala - - O
) - - O
gene - - O
and - - O
have - - O
also - - O
asked - - O
whether - - O
the - - O
lack - - O
of - - O
similar - - O
interactions - - O
accounts - - O
for - - O
the - - O
low - - O
promoter - - O
activity - - O
of - - O
a - - O
silk - - O
gland-specific - - O
tRNA - - O
( - - O
SG - - O
) - - O
( - - O
Ala - - O
) - - O
gene - - O
. - - O

Differences - - O
in - - O
the - - O
clinical - - O
presentation - - O
and - - O
the - - O
gross - - O
appearance - - O
of - - O
the - - O
two - - O
cases - - O
are - - O
described - - O
, - - O
and - - O
similarities - - O
in - - O
the - - O
microscopic - - O
features - - O
are - - O
discussed - - O
. - - O

Superoxide - - O
dismutase - - O
( - - O
SOD - - O
) - - O
activity - - O
decreased - - O
significantly - - O
in - - O
sperm - - O
subjected - - O
to - - O
direct - - O
electric - - O
current - - O
in - - O
comparison - - O
to - - O
the - - O
control - - O
or - - O
the - - O
sample - - O
incubated - - O
with - - O
electrolyzed - - O
medium - - O
. - - O

Thus - - O
, - - O
in - - O
normal - - O
intestinal - - O
epithelial - - O
goblet - - O
cells - - O
, - - O
TbetaRI - - O
and - - O
TbetaRII - - O
can - - O
respond - - O
to - - O
autocrine - - O
but - - O
not - - O
exogenous - - O
TGF-beta - - O
without - - O
the - - O
participation - - O
of - - O
TbetaRIII - - O
. - - O

Reverse - - O
transcription-PCR - - O
was - - O
then - - O
used - - O
to - - O
clone - - O
from - - O
human - - O
poly - - O
( - - O
A - - O
) - - O
+ - - O
RNA - - O
the - - O
cDNA - - O
corresponding - - O
to - - O
the - - O
expressed - - O
homolog - - O
of - - O
psi - - O
ARF - - O
4 - - O
, - - O
referred - - O
to - - O
as - - O
human - - O
ARF - - O
4 - - O
. - - O

A - - O
full-length - - O
PRL - - O
receptor - - O
( - - O
PRLR - - O
) - - O
complementary - - O
DNA - - O
from - - O
pigeons - - O
was - - O
obtained - - O
by - - O
screening - - O
pigeon - - O
crop - - O
sac - - O
libraries - - O
and - - O
by - - O
reverse - - O
transcription - - O
coupled - - O
with - - O
polymerase - - O
chain - - O
reaction - - O
. - - O

Individual - - O
mutations - - O
in - - O
motifs - - O
III - - O
, - - O
IV - - O
, - - O
and - - O
V - - O
had - - O
distinctive - - O
effects - - O
on - - O
the - - O
affinity - - O
of - - O
enzyme - - O
for - - O
GTP - - O
, - - O
the - - O
rate - - O
of - - O
covalent - - O
catalysis - - O
( - - O
EpG - - O
formation - - O
) - - O
, - - O
or - - O
the - - O
transfer - - O
of - - O
GMP - - O
from - - O
enzyme - - O
to - - O
RNA - - O
. - - O

Mutagenesis - - O
of - - O
each - - O
NRF-1 - - O
motif - - O
in - - O
the - - O
ALAS - - O
promoter - - O
gave - - O
substantially - - O
lowered - - O
levels - - O
of - - O
chloramphenicol - - O
acetyltransferase - - O
expression - - O
, - - O
whereas - - O
mutagenesis - - O
of - - O
both - - O
NRF-1 - - O
motifs - - O
resulted - - O
in - - O
the - - O
almost - - O
complete - - O
loss - - O
of - - O
expression - - O
. - - O

The - - O
C-terminal - - O
mutants - - O
were - - O
strongly - - O
dominant - - O
over - - O
TraR - - O
, - - O
suggesting - - O
that - - O
they - - O
can - - O
form - - O
heteromultimers - - O
with - - O
the - - O
wild-type - - O
activator - - O
. - - O

The - - O
major - - O
RNase - - O
E - - O
cleavage - - O
product - - O
( - - O
denoted - - O
pSok-6 - - O
) - - O
is - - O
rapidly - - O
degraded - - O
by - - O
polynucleotide - - O
phosphorylase - - O
( - - O
PNPase - - O
) - - O
. - - O

Gel - - O
mobility - - O
shift - - O
assays - - O
using - - O
a - - O
synthetic - - O
E6 - - O
motif - - O
detected - - O
a - - O
B-cell-specific - - O
complex - - O
in - - O
addition - - O
to - - O
a - - O
ubiquitous - - O
band - - O
found - - O
also - - O
in - - O
T - - O
cells - - O
and - - O
HeLa - - O
cells - - O
. - - O

Mutations - - O
in - - O
either - - O
gene - - O
block - - O
some - - O
crucial - - O
late - - O
step - - O
in - - O
assembly - - O
of - - O
F1 - - O
, - - O
causing - - O
the - - O
alpha - - O
and - - O
beta - - O
subunits - - O
to - - O
accumulate - - O
in - - O
mitochondria - - O
as - - O
inactive - - O
aggregates - - O
( - - O
Ackerman - - O
, - - O
S - - O
. - - O

Sp1 - - O
and - - O
two - - O
Sp3 - - O
isoforms - - O
were - - O
detected - - O
as - - O
the - - O
primary - - O
cellular - - O
constituents - - O
of - - O
DNA-protein - - O
complexes - - O
formed - - O
with - - O
the - - O
NF-kappaB-proximal - - O
site - - O
. - - O

Strains - - O
bearing - - O
the - - O
drs2 - - O
mutation - - O
process - - O
the - - O
20S - - O
precursor - - O
of - - O
the - - O
mature - - O
18S - - O
rRNA - - O
slowly - - O
and - - O
are - - O
deficient - - O
in - - O
40S - - O
ribosomal - - O
subunits - - O
. - - O

We - - O
observed - - O
abundant - - O
levels - - O
of - - O
Rev-erbA - - O
alpha - - O
mRNA - - O
in - - O
dividing - - O
C2C12 - - O
myoblasts - - O
, - - O
which - - O
were - - O
suppressed - - O
when - - O
the - - O
cells - - O
differentiated - - O
into - - O
postmitotic - - O
multinucleated - - O
myotubes - - O
. - - O

The - - O
recovery - - O
of - - O
labelled - - O
methoxydextrane - - O
is - - O
98 - - O
+ - - O
- - - O
7% - - O
. - - O

RESULTS - - O
: - - O
The - - O
overall - - O
FNF - - O
for - - O
1992 - - O
was - - O
12 - - O
. - - O
3% - - O
and - - O
was - - O
19 - - O
. - - O
1% - - O
, - - O
22 - - O
. - - O
2% - - O
, - - O
3 - - O
. - - O
8% - - O
and - - O
6 - - O
. - - O
1% - - O
per - - O
successive - - O
quarters - - O
in - - O
1992 - - O
. - - O

In - - O
cerebrospinal - - O
fluid - - O
, - - O
an - - O
ADA - - O
catalytic - - O
concentration - - O
above - - O
0 - - O
. - - O
15 - - O
mu - - O
kat - - O
L - - O
strongly - - O
suggests - - O
tuberculous - - O
meningitis - - O
in - - O
patients - - O
older - - O
than - - O
7 - - O
years - - O
( - - O
sensitivity - - O
1 - - O
. - - O
00 - - O
, - - O
specificity - - O
0 - - O
. - - O
99 - - O
and - - O
efficiency - - O
0 - - O
. - - O
99 - - O
) - - O
. - - O

Along - - O
with - - O
previously - - O
mapped - - O
genes - - O
including - - O
Ly-1 - - O
and - - O
CD20 - - O
, - - O
OSBP - - O
defines - - O
a - - O
new - - O
conserved - - O
syntenic - - O
group - - O
on - - O
the - - O
long - - O
arm - - O
of - - O
chromosome - - O
11 - - O
in - - O
the - - O
human - - O
and - - O
the - - O
proximal - - O
end - - O
of - - O
chromosome - - O
19 - - O
in - - O
the - - O
mouse - - O
. - - O

The - - O
proteins - - O
are - - O
more - - O
than - - O
90% - - O
identical - - O
to - - O
each - - O
other - - O
within - - O
the - - O
protein - - O
kinase - - O
domain - - O
but - - O
only - - O
51-59% - - O
identical - - O
to - - O
other - - O
casein - - O
kinase - - O
I - - O
isoforms - - O
within - - O
this - - O
region - - O
. - - O

The - - O
conserved - - O
ninth - - O
C-terminal - - O
heptad - - O
in - - O
thyroid - - O
hormone - - O
and - - O
retinoic - - O
acid - - O
receptors - - O
mediates - - O
diverse - - O
responses - - O
by - - O
affecting - - O
heterodimer - - O
but - - O
not - - O
homodimer - - O
formation - - O
. - - O

Secondly - - O
, - - O
an - - O
ethanol - - O
repression - - O
autoregulation - - O
( - - O
ERA - - O
) - - O
twelve-fold - - O
TA - - O
repeat - - O
( - - O
TAB - - O
) - - O
repressor - - O
element - - O
was - - O
identified - - O
within - - O
the - - O
promoter - - O
region - - O
of - - O
the - - O
GLK1 - - O
gene - - O
. - - O

With - - O
a - - O
sample - - O
of - - O
mothers - - O
of - - O
healthy - - O
infants - - O
, - - O
all - - O
three - - O
subscales - - O
of - - O
the - - O
revised - - O
instrument - - O
, - - O
WPL-R - - O
, - - O
had - - O
acceptable - - O
levels - - O
of - - O
internal - - O
consistency - - O
at - - O
7 - - O
, - - O
30 - - O
, - - O
and - - O
90 - - O
days - - O
postpartum - - O
, - - O
and - - O
stability - - O
across - - O
administrations - - O
. - - O

These - - O
results - - O
implicate - - O
a - - O
precursor-specific - - O
base-paired - - O
structure - - O
involving - - O
sequences - - O
on - - O
both - - O
sides - - O
of - - O
the - - O
mature - - O
cleavage - - O
site - - O
in - - O
the - - O
3' - - O
processing - - O
of - - O
human - - O
U2 - - O
RNA - - O
. - - O

To - - O
further - - O
understand - - O
the - - O
role - - O
of - - O
cis-acting - - O
elements - - O
in - - O
these - - O
regulatory - - O
mechanisms - - O
, - - O
we - - O
have - - O
characterized - - O
a - - O
transcriptional - - O
promoter - - O
that - - O
drives - - O
germline - - O
expression - - O
of - - O
TCR - - O
beta - - O
gene - - O
segments - - O
in - - O
vivo - - O
. - - O

It - - O
corresponds - - O
to - - O
the - - O
complete - - O
mitochondrial - - O
presequence - - O
and - - O
the - - O
lipoyl-bearing - - O
domain - - O
that - - O
are - - O
encoded - - O
by - - O
exons - - O
I - - O
through - - O
IV - - O
of - - O
the - - O
functional - - O
E2 - - O
gene - - O
. - - O

Viscosity - - O
experiments - - O
on - - O
the - - O
catalytic - - O
fragment - - O
kinase - - O
reaction - - O
demonstrated - - O
that - - O
the - - O
chemical - - O
( - - O
phosphoryl - - O
transfer - - O
) - - O
step - - O
had - - O
a - - O
reduced - - O
rate - - O
. - - O

To - - O
define - - O
the - - O
mechanism - - O
responsible - - O
for - - O
the - - O
loss - - O
of - - O
transcription - - O
elongation - - O
blockage - - O
and - - O
resulting - - O
c-myc - - O
deregulation - - O
in - - O
Burkitt's - - O
lymphoma - - O
, - - O
we - - O
analyzed - - O
transcription - - O
patterns - - O
after - - O
transfer - - O
of - - O
normal - - O
and - - O
Burkitt's - - O
lymphoma - - O
c-myc - - O
alleles - - O
into - - O
murine - - O
cells - - O
and - - O
Xenopus - - O
oocyte - - O
germinal - - O
vesicles - - O
. - - O

Mutation - - O
analyses - - O
identified - - O
the - - O
cobalt-responsive - - O
sequences - - O
as - - O
the - - O
stress-response - - O
elements - - O
( - - O
StREs - - O
) - - O
. - - O

Space - - O
limitations - - O
prevent - - O
an - - O
exhaustive - - O
review - - O
of - - O
all - - O
biologic - - O
pharmaceuticals - - O
, - - O
such - - O
as - - O
tissue - - O
plasminogen - - O
activating - - O
substance - - O
, - - O
hormones - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
thyroid - - O
, - - O
insulin - - O
, - - O
growth - - O
hormone - - O
, - - O
erythropoietin - - O
) - - O
, - - O
clotting - - O
factors - - O
, - - O
and - - O
blood - - O
products - - O
. - - O

Molecular - - O
characterization - - O
of - - O
type-specific - - O
capsular - - O
polysaccharide - - O
biosynthesis - - O
genes - - O
of - - O
Streptococcus - - O
agalactiae - - O
type - - O
Ia - - O
. - - O

The - - O
model - - O
also - - O
predicts - - O
that - - O
blood - - O
flow - - O
shunt - - O
fraction - - O
( - - O
Qs - - O
QT - - O
) - - O
is - - O
directly - - O
related - - O
to - - O
the - - O
oxygen - - O
sine-wave - - O
amplitude - - O
perturbations - - O
transmitted - - O
to - - O
end-expired - - O
air - - O
and - - O
arterial - - O
and - - O
mixed-venous - - O
blood - - O
through - - O
two - - O
simple - - O
equations - - O
. - - O

Filter - - O
and - - O
cytocentrifuge - - O
preparations - - O
of - - O
the - - O
urine - - O
were - - O
studied - - O
and - - O
all - - O
cases - - O
displayed - - O
numerous - - O
scattered - - O
aggregates - - O
or - - O
single - - O
tumor - - O
cells - - O
in - - O
an - - O
inflammatory - - O
background - - O
. - - O

Mean - - O
longitudinal - - O
extension - - O
of - - O
the - - O
epidural - - O
lesion - - O
was - - O
2 - - O
. - - O
6 - - O
vertebral - - O
segments - - O
. - - O

The - - O
effects - - O
of - - O
these - - O
mutations - - O
on - - O
RNA - - O
polymerase - - O
II - - O
activity - - O
were - - O
assayed - - O
by - - O
measuring - - O
the - - O
ability - - O
of - - O
mutant - - O
genes - - O
to - - O
confer - - O
alpha-amanitin - - O
resistance - - O
after - - O
transfection - - O
of - - O
susceptible - - O
rodent - - O
cells - - O
. - - O

Cis-acting - - O
CCAAT - - O
elements - - O
are - - O
frequently - - O
found - - O
in - - O
eukaryotic - - O
promoter - - O
regions - - O
. - - O

Expression - - O
of - - O
Bcl-XL - - O
inhibited - - O
the - - O
association - - O
of - - O
Apaf-1 - - O
with - - O
caspase-9 - - O
in - - O
mammalian - - O
cells - - O
. - - O

SF-1 - - O
does - - O
not - - O
have - - O
an - - O
N-terminal - - O
AF1 - - O
domain - - O
. - - O

Basing - - O
on - - O
experimental - - O
toxicity - - O
research - - O
it - - O
was - - O
established - - O
that - - O
, - - O
out - - O
of - - O
50 - - O
atmosphere - - O
metal - - O
corrosion - - O
inhibitors - - O
, - - O
some - - O
14 - - O
per - - O
cent - - O
were - - O
found - - O
extremely - - O
hazardous - - O
, - - O
42 - - O
per - - O
cent--of - - O
high - - O
level - - O
hazardous - - O
, - - O
33 - - O
percent--of - - O
moderate - - O
and - - O
11 - - O
per - - O
cent--of - - O
low - - O
hazardous - - O
. - - O

Paralemmin - - O
is - - O
also - - O
phosphorylated - - O
, - - O
and - - O
its - - O
mRNA - - O
is - - O
differentially - - O
spliced - - O
in - - O
a - - O
tissue-specific - - O
and - - O
developmentally - - O
regulated - - O
manner - - O
. - - O

Azygos - - O
vein - - O
abutting - - O
the - - O
posterior - - O
wall - - O
of - - O
the - - O
right - - O
main - - O
and - - O
upper - - O
lobe - - O
bronchi - - O
: - - O
a - - O
normal - - O
CT - - O
variant - - O
. - - O

We - - O
also - - O
report - - O
that - - O
AHR - - O
interacts - - O
with - - O
COUP-TF - - O
in - - O
transfected - - O
CV-1 - - O
cells - - O
. - - O

Acute - - O
pancreatitis - - O
as - - O
a - - O
complication - - O
of - - O
polyarteritis - - O
nodosa - - O
. - - O

Cluster - - O
formation - - O
of - - O
E-cadherin - - O
on - - O
the - - O
cell - - O
surface - - O
is - - O
believed - - O
to - - O
be - - O
of - - O
major - - O
importance - - O
for - - O
cell-cell - - O
adhesion - - O
. - - O

DPA - - O
attenuated - - O
the - - O
increase - - O
of - - O
the - - O
intensity - - O
of - - O
the - - O
ischemic - - O
and - - O
pressure - - O
pain - - O
components - - O
with - - O
increasing - - O
ischemia - - O
duration - - O
, - - O
but - - O
only - - O
the - - O
effect - - O
on - - O
the - - O
pressure - - O
pain - - O
component - - O
was - - O
significant - - O
. - - O

Following - - O
seven - - O
days' - - O
incubation - - O
both - - O
at - - O
20 - - O
degrees - - O
C - - O
and - - O
28 - - O
degrees - - O
C - - O
, - - O
Ae - - O
. - - O
vexans - - O
nip - - O
. - - O
was - - O
capable - - O
of - - O
transmitting - - O
the - - O
virus - - O
. - - O

Interplane - - O
coupling - - O
in - - O
the - - O
superconductor - - O
Y2Ba4Cu7O15 - - O
as - - O
revealed - - O
by - - O
NQR - - O
spin-echo - - O
double - - O
resonance - - O
. - - O

The - - O
evidence - - O
in - - O
support - - O
of - - O
this - - O
was - - O
derived - - O
from - - O
the - - O
fact - - O
that - - O
the - - O
affinity - - O
or - - O
interaction - - O
between - - O
the - - O
two - - O
subunits - - O
was - - O
impaired - - O
as - - O
indicated - - O
by - - O
the - - O
first - - O
order - - O
rate - - O
constant - - O
of - - O
hCG - - O
alpha - - O
1 - - O
beta - - O
( - - O
km - - O
= - - O
4 - - O
. - - O
1 - - O
x - - O
10 - - O
( - - O
-2 - - O
) - - O
min-1 - - O
) - - O
at - - O
pH - - O
3 - - O
. - - O
0 - - O
at - - O
23 - - O
degrees - - O
C - - O
which - - O
is - - O
one - - O
order - - O
of - - O
magnitude - - O
greater - - O
relative - - O
to - - O
rehCG - - O
( - - O
kw - - O
= - - O
4 - - O
. - - O
6 - - O
x - - O
10 - - O
( - - O
-3 - - O
) - - O
min-1 - - O
) - - O
. - - O

Correlation - - O
coefficients - - O
between - - O
the - - O
reference - - O
methods - - O
and - - O
NIT - - O
were - - O
> - - O
or - - O
= - - O
0 - - O
. - - O
95 - - O
for - - O
water - - O
, - - O
fat - - O
, - - O
crude - - O
protein - - O
and - - O
connective-tissue-protein - - O
frei - - O
meat - - O
protein - - O
, - - O
and - - O
> - - O
or - - O
= - - O
0 - - O
. - - O
86 - - O
for - - O
connective-tissue-protein - - O
. - - O

Further - - O
analysis - - O
of - - O
AP-1 - - O
DNA - - O
binding - - O
activities - - O
in - - O
7- - - O
to - - O
14-day - - O
culture - - O
activated - - O
HSCs - - O
led - - O
to - - O
the - - O
discovery - - O
of - - O
high - - O
mobility - - O
AP-1 - - O
complexes - - O
( - - O
HMAP-1 - - O
) - - O
. - - O

Sci - - O
. - - O

A - - O
miracle - - O
cure - - O
and - - O
its - - O
solution - - O
. - - O

The - - O
human - - O
SHBG - - O
proximal - - O
promoter - - O
was - - O
analyzed - - O
by - - O
DNase - - O
I - - O
footprinting - - O
, - - O
and - - O
the - - O
functional - - O
significance - - O
of - - O
6 - - O
footprinted - - O
regions - - O
( - - O
FP1-FP6 - - O
) - - O
within - - O
the - - O
proximal - - O
promoter - - O
was - - O
studied - - O
in - - O
human - - O
HepG2 - - O
hepatoblastoma - - O
cells - - O
. - - O

Two - - O
activities - - O
of - - O
the - - O
D - - O
protein - - O
of - - O
the - - O
miniF - - O
plasmid - - O
have - - O
been - - O
found - - O
. - - O

No - - O
patient - - O
in - - O
group - - O
2 - - O
developed - - O
HAT - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
006 - - O
versus - - O
group - - O
1 - - O
) - - O
. - - O

After - - O
nitric - - O
oxide - - O
inhalation - - O
, - - O
the - - O
results - - O
showed - - O
moderate - - O
increases - - O
in - - O
PaO2 - - O
and - - O
SaO2 - - O
( - - O
P - - O
> - - O
0 - - O
. - - O
05 - - O
) - - O
and - - O
a - - O
significant - - O
decrease - - O
in - - O
Qs - - O
Q - - O
tau - - O
ratio - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

The - - O
mass - - O
of - - O
UO2 - - O
in - - O
the - - O
extrapulmonary - - O
bronchi - - O
and - - O
first - - O
bifurcation - - O
decreased - - O
more - - O
slowly - - O
over - - O
0--8 - - O
d - - O
after - - O
inhalation - - O
than - - O
the - - O
corresponding - - O
mass - - O
on - - O
the - - O
trachea - - O
. - - O

This - - O
region - - O
is - - O
required - - O
for - - O
activation - - O
of - - O
DNA - - O
binding - - O
of - - O
MyoD - - O
and - - O
E12 - - O
homodimers - - O
and - - O
E12 - - O
MyoD - - O
heterodimers - - O
. - - O

In - - O
this - - O
paper - - O
, - - O
we - - O
report - - O
a - - O
detailed - - O
study - - O
of - - O
the - - O
structure - - O
and - - O
the - - O
functional - - O
role - - O
of - - O
the - - O
MalT - - O
binding - - O
sites - - O
located - - O
in - - O
the - - O
adjacent - - O
and - - O
divergent - - O
pulAp - - O
and - - O
pulCp - - O
promoters - - O
. - - O

Thus - - O
, - - O
the - - O
presence - - O
of - - O
the - - O
Cln2 - - O
PEST - - O
domain - - O
was - - O
sufficient - - O
to - - O
destabilize - - O
a - - O
heterologous - - O
protein - - O
. - - O

Interestingly - - O
, - - O
EGF - - O
, - - O
but - - O
not - - O
insulin - - O
, - - O
stimulated - - O
tyrosine - - O
phosphorylation - - O
of - - O
c-cbl - - O
and - - O
its - - O
association - - O
with - - O
Crk-II - - O
. - - O

Interferon-alpha - - O
may - - O
exacerbate - - O
cryoblobulinemia-related - - O
ischemic - - O
manifestations - - O
: - - O
an - - O
adverse - - O
effect - - O
potentially - - O
related - - O
to - - O
its - - O
anti-angiogenic - - O
activity - - O
. - - O

Two - - O
such - - O
genes - - O
, - - O
designated - - O
hsiggll150 - - O
and - - O
hsiggll295 - - O
, - - O
were - - O
cloned - - O
and - - O
sequenced - - O
from - - O
genomic - - O
DNA - - O
. - - O

Cyclin - - O
D1 - - O
could - - O
not - - O
be - - O
displaced - - O
from - - O
cdk4 - - O
in - - O
the - - O
resistant - - O
184A1L5R - - O
cell - - O
lysates - - O
. - - O

These - - O
characteristics - - O
indicated - - O
the - - O
pronounced - - O
activity - - O
of - - O
collagenous - - O
fiber - - O
synthesis - - O
and - - O
the - - O
matrix - - O
of - - O
the - - O
osteoid - - O
tissue - - O
. - - O

RESULTS - - O
: - - O
Patients - - O
in - - O
Group - - O
A - - O
had - - O
a - - O
higher - - O
incidence - - O
of - - O
posterolateral - - O
wall - - O
motion - - O
abnormalities - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
on - - O
radionuclide - - O
ventriculography - - O
, - - O
a - - O
larger - - O
infarct - - O
area - - O
( - - O
as - - O
evidenced - - O
by - - O
higher - - O
peak - - O
creatine - - O
kinase - - O
levels - - O
) - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
02 - - O
) - - O
and - - O
a - - O
lower - - O
left - - O
ventricular - - O
ejection - - O
fraction - - O
( - - O
LVEF - - O
) - - O
at - - O
hospital - - O
discharge - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
008 - - O
) - - O
than - - O
those - - O
in - - O
Group - - O
B - - O
. - - O

The - - O
incompatibility - - O
group - - O
W - - O
plasmid - - O
pSa - - O
suppresses - - O
Agrobacterium - - O
tumefaciens - - O
oncogenicity - - O
( - - O
J - - O
. - - O

In - - O
this - - O
report - - O
, - - O
we - - O
identify - - O
and - - O
characterize - - O
two - - O
overlapping - - O
ELL - - O
functional - - O
domains - - O
that - - O
govern - - O
its - - O
interaction - - O
with - - O
RNA - - O
polymerase - - O
II - - O
and - - O
the - - O
ternary - - O
elongation - - O
complex - - O
. - - O

The - - O
Spo0F - - O
residues - - O
making - - O
up - - O
the - - O
hydrophobic - - O
patch - - O
are - - O
very - - O
similar - - O
in - - O
all - - O
response - - O
regulators - - O
suggesting - - O
that - - O
the - - O
binding - - O
is - - O
initiated - - O
through - - O
the - - O
same - - O
residues - - O
in - - O
all - - O
interacting - - O
response - - O
regulator-kinase - - O
pairs - - O
. - - O

We - - O
performed - - O
dipole - - O
estimation - - O
of - - O
spikes - - O
and - - O
SEP - - O
components - - O
in - - O
identical - - O
patients - - O
. - - O

The - - O
so-called - - O
"SH3" - - O
segment - - O
of - - O
the - - O
linker - - O
domain - - O
, - - O
in - - O
contrast - - O
, - - O
shows - - O
species-specific - - O
sequence - - O
identity - - O
in - - O
all - - O
but - - O
one - - O
amino - - O
acid - - O
residues - - O
in - - O
both - - O
factors - - O
, - - O
in - - O
cattle - - O
, - - O
human - - O
, - - O
and - - O
mouse - - O
. - - O

Early - - O
indicators - - O
of - - O
the - - O
effect - - O
of - - O
a - - O
breast - - O
cancer - - O
screening - - O
program - - O
for - - O
low-income - - O
women - - O
. - - O

There - - O
was - - O
no - - O
significant - - O
difference - - O
in - - O
developmental - - O
scores - - O
at - - O
9 - - O
or - - O
18 - - O
months - - O
, - - O
although - - O
PDF - - O
infants - - O
had - - O
a - - O
2 - - O
. - - O
8 - - O
( - - O
-1 - - O
. - - O
3-6 - - O
. - - O
8 - - O
) - - O
point - - O
advantage - - O
in - - O
Bayley - - O
motor - - O
score - - O
scales - - O
. - - O

Analysis - - O
of - - O
its - - O
genomic - - O
region - - O
revealed - - O
that - - O
the - - O
13-kb - - O
Cdc6 - - O
gene - - O
is - - O
divided - - O
into - - O
12 - - O
exons - - O
by - - O
11 - - O
introns - - O
. - - O

These - - O
incisors - - O
were - - O
studied - - O
by - - O
scanning - - O
electron - - O
microscopy-energy - - O
dispersive - - O
spectroscopy - - O
analysis - - O
( - - O
SEM-EDS - - O
) - - O
and - - O
light - - O
microscopy - - O
to - - O
examine - - O
the - - O
calciotraumatic - - O
lines - - O
of - - O
strontium - - O
in - - O
the - - O
rat - - O
incisor - - O
labial - - O
dentin - - O
. - - O

Private - - O
hospital - - O
accreditation - - O
. - - O

One - - O
of - - O
these - - O
is - - O
located - - O
in - - O
the - - O
5'-untranslated - - O
region - - O
, - - O
and - - O
may - - O
encode - - O
regulatory - - O
sequences - - O
. - - O

Glomerular - - O
mesangial - - O
cells - - O
expressed - - O
an - - O
abundant - - O
1 - - O
. - - O
1 - - O
kb - - O
mRNA - - O
transcript - - O
for - - O
Id1 - - O
, - - O
but - - O
in - - O
contrast - - O
to - - O
other - - O
cell - - O
types - - O
Id1 - - O
mRNA - - O
was - - O
expressed - - O
in - - O
both - - O
randomly - - O
cycling - - O
cells - - O
and - - O
in - - O
serum-deprived - - O
, - - O
quiescent - - O
cultures - - O
. - - O

CNS - - O
effects - - O
of - - O
local - - O
anesthetics - - O
only - - O
partially - - O
dependent - - O
on - - O
biogenic - - O
amine - - O
mechanisms - - O
. - - O

By - - O
Felix - - O
Lagrange - - O
, - - O
1918 - - O
. - - O

Transcriptional - - O
activity - - O
was - - O
measured - - O
by - - O
slot-blot - - O
hybridization - - O
with - - O
steady-state - - O
RNA - - O
isolated - - O
from - - O
lacZ+ - - O
M - - O
. - - O
smegmatis - - O
clones - - O
. - - O

CONCLUSION - - O
: - - O
The - - O
MTD - - O
for - - O
CPT-11 - - O
administered - - O
in - - O
a - - O
3 - - O
consecutive-days-every-3 - - O
weeks - - O
schedule - - O
in - - O
this - - O
patient - - O
population - - O
is - - O
115 - - O
mg - - O
m2 - - O
day - - O
. - - O

4 - - O
. - - O

ICP4 - - O
has - - O
been - - O
shown - - O
to - - O
form - - O
tripartite - - O
complexes - - O
cooperatively - - O
with - - O
the - - O
TATA - - O
box-binding - - O
protein - - O
and - - O
TFIIB - - O
on - - O
DNA - - O
containing - - O
an - - O
ICP4 - - O
binding - - O
site - - O
and - - O
a - - O
TATA - - O
box - - O
( - - O
C - - O
. - - O

However - - O
, - - O
a - - O
specific - - O
ICE - - O
caspase-1 - - O
inhibitor - - O
called - - O
N1445 - - O
completely - - O
abolished - - O
the - - O
CK-induced - - O
apoptosis - - O
by - - O
reactivating - - O
PKB - - O
, - - O
but - - O
without - - O
affecting - - O
the - - O
CK-induced - - O
suppression - - O
of - - O
Ras - - O
transformation - - O
. - - O

OBJECTIVE - - O
: - - O
Our - - O
purpose - - O
was - - O
to - - O
determine - - O
the - - O
simultaneous - - O
concentrations - - O
of - - O
serum - - O
cotinine - - O
in - - O
both - - O
fetal - - O
and - - O
maternal - - O
blood - - O
. - - O

Records - - O
of - - O
31 - - O
children - - O
with - - O
AIDS - - O
or - - O
AIDS-related - - O
complex - - O
admitted - - O
to - - O
the - - O
pediatric - - O
intensive - - O
care - - O
unit - - O
for - - O
acute - - O
respiratory - - O
failure - - O
throughout - - O
a - - O
46-month - - O
period - - O
were - - O
reviewed - - O
. - - O

The - - O
artery - - O
cuff - - O
was - - O
slightly - - O
superior - - O
to - - O
the - - O
fat - - O
wrap - - O
, - - O
particularly - - O
in - - O
having - - O
fewer - - O
adhesions - - O
and - - O
a - - O
better - - O
histological - - O
picture - - O
. - - O

Liquid - - O
chromatographic - - O
separation - - O
was - - O
achieved - - O
on - - O
a - - O
Zorbax - - O
RX - - O
C8 - - O
analytical - - O
column - - O
using - - O
gradient - - O
elution - - O
. - - O

Estrogen - - O
treatment - - O
in - - O
high - - O
doses - - O
is - - O
effective - - O
in - - O
reducing - - O
adult - - O
stature - - O
in - - O
constitutionally - - O
tall - - O
girls - - O
. - - O

A - - O
cDNA - - O
clone - - O
corresponding - - O
to - - O
the - - O
putative - - O
GA - - O
20-oxidase - - O
genomic - - O
sequence - - O
was - - O
constructed - - O
with - - O
the - - O
reverse - - O
transcription-PCR - - O
method - - O
, - - O
and - - O
the - - O
identity - - O
of - - O
the - - O
cDNA - - O
clone - - O
was - - O
confirmed - - O
by - - O
analyzing - - O
the - - O
capability - - O
of - - O
the - - O
fusion - - O
protein - - O
expressed - - O
in - - O
Escherichia - - O
coli - - O
to - - O
convert - - O
GA53 - - O
to - - O
GA44 - - O
and - - O
GA19 - - O
to - - O
GA20 - - O
. - - O

The - - O
incidence - - O
of - - O
DNCB - - O
reactions - - O
was - - O
78 - - O
per - - O
cent - - O
for - - O
Stage - - O
I - - O
and - - O
II - - O
cancers - - O
( - - O
37 - - O
patinets - - O
) - - O
, - - O
73 - - O
per - - O
cent - - O
for - - O
resectable - - O
Stage - - O
III - - O
cancer - - O
( - - O
22 - - O
patients - - O
) - - O
, - - O
and - - O
66 - - O
per - - O
cent - - O
in - - O
patients - - O
with - - O
unresectable - - O
or - - O
inoperable - - O
Stage - - O
III - - O
cancer - - O
. - - O

An - - O
analysis - - O
of - - O
the - - O
dynamics - - O
is - - O
performed - - O
of - - O
exactly - - O
solvable - - O
models - - O
for - - O
fragile - - O
and - - O
strong - - O
glasses - - O
, - - O
exploiting - - O
the - - O
partitioning - - O
of - - O
the - - O
free-energy - - O
landscape - - O
in - - O
inherent - - O
structures - - O
. - - O

Moreover - - O
, - - O
elderly - - O
men - - O
with - - O
bioavailable - - O
estradiol - - O
levels - - O
below - - O
the - - O
median - - O
[ - - O
40 - - O
pmol - - O
liter - - O
( - - O
11 - - O
pg - - O
ml - - O
) - - O
] - - O
had - - O
significantly - - O
higher - - O
rates - - O
of - - O
bone - - O
loss - - O
and - - O
levels - - O
of - - O
bone - - O
resorption - - O
markers - - O
than - - O
men - - O
with - - O
bioavailable - - O
estradiol - - O
levels - - O
above - - O
40 - - O
pmol - - O
liter - - O
. - - O

We - - O
also - - O
report - - O
here - - O
the - - O
complete - - O
structural - - O
organization - - O
of - - O
the - - O
goat - - O
alpha - - O
s1-casein - - O
transcription - - O
unit - - O
, - - O
deduced - - O
from - - O
polymerase - - O
chain - - O
reaction - - O
experiments - - O
. - - O

Replacing - - O
residues - - O
405-419 - - O
on - - O
delta419 - - O
with - - O
the - - O
conserved - - O
AF-2 - - O
domain - - O
from - - O
the - - O
vitamin - - O
D3 - - O
receptor - - O
or - - O
the - - O
estrogen - - O
receptor - - O
results - - O
in - - O
a - - O
receptor - - O
with - - O
wild-type - - O
or - - O
low - - O
transcriptional - - O
activity - - O
, - - O
respectively - - O
. - - O

Psychological - - O
disturbance - - O
was - - O
greater - - O
in - - O
the - - O
high - - O
life - - O
stress - - O
group - - O
as - - O
indicated - - O
by - - O
significant - - O
elevations - - O
on - - O
the - - O
global - - O
severity - - O
index - - O
of - - O
the - - O
Symptom - - O
Checklist-90 - - O
and - - O
elevations - - O
on - - O
somatization - - O
, - - O
obsessive - - O
compulsive - - O
, - - O
interpersonal - - O
sensitivity - - O
, - - O
depression - - O
, - - O
anxiety - - O
and - - O
psychoticism - - O
subscales - - O
. - - O

Since - - O
electrical - - O
stimulation - - O
of - - O
neurones - - O
may - - O
activate - - O
not - - O
only - - O
cell - - O
bodies - - O
but - - O
also - - O
neuronal - - O
fibres - - O
, - - O
this - - O
study - - O
aimed - - O
to - - O
test - - O
a - - O
selectively - - O
cholinergic - - O
neurochemical - - O
stimulation - - O
of - - O
the - - O
rat - - O
substantia - - O
innominata - - O
( - - O
SI - - O
) - - O
by - - O
the - - O
local - - O
microinjection - - O
of - - O
carbachol - - O
; - - O
the - - O
effects - - O
of - - O
this - - O
acetylcholine - - O
agonist - - O
were - - O
compared - - O
with - - O
glutamate - - O
. - - O

Eucaryotic - - O
transcription - - O
factors - - O
that - - O
stimulate - - O
RNA - - O
polymerase - - O
II - - O
by - - O
increasing - - O
the - - O
efficiency - - O
of - - O
elongation - - O
of - - O
specifically - - O
or - - O
randomly - - O
initiated - - O
RNA - - O
chains - - O
have - - O
been - - O
isolated - - O
and - - O
characterized - - O
. - - O

The - - O
mRNAs - - O
of - - O
these - - O
genes - - O
contain - - O
respectively - - O
one - - O
( - - O
YAP1 - - O
uORF - - O
) - - O
and - - O
two - - O
( - - O
YAP2 - - O
uORF1 - - O
and - - O
uORF2 - - O
) - - O
upstream - - O
open - - O
reading - - O
frames - - O
. - - O
uORF-mediated - - O
modulation - - O
of - - O
post-termination - - O
events - - O
on - - O
the - - O
5'-untranslated - - O
region - - O
( - - O
5'-UTR - - O
) - - O
directs - - O
differential - - O
control - - O
not - - O
only - - O
of - - O
translation - - O
but - - O
also - - O
of - - O
mRNA - - O
decay - - O
. - - O

We - - O
used - - O
a - - O
rev- - - O
and - - O
RRE-defective - - O
HIV - - O
type - - O
1 - - O
( - - O
HIV-1 - - O
) - - O
molecular - - O
clone - - O
in - - O
complementation - - O
experiments - - O
to - - O
establish - - O
a - - O
method - - O
for - - O
the - - O
rapid - - O
isolation - - O
of - - O
posttranscriptional - - O
regulatory - - O
elements - - O
from - - O
the - - O
mammalian - - O
genome - - O
by - - O
selecting - - O
for - - O
rescue - - O
of - - O
virus - - O
replication - - O
. - - O

Evolutionary - - O
conservation - - O
of - - O
homeodomain-binding - - O
sites - - O
and - - O
other - - O
sequences - - O
upstream - - O
and - - O
within - - O
the - - O
major - - O
transcription - - O
unit - - O
of - - O
the - - O
Drosophila - - O
segmentation - - O
gene - - O
engrailed - - O
. - - O

Furthermore - - O
, - - O
the - - O
NH2-terminal - - O
portion - - O
of - - O
the - - O
homologue - - O
was - - O
not - - O
translocated - - O
into - - O
the - - O
outer - - O
membrane - - O
without - - O
its - - O
COOH-terminal - - O
part - - O
. - - O

The - - O
5' - - O
flanking - - O
regions - - O
of - - O
both - - O
pelA - - O
and - - O
pelB - - O
were - - O
translationally - - O
fused - - O
to - - O
the - - O
beta-glucuronidase - - O
gene - - O
and - - O
introduced - - O
into - - O
F - - O
. - - O
solani - - O
f - - O
. - - O
sp - - O
. - - O
pisi - - O
, - - O
and - - O
beta-glucuronidase - - O
activities - - O
of - - O
the - - O
transformants - - O
were - - O
measured - - O
. - - O

The - - O
results - - O
suggest - - O
that - - O
GATA-5 - - O
may - - O
have - - O
specific - - O
downstream - - O
targets - - O
and - - O
that - - O
GATA-4 - - O
, - - O
-5 - - O
, - - O
and - - O
-6 - - O
can - - O
only - - O
partially - - O
substitute - - O
for - - O
each - - O
other - - O
in - - O
cardiogenesis - - O
. - - O

A - - O
human - - O
recombinant - - O
cDNA - - O
clone - - O
that - - O
encoded - - O
253 - - O
amino - - O
acids - - O
residues - - O
of - - O
a - - O
zinc-finger - - O
protein - - O
( - - O
THZif-1 - - O
) - - O
was - - O
cloned - - O
by - - O
screening - - O
a - - O
cDNA - - O
library - - O
prepared - - O
from - - O
human - - O
promyelocytic - - O
leukemia - - O
HL60 - - O
cells - - O
with - - O
synthetic - - O
oligodeoxynucleotide - - O
probes - - O
that - - O
corresponded - - O
to - - O
the - - O
amino - - O
acid - - O
sequences - - O
of - - O
tryptic - - O
peptides - - O
derived - - O
from - - O
the - - O
DNA-binding - - O
protein - - O
specific - - O
for - - O
the - - O
nuclease-hypersensitive - - O
element - - O
( - - O
NHE - - O
) - - O
of - - O
the - - O
human - - O
c-myc - - O
gene - - O
. - - O

Human - - O
papillomavirus - - O
type - - O
31b - - O
late - - O
gene - - O
expression - - O
is - - O
regulated - - O
through - - O
protein - - O
kinase - - O
C-mediated - - O
changes - - O
in - - O
RNA - - O
processing - - O
. - - O

Amino - - O
acid - - O
residues - - O
of - - O
beta - - O
1' - - O
, - - O
alpha - - O
A' - - O
, - - O
alpha - - O
B' - - O
, - - O
and - - O
the - - O
loop - - O
containing - - O
His539 - - O
of - - O
the - - O
RNase - - O
H - - O
domain - - O
interact - - O
with - - O
the - - O
primer - - O
strand - - O
of - - O
the - - O
dsDNA - - O
. - - O

Regulated - - O
activity - - O
of - - O
the - - O
distal - - O
promoter-like - - O
element - - O
of - - O
the - - O
human - - O
corticotropin-releasing - - O
hormone - - O
gene - - O
and - - O
secondary - - O
structural - - O
features - - O
of - - O
its - - O
corresponding - - O
transcripts - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
further - - O
investigated - - O
the - - O
regulation - - O
of - - O
the - - O
synthesis - - O
of - - O
the - - O
c-mos - - O
oncogene - - O
product - - O
, - - O
which - - O
is - - O
necessary - - O
for - - O
the - - O
activation - - O
of - - O
Cdc2 - - O
. - - O

The - - O
60A - - O
transcripts - - O
and - - O
protein - - O
are - - O
first - - O
detected - - O
at - - O
the - - O
onset - - O
of - - O
gastrulation - - O
, - - O
primarily - - O
in - - O
the - - O
mesoderm - - O
of - - O
the - - O
extending - - O
germ - - O
band - - O
. - - O

An - - O
11-month-old - - O
girl - - O
suffering - - O
from - - O
Dandy-Walker - - O
malformation - - O
( - - O
DWM - - O
) - - O
associated - - O
with - - O
tetralogy - - O
of - - O
Fallot - - O
( - - O
TOF - - O
) - - O
is - - O
presented - - O
. - - O

Determination - - O
of - - O
transaminases - - O
with - - O
an - - O
autoanalyzer - - O
. - - O

The - - O
proteins - - O
encoded - - O
downstream - - O
of - - O
rpoN - - O
are - - O
known - - O
to - - O
negatively - - O
regulate - - O
sigma - - O
54 - - O
activity - - O
. - - O

Sings - - O
which - - O
are - - O
indicative - - O
of - - O
metaplastic - - O
erythropoiesis - - O
are - - O
absent - - O
. - - O

The - - O
genomic - - O
and - - O
transcriptional - - O
complexity - - O
of - - O
the - - O
Crry - - O
and - - O
Crry-ps - - O
genes - - O
. - - O

The - - O
apparatus - - O
consists - - O
of - - O
an - - O
Am-241 - - O
exciting - - O
source - - O
( - - O
300 - - O
mCi - - O
) - - O
and - - O
pure - - O
Ge - - O
detector - - O
( - - O
50 - - O
mm2 - - O
X - - O
5 - - O
mm - - O
) - - O
for - - O
measuring - - O
K - - O
alpha - - O
fluorescent - - O
x-rays - - O
( - - O
28 - - O
. - - O
3 - - O
and - - O
28 - - O
. - - O
6 - - O
KeV - - O
) - - O
emitted - - O
from - - O
exited - - O
iodine - - O
. - - O

The - - O
potentially - - O
SLE-inducing - - O
drugs - - O
are - - O
reviewed - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
sought - - O
to - - O
identify - - O
mechanisms - - O
that - - O
could - - O
account - - O
for - - O
the - - O
antimitogenic - - O
effects - - O
of - - O
IL-4 - - O
. - - O

12 - - O
: - - O
2684-2697 - - O
, - - O
1998 - - O
) - - O
: - - O
a - - O
key - - O
step - - O
of - - O
this - - O
model - - O
is - - O
the - - O
activation - - O
of - - O
the - - O
MAPK - - O
Fus3p - - O
through - - O
the - - O
G - - O
( - - O
betagamma - - O
) - - O
-dependent - - O
relocalization - - O
of - - O
the - - O
Ste5p-MAPK - - O
cascade - - O
to - - O
the - - O
plasma - - O
membrane - - O
. - - O

Subsequent - - O
cloning - - O
and - - O
nucleotide - - O
sequence - - O
analysis - - O
of - - O
the - - O
S - - O
. - - O
pombe - - O
adenylate - - O
kinase - - O
gene - - O
, - - O
adk1 - - O
, - - O
revealed - - O
a - - O
coding - - O
region - - O
of - - O
660 - - O
nucleotides - - O
. - - O

Three - - O
subgenomes - - O
also - - O
comprised - - O
15 - - O
to - - O
75 - - O
nucleotides - - O
derived - - O
from - - O
the - - O
5' - - O
part - - O
of - - O
the - - O
NS2 - - O
gene - - O
. - - O

The - - O
present - - O
investigation - - O
sought - - O
to - - O
identify - - O
the - - O
principal - - O
dimensions - - O
of - - O
the - - O
Framingham - - O
Type - - O
A - - O
scale - - O
( - - O
FTAS - - O
) - - O
and - - O
then - - O
to - - O
examine - - O
their - - O
physiological - - O
and - - O
psychological - - O
correlates - - O
. - - O

SCL - - O
prolonged - - O
promptly - - O
after - - O
verapamil - - O
, - - O
and - - O
sinus - - O
arrest - - O
developed - - O
in - - O
two - - O
of - - O
10 - - O
group - - O
2 - - O
and - - O
two - - O
of - - O
five - - O
group - - O
3 - - O
animals - - O
. - - O

The - - O
CRE - - O
, - - O
5'-TGACGTCA-3' - - O
, - - O
has - - O
been - - O
described - - O
as - - O
the - - O
consensus - - O
sequence - - O
for - - O
the - - O
cis-element - - O
that - - O
directs - - O
cAMP-regulated - - O
gene - - O
expression - - O
. - - O

Enhanced - - O
hepatic - - O
portal - - O
blood - - O
flow - - O
induced - - O
by - - O
prostaglandin - - O
E1 - - O
following - - O
liver - - O
transplantation - - O
in - - O
pigs - - O
. - - O

The - - O
promoter - - O
of - - O
the - - O
rat - - O
PGS-2 - - O
gene - - O
contains - - O
a - - O
CAAT - - O
enhancer-binding - - O
protein - - O
consensus - - O
site - - O
( - - O
CAAT - - O
box - - O
) - - O
which - - O
can - - O
confer - - O
hormone - - O
inducibility - - O
to - - O
a - - O
PGS-2 - - O
. - - O
CAT - - O
reporter - - O
gene - - O
, - - O
as - - O
well - - O
as - - O
a - - O
putative - - O
E-box - - O
region - - O
. - - O

A - - O
3-week - - O
regimen - - O
of - - O
erythropoietin - - O
may - - O
help - - O
prevent - - O
the - - O
donor's - - O
need - - O
to - - O
receive - - O
allogeneic - - O
blood - - O
transfusion - - O
, - - O
when - - O
the - - O
initial - - O
Hb - - O
levels - - O
were - - O
below - - O
130 - - O
milligrams - - O
. - - O

Nutritional - - O
cataracts - - O
in - - O
timber - - O
wolves - - O
. - - O

Nine - - O
strains - - O
were - - O
subtyped - - O
as - - O
Camp - - O
. - - O
jejuni - - O
subsp - - O
. - - O
jejuni - - O
biotype - - O
II - - O
and - - O
the - - O
remaining - - O
ones - - O
as - - O
biotype - - O
I - - O
. - - O

Molecular - - O
and - - O
functional - - O
characterization - - O
of - - O
the - - O
promoter - - O
of - - O
ETS2 - - O
, - - O
the - - O
human - - O
c-ets-2 - - O
gene - - O
. - - O

Calcification - - O
of - - O
a - - O
cariogenic - - O
Streptococcus - - O
and - - O
of - - O
Corynebacterium - - O
( - - O
Bacterionema - - O
) - - O
matruchotii - - O
. - - O

E - - O
. - - O
, - - O
Scott - - O
, - - O
J - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
HAC1 - - O
may - - O
also - - O
be - - O
one - - O
of - - O
the - - O
meiotic - - O
genes - - O
. - - O

Examination - - O
of - - O
the - - O
MMP-2 - - O
RE1 - - O
sequence - - O
revealed - - O
an - - O
incomplete - - O
Y-box - - O
sequence - - O
( - - O
CTGCTGGGCAAG - - O
) - - O
, - - O
which - - O
specifically - - O
interacted - - O
with - - O
recombinant - - O
YB-1 - - O
on - - O
DMS - - O
protection - - O
footprinting - - O
analysis - - O
. - - O

In - - O
some - - O
of - - O
the - - O
cases - - O
of - - O
solitary - - O
lesion - - O
, - - O
serum - - O
TSH - - O
levels - - O
, - - O
serum - - O
thyroglobulin - - O
values - - O
, - - O
and - - O
131I - - O
protein - - O
bounded - - O
iodine - - O
( - - O
131I-PBI - - O
) - - O
were - - O
measured - - O
, - - O
but - - O
there - - O
were - - O
no - - O
significant - - O
differences - - O
between - - O
successful - - O
and - - O
unsuccessful - - O
therapy - - O
. - - O

RESULTS - - O
: - - O
Each - - O
year - - O
, - - O
on - - O
average - - O
39% - - O
of - - O
cases - - O
seen - - O
in - - O
Sardinia - - O
are - - O
notified - - O
; - - O
646 - - O
( - - O
40% - - O
) - - O
of - - O
the - - O
1591 - - O
patients - - O
notified - - O
during - - O
the - - O
study - - O
period - - O
were - - O
never - - O
seen - - O
by - - O
regional - - O
medical - - O
centres - - O
. - - O

Northern - - O
blot - - O
and - - O
in - - O
situ - - O
hybridization - - O
analyses - - O
revealed - - O
GPR34 - - O
mRNA - - O
transcripts - - O
in - - O
several - - O
human - - O
and - - O
rat - - O
brain - - O
regions - - O
. - - O

A - - O
high - - O
reactor - - O
pH - - O
( - - O
+ - - O
-8 - - O
) - - O
, - - O
a - - O
short - - O
solid - - O
retention - - O
time - - O
( - - O
< - - O
150 - - O
days - - O
) - - O
, - - O
and - - O
the - - O
presence - - O
of - - O
a - - O
substantial - - O
SRB - - O
population - - O
in - - O
the - - O
inoculum - - O
may - - O
considerably - - O
reduce - - O
the - - O
time - - O
required - - O
for - - O
acetate-utilising - - O
SRB - - O
to - - O
outcompete - - O
MB - - O
. - - O

The - - O
study - - O
included - - O
139 - - O
eyes - - O
with - - O
presumed - - O
ocular - - O
histoplasmosis - - O
syndrome - - O
( - - O
POHS - - O
) - - O
and - - O
age-related - - O
macular - - O
degeneration - - O
( - - O
AMD - - O
) - - O
. - - O

Five - - O
of - - O
the - - O
patients - - O
with - - O
increased - - O
L-L - - O
size - - O
had - - O
a - - O
normal - - O
A-P - - O
diameter - - O
. - - O

Antibodies - - O
directed - - O
against - - O
the - - O
SNM1 - - O
protein - - O
immunoprecipitated - - O
RNase - - O
MRP - - O
RNA - - O
from - - O
whole-cell - - O
extracts - - O
without - - O
precipitating - - O
the - - O
structurally - - O
and - - O
functionally - - O
related - - O
RNase - - O
P - - O
RNA - - O
. - - O

METHOD - - O
: - - O
50 - - O
consecutive - - O
children - - O
aged - - O
from - - O
6 - - O
months - - O
to - - O
17 - - O
years - - O
were - - O
included - - O
into - - O
the - - O
study - - O
which - - O
comprised - - O
questionnaires - - O
of - - O
patient - - O
and - - O
family - - O
histories - - O
, - - O
serological - - O
screening - - O
tests - - O
for - - O
common - - O
inhalational - - O
allergens - - O
( - - O
CAP - - O
SX1 - - O
) - - O
, - - O
and - - O
determination - - O
of - - O
total - - O
serum - - O
immunoglobulin - - O
E - - O
( - - O
IgE - - O
) - - O
and - - O
of - - O
latex-specific - - O
serum - - O
IgE - - O
by - - O
solid-phase - - O
immunoassays - - O
. - - O

We - - O
have - - O
cloned - - O
and - - O
sequenced - - O
COX12 - - O
, - - O
the - - O
nuclear - - O
gene - - O
for - - O
subunit - - O
VIb - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
cytochrome - - O
c - - O
oxidase - - O
. - - O

Steroidogenic - - O
factor - - O
1 - - O
, - - O
an - - O
orphan - - O
nuclear - - O
receptor - - O
, - - O
regulates - - O
the - - O
expression - - O
of - - O
the - - O
rat - - O
aromatase - - O
gene - - O
in - - O
gonadal - - O
tissues - - O
. - - O

The - - O
efficacy - - O
of - - O
these - - O
immunosuppressive - - O
drugs - - O
is - - O
clinical - - O
proven - - O
. - - O

Neonatal - - O
lupus - - O
erythematosus - - O
is - - O
most - - O
often - - O
associated - - O
with - - O
autoantibodies - - O
against - - O
Ro - - O
and - - O
La - - O
antigens - - O
. - - O

The - - O
etiology - - O
, - - O
pathology - - O
, - - O
brain - - O
CT - - O
scan - - O
features - - O
, - - O
clinical - - O
manifestations - - O
and - - O
treatment - - O
of - - O
these - - O
accidents - - O
were - - O
discussed - - O
. - - O

Among - - O
booked - - O
patients - - O
the - - O
maternal - - O
mortality - - O
rate - - O
was - - O
0 - - O
. - - O
32 - - O
and - - O
among - - O
unbooked - - O
patients - - O
11 - - O
. - - O
13 - - O
per - - O
1000 - - O
deliveries - - O
. - - O

The - - O
peroxisome - - O
biogenesis - - O
disorders - - O
( - - O
PBDs - - O
) - - O
are - - O
a - - O
set - - O
of - - O
lethal - - O
genetic - - O
diseases - - O
characterized - - O
by - - O
peroxisomal - - O
metabolic - - O
deficiencies - - O
, - - O
multisystem - - O
abnormalities - - O
, - - O
mental - - O
retardation - - O
, - - O
and - - O
premature - - O
death - - O
. - - O

Effect - - O
of - - O
nitrous - - O
oxide - - O
( - - O
N2O - - O
) - - O
on - - O
the - - O
somatosympathetic - - O
A- - - O
and - - O
C-reflexes - - O
was - - O
investigated - - O
using - - O
artificially - - O
ventilated - - O
rats - - O
anesthetized - - O
with - - O
alpha-chloralose - - O
and - - O
urethane - - O
. - - O

The - - O
sensitivity - - O
of - - O
the - - O
vas - - O
deferens - - O
to - - O
adrenaline - - O
was - - O
also - - O
reduced - - O
in - - O
scorbutic - - O
guinea - - O
pigs - - O
, - - O
thus - - O
decreasing - - O
their - - O
fertility - - O
rate - - O
. - - O

An - - O
amino-acid - - O
sequence - - O
comparison - - O
revealed - - O
that - - O
Bacillus - - O
YM55-1 - - O
aspartase - - O
shared - - O
71% - - O
homology - - O
with - - O
Bacillus - - O
subtilis - - O
aspartase - - O
and - - O
49% - - O
with - - O
Escherichia - - O
coli - - O
and - - O
Pseudomonas - - O
fluorescens - - O
aspartases - - O
. - - O

In - - O
contrast - - O
, - - O
the - - O
full - - O
mu-opioid - - O
agonists - - O
fentanyl - - O
, - - O
morphine - - O
, - - O
I-methadone - - O
and - - O
levorphanol - - O
produced - - O
50% - - O
fentanyl-appropriate - - O
responding - - O
at - - O
doses - - O
only - - O
1 - - O
. - - O
3 - - O
to - - O
10 - - O
. - - O
9 - - O
times - - O
smaller - - O
than - - O
those - - O
required - - O
to - - O
decrease - - O
response - - O
rates - - O
by - - O
50% - - O
. - - O

This - - O
activity - - O
is - - O
stimulated - - O
by - - O
complex - - O
formation - - O
with - - O
the - - O
other - - O
eIF2B - - O
subunits - - O
. - - O

A - - O
portion - - O
of - - O
p193 - - O
is - - O
nuclear - - O
and - - O
localizes - - O
to - - O
the - - O
mitotic - - O
spindle - - O
. - - O

Evolutive - - O
morphology - - O
of - - O
the - - O
olfactory - - O
bulb - - O
in - - O
man - - O
and - - O
certain - - O
non-human - - O
mammals - - O
. - - O

The - - O
core - - O
promoter - - O
of - - O
human - - O
thioredoxin - - O
reductase - - O
1 - - O
. - - O
cloning - - O
, - - O
transcriptional - - O
activity - - O
, - - O
and - - O
oct-1 - - O
, - - O
sp1 - - O
, - - O
and - - O
sp3 - - O
binding - - O
reveal - - O
a - - O
housekeeping-type - - O
promoter - - O
for - - O
the - - O
au-rich - - O
element-regulated - - O
gene - - O
. - - O

The - - O
five-drug - - O
combination - - O
of - - O
fluorouracil - - O
imidazole - - O
carboxamide - - O
dimethyl - - O
triazeno - - O
, - - O
vincristine - - O
, - - O
bis-chloroethyl - - O
nitrosourea - - O
, - - O
and - - O
prednisone - - O
( - - O
FIVB - - O
+ - - O
P - - O
) - - O
was - - O
given - - O
to - - O
120 - - O
women - - O
with - - O
metastatic - - O
breast - - O
cancer - - O
. - - O

Recombinant - - O
prenylcysteine - - O
lyase - - O
was - - O
produced - - O
in - - O
a - - O
baculovirus-Sf9 - - O
expression - - O
system - - O
. - - O

Here - - O
, - - O
we - - O
correlate - - O
Dox - - O
effects - - O
on - - O
cell - - O
cycle - - O
with - - O
changes - - O
of - - O
E2F - - O
DP - - O
complexes - - O
and - - O
activity - - O
in - - O
differentiating - - O
C2C12 - - O
myocytes - - O
. - - O

We - - O
have - - O
determined - - O
the - - O
structure - - O
of - - O
the - - O
WNT-2B - - O
gene - - O
. - - O

Positive - - O
genetic - - O
selections - - O
for - - O
inhibition - - O
of - - O
cyclin - - O
CDK - - O
function - - O
were - - O
characterized - - O
using - - O
the - - O
E - - O
. - - O
coli - - O
neo - - O
and - - O
yeast - - O
LEU2 - - O
genes - - O
. - - O

Finger - - O
associated - - O
box-zinc - - O
finger - - O
proteins - - O
( - - O
FAX-ZFPs - - O
) - - O
constitute - - O
a - - O
subfamily - - O
of - - O
the - - O
many - - O
C2H2 - - O
type - - O
ZFPs - - O
in - - O
Xenopus - - O
laevis - - O
. - - O

Neither - - O
class - - O
II - - O
nor - - O
IV - - O
infections - - O
precluded - - O
transplantation - - O
. - - O

This - - O
report - - O
has - - O
reviewed - - O
some - - O
of - - O
the - - O
reasons - - O
for - - O
treatment - - O
failures - - O
and - - O
has - - O
presented - - O
a - - O
philosophy - - O
for - - O
their - - O
management - - O
. - - O

Ceftazidime - - O
shows - - O
promise - - O
as - - O
single-agent - - O
therapy - - O
for - - O
serious - - O
gram-negative - - O
bacillary - - O
infections - - O
. - - O

Anti-anxiety - - O
action - - O
of - - O
diazepam - - O
after - - O
intra-amygdaloid - - O
application - - O
in - - O
the - - O
rat - - O
. - - O

The - - O
Ogg1 - - O
protein - - O
efficiently - - O
cleaves - - O
a - - O
DNA - - O
duplex - - O
where - - O
a - - O
preformed - - O
AP - - O
site - - O
is - - O
placed - - O
opposite - - O
a - - O
cytosine - - O
( - - O
AP - - O
C - - O
) - - O
. - - O

We - - O
report - - O
here - - O
that - - O
a - - O
25-bp - - O
promoter - - O
element - - O
previously - - O
shown - - O
to - - O
be - - O
important - - O
for - - O
the - - O
G1-S - - O
activation - - O
of - - O
the - - O
human - - O
thymidine - - O
kinase - - O
( - - O
htk - - O
) - - O
promoter - - O
in - - O
growth-stimulated - - O
cells - - O
is - - O
a - - O
cellular - - O
target - - O
of - - O
cyclin - - O
A - - O
and - - O
the - - O
p33cdk2 - - O
complexes - - O
. - - O

Molecular - - O
structure - - O
and - - O
evolutionary - - O
origin - - O
of - - O
human - - O
cardiac - - O
muscle - - O
actin - - O
gene - - O
. - - O

Serine - - O
phosphorylation - - O
of - - O
STAT3 - - O
was - - O
only - - O
apparent - - O
after - - O
somatostatin - - O
treatment - - O
and - - O
was - - O
abolished - - O
by - - O
pertussis - - O
toxin - - O
or - - O
PD - - O
98059 - - O
, - - O
together - - O
with - - O
the - - O
associated - - O
increases - - O
in - - O
proliferation - - O
. - - O

The - - O
genome - - O
of - - O
avian - - O
erythroblastosis - - O
virus - - O
contains - - O
two - - O
independently - - O
expressed - - O
genetic - - O
loci - - O
( - - O
v-erbA - - O
and - - O
v-erbB - - O
) - - O
whose - - O
activities - - O
are - - O
probably - - O
responsible - - O
for - - O
oncogenesis - - O
by - - O
the - - O
virus - - O
. - - O

This - - O
phenomenon - - O
did - - O
not - - O
require - - O
DNA - - O
binding - - O
by - - O
the - - O
"interfering" - - O
receptor - - O
but - - O
required - - O
it - - O
to - - O
be - - O
hormone-bound - - O
, - - O
indicating - - O
that - - O
a - - O
transcriptionally - - O
active - - O
form - - O
of - - O
the - - O
interfering - - O
receptor - - O
is - - O
essential - - O
for - - O
the - - O
interfering - - O
effect - - O
. - - O

Here - - O
we - - O
report - - O
that - - O
in - - O
cultured - - O
cells - - O
from - - O
Drosophila - - O
melanogaster - - O
human - - O
Sp1 - - O
efficiently - - O
activates - - O
transcription - - O
from - - O
synthetic - - O
promoters - - O
containing - - O
TATA - - O
boxes - - O
, - - O
but - - O
not - - O
from - - O
promoters - - O
that - - O
contain - - O
an - - O
initiator - - O
instead - - O
of - - O
a - - O
TATA - - O
box - - O
. - - O

We - - O
recommend - - O
that - - O
paracervical - - O
block - - O
with - - O
lignocaine - - O
should - - O
be - - O
used - - O
in - - O
conjunction - - O
with - - O
i - - O
. - - O
v - - O
. - - O
sedation - - O
analgesia - - O
during - - O
egg - - O
collection - - O
performed - - O
through - - O
the - - O
transvaginal - - O
route - - O
under - - O
ultrasound - - O
guidance - - O
( - - O
TUGOR - - O
) - - O
to - - O
reduce - - O
the - - O
pain - - O
of - - O
the - - O
procedure - - O
. - - O

Thyroid - - O
disease - - O
and - - O
pregnancy - - O
. - - O

To - - O
study - - O
retinoid - - O
signalling - - O
in - - O
zebrafish - - O
embryos - - O
, - - O
we - - O
developed - - O
a - - O
novel - - O
method - - O
to - - O
detect - - O
endogenous - - O
retinoids - - O
in - - O
situ - - O
in - - O
embryos - - O
, - - O
using - - O
a - - O
fusion - - O
protein - - O
of - - O
the - - O
ligand - - O
inducible - - O
transactivation - - O
domain - - O
of - - O
a - - O
retinoic - - O
acid - - O
receptor - - O
and - - O
a - - O
heterologous - - O
DNA - - O
binding - - O
domain - - O
. - - O

Northern - - O
blot - - O
analysis - - O
revealed - - O
that - - O
mlt - - O
1 - - O
is - - O
normally - - O
expressed - - O
in - - O
brain - - O
, - - O
spleen - - O
, - - O
stom - - O
ach - - O
, - - O
and - - O
liver - - O
. - - O

The - - O
results - - O
indicated - - O
that - - O
two - - O
genes - - O
( - - O
citA - - O
and - - O
citB - - O
) - - O
have - - O
separate - - O
promoters - - O
, - - O
and - - O
the - - O
location - - O
of - - O
the - - O
promoter - - O
for - - O
the - - O
citB - - O
gene - - O
in - - O
the - - O
Tn3411 - - O
nucleotide - - O
sequence - - O
was - - O
different - - O
from - - O
that - - O
in - - O
pMS185 - - O
. - - O

This - - O
distinction - - O
was - - O
based - - O
upon - - O
whether - - O
the - - O
diagnosis - - O
provided - - O
a - - O
straightforward - - O
range - - O
of - - O
prognoses - - O
or - - O
an - - O
ambiguous - - O
clinical - - O
implication - - O
. - - O

However - - O
, - - O
vancomycin - - O
and - - O
fosfomycin - - O
, - - O
which - - O
revealed - - O
suboptimal - - O
in - - O
vitro - - O
bactericidal - - O
activity - - O
, - - O
proved - - O
as - - O
efficacious - - O
as - - O
penicillin - - O
G - - O
and - - O
imipenem - - O
in - - O
an - - O
experimental - - O
mode - - O
of - - O
murine - - O
gas - - O
gangrene - - O
. - - O

For - - O
HeLa - - O
, - - O
293 - - O
, - - O
U937 - - O
, - - O
and - - O
A549 - - O
cells - - O
, - - O
participation - - O
of - - O
E2F-1 - - O
, - - O
DP-1 - - O
, - - O
cyclin - - O
A - - O
, - - O
and - - O
RB - - O
was - - O
involved - - O
in - - O
formation - - O
of - - O
some - - O
complexes - - O
only - - O
, - - O
assuming - - O
participation - - O
of - - O
factors - - O
different - - O
from - - O
E2F-1 - - O
or - - O
DP-1 - - O
in - - O
others - - O
. - - O

The - - O
severity - - O
of - - O
clinical - - O
course - - O
was - - O
expressed - - O
by - - O
means - - O
of - - O
SOFA - - O
score - - O
( - - O
group - - O
A - - O
0 - - O
. - - O
3-1-1 - - O
. - - O
3 - - O
point - - O
, - - O
group - - O
B - - O
2 - - O
. - - O
2-2 - - O
. - - O
9-2 - - O
. - - O
6 - - O
point - - O
, - - O
group - - O
C - - O
7 - - O
. - - O
4-8 - - O
. - - O
3-7 - - O
. - - O
7 - - O
point - - O
) - - O
and - - O
APACHE - - O
II - - O
score - - O
( - - O
group - - O
A - - O
3 - - O
. - - O
7-7 - - O
. - - O
6-8 - - O
. - - O
1 - - O
point - - O
, - - O
group - - O
B - - O
8 - - O
. - - O
6-11 - - O
. - - O
1-10 - - O
. - - O
5 - - O
point - - O
, - - O
group - - O
C - - O
16 - - O
. - - O
3-15 - - O
. - - O
2-14 - - O
. - - O
3 - - O
point - - O
) - - O
. - - O

5 - - O
microU - - O
l - - O
thyrotropin - - O
: - - O
75% - - O
( - - O
1974 - - O
) - - O
, - - O
45% - - O
( - - O
1977 - - O
) - - O
and - - O
20% - - O
( - - O
1980 - - O
) - - O
. - - O

Partial - - O
N-terminal - - O
amino - - O
acid - - O
sequence - - O
analysis - - O
showed - - O
that - - O
the - - O
43K - - O
and - - O
42K - - O
T - - O
antigens - - O
contain - - O
methionine - - O
at - - O
residues - - O
1 - - O
and - - O
5 - - O
, - - O
as - - O
predicted - - O
from - - O
the - - O
DNA - - O
sequence - - O
, - - O
whereas - - O
no - - O
methionine - - O
was - - O
released - - O
from - - O
the - - O
39K - - O
T - - O
antigen - - O
during - - O
the - - O
first - - O
six - - O
cycles - - O
of - - O
Edman - - O
degradation - - O
. - - O

A - - O
new - - O
Onchocerca - - O
species - - O
, - - O
a - - O
parasite - - O
of - - O
domestic - - O
cattle - - O
, - - O
in - - O
Senegal - - O
. - - O

Ga-67 - - O
and - - O
Tl-201 - - O
scintigraphy - - O
in - - O
extramedullary - - O
plasmacytoma - - O
: - - O
a - - O
case - - O
report - - O
. - - O

The - - O
addition - - O
of - - O
diatrizoate - - O
to - - O
the - - O
IPRK - - O
led - - O
to - - O
a - - O
dose-dependent - - O
biphasic - - O
change - - O
in - - O
RPF - - O
and - - O
GFR - - O
characterized - - O
by - - O
an - - O
initial - - O
transient - - O
increase - - O
followed - - O
by - - O
a - - O
marked - - O
and - - O
sustained - - O
decrease - - O
. - - O

Role - - O
of - - O
estrogen - - O
receptor - - O
ligand - - O
and - - O
estrogen - - O
response - - O
element - - O
sequence - - O
on - - O
interaction - - O
with - - O
chicken - - O
ovalbumin - - O
upstream - - O
promoter - - O
transcription - - O
factor - - O
( - - O
COUP-TF - - O
) - - O
. - - O

Chemical - - O
stability - - O
tests - - O
and - - O
site-specific - - O
mutagenesis - - O
identified - - O
amino - - O
acids - - O
H219 - - O
and - - O
D63 - - O
of - - O
RegS - - O
and - - O
RegR - - O
, - - O
respectively - - O
, - - O
as - - O
the - - O
phosphorylated - - O
residues - - O
. - - O

Prostacyclin - - O
formation - - O
, - - O
reflected - - O
by - - O
the - - O
excretion - - O
rate - - O
of - - O
its - - O
stable - - O
metabolite - - O
6-keto-prostaglandin - - O
F1 - - O
alpha - - O
, - - O
was - - O
measured - - O
by - - O
means - - O
of - - O
radioimmunoassay - - O
in - - O
4-hour - - O
urine - - O
specimens - - O
obtained - - O
during - - O
a - - O
smoking-free - - O
period - - O
and - - O
after - - O
participants - - O
had - - O
inhaled - - O
smoke - - O
from - - O
four - - O
high-nicotine - - O
cigarettes - - O
. - - O

There - - O
were - - O
gene - - O
clusters - - O
encoding - - O
photosynthesis - - O
components - - O
such - - O
as - - O
the - - O
psbB-psbH-petB-petD - - O
and - - O
the - - O
psbE-psbF - - O
clusters - - O
. - - O

Together - - O
, - - O
these - - O
results - - O
suggest - - O
that - - O
EGF - - O
Ras - - O
Raf - - O
induces - - O
transcription - - O
via - - O
combined - - O
activation - - O
of - - O
ATF3 - - O
c-Jun - - O
and - - O
a - - O
52-kDa - - O
nuclear - - O
factor - - O
, - - O
whereas - - O
JunD - - O
acts - - O
as - - O
a - - O
repressor - - O
of - - O
this - - O
response - - O
. - - O

Both - - O
Rep78 - - O
and - - O
Rep68 - - O
cut - - O
the - - O
terminal - - O
AAV - - O
sequence - - O
at - - O
the - - O
same - - O
site - - O
( - - O
nucleotide - - O
124 - - O
) - - O
. - - O

The - - O
SR - - O
protein - - O
family - - O
is - - O
involved - - O
in - - O
constitutive - - O
and - - O
regulated - - O
pre-mRNA - - O
splicing - - O
and - - O
has - - O
been - - O
found - - O
to - - O
be - - O
evolutionarily - - O
conserved - - O
in - - O
metazoan - - O
organisms - - O
. - - O

Here - - O
we - - O
describe - - O
and - - O
map - - O
two - - O
more - - O
new - - O
genes - - O
identified - - O
as - - O
allele-specific - - O
suppressors - - O
that - - O
compensate - - O
for - - O
carboxy-terminal - - O
truncation - - O
of - - O
PET122 - - O
. - - O

2 - - O
. - - O

Analysis - - O
of - - O
Msy2 - - O
mRNA - - O
expression - - O
in - - O
prepubertal - - O
and - - O
adult - - O
mouse - - O
testes - - O
, - - O
and - - O
in - - O
isolated - - O
populations - - O
of - - O
germ - - O
cells - - O
, - - O
reveals - - O
maximal - - O
expression - - O
in - - O
postmeiotic - - O
round - - O
spermatids - - O
, - - O
a - - O
cell - - O
type - - O
with - - O
abundant - - O
amounts - - O
of - - O
stored - - O
messenger - - O
ribonucleoproteins - - O
. - - O

Northern - - O
( - - O
RNA - - O
) - - O
analysis - - O
demonstrated - - O
expression - - O
of - - O
human - - O
PI - - O
3-kinase - - O
in - - O
all - - O
tissues - - O
and - - O
cell - - O
lines - - O
tested - - O
. - - O

In - - O
vitro - - O
metabolism - - O
of - - O
progesterone - - O
by - - O
the - - O
human - - O
undescended - - O
testis - - O
. - - O

Asthmatic - - O
patients - - O
showed - - O
greater - - O
responses - - O
of - - O
both - - O
parameters - - O
to - - O
adrenaline - - O
than - - O
controls - - O
indicating - - O
that - - O
long-term - - O
corticosteroid - - O
treatment - - O
enhances - - O
the - - O
acute - - O
responses - - O
of - - O
plasminogen - - O
activator - - O
and - - O
clotting - - O
factor - - O
VIII - - O
to - - O
adrenaline - - O
infusion - - O
. - - O

The - - O
heart - - O
rate - - O
, - - O
respiratory - - O
rate - - O
, - - O
arterial - - O
O2 - - O
and - - O
systemic - - O
vascular - - O
resistance - - O
were - - O
not - - O
significantly - - O
altered - - O
. - - O

National - - O
abortion - - O
laws - - O
usually - - O
do - - O
not - - O
allow - - O
abortion - - O
when - - O
a - - O
foetus - - O
is - - O
independently - - O
viable - - O
, - - O
i - - O
. - - O
e - - O
. - - O
from - - O
a - - O
gestational - - O
age - - O
of - - O
about - - O
24 - - O
weeks - - O
. - - O

Chernoff - - O
, - - O
submitted - - O
for - - O
publication - - O
) - - O
. - - O

Although - - O
E2FBP1 - - O
lacks - - O
the - - O
transactivation - - O
domain - - O
, - - O
it - - O
stimulates - - O
E2F - - O
site-dependent - - O
transcription - - O
in - - O
cooperation - - O
with - - O
E2F-1 - - O
. - - O

Although - - O
olfactory - - O
associative - - O
conditioning - - O
in - - O
newborn - - O
rats - - O
produces - - O
marked - - O
structural - - O
and - - O
functional - - O
changes - - O
in - - O
the - - O
olfactory - - O
bulb - - O
, - - O
recent - - O
evidence - - O
suggests - - O
that - - O
extrabulbar - - O
circuits - - O
must - - O
be - - O
involved - - O
in - - O
storing - - O
these - - O
early - - O
memories - - O
. - - O

The - - O
3' - - O
region - - O
, - - O
GA2 - - O
, - - O
is - - O
necessary - - O
for - - O
maximal - - O
expression - - O
. - - O

There - - O
was - - O
no - - O
clear - - O
correlation - - O
between - - O
the - - O
MFA - - O
and - - O
the - - O
severity - - O
of - - O
the - - O
UTS - - O
phenotype - - O
. - - O

A - - O
high - - O
degree - - O
of - - O
correlation - - O
in - - O
the - - O
sense - - O
of - - O
the - - O
classic - - O
conception - - O
of - - O
brain - - O
localization - - O
of - - O
neuropsychological - - O
syndromes - - O
was - - O
found - - O
. - - O

Encouraged - - O
by - - O
a - - O
Dutch - - O
study - - O
using - - O
etidronate - - O
fluoride - - O
in - - O
corticoid-induced - - O
osteoporosis - - O
, - - O
we - - O
performed - - O
a - - O
pilot - - O
study - - O
in - - O
33 - - O
men - - O
with - - O
severe - - O
established - - O
primary - - O
osteoporosis - - O
giving - - O
cyclically - - O
etidronate - - O
for - - O
14 - - O
days - - O
followed - - O
by - - O
fluoride - - O
plus - - O
calcium - - O
vitamin - - O
D - - O
for - - O
76 - - O
days - - O
. - - O

The - - O
prevalence - - O
of - - O
malnutrition - - O
was - - O
30% - - O
in - - O
the - - O
47 - - O
patients - - O
without - - O
CVD - - O
and - - O
was - - O
significantly - - O
higher - - O
( - - O
70% - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
in - - O
the - - O
70 - - O
patients - - O
with - - O
CVD - - O
, - - O
who - - O
also - - O
had - - O
lower - - O
tHcy - - O
, - - O
SAlb - - O
, - - O
plasma - - O
IGF-1 - - O
, - - O
serum - - O
creatinine - - O
( - - O
SCr - - O
) - - O
, - - O
and - - O
blood - - O
hemoglobin - - O
. - - O

The - - O
assay - - O
exhibits - - O
a - - O
dynamic - - O
range - - O
of - - O
0 - - O
. - - O
1-100 - - O
micrograms - - O
l-1 - - O
using - - O
a - - O
monoclonal - - O
antibody - - O
or - - O
alternatively - - O
10 - - O
micrograms - - O
l-1 - - O
to - - O
10 - - O
mg - - O
l-1 - - O
using - - O
commercially - - O
available - - O
antiserum - - O
. - - O

Mapping - - O
results - - O
suggested - - O
that - - O
the - - O
complementation - - O
group - - O
identified - - O
by - - O
these - - O
mutants - - O
is - - O
allelic - - O
to - - O
the - - O
ag - - O
alpha - - O
1 - - O
mutation - - O
identified - - O
previously - - O
. - - O

Some - - O
of - - O
the - - O
mutations - - O
obtained - - O
do - - O
not - - O
contain - - O
a - - O
copy - - O
of - - O
the - - O
Ulysses - - O
element - - O
at - - O
the - - O
mutant - - O
locus - - O
, - - O
suggesting - - O
that - - O
a - - O
different - - O
transposable - - O
element - - O
may - - O
be - - O
responsible - - O
for - - O
the - - O
mutation - - O
. - - O

3 - - O
. - - O
04+ - - O
-1 - - O
. - - O
2 - - O
, - - O
P - - O
< - - O
0 - - O
. - - O
0001 - - O
) - - O
, - - O
large - - O
accelerations - - O
30 - - O
min - - O
( - - O
1 - - O
. - - O
46+ - - O
-1 - - O
. - - O
96 - - O
vs - - O
. - - O

We - - O
describe - - O
a - - O
total - - O
of - - O
39 - - O
DEAH - - O
helicases - - O
in - - O
these - - O
four - - O
species - - O
. - - O

Quantitation - - O
of - - O
exocrine - - O
IgA - - O
in - - O
human - - O
serum - - O
in - - O
health - - O
and - - O
disease - - O
. - - O

For - - O
228 - - O
of - - O
425 - - O
deaths - - O
( - - O
54% - - O
) - - O
occurring - - O
among - - O
26 - - O
100 - - O
people - - O
of - - O
known - - O
age - - O
in - - O
the - - O
Malumfashi - - O
area - - O
of - - O
northern - - O
Nigeria - - O
, - - O
data - - O
were - - O
collected - - O
on - - O
symptoms - - O
present - - O
prior - - O
to - - O
death - - O
. - - O

The - - O
transcription - - O
of - - O
most - - O
RP - - O
genes - - O
is - - O
activated - - O
by - - O
two - - O
Rap1p - - O
binding - - O
sites - - O
, - - O
250 - - O
to - - O
400 - - O
bp - - O
upstream - - O
from - - O
the - - O
initiation - - O
of - - O
transcription - - O
. - - O

As - - O
regards - - O
lipid - - O
metabolism - - O
, - - O
the - - O
mean - - O
values - - O
for - - O
total - - O
triglycerides - - O
, - - O
cholesterol - - O
, - - O
LDL-cholesterol - - O
and - - O
HDL-cholesterol - - O
seen - - O
at - - O
the - - O
end - - O
of - - O
five - - O
years - - O
of - - O
Norplant-2 - - O
rod - - O
use - - O
and - - O
six - - O
months - - O
postremoval - - O
were - - O
similar - - O
to - - O
the - - O
preinsertion - - O
mean - - O
. - - O

We - - O
have - - O
recently - - O
shown - - O
that - - O
the - - O
tissue-specific - - O
expression - - O
of - - O
the - - O
RAR - - O
beta - - O
2 - - O
gene - - O
in - - O
mouse - - O
embryos - - O
is - - O
regulated - - O
at - - O
the - - O
translational - - O
level - - O
by - - O
short - - O
upstream - - O
open - - O
reading - - O
frames - - O
( - - O
uORFs - - O
) - - O
In - - O
the - - O
5'-untranslated - - O
region - - O
( - - O
Zimmer - - O
, - - O
A - - O
. - - O
, - - O
A - - O
. - - O
M - - O
. - - O

Frequent - - O
loss - - O
of - - O
heterozygosity - - O
( - - O
LOH - - O
) - - O
of - - O
> - - O
30% - - O
of - - O
the - - O
informative - - O
cases - - O
was - - O
observed - - O
on - - O
chromosomes - - O
3p - - O
( - - O
41 - - O
. - - O
1% - - O
) - - O
, - - O
5q - - O
( - - O
52 - - O
. - - O
6% - - O
) - - O
, - - O
6p - - O
( - - O
30 - - O
. - - O
4% - - O
) - - O
, - - O
8p - - O
( - - O
33 - - O
. - - O
3% - - O
) - - O
, - - O
9p - - O
( - - O
35 - - O
. - - O
7% - - O
) - - O
, - - O
9q - - O
( - - O
30 - - O
. - - O
8% - - O
) - - O
, - - O
11p - - O
( - - O
32 - - O
. - - O
4% - - O
) - - O
, - - O
13q - - O
( - - O
52 - - O
. - - O
7% - - O
) - - O
, - - O
17p - - O
( - - O
55 - - O
. - - O
2% - - O
) - - O
, - - O
17q - - O
( - - O
33 - - O
. - - O
3% - - O
) - - O
, - - O
18q - - O
( - - O
45 - - O
. - - O
7% - - O
) - - O
, - - O
and - - O
19q - - O
( - - O
30 - - O
. - - O
4% - - O
) - - O
. - - O

PowerBLAST - - O
analysis - - O
identified - - O
six - - O
clusters - - O
of - - O
expressed - - O
sequence - - O
tags - - O
( - - O
ESTs - - O
) - - O
, - - O
two - - O
known - - O
genes - - O
( - - O
BIR - - O
, - - O
SUR1 - - O
) - - O
mapped - - O
previously - - O
to - - O
this - - O
region - - O
, - - O
and - - O
a - - O
previously - - O
characterized - - O
but - - O
unmapped - - O
gene - - O
NEFA - - O
( - - O
DNA - - O
binding - - O
EF - - O
hand - - O
acidic - - O
amino-acid-rich - - O
) - - O
. - - O

A - - O
cDNA - - O
clone - - O
pCZ1 - - O
, - - O
with - - O
a - - O
1 - - O
. - - O
1 - - O
kb - - O
insert - - O
, - - O
was - - O
isolated - - O
from - - O
a - - O
NaCl-adapted - - O
tobacco - - O
cell - - O
cDNA - - O
library - - O
that - - O
encodes - - O
an - - O
apparently - - O
full-length - - O
29 - - O
kDa - - O
protein - - O
( - - O
251 - - O
amino - - O
acids - - O
) - - O
with - - O
a - - O
calculated - - O
pI - - O
of - - O
5 - - O
. - - O
7 - - O
. - - O

MEASUREMENTS - - O
AND - - O
MAIN - - O
RESULTS - - O
: - - O
The - - O
two - - O
groups - - O
were - - O
similar - - O
on - - O
entry - - O
into - - O
the - - O
study - - O
, - - O
including - - O
mean - - O
FEV1 - - O
measurements - - O
( - - O
0 - - O
. - - O
70 - - O
L - - O
atropine - - O
0 - - O
. - - O
60 - - O
L - - O
metaproterenol - - O
, - - O
P - - O
greater - - O
than - - O
. - - O
05 - - O
) - - O
. - - O

Decreased - - O
levels - - O
of - - O
alpha2-antiplasmin - - O
were - - O
also - - O
observed - - O
in - - O
the - - O
mediastinum - - O
( - - O
0 - - O
. - - O
50 - - O
versus - - O
0 - - O
. - - O
61 - - O
U - - O
mL - - O
; - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

Postnatal - - O
volumetric - - O
development - - O
of - - O
the - - O
prefrontal - - O
cortex - - O
in - - O
the - - O
rat - - O
. - - O

There - - O
was - - O
no - - O
significant - - O
correlation - - O
between - - O
baseline - - O
PC40 - - O
methacholine - - O
and - - O
the - - O
maximal - - O
fall - - O
in - - O
Vp30 - - O
after - - O
either - - O
the - - O
first - - O
( - - O
12 - - O
micrograms - - O
) - - O
or - - O
the - - O
second - - O
dose - - O
( - - O
24 - - O
micrograms - - O
) - - O
of - - O
platelet - - O
activating - - O
factor - - O
. - - O

S1 - - O
nuclease - - O
analysis - - O
of - - O
RNA - - O
prepared - - O
after - - O
transfection - - O
of - - O
these - - O
HIV - - O
constructs - - O
into - - O
HeLa - - O
cells - - O
infected - - O
with - - O
wild-type - - O
adenovirus - - O
indicated - - O
that - - O
the - - O
enhancer - - O
, - - O
SP1 - - O
, - - O
TATA - - O
, - - O
and - - O
a - - O
portion - - O
of - - O
the - - O
transactivation-responsive - - O
element - - O
were - - O
each - - O
required - - O
for - - O
complete - - O
E1A - - O
E1B-mediated - - O
activation - - O
of - - O
the - - O
HIV - - O
LTR - - O
. - - O

Long-range - - O
mapping - - O
of - - O
the - - O
11q23 - - O
region - - O
involved - - O
in - - O
chromosome - - O
aberrations - - O
in - - O
human - - O
tumors - - O
by - - O
pulsed-field - - O
gel - - O
electrophoresis - - O
with - - O
a - - O
yeast - - O
artificial - - O
chromosome - - O
. - - O

An - - O
implant - - O
may - - O
release - - O
a - - O
drug - - O
either - - O
by - - O
diffusion - - O
concurrent - - O
with - - O
dissolution - - O
of - - O
the - - O
polymeric - - O
implant - - O
material - - O
without - - O
depolymerization - - O
( - - O
Type - - O
A - - O
) - - O
or - - O
by - - O
bioerosion - - O
involving - - O
depolymerization - - O
( - - O
Type - - O
B - - O
) - - O
. - - O

Plasma - - O
secretin - - O
, - - O
pancreozymin - - O
, - - O
and - - O
somatostatin-like - - O
hormone - - O
in - - O
chronic - - O
renal - - O
failure - - O
patients - - O
. - - O

Insertion - - O
of - - O
4 - - O
bp - - O
reduced - - O
SV40 - - O
early - - O
promoter-dependent - - O
chloramphenicol - - O
acetyltransferase - - O
( - - O
CAT - - O
) - - O
expression - - O
by - - O
six- - - O
to - - O
eightfold - - O
. - - O

CONCLUSIONS - - O
: - - O
AMVT - - O
is - - O
rare - - O
but - - O
a - - O
potentially - - O
lethal - - O
emergency - - O
disease - - O
. - - O

Lewis - - O
, - - O
N - - O
. - - O

The - - O
preferences - - O
were - - O
for - - O
intact - - O
vis-a-vis - - O
castrated - - O
males - - O
, - - O
though - - O
injections - - O
of - - O
TP - - O
restored - - O
the - - O
castrates' - - O
attractiveness - - O
to - - O
the - - O
females - - O
. - - O

This - - O
animal - - O
model - - O
of - - O
dystonia - - O
appears - - O
to - - O
be - - O
a - - O
model - - O
of - - O
NAD - - O
in - - O
man - - O
from - - O
the - - O
viewpoint - - O
of - - O
treatment-response - - O
. - - O

These - - O
changes - - O
correlate - - O
directly - - O
with - - O
an - - O
increase - - O
in - - O
the - - O
acetylation - - O
levels - - O
of - - O
all - - O
four - - O
core - - O
histones - - O
in - - O
vivo - - O
. - - O

In - - O
group - - O
B - - O
37 - - O
MBq - - O
in - - O
150 - - O
microL - - O
of - - O
99mTc-HSA - - O
nanocolloid - - O
was - - O
additionally - - O
injected - - O
intradermally - - O
18 - - O
h - - O
before - - O
surgery - - O
( - - O
3-6 - - O
aliquots - - O
injected - - O
perilesionally - - O
) - - O
. - - O

Coronary - - O
flow - - O
was - - O
reduced - - O
by - - O
10% - - O
in - - O
the - - O
phosphocreatine - - O
and - - O
by - - O
18% - - O
in - - O
the - - O
control - - O
group - - O
. - - O

In - - O
vivo - - O
, - - O
MyoD - - O
requires - - O
this - - O
tryptophan - - O
motif - - O
to - - O
evoke - - O
chromatin - - O
remodeling - - O
in - - O
the - - O
Myogenin - - O
promoter - - O
and - - O
to - - O
activate - - O
Myogenin - - O
transcription - - O
. - - O

Using - - O
autoantibodies - - O
from - - O
a - - O
Sjogren's - - O
syndrome - - O
patient - - O
, - - O
we - - O
have - - O
previously - - O
identified - - O
a - - O
230-kDa - - O
peripheral - - O
membrane - - O
protein - - O
associated - - O
with - - O
the - - O
cytosolic - - O
face - - O
of - - O
the - - O
trans-Golgi - - O
( - - O
Kooy - - O
, - - O
J - - O
. - - O
, - - O
Toh - - O
, - - O
B - - O
. - - O

The - - O
single - - O
strandedness - - O
is - - O
manifested - - O
as - - O
a - - O
terminal - - O
extension - - O
of - - O
the - - O
G-rich - - O
strand - - O
( - - O
G - - O
tails - - O
) - - O
that - - O
can - - O
occur - - O
independently - - O
of - - O
telomerase - - O
, - - O
suggesting - - O
that - - O
cdc17 - - O
pol1 - - O
mutants - - O
exhibit - - O
defects - - O
in - - O
telomeric - - O
lagging-strand - - O
synthesis - - O
. - - O

The - - O
plasmatic - - O
albumin - - O
concentration - - O
( - - O
3 - - O
. - - O
5-4 - - O
. - - O
5 - - O
g - - O
dl - - O
) - - O
represents - - O
about - - O
60% - - O
of - - O
the - - O
total - - O
plasma - - O
protein - - O
. - - O

Group - - O
6 - - O
was - - O
given - - O
physostigmine - - O
, - - O
0 - - O
. - - O
1 - - O
mg - - O
kg - - O
i - - O
. - - O
v - - O
. - - O
, - - O
known - - O
to - - O
inhibit - - O
cholinesterase - - O
degradation - - O
, - - O
5 - - O
min - - O
before - - O
bupivacaine - - O
administration - - O
, - - O
and - - O
Group - - O
7 - - O
received - - O
a - - O
combination - - O
of - - O
physostigmine - - O
pretreatment - - O
and - - O
electrical - - O
vagal - - O
stimulation - - O
. - - O

We - - O
conclude - - O
that - - O
, - - O
with - - O
autonomic - - O
nervous - - O
system - - O
activity - - O
intact - - O
, - - O
carotid - - O
chemoreceptor - - O
reflex - - O
activation - - O
can - - O
elicit - - O
an - - O
absolute - - O
reflexly - - O
mediated - - O
reduction - - O
in - - O
coronary - - O
blood - - O
flow - - O
in - - O
the - - O
normal - - O
, - - O
conscious - - O
dog - - O
, - - O
despite - - O
an - - O
increase - - O
in - - O
arterial - - O
pressure - - O
. - - O

Furthermore - - O
, - - O
in - - O
the - - O
ischemia - - O
angiotension - - O
II-induced - - O
AHF - - O
model - - O
, - - O
NIC - - O
decreased - - O
left - - O
ventricular - - O
end-diastolic - - O
pressure - - O
( - - O
LVEDP - - O
) - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
decreased - - O
class - - O
I - - O
enhancer - - O
activity - - O
in - - O
Ad12-transformed - - O
cells - - O
may - - O
, - - O
at - - O
least - - O
in - - O
part - - O
, - - O
be - - O
due - - O
to - - O
the - - O
higher - - O
levels - - O
of - - O
an - - O
enhancer-specific - - O
factor - - O
, - - O
possibly - - O
acting - - O
as - - O
a - - O
repressor - - O
. - - O

Evaluation - - O
of - - O
thyroid - - O
function - - O
. - - O

Combined - - O
expression - - O
of - - O
c-Jun - - O
and - - O
p65 - - O
induced - - O
vigorous - - O
transcription - - O
of - - O
IL-2 - - O
promoter- - - O
and - - O
CD28RE-driven - - O
reporter - - O
constructs - - O
in - - O
both - - O
LFA-3- - - O
and - - O
B7-1-costimulated - - O
Jurkat - - O
cells - - O
. - - O

Treadmill - - O
training - - O
at - - O
least - - O
for - - O
2 - - O
weeks - - O
can - - O
reduce - - O
the - - O
infarction - - O
size - - O
and - - O
edema - - O
caused - - O
by - - O
MCA - - O
occlusion - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

However - - O
, - - O
unlike - - O
the - - O
SIN3 - - O
gene - - O
of - - O
Saccharomyces - - O
cerevisiae - - O
, - - O
pst1 - - O
( - - O
+ - - O
) - - O
is - - O
essential - - O
for - - O
cell - - O
viability - - O
. - - O

Calmodulin-binding - - O
peptide - - O
( - - O
CBP - - O
) - - O
, - - O
a - - O
peptide - - O
of - - O
26 - - O
amino - - O
acids - - O
derived - - O
from - - O
muscle - - O
myosin - - O
light - - O
chain - - O
kinase - - O
( - - O
MLCK - - O
) - - O
, - - O
binds - - O
to - - O
calmodulin - - O
with - - O
nanomolar - - O
affinity - - O
. - - O

After - - O
the - - O
meal - - O
containing - - O
potato - - O
, - - O
plasma - - O
glucose - - O
levels - - O
rose - - O
sharply - - O
, - - O
peaked - - O
at - - O
30-45 - - O
min - - O
and - - O
fell - - O
below - - O
initial - - O
levels - - O
2 - - O
to - - O
3 - - O
h - - O
later - - O
. - - O

ATP - - O
gamma - - O
S - - O
inhibition - - O
can - - O
be - - O
overcome - - O
by - - O
high - - O
concentrations - - O
of - - O
ATP - - O
, - - O
dATP - - O
, - - O
araATP - - O
, - - O
or - - O
ddATP - - O
. - - O

The - - O
gene - - O
encodes - - O
an - - O
ATP-binding - - O
cassette - - O
, - - O
ABC - - O
transporter - - O
. - - O

Muscle - - O
GSH-Px - - O
activity - - O
after - - O
prolonged - - O
exercise - - O
, - - O
training - - O
, - - O
and - - O
selenium - - O
supplementation - - O
. - - O

RESULTS - - O
: - - O
The - - O
bovine - - O
cDNA - - O
insert - - O
sequence - - O
was - - O
273 - - O
nucleotides - - O
in - - O
length - - O
for - - O
the - - O
entire - - O
mRNA - - O
coding - - O
region - - O
, - - O
212 - - O
nucleotides - - O
in - - O
the - - O
5' - - O
untranslated - - O
region - - O
, - - O
83 - - O
nucleotides - - O
in - - O
the - - O
3' - - O
untranslated - - O
region - - O
and - - O
a - - O
poly - - O
( - - O
A - - O
) - - O
tail - - O
. - - O

Therapeutic - - O
use - - O
of - - O
cannabis - - O
. - - O

Toxicity - - O
was - - O
mild - - O
, - - O
mainly - - O
consisting - - O
of - - O
emesis - - O
( - - O
81% - - O
of - - O
the - - O
patients - - O
; - - O
66% - - O
of - - O
the - - O
courses - - O
) - - O
, - - O
leukopenia - - O
of - - O
World - - O
Health - - O
Organization - - O
( - - O
WHO - - O
) - - O
grade - - O
1 - - O
to - - O
2 - - O
( - - O
47% - - O
of - - O
the - - O
patients - - O
; - - O
18% - - O
of - - O
the - - O
courses - - O
) - - O
, - - O
and - - O
thrombocytopenia - - O
( - - O
12% - - O
of - - O
the - - O
patients - - O
; - - O
3% - - O
of - - O
the - - O
courses - - O
) - - O
. - - O

Refractory - - O
periods - - O
of - - O
the - - O
AV - - O
junction - - O
were - - O
altered - - O
in - - O
a - - O
comparable - - O
fashion - - O
to - - O
conduction - - O
through - - O
the - - O
AV - - O
node - - O
. - - O

Development - - O
of - - O
a - - O
yeast - - O
system - - O
to - - O
assay - - O
mutational - - O
specificity - - O
. - - O

Although - - O
some - - O
residues - - O
are - - O
found - - O
reactive - - O
toward - - O
dimethylsulphate - - O
and - - O
kethoxal - - O
in - - O
regions - - O
predicted - - O
to - - O
be - - O
unpaired - - O
by - - O
the - - O
phylogenetic - - O
secondary - - O
structure - - O
model - - O
of - - O
4 - - O
. - - O
5S - - O
RNA - - O
, - - O
generally - - O
the - - O
reactivity - - O
is - - O
low - - O
, - - O
and - - O
some - - O
residues - - O
in - - O
internal - - O
loops - - O
are - - O
not - - O
reactive - - O
at - - O
all - - O
. - - O

Interpersonal - - O
style - - O
differences - - O
among - - O
drug - - O
abusers - - O
were - - O
explored - - O
using - - O
Ryan's - - O
( - - O
1977 - - O
) - - O
typological - - O
system - - O
of - - O
FIRO-B - - O
interpretation - - O
. - - O

Fasting - - O
plasma - - O
and - - O
lipoprotein - - O
lipid - - O
concentrations - - O
, - - O
adipose - - O
tissue - - O
lipoprotein - - O
lipase - - O
activity - - O
, - - O
anthropometric - - O
data - - O
, - - O
alcohol - - O
consumption - - O
, - - O
smoking - - O
habits - - O
, - - O
weekly - - O
mileage - - O
run - - O
and - - O
performance - - O
on - - O
a - - O
bicycle - - O
ergometer - - O
were - - O
recorded - - O
before - - O
and - - O
after - - O
the - - O
training - - O
period - - O
. - - O

The - - O
presence - - O
of - - O
circulating - - O
platelet - - O
aggregates - - O
and - - O
elevated - - O
levels - - O
of - - O
fibrinopeptide - - O
A - - O
( - - O
a - - O
cleavage - - O
product - - O
of - - O
fibrin - - O
) - - O
suggests - - O
that - - O
platelet - - O
activation - - O
and - - O
fibrin - - O
deposition - - O
may - - O
play - - O
a - - O
role - - O
in - - O
the - - O
pathogenesis - - O
of - - O
this - - O
disorder - - O
. - - O

Additionally - - O
in - - O
seven - - O
subjects - - O
adrenaline - - O
( - - O
A - - O
) - - O
and - - O
noradrenaline - - O
( - - O
NA - - O
) - - O
concentrations - - O
were - - O
determined - - O
. - - O

Direct - - O
current - - O
polarography - - O
and - - O
differential - - O
pulse - - O
polarographic - - O
methods - - O
have - - O
been - - O
developed - - O
for - - O
the - - O
qualitative - - O
as - - O
well - - O
as - - O
quantitative - - O
analysis - - O
of - - O
vitamin - - O
B1 - - O
, - - O
B2 - - O
and - - O
B6 - - O
. - - O

Body - - O
fat - - O
distribution - - O
was - - O
determined - - O
by - - O
abdominal - - O
computed - - O
tomography - - O
. - - O

Induction - - O
of - - O
Jurkat - - O
leukemic - - O
T - - O
cells - - O
with - - O
phorbol - - O
12-myristate - - O
13-acetate - - O
and - - O
ionomycin - - O
did - - O
not - - O
affect - - O
the - - O
level - - O
of - - O
FKBP - - O
mRNA - - O
. - - O

Because - - O
the - - O
DPPD - - O
gene - - O
is - - O
not - - O
present - - O
in - - O
non-tuberculous - - O
bacilli - - O
, - - O
these - - O
results - - O
suggest - - O
that - - O
this - - O
molecule - - O
can - - O
be - - O
an - - O
additional - - O
tool - - O
for - - O
a - - O
more - - O
specific - - O
diagnosis - - O
of - - O
tuberculosis - - O
. - - O

Mo - - O
+ - - O
SV - - O
M-MuLV-inoculated - - O
animals - - O
became - - O
moribund - - O
at - - O
3 - - O
to - - O
13 - - O
months - - O
postinoculation - - O
, - - O
whereas - - O
delta - - O
Mo - - O
+ - - O
SV - - O
M-MuLV-inoculated - - O
animals - - O
became - - O
moribund - - O
at - - O
6 - - O
to - - O
24 - - O
months - - O
postinoculation - - O
. - - O

Cowpox - - O
virus - - O
contains - - O
two - - O
copies - - O
of - - O
an - - O
early - - O
gene - - O
encoding - - O
a - - O
soluble - - O
secreted - - O
form - - O
of - - O
the - - O
type - - O
II - - O
TNF - - O
receptor - - O
. - - O

Fetal - - O
growth - - O
retardation - - O
as - - O
a - - O
cause - - O
of - - O
impaired - - O
ovarian - - O
development - - O
. - - O

Gas6 - - O
contains - - O
an - - O
NH2-terminal - - O
Gla - - O
domain - - O
followed - - O
by - - O
four - - O
epidermal - - O
growth - - O
factor-like - - O
repeats - - O
and - - O
tandem - - O
globular - - O
( - - O
G - - O
) - - O
domains - - O
. - - O

As - - O
control - - O
, - - O
the - - O
cells - - O
were - - O
transfected - - O
with - - O
DNA - - O
mixtures - - O
containing - - O
vector - - O
mU6-C1 - - O
or - - O
mU6-C2 - - O
. - - O

This - - O
result - - O
suggests - - O
that - - O
phosphorylation - - O
of - - O
Thr - - O
14 - - O
and - - O
or - - O
Tyr - - O
15 - - O
inhibits - - O
p34cdc2 - - O
kinase - - O
activity - - O
, - - O
in - - O
line - - O
with - - O
the - - O
location - - O
of - - O
these - - O
residues - - O
within - - O
the - - O
putative - - O
ATP - - O
binding - - O
site - - O
of - - O
the - - O
kinase - - O
. - - O

We - - O
have - - O
previously - - O
identified - - O
a - - O
liver-enriched - - O
transcription - - O
factor - - O
, - - O
HNF-6 - - O
, - - O
which - - O
is - - O
required - - O
for - - O
HNF-3 - - O
beta - - O
promoter - - O
activity - - O
and - - O
also - - O
recognizes - - O
the - - O
regulatory - - O
region - - O
of - - O
numerous - - O
hepatocyte-specific - - O
genes - - O
. - - O

Two - - O
evolutionarily - - O
conserved - - O
kinases - - O
, - - O
the - - O
cyclin - - O
B - - O
( - - O
Clb - - O
) - - O
cyclin-dependent - - O
kinase - - O
( - - O
Cdk - - O
Cdc28p - - O
) - - O
and - - O
Cdc7p - - O
along - - O
with - - O
its - - O
interacting - - O
factor - - O
Dbf4p - - O
, - - O
are - - O
required - - O
late - - O
in - - O
G1 - - O
to - - O
initiate - - O
DNA - - O
replication - - O
. - - O

An - - O
ion - - O
chromatographic - - O
method - - O
was - - O
used - - O
to - - O
determine - - O
Br - - O
ion - - O
in - - O
the - - O
urine - - O
of - - O
Greyhounds - - O
. - - O

On - - O
the - - O
other - - O
hand - - O
, - - O
knowledge - - O
of - - O
the - - O
epidemiology - - O
of - - O
Parkinson's - - O
disease - - O
is - - O
necessary - - O
in - - O
creating - - O
etiological - - O
hypotheses - - O
, - - O
since - - O
only - - O
hypotheses - - O
consistent - - O
with - - O
the - - O
epidemiological - - O
profile - - O
deserve - - O
careful - - O
testing - - O
. - - O

To - - O
define - - O
transcriptional - - O
control - - O
elements - - O
responsible - - O
for - - O
muscle-specific - - O
expression - - O
of - - O
the - - O
human - - O
myoglobin - - O
gene - - O
, - - O
we - - O
performed - - O
mutational - - O
analysis - - O
of - - O
upstream - - O
sequences - - O
( - - O
nucleotide - - O
positions - - O
-373 - - O
to - - O
+7 - - O
relative - - O
to - - O
the - - O
transcriptional - - O
start - - O
site - - O
) - - O
linked - - O
to - - O
a - - O
firefly - - O
luciferase - - O
gene - - O
. - - O

A - - O
DNA - - O
fragment - - O
carrying - - O
1 - - O
, - - O
100 - - O
nucleotides - - O
derived - - O
from - - O
the - - O
5'-flanking - - O
region - - O
of - - O
the - - O
UGT1A1 - - O
gene - - O
was - - O
enough - - O
for - - O
MC - - O
induction - - O
. - - O

The - - O
present - - O
chemotherapy - - O
of - - O
AE - - O
is - - O
based - - O
on - - O
the - - O
administration - - O
of - - O
benzimidazole - - O
carbamate - - O
derivatives - - O
, - - O
such - - O
as - - O
mebendazole - - O
and - - O
albendazole - - O
. - - O

Limits - - O
of - - O
energy - - O
turnover - - O
in - - O
relation - - O
to - - O
physical - - O
performance - - O
were - - O
addressed - - O
in - - O
terms - - O
of - - O
upper - - O
and - - O
lower - - O
limit - - O
, - - O
changes - - O
during - - O
a - - O
training - - O
programme - - O
and - - O
how - - O
to - - O
regulate - - O
energy - - O
balance - - O
at - - O
a - - O
changing - - O
energy - - O
turnover - - O
. - - O

Non-poliomyelitis - - O
AFP - - O
rate - - O
had - - O
increased - - O
from - - O
0 - - O
. - - O
9 - - O
in - - O
1997 - - O
to - - O
2 - - O
. - - O
8 - - O
in - - O
1998 - - O
. - - O

Most - - O
yeast - - O
peroxisomal - - O
matrix - - O
proteins - - O
contain - - O
a - - O
type - - O
1C-terminal - - O
peroxisomal - - O
targeting - - O
signal - - O
( - - O
PTS1 - - O
) - - O
consisting - - O
of - - O
the - - O
tripeptide - - O
SKL - - O
or - - O
a - - O
conservative - - O
variant - - O
thereof - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
these - - O
relations - - O
, - - O
a - - O
risk - - O
factor-selection - - O
scale - - O
( - - O
RFSS - - O
) - - O
( - - O
range - - O
, - - O
0 - - O
to - - O
10 - - O
) - - O
was - - O
developed - - O
by - - O
computing - - O
appropriate - - O
weights - - O
for - - O
each - - O
risk - - O
factor - - O
. - - O

Mis3 - - O
is - - O
needed - - O
for - - O
the - - O
formation - - O
of - - O
18S - - O
ribosome - - O
RNA - - O
, - - O
and - - O
may - - O
hence - - O
direct - - O
the - - O
level - - O
of - - O
proteins - - O
required - - O
for - - O
the - - O
coupling - - O
. - - O

GRFI - - O
bound - - O
to - - O
sequences - - O
at - - O
the - - O
negative - - O
regulatory - - O
elements - - O
( - - O
silencers - - O
) - - O
of - - O
the - - O
silent - - O
mating - - O
type - - O
loci - - O
HML - - O
E - - O
and - - O
HMR - - O
E - - O
and - - O
to - - O
the - - O
upstream - - O
activating - - O
sequence - - O
( - - O
UAS - - O
) - - O
required - - O
for - - O
transcription - - O
of - - O
the - - O
MAT - - O
alpha - - O
genes - - O
. - - O

Large-scale - - O
sequencing - - O
of - - O
two - - O
regions - - O
in - - O
human - - O
chromosome - - O
7q22 - - O
: - - O
analysis - - O
of - - O
650 - - O
kb - - O
of - - O
genomic - - O
sequence - - O
around - - O
the - - O
EPO - - O
and - - O
CUTL1 - - O
loci - - O
reveals - - O
17 - - O
genes - - O
. - - O

Taken - - O
together - - O
, - - O
our - - O
results - - O
indicate - - O
that - - O
the - - O
FCR1 - - O
gene - - O
behaves - - O
as - - O
a - - O
negative - - O
regulator - - O
of - - O
drug - - O
resistance - - O
in - - O
C - - O
. - - O
albicans - - O
and - - O
constitute - - O
the - - O
first - - O
evidence - - O
that - - O
FCZ - - O
resistance - - O
can - - O
result - - O
from - - O
the - - O
inactivation - - O
of - - O
a - - O
regulatory - - O
factor - - O
such - - O
as - - O
Fcr1p - - O
. - - O

This - - O
emancipation - - O
of - - O
the - - O
ability - - O
to - - O
copulate - - O
from - - O
hormonal - - O
influence - - O
makes - - O
female - - O
sexual - - O
motivation - - O
the - - O
primary - - O
regulator - - O
of - - O
mating - - O
in - - O
primates - - O
. - - O

These - - O
data - - O
demonstrate - - O
that - - O
the - - O
STR - - O
family - - O
of - - O
genes - - O
is - - O
represented - - O
in - - O
a - - O
nematode - - O
whose - - O
ancestor - - O
appeared - - O
well - - O
before - - O
the - - O
branching - - O
that - - O
gave - - O
rise - - O
to - - O
the - - O
Arthropoda - - O
and - - O
Chordata - - O
. - - O

The - - O
Saccharomyces - - O
cerevisiae - - O
APS1 - - O
gene - - O
encodes - - O
a - - O
homolog - - O
of - - O
the - - O
small - - O
subunit - - O
of - - O
the - - O
mammalian - - O
clathrin - - O
AP-1 - - O
complex - - O
: - - O
evidence - - O
for - - O
functional - - O
interaction - - O
with - - O
clathrin - - O
at - - O
the - - O
Golgi - - O
complex - - O
. - - O

In - - O
girls - - O
prolactin - - O
levels - - O
rise - - O
at - - O
stage - - O
2 - - O
, - - O
and - - O
are - - O
higher - - O
after - - O
menarche - - O
; - - O
in - - O
boys - - O
there - - O
is - - O
no - - O
change - - O
in - - O
prolactin - - O
levels - - O
. - - O

Spasmus - - O
nutans - - O
: - - O
a - - O
syndrome - - O
of - - O
auto-arousal - - O
. - - O

The - - O
effects - - O
of - - O
diltiazem - - O
were - - O
stereoselective - - O
, - - O
thus - - O
the - - O
potentiation - - O
induced - - O
by - - O
d-cis - - O
diltiazem - - O
was - - O
significantly - - O
greater - - O
in - - O
all - - O
cases - - O
than - - O
that - - O
induced - - O
by - - O
l-cis - - O
diltiazem - - O
, - - O
which - - O
suggests - - O
that - - O
calcium - - O
channel - - O
blockade - - O
plays - - O
a - - O
role - - O
in - - O
these - - O
interactions - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
the - - O
c-met - - O
gene - - O
is - - O
also - - O
a - - O
target - - O
of - - O
p53 - - O
gene - - O
regulation - - O
. - - O

Dorsal - - O
foot - - O
TcpO2 - - O
was - - O
measured - - O
by - - O
using - - O
oxygen-sensing - - O
electrodes - - O
with - - O
surface - - O
temperatures - - O
of - - O
42 - - O
degrees - - O
C - - O
and - - O
45 - - O
degrees - - O
C - - O
; - - O
in - - O
theory - - O
, - - O
changes - - O
in - - O
sympathetic - - O
activity - - O
should - - O
affect - - O
vasomotor - - O
tone - - O
and - - O
TcpO2 - - O
in - - O
skin - - O
beneath - - O
an - - O
electrode - - O
at - - O
42 - - O
degrees - - O
C - - O
( - - O
submaximal - - O
vasodilation - - O
) - - O
, - - O
but - - O
not - - O
at - - O
45 - - O
degrees - - O
C - - O
( - - O
maximal - - O
vasodilation - - O
) - - O
. - - O

The - - O
84 - - O
. - - O
1C - - O
mAb - - O
recognizes - - O
a - - O
site - - O
on - - O
IgE - - O
which - - O
is - - O
identical - - O
or - - O
very - - O
close - - O
to - - O
the - - O
Fc - - O
epsilon - - O
R - - O
binding - - O
site - - O
, - - O
and - - O
95 - - O
. - - O
3 - - O
recognizes - - O
a - - O
site - - O
on - - O
IgE - - O
which - - O
is - - O
related - - O
, - - O
but - - O
not - - O
identical - - O
to - - O
the - - O
Fc - - O
epsilon - - O
R - - O
binding - - O
site - - O
. - - O

Previous - - O
studies - - O
have - - O
shown - - O
that - - O
the - - O
pro-inflammatory - - O
cytokines - - O
tumor - - O
necrosis - - O
factor - - O
alpha - - O
and - - O
interferon - - O
gamma - - O
reduce - - O
the - - O
expression - - O
of - - O
the - - O
cystic - - O
fibrosis - - O
transmembrane - - O
conductance - - O
regulator - - O
( - - O
CFTR - - O
) - - O
gene - - O
( - - O
CFTR - - O
) - - O
in - - O
HT-29 - - O
and - - O
T84 - - O
cells - - O
by - - O
acting - - O
post-transcriptionally - - O
. - - O

Therefore - - O
, - - O
we - - O
propose - - O
that - - O
p27 - - O
represents - - O
a - - O
crucial - - O
molecule - - O
in - - O
HMBA - - O
signaling - - O
that - - O
cannot - - O
be - - O
replaced - - O
by - - O
p21 - - O
. - - O

No - - O
case - - O
of - - O
SMF - - O
demonstrated - - O
expansive - - O
tumorous - - O
growth - - O
. - - O

The - - O
injection - - O
of - - O
XDRP1 - - O
protein - - O
into - - O
fertilized - - O
Xenopus - - O
eggs - - O
blocked - - O
embryonic - - O
cell - - O
division - - O
. - - O

Lck - - O
has - - O
been - - O
postulated - - O
to - - O
dimerize - - O
through - - O
the - - O
SH2 - - O
and - - O
SH3 - - O
domains - - O
. - - O

The - - O
kinase - - O
activity - - O
of - - O
PfPK6 - - O
is - - O
sensitive - - O
to - - O
CDK - - O
inhibitors - - O
such - - O
as - - O
olomoucine - - O
and - - O
roscovitine - - O
. - - O

Both - - O
HERV-K - - O
type - - O
1 - - O
and - - O
2 - - O
clones - - O
were - - O
isolated - - O
. - - O

These - - O
results - - O
were - - O
compared - - O
with - - O
the - - O
estimates - - O
of - - O
penetration - - O
from - - O
steady-state - - O
calculations - - O
, - - O
square - - O
root - - O
of - - O
time - - O
calculations - - O
, - - O
and - - O
a - - O
biologically - - O
based - - O
mathematical - - O
model - - O
. - - O

Human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
Vpr - - O
is - - O
a - - O
virion-associated - - O
, - - O
regulatory - - O
protein - - O
that - - O
is - - O
required - - O
for - - O
efficient - - O
viral - - O
replication - - O
in - - O
monocytes - - O
macrophages - - O
. - - O

Treatment - - O
of - - O
Paget's - - O
disease - - O
. - - O

Furthermore - - O
, - - O
bone - - O
marrow-derived - - O
macrophages - - O
from - - O
LAT-deficient - - O
mice - - O
displayed - - O
reduced - - O
phagocytic - - O
efficiency - - O
in - - O
comparison - - O
to - - O
the - - O
macrophages - - O
from - - O
wild-type - - O
mice - - O
. - - O

SETTING - - O
: - - O
University - - O
of - - O
Paris - - O
VII - - O
hospital - - O
. - - O
Patient - - O
( - - O
s - - O
) - - O
: - - O
Nine - - O
women - - O
had - - O
embolization - - O
for - - O
symptomatic - - O
myoma - - O
, - - O
with - - O
12 - - O
pregnancies - - O
observed - - O
. - - O

Analysis - - O
of - - O
functional - - O
domains - - O
of - - O
Arix - - O
reveals - - O
an - - O
N-terminal - - O
activation - - O
domain - - O
and - - O
a - - O
C-terminal - - O
repression - - O
domain - - O
. - - O

Nuclear - - O
receptors - - O
( - - O
NRs - - O
) - - O
can - - O
function - - O
as - - O
ligandinducible - - O
transregulators - - O
in - - O
both - - O
mammalian - - O
and - - O
yeast - - O
cells - - O
, - - O
indicating - - O
that - - O
important - - O
features - - O
of - - O
transcriptional - - O
control - - O
have - - O
been - - O
conserved - - O
throughout - - O
evolution - - O
. - - O

Mn2+ - - O
increased - - O
both - - O
the - - O
junction - - O
binding - - O
and - - O
cleaving - - O
activities - - O
of - - O
the - - O
mutant - - O
proteins - - O
. - - O

The - - O
Drosophila - - O
suppressor - - O
of - - O
sable - - O
gene - - O
encodes - - O
a - - O
polypeptide - - O
with - - O
regions - - O
similar - - O
to - - O
those - - O
of - - O
RNA-binding - - O
proteins - - O
. - - O

High - - O
resolution - - O
computed - - O
tomography - - O
of - - O
the - - O
lungs - - O
in - - O
patients - - O
with - - O
rheumatoid - - O
arthritis - - O
. - - O

RESULTS - - O
: - - O
During - - O
the - - O
7-year - - O
period - - O
, - - O
10 - - O
, - - O
331 - - O
symptomatic - - O
duodenal - - O
ulcer - - O
diseases - - O
were - - O
diagnosed - - O
. - - O

In - - O
our - - O
opinion - - O
, - - O
the - - O
SM-CMA - - O
system - - O
is - - O
, - - O
despite - - O
some - - O
shortcomings - - O
in - - O
its - - O
user-interface - - O
, - - O
a - - O
useful - - O
and - - O
versatile - - O
instrument - - O
for - - O
examination - - O
of - - O
human - - O
semen - - O
samples - - O
, - - O
with - - O
desirable - - O
features - - O
. - - O

These - - O
results - - O
support - - O
the - - O
diagnostic - - O
validity - - O
of - - O
NFPD - - O
in - - O
CP - - O
NCA - - O
patients - - O
, - - O
because - - O
such - - O
patients - - O
had - - O
a - - O
family - - O
history - - O
of - - O
panic - - O
disorder - - O
similar - - O
to - - O
patients - - O
with - - O
a - - O
more - - O
classical - - O
panic - - O
disorder - - O
presentation - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
histopathological - - O
findings - - O
, - - O
the - - O
origin - - O
of - - O
amyloid - - O
appeared - - O
to - - O
be - - O
closely - - O
related - - O
to - - O
the - - O
fibroblasts - - O
. - - O

We - - O
have - - O
isolated - - O
a - - O
Drosophila - - O
melanogaster - - O
( - - O
Dm - - O
) - - O
cDNA - - O
encoding - - O
a - - O
polypeptide - - O
that - - O
has - - O
extensive - - O
sequence - - O
similarity - - O
to - - O
the - - O
mammalian - - O
MAPKAPK-2 - - O
. - - O

Here - - O
, - - O
we - - O
present - - O
evidence - - O
that - - O
exposure - - O
of - - O
DT40 - - O
lymphoma - - O
B - - O
cells - - O
to - - O
low - - O
energy - - O
electromagnetic - - O
field - - O
( - - O
EMF - - O
) - - O
results - - O
in - - O
a - - O
tyrosine - - O
kinase-dependent - - O
activation - - O
of - - O
phospholipase - - O
Cgamma2 - - O
( - - O
PLC-gamma2 - - O
) - - O
leading - - O
to - - O
increased - - O
inositol - - O
phospholipid - - O
turnover - - O
. - - O

Inhibition - - O
of - - O
RNA2 - - O
translation - - O
was - - O
selective - - O
, - - O
with - - O
no - - O
effect - - O
on - - O
general - - O
cellular - - O
translation - - O
or - - O
translation - - O
of - - O
BMV - - O
RNA1-encoded - - O
replication - - O
factor - - O
1a - - O
, - - O
and - - O
was - - O
independent - - O
of - - O
p20 - - O
, - - O
a - - O
cellular - - O
antagonist - - O
of - - O
DED1 - - O
function - - O
in - - O
translation - - O
. - - O

Clinical - - O
and - - O
anatomical - - O
considerations - - O
. - - O

Salazopyrine - - O
desensitization - - O
. - - O

Despite - - O
the - - O
favourable - - O
natural - - O
history - - O
of - - O
acute - - O
BI - - O
, - - O
mild - - O
, - - O
moderate - - O
, - - O
and - - O
severe - - O
posttraumatic - - O
changes - - O
were - - O
shown - - O
to - - O
appear - - O
as - - O
cicatricial-adhesive - - O
and - - O
atrophic - - O
processes - - O
, - - O
intracerebral - - O
cysts - - O
, - - O
porencephaly - - O
, - - O
which - - O
result - - O
in - - O
posttraumatic - - O
epilepsy - - O
, - - O
hydrocephalus - - O
, - - O
etc - - O
. - - O

Third- - - O
and - - O
later-parity - - O
cows - - O
were - - O
randomly - - O
assigned - - O
after - - O
each - - O
parturition - - O
to - - O
Charolais - - O
and - - O
Red - - O
Poll - - O
bulls - - O
in - - O
multiple-sire - - O
pastures - - O
. - - O

Under - - O
our - - O
conditions - - O
, - - O
the - - O
combination - - O
O3 - - O
UV - - O
did - - O
not - - O
improve - - O
the - - O
degradation - - O
rate - - O
obtained - - O
by - - O
ozonation - - O
. - - O

For - - O
sputum - - O
interleukin-8 - - O
there - - O
was - - O
an - - O
estimated - - O
true - - O
treatment - - O
median - - O
difference - - O
of - - O
142 - - O
pg - - O
ml - - O
( - - O
95% - - O
confidence - - O
interval - - O
( - - O
CI - - O
) - - O
8 - - O
to - - O
2866 - - O
pg - - O
ml - - O
) - - O
in - - O
favour - - O
of - - O
placebo - - O
; - - O
while - - O
for - - O
maximal - - O
expiratory - - O
flow - - O
at - - O
25% - - O
( - - O
MEF25% - - O
) - - O
remaining - - O
forced - - O
vital - - O
capacity - - O
predicted - - O
for - - O
sex - - O
and - - O
height - - O
there - - O
was - - O
a - - O
15 - - O
percentage - - O
points - - O
( - - O
pp - - O
) - - O
( - - O
95% - - O
CI - - O
4 - - O
to - - O
26 - - O
pp - - O
) - - O
mean - - O
treatment - - O
difference - - O
in - - O
favour - - O
of - - O
placebo - - O
. - - O

Genetic - - O
alterations - - O
in - - O
elements - - O
of - - O
normal - - O
signal - - O
transduction - - O
mechanisms - - O
are - - O
known - - O
to - - O
be - - O
oncogenic - - O
events - - O
often - - O
resulting - - O
in - - O
aberrant - - O
activation - - O
of - - O
programs - - O
of - - O
gene - - O
transcription - - O
. - - O

In - - O
the - - O
diabetics - - O
, - - O
Ca2+ - - O
infusions - - O
induced - - O
a - - O
rise - - O
of - - O
plasma - - O
Ca2+ - - O
up - - O
to - - O
3 - - O
. - - O
2 - - O
+ - - O
- - - O
0 - - O
. - - O
1 - - O
mmol - - O
1 - - O
and - - O
a - - O
fall - - O
of - - O
circulating - - O
glucagon - - O
( - - O
-26 - - O
. - - O
4 - - O
+ - - O
- - - O
5 - - O
. - - O
7% - - O
; - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
and - - O
glucose - - O
( - - O
-23 - - O
. - - O
3 - - O
+ - - O
- - - O
3 - - O
. - - O
6% - - O
; - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

This - - O
gene - - O
spans - - O
23 - - O
kb - - O
and - - O
is - - O
composed - - O
of - - O
five - - O
exons - - O
and - - O
four - - O
introns - - O
. - - O

They - - O
observed - - O
depressed - - O
protein - - O
C - - O
activity - - O
that - - O
significantly - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
005 - - O
) - - O
increased - - O
and - - O
became - - O
normal - - O
immediately - - O
after - - O
hemodialysis - - O
while - - O
factor - - O
X - - O
and - - O
factor - - O
VII - - O
increased - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
; - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
despite - - O
heparinization - - O
together - - O
with - - O
amount - - O
of - - O
serum - - O
lipoprotein - - O
( - - O
a - - O
) - - O
. - - O

The - - O
data - - O
presented - - O
in - - O
this - - O
work - - O
indicate - - O
that - - O
thi1 - - O
may - - O
also - - O
be - - O
involved - - O
in - - O
DNA - - O
damage - - O
tolerance - - O
in - - O
plant - - O
cells - - O
. - - O

For - - O
the - - O
5HT5A - - O
receptor - - O
the - - O
addition - - O
of - - O
yohimbine - - O
resulted - - O
in - - O
a - - O
similar - - O
but - - O
smaller - - O
effect - - O
. - - O

Sequence - - O
comparisons - - O
have - - O
shown - - O
that - - O
Aps1p - - O
is - - O
more - - O
similar - - O
to - - O
the - - O
sigma - - O
subunit - - O
of - - O
the - - O
Golgi-localized - - O
mammalian - - O
AP-1 - - O
complex - - O
than - - O
Aps2p - - O
, - - O
which - - O
is - - O
more - - O
related - - O
to - - O
the - - O
plasma - - O
membrane - - O
AP-2 - - O
sigma - - O
subunit - - O
. - - O

The - - O
levels - - O
of - - O
fibrinogen - - O
as - - O
well - - O
as - - O
antithrombin - - O
III - - O
( - - O
ATIII - - O
) - - O
and - - O
heparin - - O
cofactor - - O
II - - O
( - - O
HCII - - O
) - - O
activities - - O
were - - O
steadily - - O
increased - - O
in - - O
loop-bearing - - O
animals - - O
. - - O

Another - - O
group - - O
of - - O
HIPP- - - O
and - - O
HCX-lesioned - - O
animals - - O
trained - - O
on - - O
the - - O
tasks - - O
after - - O
the - - O
lesion - - O
showed - - O
reduced - - O
impairments - - O
of - - O
the - - O
type - - O
described - - O
above - - O
, - - O
suggesting - - O
that - - O
extrahippocampal - - O
structures - - O
trained - - O
after - - O
the - - O
lesion - - O
can - - O
assume - - O
the - - O
role - - O
of - - O
the - - O
hippocampus - - O
to - - O
some - - O
degree - - O
. - - O

Two - - O
domains - - O
of - - O
EBNA2 - - O
defined - - O
by - - O
deletion - - O
of - - O
amino - - O
acids - - O
247-337 - - O
and - - O
437-476 - - O
were - - O
found - - O
to - - O
be - - O
important - - O
for - - O
the - - O
activation - - O
of - - O
both - - O
promoters - - O
, - - O
while - - O
two - - O
different - - O
domains - - O
corresponding - - O
to - - O
residues - - O
4-18 - - O
and - - O
118-198 - - O
were - - O
required - - O
solely - - O
for - - O
the - - O
LMP1 - - O
promoter - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
the - - O
total - - O
number - - O
of - - O
subunit - - O
c - - O
in - - O
F0 - - O
should - - O
be - - O
a - - O
multiple - - O
of - - O
2 - - O
and - - O
3 - - O
. - - O

At - - O
termination - - O
( - - O
gd - - O
20 - - O
) - - O
, - - O
confirmed-pregnant - - O
females - - O
( - - O
21 - - O
to - - O
25 - - O
per - - O
group - - O
) - - O
were - - O
evaluated - - O
for - - O
clinical - - O
status - - O
and - - O
gestational - - O
outcome - - O
; - - O
live - - O
fetuses - - O
were - - O
examined - - O
for - - O
external - - O
, - - O
visceral - - O
, - - O
and - - O
skeletal - - O
malformations - - O
. - - O

Is - - O
more - - O
better - - O
? - - O
About - - O
dose - - O
levels - - O
of - - O
ACE - - O
inhibitors - - O
in - - O
chronic - - O
heart - - O
failure - - O
. - - O

To - - O
determine - - O
which - - O
region - - O
of - - O
SulA - - O
is - - O
essential - - O
for - - O
the - - O
inhibition - - O
of - - O
cell - - O
division - - O
, - - O
we - - O
constructed - - O
a - - O
series - - O
of - - O
N-terminal - - O
and - - O
C-terminal - - O
deletions - - O
of - - O
SulA - - O
and - - O
a - - O
series - - O
of - - O
alanine - - O
substitution - - O
mutants - - O
. - - O

Shape - - O
factor - - O
correlated - - O
well - - O
with - - O
hemodynamic - - O
data - - O
for - - O
RV - - O
LV - - O
systolic - - O
pressure - - O
ratios - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
93 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
for - - O
normalized - - O
interventricular - - O
pressure - - O
differences - - O
( - - O
r - - O
= - - O
-0 - - O
. - - O
95 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

The - - O
mutation - - O
experiments - - O
showed - - O
that - - O
the - - O
most - - O
critical - - O
sequence - - O
for - - O
the - - O
repression - - O
of - - O
PTH - - O
was - - O
5'-GGGGGAGGGGAG-3' - - O
( - - O
+1 - - O
to - - O
+12 - - O
) - - O
of - - O
PTHSR - - O
. - - O

In - - O
general - - O
, - - O
the - - O
filtration - - O
rate - - O
in - - O
relevant - - O
areas - - O
appears - - O
to - - O
be - - O
an - - O
integrative - - O
and - - O
easily - - O
determined - - O
parameter - - O
, - - O
reflecting - - O
hormonal - - O
and - - O
neurogenic - - O
vascular - - O
as - - O
well - - O
as - - O
local - - O
interstitial - - O
control - - O
of - - O
the - - O
Starling - - O
forces - - O
. - - O

Two - - O
putative - - O
12-O-tetradecanoyl-phorbol-13-acetate - - O
( - - O
TPA - - O
) - - O
response - - O
elements - - O
, - - O
that - - O
might - - O
serve - - O
as - - O
binding - - O
sites - - O
for - - O
the - - O
transcription - - O
factor - - O
AP-1 - - O
and - - O
a - - O
consensus - - O
sequence - - O
of - - O
a - - O
transforming - - O
growth - - O
factor - - O
beta - - O
1 - - O
( - - O
TGF-beta - - O
1 - - O
) - - O
inhibitory - - O
element - - O
were - - O
found - - O
in - - O
the - - O
promoter - - O
region - - O
. - - O

Crosstalk - - O
among - - O
the - - O
pathways - - O
may - - O
explain - - O
how - - O
some - - O
forms - - O
of - - O
stress - - O
can - - O
contribute - - O
to - - O
the - - O
development - - O
of - - O
a - - O
malignancy - - O
. - - O

Analysis - - O
of - - O
electrically - - O
evoked - - O
response - - O
( - - O
EER - - O
) - - O
in - - O
relation - - O
to - - O
the - - O
central - - O
visual - - O
pathway - - O
of - - O
the - - O
cat - - O
( - - O
1 - - O
) - - O
. - - O

The - - O
effectiveness - - O
of - - O
alpha-mercapto-beta- - - O
( - - O
2-furyl - - O
) - - O
acrylic - - O
acid - - O
( - - O
MFA - - O
) - - O
and - - O
N-benzyl-N-dithiocarboxy-D-glucamine - - O
( - - O
NaB - - O
) - - O
, - - O
used - - O
in - - O
combination - - O
, - - O
in - - O
the - - O
mobilization - - O
and - - O
excretion - - O
of - - O
lead - - O
was - - O
investigated - - O
in - - O
rats - - O
. - - O

The - - O
319 - - O
base - - O
pair - - O
region - - O
immediately - - O
upstream - - O
of - - O
the - - O
CAP - - O
site - - O
is - - O
characterized - - O
by - - O
the - - O
lack - - O
of - - O
a - - O
proximal - - O
TATA - - O
box - - O
and - - O
the - - O
presence - - O
of - - O
sequences - - O
similar - - O
to - - O
GC - - O
boxes - - O
, - - O
CACCC - - O
boxes - - O
, - - O
CCAAT - - O
boxes - - O
, - - O
activator - - O
protein - - O
2 - - O
( - - O
Ap-2 - - O
) - - O
sites - - O
, - - O
partial - - O
glucocorticoid - - O
response - - O
elements - - O
( - - O
GREs - - O
) - - O
, - - O
and - - O
partial - - O
cyclic - - O
AMP - - O
response - - O
elements - - O
( - - O
CREs - - O
) - - O
. - - O

This - - O
two-helix - - O
motif - - O
is - - O
thought - - O
to - - O
be - - O
involved - - O
in - - O
specific - - O
DNA - - O
sequence - - O
recognition - - O
by - - O
CAP - - O
. - - O

Vitamin - - O
D3 - - O
and - - O
calcium - - O
absorption - - O
in - - O
the - - O
chick - - O
. - - O

Far - - O
from - - O
this - - O
being - - O
the - - O
case - - O
, - - O
however - - O
, - - O
the - - O
measurement - - O
of - - O
apo - - O
B - - O
has - - O
met - - O
every - - O
reasonable - - O
standard - - O
of - - O
laboratory - - O
precision - - O
and - - O
reliability - - O
to - - O
allow - - O
its - - O
widespread - - O
introduction - - O
in - - O
clinical - - O
laboratories - - O
. - - O

Under - - O
halothane - - O
anesthesia - - O
, - - O
the - - O
flow - - O
pneumocardiogram - - O
( - - O
PnCG - - O
) - - O
and - - O
its - - O
time - - O
derivative - - O
( - - O
acceleration - - O
pneumocardiogram - - O
or - - O
dPn - - O
dt - - O
) - - O
were - - O
transduced - - O
during - - O
apnea - - O
by - - O
a - - O
small - - O
high-gain - - O
pneumotachograph - - O
. - - O

Phosphorylation - - O
of - - O
myosin-binding - - O
subunit - - O
( - - O
MBS - - O
) - - O
of - - O
myosin - - O
phosphatase - - O
by - - O
Rho-kinase - - O
in - - O
vivo - - O
. - - O

GTRE - - O
, - - O
TRE - - O
, - - O
and - - O
CRE - - O
oligonucleotides - - O
all - - O
compete - - O
more - - O
efficiently - - O
for - - O
protein - - O
binding - - O
to - - O
their - - O
labeled - - O
congeners - - O
than - - O
for - - O
protein - - O
binding - - O
to - - O
either - - O
of - - O
the - - O
other - - O
labeled - - O
oligonucleotides - - O
, - - O
suggesting - - O
that - - O
the - - O
GTRE - - O
, - - O
TRE - - O
, - - O
and - - O
CRE - - O
oligonucleotides - - O
, - - O
suggesting - - O
that - - O
the - - O
GTRE - - O
, - - O
TRE - - O
, - - O
and - - O
CRE - - O
oligonucleotides - - O
each - - O
bind - - O
unique - - O
as - - O
well - - O
as - - O
common - - O
proteins - - O
, - - O
likely - - O
to - - O
be - - O
members - - O
of - - O
the - - O
Jun - - O
Fos - - O
and - - O
cAMP-responsive - - O
element-binding - - O
protein - - O
activating - - O
transcription - - O
factors - - O
( - - O
CREB - - O
ATF - - O
) - - O
families - - O
of - - O
transcription - - O
factors - - O
, - - O
in - - O
chromaffin - - O
cells - - O
. - - O

We - - O
have - - O
generated - - O
various - - O
base - - O
substitutions - - O
and - - O
internal - - O
deletions - - O
in - - O
and - - O
around - - O
DRE - - O
( - - O
nucleotide - - O
positions - - O
-93 - - O
to - - O
-100 - - O
with - - O
respect - - O
to - - O
the - - O
transcription - - O
initiation - - O
site - - O
) - - O
of - - O
the - - O
PCNA - - O
gene - - O
in - - O
vitro - - O
and - - O
subsequently - - O
examined - - O
their - - O
effects - - O
on - - O
the - - O
binding - - O
to - - O
DREF - - O
( - - O
DRE-binding - - O
factor - - O
) - - O
and - - O
PCNA - - O
gene - - O
promote - - O
activity - - O
in - - O
cultured - - O
Drosophila - - O
Kc - - O
cells - - O
as - - O
well - - O
as - - O
in - - O
living - - O
flies - - O
. - - O

Transient - - O
transfections - - O
showed - - O
that - - O
a - - O
single - - O
mutation - - O
( - - O
556M - - O
) - - O
decreased - - O
TBLV - - O
enhancer - - O
activity - - O
at - - O
least - - O
20-fold - - O
in - - O
two - - O
different - - O
T-cell - - O
lines - - O
. - - O

Fas - - O
has - - O
been - - O
shown - - O
to - - O
require - - O
ICE - - O
( - - O
interleukin-1 - - O
beta-converting - - O
enzyme - - O
) - - O
family - - O
proteases - - O
to - - O
induce - - O
apoptosis - - O
from - - O
studies - - O
utilizing - - O
the - - O
cowpox - - O
ICE - - O
inhibitor - - O
protein - - O
CrmA - - O
, - - O
the - - O
synthetic - - O
tetrapeptide - - O
ICE - - O
inhibitor - - O
YVAD-CMK - - O
, - - O
and - - O
the - - O
tripeptide - - O
pan-ICE - - O
inhibitor - - O
Z-VAD-FMK - - O
. - - O

However - - O
, - - O
the - - O
lens - - O
dose - - O
( - - O
3 - - O
. - - O
6 - - O
Gy - - O
25 - - O
fractions - - O
) - - O
was - - O
higher - - O
compared - - O
to - - O
the - - O
other - - O
techniques - - O
. - - O

An - - O
inverted - - O
Alu - - O
repeat - - O
element - - O
, - - O
flanked - - O
by - - O
nonamer - - O
direct - - O
repeats - - O
, - - O
was - - O
identified - - O
within - - O
the - - O
region - - O
-913 - - O
-620 - - O
, - - O
relative - - O
to - - O
the - - O
cap - - O
site - - O
. - - O

Studies - - O
using - - O
a - - O
reporter - - O
plasmid - - O
with - - O
a - - O
functionally - - O
disrupted - - O
sterol-responsive - - O
element - - O
( - - O
SRE - - O
) - - O
-1 - - O
revealed - - O
a - - O
reduced - - O
stimulatory - - O
response - - O
to - - O
IL-6 - - O
. - - O

The - - O
proposed - - O
algorithm - - O
consists - - O
of - - O
several - - O
steps - - O
. - - O

Ganciclovir - - O
and - - O
foscarnet - - O
efficacy - - O
in - - O
AIDS-related - - O
CMV - - O
polyradiculopathy - - O
. - - O

A - - O
. - - O

Although - - O
both - - O
transfected - - O
cell - - O
lines - - O
contain - - O
FGF-1 - - O
cell - - O
surface - - O
receptors - - O
as - - O
judged - - O
by - - O
crosslinking - - O
studies - - O
, - - O
the - - O
wild-type - - O
transfectants - - O
are - - O
refractory - - O
to - - O
exogenous - - O
FGF-1 - - O
, - - O
whereas - - O
the - - O
mutant - - O
transfectants - - O
respond - - O
normally - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

This - - O
report - - O
presents - - O
the - - O
isolation - - O
and - - O
characterization - - O
of - - O
the - - O
5'-flanking - - O
region - - O
( - - O
1 - - O
. - - O
2 - - O
kb - - O
) - - O
and - - O
exon - - O
1 - - O
of - - O
the - - O
human - - O
RII - - O
alpha - - O
gene - - O
. - - O

It - - O
is - - O
also - - O
homologous - - O
to - - O
other - - O
sugar - - O
carriers - - O
from - - O
human - - O
, - - O
mouse - - O
and - - O
Escherichia - - O
coli - - O
. - - O

Our - - O
results - - O
confirm - - O
the - - O
participation - - O
of - - O
intron - - O
1 - - O
in - - O
transcriptional - - O
regulation - - O
of - - O
the - - O
c-myb - - O
gene - - O
( - - O
in - - O
mouse - - O
and - - O
human - - O
) - - O
and - - O
implicate - - O
multiple - - O
and - - O
complex - - O
regulatory - - O
mechanisms - - O
of - - O
activation - - O
during - - O
myelomonocytic - - O
differentiation - - O
and - - O
leukemic - - O
cell - - O
growth - - O
control - - O
. - - O

There - - O
was - - O
a - - O
general - - O
broadening - - O
of - - O
proton - - O
resonances - - O
for - - O
a - - O
three-nucleotide - - O
segment - - O
centered - - O
about - - O
the - - O
lesion - - O
site - - O
which - - O
resulted - - O
in - - O
a - - O
tentative - - O
assignment - - O
for - - O
the - - O
sugar - - O
protons - - O
of - - O
the - - O
C7 - - O
residue - - O
in - - O
the - - O
spectrum - - O
of - - O
the - - O
adduct - - O
duplex - - O
. - - O

We - - O
report - - O
here - - O
the - - O
cloning - - O
of - - O
the - - O
human - - O
goosecoid - - O
gene - - O
( - - O
GSC - - O
) - - O
from - - O
a - - O
genomic - - O
library - - O
and - - O
the - - O
sequence - - O
of - - O
its - - O
encoded - - O
protein - - O
. - - O

The - - O
accumulated - - O
products - - O
of - - O
ancient - - O
duplication - - O
events - - O
can - - O
be - - O
readily - - O
observed - - O
among - - O
the - - O
genes - - O
encoding - - O
voltage-dependent - - O
Ca - - O
( - - O
2+ - - O
) - - O
ion - - O
channels - - O
. - - O

On - - O
the - - O
other - - O
hand - - O
, - - O
lack - - O
of - - O
conservation - - O
of - - O
the - - O
membrane - - O
attachment - - O
sequence - - O
arginine-glycine-aspartic - - O
acid - - O
argues - - O
against - - O
its - - O
functional - - O
importance - - O
in - - O
CgA - - O
. - - O

The - - O
hcKrox - - O
gene - - O
family - - O
regulates - - O
multiple - - O
extracellular - - O
matrix - - O
genes - - O
. - - O

A - - O
noncatalytic - - O
domain - - O
conserved - - O
among - - O
cytoplasmic - - O
protein-tyrosine - - O
kinases - - O
modifies - - O
the - - O
kinase - - O
function - - O
and - - O
transforming - - O
activity - - O
of - - O
Fujinami - - O
sarcoma - - O
virus - - O
P130gag-fps - - O
. - - O

Northern - - O
blot - - O
analysis - - O
indicates - - O
that - - O
AHA2 - - O
mRNA - - O
relative - - O
to - - O
total - - O
cellular - - O
RNA - - O
is - - O
expressed - - O
at - - O
significantly - - O
higher - - O
levels - - O
in - - O
root - - O
tissue - - O
as - - O
compared - - O
with - - O
shoot - - O
tissue - - O
. - - O

A - - O
unified - - O
approach - - O
to - - O
the - - O
standardization - - O
of - - O
allergens - - O
. - - O

Sevelamer - - O
hydrochloride - - O
( - - O
Renagel - - O
) - - O
is - - O
a - - O
nonabsorbed - - O
phosphate-binding - - O
polymer - - O
marketed - - O
for - - O
the - - O
treatment - - O
of - - O
hyperphosphatemia - - O
in - - O
adult - - O
patients - - O
receiving - - O
hemodialysis - - O
. - - O

Here - - O
we - - O
show - - O
that - - O
messenger - - O
RNAs - - O
encoding - - O
trans-sialidases - - O
containing - - O
the - - O
repeats - - O
are - - O
not - - O
present - - O
in - - O
epimastigotes - - O
but - - O
are - - O
abundant - - O
in - - O
trypomastigotes - - O
. - - O

Doctor - - O
Berglund - - O
warns - - O
members - - O
of - - O
union - - O
pitfalls - - O
. - - O

Enzyme-linked - - O
immunosorbent - - O
assay - - O
for - - O
screening - - O
aflatoxin - - O
B1 - - O
in - - O
cottonseed - - O
products - - O
and - - O
mixed - - O
feed - - O
: - - O
collaborative - - O
study - - O
. - - O

Molecular - - O
characterization - - O
and - - O
expression - - O
of - - O
the - - O
Erwinia - - O
carotovora - - O
hrpNEcc - - O
gene - - O
, - - O
which - - O
encodes - - O
an - - O
elicitor - - O
of - - O
the - - O
hypersensitive - - O
reaction - - O
. - - O

CONCLUSIONS - - O
: - - O
Although - - O
the - - O
levels - - O
of - - O
oxLDL - - O
antibodies - - O
might - - O
be - - O
modified - - O
in - - O
early - - O
hypertension - - O
, - - O
once - - O
advanced - - O
coronary - - O
artery - - O
disease - - O
has - - O
developed - - O
the - - O
presence - - O
of - - O
hypertension - - O
does - - O
not - - O
affect - - O
anti-oxLDL - - O
levels - - O
. - - O

The - - O
strategy - - O
has - - O
been - - O
used - - O
to - - O
determine - - O
2 - - O
. - - O
6 - - O
kilobases - - O
of - - O
nucleotide - - O
sequence - - O
in - - O
the - - O
Saccharomyces - - O
cerevisiae - - O
ADE - - O
1 - - O
locus - - O
. - - O

A - - O
subset - - O
of - - O
mutations - - O
in - - O
the - - O
Psi - - O
synthase - - O
domain - - O
impairs - - O
association - - O
of - - O
the - - O
altered - - O
Cbf5p - - O
proteins - - O
with - - O
selected - - O
box - - O
H - - O
ACA - - O
snoRNAs - - O
, - - O
suggesting - - O
that - - O
the - - O
functional - - O
catalytic - - O
domain - - O
is - - O
essential - - O
for - - O
that - - O
interaction - - O
. - - O

Female - - O
Wistar - - O
rats - - O
were - - O
fed - - O
a - - O
liquid - - O
diet - - O
, - - O
Sustacal - - O
, - - O
which - - O
contained - - O
ethanol - - O
( - - O
40% - - O
of - - O
calories - - O
) - - O
or - - O
isocaloric - - O
sucrose - - O
. - - O

They - - O
share - - O
many - - O
downstream - - O
targets - - O
, - - O
including - - O
remodeling - - O
of - - O
the - - O
actin - - O
cytoskeleton - - O
, - - O
activation - - O
of - - O
p70 - - O
( - - O
S6 - - O
) - - O
kinase - - O
and - - O
c-jun - - O
N-terminal - - O
kinase - - O
( - - O
JNK - - O
) - - O
, - - O
and - - O
regulation - - O
of - - O
transcription - - O
and - - O
cell - - O
proliferation - - O
. - - O

272 - - O
, - - O
19107-19110 - - O
) - - O
. - - O

In - - O
the - - O
further - - O
development - - O
of - - O
bladder - - O
neck - - O
suspension - - O
according - - O
to - - O
Stamey-Pereyra - - O
, - - O
the - - O
use - - O
of - - O
miniature - - O
bone - - O
anchors - - O
received - - O
considerable - - O
support - - O
. - - O

GHB - - O
, - - O
2 - - O
CB - - O
, - - O
HMB - - O
, - - O
are - - O
some - - O
of - - O
these - - O
recent - - O
substances - - O
. - - O

Previous - - O
transactivation - - O
experiments - - O
indicated - - O
that - - O
three - - O
amino - - O
acids - - O
residing - - O
in - - O
this - - O
region - - O
, - - O
Gly - - O
, - - O
Ser - - O
and - - O
Val - - O
, - - O
appear - - O
to - - O
be - - O
critical - - O
for - - O
target-site - - O
discrimination - - O
. - - O

Control - - O
of - - O
fatty - - O
liver - - O
syndrome - - O
in - - O
a - - O
Jersey - - O
herd - - O
by - - O
a - - O
change - - O
of - - O
diet - - O
and - - O
the - - O
use - - O
of - - O
recombinant - - O
bovine - - O
somatotrophin - - O
. - - O

A - - O
comparison - - O
of - - O
physical - - O
and - - O
cytogenetic - - O
estimates - - O
of - - O
radiation - - O
dose - - O
in - - O
patients - - O
treated - - O
with - - O
iodine-131 - - O
for - - O
thyroid - - O
carcinoma - - O
. - - O

Initial - - O
experience - - O
with - - O
the - - O
new - - O
technology - - O
indicates - - O
that - - O
SieScape - - O
is - - O
an - - O
alternative - - O
to - - O
other - - O
methods - - O
such - - O
as - - O
CT - - O
and - - O
MRI - - O
. - - O

To - - O
map - - O
this - - O
regulatory - - O
serine - - O
phosphorylation - - O
site - - O
we - - O
developed - - O
a - - O
baculovirus-mediated - - O
expression - - O
system - - O
for - - O
wild-type - - O
annexin - - O
II - - O
and - - O
for - - O
a - - O
series - - O
of - - O
annexin - - O
II - - O
mutants - - O
which - - O
contained - - O
substitutions - - O
in - - O
one - - O
or - - O
more - - O
serine - - O
residues - - O
present - - O
in - - O
the - - O
N-terminal - - O
domain - - O
. - - O

No - - O
difference - - O
in - - O
elastin - - O
peptide - - O
concentration - - O
was - - O
observed - - O
between - - O
emphysematous - - O
patients - - O
and - - O
control - - O
subjects - - O
( - - O
mean - - O
+ - - O
- - - O
SD - - O
= - - O
2 - - O
. - - O
39 - - O
+ - - O
- - - O
1 - - O
. - - O
18 - - O
micrograms - - O
ml - - O
in - - O
patients - - O
versus - - O
2 - - O
. - - O
55 - - O
+ - - O
- - - O
1 - - O
. - - O
34 - - O
micrograms - - O
ml - - O
in - - O
policemen - - O
and - - O
2 - - O
. - - O
59 - - O
+ - - O
- - - O
1 - - O
. - - O
20 - - O
micrograms - - O
ml - - O
in - - O
coal - - O
miners - - O
) - - O
. - - O

CONCLUSIONS - - O
: - - O
In - - O
healthy - - O
individuals - - O
, - - O
whole - - O
body - - O
insulin - - O
sensitivity - - O
is - - O
related - - O
, - - O
or - - O
"coupled - - O
, - - O
" - - O
to - - O
the - - O
anaerobic - - O
threshold - - O
. - - O

The - - O
survival - - O
rate - - O
at - - O
forty - - O
months - - O
in - - O
15 - - O
patients - - O
with - - O
N2 - - O
disease - - O
who - - O
underwent - - O
R2b - - O
operation - - O
was - - O
51% - - O
. - - O

Furthermore - - O
, - - O
we - - O
have - - O
identified - - O
a - - O
43-bp - - O
region - - O
of - - O
the - - O
24p3 - - O
promoter - - O
required - - O
for - - O
the - - O
Dex - - O
responsiveness - - O
. - - O

Histamine - - O
reactivity - - O
was - - O
significantly - - O
reduced - - O
after - - O
the - - O
nifedipine - - O
aerosol - - O
, - - O
the - - O
geometric - - O
mean - - O
provocative - - O
concentration - - O
causing - - O
a - - O
35% - - O
fall - - O
in - - O
specific - - O
airway - - O
conductance - - O
, - - O
rising - - O
from - - O
5 - - O
. - - O
0 - - O
to - - O
10 - - O
. - - O
9 - - O
mg - - O
ml - - O
of - - O
histamine - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

Handgrip - - O
dynamometry - - O
was - - O
also - - O
carried - - O
out - - O
in - - O
249 - - O
of - - O
the - - O
patients - - O
. - - O

By - - O
applying - - O
the - - O
potentiometric - - O
method - - O
, - - O
in - - O
aqueous - - O
medium - - O
of - - O
ionic - - O
strength - - O
mu - - O
= - - O
0 - - O
. - - O
2 - - O
, - - O
the - - O
stability - - O
constants - - O
, - - O
log - - O
beta - - O
1 - - O
= - - O
4 - - O
. - - O
42 - - O
and - - O
log - - O
beta - - O
2 - - O
= - - O
8 - - O
. - - O
57 - - O
were - - O
obtained - - O
. - - O

Induction - - O
of - - O
B - - O
cell - - O
apoptosis - - O
by - - O
co-cross-linking - - O
CD23 - - O
and - - O
sIg - - O
involves - - O
aberrant - - O
regulation - - O
of - - O
c-myc - - O
and - - O
is - - O
inhibited - - O
by - - O
bcl-2 - - O
. - - O

SAECG - - O
, - - O
echocardiography - - O
and - - O
thallium-201 - - O
imaging - - O
were - - O
performed - - O
before - - O
and - - O
1 - - O
month - - O
after - - O
attempted - - O
angioplasty - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
protein - - O
binding - - O
to - - O
the - - O
E2F-like - - O
sequences - - O
may - - O
act - - O
to - - O
reduce - - O
expression - - O
. - - O

The - - O
patient - - O
was - - O
homozygous - - O
for - - O
the - - O
underlying - - O
mutation - - O
, - - O
which - - O
was - - O
found - - O
to - - O
be - - O
a - - O
G-- - - O
> - - O
T - - O
transversion - - O
within - - O
the - - O
acceptor - - O
splice - - O
site - - O
between - - O
intron - - O
e - - O
and - - O
exon - - O
6 - - O
, - - O
abolishing - - O
normal - - O
RNA - - O
splicing - - O
. - - O

The - - O
genomic - - O
structure - - O
of - - O
four - - O
members - - O
of - - O
the - - O
SRC-family - - O
revealed - - O
nearly - - O
identical - - O
exon - - O
intron - - O
boundaries - - O
within - - O
the - - O
catalytic - - O
domain - - O
of - - O
this - - O
family - - O
. - - O

The - - O
students - - O
who - - O
had - - O
abnormal - - O
urine - - O
screening - - O
results - - O
at - - O
the - - O
first - - O
time - - O
received - - O
a - - O
second - - O
urine - - O
analysis - - O
10 - - O
to - - O
15 - - O
days - - O
later - - O
to - - O
confirm - - O
the - - O
abnormal - - O
urine - - O
analysis - - O
. - - O

However - - O
, - - O
addition - - O
of - - O
core - - O
DNA - - O
polymerase - - O
III - - O
to - - O
preinitiation - - O
complex - - O
, - - O
fully - - O
reconstituting - - O
holoenzyme - - O
resulted - - O
in - - O
replacement - - O
of - - O
gamma - - O
by - - O
alpha - - O
at - - O
the - - O
primer - - O
terminus - - O
. - - O

Characterisation - - O
of - - O
the - - O
chicken - - O
apolipoprotein - - O
A-I - - O
gene - - O
5'-flanking - - O
region - - O
. - - O

Plasma - - O
, - - O
LDL - - O
and - - O
liver - - O
cholesterol - - O
concentrations - - O
were - - O
higher - - O
in - - O
the - - O
hyperlipidemic - - O
control - - O
than - - O
the - - O
nonhyperlipidemic - - O
control - - O
and - - O
lower - - O
in - - O
the - - O
groups - - O
fed - - O
diets - - O
containing - - O
pectin - - O
or - - O
prune - - O
fiber - - O
than - - O
in - - O
the - - O
hyperlipidemic - - O
control - - O
group - - O
. - - O

All - - O
of - - O
these - - O
data - - O
suggest - - O
that - - O
replication - - O
of - - O
UV-damaged - - O
templates - - O
occurs - - O
in - - O
vitro - - O
as - - O
it - - O
does - - O
in - - O
vivo - - O
and - - O
that - - O
this - - O
replication - - O
results - - O
in - - O
mutation - - O
fixation - - O
. - - O

In - - O
group - - O
I - - O
adults - - O
both - - O
of - - O
these - - O
variables - - O
increased - - O
. - - O

The - - O
plasma - - O
growth - - O
hormone - - O
concentration - - O
of - - O
the - - O
foetal - - O
lamb - - O
. - - O

Despite - - O
resolution - - O
of - - O
the - - O
solid - - O
portion - - O
of - - O
the - - O
tumor - - O
, - - O
serial - - O
MRI - - O
showed - - O
enlargement - - O
of - - O
a - - O
bilobar - - O
tumor - - O
cyst - - O
3 - - O
years - - O
after - - O
the - - O
original - - O
diagnosis - - O
. - - O

This - - O
approximately - - O
125-nt - - O
RNA - - O
proved - - O
to - - O
arise - - O
via - - O
RNase - - O
E - - O
cleavage - - O
from - - O
the - - O
3'-terminal - - O
region - - O
of - - O
the - - O
mRNAs - - O
bearing - - O
the - - O
terminator - - O
. - - O

Electrophoretic - - O
mobility - - O
shift - - O
assays - - O
using - - O
crude - - O
extracts - - O
from - - O
FREJ4 - - O
cells - - O
revealed - - O
the - - O
binding - - O
of - - O
a - - O
member - - O
( - - O
s - - O
) - - O
of - - O
the - - O
Ets - - O
family - - O
of - - O
transcription - - O
factors - - O
to - - O
the - - O
P4 - - O
EBS - - O
, - - O
as - - O
well - - O
as - - O
the - - O
interaction - - O
of - - O
two - - O
members - - O
of - - O
the - - O
Sp1 - - O
family - - O
, - - O
Sp1 - - O
and - - O
Sp3 - - O
, - - O
with - - O
the - - O
adjacent - - O
GC - - O
box - - O
. - - O

The - - O
binary - - O
and - - O
tertiary - - O
combinations - - O
of - - O
plant-derived - - O
molluscicides - - O
Azadirachta - - O
indica - - O
and - - O
Cedrus - - O
deodara - - O
oil - - O
with - - O
synergists - - O
MGK-264 - - O
, - - O
piperonyl - - O
butoxide - - O
( - - O
PB - - O
) - - O
and - - O
fruit - - O
powder - - O
of - - O
Embelia - - O
ribes - - O
were - - O
used - - O
against - - O
the - - O
Lymnaea - - O
acuminata - - O
. - - O

The - - O
known - - O
B1 - - O
- - - O
deficiency - - O
reaches - - O
excessive - - O
high - - O
values - - O
with - - O
light - - O
exercise - - O
. - - O

The - - O
rate - - O
of - - O
enzymic - - O
stimulation - - O
induced - - O
by - - O
a - - O
given - - O
nitrate - - O
correlates - - O
closely - - O
with - - O
the - - O
rate - - O
of - - O
measured - - O
NO - - O
production - - O
from - - O
the - - O
nitrate - - O
molecule - - O
. - - O

Physiology - - O
and - - O
Physiopathology - - O
. - - O

Experiments - - O
were - - O
performed - - O
in - - O
which - - O
brain-stem - - O
auditory-evoked - - O
responses - - O
( - - O
BAERs - - O
) - - O
were - - O
elicited - - O
by - - O
two - - O
types - - O
of - - O
pseudorandom - - O
pulse - - O
trains - - O
: - - O
maximum - - O
length - - O
sequences - - O
( - - O
MLS - - O
) - - O
and - - O
Legendre - - O
sequences - - O
( - - O
LGS - - O
) - - O
. - - O

Six - - O
patients - - O
with - - O
the - - O
diagnosis - - O
of - - O
acute - - O
mania - - O
were - - O
treated - - O
with - - O
high - - O
doses - - O
of - - O
the - - O
beta-adrenergic - - O
blocking - - O
agent - - O
propranolol - - O
. - - O

PKA - - O
phosphorylated - - O
WT1 - - O
at - - O
Ser-365 - - O
and - - O
Ser-393 - - O
in - - O
vitro - - O
, - - O
as - - O
well - - O
as - - O
at - - O
additional - - O
sites - - O
, - - O
and - - O
this - - O
phosphorylation - - O
abolished - - O
the - - O
DNA-binding - - O
activity - - O
of - - O
WT1 - - O
in - - O
vitro - - O
. - - O

The - - O
color-word - - O
interference - - O
effect - - O
previously - - O
reported - - O
with - - O
normal - - O
populations - - O
when - - O
given - - O
the - - O
Stroop - - O
test - - O
was - - O
demonstrated - - O
for - - O
this - - O
retarded - - O
sample - - O
using - - O
a - - O
special - - O
format - - O
. - - O

Estral - - O
cycle - - O
in - - O
white - - O
rats - - O
in - - O
the - - O
low - - O
and - - O
high - - O
mountains - - O
of - - O
Kirghizia - - O
. - - O

Use - - O
of - - O
Selenastrum - - O
capricornutum - - O
and - - O
Microfeast - - O
as - - O
food - - O
for - - O
Daphnia - - O
pulex - - O
. - - O

The - - O
other - - O
is - - O
located - - O
at - - O
-1335 - - O
, - - O
outside - - O
this - - O
highly - - O
conserved - - O
region - - O
. - - O

No - - O
consistent - - O
correlation - - O
between - - O
blood - - O
pressure - - O
change - - O
and - - O
SCR-change - - O
was - - O
seen - - O
. - - O

Although - - O
YopH - - O
is - - O
a - - O
highly - - O
active - - O
PTP - - O
, - - O
it - - O
preferentially - - O
targets - - O
a - - O
subset - - O
of - - O
tyrosine-phosphorylated - - O
proteins - - O
in - - O
host - - O
cells - - O
, - - O
including - - O
p130Cas - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
baculovirus-expressed - - O
TR - - O
mediates - - O
transcriptional - - O
activation - - O
and - - O
repression - - O
in - - O
a - - O
promoter-specific - - O
manner - - O
in - - O
vitro - - O
. - - O

The - - O
carboxyl-terminal - - O
proline-rich - - O
domain - - O
of - - O
SOS1 - - O
is - - O
involved - - O
in - - O
the - - O
interaction - - O
with - - O
the - - O
PLC-gamma1 - - O
SH3 - - O
domain - - O
. - - O

The - - O
pilE - - O
gene - - O
product - - O
of - - O
Pseudomonas - - O
aeruginosa - - O
, - - O
required - - O
for - - O
pilus - - O
biogenesis - - O
, - - O
shares - - O
amino - - O
acid - - O
sequence - - O
identity - - O
with - - O
the - - O
N-termini - - O
of - - O
type - - O
4 - - O
prepilin - - O
proteins - - O
. - - O

In - - O
contrast - - O
to - - O
the - - O
signaling - - O
triggered - - O
by - - O
surface - - O
Ig - - O
engagement - - O
in - - O
B - - O
lymphocytes - - O
, - - O
CD38 - - O
ligation - - O
did - - O
not - - O
appear - - O
to - - O
induce - - O
tyrosine - - O
phosphorylation - - O
of - - O
the - - O
src-like - - O
protein - - O
tyrosine - - O
kinases - - O
lyn - - O
, - - O
fyn - - O
, - - O
and - - O
btk - - O
, - - O
or - - O
of - - O
vav- - - O
and - - O
ras-GTPase-activating - - O
protein - - O
, - - O
nor - - O
did - - O
it - - O
induce - - O
detectable - - O
changes - - O
in - - O
cytosolic - - O
CA2+ - - O
concentrations - - O
. - - O

A - - O
total - - O
of - - O
57 - - O
patients - - O
with - - O
Hodgkin's - - O
disease - - O
limited - - O
to - - O
above - - O
the - - O
diaphragm - - O
( - - O
Stages - - O
I - - O
and - - O
II - - O
, - - O
A - - O
and - - O
B - - O
) - - O
were - - O
treated - - O
with - - O
radiation - - O
therapy - - O
alone - - O
at - - O
the - - O
University - - O
of - - O
Florida - - O
between - - O
1964 - - O
and - - O
1974 - - O
. - - O

The - - O
RET - - O
PTC3 - - O
rearrangement - - O
is - - O
formed - - O
by - - O
fusion - - O
of - - O
the - - O
ELE1 - - O
and - - O
RET - - O
genes - - O
, - - O
and - - O
is - - O
highly - - O
prevalent - - O
in - - O
radiation-induced - - O
post-Chernobyl - - O
papillary - - O
thyroid - - O
carcinomas - - O
. - - O

The - - O
ns2 - - O
gene - - O
comprises - - O
an - - O
open - - O
reading - - O
frame - - O
( - - O
ORF - - O
) - - O
encoding - - O
a - - O
putative - - O
nonstructural - - O
( - - O
ns - - O
) - - O
protein - - O
of - - O
279 - - O
amino - - O
acids - - O
with - - O
a - - O
predicted - - O
molecular - - O
mass - - O
of - - O
32-kDa - - O
. - - O

These - - O
cognitive - - O
deficits - - O
were - - O
prevented - - O
in - - O
animals - - O
treated - - O
with - - O
MK-801 - - O
during - - O
SE - - O
. - - O

We - - O
previously - - O
showed - - O
that - - O
v-Rel - - O
, - - O
the - - O
oncoprotein - - O
of - - O
the - - O
avian - - O
retrovirus - - O
Rev-T - - O
, - - O
can - - O
increase - - O
expression - - O
from - - O
promoters - - O
containing - - O
binding - - O
sites - - O
for - - O
the - - O
cellular - - O
transcription - - O
factor - - O
Sp1 - - O
in - - O
chicken - - O
embryo - - O
fibroblasts - - O
( - - O
S - - O
. - - O

Allergic - - O
reaction - - O
to - - O
Patent - - O
Blue - - O
Violet - - O
during - - O
lymphography - - O
. - - O

The - - O
data - - O
indicate - - O
that - - O
Bmp2 - - O
is - - O
directly - - O
regulated - - O
by - - O
retinoic - - O
acid-bound - - O
receptors - - O
and - - O
Sp1 - - O
. - - O

NuA4 - - O
has - - O
an - - O
apparent - - O
molecular - - O
mass - - O
of - - O
1 - - O
. - - O
3 - - O
MDa - - O
. - - O

We - - O
also - - O
raised - - O
a - - O
polyclonal - - O
antibody - - O
against - - O
the - - O
glutathione - - O
S-transferase - - O
fusion - - O
protein - - O
containing - - O
the - - O
NH2-terminal - - O
86 - - O
amino - - O
acids - - O
of - - O
human - - O
NRAMP2 - - O
. - - O

The - - O
protein - - O
coding - - O
region - - O
, - - O
1 - - O
, - - O
696 - - O
bps - - O
long - - O
, - - O
is - - O
divided - - O
by - - O
an - - O
intron - - O
into - - O
two - - O
exons - - O
. - - O

Transcription - - O
of - - O
the - - O
gene - - O
for - - O
ivanolysin - - O
O - - O
and - - O
expression - - O
of - - O
other - - O
genes - - O
of - - O
the - - O
virulence - - O
gene - - O
cluster - - O
in - - O
L - - O
. - - O
ivanovii - - O
were - - O
dependent - - O
on - - O
PrfA - - O
. - - O

MBP-Rep68 - - O
delta-mediated - - O
DNA-RNA - - O
helicase - - O
activity - - O
required - - O
ATP - - O
hydrolysis - - O
and - - O
the - - O
presence - - O
of - - O
Mg2+ - - O
ions - - O
and - - O
was - - O
inhibited - - O
by - - O
high - - O
ionic - - O
strength - - O
. - - O

The - - O
nm23-H1 - - O
nm23-H2 - - O
gene - - O
transcriptional - - O
activity - - O
ratio - - O
varied - - O
depending - - O
on - - O
the - - O
cell - - O
line - - O
. - - O

Experimentally - - O
in - - O
green - - O
monkeys - - O
, - - O
Syrian - - O
hamsters - - O
and - - O
white - - O
mice - - O
the - - O
authors - - O
studied - - O
the - - O
pathogenic - - O
properties - - O
of - - O
a - - O
new - - O
virus - - O
Issyk-Kul - - O
. - - O

METHODS - - O
: - - O
Millipore - - O
ultrafiltration - - O
membranes - - O
of - - O
three - - O
different - - O
pore - - O
sizes - - O
were - - O
used - - O
as - - O
model - - O
lenticule - - O
materials - - O
. - - O
The - - O
nominal - - O
membrane - - O
pore - - O
sizes - - O
were - - O
0 - - O
. - - O
1 - - O
microm - - O
, - - O
0 - - O
. - - O
45 - - O
microm - - O
, - - O
and - - O
3 - - O
microm - - O
; - - O
the - - O
surface - - O
roughness - - O
increased - - O
in - - O
the - - O
same - - O
order - - O
The - - O
membranes - - O
were - - O
coated - - O
with - - O
a - - O
thin - - O
layer - - O
of - - O
collagen - - O
I - - O
and - - O
implanted - - O
in - - O
a - - O
circular - - O
pocket - - O
of - - O
the - - O
anterior - - O
cornea - - O
of - - O
adult - - O
cats - - O
, - - O
and - - O
were - - O
clinically - - O
evaluated - - O
for - - O
the - - O
extent - - O
of - - O
epithelialization - - O
and - - O
the - - O
persistence - - O
of - - O
epithelial - - O
attachment - - O
. - - O

Comparative - - O
study - - O
on - - O
acute - - O
oral - - O
overload - - O
using - - O
tolbutamide - - O
and - - O
tolazamide - - O
in - - O
normal - - O
and - - O
diabetic - - O
subjects - - O
. - - O

3 - - O
. - - O

According - - O
to - - O
the - - O
changes - - O
of - - O
perfusion - - O
defects - - O
between - - O
Ex - - O
, - - O
RD - - O
and - - O
ReI - - O
images - - O
, - - O
they - - O
were - - O
classified - - O
into - - O
3 - - O
types - - O
: - - O
Type - - O
I - - O
; - - O
perfusion - - O
defect - - O
on - - O
the - - O
RD - - O
image - - O
was - - O
identical - - O
to - - O
ReI - - O
image - - O
( - - O
75% - - O
) - - O
Type - - O
I - - O
was - - O
divided - - O
into - - O
2 - - O
subgroups - - O
whether - - O
perfusion - - O
defect - - O
at - - O
Ex - - O
was - - O
unchanged - - O
( - - O
Ia - - O
, - - O
42% - - O
) - - O
or - - O
improved - - O
( - - O
Ib - - O
, - - O
33% - - O
) - - O
on - - O
the - - O
RD - - O
image - - O
. - - O

The - - O
associations - - O
between - - O
sex-hormone-binding - - O
globulin - - O
capacity - - O
( - - O
SHBG - - O
) - - O
, - - O
age - - O
, - - O
body - - O
mass - - O
index - - O
( - - O
BMI - - O
) - - O
, - - O
and - - O
physical - - O
fitness - - O
have - - O
been - - O
studied - - O
in - - O
34 - - O
men - - O
and - - O
36 - - O
women - - O
. - - O

In - - O
Malmo - - O
, - - O
Sweden - - O
, - - O
17 - - O
, - - O
181 - - O
school - - O
children - - O
born - - O
in - - O
the - - O
years - - O
1961-1965 - - O
were - - O
screened - - O
for - - O
scoliosis - - O
once - - O
a - - O
year - - O
between - - O
the - - O
ages - - O
of - - O
7 - - O
and - - O
16 - - O
years - - O
, - - O
during - - O
1971-1980 - - O
. - - O

A - - O
platelet-derived - - O
growth - - O
factor - - O
receptor - - O
( - - O
PDGF-R - - O
) - - O
phosphopeptide - - O
containing - - O
Tyr-857 - - O
does - - O
not - - O
bind - - O
appreciably - - O
to - - O
the - - O
Src - - O
SH2 - - O
domain - - O
, - - O
suggesting - - O
it - - O
is - - O
not - - O
the - - O
PDGF-R - - O
binding - - O
site - - O
for - - O
Src - - O
as - - O
previously - - O
reported - - O
. - - O

Amplification - - O
and - - O
overexpression - - O
of - - O
the - - O
c-erbB-2 - - O
gene - - O
in - - O
21MT-2 - - O
and - - O
21MT-1 - - O
human - - O
breast - - O
carcinoma - - O
cells - - O
results - - O
in - - O
progressively - - O
elevated - - O
levels - - O
of - - O
constitutively - - O
tyrosine-phosphorylated - - O
p185erbB-2 - - O
and - - O
is - - O
associated - - O
with - - O
progressive - - O
insulin-like - - O
growth - - O
factor - - O
( - - O
IGF - - O
) - - O
and - - O
combined - - O
IGF - - O
epidermal - - O
growth - - O
factor - - O
( - - O
EGF - - O
) - - O
independence - - O
in - - O
culture - - O
. - - O

Here - - O
we - - O
have - - O
tested - - O
the - - O
hypothesis - - O
that - - O
the - - O
short - - O
transcripts - - O
, - - O
or - - O
proteins - - O
translated - - O
from - - O
the - - O
short - - O
transcripts - - O
, - - O
are - - O
also - - O
required - - O
for - - O
respiration - - O
. - - O

Also - - O
, - - O
the - - O
human - - O
glycoprotein - - O
alpha-subunit - - O
promoter - - O
was - - O
induced - - O
10-fold - - O
by - - O
FSK - - O
in - - O
GH4 - - O
rat - - O
pituitary - - O
cells - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
400 - - O
WORDS - - O
) - - O

Three - - O
chromosomal - - O
crsA - - O
mutations - - O
, - - O
crsA1 - - O
, - - O
crsA4 - - O
, - - O
and - - O
crsA47 - - O
, - - O
were - - O
transferred - - O
by - - O
the - - O
"gene - - O
conversion" - - O
process - - O
to - - O
B - - O
. - - O
subtilis - - O
plasmid - - O
pRPD11 - - O
, - - O
which - - O
consists - - O
of - - O
the - - O
entire - - O
wild-type - - O
rpoD - - O
coding - - O
sequence - - O
, - - O
encoding - - O
the - - O
major - - O
sigma - - O
43 - - O
factor - - O
of - - O
B - - O
. - - O
subtilis - - O
RNA - - O
polymerase - - O
, - - O
and - - O
pUB110 - - O
. - - O

Lymphocytes - - O
from - - O
all - - O
3 - - O
species - - O
yielded - - O
maximum - - O
responses - - O
with - - O
a - - O
48-hour - - O
prelabel - - O
and - - O
12- - - O
to- - - O
16 - - O
hour - - O
postlabel - - O
incubation - - O
period - - O
at - - O
41 - - O
C - - O
and - - O
1 - - O
: - - O
20 - - O
blood - - O
dilution - - O
. - - O

The - - O
persistence - - O
of - - O
members - - O
of - - O
the - - O
prostigmatid - - O
families - - O
Tydeidae - - O
, - - O
Nanorchestidae - - O
and - - O
Tarsonemidae - - O
in - - O
the - - O
moisture-deficient - - O
90%-concentration - - O
treatments - - O
supports - - O
previous - - O
evidence - - O
of - - O
adaptations - - O
to - - O
low-water-content - - O
habitats - - O
. - - O

Unlike - - O
class - - O
II- - - O
and - - O
III-specific - - O
TBP-TAF - - O
complexes - - O
, - - O
the - - O
corresponding - - O
murine - - O
and - - O
human - - O
class - - O
I-specific - - O
transcription - - O
initiation - - O
factor - - O
TIF-IB - - O
SL1 - - O
exhibits - - O
a - - O
pronounced - - O
selectivity - - O
for - - O
its - - O
homologous - - O
promoter - - O
. - - O

The - - O
suppression - - O
was - - O
also - - O
demonstrated - - O
in - - O
a - - O
transient - - O
expression - - O
assay - - O
in - - O
vivo - - O
using - - O
isolated - - O
barley - - O
endosperms - - O
. - - O

CREST - - O
syndrome - - O
; - - O
a - - O
changing - - O
clinical - - O
significance - - O
. - - O

Hormonal - - O
regulation - - O
of - - O
multiple - - O
promoters - - O
of - - O
the - - O
rat - - O
mitochondrial - - O
glycerol-3-phosphate - - O
dehydrogenase - - O
gene - - O
: - - O
identification - - O
of - - O
a - - O
complex - - O
hormone-response - - O
element - - O
in - - O
the - - O
ubiquitous - - O
promoter - - O
B - - O
. - - O

Mutants - - O
with - - O
mild - - O
lace - - O
alleles - - O
grow - - O
to - - O
become - - O
adults - - O
with - - O
multiple - - O
aberrant - - O
morphologies - - O
in - - O
the - - O
appendages - - O
, - - O
compound - - O
eye - - O
, - - O
and - - O
bristles - - O
. - - O

Isolation - - O
and - - O
characterization - - O
of - - O
a - - O
vinculin - - O
cDNA - - O
from - - O
chick-embryo - - O
fibroblasts - - O
. - - O

Long-term - - O
effects - - O
of - - O
clofibrate - - O
( - - O
Atromid-S - - O
) - - O
on - - O
serum - - O
lipids - - O
in - - O
man - - O
. - - O

Drosophila - - O
230-kD - - O
TFIID - - O
subunit - - O
, - - O
a - - O
functional - - O
homolog - - O
of - - O
the - - O
human - - O
cell - - O
cycle - - O
gene - - O
product - - O
, - - O
negatively - - O
regulates - - O
DNA - - O
binding - - O
of - - O
the - - O
TATA - - O
box-binding - - O
subunit - - O
of - - O
TFIID - - O
. - - O

Recent - - O
investigations - - O
have - - O
shown - - O
that - - O
Grenz - - O
rays - - O
can - - O
suppress - - O
the - - O
allergic - - O
contact - - O
dermatitis - - O
reaction - - O
completely - - O
and - - O
that - - O
Langerhans - - O
cells - - O
, - - O
identified - - O
by - - O
OKT6 - - O
antibodies - - O
and - - O
electron - - O
microscopy - - O
, - - O
disappear - - O
from - - O
the - - O
epidermis - - O
at - - O
the - - O
same - - O
time - - O
. - - O

SBF - - O
binds - - O
to - - O
the - - O
promoter - - O
prior - - O
to - - O
the - - O
activation - - O
of - - O
transcription - - O
in - - O
late - - O
G1 - - O
, - - O
suggesting - - O
that - - O
Cln - - O
Cdc28 - - O
kinase - - O
regulates - - O
the - - O
ability - - O
of - - O
previously - - O
bound - - O
SBF - - O
to - - O
activate - - O
transcription - - O
. - - O

Recombinant - - O
Leishmania - - O
surface - - O
glycoprotein - - O
GP63 - - O
is - - O
secreted - - O
in - - O
the - - O
baculovirus - - O
expression - - O
system - - O
as - - O
a - - O
latent - - O
metalloproteinase - - O
. - - O

The - - O
mean - - O
jitter - - O
and - - O
the - - O
fiber - - O
density - - O
did - - O
not - - O
change - - O
significantly - - O
from - - O
day - - O
0 - - O
( - - O
30 - - O
. - - O
1 - - O
+ - - O
- - - O
3 - - O
. - - O
6 - - O
microseconds - - O
; - - O
1 - - O
. - - O
4 - - O
+ - - O
- - - O
0 - - O
. - - O
07 - - O
) - - O
to - - O
day - - O
30 - - O
( - - O
34 - - O
. - - O
5 - - O
+ - - O
- - - O
2 - - O
. - - O
7 - - O
microseconds - - O
; - - O
1 - - O
. - - O
6 - - O
+ - - O
- - - O
0 - - O
. - - O
13 - - O
) - - O
. - - O

9 - - O
, - - O
11-Seco - - O
steroids - - O
derived - - O
from - - O
estradiol - - O
3-methyl - - O
ether - - O
. - - O

Several - - O
demographic - - O
indices - - O
of - - O
isolated - - O
populations - - O
in - - O
Uzbekistan - - O
. - - O

Interferon-alpha - - O
may - - O
exacerbate - - O
cryoblobulinemia-related - - O
ischemic - - O
manifestations - - O
: - - O
an - - O
adverse - - O
effect - - O
potentially - - O
related - - O
to - - O
its - - O
anti-angiogenic - - O
activity - - O
. - - O

Our - - O
findings - - O
confirm - - O
the - - O
high - - O
frequency - - O
of - - O
proximal - - O
nerve - - O
lesions - - O
in - - O
early - - O
GBS - - O
and - - O
CIDP - - O
, - - O
not - - O
all - - O
of - - O
which - - O
are - - O
associated - - O
with - - O
distal - - O
motor - - O
conduction - - O
abnormalities - - O
, - - O
and - - O
suggest - - O
that - - O
assessment - - O
of - - O
multiple - - O
F - - O
wave - - O
parameters - - O
, - - O
in - - O
particular - - O
chronodispersion - - O
, - - O
mean - - O
latency - - O
and - - O
mean - - O
amplitude - - O
( - - O
in - - O
addition - - O
to - - O
absence - - O
and - - O
minimum - - O
latency - - O
) - - O
, - - O
increases - - O
the - - O
yield - - O
of - - O
F - - O
wave - - O
studies - - O
. - - O

Each - - O
causative - - O
organism - - O
has - - O
a - - O
species-specific - - O
preference - - O
and - - O
requirement - - O
for - - O
temperature - - O
, - - O
salinity - - O
, - - O
pH - - O
, - - O
the - - O
basic - - O
nutrients - - O
, - - O
and - - O
growth - - O
factors - - O
, - - O
and - - O
the - - O
toxin - - O
formation - - O
is - - O
affected - - O
by - - O
these - - O
environmental - - O
factors - - O
. - - O

Structural - - O
analysis - - O
and - - O
characterization - - O
of - - O
tissue - - O
and - - O
hormonal - - O
responsive - - O
expression - - O
of - - O
the - - O
avian - - O
bone - - O
sialoprotein - - O
( - - O
BSP - - O
) - - O
gene - - O
. - - O

I - - O
. - - O

This - - O
emphasizes - - O
the - - O
conclusion - - O
that - - O
CDF-1 - - O
is - - O
not - - O
an - - O
E2F - - O
family - - O
member - - O
and - - O
points - - O
to - - O
profound - - O
differences - - O
in - - O
the - - O
cell - - O
cycle - - O
regulation - - O
of - - O
CDF-1 - - O
and - - O
E2F - - O
. - - O

Identical - - O
results - - O
were - - O
obtained - - O
when - - O
transfections - - O
and - - O
mobility - - O
shift - - O
assays - - O
were - - O
performed - - O
in - - O
primary - - O
rat - - O
hepatocytes - - O
in - - O
which - - O
the - - O
endogenous - - O
ALS - - O
gene - - O
is - - O
expressed - - O
. - - O

Elimination - - O
of - - O
gamma-irradiation - - O
induced - - O
oxidation - - O
in - - O
aqueous - - O
drug - - O
preparations - - O
. - - O

The - - O
timing - - O
of - - O
fla - - O
gene - - O
expression - - O
in - - O
the - - O
cell - - O
cycle - - O
is - - O
determined - - O
by - - O
specialized - - O
forms - - O
of - - O
RNA - - O
polymerase - - O
and - - O
the - - O
appearance - - O
and - - O
or - - O
activation - - O
of - - O
regulatory - - O
proteins - - O
. - - O

Growth - - O
, - - O
4-PA - - O
and - - O
14C - - O
turnover - - O
data - - O
indicated - - O
that - - O
WB - - O
contributed - - O
to - - O
B-6 - - O
intake - - O
of - - O
these - - O
rats - - O
. - - O

Catheter - - O
transit - - O
slows - - O
the - - O
response - - O
to - - O
a - - O
step - - O
increase - - O
in - - O
concentration - - O
by - - O
about - - O
0 - - O
. - - O
13 - - O
s - - O
( - - O
from - - O
10 - - O
per - - O
cent-90 - - O
per - - O
cent - - O
) - - O
and - - O
prolongs - - O
the - - O
transit - - O
time - - O
through - - O
the - - O
catheter - - O
for - - O
a - - O
volatile - - O
anesthetic - - O
by - - O
about - - O
0 - - O
. - - O
04 - - O
s - - O
more - - O
than - - O
N2 - - O
. - - O

Advances - - O
in - - O
the - - O
management - - O
of - - O
gynecologic - - O
cancer--radiation - - O
therapy - - O
. - - O

To - - O
test - - O
the - - O
role - - O
of - - O
ML - - O
in - - O
human - - O
reproductive - - O
axis - - O
, - - O
128 - - O
healthy - - O
children - - O
, - - O
68 - - O
boys - - O
and - - O
60 - - O
girls - - O
, - - O
were - - O
studied - - O
. - - O

It - - O
has - - O
been - - O
suggested - - O
that - - O
members - - O
of - - O
this - - O
protein - - O
family - - O
exhibit - - O
both - - O
prolyl - - O
isomerase - - O
and - - O
chaperone - - O
activity - - O
. - - O

Recently - - O
, - - O
identical - - O
RBE - - O
sequences - - O
have - - O
been - - O
identified - - O
at - - O
other - - O
locations - - O
in - - O
the - - O
human - - O
genome - - O
. - - O

The - - O
appropriate - - O
use - - O
and - - O
benefits - - O
of - - O
bile - - O
acid - - O
sequestrants - - O
, - - O
nicotinic - - O
acid - - O
, - - O
fibric - - O
acids - - O
, - - O
3-hydroxy-3-methylglutaryl - - O
coenzyme - - O
A - - O
( - - O
HMG-CoA - - O
) - - O
reductase - - O
inhibitors - - O
, - - O
and - - O
probucol - - O
are - - O
individually - - O
discussed - - O
, - - O
whereas - - O
nonpharmacologic - - O
approaches - - O
used - - O
in - - O
conjunction - - O
with - - O
the - - O
drugs - - O
are - - O
recommended - - O
emphatically - - O
. - - O

Increased - - O
granulocyte-colony - - O
stimulating - - O
factor - - O
( - - O
G-CSF - - O
) - - O
levels - - O
in - - O
neonates - - O
with - - O
perinatal - - O
complications - - O
. - - O

In - - O
some - - O
instances - - O
, - - O
this - - O
is - - O
partly - - O
mediated - - O
by - - O
the - - O
expression - - O
of - - O
virally - - O
encoded - - O
proteases - - O
which - - O
lead - - O
to - - O
the - - O
cleavage - - O
of - - O
initiation - - O
factor - - O
eIF4G - - O
. - - O

In - - O
contrast - - O
, - - O
tobacco - - O
GS-2 - - O
is - - O
composed - - O
of - - O
subunits - - O
of - - O
identical - - O
size - - O
in - - O
all - - O
organs - - O
examined - - O
. - - O

Women's - - O
opportunities - - O
for - - O
paid - - O
work - - O
outside - - O
the - - O
home - - O
are - - O
constrained - - O
by - - O
their - - O
role - - O
as - - O
primary - - O
carer - - O
within - - O
the - - O
family - - O
, - - O
writes - - O
Trudy - - O
Wynne - - O
. - - O

Multi - - O
drug - - O
regimens - - O
like - - O
C-MOPP - - O
, - - O
CHOP - - O
and - - O
BACOP - - O
led - - O
to - - O
high - - O
remission - - O
rates - - O
and - - O
in - - O
some - - O
cases - - O
probably - - O
also - - O
to - - O
a - - O
cure - - O
of - - O
the - - O
disease - - O
. - - O

The - - O
mean - - O
percentage - - O
of - - O
linoleic - - O
acid - - O
in - - O
the - - O
triglycerides - - O
of - - O
the - - O
subcutaneous - - O
adipose - - O
tissue - - O
( - - O
PLASAT - - O
) - - O
of - - O
these - - O
subjects - - O
was - - O
substantially - - O
higher - - O
than - - O
that - - O
in - - O
a - - O
similar - - O
group - - O
examined - - O
in - - O
1975-1976 - - O
. - - O

However - - O
, - - O
the - - O
ratio - - O
M - - O
Pc - - O
provides - - O
a - - O
useful - - O
index - - O
that - - O
seems - - O
to - - O
be - - O
independent - - O
of - - O
the - - O
metabolic - - O
demand - - O
. - - O

Cys-757 - - O
within - - O
the - - O
( - - O
Fe4S4 - - O
) - - O
-siroheme-binding - - O
domain - - O
was - - O
essential - - O
for - - O
native - - O
enzyme - - O
activity - - O
. - - O

The - - O
amplitude - - O
of - - O
detrusor - - O
contractions - - O
at - - O
6 - - O
, - - O
12 - - O
, - - O
and - - O
24 - - O
hours - - O
showed - - O
no - - O
significant - - O
difference - - O
from - - O
that - - O
in - - O
the - - O
controls - - O
. - - O

A - - O
third - - O
is - - O
a - - O
partial - - O
element - - O
terminating - - O
at - - O
a - - O
probable - - O
internal - - O
restriction - - O
site - - O
used - - O
for - - O
cloning - - O
. - - O

Zebrafish - - O
cyclops - - O
( - - O
cyc - - O
) - - O
encodes - - O
a - - O
Transforming - - O
Growth - - O
Factor - - O
beta - - O
( - - O
TGFbeta - - O
) - - O
signaling - - O
factor - - O
closely - - O
related - - O
to - - O
mouse - - O
Nodal - - O
. - - O

Breitbart - - O
, - - O
L - - O
. - - O

A - - O
newly - - O
synthesized - - O
anti-inflammatory - - O
agent - - O
, - - O
Y-8004 - - O
demonstrated - - O
a - - O
greater - - O
inhibition - - O
than - - O
did - - O
indomethacin - - O
( - - O
IM - - O
) - - O
. - - O
on - - O
inflammatory - - O
response - - O
such - - O
as - - O
ultraviolet - - O
erythema - - O
in - - O
guinea - - O
pigs - - O
, - - O
carrageenin - - O
edema - - O
, - - O
evans - - O
blue - - O
and - - O
carrageenin-induced - - O
pleuritis - - O
and - - O
acetic - - O
acid-induced - - O
peritonitis - - O
in - - O
rats - - O
. - - O

Polyvinyl - - O
alcohol - - O
as - - O
a - - O
solution - - O
mediator - - O
. - - O

Herein - - O
PPARgamma - - O
, - - O
liganded - - O
by - - O
either - - O
natural - - O
( - - O
15d-PGJ - - O
( - - O
2 - - O
) - - O
and - - O
PGD - - O
( - - O
2 - - O
) - - O
) - - O
or - - O
synthetic - - O
ligands - - O
( - - O
BRL49653 - - O
and - - O
troglitazone - - O
) - - O
, - - O
selectively - - O
inhibited - - O
expression - - O
of - - O
the - - O
cyclin - - O
D1 - - O
gene - - O
. - - O

Ovaries - - O
of - - O
10 - - O
animals - - O
per - - O
group - - O
from - - O
16 - - O
studies - - O
in - - O
CD-1 - - O
mice - - O
and - - O
1 - - O
study - - O
each - - O
in - - O
C3H - - O
and - - O
C57BL - - O
6 - - O
mice - - O
were - - O
sectioned - - O
serially - - O
at - - O
6 - - O
&mgr - - O
; - - O
m - - O
. - - O

5'-RACE - - O
analysis - - O
suggested - - O
a - - O
single - - O
transcription - - O
initiation - - O
site - - O
187 - - O
bp - - O
upstream - - O
from - - O
the - - O
translational - - O
start - - O
site - - O
. - - O

Treatment - - O
also - - O
led - - O
to - - O
a - - O
significant - - O
dose - - O
dependent - - O
reduction - - O
in - - O
the - - O
sum - - O
of - - O
ST - - O
segment - - O
depression - - O
at - - O
both - - O
trough - - O
and - - O
peak - - O
concentrations - - O
. - - O

Our - - O
data - - O
demonstrate - - O
directly - - O
that - - O
Rpm1r - - O
is - - O
transcribed - - O
with - - O
its - - O
substrates - - O
, - - O
tRNA - - O
met - - O
f - - O
and - - O
tRNAPro - - O
, - - O
from - - O
a - - O
promoter - - O
located - - O
upstream - - O
of - - O
the - - O
tRNA - - O
met - - O
f - - O
gene - - O
and - - O
suggest - - O
that - - O
a - - O
portion - - O
also - - O
originates - - O
from - - O
a - - O
second - - O
promoter - - O
, - - O
located - - O
between - - O
the - - O
tRNA - - O
met - - O
f - - O
gene - - O
and - - O
RPM1 - - O
. - - O

Furthermore - - O
, - - O
expression - - O
of - - O
the - - O
promoter - - O
in - - O
embryonic - - O
Drosophila - - O
melanogaster - - O
cells - - O
that - - O
lack - - O
MyoD1 - - O
and - - O
Sp1 - - O
is - - O
strictly - - O
dependent - - O
on - - O
all - - O
three - - O
sites - - O
remaining - - O
intact - - O
and - - O
on - - O
the - - O
presence - - O
of - - O
exogenously - - O
supplied - - O
Sp1 - - O
and - - O
MyoD1 - - O
. - - O

Retinoid-dependent - - O
activation - - O
of - - O
the - - O
tissue - - O
transglutaminase - - O
promoter - - O
depends - - O
on - - O
both - - O
a - - O
proximal - - O
regulatory - - O
region - - O
containing - - O
sequences - - O
highly - - O
conserved - - O
between - - O
the - - O
human - - O
and - - O
the - - O
mouse - - O
tissue - - O
transglutaminase - - O
promoters - - O
and - - O
a - - O
distal - - O
region - - O
that - - O
includes - - O
a - - O
30-base - - O
pair - - O
retinoid - - O
response - - O
element - - O
( - - O
mTGRRE1 - - O
) - - O
. - - O
mTGRRE1 - - O
contains - - O
three - - O
hexanucleotide - - O
half-sites - - O
( - - O
two - - O
canonical - - O
and - - O
one - - O
non-canonical - - O
) - - O
in - - O
a - - O
DR7 - - O
DR5 - - O
motif - - O
that - - O
bind - - O
both - - O
RAR*RXR - - O
heterodimers - - O
and - - O
RXR - - O
homodimers - - O
. - - O

However - - O
, - - O
the - - O
published - - O
reports - - O
consist - - O
of - - O
a - - O
small - - O
number - - O
of - - O
patients - - O
and - - O
limited - - O
data - - O
. - - O

Relationship - - O
between - - O
mitochondrial - - O
NADH-ubiquinone - - O
reductase - - O
and - - O
a - - O
bacterial - - O
NAD-reducing - - O
hydrogenase - - O
. - - O

The - - O
combination - - O
of - - O
hydralazine - - O
hydrochloride - - O
and - - O
isosorbide - - O
dinitrate - - O
also - - O
improves - - O
survival - - O
, - - O
but - - O
direct - - O
comparison - - O
of - - O
both - - O
regimens - - O
provided - - O
evidence - - O
for - - O
a - - O
less - - O
favourable - - O
effect - - O
than - - O
that - - O
of - - O
the - - O
ACE - - O
inhibitors - - O
. - - O

Quinone-binding - - O
domain - - O
and - - O
amino - - O
acid - - O
residues - - O
involved - - O
in - - O
quinone - - O
binding - - O
. - - O

In - - O
fact - - O
, - - O
families - - O
of - - O
polypeptides - - O
were - - O
produced - - O
by - - O
initiation - - O
of - - O
translation - - O
at - - O
AUG - - O
codons - - O
within - - O
sequences - - O
coding - - O
for - - O
VP1 - - O
and - - O
T - - O
, - - O
presumably - - O
as - - O
a - - O
result - - O
of - - O
transcription - - O
initiation - - O
events - - O
that - - O
generated - - O
5' - - O
ends - - O
immediately - - O
upstream - - O
from - - O
these - - O
AUGs - - O
. - - O

Although - - O
the - - O
expression - - O
of - - O
the - - O
4E-BP1 - - O
gene - - O
alone - - O
has - - O
not - - O
yet - - O
been - - O
accomplished - - O
, - - O
the - - O
gene - - O
was - - O
expressed - - O
in - - O
Escherichia - - O
coli - - O
[ - - O
BL21 - - O
( - - O
DE3 - - O
) - - O
] - - O
as - - O
a - - O
fusion - - O
gene - - O
with - - O
the - - O
glutathione-S-transferase - - O
( - - O
GST - - O
) - - O
gene - - O
using - - O
a - - O
prokaryotic - - O
gene - - O
fusion - - O
vector - - O
( - - O
pGEX-4T-2 - - O
) - - O
, - - O
which - - O
contains - - O
a - - O
gene - - O
sequence - - O
coding - - O
the - - O
cleavage - - O
site - - O
for - - O
a - - O
specific - - O
protease - - O
, - - O
alpha-thrombin - - O
. - - O

Reporter - - O
gene - - O
expression - - O
analyses - - O
indicate - - O
that - - O
both - - O
WASP - - O
promoters - - O
show - - O
high - - O
levels - - O
of - - O
expression - - O
in - - O
different - - O
hematopoietic - - O
cell - - O
lines - - O
. - - O

The - - O
geometric - - O
mean - - O
hemagglutination-inhibition - - O
antibody - - O
titers - - O
( - - O
GMT - - O
) - - O
of - - O
non-immunized - - O
, - - O
once-immunized - - O
, - - O
and - - O
twice-immunized - - O
chickens - - O
were - - O
compared - - O
at - - O
2-week - - O
intervals - - O
following - - O
primary - - O
immunization - - O
, - - O
secondary - - O
immunization - - O
, - - O
and - - O
challenge - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
FK - - O
506 - - O
is - - O
a - - O
useful - - O
immunosuppressive - - O
agent - - O
in - - O
kidney - - O
transplantation - - O
. - - O

The - - O
micturition - - O
pressure - - O
was - - O
significantly - - O
decreased - - O
only - - O
after - - O
injection - - O
with - - O
BUP-4 - - O
in - - O
both - - O
normal - - O
and - - O
obstructed - - O
rats - - O
. - - O

We - - O
have - - O
previously - - O
isolated - - O
a - - O
cDNA - - O
for - - O
a - - O
transcription - - O
factor - - O
referred - - O
to - - O
as - - O
Zfhep - - O
( - - O
zinc - - O
finger - - O
homeodomain - - O
enhancer-binding - - O
protein - - O
) - - O
containing - - O
two - - O
separate - - O
zinc - - O
finger - - O
domains - - O
, - - O
ZD1 - - O
and - - O
ZD2 - - O
, - - O
each - - O
of - - O
which - - O
binds - - O
DNA - - O
, - - O
and - - O
a - - O
homeodomain - - O
. - - O

Inactivation - - O
of - - O
p53 - - O
but - - O
not - - O
p73 - - O
by - - O
adenovirus - - O
type - - O
5 - - O
E1B - - O
55-kilodalton - - O
and - - O
E4 - - O
34-kilodalton - - O
oncoproteins - - O
. - - O

Following - - O
EPI-C0401 - - O
, - - O
but - - O
not - - O
saline - - O
or - - O
DepoFoam - - O
vehicle - - O
, - - O
there - - O
were - - O
transient - - O
( - - O
< - - O
72 - - O
hr - - O
) - - O
decreases - - O
in - - O
food - - O
consumption - - O
, - - O
arousal - - O
, - - O
hindlimb - - O
muscle - - O
tone - - O
, - - O
and - - O
body - - O
temperature - - O
. - - O

Upstream - - O
activating - - O
sequences - - O
( - - O
UASs - - O
) - - O
derived - - O
from - - O
known - - O
Ste12p-dependent - - O
genes - - O
have - - O
previously - - O
been - - O
characterized - - O
to - - O
require - - O
either - - O
multiple - - O
PREs - - O
or - - O
a - - O
single - - O
PRE - - O
coupled - - O
to - - O
a - - O
binding - - O
site - - O
for - - O
a - - O
second - - O
protein - - O
. - - O

Deletion - - O
studies - - O
identified - - O
a - - O
distal - - O
response - - O
element - - O
that - - O
is - - O
responsible - - O
for - - O
the - - O
cytokine - - O
response - - O
and - - O
has - - O
properties - - O
of - - O
an - - O
inducible - - O
transcriptional - - O
enhancer - - O
. - - O

195mPt-labeled - - O
cisplatin - - O
was - - O
administered - - O
iv - - O
and - - O
ip - - O
to - - O
control - - O
mice - - O
and - - O
to - - O
mice - - O
bearing - - O
Sarcoma - - O
180 - - O
. - - O

Both - - O
groups - - O
rejected - - O
pops - - O
with - - O
added - - O
SOA - - O
, - - O
decreasing - - O
mouthing - - O
times - - O
as - - O
SOA - - O
concentration - - O
increased - - O
. - - O

One - - O
millimolar - - O
ouabain - - O
completely - - O
inhibited - - O
net - - O
HCO3- - - O
secretion - - O
. - - O

These - - O
results - - O
are - - O
consistent - - O
with - - O
the - - O
well - - O
established - - O
polarity - - O
of - - O
RXR - - O
heterodimer - - O
binding - - O
to - - O
bipartite - - O
hormone - - O
response - - O
elements - - O
, - - O
with - - O
the - - O
VDR - - O
recognizing - - O
the - - O
3'-half-element - - O
. - - O

The - - O
uncomplicated - - O
cases - - O
of - - O
typhoid - - O
fever - - O
were - - O
found - - O
to - - O
have - - O
an - - O
intact - - O
CMIR - - O
as - - O
compared - - O
to - - O
the - - O
complicated - - O
cases - - O
. - - O

Copyright - - O
1998 - - O
Academic - - O
Press - - O
. - - O

Zatebradine - - O
weakly - - O
depressed - - O
the - - O
ectopic - - O
ventricular - - O
rate - - O
but - - O
not - - O
the - - O
arrhythmic - - O
ratio - - O
of - - O
the - - O
ventricular - - O
arrhythmias - - O
induced - - O
by - - O
two-stage - - O
coronary - - O
ligation - - O
24 - - O
h - - O
after - - O
the - - O
ligation - - O
in - - O
conscious - - O
dogs - - O
. - - O

The - - O
sense - - O
of - - O
self - - O
. - - O

On - - O
catabolism - - O
of - - O
aminoketones - - O
in - - O
climacteric - - O
age - - O
. - - O

The - - O
existence - - O
of - - O
these - - O
two - - O
categories - - O
of - - O
strains - - O
offers - - O
a - - O
new - - O
genetic - - O
system - - O
in - - O
which - - O
the - - O
properties - - O
of - - O
a - - O
potential - - O
invertebrate - - O
retrovirus - - O
can - - O
be - - O
tested - - O
. - - O

( - - O
ii - - O
) - - O
ICP27 - - O
binds - - O
preferentially - - O
to - - O
less - - O
modified - - O
forms - - O
of - - O
ICP4 - - O
, - - O
a - - O
protein - - O
that - - O
is - - O
extensively - - O
modified - - O
posttranslationally - - O
. - - O

To - - O
prepare - - O
for - - O
analyses - - O
with - - O
the - - O
family - - O
variables - - O
, - - O
we - - O
next - - O
present - - O
descriptive - - O
data - - O
based - - O
on - - O
separate - - O
principal - - O
components - - O
analysis - - O
( - - O
PCA - - O
) - - O
and - - O
multidimensional - - O
scaling - - O
analysis - - O
( - - O
MDS - - O
) - - O
of - - O
14 - - O
self-reported - - O
health - - O
scores - - O
for - - O
husbands - - O
and - - O
for - - O
wives - - O
. - - O

Based - - O
on - - O
16S - - O
rRNA - - O
gene - - O
sequence - - O
analysis - - O
, - - O
the - - O
11 - - O
species - - O
having - - O
two - - O
tuf - - O
genes - - O
all - - O
have - - O
a - - O
common - - O
ancestor - - O
, - - O
while - - O
the - - O
six - - O
species - - O
having - - O
only - - O
one - - O
copy - - O
diverged - - O
from - - O
the - - O
enterococcal - - O
lineage - - O
before - - O
that - - O
common - - O
ancestor - - O
. - - O

In - - O
addition - - O
, - - O
the - - O
acetyltransferase - - O
activity - - O
of - - O
p300 - - O
was - - O
observed - - O
to - - O
be - - O
distinct - - O
from - - O
the - - O
broadly - - O
essential - - O
activation - - O
function - - O
of - - O
the - - O
CH3 - - O
domain - - O
E1A-binding - - O
region - - O
. - - O

The - - O
locus - - O
encoding - - O
the - - O
XD - - O
gene - - O
( - - O
designated - - O
Xd - - O
) - - O
was - - O
mapped - - O
to - - O
the - - O
distal - - O
part - - O
of - - O
mouse - - O
chromosome - - O
17 - - O
by - - O
haplotype - - O
analysis - - O
of - - O
114 - - O
interspecific - - O
backcross - - O
mice - - O
. - - O

Merosin - - O
positive - - O
congenital - - O
muscular - - O
dystrophy - - O
with - - O
mental - - O
deficiency - - O
, - - O
epilepsy - - O
and - - O
MRI - - O
changes - - O
in - - O
the - - O
cerebral - - O
white - - O
matter - - O
. - - O

Lacrimal - - O
secretion - - O
in - - O
hyperthyroidism - - O
. - - O

Once - - O
ICP - - O
reaches - - O
critical - - O
values - - O
( - - O
> - - O
30 - - O
mm - - O
Hg - - O
) - - O
herniation - - O
occurs - - O
, - - O
usually - - O
within - - O
2 - - O
to - - O
5 - - O
days - - O
. - - O

The - - O
proofreading - - O
domain - - O
of - - O
Escherichia - - O
coli - - O
DNA - - O
polymerase - - O
I - - O
and - - O
other - - O
DNA - - O
and - - O
or - - O
RNA - - O
exonuclease - - O
domains - - O
. - - O

Changes - - O
following - - O
periodontal - - O
surgery - - O
. - - O

Pro-inflammatory - - O
cytokine - - O
, - - O
tumor - - O
necrosis - - O
factor-alpha - - O
( - - O
TNF-alpha - - O
) - - O
, - - O
produced - - O
from - - O
adipose - - O
tissues - - O
in - - O
obese - - O
subjects - - O
, - - O
is - - O
known - - O
to - - O
play - - O
a - - O
predominant - - O
role - - O
in - - O
inducing - - O
insulin - - O
resistance - - O
. - - O

Below - - O
50% - - O
decrease - - O
of - - O
PaO2 - - O
, - - O
NADH - - O
was - - O
reduced - - O
largely - - O
. - - O

In - - O
all - - O
cases - - O
, - - O
high-level - - O
expression - - O
of - - O
the - - O
truncated - - O
avian - - O
integrins - - O
was - - O
obtained - - O
. - - O

Her - - O
serum - - O
FT3 - - O
concentration - - O
was - - O
, - - O
however - - O
, - - O
much - - O
higher - - O
than - - O
the - - O
ranges - - O
in - - O
normal - - O
pregnancy - - O
or - - O
in - - O
GTD - - O
patients - - O
without - - O
clinical - - O
hyperthyroidism - - O
. - - O

A - - O
system - - O
is - - O
described - - O
in - - O
which - - O
the - - O
volume - - O
flow - - O
rate - - O
of - - O
blood - - O
in - - O
a - - O
vessel - - O
is - - O
determined - - O
using - - O
transverse - - O
colour - - O
Doppler - - O
ultrasound - - O
imaging - - O
. - - O

Studies - - O
of - - O
lipogenesis - - O
by - - O
labelled - - O
precursors - - O
in - - O
the - - O
pregnant - - O
rat - - O
. - - O

A - - O
prospective - - O
trial - - O
was - - O
carried - - O
out - - O
in - - O
156 - - O
unselected - - O
patients - - O
( - - O
41 - - O
men - - O
, - - O
mean - - O
age - - O
67 - - O
. - - O
5 - - O
years - - O
, - - O
115 - - O
women - - O
, - - O
mean - - O
age - - O
71 - - O
. - - O
4 - - O
years - - O
) - - O
who - - O
had - - O
undergone - - O
total - - O
hip - - O
joint - - O
replacement - - O
because - - O
of - - O
degenerative - - O
or - - O
inflammatory - - O
arthritis - - O
or - - O
fracture - - O
of - - O
the - - O
neck - - O
of - - O
the - - O
femur - - O
. - - O

Nucleotide - - O
sequence - - O
and - - O
transcriptional - - O
analysis - - O
of - - O
the - - O
DNA - - O
polymerase - - O
gene - - O
of - - O
Bombyx - - O
mori - - O
nuclear - - O
polyhedrosis - - O
virus - - O
. - - O

In - - O
view - - O
of - - O
these - - O
results - - O
, - - O
simultaneous - - O
pancreas-kidney - - O
transplantation - - O
appears - - O
to - - O
be - - O
the - - O
treatment - - O
of - - O
choice - - O
for - - O
Type - - O
I - - O
diabetic - - O
patients - - O
. - - O

Sequence - - O
analysis - - O
of - - O
a - - O
6 - - O
. - - O
3-kbp - - O
genomic - - O
EcoRI-fragment - - O
of - - O
Alcaligenes - - O
eutrophus - - O
, - - O
which - - O
was - - O
recently - - O
identified - - O
by - - O
using - - O
a - - O
dihydrolipoamide - - O
dehydrogenase-specific - - O
DNA - - O
probe - - O
( - - O
A - - O
. - - O

Polysome - - O
analysis - - O
further - - O
indicated - - O
that - - O
these - - O
germ - - O
cell-specific - - O
Sp1 - - O
mRNAs - - O
are - - O
translated - - O
, - - O
albeit - - O
with - - O
a - - O
lower - - O
efficiency - - O
than - - O
the - - O
somatic - - O
transcript - - O
. - - O

Transgenic - - O
tobacco - - O
plants - - O
( - - O
ppa-1 - - O
) - - O
constitutively - - O
expressing - - O
Escherichia - - O
coli - - O
pyrophosphatase - - O
behind - - O
the - - O
35S - - O
CaMV - - O
promoter - - O
accumulate - - O
high - - O
levels - - O
of - - O
soluble - - O
sugars - - O
in - - O
their - - O
leaves - - O
[ - - O
27 - - O
] - - O
. - - O

Deletions - - O
were - - O
examined - - O
in - - O
the - - O
LYS2 - - O
gene - - O
, - - O
using - - O
a - - O
set - - O
of - - O
31- - - O
to - - O
156-bp - - O
inserts - - O
that - - O
included - - O
inserts - - O
with - - O
no - - O
apparent - - O
potential - - O
for - - O
secondary - - O
structure - - O
as - - O
well - - O
as - - O
two - - O
quasipalindromes - - O
. - - O

Since - - O
1948 - - O
, - - O
the - - O
use - - O
of - - O
saline-washed - - O
red - - O
cells - - O
( - - O
WRBCs - - O
) - - O
has - - O
been - - O
advocated - - O
to - - O
minimize - - O
hemolysis - - O
after - - O
transfusion - - O
to - - O
patients - - O
with - - O
PNH - - O
. - - O

Diagnosis - - O
and - - O
differential - - O
diagnosis - - O
. - - O

In - - O
addition - - O
, - - O
the - - O
utility - - O
of - - O
beta - - O
2 - - O
transferrin - - O
assay - - O
in - - O
the - - O
diagnosis - - O
of - - O
cerebrospinal - - O
fluid - - O
otorrhea - - O
is - - O
presented - - O
. - - O

We - - O
show - - O
here - - O
that - - O
, - - O
despite - - O
their - - O
structural - - O
and - - O
functional - - O
similarities - - O
, - - O
the - - O
pop1 - - O
and - - O
pop2 - - O
genes - - O
fail - - O
to - - O
complement - - O
each - - O
other's - - O
deletion - - O
phenotypes - - O
, - - O
indicating - - O
that - - O
they - - O
perform - - O
non-redundant - - O
, - - O
but - - O
potentially - - O
interdependent - - O
, - - O
functions - - O
in - - O
proteolysis - - O
. - - O

To - - O
identify - - O
the - - O
precise - - O
location - - O
of - - O
the - - O
phosphorylation - - O
site - - O
on - - O
the - - O
64-kDa - - O
protein - - O
, - - O
a - - O
step-by-step - - O
mutagenesis - - O
procedures - - O
was - - O
followed - - O
. - - O

A - - O
major - - O
task - - O
for - - O
sports - - O
scientists - - O
may - - O
be - - O
to - - O
verify - - O
empirically - - O
the - - O
nature - - O
of - - O
an - - O
integrated - - O
model - - O
of - - O
the - - O
sport - - O
performer - - O
. - - O

To - - O
better - - O
understand - - O
the - - O
role - - O
of - - O
Ets - - O
proteins - - O
in - - O
Ras - - O
transformation - - O
, - - O
we - - O
have - - O
now - - O
analyzed - - O
the - - O
effects - - O
of - - O
stably - - O
expressing - - O
a - - O
variety - - O
of - - O
Ets2 - - O
constructs - - O
in - - O
Ras-transformed - - O
NIH3T3 - - O
( - - O
DT - - O
) - - O
cells - - O
. - - O

They - - O
were - - O
randomly - - O
allocated - - O
to - - O
receive - - O
either - - O
625 - - O
mg - - O
of - - O
calcium - - O
carbonate - - O
( - - O
250 - - O
mg - - O
of - - O
elemental - - O
calcium - - O
) - - O
at - - O
the - - O
end - - O
of - - O
a - - O
meal - - O
three - - O
times - - O
a - - O
day - - O
( - - O
group - - O
A - - O
, - - O
n - - O
= - - O
26 - - O
) - - O
or - - O
calcium - - O
carbonate - - O
in - - O
the - - O
same - - O
manner - - O
plus - - O
0 - - O
. - - O
625 - - O
mg - - O
day - - O
of - - O
conjugated - - O
equine - - O
estrogen - - O
and - - O
5 - - O
mg - - O
medrogestone - - O
acetate - - O
from - - O
day - - O
1-12 - - O
each - - O
month - - O
( - - O
group - - O
B - - O
, - - O
n - - O
= - - O
30 - - O
) - - O
. - - O

In - - O
addition - - O
to - - O
the - - O
signals - - O
obtained - - O
by - - O
ligation - - O
of - - O
the - - O
TCR - - O
, - - O
T - - O
cells - - O
need - - O
additional - - O
, - - O
co-stimulatory - - O
signals - - O
to - - O
be - - O
activated - - O
. - - O

However - - O
, - - O
most - - O
produced - - O
significant - - O
alteration - - O
of - - O
small - - O
intestinal - - O
permeability - - O
. - - O

Cyclin - - O
D1 - - O
promoter - - O
activity - - O
was - - O
stimulated - - O
by - - O
overexpression - - O
of - - O
mitogen-activated - - O
protein - - O
kinase - - O
( - - O
p41MAPK - - O
) - - O
or - - O
c-Ets-2 - - O
through - - O
the - - O
proximal - - O
22 - - O
base - - O
pairs - - O
. - - O

Synthetic - - O
enantiomers - - O
of - - O
drugs - - O
. - - O

Furthermore - - O
, - - O
in - - O
vitro - - O
decay - - O
reaction - - O
mixtures - - O
supplemented - - O
with - - O
the - - O
20-nt - - O
sense - - O
RNA - - O
transcript - - O
resulted - - O
in - - O
stabilization - - O
of - - O
R2 - - O
message - - O
. - - O

The - - O
5' - - O
and - - O
3' - - O
untranslated - - O
sequences - - O
contain - - O
characteristic - - O
sequences - - O
that - - O
are - - O
involved - - O
in - - O
the - - O
initiation - - O
and - - O
termination - - O
of - - O
transcription - - O
, - - O
including - - O
two - - O
possible - - O
promoters - - O
, - - O
one - - O
of - - O
which - - O
may - - O
contain - - O
two - - O
overlapping - - O
-10 - - O
sequences - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
investigated - - O
the - - O
molecular - - O
mechanisms - - O
underlying - - O
the - - O
inducible - - O
expression - - O
of - - O
the - - O
flt-1 - - O
gene - - O
during - - O
the - - O
activation - - O
of - - O
THP-1 - - O
cells - - O
. - - O

Estimated - - O
daily - - O
intakes - - O
( - - O
EDIs - - O
) - - O
per - - O
person - - O
were - - O
0 - - O
. - - O
56 - - O
microgram - - O
for - - O
total - - O
HCH - - O
, - - O
0 - - O
. - - O
20 - - O
microgram - - O
for - - O
gamma-HCH - - O
, - - O
0 - - O
. - - O
09 - - O
microgram - - O
for - - O
dieldrin - - O
, - - O
1 - - O
. - - O
42 - - O
micrograms - - O
for - - O
total - - O
DDT - - O
, - - O
and - - O
0 - - O
. - - O
15 - - O
microgram - - O
for - - O
HCB - - O
. - - O

A - - O
protocol - - O
is - - O
elaborated - - O
for - - O
the - - O
preparation - - O
and - - O
characterization - - O
of - - O
a - - O
quality - - O
control - - O
material - - O
( - - O
QCM - - O
) - - O
containing - - O
intrinsic - - O
concentration - - O
of - - O
cadmium - - O
( - - O
Cd - - O
) - - O
( - - O
0 - - O
. - - O
8 - - O
microgram - - O
L - - O
) - - O
and - - O
lead - - O
( - - O
Pb - - O
) - - O
( - - O
13 - - O
. - - O
4 - - O
micrograms - - O
dL - - O
) - - O
from - - O
bovine - - O
blood - - O
and - - O
an - - O
elevated - - O
QCM - - O
containing - - O
Cd - - O
( - - O
5 - - O
. - - O
0 - - O
micrograms - - O
L - - O
) - - O
, - - O
mercury - - O
( - - O
Hg - - O
) - - O
( - - O
11 - - O
. - - O
2 - - O
micrograms - - O
L - - O
) - - O
, - - O
and - - O
Pb - - O
( - - O
34 - - O
. - - O
5 - - O
micrograms - - O
dL - - O
) - - O
from - - O
bovine - - O
blood - - O
spiked - - O
with - - O
aqueous - - O
spiking-solutions - - O
prepared - - O
with - - O
salts - - O
of - - O
Cd - - O
, - - O
Hg - - O
, - - O
and - - O
Pb - - O
. - - O

Gab2 - - O
, - - O
a - - O
new - - O
pleckstrin - - O
homology - - O
domain-containing - - O
adapter - - O
protein - - O
, - - O
acts - - O
to - - O
uncouple - - O
signaling - - O
from - - O
ERK - - O
kinase - - O
to - - O
Elk-1 - - O
. - - O

In - - O
HeLa - - O
cells - - O
, - - O
it - - O
activated - - O
transcription - - O
from - - O
the - - O
herpes - - O
simplex - - O
virus - - O
type - - O
1 - - O
thymidine - - O
kinase - - O
promoter - - O
linked - - O
to - - O
the - - O
chloramphenicol - - O
acetyltransferase - - O
gene - - O
when - - O
located - - O
in - - O
inverted - - O
orientation - - O
upstream - - O
of - - O
the - - O
thymidine - - O
kinase - - O
promoter - - O
or - - O
downstream - - O
of - - O
the - - O
chloramphenicol - - O
acetyltransferase - - O
gene - - O
coding - - O
sequence - - O
. - - O

Guiding - - O
patients - - O
in - - O
the - - O
decision - - O
should - - O
involve - - O
a - - O
multidisciplinary - - O
team - - O
composed - - O
of - - O
a - - O
surgical - - O
oncologist - - O
, - - O
geneticist - - O
, - - O
pathologist - - O
, - - O
psychotherapist - - O
and - - O
plastic - - O
surgeon - - O
. - - O

Neither - - O
model - - O
, - - O
as - - O
applied - - O
, - - O
provided - - O
a - - O
satisfactory - - O
account - - O
of - - O
the - - O
effects - - O
of - - O
the - - O
main - - O
variables - - O
of - - O
number - - O
of - - O
tones - - O
and - - O
amount - - O
of - - O
perturbation - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
400 - - O
WORDS - - O
) - - O

Treatment - - O
of - - O
ovarian - - O
neoplasms - - O
. - - O

The - - O
variable - - O
HMG - - O
dosage - - O
regimen - - O
was - - O
found - - O
to - - O
offer - - O
no - - O
advantages - - O
when - - O
compared - - O
with - - O
our - - O
standard - - O
daily - - O
dosage - - O
regimen - - O
. - - O

The - - O
improved - - O
CSF - - O
outflow - - O
conductance - - O
may - - O
increase - - O
the - - O
intracranial - - O
compliance - - O
and - - O
thereby - - O
dampen - - O
a - - O
pathological - - O
ICP - - O
waveform - - O
. - - O

The - - O
sequence - - O
of - - O
this - - O
region - - O
shows - - O
high - - O
G+C - - O
content - - O
( - - O
62% - - O
) - - O
, - - O
which - - O
is - - O
particularly - - O
emphasized - - O
in - - O
the - - O
200 - - O
bp - - O
upstream - - O
from - - O
the - - O
mRNA - - O
start - - O
( - - O
80% - - O
G+C - - O
) - - O
. - - O

This - - O
difference - - O
may - - O
result - - O
from - - O
the - - O
lower - - O
match - - O
to - - O
the - - O
ARG - - O
box - - O
consensus - - O
of - - O
the - - O
O - - O
( - - O
rocD - - O
) - - O
site - - O
. - - O

Expression - - O
, - - O
nucleotide - - O
sequence - - O
and - - O
mutational - - O
analysis - - O
of - - O
two - - O
open - - O
reading - - O
frames - - O
in - - O
the - - O
nif - - O
gene - - O
region - - O
of - - O
Anabaena - - O
sp - - O
. - - O
strain - - O
PCC7120 - - O
. - - O

We - - O
postulate - - O
that - - O
CaM - - O
binding - - O
by - - O
HIV - - O
envelope - - O
proteins - - O
is - - O
likely - - O
to - - O
exert - - O
diverse - - O
modulatory - - O
effects - - O
, - - O
and - - O
the - - O
mechanism - - O
for - - O
HIV-induced - - O
cytotoxicity - - O
may - - O
involve - - O
, - - O
in - - O
part - - O
, - - O
inhibition - - O
of - - O
CaM-regulated - - O
cellular - - O
functions - - O
. - - O

Both - - O
of - - O
these - - O
domains - - O
have - - O
striking - - O
sequence - - O
homology - - O
with - - O
human - - O
SIM - - O
and - - O
Drosophila - - O
SIM - - O
proteins - - O
. - - O

Truncations - - O
composed - - O
of - - O
78 - - O
and - - O
64 - - O
amino - - O
acids - - O
were - - O
translocated - - O
across - - O
the - - O
endoplasmic - - O
reticulum - - O
membrane - - O
, - - O
and - - O
translocation - - O
was - - O
found - - O
to - - O
be - - O
strictly - - O
co-translational - - O
and - - O
SRP-dependent - - O
. - - O

Toxicity - - O
was - - O
very - - O
mild - - O
with - - O
both - - O
regimens - - O
, - - O
although - - O
sedation - - O
was - - O
significantly - - O
higher - - O
in - - O
arm - - O
B - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

6 - - O
. - - O

The - - O
uterine - - O
response - - O
to - - O
prostaglandin - - O
E2 - - O
( - - O
PGE2 - - O
) - - O
and - - O
prostaglandin - - O
F2alpha - - O
( - - O
administered - - O
by - - O
intravenous - - O
and - - O
intrauterine - - O
routes - - O
) - - O
was - - O
evaluated - - O
during - - O
different - - O
phases - - O
of - - O
the - - O
menstrual - - O
cycle - - O
in - - O
five - - O
functionally - - O
infertile - - O
women - - O
. - - O

Shift-down - - O
experiments - - O
indicated - - O
that - - O
the - - O
10 - - O
( - - O
4 - - O
) - - O
- - - O
to - - O
10 - - O
( - - O
5 - - O
) - - O
-fold - - O
reduction - - O
in - - O
virus - - O
yield - - O
at - - O
the - - O
nonpermissive - - O
temperature - - O
was - - O
due - - O
to - - O
the - - O
disfunction - - O
of - - O
alpha - - O
TIF - - O
late - - O
in - - O
infection - - O
, - - O
presumably - - O
in - - O
virion - - O
maturation - - O
. - - O

Specifically - - O
, - - O
the - - O
deduced - - O
FR-19 - - O
amino - - O
acid - - O
sequence - - O
has - - O
approximately89 - - O
, - - O
77 - - O
, - - O
and - - O
68% - - O
overall - - O
identity - - O
to - - O
chicken - - O
TEF-1A - - O
, - - O
mouse - - O
TEF-1 - - O
, - - O
and - - O
mouse - - O
embryonic - - O
TEA - - O
domain-containing - - O
factor - - O
, - - O
respectively - - O
. - - O

We - - O
examined - - O
the - - O
effects - - O
of - - O
long-term - - O
perfusion - - O
with - - O
pyridoxalated - - O
hemoglobin - - O
polyoxyethylene - - O
conjugate - - O
( - - O
PHP - - O
) - - O
solution - - O
on - - O
cardiac - - O
function - - O
of - - O
isolated - - O
rat - - O
hearts - - O
. - - O

Two - - O
classes - - O
of - - O
mutations - - O
were - - O
obtained - - O
: - - O
( - - O
i - - O
) - - O
those - - O
that - - O
altered - - O
the - - O
coding - - O
region - - O
of - - O
HOL1 - - O
, - - O
conferring - - O
the - - O
ability - - O
to - - O
take - - O
up - - O
histidinol - - O
; - - O
and - - O
( - - O
ii - - O
) - - O
cis-acting - - O
mutations - - O
( - - O
selected - - O
in - - O
a - - O
mutant - - O
HOL1-1 - - O
background - - O
) - - O
that - - O
increased - - O
expression - - O
of - - O
the - - O
Hol1 - - O
protein - - O
. - - O

INTERVENTION - - O
( - - O
S - - O
) - - O
: - - O
Twenty-six - - O
hemostasis - - O
parameters - - O
evaluated - - O
repeatedly - - O
in - - O
patients - - O
undergoing - - O
IVF-ET - - O
. - - O

NF - - O
kappa - - O
B - - O
was - - O
activated - - O
to - - O
a - - O
much - - O
greater - - O
extent - - O
by - - O
roscovitine - - O
in - - O
the - - O
WT - - O
cells - - O
than - - O
in - - O
Y8 - - O
cells - - O
. - - O

Although - - O
pathological - - O
thyroid - - O
function - - O
is - - O
related - - O
to - - O
changes - - O
in - - O
energy - - O
expenditure - - O
and - - O
body - - O
composition - - O
, - - O
its - - O
possible - - O
influence - - O
on - - O
leptin - - O
levels - - O
remains - - O
to - - O
be - - O
determined - - O
. - - O

Identification - - O
and - - O
characterization - - O
of - - O
the - - O
promoter - - O
for - - O
the - - O
cytotactin - - O
gene - - O
. - - O

A - - O
coiled-coil - - O
domain - - O
, - - O
conserved - - O
within - - O
each - - O
encoded - - O
protein - - O
, - - O
serves - - O
as - - O
a - - O
potential - - O
interaction - - O
motif - - O
for - - O
FLI - - O
LRR - - O
. - - O

We - - O
have - - O
identified - - O
two - - O
Marek's - - O
Disease - - O
Virus - - O
( - - O
MDV - - O
) - - O
genes - - O
within - - O
the - - O
EcoRI-B - - O
fragment - - O
of - - O
MDV-GA - - O
genomic - - O
DNA - - O
. - - O

Twenty-eight - - O
were - - O
excluded - - O
as - - O
gallstones - - O
were - - O
not - - O
proved - - O
: - - O
of - - O
the - - O
remainder - - O
, - - O
21 - - O
patients - - O
received - - O
glucagon - - O
and - - O
22 - - O
placebo - - O
. - - O

Fibrinogen - - O
determination - - O
using - - O
the - - O
KZM-1 - - O
meter - - O
. - - O

Unexpectedly - - O
, - - O
ALK7 - - O
signaling - - O
produced - - O
a - - O
remarkable - - O
change - - O
in - - O
cell - - O
morphology - - O
characterized - - O
by - - O
cell - - O
flattening - - O
and - - O
elaboration - - O
of - - O
blunt - - O
, - - O
short - - O
cell - - O
processes - - O
. - - O

The - - O
effect - - O
of - - O
echothiophate - - O
on - - O
the - - O
biphasic - - O
response - - O
of - - O
rabbit - - O
ocular - - O
pressure - - O
to - - O
dipivefrin - - O
. - - O

At - - O
the - - O
time - - O
of - - O
the - - O
blind - - O
therapeutic - - O
doses - - O
, - - O
Tg-off - - O
values - - O
ranged - - O
from - - O
8 - - O
to - - O
608 - - O
microg - - O
l - - O
. - - O

We - - O
report - - O
here - - O
the - - O
cloning - - O
of - - O
the - - O
murine - - O
p44 - - O
MAP - - O
kinase - - O
( - - O
extracellular - - O
signal-regulated - - O
kinase - - O
1 - - O
) - - O
gene - - O
, - - O
the - - O
determination - - O
of - - O
its - - O
intron - - O
exon - - O
boundaries - - O
, - - O
and - - O
the - - O
characterization - - O
of - - O
its - - O
promoter - - O
. - - O

Besides - - O
, - - O
we - - O
found - - O
in - - O
3 - - O
patients - - O
increased - - O
serum - - O
immunoglobulins - - O
, - - O
chiefly - - O
IgG - - O
, - - O
as - - O
first - - O
Russe - - O
, - - O
Busey - - O
and - - O
Barbeau - - O
demonstrated - - O
in - - O
a - - O
large - - O
French-Canadian - - O
family - - O
. - - O

Uptake - - O
of - - O
ofloxacin - - O
by - - O
Escherichia - - O
coli - - O
. - - O

A - - O
rapid - - O
staining - - O
technique - - O
for - - O
Leishmania - - O
parasites - - O
in - - O
splenic - - O
aspirate - - O
smears - - O
. - - O

Role - - O
of - - O
superoxide - - O
dismutase - - O
in - - O
cellular - - O
oxidative - - O
processes - - O
and - - O
method - - O
of - - O
its - - O
determination - - O
in - - O
biological - - O
materials - - O
. - - O

This - - O
study - - O
analyzed - - O
whether - - O
the - - O
localization - - O
of - - O
an - - O
accessory - - O
pathway - - O
could - - O
be - - O
predicted - - O
by - - O
using - - O
the - - O
polarity - - O
of - - O
the - - O
QRS - - O
complex - - O
during - - O
sinus - - O
rhythm - - O
on - - O
the - - O
surface - - O
ECG - - O
, - - O
instead - - O
of - - O
the - - O
delta - - O
wave - - O
polarity - - O
as - - O
used - - O
in - - O
many - - O
reports - - O
. - - O

Here - - O
we - - O
show - - O
that - - O
phosphorylation-induced - - O
loss - - O
of - - O
the - - O
protein - - O
kinase - - O
activity - - O
of - - O
DNA-PK - - O
is - - O
restored - - O
by - - O
the - - O
addition - - O
of - - O
the - - O
purified - - O
catalytic - - O
subunit - - O
of - - O
either - - O
protein - - O
phosphatase - - O
1 - - O
or - - O
protein - - O
phosphatase - - O
2A - - O
( - - O
PP2A - - O
) - - O
and - - O
that - - O
this - - O
reactivation - - O
is - - O
blocked - - O
by - - O
the - - O
potent - - O
protein - - O
phosphatase - - O
inhibitor - - O
, - - O
microcystin - - O
. - - O

Transcripts - - O
for - - O
both - - O
ODV-E18 - - O
and - - O
ODV-EC27 - - O
initiate - - O
from - - O
conserved - - O
TAAG - - O
motifs - - O
, - - O
and - - O
transcripts - - O
are - - O
detected - - O
from - - O
16 - - O
through - - O
72 - - O
hr - - O
p - - O
. - - O
i - - O
. - - O

Control - - O
of - - O
transcription - - O
of - - O
the - - O
erbB-2 - - O
gene - - O
is - - O
an - - O
important - - O
determinant - - O
of - - O
receptor - - O
expression - - O
. - - O

The - - O
incidence - - O
of - - O
second - - O
malignant - - O
neoplasms - - O
was - - O
lower - - O
( - - O
1 - - O
. - - O
3% - - O
) - - O
in - - O
the - - O
group - - O
treated - - O
with - - O
5-fluorouracil - - O
, - - O
doxorubicin - - O
, - - O
and - - O
cyclophosphamide - - O
than - - O
in - - O
the - - O
historical - - O
control - - O
group - - O
( - - O
4 - - O
. - - O
8% - - O
) - - O
. - - O

The - - O
aim - - O
of - - O
the - - O
present - - O
study - - O
was - - O
to - - O
examine - - O
the - - O
antimicrobial - - O
susceptibility - - O
to - - O
10 - - O
currently - - O
used - - O
antimicrobial - - O
agents - - O
of - - O
50 - - O
strains - - O
of - - O
P - - O
. - - O
acnes - - O
isolated - - O
from - - O
acne - - O
lesions - - O
and - - O
identified - - O
using - - O
a - - O
Rap - - O
ID - - O
ANA - - O
II - - O
panel - - O
. - - O

Polyhomeotic - - O
and - - O
Posterior - - O
Sex - - O
Combs - - O
may - - O
participate - - O
in - - O
a - - O
more - - O
general - - O
transcriptional - - O
mechanism - - O
that - - O
causes - - O
modulated - - O
gene - - O
repression - - O
, - - O
whereas - - O
the - - O
inclusion - - O
of - - O
Polycomb - - O
protein - - O
in - - O
the - - O
complex - - O
at - - O
PREs - - O
leads - - O
to - - O
stable - - O
silencing - - O
. - - O

The - - O
tumorigenic - - O
E1A - - O
+ - - O
cHa-ras - - O
cells - - O
are - - O
characterized - - O
by - - O
high - - O
and - - O
constitutive - - O
DNA - - O
binding - - O
activities - - O
of - - O
AP-1 - - O
, - - O
in - - O
contrast - - O
to - - O
nontransformed - - O
cells - - O
and - - O
the - - O
E1A - - O
cells - - O
. - - O

Unitary-group - - O
approach - - O
to - - O
spin-dependent - - O
operators - - O
. - - O

The - - O
transcription - - O
factor - - O
E2F - - O
plays - - O
an - - O
important - - O
role - - O
in - - O
G - - O
( - - O
1 - - O
) - - O
to - - O
S - - O
phase - - O
transition - - O
in - - O
the - - O
higher - - O
eukaryotic - - O
cell - - O
cycle - - O
. - - O

The - - O
RMR - - O
was - - O
measured - - O
twice - - O
in - - O
each - - O
phase - - O
and - - O
found - - O
to - - O
be - - O
similar - - O
( - - O
F - - O
( - - O
1 - - O
, - - O
18 - - O
) - - O
= - - O
0 - - O
. - - O
863 - - O
) - - O
across - - O
the - - O
follicular - - O
( - - O
5018 - - O
kJ - - O
24 - - O
h - - O
) - - O
and - - O
the - - O
luteal - - O
( - - O
5098 - - O
kJ - - O
24 - - O
h - - O
) - - O
phases - - O
. - - O

Inductively - - O
coupled - - O
plasma - - O
atomic - - O
emission - - O
spectroscopy - - O
was - - O
employed - - O
to - - O
obtain - - O
the - - O
tissue - - O
silicon - - O
measurements - - O
. - - O

The - - O
expression - - O
of - - O
alpha-amylase - - O
can - - O
be - - O
transactivated - - O
by - - O
the - - O
transcription - - O
factor - - O
GAMyb - - O
, - - O
which - - O
is - - O
itself - - O
induced - - O
by - - O
GA - - O
. - - O

Zn - - O
( - - O
II - - O
) - - O
coordination - - O
domain - - O
mutants - - O
of - - O
T4 - - O
gene - - O
32 - - O
protein - - O
. - - O

Deletion - - O
of - - O
the - - O
NF-IL6 - - O
beta - - O
leucine - - O
zipper - - O
domain - - O
also - - O
greatly - - O
diminished - - O
the - - O
interaction - - O
between - - O
these - - O
two - - O
proteins - - O
. - - O

These - - O
findings - - O
suggest - - O
that - - O
the - - O
increase - - O
in - - O
V - - O
O2 - - O
may - - O
have - - O
been - - O
a - - O
consequence - - O
of - - O
the - - O
increase - - O
in - - O
Q - - O
O2 - - O
rather - - O
than - - O
a - - O
response - - O
to - - O
the - - O
procedure - - O
itself - - O
. - - O

Significant - - O
alterations - - O
in - - O
CBC - - O
results - - O
and - - O
serum - - O
CRP - - O
concentration - - O
, - - O
compared - - O
with - - O
baseline - - O
values - - O
, - - O
were - - O
lacking - - O
in - - O
dogs - - O
of - - O
the - - O
control - - O
group - - O
. - - O

For - - O
Al - - O
, - - O
the - - O
exposure - - O
to - - O
1 - - O
. - - O
36 - - O
mg - - O
m3 - - O
during - - O
the - - O
shift - - O
corresponded - - O
to - - O
a - - O
urinary - - O
concentration - - O
at - - O
the - - O
end - - O
of - - O
the - - O
shift - - O
of - - O
200 - - O
microgram - - O
g - - O
creatinine - - O
. - - O

The - - O
tetraphasic - - O
action - - O
of - - O
lidocaine - - O
on - - O
CNS - - O
electrical - - O
activity - - O
and - - O
behavior - - O
in - - O
cats - - O
. - - O

An - - O
analytic - - O
method - - O
for - - O
comparative - - O
parameter - - O
weighting - - O
in - - O
magnetic - - O
resonance - - O
( - - O
MR - - O
) - - O
imaging - - O
has - - O
been - - O
developed - - O
using - - O
the - - O
concept - - O
of - - O
"fractional - - O
sensitivity - - O
. - - O
" - - O
This - - O
new - - O
approach - - O
results - - O
in - - O
easily - - O
calculated - - O
indexes - - O
for - - O
T1 - - O
, - - O
T2 - - O
, - - O
and - - O
hydrogen - - O
weighting - - O
. - - O

Here - - O
we - - O
report - - O
the - - O
purification - - O
of - - O
this - - O
larger - - O
form - - O
as - - O
an - - O
approximately - - O
320-kDa - - O
particle - - O
that - - O
contains - - O
mRNP3+4 - - O
and - - O
nine - - O
additional - - O
polypeptides - - O
, - - O
including - - O
mRNA-binding - - O
polypeptides - - O
of - - O
34 - - O
and - - O
36 - - O
kDa - - O
and - - O
a - - O
doublet - - O
of - - O
110 - - O
105 - - O
kDa - - O
that - - O
proved - - O
to - - O
be - - O
nucleolin - - O
. - - O

SIP1 - - O
( - - O
Smad - - O
interacting - - O
protein - - O
1 - - O
) - - O
and - - O
deltaEF1 - - O
( - - O
delta-crystallin - - O
enhancer - - O
binding - - O
factor - - O
) - - O
are - - O
structurally - - O
similar - - O
transcriptional - - O
repressors - - O
. - - O

A - - O
new - - O
non-LTR - - O
retrotransposon - - O
provides - - O
evidence - - O
for - - O
multiple - - O
distinct - - O
site-specific - - O
elements - - O
in - - O
Crithidia - - O
fasciculata - - O
miniexon - - O
arrays - - O
. - - O

Overproduction - - O
of - - O
HrcA - - O
protein - - O
from - - O
a - - O
second - - O
copy - - O
of - - O
hrcA - - O
derived - - O
from - - O
a - - O
plasmid - - O
( - - O
phrcA+ - - O
) - - O
in - - O
B - - O
. - - O
subtilis - - O
wild-type - - O
and - - O
delta - - O
hrcA - - O
strains - - O
prevented - - O
heat - - O
shock - - O
induction - - O
of - - O
the - - O
dnaK - - O
and - - O
groE - - O
operons - - O
at - - O
the - - O
level - - O
of - - O
transcription - - O
almost - - O
completely - - O
and - - O
strongly - - O
reduced - - O
the - - O
amounts - - O
of - - O
mRNA - - O
at - - O
a - - O
low - - O
temperature - - O
as - - O
well - - O
. - - O

The - - O
construct - - O
was - - O
introduced - - O
into - - O
BW2001 - - O
( - - O
xth-11 - - O
, - - O
nfo-2 - - O
) - - O
strain - - O
cells - - O
of - - O
Escherichia - - O
coli - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
: - - O
( - - O
a - - O
) - - O
proSRIF - - O
cleavage - - O
is - - O
initiated - - O
in - - O
the - - O
TGN - - O
, - - O
and - - O
( - - O
b - - O
) - - O
this - - O
reaction - - O
requires - - O
an - - O
acidic - - O
pH - - O
which - - O
is - - O
facilitated - - O
by - - O
a - - O
Golgi-associated - - O
vacuolar-type - - O
ATPase - - O
. - - O

High-resolution - - O
structure - - O
of - - O
the - - O
diphtheria - - O
toxin - - O
repressor - - O
complexed - - O
with - - O
cobalt - - O
and - - O
manganese - - O
reveals - - O
an - - O
SH3-like - - O
third - - O
domain - - O
and - - O
suggests - - O
a - - O
possible - - O
role - - O
of - - O
phosphate - - O
as - - O
co-corepressor - - O
. - - O

Second - - O
, - - O
nitrate - - O
induction - - O
of - - O
aeg-46 - - O
. - - O
5 - - O
operon - - O
expression - - O
is - - O
substantially - - O
enhanced - - O
in - - O
narL - - O
null - - O
strains - - O
( - - O
M - - O
. - - O
H - - O
. - - O

In - - O
spite - - O
of - - O
this - - O
and - - O
other - - O
complications - - O
of - - O
corticosteroids - - O
, - - O
she - - O
made - - O
a - - O
full - - O
recovery - - O
from - - O
the - - O
fungal - - O
infection - - O
following - - O
treatment - - O
with - - O
amphotericin - - O
B - - O
and - - O
surgical - - O
excision - - O
of - - O
the - - O
lung - - O
abscess - - O
. - - O

The - - O
GALT-primed - - O
calves - - O
had - - O
increased - - O
serum - - O
IgG - - O
, - - O
lavage - - O
IgG - - O
and - - O
IgA - - O
and - - O
increased - - O
LNA - - O
titers - - O
in - - O
both - - O
lavage - - O
fluids - - O
and - - O
serum - - O
following - - O
the - - O
SC - - O
dose - - O
of - - O
killed - - O
bacteria - - O
. - - O

We - - O
describe - - O
a - - O
case - - O
of - - O
a - - O
perinephric - - O
abscess - - O
treated - - O
with - - O
amphotericin - - O
B - - O
and - - O
nephrectomy - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
the - - O
binding - - O
of - - O
CBF - - O
NF-Y - - O
to - - O
the - - O
inverted - - O
CCAAT - - O
box - - O
is - - O
responsible - - O
for - - O
transcriptional - - O
activation - - O
of - - O
the - - O
nTPH - - O
gene - - O
. - - O

Mutation - - O
of - - O
the - - O
C - - O
EBP - - O
binding - - O
sites - - O
in - - O
the - - O
Rous - - O
sarcoma - - O
virus - - O
long - - O
terminal - - O
repeat - - O
and - - O
gag - - O
enhancers - - O
. - - O

There - - O
were - - O
27 - - O
men - - O
and - - O
156 - - O
women - - O
. - - O

A - - O
new - - O
set - - O
of - - O
cDNA - - O
clones - - O
spanning - - O
approximately - - O
3 - - O
. - - O
2 - - O
kb - - O
was - - O
isolated - - O
from - - O
a - - O
lambda-ZAP - - O
goose - - O
liver - - O
cDNA - - O
library - - O
using - - O
the - - O
5'-most - - O
exon-containing - - O
fragment - - O
of - - O
the - - O
5'-most - - O
genomic - - O
DNA - - O
clone - - O
. - - O

The - - O
sequence - - O
contains - - O
an - - O
open - - O
reading - - O
frame - - O
of - - O
1744 - - O
nt - - O
in - - O
the - - O
virus-sense - - O
strand - - O
, - - O
a - - O
3' - - O
untranslated - - O
region - - O
of - - O
1360 - - O
nt - - O
and - - O
a - - O
3' - - O
poly - - O
( - - O
A - - O
) - - O
tail - - O
. - - O

We - - O
found - - O
that - - O
total - - O
PSA - - O
can - - O
be - - O
detected - - O
in - - O
all - - O
cyst - - O
fluids - - O
and - - O
in - - O
about - - O
75% - - O
of - - O
female - - O
sera - - O
. - - O

Depending - - O
on - - O
the - - O
location - - O
and - - O
size - - O
of - - O
the - - O
mass - - O
, - - O
a - - O
wide - - O
range - - O
of - - O
clinical - - O
presentations - - O
is - - O
associated - - O
with - - O
the - - O
lesion - - O
. - - O

Human - - O
adenovirus - - O
type - - O
41 - - O
contains - - O
two - - O
fibers - - O
. - - O

The - - O
likelihood - - O
that - - O
a - - O
common - - O
region - - O
of - - O
deletions - - O
would - - O
contain - - O
a - - O
tumor - - O
suppressor - - O
is - - O
strongly - - O
enhanced - - O
by - - O
coincidence - - O
of - - O
that - - O
region - - O
with - - O
a - - O
chromosome - - O
fragment - - O
suppressing - - O
tumorigenicity - - O
upon - - O
introduction - - O
in - - O
tumor - - O
cells - - O
. - - O

Denaturation - - O
of - - O
the - - O
simian - - O
virus - - O
40 - - O
origin - - O
of - - O
replication - - O
mediated - - O
by - - O
human - - O
replication - - O
protein - - O
A - - O
. - - O

In - - O
both - - O
these - - O
respects - - O
, - - O
however - - O
, - - O
the - - O
DBP - - O
mRNA - - O
resembles - - O
the - - O
late - - O
messengers - - O
of - - O
SV40 - - O
and - - O
polyoma - - O
viruses - - O
. - - O

Genomic - - O
clones - - O
encompassing - - O
the - - O
human - - O
ETS1 - - O
gene - - O
were - - O
isolated - - O
and - - O
utilized - - O
to - - O
define - - O
its - - O
molecular - - O
organization - - O
. - - O

Type - - O
2 - - O
genomes - - O
containing - - O
this - - O
sequence - - O
presumably - - O
more - - O
closely - - O
reflect - - O
the - - O
structure - - O
of - - O
the - - O
infectious - - O
, - - O
replication-competent - - O
retrovirus - - O
ancestors - - O
of - - O
the - - O
HERV-K - - O
family - - O
than - - O
do - - O
type - - O
1 - - O
genomes - - O
that - - O
lack - - O
the - - O
sequence - - O
. - - O

Multidrug - - O
resistance - - O
in - - O
Saccharomyces - - O
cerevisiae - - O
mainly - - O
results - - O
from - - O
the - - O
overexpression - - O
of - - O
genes - - O
coding - - O
for - - O
the - - O
membrane - - O
efflux - - O
pumps - - O
, - - O
the - - O
major - - O
facilitators - - O
and - - O
the - - O
ABC - - O
binding - - O
cassette - - O
transporters - - O
, - - O
under - - O
the - - O
control - - O
of - - O
key - - O
transcription - - O
regulators - - O
encoded - - O
by - - O
the - - O
PDR1 - - O
and - - O
PDR3 - - O
genes - - O
. - - O

In - - O
the - - O
Oct-1 - - O
crystal - - O
, - - O
the - - O
POU-specific - - O
domain - - O
recognizes - - O
a - - O
GCAT - - O
half-site - - O
, - - O
while - - O
the - - O
corresponding - - O
sequence - - O
recognized - - O
by - - O
the - - O
Pit-1 - - O
POU-specific - - O
domain - - O
, - - O
GTAT - - O
, - - O
is - - O
on - - O
the - - O
opposing - - O
strand - - O
. - - O

Blood - - O
samples - - O
were - - O
obtained - - O
daily - - O
during - - O
this - - O
supplementation - - O
period - - O
and - - O
5 - - O
d - - O
thereafter - - O
( - - O
d - - O
11 - - O
to - - O
15 - - O
) - - O
. - - O

We - - O
were - - O
able - - O
to - - O
detect - - O
significant - - O
differences - - O
in - - O
functional - - O
residual - - O
capacity - - O
adjusted - - O
for - - O
weight - - O
or - - O
height - - O
, - - O
and - - O
compliance - - O
of - - O
the - - O
respiratory - - O
system - - O
adjusted - - O
for - - O
weight - - O
or - - O
lung - - O
volume - - O
in - - O
the - - O
ILD - - O
infants - - O
compared - - O
to - - O
the - - O
healthy - - O
controls - - O
or - - O
infants - - O
who - - O
had - - O
PPHN - - O
, - - O
indicating - - O
that - - O
these - - O
PFTs - - O
were - - O
sensitive - - O
enough - - O
to - - O
determine - - O
abnormal - - O
lung - - O
function - - O
in - - O
this - - O
age - - O
group - - O
. - - O

The - - O
in - - O
vitro - - O
antibacterial - - O
potency - - O
is - - O
greatest - - O
when - - O
the - - O
1-substituent - - O
is - - O
2 - - O
, - - O
4-difluorophenyl - - O
and - - O
the - - O
7-substituent - - O
is - - O
a - - O
3-amino-1-pyrrolidinyl - - O
group - - O
. - - O

Previous - - O
analysis - - O
of - - O
the - - O
98-bp - - O
sequence - - O
has - - O
delineated - - O
several - - O
protein-binding - - O
domains - - O
that - - O
are - - O
recognized - - O
by - - O
nuclear - - O
factors - - O
present - - O
in - - O
human - - O
brain - - O
cells - - O
. - - O

There - - O
is - - O
no - - O
correlation - - O
between - - O
C2-C3 - - O
disk - - O
morphology - - O
and - - O
the - - O
diskographically - - O
provoked - - O
response - - O
. - - O

In - - O
experiment - - O
2 - - O
the - - O
rats - - O
had - - O
free - - O
access - - O
to - - O
two - - O
bottles - - O
, - - O
one - - O
of - - O
which - - O
contained - - O
tap - - O
water - - O
, - - O
and - - O
the - - O
other - - O
contained - - O
either - - O
an - - O
ethanol - - O
( - - O
6% - - O
) - - O
or - - O
a - - O
sucrose - - O
( - - O
5% - - O
) - - O
solution - - O
. - - O

The - - O
phenotypes - - O
of - - O
the - - O
ICP0 - - O
nonsense - - O
mutants - - O
were - - O
intermediate - - O
between - - O
those - - O
of - - O
the - - O
wild-type - - O
virus - - O
and - - O
7134 - - O
in - - O
that - - O
the - - O
more - - O
ICP0-coding - - O
sequence - - O
expressed - - O
by - - O
a - - O
given - - O
nonsense - - O
mutant - - O
, - - O
the - - O
more - - O
wild - - O
type-like - - O
was - - O
its - - O
phenotype - - O
. - - O

Here - - O
we - - O
describe - - O
a - - O
mutant - - O
alpha - - O
subunit - - O
designed - - O
to - - O
inhibit - - O
receptor-mediated - - O
hormonal - - O
activation - - O
of - - O
Gs - - O
, - - O
the - - O
stimulatory - - O
regulator - - O
of - - O
adenylyl - - O
cyclase - - O
. - - O

An - - O
inactive - - O
analog - - O
of - - O
wortmannin - - O
, - - O
WM12 - - O
, - - O
did - - O
not - - O
affect - - O
TCR - - O
CD3-induced - - O
Erk2 - - O
activation - - O
, - - O
and - - O
wortmannin - - O
had - - O
no - - O
effect - - O
on - - O
the - - O
activity - - O
of - - O
Erk2 - - O
when - - O
added - - O
directly - - O
to - - O
the - - O
in - - O
vitro - - O
assays - - O
. - - O

Concordance - - O
of - - O
IBDQ - - O
scores - - O
was - - O
tested - - O
in - - O
280 - - O
stable - - O
subjects - - O
. - - O

The - - O
UCR - - O
core - - O
sequence - - O
, - - O
CGCCATTTT - - O
, - - O
binds - - O
a - - O
ubiquitous - - O
nuclear - - O
factor - - O
and - - O
mediates - - O
negative - - O
regulation - - O
of - - O
MuLV - - O
promoter - - O
activity - - O
. - - O

The - - O
systolic - - O
peak - - O
of - - O
pulmonary - - O
vein - - O
was - - O
higher - - O
than - - O
the - - O
diastolic - - O
peak - - O
in - - O
45 - - O
out - - O
of - - O
56 - - O
cases - - O
. - - O

The - - O
effects - - O
of - - O
Codonopsis - - O
pilosula - - O
oral - - O
liquor - - O
( - - O
CPOL - - O
) - - O
on - - O
tissue-type - - O
plasminogen - - O
activator - - O
( - - O
t-PA - - O
) - - O
and - - O
plasminogen - - O
activator - - O
inhibitor - - O
( - - O
PAI - - O
) - - O
in - - O
the - - O
plasma - - O
of - - O
25 - - O
patients - - O
of - - O
coronary - - O
heart - - O
disease - - O
with - - O
blood - - O
stasis - - O
were - - O
studied - - O
. - - O

Here - - O
, - - O
the - - O
PEX5-TPR - - O
domains - - O
from - - O
human - - O
, - - O
tobacco - - O
, - - O
and - - O
nematode - - O
were - - O
inserted - - O
into - - O
a - - O
TPR-less - - O
yeast - - O
Pex5p - - O
construct - - O
to - - O
generate - - O
Pex5p - - O
chimaeras - - O
. - - O

Despite - - O
total - - O
tumor - - O
resection - - O
, - - O
multiple - - O
intraperitoneal - - O
tumor - - O
nodules - - O
of - - O
varying - - O
sizes - - O
were - - O
found - - O
and - - O
resected - - O
six - - O
months - - O
and - - O
one - - O
year - - O
later - - O
. - - O

Primary - - O
adrenal - - O
hypersensitivity - - O
to - - O
ACTH - - O
drive - - O
in - - O
obesity - - O
has - - O
also - - O
been - - O
suggested - - O
. - - O

The - - O
goal - - O
of - - O
the - - O
present - - O
study - - O
was - - O
to - - O
determine - - O
the - - O
feasibility - - O
of - - O
retrovirus - - O
mediated - - O
expression - - O
of - - O
rp47phox - - O
in - - O
the - - O
HL60 - - O
and - - O
U937 - - O
human - - O
hematopoietic - - O
cell - - O
lines - - O
, - - O
and - - O
in - - O
an - - O
Epstein-Barr - - O
virus - - O
transformed - - O
B-lymphocyte - - O
cell - - O
line - - O
( - - O
EBV-BCL - - O
) - - O
derived - - O
from - - O
a - - O
p47phox-deficient - - O
CGD - - O
patient - - O
. - - O

To - - O
determine - - O
which - - O
sequences - - O
in - - O
the - - O
rat - - O
P450c17 - - O
promoter - - O
may - - O
be - - O
responsible - - O
for - - O
basal - - O
and - - O
cAMP-stimulated - - O
gene - - O
transcription - - O
, - - O
deletion - - O
constructs - - O
containing - - O
between - - O
-1 - - O
, - - O
560 - - O
and - - O
-53 - - O
base - - O
pairs - - O
of - - O
5'-flanking - - O
DNA - - O
from - - O
the - - O
rat - - O
P450c17 - - O
gene - - O
were - - O
ligated - - O
to - - O
plasmids - - O
expressing - - O
the - - O
reporter - - O
gene - - O
luciferase - - O
and - - O
transfected - - O
into - - O
two - - O
mouse - - O
cell - - O
lines - - O
, - - O
adrenal - - O
Y-1 - - O
cells - - O
, - - O
and - - O
testicular - - O
Leydig - - O
MA-10 - - O
cells - - O
. - - O

Eliminating - - O
any - - O
subset - - O
of - - O
ASCUS - - O
reduces - - O
the - - O
ASCUS - - O
SIL - - O
ratio - - O
but - - O
also - - O
significantly - - O
diminishes - - O
the - - O
sensitivity - - O
of - - O
the - - O
Papanicolaou - - O
test - - O
. - - O

However - - O
, - - O
besides - - O
the - - O
kinase - - O
catalytic - - O
domain - - O
and - - O
double - - O
leucine - - O
isoleucine - - O
zippers - - O
, - - O
there - - O
was - - O
no - - O
significant - - O
homology - - O
with - - O
known - - O
proteins - - O
. - - O

We - - O
characterized - - O
the - - O
structure - - O
of - - O
this - - O
leader - - O
mRNA - - O
by - - O
using - - O
the - - O
program - - O
Mfold - - O
and - - O
a - - O
combination - - O
of - - O
nested - - O
and - - O
internal - - O
deletions - - O
transcriptionally - - O
fused - - O
to - - O
a - - O
promoterless - - O
lac - - O
operon - - O
. - - O

Despite - - O
continuous - - O
compliance - - O
, - - O
unexplained - - O
resurgence - - O
of - - O
serum - - O
ferritin - - O
levels - - O
occurred - - O
in - - O
4 - - O
7 - - O
patients - - O
of - - O
the - - O
'veteran' - - O
group - - O
after - - O
4-5 - - O
years - - O
on - - O
L1 - - O
. - - O

Signal - - O
transduction - - O
via - - O
modulation - - O
of - - O
phosphorylation - - O
after - - O
selective - - O
inhibition - - O
of - - O
protein - - O
phosphatase - - O
( - - O
PP - - O
) - - O
1 - - O
and - - O
or - - O
PP2A - - O
appears - - O
to - - O
play - - O
a - - O
role - - O
in - - O
okadaic - - O
acid - - O
( - - O
OA - - O
) - - O
-mediated - - O
effects - - O
. - - O

The - - O
dual - - O
specificity - - O
kinases - - O
mitogen-activated - - O
protein - - O
kinase - - O
( - - O
MAPK - - O
) - - O
kinase - - O
( - - O
MKK - - O
) - - O
7 - - O
and - - O
MKK4 - - O
are - - O
the - - O
only - - O
molecules - - O
known - - O
to - - O
directly - - O
activate - - O
the - - O
stress - - O
kinases - - O
stress-activated - - O
protein - - O
kinases - - O
( - - O
SAPKs - - O
) - - O
c-Jun - - O
N-terminal - - O
kinases - - O
( - - O
JNKs - - O
) - - O
in - - O
response - - O
to - - O
environmental - - O
or - - O
mitogenic - - O
stimuli - - O
. - - O

After - - O
2 - - O
min - - O
of - - O
dobutamine - - O
injection - - O
, - - O
or - - O
after - - O
20 - - O
min - - O
of - - O
pimobendan - - O
injection - - O
, - - O
the - - O
myocardium - - O
was - - O
removed - - O
, - - O
and - - O
used - - O
for - - O
determination - - O
of - - O
the - - O
tissue - - O
levels - - O
of - - O
metabolites - - O
of - - O
energy - - O
and - - O
carbohydrate - - O
metabolism - - O
. - - O

Quantitative - - O
evaluation - - O
of - - O
the - - O
steady - - O
state - - O
kinetics - - O
of - - O
MEK - - O
inhibition - - O
by - - O
these - - O
compounds - - O
reveals - - O
that - - O
U0126 - - O
has - - O
approximately - - O
100-fold - - O
higher - - O
affinity - - O
for - - O
deltaN3-S218E - - O
S222D - - O
MEK - - O
than - - O
does - - O
PD098059 - - O
. - - O

Technetium-99m - - O
methylene - - O
diphosphonate - - O
scintimammography - - O
for - - O
evaluation - - O
of - - O
palpable - - O
breast - - O
masses - - O
. - - O

Although - - O
there - - O
was - - O
a - - O
high - - O
correlation - - O
between - - O
sap - - O
flux - - O
densities - - O
registered - - O
by - - O
the - - O
old - - O
and - - O
new - - O
sensors - - O
, - - O
significant - - O
differences - - O
in - - O
sap - - O
flux - - O
densities - - O
between - - O
the - - O
duplicated - - O
sensors - - O
were - - O
detected - - O
. - - O

Modern - - O
cancer - - O
therapy - - O
has - - O
included - - O
surgery - - O
, - - O
radiotherapy - - O
, - - O
chemotherapy - - O
, - - O
and - - O
most - - O
recently - - O
, - - O
immunotherapy - - O
and - - O
hyperthermia - - O
. - - O

One - - O
skull - - O
does - - O
not - - O
a - - O
species - - O
make - - O
. - - O

Clones - - O
33F - - O
and - - O
34B - - O
encoded - - O
identical - - O
aromatase - - O
proteins - - O
of - - O
503 - - O
amino - - O
acids - - O
, - - O
but - - O
differed - - O
in - - O
size - - O
due - - O
to - - O
alternative - - O
polyadenylation - - O
signal - - O
usage - - O
for - - O
the - - O
corresponding - - O
mRNAs - - O
. - - O

Constitutive - - O
phosphorylation - - O
and - - O
nuclear - - O
localization - - O
of - - O
Smad3 - - O
are - - O
correlated - - O
with - - O
increased - - O
collagen - - O
gene - - O
transcription - - O
in - - O
activated - - O
hepatic - - O
stellate - - O
cells - - O
. - - O

The - - O
aim - - O
of - - O
this - - O
study - - O
was - - O
to - - O
determine - - O
the - - O
risk - - O
factors - - O
for - - O
background - - O
diabetic - - O
retinopathy - - O
( - - O
BDR - - O
) - - O
and - - O
PDR - - O
by - - O
following - - O
394 - - O
Japanese - - O
patients - - O
with - - O
early-onset - - O
type - - O
2 - - O
diabetes - - O
diagnosed - - O
before - - O
30 - - O
years - - O
of - - O
age - - O
( - - O
mean - - O
age - - O
27 - - O
, - - O
mean - - O
blood - - O
pressure - - O
at - - O
entry - - O
116 - - O
73 - - O
mm - - O
Hg - - O
) - - O
. - - O

The - - O
possible - - O
benefits - - O
of - - O
LMW - - O
heparin - - O
( - - O
reduced - - O
frequency - - O
of - - O
bleeding - - O
, - - O
alleviation - - O
of - - O
hypertriglyceridemia - - O
) - - O
were - - O
not - - O
, - - O
however - - O
, - - O
apparent - - O
, - - O
possibly - - O
because - - O
of - - O
the - - O
short - - O
observation - - O
period - - O
and - - O
the - - O
low - - O
incidence - - O
of - - O
hemorrhagic - - O
complications - - O
in - - O
routine - - O
dialyses - - O
. - - O

Percentages - - O
of - - O
recovery - - O
for - - O
overload - - O
and - - O
dilution - - O
tests - - O
were - - O
between - - O
87 - - O
and - - O
120% - - O
. - - O

Different - - O
cortical - - O
malformations - - O
were - - O
produced - - O
in - - O
rats - - O
by - - O
a - - O
single - - O
dose - - O
of - - O
X-rays - - O
( - - O
200 - - O
cGy - - O
) - - O
given - - O
on - - O
different - - O
days - - O
during - - O
gestation - - O
. - - O

Thus - - O
, - - O
growth - - O
factor - - O
activation - - O
of - - O
ER - - O
can - - O
mediate - - O
transactivation - - O
vs - - O
ER - - O
Sp1 - - O
binding - - O
to - - O
GC-rich - - O
sites - - O
and - - O
represents - - O
a - - O
novel - - O
pathway - - O
for - - O
ligand-independent - - O
ER - - O
action - - O
. - - O

The - - O
yeast - - O
gene - - O
that - - O
encodes - - O
eIF-5 - - O
, - - O
designated - - O
TIF5 - - O
, - - O
has - - O
been - - O
isolated - - O
and - - O
expressed - - O
in - - O
Escherichia - - O
coli - - O
to - - O
yield - - O
a - - O
catalytically - - O
active - - O
eIF-5 - - O
protein - - O
. - - O

After - - O
nerve - - O
injury - - O
, - - O
the - - O
nociceptive - - O
responses - - O
through - - O
type - - O
I - - O
neurons - - O
, - - O
which - - O
are - - O
polymodal - - O
C-fibers - - O
and - - O
drive - - O
NK1-receptor - - O
mechanisms - - O
in - - O
spinal - - O
pain - - O
transmission - - O
, - - O
were - - O
completely - - O
lost - - O
, - - O
but - - O
without - - O
changes - - O
in - - O
type - - O
II - - O
ones - - O
, - - O
which - - O
are - - O
polymodal - - O
C-fibers - - O
and - - O
drive - - O
NMDA - - O
receptor-mechanisms - - O
, - - O
while - - O
type - - O
III - - O
ones - - O
, - - O
which - - O
are - - O
capsaicin-insensitive - - O
( - - O
possibly - - O
A-fibers - - O
) - - O
and - - O
drive - - O
NMDA-receptor - - O
mechanisms - - O
, - - O
were - - O
markedly - - O
enhanced - - O
. - - O

Respondents - - O
who - - O
lived - - O
with - - O
a - - O
spouse - - O
partner - - O
only - - O
were - - O
less - - O
likely - - O
to - - O
have - - O
an - - O
unfavorable - - O
BMI - - O
status - - O
than - - O
people - - O
in - - O
the - - O
other - - O
two - - O
groups - - O
. - - O

Catalytic - - O
activation - - O
of - - O
mitogen-activated - - O
protein - - O
( - - O
MAP - - O
) - - O
kinase - - O
phosphatase-1 - - O
by - - O
binding - - O
to - - O
p38 - - O
MAP - - O
kinase - - O
: - - O
critical - - O
role - - O
of - - O
the - - O
p38 - - O
C-terminal - - O
domain - - O
in - - O
its - - O
negative - - O
regulation - - O
. - - O

Mastocytosis - - O
. - - O

Whereas - - O
a - - O
PR55 - - O
beta - - O
transcript - - O
of - - O
about - - O
2 - - O
. - - O
3 - - O
kb - - O
was - - O
detected - - O
at - - O
high - - O
levels - - O
in - - O
the - - O
neuroblastoma - - O
derived - - O
cell - - O
line - - O
LA-N-1 - - O
, - - O
the - - O
level - - O
of - - O
the - - O
mRNA - - O
was - - O
very - - O
low - - O
in - - O
the - - O
other - - O
human - - O
cell - - O
lines - - O
analyzed - - O
. - - O

These - - O
observations - - O
indicate - - O
that - - O
there - - O
are - - O
multiple - - O
mechanisms - - O
by - - O
which - - O
an - - O
individual - - O
transcript - - O
can - - O
be - - O
degraded - - O
following - - O
deadenylation - - O
. - - O

Total - - O
PGE - - O
levels - - O
in - - O
synovial - - O
fluid - - O
remained - - O
significantly - - O
depressed - - O
in - - O
the - - O
patient - - O
group - - O
for - - O
24 - - O
hours - - O
after - - O
the - - O
400-mg - - O
test - - O
dose - - O
of - - O
tolmetin - - O
on - - O
day - - O
8 - - O
. - - O

Mutually - - O
exclusive - - O
interaction - - O
of - - O
the - - O
adenovirus - - O
E4-6 - - O
7 - - O
protein - - O
and - - O
the - - O
retinoblastoma - - O
gene - - O
product - - O
with - - O
internal - - O
domains - - O
of - - O
E2F-1 - - O
and - - O
DP-1 - - O
. - - O

BACKGROUND - - O
PURPOSE - - O
: - - O
Anomalous - - O
arrangement - - O
of - - O
the - - O
pancreaticobiliary - - O
duct - - O
( - - O
AAPBD - - O
) - - O
is - - O
closely - - O
related - - O
to - - O
congenital - - O
biliary - - O
dilatation - - O
and - - O
frequently - - O
associated - - O
with - - O
biliary - - O
tract - - O
malignancy - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
mutL - - O
, - - O
miaA - - O
, - - O
and - - O
hfq - - O
expression - - O
could - - O
be - - O
regulated - - O
by - - O
multiple - - O
mechanisms - - O
, - - O
including - - O
degree - - O
of - - O
cotranscription - - O
from - - O
upstream - - O
genes - - O
, - - O
modulation - - O
of - - O
internal - - O
promoter - - O
strength - - O
, - - O
and - - O
by - - O
RNase - - O
E - - O
activity - - O
. - - O

Transfection - - O
and - - O
in - - O
vitro - - O
binding - - O
studies - - O
identified - - O
within - - O
HEFT1 - - O
a - - O
promoter - - O
whose - - O
basal - - O
activity - - O
required - - O
a - - O
GC - - O
box - - O
activated - - O
by - - O
Sp1 - - O
or - - O
Sp3 - - O
. - - O

The - - O
RAS-cyclic - - O
AMP-dependent - - O
protein - - O
kinase - - O
cAPK - - O
pathway - - O
prevents - - O
the - - O
UAS - - O
activity - - O
of - - O
IREu - - O
in - - O
the - - O
presence - - O
of - - O
glucose - - O
as - - O
the - - O
sole - - O
carbon - - O
source - - O
, - - O
while - - O
the - - O
transcriptional - - O
activators - - O
Msn2p - - O
and - - O
Msn4p - - O
promote - - O
the - - O
UAS - - O
activity - - O
of - - O
this - - O
repeat - - O
in - - O
the - - O
presence - - O
of - - O
acetate - - O
. - - O

CONCLUSIONS - - O
: - - O
In - - O
essential - - O
hypertension - - O
an - - O
acute - - O
protein - - O
load - - O
induces - - O
a - - O
decrease - - O
in - - O
GFR - - O
that - - O
may - - O
normalize - - O
under - - O
antihypertensive - - O
treatment - - O
. - - O

In - - O
contrast - - O
, - - O
peak - - O
filling - - O
rate - - O
( - - O
PFR - - O
) - - O
, - - O
normalized - - O
to - - O
end - - O
diastolic - - O
volume - - O
( - - O
EDV - - O
) - - O
, - - O
or - - O
stroke - - O
volume - - O
( - - O
SV - - O
) - - O
, - - O
or - - O
expressed - - O
as - - O
the - - O
ratio - - O
of - - O
PFR-to-PER - - O
was - - O
reduced - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
, - - O
time - - O
to - - O
PFR - - O
( - - O
TPFR - - O
) - - O
was - - O
prolonged - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
, - - O
and - - O
echocardiographic - - O
left - - O
ventricular - - O
mass - - O
index - - O
was - - O
higher - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
in - - O
patients - - O
with - - O
acromegaly - - O
compared - - O
to - - O
normals - - O
. - - O

Beta - - O
blocking - - O
agents - - O
. - - O

There - - O
was - - O
no - - O
further - - O
increase - - O
in - - O
oxygen - - O
consumption - - O
when - - O
these - - O
subjects - - O
breathed - - O
with - - O
inspiratory - - O
pressures - - O
above - - O
SIP - - O
. - - O

This - - O
dimer - - O
interface - - O
is - - O
likely - - O
important - - O
for - - O
increasing - - O
the - - O
DNA-binding - - O
specificity - - O
and - - O
affinity - - O
of - - O
the - - O
trimeric - - O
form - - O
of - - O
HSF - - O
, - - O
as - - O
well - - O
as - - O
for - - O
increasing - - O
cooperativity - - O
between - - O
adjacent - - O
trimers - - O
. - - O

Three - - O
missense - - O
mutants - - O
in - - O
subunit - - O
a - - O
of - - O
the - - O
Escherichia - - O
coli - - O
F1F0-ATPase - - O
were - - O
isolated - - O
and - - O
characterized - - O
after - - O
hydroxylamine - - O
mutagenesis - - O
of - - O
a - - O
plasmid - - O
carrying - - O
the - - O
uncB - - O
( - - O
subunit - - O
a - - O
) - - O
gene - - O
. - - O

CONCLUSIONS - - O
: - - O
The - - O
surgical - - O
or - - O
multimodality - - O
treatment - - O
of - - O
MSGT - - O
has - - O
provided - - O
a - - O
good - - O
locoregional - - O
control - - O
( - - O
78% - - O
) - - O
and - - O
68% - - O
10-year - - O
survival - - O
in - - O
a - - O
series - - O
of - - O
patients - - O
treated - - O
at - - O
the - - O
oncology - - O
department - - O
of - - O
a - - O
general - - O
hospital - - O
in - - O
Quito - - O
, - - O
Ecuador - - O
. - - O

The - - O
predicted - - O
DNA-binding - - O
, - - O
zinc - - O
finger - - O
domain - - O
protein - - O
sequence - - O
was - - O
strictly - - O
conserved - - O
. - - O

In - - O
transient - - O
cotransfection - - O
assays - - O
using - - O
Chang - - O
liver - - O
cells - - O
( - - O
CCL - - O
13 - - O
) - - O
, - - O
pM1 - - O
DNA - - O
exerts - - O
a - - O
6- - - O
to - - O
10-fold - - O
trans-activating - - O
effect - - O
on - - O
the - - O
expression - - O
of - - O
the - - O
pSV2CAT - - O
reporter - - O
plasmid - - O
. - - O

During - - O
treatment - - O
, - - O
the - - O
phosphorylation - - O
state - - O
of - - O
Rb - - O
shifted - - O
to - - O
a - - O
hypophosphorylated - - O
form - - O
. - - O
mRNA - - O
for - - O
the - - O
HPV - - O
E6 - - O
E7 - - O
genes - - O
decreased - - O
; - - O
however - - O
, - - O
significant - - O
changes - - O
in - - O
the - - O
E7 - - O
protein - - O
were - - O
not - - O
observed - - O
, - - O
while - - O
increased - - O
levels - - O
of - - O
Rb - - O
immunoprecipitated - - O
with - - O
anti-E7 - - O
antibodies - - O
were - - O
observed - - O
. - - O

51 - - O
. - - O
9% - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
0006 - - O
) - - O
in - - O
the - - O
MMF - - O
versus - - O
the - - O
AZA - - O
groups - - O
, - - O
respectively - - O
. - - O

The - - O
General - - O
Practice - - O
Research - - O
Database - - O
( - - O
GPRD - - O
) - - O
is - - O
the - - O
world's - - O
largest - - O
computerized - - O
database - - O
of - - O
anonymized - - O
longitudinal - - O
patient - - O
records - - O
from - - O
general - - O
practice - - O
and - - O
is - - O
a - - O
unique - - O
public - - O
health - - O
research - - O
tool - - O
. - - O

Velocity - - O
sedimentation - - O
, - - O
cross-linking - - O
, - - O
and - - O
immunoprecipitation - - O
analyses - - O
of - - O
detergent-solubilized - - O
rat - - O
brain - - O
revealed - - O
that - - O
the - - O
32 - - O
and - - O
34 - - O
kDa - - O
polypeptides - - O
reside - - O
within - - O
heterotetramers - - O
. - - O

Characterization - - O
of - - O
the - - O
3' - - O
ends - - O
of - - O
the - - O
plus-strand - - O
DNA - - O
fragments - - O
reveals - - O
( - - O
1 - - O
) - - O
that - - O
the - - O
upstream - - O
fragment - - O
is - - O
elongated - - O
beyond - - O
PPT2 - - O
creating - - O
a - - O
plus-strand - - O
overlap - - O
and - - O
( - - O
2 - - O
) - - O
that - - O
the - - O
majority - - O
of - - O
plus-strand - - O
strong-stop - - O
DNA - - O
fragments - - O
bear - - O
a - - O
copy - - O
of - - O
the - - O
minus-strand - - O
primer - - O
binding - - O
site - - O
in - - O
agreement - - O
with - - O
the - - O
accepted - - O
model - - O
of - - O
retroviral - - O
genomic - - O
RNA - - O
reverse - - O
transcription - - O
. - - O

Further - - O
, - - O
they - - O
are - - O
consistent - - O
with - - O
the - - O
suggestion - - O
that - - O
sites - - O
homologous - - O
to - - O
the - - O
CAR1 - - O
URS - - O
may - - O
be - - O
situated - - O
in - - O
the - - O
5'-flanking - - O
regions - - O
of - - O
multiple - - O
unrelated - - O
yeast - - O
genes - - O
. - - O

A23187 - - O
did - - O
not - - O
induce - - O
any - - O
modifications - - O
of - - O
the - - O
endolymphatic - - O
potential - - O
, - - O
the - - O
ampullar - - O
direct - - O
current - - O
or - - O
the - - O
frequency - - O
of - - O
the - - O
evoked - - O
afferent - - O
spikes - - O
. - - O

Electrophoretic - - O
characteriaztion - - O
of - - O
virus-induced - - O
interferon - - O
of - - O
the - - O
blood - - O
and - - O
urine - - O
in - - O
rabbits - - O
. - - O

GnRH - - O
treatment - - O
was - - O
found - - O
to - - O
increase - - O
the - - O
phosphorylation - - O
of - - O
tyrosine - - O
residues - - O
of - - O
MAPK - - O
and - - O
to - - O
increase - - O
MAPK - - O
activity - - O
, - - O
as - - O
determined - - O
by - - O
an - - O
immune - - O
complex - - O
kinase - - O
assay - - O
. - - O

Hemodynamics - - O
changes - - O
in - - O
man - - O
during - - O
flight - - O
. - - O

Nasal - - O
absorption - - O
was - - O
rapid - - O
, - - O
nasal - - O
bioavailability - - O
was - - O
43% - - O
, - - O
and - - O
the - - O
iv - - O
and - - O
nasal - - O
elimination - - O
profiles - - O
were - - O
similar - - O
. - - O

In - - O
experiment - - O
2 - - O
, - - O
no - - O
difference - - O
in - - O
gastric - - O
emptying - - O
of - - O
40% - - O
peptone - - O
or - - O
25% - - O
glucose - - O
was - - O
found - - O
between - - O
rats - - O
receiving - - O
TPN - - O
and - - O
those - - O
receiving - - O
intragastric - - O
nutrition - - O
for - - O
10 - - O
to - - O
12 - - O
days - - O
. - - O

To - - O
derive - - O
quantitative - - O
concentration - - O
changes - - O
from - - O
measurements - - O
of - - O
light - - O
attenuation - - O
, - - O
the - - O
optical - - O
path - - O
length - - O
must - - O
be - - O
known - - O
. - - O

Analysis - - O
of - - O
chromosomal - - O
DNA - - O
sequence - - O
immediately - - O
downstream - - O
of - - O
the - - O
transposon - - O
insertion - - O
identified - - O
two - - O
open - - O
reading - - O
frames - - O
, - - O
designated - - O
csrR - - O
and - - O
csrS - - O
, - - O
which - - O
exhibited - - O
sequence - - O
similarity - - O
to - - O
bacterial - - O
two-component - - O
regulatory - - O
systems - - O
. - - O

Rev-erbAalpha - - O
beta - - O
) - - O
, - - O
Mxi-1 - - O
and - - O
Mad - - O
bHLH-zip - - O
proteins - - O
and - - O
the - - O
oncoproteins - - O
PLZF - - O
and - - O
LAZ3 - - O
BCL6 - - O
is - - O
mediated - - O
by - - O
the - - O
corepressors - - O
N-CoR - - O
and - - O
SMRT - - O
. - - O

Reporting - - O
of - - O
adverse - - O
events - - O
occurring - - O
during - - O
clinical - - O
trials - - O
of - - O
investigational - - O
drugs - - O
is - - O
a - - O
complex - - O
and - - O
controversial - - O
issue - - O
. - - O

The - - O
effects - - O
of - - O
two - - O
levels - - O
of - - O
caffeine - - O
ingestion - - O
on - - O
excess - - O
postexercise - - O
oxygen - - O
consumption - - O
in - - O
untrained - - O
women - - O
. - - O

Of - - O
the - - O
117 - - O
patients - - O
( - - O
out - - O
of - - O
the - - O
136 - - O
) - - O
with - - O
serologic - - O
evidence - - O
of - - O
chronic - - O
thyroiditis - - O
who - - O
could - - O
be - - O
studied - - O
, - - O
eight - - O
( - - O
7% - - O
) - - O
had - - O
hyperthyroidism - - O
and - - O
45 - - O
( - - O
38% - - O
) - - O
were - - O
hypothyroid - - O
. - - O

Unfortunately - - O
, - - O
these - - O
preservatives - - O
may - - O
also - - O
interfere - - O
with - - O
microbiological - - O
assays - - O
used - - O
to - - O
determine - - O
product - - O
sterility - - O
or - - O
bioburden - - O
levels - - O
. - - O

Where - - O
UMDNJ - - O
is - - O
headed - - O
. - - O

Serum - - O
relaxin - - O
levels - - O
in - - O
prostaglandin - - O
E2 - - O
induced - - O
abortions - - O
. - - O

Human - - O
GATA-3 - - O
: - - O
a - - O
lineage-restricted - - O
transcription - - O
factor - - O
that - - O
regulates - - O
the - - O
expression - - O
of - - O
the - - O
T - - O
cell - - O
receptor - - O
alpha - - O
gene - - O
. - - O

Induction - - O
of - - O
Fas - - O
ligand - - O
expression - - O
by - - O
HIV - - O
involves - - O
the - - O
interaction - - O
of - - O
Nef - - O
with - - O
the - - O
T - - O
cell - - O
receptor - - O
zeta - - O
chain - - O
. - - O

Telomeres - - O
prevent - - O
end-to-end - - O
fusions - - O
and - - O
exonucleolytic - - O
degradation - - O
, - - O
enable - - O
the - - O
end - - O
of - - O
the - - O
linear - - O
DNA - - O
molecule - - O
to - - O
replicate - - O
, - - O
and - - O
function - - O
in - - O
cell - - O
division - - O
. - - O

Specifically - - O
, - - O
by - - O
the - - O
type - - O
of - - O
adjuvant - - O
therapy - - O
, - - O
the - - O
median - - O
disease-free - - O
interval - - O
and - - O
survival - - O
from - - O
stage - - O
IVA - - O
for - - O
23 - - O
patients - - O
receiving - - O
Corynebacterium - - O
parvum - - O
were - - O
6 - - O
. - - O
9 - - O
and - - O
19 - - O
months - - O
; - - O
for - - O
39 - - O
patients - - O
receiving - - O
BCG - - O
, - - O
eight - - O
months - - O
and - - O
26 - - O
months - - O
; - - O
for - - O
24 - - O
patients - - O
receiving - - O
BCG - - O
+ - - O
DTIC - - O
, - - O
eight - - O
and - - O
17 - - O
. - - O
4 - - O
months - - O
; - - O
and - - O
for - - O
all - - O
51 - - O
DTIC - - O
treated - - O
patients - - O
6 - - O
. - - O
3 - - O
and - - O
17 - - O
. - - O
8 - - O
months - - O
, - - O
respectively - - O
. - - O

Merr - - O
. - - O
) - - O
embryo - - O
library - - O
. - - O

Altogether - - O
, - - O
we - - O
confirm - - O
that - - O
all - - O
genes - - O
of - - O
the - - O
Rad52 - - O
recombinational - - O
repair - - O
pathway - - O
are - - O
required - - O
for - - O
the - - O
survival - - O
of - - O
rad27 - - O
Delta - - O
strains - - O
at - - O
both - - O
permissive - - O
( - - O
23 - - O
degrees - - O
C - - O
) - - O
and - - O
semipermissive - - O
( - - O
30 - - O
degrees - - O
C - - O
) - - O
temperatures - - O
for - - O
growth - - O
. - - O

A - - O
single - - O
amino - - O
acid - - O
substitution - - O
in - - O
the - - O
cyclin - - O
D - - O
binding - - O
domain - - O
of - - O
the - - O
infected - - O
cell - - O
protein - - O
no - - O
. - - O

Improving - - O
the - - O
evidence - - O
base - - O
for - - O
anaesthesia - - O
. - - O

Seven - - O
of - - O
these - - O
had - - O
counterparts - - O
in - - O
the - - O
US - - O
of - - O
herpes - - O
simplex - - O
type - - O
1 - - O
( - - O
HSV-1 - - O
) - - O
, - - O
pseudorabies - - O
virus - - O
( - - O
PRV - - O
) - - O
, - - O
and - - O
equine - - O
herpesvirus - - O
type - - O
1 - - O
( - - O
EHV-1 - - O
) - - O
. - - O

Since - - O
high - - O
levels - - O
of - - O
immunoglobulin - - O
G - - O
were - - O
demonstrated - - O
against - - O
the - - O
surface - - O
of - - O
the - - O
NVS - - O
after - - O
immunization - - O
, - - O
passive - - O
transfer - - O
experiments - - O
were - - O
initiated - - O
. - - O

Our - - O
results - - O
show - - O
that - - O
CVN - - O
specifically - - O
recognizes - - O
with - - O
nanomolar - - O
affinity - - O
Man - - O
( - - O
9 - - O
) - - O
GlcNAc - - O
( - - O
2 - - O
) - - O
and - - O
the - - O
D1D3 - - O
isomer - - O
of - - O
Man - - O
( - - O
8 - - O
) - - O
GlcNAc - - O
( - - O
2 - - O
) - - O
. - - O

No - - O
definite - - O
conclusions - - O
are - - O
possible - - O
because - - O
of - - O
the - - O
small - - O
number - - O
of - - O
patients - - O
involved - - O
in - - O
this - - O
phase - - O
II - - O
trial - - O
. - - O

Out - - O
of - - O
these - - O
families - - O
74 - - O
, - - O
3% - - O
planned - - O
next - - O
pregnancy - - O
( - - O
table - - O
IX - - O
) - - O
, - - O
57 - - O
, - - O
6% - - O
wanted - - O
to - - O
have - - O
prenatal - - O
diagnosis - - O
( - - O
table - - O
VI - - O
) - - O
. - - O

CONCLUSIONS - - O
: - - O
The - - O
special - - O
clinical - - O
presentation - - O
of - - O
our - - O
case - - O
of - - O
possible - - O
Gardner's - - O
syndrome - - O
is - - O
discussed - - O
. - - O

Interestingly - - O
, - - O
addition - - O
of - - O
purified - - O
CBP - - O
to - - O
the - - O
nuclear - - O
extracts - - O
of - - O
T47D - - O
cells - - O
markedly - - O
stimulated - - O
progesterone- - - O
and - - O
PR-dependent - - O
transcription - - O
from - - O
a - - O
nucleosome-free - - O
, - - O
progesterone - - O
response - - O
element - - O
( - - O
PRE - - O
) - - O
-linked - - O
reporter - - O
DNA - - O
template - - O
. - - O

Therefore - - O
, - - O
it - - O
was - - O
concluded - - O
that - - O
thrombotic - - O
tendency - - O
certainly - - O
existed - - O
in - - O
patients - - O
with - - O
MS - - O
compared - - O
to - - O
those - - O
with - - O
non - - O
RHD - - O
and - - O
that - - O
it - - O
was - - O
one - - O
of - - O
the - - O
causes - - O
of - - O
the - - O
significantly - - O
high - - O
incidence - - O
of - - O
thromboembolism - - O
in - - O
comparison - - O
with - - O
non - - O
RHD - - O
. - - O

Before - - O
PO3 - - O
administration - - O
, - - O
more - - O
than - - O
half - - O
( - - O
57 - - O
. - - O
4% - - O
) - - O
of - - O
the - - O
patients - - O
received - - O
only - - O
1 - - O
or - - O
2 - - O
antituberculous - - O
drugs - - O
( - - O
ethambutole - - O
and - - O
ethionamide - - O
or - - O
ethambutole - - O
and - - O
oprofloxacin - - O
) - - O
. - - O

Routine - - O
psychometric - - O
screening - - O
of - - O
IHD - - O
patients - - O
may - - O
provide - - O
a - - O
cost-effective - - O
means - - O
of - - O
alerting - - O
cardiologists - - O
and - - O
internists - - O
to - - O
the - - O
relatively - - O
high - - O
levels - - O
of - - O
distress - - O
among - - O
their - - O
patients - - O
. - - O

In - - O
addition - - O
, - - O
computer - - O
analysis - - O
suggests - - O
that - - O
sequences - - O
similar - - O
to - - O
the - - O
A - - O
stem - - O
element - - O
are - - O
present - - O
within - - O
the - - O
three - - O
AAV - - O
promoter - - O
regions - - O
. - - O

Another - - O
cis-acting - - O
element - - O
, - - O
exonic - - O
splicing - - O
suppressor - - O
1 - - O
( - - O
ESS1 - - O
) - - O
, - - O
represses - - O
use - - O
of - - O
the - - O
nt - - O
3225 - - O
3' - - O
splice - - O
site - - O
. - - O

After - - O
hemodynamic - - O
stabilization - - O
, - - O
the - - O
goal - - O
of - - O
therapy - - O
is - - O
to - - O
diminish - - O
the - - O
chance - - O
that - - O
an - - O
ulcer - - O
will - - O
continue - - O
to - - O
bleed - - O
or - - O
will - - O
rebleed - - O
. - - O

Two - - O
splice - - O
variants - - O
of - - O
ALF1 - - O
cDNA - - O
have - - O
been - - O
found - - O
, - - O
differing - - O
by - - O
a - - O
72-bp - - O
insertion - - O
, - - O
coding - - O
for - - O
putative - - O
proteins - - O
of - - O
682 - - O
and - - O
706 - - O
amino - - O
acids - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
while - - O
many - - O
muscle - - O
gene - - O
E-boxes - - O
are - - O
capable - - O
of - - O
binding - - O
the - - O
previously - - O
characterized - - O
spectrum - - O
of - - O
MDF - - O
bH-L-H - - O
heterodimers - - O
in - - O
vitro - - O
, - - O
MCK-L - - O
type - - O
E-boxes - - O
probably - - O
bind - - O
qualitatively - - O
different - - O
factors - - O
in - - O
vivo - - O
. - - O

The - - O
amino - - O
acid - - O
sequence - - O
of - - O
matrilysin-2 - - O
also - - O
contains - - O
a - - O
threonine - - O
residue - - O
adjacent - - O
to - - O
the - - O
Zn-binding - - O
site - - O
that - - O
has - - O
been - - O
defined - - O
as - - O
a - - O
specific - - O
feature - - O
of - - O
matrilysin - - O
. - - O

Value - - O
of - - O
determination - - O
of - - O
alkaline - - O
phosphatase - - O
isoenzymes - - O
for - - O
differential - - O
diagnosis - - O
of - - O
obstructive - - O
jaundice - - O
and - - O
biliary - - O
liver - - O
cirrhosis - - O
. - - O

Aedes - - O
aegypti - - O
( - - O
L - - O
. - - O
) - - O
and - - O
Aedes - - O
albopictus - - O
( - - O
Skuse - - O
) - - O
in - - O
Singapore - - O
City - - O
. - - O

Ras- - - O
and - - O
ultra-violet-responsive - - O
protein - - O
kinases - - O
that - - O
phosphorylate - - O
c-Jun - - O
on - - O
serine - - O
residues - - O
at - - O
positions - - O
63 - - O
and - - O
73 - - O
and - - O
stimulate - - O
its - - O
transcriptional - - O
activity - - O
have - - O
been - - O
identified - - O
. - - O

CONCLUSIONS - - O
: - - O
Lymphoscintigraphy - - O
of - - O
the - - O
cynomolgus - - O
monkey - - O
eyelids - - O
reveals - - O
discrete - - O
lymphatic - - O
drainage - - O
pathways - - O
for - - O
the - - O
upper - - O
and - - O
lower - - O
eyelids - - O
and - - O
a - - O
dual - - O
pathway - - O
for - - O
the - - O
central - - O
upper - - O
eyelid - - O
. - - O

Regional - - O
blood - - O
blow - - O
was - - O
measured - - O
by - - O
means - - O
of - - O
microspheres - - O
in - - O
predefined - - O
regions - - O
of - - O
the - - O
C6 - - O
, - - O
T11 - - O
, - - O
and - - O
L6 - - O
vertebrae - - O
. - - O

CMV - - O
hyperimmunoglobulin - - O
treatment - - O
( - - O
Cytotect - - O
, - - O
Biotest - - O
) - - O
was - - O
started - - O
( - - O
2 - - O
ml - - O
kg - - O
bw - - O
on - - O
day - - O
1 - - O
and - - O
3 - - O
, - - O
and - - O
1 - - O
ml - - O
kg - - O
on - - O
days - - O
5 - - O
, - - O
7 - - O
and - - O
9 - - O
) - - O
, - - O
which - - O
led - - O
to - - O
the - - O
eradication - - O
of - - O
the - - O
residual - - O
infiltrate - - O
and - - O
CMV-DNA - - O
in - - O
the - - O
myocardium - - O
. - - O

The - - O
ewes - - O
were - - O
returned - - O
to - - O
normoxia - - O
, - - O
and - - O
monitoring - - O
was - - O
continued - - O
for - - O
1 - - O
h - - O
. - - O

The - - O
major - - O
promoter - - O
responds - - O
strongly - - O
to - - O
virus-encoded - - O
trans - - O
activators - - O
EIA - - O
and - - O
EIV - - O
and - - O
contains - - O
four - - O
elements - - O
: - - O
a - - O
TAGA - - O
motif - - O
analogous - - O
to - - O
the - - O
TATA - - O
box - - O
, - - O
two - - O
EIIF - - O
sites - - O
present - - O
in - - O
an - - O
inverted - - O
orientation - - O
, - - O
and - - O
an - - O
ATF - - O
CREB - - O
site - - O
. - - O

Interestingly - - O
, - - O
in - - O
the - - O
adult - - O
, - - O
transgene - - O
expression - - O
patterns - - O
within - - O
the - - O
cerebellum - - O
in - - O
two - - O
lines - - O
appeared - - O
to - - O
mark - - O
distinct - - O
anterior-posterior - - O
compartments - - O
. - - O

Heterogeneous - - O
nuclear - - O
ribonucleoprotein - - O
A1 - - O
binds - - O
to - - O
the - - O
transcription-regulatory - - O
region - - O
of - - O
mouse - - O
hepatitis - - O
virus - - O
RNA - - O
. - - O

In - - O
17 - - O
patients - - O
with - - O
deletions - - O
, - - O
the - - O
parental - - O
origin - - O
of - - O
deletion - - O
was - - O
determined - - O
. - - O

Clinical - - O
accuracy - - O
of - - O
updated - - O
version - - O
of - - O
the - - O
Phadebas - - O
RAST - - O
test - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
the - - O
mechanism - - O
of - - O
action - - O
, - - O
two - - O
groups - - O
of - - O
inodilators - - O
are - - O
distinguished - - O
, - - O
the - - O
phosphodiesterase - - O
inhibitors - - O
and - - O
the - - O
dopaminergic - - O
agents - - O
. - - O

The - - O
detection - - O
ratio - - O
peaked - - O
at - - O
ages - - O
30 - - O
to - - O
34 - - O
and - - O
decreased - - O
heavily - - O
during - - O
the - - O
next - - O
15 - - O
years - - O
of - - O
age - - O
. - - O

Phase - - O
II - - O
trial - - O
of - - O
the - - O
anti-G - - O
( - - O
D2 - - O
) - - O
monoclonal - - O
antibody - - O
3F8 - - O
and - - O
granulocyte-macrophage - - O
colony-stimulating - - O
factor - - O
for - - O
neuroblastoma - - O
. - - O

Another - - O
ORF - - O
, - - O
dda - - O
. - - O
2 - - O
located - - O
between - - O
modA - - O
and - - O
dda - - O
, - - O
shares - - O
sequence - - O
similarity - - O
with - - O
sigma70 - - O
, - - O
and - - O
we - - O
call - - O
it - - O
srd - - O
. - - O

The - - O
authors - - O
present - - O
the - - O
only - - O
two - - O
studies - - O
that - - O
have - - O
proved - - O
successful - - O
in - - O
treating - - O
animal - - O
models - - O
of - - O
osteoarthritis - - O
using - - O
gene - - O
therapy - - O
, - - O
and - - O
propose - - O
an - - O
overview - - O
of - - O
several - - O
strategies - - O
for - - O
the - - O
development - - O
of - - O
gene - - O
therapy - - O
in - - O
osteoarthritis - - O
treatment - - O
in - - O
the - - O
future - - O
. - - O

There - - O
was - - O
significant - - O
correlation - - O
of - - O
LVM - - O
M2 - - O
and - - O
PWVn - - O
for - - O
pre-AVR - - O
and - - O
post - - O
AVR - - O
studies - - O
. - - O

A - - O
gene - - O
in - - O
Drosophila - - O
melanogaster - - O
that - - O
maps - - O
cytologically - - O
to - - O
2C1-3 - - O
on - - O
the - - O
distal - - O
portion - - O
of - - O
the - - O
X-chromosome - - O
encodes - - O
a - - O
member - - O
of - - O
the - - O
steroid - - O
thyroid - - O
hormone - - O
receptor - - O
superfamily - - O
. - - O

We - - O
investigated - - O
the - - O
diagnostic - - O
value - - O
of - - O
a - - O
new - - O
in - - O
vitro - - O
test - - O
, - - O
Pharmacia - - O
CAP - - O
System - - O
( - - O
Pharmacia - - O
Diagnostics - - O
AB - - O
, - - O
Uppsala - - O
, - - O
Sweden - - O
) - - O
, - - O
for - - O
the - - O
quantitative - - O
measurement - - O
of - - O
allergen-specific - - O
IgE - - O
antibodies - - O
by - - O
comparison - - O
with - - O
RAST - - O
in - - O
2 - - O
groups - - O
of - - O
patients - - O
, - - O
71 - - O
atopic - - O
and - - O
48 - - O
non-atopic - - O
. - - O

One - - O
complex - - O
containing - - O
a - - O
70 - - O
D - - O
protein - - O
was - - O
found - - O
to - - O
be - - O
associated - - O
specifically - - O
with - - O
transcriptionally - - O
active - - O
leukemia - - O
cells - - O
. - - O

This - - O
finding - - O
suggested - - O
that - - O
the - - O
PI3K-Akt - - O
activation - - O
pathway - - O
plays - - O
some - - O
role - - O
in - - O
the - - O
antiapoptotic - - O
effect - - O
of - - O
EPO - - O
. - - O

G - - O
. - - O

Strikingly - - O
, - - O
this - - O
subdomain - - O
is - - O
also - - O
present - - O
in - - O
the - - O
otherwise - - O
unrelated - - O
N-terminal - - O
activating - - O
region - - O
of - - O
p58c-ets-2 - - O
and - - O
was - - O
thus - - O
named - - O
BEC - - O
for - - O
Ets-1-beta - - O
Ets-2-Conserved - - O
sequence - - O
. - - O

Consistent - - O
with - - O
the - - O
hepatic - - O
and - - O
epidermal - - O
expression - - O
of - - O
histidase - - O
, - - O
this - - O
finding - - O
suggests - - O
that - - O
histidase - - O
transcription - - O
may - - O
be - - O
regulated - - O
by - - O
these - - O
factors - - O
. - - O

The - - O
respiratory - - O
rate - - O
was - - O
13 - - O
+ - - O
- - - O
1 - - O
breaths - - O
min - - O
with - - O
52 - - O
+ - - O
- - - O
4% - - O
of - - O
the - - O
respiratory - - O
cycle - - O
spent - - O
in - - O
inspiration - - O
; - - O
end-tidal - - O
CO2 - - O
pressure - - O
increased - - O
by - - O
3 - - O
. - - O
3 - - O
+ - - O
- - - O
1 - - O
. - - O
0 - - O
Torr - - O
during - - O
runs - - O
at - - O
SIP - - O
. - - O

Previous - - O
studies - - O
have - - O
indicated - - O
that - - O
a - - O
hamster - - O
cell - - O
line - - O
( - - O
ts13 - - O
) - - O
with - - O
a - - O
point - - O
mutation - - O
in - - O
the - - O
TAF - - O
( - - O
II - - O
) - - O
250 - - O
CCG1 - - O
( - - O
TAF - - O
( - - O
II - - O
) - - O
250 - - O
) - - O
gene - - O
shows - - O
temperature-sensitive - - O
expression - - O
of - - O
a - - O
subset - - O
of - - O
genes - - O
and - - O
arrests - - O
in - - O
late - - O
G1 - - O
at - - O
39 - - O
. - - O
5 - - O
degrees - - O
C - - O
. - - O

Model - - O
of - - O
spatiotemporal - - O
dynamics - - O
of - - O
stick-slip - - O
motion - - O
. - - O

A - - O
hydrodynamic - - O
description - - O
of - - O
the - - O
osmotic - - O
reflection - - O
coefficient - - O
with - - O
application - - O
to - - O
the - - O
pore - - O
theory - - O
of - - O
transcapillary - - O
exchange - - O
. - - O

Sequential - - O
MR - - O
examinations - - O
of - - O
the - - O
nasal - - O
cavity - - O
and - - O
paranasal - - O
sinuses - - O
were - - O
performed - - O
within - - O
a - - O
6-8 - - O
h - - O
period - - O
in - - O
five - - O
normal - - O
volunteers - - O
. - - O

Comparison - - O
of - - O
patients - - O
receiving - - O
phenytoin - - O
and - - O
those - - O
who - - O
were - - O
not - - O
showed - - O
significantly - - O
lower - - O
serum - - O
folate - - O
in - - O
the - - O
sub-group - - O
receiving - - O
phenytoin - - O
, - - O
but - - O
there - - O
was - - O
no - - O
significant - - O
difference - - O
between - - O
the - - O
sub-groups - - O
with - - O
respect - - O
to - - O
vitamin - - O
B12 - - O
or - - O
behaviour - - O
problem - - O
rating - - O
. - - O

Jerseys - - O
had - - O
higher - - O
hepatic - - O
Cu - - O
concentrations - - O
than - - O
did - - O
Holsteins - - O
on - - O
d - - O
60 - - O
( - - O
346 - - O
vs - - O
. - - O

A - - O
region - - O
approximately - - O
100 - - O
bp - - O
upstream - - O
from - - O
the - - O
transcription - - O
start - - O
point - - O
of - - O
virB - - O
was - - O
identified - - O
as - - O
being - - O
necessary - - O
for - - O
full - - O
activation - - O
of - - O
this - - O
promoter - - O
by - - O
VirF - - O
. - - O

We - - O
also - - O
found - - O
that - - O
the - - O
same - - O
males - - O
, - - O
breeding - - O
in - - O
different - - O
years - - O
on - - O
the - - O
same - - O
territories - - O
, - - O
had - - O
significantly - - O
larger - - O
harems - - O
in - - O
the - - O
years - - O
they - - O
had - - O
familiar - - O
neighbors - - O
. - - O

Galoyan - - O
has - - O
summarized - - O
the - - O
results - - O
of - - O
his - - O
discovery - - O
of - - O
cardioactive - - O
neurohormones - - O
. - - O

The - - O
authors - - O
proposed - - O
that - - O
the - - O
highly - - O
convergent - - O
inputs - - O
to - - O
the - - O
entorhinal - - O
cortex - - O
indicate - - O
this - - O
region - - O
may - - O
be - - O
particularly - - O
important - - O
for - - O
selecting - - O
or - - O
compressing - - O
information - - O
. - - O

Serum - - O
TNF - - O
concentrations - - O
were - - O
elevated - - O
at - - O
diagnosis - - O
and - - O
gradually - - O
decreased - - O
toward - - O
the - - O
reference - - O
limits - - O
by - - O
week - - O
16 - - O
. - - O

In - - O
group - - O
III - - O
, - - O
patients - - O
also - - O
received - - O
their - - O
own - - O
mediastinal - - O
drainage - - O
blood - - O
, - - O
shed - - O
for - - O
6 - - O
hours - - O
after - - O
operation - - O
, - - O
after - - O
concentration - - O
and - - O
washing - - O
in - - O
a - - O
MBRS - - O
. - - O

The - - O
importance - - O
of - - O
selective - - O
renal - - O
vein - - O
phlebography - - O
in - - O
the - - O
evaluation - - O
of - - O
unexplained - - O
hematuria - - O
and - - O
filing - - O
defects - - O
in - - O
the - - O
excretory - - O
urogram - - O
is - - O
illustrated - - O
. - - O

Gluzman - - O
, - - O
EMBO - - O
J - - O
. - - O

Comparison - - O
was - - O
made - - O
with - - O
other - - O
neuroradiological - - O
imaging - - O
modalities - - O
including - - O
CT - - O
, - - O
myelography - - O
, - - O
CT - - O
ventriculography - - O
, - - O
and - - O
CT - - O
myelocisternography - - O
. - - O

The - - O
best - - O
regression - - O
model - - O
for - - O
predicting - - O
changes - - O
in - - O
the - - O
WCXR - - O
included - - O
time - - O
to - - O
first - - O
positive - - O
culture - - O
and - - O
antibody - - O
titer - - O
for - - O
Pa - - O
elastase - - O
. - - O

Two - - O
patients - - O
had - - O
immediate - - O
adverse - - O
effects - - O
from - - O
NMF - - O
; - - O
one - - O
had - - O
a - - O
grand - - O
mal - - O
seizure - - O
and - - O
the - - O
other - - O
developed - - O
severe - - O
abdominal - - O
pain - - O
. - - O

A - - O
possible - - O
role - - O
for - - O
the - - O
mixed - - O
function - - O
oxidase - - O
enzyme - - O
system - - O
in - - O
the - - O
requirement - - O
for - - O
selenium - - O
in - - O
the - - O
rat - - O
. - - O

Monospecific - - O
antibodies - - O
raised - - O
against - - O
rat - - O
cytochrome - - O
P-450 - - O
1A1 - - O
recognized - - O
a - - O
protein - - O
in - - O
the - - O
hepatic - - O
microsomes - - O
of - - O
the - - O
double-crested - - O
cormorant - - O
, - - O
and - - O
also - - O
in - - O
those - - O
of - - O
the - - O
great - - O
blue - - O
heron - - O
( - - O
Ardea - - O
herodias - - O
) - - O
, - - O
using - - O
immunoblotting - - O
. - - O

Blood - - O
sampling - - O
procedures - - O
were - - O
videotaped - - O
. - - O

Calcimimetic - - O
agents - - O
directly - - O
inhibit - - O
PTH - - O
secretion - - O
by - - O
activating - - O
the - - O
calcium-sensing - - O
receptor - - O
in - - O
the - - O
parathyroid - - O
glands - - O
, - - O
but - - O
clinical - - O
experience - - O
with - - O
them - - O
is - - O
limited - - O
. - - O

The - - O
drug-resistant - - O
cell - - O
lines - - O
P388 - - O
ADR - - O
3 - - O
and - - O
P388 - - O
ADR - - O
7 - - O
express - - O
a - - O
shortened - - O
topo - - O
II - - O
alpha - - O
mRNA - - O
transcript - - O
in - - O
addition - - O
to - - O
the - - O
native - - O
transcript - - O
present - - O
in - - O
the - - O
drug-sensitive - - O
P388 - - O
4 - - O
cell - - O
line - - O
. - - O

Taken - - O
together - - O
, - - O
differences - - O
in - - O
signaling - - O
and - - O
tissue - - O
expression - - O
suggest - - O
that - - O
the - - O
human - - O
intermediate - - O
PRLr - - O
differs - - O
from - - O
the - - O
long - - O
PRLr - - O
in - - O
physiological - - O
function - - O
. - - O

Conservative - - O
treatment - - O
of - - O
bladder - - O
carcinoma - - O
by - - O
partial - - O
cystectomy - - O
and - - O
interstitial - - O
iridium - - O
192 - - O
. - - O

This - - O
fragment - - O
can - - O
bind - - O
several - - O
trans-acting - - O
factors - - O
in - - O
vitro - - O
, - - O
including - - O
GATA-1 - - O
and - - O
members - - O
of - - O
the - - O
Ets - - O
family - - O
. - - O

This - - O
study - - O
determined - - O
the - - O
arthritogenic - - O
potential - - O
of - - O
silicone - - O
gel - - O
by - - O
either - - O
mixing - - O
it - - O
with - - O
bovine - - O
collagen - - O
II - - O
( - - O
BII - - O
) - - O
or - - O
by - - O
injecting - - O
silicone - - O
gel - - O
alone - - O
in - - O
DA - - O
rats - - O
. - - O

Administration - - O
of - - O
the - - O
dopamine - - O
agonist - - O
bromocriptine - - O
( - - O
2 - - O
. - - O
5 - - O
mg - - O
three - - O
times - - O
a - - O
day - - O
for - - O
4 - - O
days - - O
) - - O
suppressed - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
mean - - O
24-h - - O
plasma - - O
18-OHB - - O
levels - - O
from - - O
21 - - O
. - - O
9 - - O
+ - - O
- - - O
2 - - O
. - - O
0 - - O
to - - O
14 - - O
. - - O
8 - - O
+ - - O
- - - O
1 - - O
. - - O
4 - - O
ng - - O
dl - - O
. - - O

Group - - O
I - - O
comprised - - O
5 - - O
adult - - O
Collies - - O
that - - O
received - - O
at - - O
least - - O
400 - - O
microg - - O
kg - - O
ivermectin - - O
p - - O
. - - O
o - - O
. - - O
and - - O
were - - O
presented - - O
to - - O
the - - O
VMTH - - O
3 - - O
hours - - O
after - - O
intoxication - - O
. - - O

At - - O
cuticular - - O
positions - - O
exhibiting - - O
the - - O
Brd - - O
bristle - - O
loss - - O
phenotype - - O
, - - O
we - - O
have - - O
found - - O
that - - O
the - - O
progeny - - O
of - - O
the - - O
multiplied - - O
SOPs - - O
develop - - O
aberrantly - - O
, - - O
in - - O
that - - O
neurons - - O
and - - O
thecogen - - O
( - - O
sheath - - O
) - - O
cells - - O
appear - - O
but - - O
not - - O
trichogen - - O
( - - O
shaft - - O
) - - O
and - - O
tormogen - - O
( - - O
socket - - O
) - - O
cells - - O
. - - O

Optimal - - O
activation - - O
of - - O
T - - O
cells - - O
requires - - O
at - - O
least - - O
two - - O
signals - - O
. - - O

Use - - O
of - - O
free-access - - O
minerals - - O
. - - O

63 - - O
. - - O
3 - - O
micromol - - O
1 - - O
, - - O
p - - O
< - - O
0 - - O
. - - O
01 - - O
) - - O
and - - O
area - - O
under - - O
the - - O
plasma - - O
concentration-time - - O
curve - - O
extrapolated - - O
to - - O
infinity - - O
AUC - - O
9 - - O
( - - O
0-infinity - - O
) - - O
( - - O
518 - - O
. - - O
7 - - O
vs - - O
. - - O

Purified - - O
Pra - - O
was - - O
also - - O
shown - - O
to - - O
physically - - O
interact - - O
with - - O
pyruvate - - O
kinase - - O
( - - O
Pk - - O
) - - O
; - - O
Pk - - O
and - - O
Pra - - O
can - - O
form - - O
a - - O
complex - - O
, - - O
but - - O
when - - O
the - - O
12-kDa - - O
Ndk - - O
, - - O
Pk - - O
, - - O
and - - O
Pra - - O
are - - O
all - - O
present - - O
, - - O
Pk - - O
has - - O
a - - O
higher - - O
affinity - - O
than - - O
Pra - - O
for - - O
forming - - O
a - - O
complex - - O
with - - O
the - - O
12-kDa - - O
Ndk - - O
. - - O

The - - O
data - - O
suggest - - O
that - - O
plasminogen - - O
, - - O
alpha - - O
2AP - - O
, - - O
and - - O
C1-INH - - O
, - - O
should - - O
be - - O
considered - - O
equine - - O
acute-phase - - O
proteins - - O
. - - O

We - - O
here - - O
demonstrate - - O
that - - O
a - - O
temperature-sensitive - - O
fission - - O
yeast - - O
mutant - - O
which - - O
has - - O
a - - O
mutation - - O
in - - O
a - - O
homologous - - O
gene - - O
, - - O
and - - O
two - - O
of - - O
three - - O
additional - - O
( - - O
mtr1 - - O
prp20 - - O
srm1 - - O
) - - O
mutants - - O
accumulate - - O
nuclear - - O
poly - - O
( - - O
A - - O
) - - O
+ - - O
RNA - - O
at - - O
37 - - O
degrees - - O
C - - O
. - - O

Grossly - - O
, - - O
the - - O
experimental - - O
vulvitis - - O
was - - O
identical - - O
to - - O
the - - O
field - - O
condition - - O
, - - O
and - - O
bacteria - - O
indistinguishable - - O
from - - O
the - - O
inoculated - - O
strains - - O
were - - O
reisolated - - O
. - - O

Inhibition - - O
of - - O
the - - O
Mek - - O
Erk - - O
pathway - - O
in - - O
Rat1 - - O
ras - - O
cells - - O
, - - O
using - - O
the - - O
Mek - - O
inhibitor - - O
, - - O
PD98059 - - O
, - - O
resulted - - O
in - - O
complete - - O
cytoskeletal - - O
recovery - - O
, - - O
indistinguishable - - O
from - - O
that - - O
induced - - O
by - - O
HR12 - - O
. - - O

In - - O
Saccharomyces - - O
cerevisiae - - O
, - - O
PHO85 - - O
encodes - - O
a - - O
cyclin-dependent - - O
protein - - O
kinase - - O
( - - O
Cdk - - O
) - - O
catalytic - - O
subunit - - O
with - - O
multiple - - O
regulatory - - O
roles - - O
thought - - O
to - - O
be - - O
specified - - O
by - - O
association - - O
with - - O
different - - O
cyclin - - O
partners - - O
( - - O
Pcls - - O
) - - O
. - - O

Tonometry - - O
of - - O
blood - - O
samples - - O
from - - O
patients - - O
may - - O
also - - O
be - - O
used - - O
in - - O
the - - O
determination - - O
of - - O
acid-base - - O
quantities - - O
and - - O
hemoglobin-oxygen - - O
affinity - - O
e - - O
. - - O
g - - O
. - - O
p50 - - O
. - - O

The - - O
natural - - O
history - - O
of - - O
these - - O
lesions - - O
, - - O
locoregional - - O
efficiency - - O
of - - O
the - - O
different - - O
treatments - - O
used - - O
, - - O
the - - O
part - - O
played - - O
by - - O
chemotherapy - - O
, - - O
survival - - O
, - - O
causes - - O
of - - O
death - - O
and - - O
therapeutic - - O
modalities - - O
used - - O
as - - O
a - - O
last - - O
measure - - O
, - - O
have - - O
been - - O
analysed - - O
. - - O

The - - O
homologies - - O
between - - O
RAD16 - - O
, - - O
RAD54 - - O
and - - O
SNF2 - - O
are - - O
also - - O
shared - - O
by - - O
several - - O
additional - - O
, - - O
recently - - O
isolated - - O
yeast - - O
and - - O
Drosophila - - O
genes - - O
. - - O

Plasma - - O
secretin - - O
levels - - O
also - - O
augmented - - O
after - - O
the - - O
administration - - O
of - - O
ethanol - - O
solutions - - O
, - - O
with - - O
a - - O
delay - - O
of - - O
about - - O
one - - O
hour - - O
after - - O
the - - O
onset - - O
of - - O
acid - - O
secretion - - O
. - - O

Background - - O
Aims - - O
: - - O
Hepatitis - - O
C - - O
and - - O
nonalcoholic - - O
fatty - - O
liver - - O
disease - - O
( - - O
NAFL - - O
) - - O
are - - O
the - - O
two - - O
most - - O
common - - O
forms - - O
of - - O
liver - - O
disease - - O
in - - O
the - - O
United - - O
States - - O
. - - O

The - - O
progression - - O
of - - O
acute - - O
bronchitis - - O
is - - O
associated - - O
with - - O
elevated - - O
blood - - O
concentrations - - O
of - - O
acute-phase - - O
proteins - - O
, - - O
KKS - - O
activation - - O
in - - O
the - - O
blood - - O
and - - O
high - - O
serotonin - - O
and - - O
lactic - - O
acid - - O
content - - O
in - - O
the - - O
humor - - O
condensated - - O
from - - O
the - - O
exhaled - - O
air - - O
. - - O

Topical - - O
1 - - O
percent - - O
isoproterenol - - O
in - - O
the - - O
presence - - O
of - - O
the - - O
phosphodiesterase - - O
inhibitor - - O
theophylline - - O
was - - O
tested - - O
for - - O
its - - O
ability - - O
to - - O
stimulate - - O
the - - O
rate - - O
of - - O
aqueous - - O
humor - - O
flow - - O
through - - O
the - - O
anterior - - O
chamber - - O
of - - O
the - - O
normal - - O
and - - O
the - - O
partially - - O
adrenergically - - O
denervated - - O
human - - O
eye - - O
( - - O
Horner's - - O
syndrome - - O
) - - O
. - - O

Copyright - - O
2000 - - O
Academic - - O
Press - - O
. - - O

Some - - O
mutations - - O
affected - - O
Dhfr - - O
in - - O
a - - O
qualitative - - O
manner - - O
, - - O
such - - O
as - - O
by - - O
changing - - O
the - - O
startpoint - - O
of - - O
one - - O
of - - O
the - - O
major - - O
Dhfr - - O
transcripts - - O
or - - O
changing - - O
the - - O
relative - - O
abundance - - O
of - - O
the - - O
two - - O
major - - O
Dhfr - - O
transcripts - - O
. - - O

The - - O
sequencing - - O
of - - O
Stellate - - O
copies - - O
located - - O
along - - O
the - - O
discontinuous - - O
cluster - - O
revealed - - O
a - - O
complex - - O
pattern - - O
of - - O
diversification - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
the - - O
phenotype - - O
of - - O
XLP - - O
may - - O
result - - O
from - - O
perturbed - - O
signaling - - O
not - - O
only - - O
through - - O
SLAM - - O
, - - O
but - - O
also - - O
other - - O
cell - - O
surface - - O
molecules - - O
that - - O
utilize - - O
SAP - - O
as - - O
a - - O
signaling - - O
adaptor - - O
protein - - O
. - - O

Only - - O
one - - O
ADR - - O
was - - O
related - - O
definitely - - O
to - - O
ciprofloxacin - - O
therapy - - O
. - - O

Here - - O
, - - O
a - - O
case - - O
of - - O
Sjogren's - - O
syndrome - - O
is - - O
presented - - O
that - - O
was - - O
initially - - O
diagnosed - - O
because - - O
of - - O
dental - - O
complaints - - O
, - - O
and - - O
long-term - - O
treatment - - O
of - - O
Sjogren's - - O
patients - - O
is - - O
discussed - - O
. - - O

The - - O
12S - - O
E1A - - O
product - - O
does - - O
not - - O
activate - - O
a - - O
TRE - - O
sequence - - O
, - - O
but - - O
cotransfection - - O
with - - O
c-jun - - O
circumvents - - O
this - - O
lack - - O
of - - O
stimulation - - O
. - - O

Second - - O
, - - O
the - - O
wild-type - - O
m8 - - O
3' - - O
UTR - - O
strongly - - O
reduces - - O
accumulation - - O
of - - O
heterologous - - O
transcripts - - O
in - - O
vivo - - O
, - - O
an - - O
activity - - O
that - - O
requires - - O
its - - O
K - - O
box - - O
sequences - - O
. - - O

Thus - - O
it - - O
appears - - O
that - - O
insertion - - O
of - - O
a - - O
transposable - - O
element - - O
near - - O
the - - O
5' - - O
terminus - - O
of - - O
the - - O
structural - - O
gene - - O
can - - O
produce - - O
constitutive - - O
expression - - O
of - - O
a - - O
normally - - O
glucose-repressed - - O
enzyme - - O
. - - O

The - - O
IE13 - - O
. - - O
1 - - O
cell - - O
line - - O
was - - O
able - - O
to - - O
complement - - O
a - - O
recombinant - - O
virus - - O
in - - O
which - - O
both - - O
copies - - O
of - - O
the - - O
IE - - O
gene - - O
were - - O
replaced - - O
by - - O
insertion - - O
of - - O
the - - O
Escherichia - - O
coli - - O
lacZ - - O
gene - - O
. - - O

After - - O
taking - - O
smears - - O
from - - O
lesions - - O
of - - O
the - - O
oral - - O
mucosa - - O
( - - O
tongue - - O
, - - O
cheeks - - O
, - - O
palate - - O
) - - O
and - - O
the - - O
contiguous - - O
denture - - O
surface - - O
by - - O
cotton - - O
wool - - O
swabs - - O
and - - O
inoculating - - O
them - - O
onto - - O
Sabouraud - - O
glucose - - O
agar - - O
and - - O
CHROMagar - - O
Candida - - O
, - - O
individual - - O
yeast - - O
species - - O
were - - O
identified - - O
by - - O
a - - O
germ - - O
tube - - O
, - - O
filamentous - - O
, - - O
and - - O
assimilation - - O
tests - - O
employing - - O
the - - O
commercial - - O
kit - - O
AuxaColor - - O
. - - O

[ - - O
18F - - O
] - - O
( - - O
+ - - O
) - - O
-4-fluorobenzyltrozamicol - - O
( - - O
FBT - - O
) - - O
, - - O
which - - O
selectively - - O
binds - - O
to - - O
the - - O
vesicular - - O
acetylcholine - - O
transporter - - O
in - - O
the - - O
presynaptic - - O
cholinergic - - O
neuron - - O
, - - O
has - - O
previously - - O
been - - O
shown - - O
to - - O
be - - O
a - - O
useful - - O
ligand - - O
for - - O
the - - O
study - - O
of - - O
cholinergic - - O
terminal - - O
density - - O
in - - O
the - - O
basal - - O
ganglia - - O
with - - O
PET - - O
. - - O

A - - O
genomic - - O
clone - - O
was - - O
isolated - - O
that - - O
contained - - O
12 - - O
. - - O
5 - - O
kb - - O
of - - O
the - - O
5'-flanking - - O
region - - O
and - - O
the - - O
first - - O
exon - - O
of - - O
the - - O
p69 - - O
71 - - O
2-5A - - O
synthetase - - O
gene - - O
. - - O

Here - - O
we - - O
report - - O
the - - O
cloning - - O
and - - O
characterization - - O
of - - O
Xenopus - - O
Pax-5 - - O
and - - O
Pax-8 - - O
, - - O
two - - O
orthologues - - O
of - - O
the - - O
Pax-2 - - O
5 - - O
8 - - O
gene - - O
family - - O
. - - O

However - - O
, - - O
cotransfection - - O
studies - - O
indicate - - O
that - - O
RVR - - O
does - - O
not - - O
activate - - O
transcription - - O
when - - O
this - - O
hormone - - O
response - - O
element - - O
is - - O
linked - - O
to - - O
a - - O
reporter - - O
gene - - O
but - - O
rather - - O
acts - - O
as - - O
a - - O
potent - - O
competitive - - O
repressor - - O
of - - O
ROR - - O
alpha - - O
function - - O
. - - O

The - - O
level - - O
of - - O
carboxyl-terminal - - O
parathyroid - - O
hormone - - O
in - - O
the - - O
patients - - O
with - - O
thyroid - - O
carcinoma - - O
was - - O
higher - - O
than - - O
that - - O
in - - O
the - - O
patients - - O
without - - O
thyroid - - O
carcinoma - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

The - - O
prothrombin - - O
gene - - O
G20210A - - O
mutation - - O
is - - O
not - - O
found - - O
among - - O
Japanese - - O
patients - - O
with - - O
deep - - O
vein - - O
thrombosis - - O
and - - O
healthy - - O
individuals - - O
. - - O

The - - O
correct - - O
termination - - O
of - - O
retroviral - - O
transcripts - - O
at - - O
the - - O
3' - - O
LTR - - O
R - - O
U5 - - O
junction - - O
is - - O
primarily - - O
dependent - - O
on - - O
the - - O
canonical - - O
AAUAAA - - O
polyadenylation - - O
signal - - O
, - - O
so - - O
we - - O
have - - O
analyzed - - O
the - - O
effect - - O
of - - O
mutating - - O
the - - O
polyadenylation - - O
signal - - O
sequences - - O
on - - O
the - - O
properties - - O
of - - O
a - - O
selectable - - O
murine - - O
retroviral - - O
vector - - O
. - - O

When - - O
the - - O
coronary - - O
sinus - - O
pressure - - O
reached - - O
15 - - O
torr - - O
, - - O
there - - O
was - - O
a - - O
significant - - O
decrease - - O
in - - O
cardiac - - O
index - - O
( - - O
3 - - O
. - - O
60 - - O
+ - - O
- - - O
0 - - O
. - - O
5 - - O
to - - O
2 - - O
. - - O
70 - - O
+ - - O
- - - O
0 - - O
. - - O
6 - - O
L - - O
min - - O
m2 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
coronary - - O
blood - - O
flow - - O
( - - O
13 - - O
. - - O
7 - - O
+ - - O
- - - O
3 - - O
. - - O
1 - - O
to - - O
7 - - O
. - - O
0 - - O
+ - - O
- - - O
2 - - O
. - - O
1 - - O
ml - - O
min - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
rate - - O
of - - O
rise - - O
of - - O
left - - O
ventricular - - O
pressure - - O
( - - O
1 - - O
, - - O
567 - - O
+ - - O
- - - O
275 - - O
to - - O
1 - - O
, - - O
331 - - O
+ - - O
- - - O
314 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
, - - O
and - - O
an - - O
increase - - O
in - - O
coronary - - O
arteriovenous - - O
difference - - O
( - - O
62 - - O
. - - O
8% - - O
+ - - O
- - - O
9 - - O
. - - O
3% - - O
to - - O
70 - - O
. - - O
5% - - O
+ - - O
- - - O
5 - - O
. - - O
4% - - O
saturation - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
03 - - O
) - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
ULK2 - - O
is - - O
involved - - O
in - - O
a - - O
previously - - O
uncharacterized - - O
signaling - - O
pathway - - O
in - - O
mammalian - - O
cells - - O
. - - O

We - - O
compared - - O
previously - - O
the - - O
methylation - - O
status - - O
between - - O
normal - - O
liver - - O
and - - O
liver - - O
tumors - - O
in - - O
SV40 - - O
T - - O
t - - O
antigen - - O
transgenic - - O
mice - - O
( - - O
MT-D2 - - O
mice - - O
) - - O
using - - O
Restriction - - O
Landmark - - O
Genomic - - O
Scanning - - O
for - - O
Methylation - - O
( - - O
RLGS-M - - O
) - - O
and - - O
identified - - O
several - - O
loci - - O
spots - - O
that - - O
appeared - - O
to - - O
be - - O
methylated - - O
frequently - - O
in - - O
liver - - O
tumors - - O
. - - O

The - - O
5'-flanking - - O
region - - O
of - - O
the - - O
human - - O
lactoferrin - - O
gene - - O
was - - O
isolated - - O
from - - O
a - - O
human - - O
placental - - O
genomic - - O
library - - O
. - - O

Additionally - - O
, - - O
observations - - O
that - - O
patients - - O
with - - O
mitral - - O
versus - - O
aortic - - O
regurgitation - - O
respond - - O
differently - - O
to - - O
valve - - O
replacement - - O
suggest - - O
that - - O
differences - - O
exist - - O
preoperatively - - O
between - - O
these - - O
two - - O
types - - O
of - - O
volume - - O
overload - - O
. - - O

GH - - O
deficiency - - O
may - - O
be - - O
absolute - - O
, - - O
but - - O
often - - O
is - - O
not - - O
and - - O
the - - O
diagnosis - - O
may - - O
be - - O
complicated - - O
by - - O
a - - O
constellation - - O
of - - O
physical - - O
and - - O
hormonal - - O
findings - - O
that - - O
are - - O
along - - O
a - - O
spectrum - - O
from - - O
low - - O
normal - - O
GH - - O
sufficiency - - O
to - - O
absent - - O
GH - - O
secretion - - O
. - - O

The - - O
bovine - - O
PGHS-2 - - O
cDNA - - O
was - - O
cloned - - O
by - - O
a - - O
combination - - O
of - - O
reverse - - O
transcription-polymerase - - O
chain - - O
reaction - - O
and - - O
cDNA - - O
library - - O
screening - - O
. - - O

Previous - - O
studies - - O
have - - O
suggested - - O
that - - O
moderate - - O
cooling - - O
increases - - O
the - - O
responsiveness - - O
of - - O
vascular - - O
alpha2-adrenoceptors - - O
. - - O

Copyright - - O
2002 - - O
American - - O
Cancer - - O
Society - - O
. - - O
DOI - - O
10 - - O
. - - O
1002 - - O
cncr - - O
. - - O
10318 - - O

Stable - - O
association - - O
of - - O
U2 - - O
snRNP - - O
with - - O
the - - O
branchpoint - - O
sequence - - O
of - - O
mammalian - - O
pre-mRNAs - - O
requires - - O
binding - - O
of - - O
a - - O
non-snRNP - - O
protein - - O
to - - O
the - - O
polypyrimidine - - O
tract - - O
. - - O

Patterns - - O
defined - - O
by - - O
combinations - - O
of - - O
normal - - O
and - - O
abnormal - - O
laboratory - - O
results - - O
had - - O
decreased - - O
the - - O
likelihood - - O
of - - O
PEM - - O
from - - O
an - - O
all-2 - - O
to - - O
all-0 - - O
pattern - - O
. - - O

Nucleotide - - O
sequencing - - O
indicates - - O
that - - O
this - - O
E1 - - O
alpha - - O
cDNA - - O
clone - - O
is - - O
1821 - - O
base - - O
pairs - - O
( - - O
bp - - O
) - - O
in - - O
length - - O
with - - O
an - - O
open - - O
reading - - O
frame - - O
of - - O
1365 - - O
bp - - O
and - - O
a - - O
3'-untranslated - - O
region - - O
of - - O
356 - - O
bp - - O
. - - O

Retinoblastoma - - O
: - - O
a - - O
study - - O
of - - O
natural - - O
history - - O
and - - O
prognosis - - O
of - - O
268 - - O
cases - - O
. - - O

We - - O
have - - O
recently - - O
identified - - O
a - - O
mouse - - O
enzyme - - O
termed - - O
gamma-glutamyl - - O
leukotrienase - - O
( - - O
GGL - - O
) - - O
that - - O
converts - - O
leukotriene - - O
C4 - - O
( - - O
LTC4 - - O
) - - O
to - - O
leukotriene - - O
D4 - - O
( - - O
LTD4 - - O
) - - O
. - - O

The - - O
results - - O
suggest - - O
that - - O
the - - O
role - - O
of - - O
S - - O
. - - O
argyrostoma - - O
in - - O
the - - O
dissemination - - O
of - - O
Trichinella - - O
larvae - - O
in - - O
nature - - O
is - - O
limited - - O
in - - O
comparison - - O
to - - O
the - - O
role - - O
played - - O
by - - O
mammals - - O
with - - O
scavenger - - O
and - - O
cannibalistic - - O
behavior - - O
. - - O

Karger - - O
AG - - O
, - - O
Basel - - O

Proceedings - - O
: - - O
Reversible - - O
complete - - O
heart - - O
block - - O
following - - O
surgery - - O
of - - O
congenital - - O
heart - - O
defects - - O
. - - O

GABA - - O
( - - O
B - - O
) - - O
R1g - - O
was - - O
expressed - - O
in - - O
both - - O
brain - - O
and - - O
peripheral - - O
tissues - - O
. - - O

A - - O
malignant - - O
true - - O
teratoma - - O
of - - O
liver - - O
in - - O
childhood - - O
. - - O

To - - O
assess - - O
the - - O
health - - O
significance - - O
of - - O
the - - O
early - - O
renal - - O
changes - - O
after - - O
chronic - - O
exposure - - O
to - - O
cadmium - - O
, - - O
23 - - O
workers - - O
removed - - O
from - - O
exposure - - O
because - - O
of - - O
the - - O
discovery - - O
of - - O
an - - O
increased - - O
urinary - - O
excretion - - O
of - - O
beta - - O
2-microglobulin - - O
or - - O
retinol - - O
binding - - O
protein - - O
, - - O
or - - O
both - - O
, - - O
have - - O
been - - O
examined - - O
once - - O
a - - O
year - - O
for - - O
five - - O
years - - O
. - - O

We - - O
have - - O
examined - - O
reporter - - O
gene - - O
( - - O
beta-gal - - O
) - - O
expression - - O
directed - - O
by - - O
human - - O
heat - - O
shock - - O
transcription - - O
factors - - O
1 - - O
and - - O
2 - - O
( - - O
HSF1 - - O
and - - O
HSF2 - - O
) - - O
in - - O
HeLa - - O
cells - - O
and - - O
in - - O
yeast - - O
( - - O
Saccharomyces - - O
cerevisiae - - O
) - - O
. - - O

Therefore - - O
, - - O
use - - O
of - - O
presaturation - - O
is - - O
recommended - - O
for - - O
myocardial - - O
motion - - O
studies - - O
using - - O
cine - - O
PC - - O
velocity - - O
data - - O
. - - O

The - - O
histological - - O
grading - - O
was - - O
certified - - O
in - - O
68 - - O
cases - - O
: - - O
12 - - O
G1 - - O
, - - O
39 - - O
G2 - - O
, - - O
17 - - O
G3 - - O
; - - O
extracapsular - - O
spread - - O
was - - O
found - - O
in - - O
20 - - O
54 - - O
cases - - O
( - - O
37% - - O
) - - O
. - - O

( - - O
3 - - O
) - - O
. - - O

Expression - - O
of - - O
Msp - - O
was - - O
toxic - - O
to - - O
E - - O
. - - O
coli - - O
when - - O
the - - O
entire - - O
msp - - O
gene - - O
was - - O
present - - O
. - - O

High-mobility-group - - O
protein - - O
I - - O
can - - O
modulate - - O
binding - - O
of - - O
transcription - - O
factors - - O
to - - O
the - - O
U5 - - O
region - - O
of - - O
the - - O
human - - O
immunodeficiency - - O
virus - - O
type - - O
1 - - O
proviral - - O
promoter - - O
. - - O

There - - O
was - - O
a - - O
significant - - O
correlation - - O
between - - O
tubular - - O
diameter - - O
and - - O
spg - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
68 - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
suggesting - - O
that - - O
tubular - - O
diameter - - O
measurements - - O
in - - O
histological - - O
sections - - O
could - - O
be - - O
used - - O
to - - O
predict - - O
sperm - - O
production - - O
. - - O

The - - O
rho - - O
genes - - O
comprise - - O
an - - O
evolutionarily - - O
conserved - - O
family - - O
with - - O
significant - - O
homology - - O
to - - O
the - - O
ras - - O
oncogene - - O
family - - O
. - - O

The - - O
effect - - O
of - - O
ICRF-187 - - O
on - - O
the - - O
antitumor - - O
response - - O
induced - - O
by - - O
the - - O
combination - - O
of - - O
ADR - - O
and - - O
WBH - - O
was - - O
also - - O
investigated - - O
in - - O
order - - O
to - - O
assess - - O
alterations - - O
in - - O
the - - O
therapeutic - - O
index - - O
of - - O
this - - O
combined - - O
therapeutic - - O
modality - - O
treatment - - O
. - - O

The - - O
syndrome - - O
of - - O
resistance - - O
to - - O
thyroid - - O
hormone - - O
is - - O
characterized - - O
by - - O
elevated - - O
serum - - O
free - - O
thyroid - - O
hormones - - O
, - - O
failure - - O
to - - O
suppress - - O
pituitary - - O
thyrotropin - - O
secretion - - O
, - - O
and - - O
variable - - O
peripheral - - O
refractoriness - - O
to - - O
hormone - - O
action - - O
. - - O

Survival - - O
rates - - O
for - - O
the - - O
original - - O
treatment - - O
group - - O
were - - O
84 - - O
. - - O
5% - - O
and - - O
57 - - O
. - - O
6% - - O
at - - O
12 - - O
and - - O
21 - - O
months - - O
, - - O
respectively - - O
; - - O
for - - O
the - - O
delayed - - O
treatment - - O
group - - O
, - - O
78 - - O
. - - O
8% - - O
and - - O
64 - - O
. - - O
6% - - O
at - - O
12 - - O
and - - O
21 - - O
months - - O
, - - O
respectively - - O
, - - O
and - - O
78 - - O
. - - O
8% - - O
and - - O
47 - - O
. - - O
5% - - O
at - - O
12 - - O
and - - O
21 - - O
months - - O
, - - O
respectively - - O
, - - O
for - - O
77 - - O
subjects - - O
with - - O
AIDS - - O
and - - O
93 - - O
. - - O
0% - - O
and - - O
71 - - O
. - - O
8% - - O
, - - O
respectively - - O
, - - O
for - - O
50 - - O
subjects - - O
with - - O
AIDS-related - - O
complex - - O
in - - O
the - - O
original - - O
treatment - - O
group - - O
. - - O

The - - O
signalling - - O
molecules - - O
Wnt1 - - O
and - - O
Sonic - - O
hedgehog - - O
, - - O
implicated - - O
in - - O
the - - O
activation - - O
of - - O
Myf5 - - O
in - - O
myogenic - - O
progenitor - - O
cells - - O
in - - O
the - - O
somite - - O
, - - O
are - - O
also - - O
produced - - O
in - - O
the - - O
viscinity - - O
of - - O
the - - O
Myf5 - - O
expression - - O
domain - - O
in - - O
the - - O
mesencephalon - - O
. - - O

Sequence - - O
analysis - - O
of - - O
this - - O
100-bp - - O
Col2a1 - - O
enhancer - - O
revealed - - O
several - - O
sequence - - O
motifs - - O
similar - - O
to - - O
motifs - - O
present - - O
within - - O
the - - O
regulatory - - O
region - - O
of - - O
the - - O
link - - O
protein - - O
gene - - O
, - - O
another - - O
cartilage - - O
gene - - O
. - - O

This - - O
is - - O
in - - O
contrast - - O
with - - O
the - - O
classical - - O
'oxygen - - O
debt - - O
hypothesis' - - O
, - - O
which - - O
states - - O
that - - O
the - - O
oxygen - - O
debt - - O
and - - O
lactate - - O
clearance - - O
are - - O
linked - - O
. - - O

Mental - - O
development - - O
is - - O
generally - - O
normal - - O
. - - O

Reactivities - - O
to - - O
horse - - O
anti-lymphocyte - - O
globulin - - O
. - - O

Further - - O
studies - - O
in - - O
T-24 - - O
cells - - O
demonstrated - - O
that - - O
HA - - O
fragments - - O
also - - O
induced - - O
I - - O
kappa - - O
B - - O
alpha - - O
phosphorylation - - O
and - - O
degradation - - O
, - - O
kappa - - O
B-linked - - O
reporter - - O
gene - - O
expression - - O
, - - O
and - - O
ICAM-1 - - O
promoter - - O
activity - - O
in - - O
an - - O
NF-kappa - - O
B-dependent - - O
manner - - O
. - - O

Acetoin - - O
can - - O
be - - O
reused - - O
by - - O
the - - O
bacteria - - O
during - - O
stationary - - O
phase - - O
when - - O
other - - O
carbon - - O
sources - - O
have - - O
been - - O
depleted - - O
. - - O

An - - O
epidemic - - O
of - - O
hepatitis - - O
B - - O
virus - - O
infection - - O
among - - O
intravenous - - O
drug - - O
users - - O
in - - O
Iceland - - O
. - - O

Transformations - - O
in - - O
the - - O
morphine - - O
series - - O
. - - O

Morphology - - O
of - - O
bacteriophages - - O
of - - O
Klebsiella - - O
bacilli - - O
. - - O

During - - O
the - - O
biosynthesis - - O
of - - O
all - - O
three - - O
mutant - - O
polypeptides - - O
, - - O
the - - O
signal - - O
peptide - - O
is - - O
efficiently - - O
and - - O
accurately - - O
cleaved - - O
from - - O
the - - O
nascent - - O
protein - - O
, - - O
even - - O
though - - O
in - - O
mutants - - O
X2 - - O
and - - O
X3 - - O
the - - O
cleavage - - O
site - - O
itself - - O
has - - O
been - - O
altered - - O
. - - O

Influence - - O
of - - O
cyclo-oxygenase - - O
inhibition - - O
and - - O
of - - O
leukotriene - - O
receptor - - O
blockade - - O
on - - O
pulmonary - - O
vascular - - O
pressure - - O
cardiac - - O
index - - O
relationships - - O
in - - O
hyperoxic - - O
and - - O
in - - O
hypoxic - - O
dogs - - O
. - - O

Of - - O
the - - O
remaining - - O
seven - - O
, - - O
five - - O
reacted - - O
either - - O
with - - O
immediate - - O
and - - O
strong - - O
symptoms - - O
or - - O
had - - O
spontaneously - - O
reduced - - O
gluten - - O
intake - - O
, - - O
or - - O
had - - O
an - - O
acquired - - O
IgA - - O
deficiency - - O
. - - O

Polysorbate - - O
80 - - O
did - - O
not - - O
have - - O
a - - O
direct - - O
stimulant - - O
or - - O
relaxant - - O
effect - - O
on - - O
either - - O
guinea - - O
pig - - O
ileum - - O
or - - O
rat - - O
uterus - - O
, - - O
however - - O
, - - O
it - - O
antagonised - - O
the - - O
contractions - - O
induced - - O
by - - O
acetylcholine - - O
, - - O
histamine - - O
, - - O
barium - - O
, - - O
5-hydroxytryptamine - - O
and - - O
carbachol - - O
in - - O
a - - O
dose-dependent - - O
manner - - O
. - - O

The - - O
molecular - - O
mechanism - - O
by - - O
which - - O
Gle2p - - O
and - - O
the - - O
Gle2p-Nup116p - - O
interaction - - O
function - - O
in - - O
mRNA - - O
export - - O
is - - O
unknown - - O
. - - O

The - - O
C4BP - - O
alpha - - O
gene - - O
is - - O
organized - - O
as - - O
follows - - O
: - - O
the - - O
first - - O
exon - - O
codes - - O
for - - O
the - - O
first - - O
198 - - O
nucleotides - - O
of - - O
the - - O
5' - - O
UTR - - O
. - - O

EXERCISE - - O
IN - - O
THE - - O
TERRESTRIAL - - O
CHRISTMAS - - O
ISLAND - - O
RED - - O
CRAB - - O
GECARCOIDEA - - O
NATALIS - - O
- - - O
ENERGETICS - - O
OF - - O
LOCOMOTION - - O
. - - O

We - - O
have - - O
now - - O
located - - O
the - - O
5' - - O
ends - - O
of - - O
the - - O
two - - O
remaining - - O
late - - O
mRNAs - - O
. - - O

Acta - - O
572 - - O
, - - O
113-120 - - O
] - - O
. - - O

The - - O
RNA - - O
polymerase - - O
III-recruiting - - O
factor - - O
TFIIIB - - O
induces - - O
a - - O
DNA - - O
bend - - O
between - - O
the - - O
TATA - - O
box - - O
and - - O
the - - O
transcriptional - - O
start - - O
site - - O
. - - O

To - - O
search - - O
for - - O
genes - - O
that - - O
interact - - O
with - - O
the - - O
SLK1-SLT2 - - O
pathway - - O
, - - O
a - - O
synthetic - - O
lethal - - O
suppression - - O
screen - - O
was - - O
carried - - O
out - - O
. - - O

Scotchbond - - O
2 - - O
showed - - O
the - - O
least - - O
dye - - O
penetration - - O
but - - O
not - - O
statistically - - O
less - - O
than - - O
the - - O
XR - - O
bond - - O
Silus - - O
Plus - - O
combination - - O
. - - O

The - - O
consequences - - O
of - - O
intensive - - O
swine - - O
production - - O
on - - O
the - - O
environment - - O
and - - O
possible - - O
solutions - - O
by - - O
means - - O
of - - O
nutrition - - O
are - - O
outlined - - O
. - - O

Pitx2 - - O
rescues - - O
the - - O
GABAergic - - O
differentiation - - O
defect - - O
and - - O
partially - - O
rescues - - O
the - - O
axon - - O
guidance - - O
and - - O
behavioral - - O
phenotypes - - O
of - - O
unc-30 - - O
mutants - - O
, - - O
indicating - - O
a - - O
high - - O
degree - - O
of - - O
functional - - O
conservation - - O
between - - O
these - - O
evolutionarily - - O
related - - O
genes - - O
. - - O

These - - O
data - - O
strongly - - O
implicate - - O
the - - O
normal - - O
product - - O
of - - O
the - - O
int-2 - - O
gene - - O
, - - O
which - - O
is - - O
related - - O
to - - O
the - - O
fibroblast - - O
growth - - O
factor - - O
family - - O
, - - O
as - - O
a - - O
contributory - - O
factor - - O
in - - O
virally - - O
induced - - O
mammary - - O
tumors - - O
. - - O

Similarity - - O
of - - O
DNA - - O
binding - - O
and - - O
transcriptional - - O
regulation - - O
by - - O
Caenorhabditis - - O
elegans - - O
MAB-3 - - O
and - - O
Drosophila - - O
melanogaster - - O
DSX - - O
suggests - - O
conservation - - O
of - - O
sex - - O
determining - - O
mechanisms - - O
. - - O

Serum - - O
gastrin - - O
and - - O
AFP - - O
levels - - O
had - - O
the - - O
same - - O
evolution - - O
and - - O
appear - - O
to - - O
have - - O
the - - O
same - - O
interest - - O
to - - O
follow - - O
the - - O
course - - O
of - - O
the - - O
disease - - O
. - - O

Pokeweed - - O
mitogen - - O
( - - O
PWM - - O
) - - O
or - - O
anti-CD3 - - O
significantly - - O
increases - - O
c-jun - - O
messenger - - O
RNA - - O
( - - O
mRNA - - O
) - - O
levels - - O
in - - O
T - - O
cells - - O
. - - O

The - - O
same - - O
trend - - O
was - - O
noted - - O
between - - O
YG - - O
4 - - O
. - - O
5 - - O
heifers - - O
and - - O
YG - - O
5 - - O
. - - O
5 - - O
steers - - O
, - - O
indicating - - O
a - - O
sex-related - - O
deposition - - O
of - - O
seam - - O
fat - - O
in - - O
fed - - O
cattle - - O
. - - O

Nucleoprotein - - O
( - - O
N - - O
) - - O
expressed - - O
by - - O
both - - O
recombinant - - O
vaccinia - - O
virus - - O
and - - O
TGEV - - O
had - - O
a - - O
relative - - O
molecular - - O
mass - - O
( - - O
Mr - - O
) - - O
of - - O
47 - - O
, - - O
000 - - O
and - - O
was - - O
susceptible - - O
to - - O
degradation - - O
at - - O
the - - O
C-terminus - - O
yielding - - O
discrete - - O
breakdown - - O
products - - O
. - - O

A - - O
herpesvirus - - O
proteinase - - O
activity - - O
has - - O
been - - O
identified - - O
and - - O
partially - - O
characterized - - O
by - - O
using - - O
the - - O
cloned - - O
enzyme - - O
and - - O
substrate - - O
genes - - O
in - - O
transient - - O
transfection - - O
assays - - O
. - - O

Molecular - - O
cloning - - O
and - - O
expression - - O
of - - O
human - - O
UDP-d-Xylose - - O
: - - O
proteoglycan - - O
core - - O
protein - - O
beta-d-xylosyltransferase - - O
and - - O
its - - O
first - - O
isoform - - O
XT-II - - O
. - - O

Microwave - - O
hyperthermia-induced - - O
blood-brain - - O
barrier - - O
alterations - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
less - - O
antidopaminergic - - O
activity - - O
of - - O
RHAL - - O
in - - O
this - - O
neuroleptic - - O
test - - O
might - - O
be - - O
explained - - O
by - - O
the - - O
lesser - - O
conversion - - O
of - - O
RHAL - - O
to - - O
HAL - - O
. - - O

All - - O
patients - - O
had - - O
the - - O
CA - - O
125 - - O
assay - - O
performed - - O
within - - O
one - - O
week - - O
before - - O
their - - O
second-look - - O
operation - - O
. - - O

Early - - O
disagnosis - - O
of - - O
cancer--50 - - O
per - - O
cent - - O
of - - O
all - - O
patients - - O
could - - O
be - - O
cured - - O
. - - O

Thiopentone - - O
sodium - - O
administered - - O
at - - O
30 - - O
and - - O
10 - - O
min - - O
before - - O
or - - O
5 - - O
, - - O
10 - - O
and - - O
15 - - O
min - - O
after - - O
exposure - - O
to - - O
NOC-5 - - O
, - - O
but - - O
not - - O
thereafter - - O
, - - O
significantly - - O
attenuated - - O
NO-induced - - O
neurotoxicity - - O
compared - - O
with - - O
controls - - O
. - - O

Essentially - - O
, - - O
2'- - - O
O - - O
-methyl - - O
oligoribonucleotides - - O
( - - O
2'OMeRNA - - O
) - - O
were - - O
delivered - - O
to - - O
the - - O
nuclei - - O
of - - O
primary - - O
mdx - - O
myoblasts - - O
in - - O
culture - - O
. - - O

Microscopic - - O
anatomy - - O
and - - O
cell - - O
population - - O
dynamics - - O
. - - O

Angina - - O
( - - O
Q - - O
) - - O
persistence - - O
showed - - O
marked - - O
associations - - O
with - - O
previous - - O
myocardial - - O
infarction - - O
, - - O
diagnosed - - O
angina - - O
, - - O
electrocardiogram - - O
ischemia - - O
, - - O
and - - O
subsequent - - O
major - - O
ischemic - - O
heart - - O
disease - - O
events - - O
from - - O
Q5 - - O
onward - - O
. - - O

We - - O
propose - - O
that - - O
Mad - - O
and - - O
Medea - - O
encode - - O
rate-limiting - - O
components - - O
integral - - O
to - - O
dpp - - O
pathways - - O
throughout - - O
development - - O
. - - O

Furthermore - - O
, - - O
we - - O
demonstrate - - O
that - - O
transcription - - O
from - - O
the - - O
MMTV - - O
5' - - O
LTR - - O
is - - O
highly - - O
active - - O
in - - O
the - - O
absence - - O
of - - O
Stat5a - - O
, - - O
a - - O
transcription - - O
factor - - O
that - - O
had - - O
been - - O
shown - - O
previously - - O
to - - O
be - - O
required - - O
for - - O
transcription - - O
from - - O
the - - O
MMTV - - O
LTR - - O
. - - O

Functional - - O
magnetic - - O
resonance - - O
imaging - - O
( - - O
fMRI - - O
) - - O
has - - O
been - - O
increasingly - - O
used - - O
in - - O
studying - - O
human - - O
brain - - O
function - - O
given - - O
its - - O
non-invasive - - O
feature - - O
and - - O
good - - O
spatial - - O
resolution - - O
. - - O

Viral - - O
infections - - O
have - - O
long - - O
been - - O
suspected - - O
to - - O
be - - O
causative - - O
agents - - O
in - - O
a - - O
number - - O
of - - O
inner - - O
ear - - O
dysfunctions - - O
. - - O

Microdetermination - - O
of - - O
adrenocortical - - O
steroids - - O
by - - O
double - - O
isotope - - O
method - - O
. - - O

STUDY - - O
DESIGN - - O
: - - O
Salivary - - O
immunoglobulin - - O
A - - O
levels - - O
of - - O
each - - O
of - - O
20 - - O
subjects - - O
were - - O
determined - - O
on - - O
3 - - O
occasions - - O
: - - O
first - - O
, - - O
while - - O
the - - O
subject - - O
was - - O
still - - O
smoking - - O
; - - O
second - - O
, - - O
7 - - O
days - - O
after - - O
cessation - - O
of - - O
smoking - - O
; - - O
third - - O
, - - O
on - - O
the - - O
14th - - O
day - - O
after - - O
cessation - - O
. - - O

Practical - - O
interest - - O
of - - O
such - - O
studies - - O
is - - O
limited - - O
since - - O
the - - O
pharmacokinetic - - O
parameters - - O
are - - O
systematically - - O
evaluated - - O
in - - O
man - - O
during - - O
phase - - O
I - - O
trials - - O
. - - O

Martin - - O
Luther - - O
and - - O
his - - O
physicians - - O
. - - O

40 - - O
, - - O
000 - - O
) - - O
. - - O

These - - O
results - - O
also - - O
suggest - - O
the - - O
involvement - - O
of - - O
additional - - O
elements - - O
in - - O
the - - O
UPR - - O
. - - O

RESULTS - - O
: - - O
Abnormal - - O
color - - O
perception - - O
was - - O
found - - O
in - - O
32% - - O
of - - O
the - - O
epilepsy - - O
patients - - O
treated - - O
with - - O
vigabatrin - - O
monotherapy - - O
and - - O
28% - - O
of - - O
the - - O
epilepsy - - O
patients - - O
treated - - O
with - - O
carbamazepine - - O
monotherapy - - O
. - - O

Cramps - - O
in - - O
extrapyramidal - - O
disorders - - O
. - - O

Interestingly - - O
, - - O
the - - O
similarities - - O
with - - O
the - - O
endophilin - - O
proteins - - O
cover - - O
the - - O
entire - - O
sequence - - O
of - - O
the - - O
SH3GLB - - O
family - - O
, - - O
suggesting - - O
a - - O
common - - O
fold - - O
and - - O
presumably - - O
a - - O
common - - O
mode - - O
of - - O
action - - O
. - - O

Each - - O
of - - O
these - - O
spliced - - O
mRNAs - - O
has - - O
an - - O
untranslated - - O
leader - - O
sequence - - O
of - - O
249 - - O
bases - - O
and - - O
a - - O
single - - O
intron - - O
of - - O
approximately - - O
540 - - O
bases - - O
which - - O
are - - O
contained - - O
entirely - - O
within - - O
TRs - - O
IRs - - O
sequences - - O
. - - O

We - - O
previously - - O
described - - O
the - - O
purification - - O
of - - O
an - - O
83-kDa - - O
phosphatidic - - O
acid - - O
phosphatase - - O
( - - O
PAP - - O
) - - O
from - - O
the - - O
porcine - - O
thymus - - O
membranes - - O
( - - O
Kanoh - - O
, - - O
H - - O
. - - O
, - - O
Imai - - O
, - - O
S - - O
. - - O
-i - - O
. - - O
, - - O
Yamada - - O
, - - O
K - - O
. - - O
and - - O
Sakane - - O
, - - O
F - - O
. - - O
( - - O
1992 - - O
) - - O
J - - O
. - - O

Tilmicosin - - O
is - - O
a - - O
novel - - O
macrolide - - O
antibiotic - - O
developed - - O
for - - O
exclusive - - O
use - - O
in - - O
veterinary - - O
medicine - - O
. - - O

TSC1 - - O
mutations - - O
include - - O
two - - O
nonsense - - O
mutations - - O
, - - O
four - - O
insertions - - O
, - - O
and - - O
three - - O
splice - - O
mutations - - O
. - - O

We - - O
have - - O
now - - O
tested - - O
all - - O
known - - O
mammalian - - O
Groucho - - O
family - - O
members - - O
for - - O
their - - O
ability - - O
to - - O
interact - - O
specifically - - O
with - - O
individual - - O
Tcf - - O
Lef - - O
family - - O
members - - O
. - - O

Fenfluramine - - O
( - - O
in - - O
doses - - O
ranging - - O
from - - O
0 - - O
. - - O
0625-4 - - O
. - - O
0 - - O
mg - - O
kg - - O
infusion - - O
) - - O
did - - O
not - - O
maintain - - O
self-administration - - O
behavior - - O
at - - O
or - - O
above - - O
the - - O
minimum - - O
requirement - - O
( - - O
FR - - O
30 - - O
) - - O
. - - O

No - - O
difference - - O
in - - O
telomere - - O
length - - O
was - - O
seen - - O
in - - O
mutants - - O
affected - - O
in - - O
the - - O
regulation - - O
of - - O
Cdc2 - - O
, - - O
whereas - - O
some - - O
of - - O
the - - O
DNA - - O
repair - - O
mutants - - O
examined - - O
had - - O
slightly - - O
longer - - O
telomeres - - O
than - - O
did - - O
the - - O
wild - - O
type - - O
. - - O

Using - - O
an - - O
opsonophagocytic - - O
bacterial - - O
assay - - O
and - - O
a - - O
suckling - - O
rat - - O
model - - O
of - - O
GBS - - O
sepsis - - O
, - - O
we - - O
analyzed - - O
a - - O
modified - - O
human - - O
immunoglobulin - - O
for - - O
opsonic - - O
and - - O
protective - - O
antibody - - O
. - - O

Near - - O
term - - O
, - - O
under - - O
experimental - - O
conditions - - O
, - - O
maternal - - O
and - - O
fetal - - O
blood - - O
gases - - O
, - - O
pH - - O
, - - O
uterine - - O
and - - O
umbilical - - O
blood - - O
flows - - O
were - - O
measured - - O
or - - O
calculated - - O
. - - O

Translation - - O
of - - O
the - - O
coding - - O
segment - - O
, - - O
which - - O
was - - O
designated - - O
MsPRP2 - - O
, - - O
suggested - - O
it - - O
encodes - - O
a - - O
chimeric - - O
40 - - O
, - - O
569 - - O
Da - - O
cell - - O
wall - - O
protein - - O
with - - O
an - - O
amino-terminal - - O
signal - - O
sequence - - O
, - - O
a - - O
repetitive - - O
proline-rich - - O
sequence - - O
, - - O
and - - O
a - - O
cysteine-rich - - O
carboxyl-terminal - - O
sequence - - O
homologous - - O
to - - O
nonspecific - - O
lipid - - O
transfer - - O
proteins - - O
. - - O

Cloning - - O
, - - O
expression - - O
, - - O
and - - O
nucleotide - - O
sequence - - O
of - - O
rat - - O
liver - - O
sterol - - O
carrier - - O
protein - - O
2 - - O
cDNAs - - O
. - - O

Just - - O
before - - O
inserting - - O
on - - O
the - - O
anterior - - O
margin - - O
and - - O
apex - - O
of - - O
the - - O
iliac - - O
crest - - O
it - - O
widens - - O
, - - O
assuming - - O
the - - O
aspect - - O
of - - O
a - - O
small - - O
cone - - O
. - - O

Integrated - - O
mapping - - O
analysis - - O
of - - O
the - - O
Werner - - O
syndrome - - O
region - - O
of - - O
chromosome - - O
8 - - O
. - - O

The - - O
cis-acting - - O
regulatory - - O
properties - - O
of - - O
an - - O
872 - - O
bp - - O
promoter - - O
fragment - - O
of - - O
a - - O
B - - O
. - - O
napus - - O
oleosin - - O
gene - - O
were - - O
examined - - O
by - - O
analysis - - O
of - - O
beta-glucuronidase - - O
( - - O
GUS - - O
) - - O
expression - - O
in - - O
transgenic - - O
tobacco - - O
plants - - O
containing - - O
an - - O
oleosin - - O
promoter-GUS - - O
transcriptional - - O
fusion - - O
. - - O

Plasma - - O
DHE - - O
concentration - - O
rose - - O
promptly - - O
above - - O
5 - - O
ng - - O
ml - - O
after - - O
the - - O
application - - O
of - - O
the - - O
PSA - - O
tape - - O
onto - - O
the - - O
damaged - - O
skin - - O
in - - O
hairless - - O
rat - - O
. - - O

39-47 - - O
. - - O

In - - O
the - - O
first - - O
group - - O
, - - O
0 - - O
. - - O
02% - - O
Prazosin - - O
( - - O
0 - - O
. - - O
5 - - O
mg - - O
kg - - O
) - - O
was - - O
administered - - O
intravenously - - O
for - - O
1 - - O
. - - O
5 - - O
hours - - O
before - - O
the - - O
application - - O
of - - O
Oxy-Hb - - O
or - - O
PGF2 - - O
alpha - - O
. - - O

Based - - O
on - - O
previous - - O
mapping - - O
of - - O
the - - O
G - - O
beta - - O
gamma - - O
binding - - O
region - - O
of - - O
beta - - O
ARK - - O
, - - O
and - - O
conserved - - O
residues - - O
within - - O
the - - O
PH - - O
domain - - O
, - - O
we - - O
have - - O
constructed - - O
a - - O
series - - O
of - - O
mutants - - O
in - - O
the - - O
carboxyl - - O
terminus - - O
of - - O
beta - - O
ARK - - O
in - - O
order - - O
to - - O
determine - - O
important - - O
residues - - O
involved - - O
in - - O
G - - O
beta - - O
gamma - - O
and - - O
PIP2 - - O
binding - - O
. - - O

Altogether - - O
, - - O
the - - O
results - - O
demonstrate - - O
that - - O
the - - O
two - - O
isoforms - - O
elicit - - O
similar - - O
responses - - O
in - - O
vivo - - O
despite - - O
differences - - O
in - - O
their - - O
regulation - - O
. - - O

An - - O
InlC - - O
deletion - - O
mutant - - O
shows - - O
reduced - - O
virulence - - O
when - - O
tested - - O
in - - O
an - - O
intravenous - - O
mouse - - O
model - - O
, - - O
but - - O
intracellular - - O
replication - - O
of - - O
the - - O
mutant - - O
in - - O
Caco-2 - - O
and - - O
J774 - - O
cells - - O
appears - - O
to - - O
be - - O
comparable - - O
with - - O
that - - O
of - - O
the - - O
wild-type - - O
strain - - O
. - - O

Zinc - - O
fingers - - O
( - - O
Zf - - O
) - - O
are - - O
a - - O
common - - O
structural - - O
motif - - O
found - - O
in - - O
many - - O
nucleic - - O
acid-binding - - O
proteins - - O
. - - O

When - - O
normalized - - O
for - - O
imaging - - O
time - - O
, - - O
all - - O
parameters - - O
are - - O
significantly - - O
higher - - O
with - - O
RASE - - O
, - - O
with - - O
a - - O
C - - O
A - - O
per - - O
unit - - O
time - - O
that - - O
was - - O
338% - - O
higher - - O
. - - O

The - - O
levels - - O
of - - O
NPY-ir - - O
in - - O
the - - O
rat - - O
vas - - O
deferens - - O
were - - O
not - - O
affected - - O
by - - O
either - - O
surgical - - O
or - - O
pharmacological - - O
treatment - - O
. - - O

Gimpl - - O
, - - O
F - - O
. - - O

A - - O
transparent - - O
overlay - - O
for - - O
assessing - - O
amplitude - - O
of - - O
ECG - - O
wave - - O
forms - - O
. - - O

Mono-ADP-ribosylation - - O
is - - O
a - - O
reversible - - O
modification - - O
of - - O
proteins - - O
, - - O
with - - O
NAD - - O
: - - O
arginine - - O
ADP-ribosyltransferases - - O
( - - O
EC - - O
2 - - O
. - - O
4 - - O
. - - O
2 - - O
. - - O
31 - - O
) - - O
and - - O
ADP-ribosylarginine - - O
hydrolases - - O
( - - O
EC - - O
3 - - O
. - - O
2 - - O
. - - O
2 - - O
. - - O
19 - - O
) - - O
catalyzing - - O
the - - O
opposing - - O
reactions - - O
in - - O
an - - O
ADP-ribosylation - - O
cycle - - O
. - - O

A - - O
single - - O
nucleotide - - O
polymorphism - - O
( - - O
SNP - - O
) - - O
in - - O
exon - - O
2 - - O
, - - O
which - - O
is - - O
tightly - - O
liked - - O
to - - O
another - - O
SNP - - O
( - - O
GTG83 - - O
ATG83 - - O
) - - O
, - - O
creates - - O
an - - O
additional - - O
alternative - - O
in-frame - - O
AUG - - O
in - - O
B-type - - O
MTH1 - - O
mRNAs - - O
yielding - - O
the - - O
fourth - - O
MTH1 - - O
polypeptide - - O
, - - O
p26 - - O
that - - O
possesses - - O
an - - O
additional - - O
mitochondrial - - O
targeting - - O
signal - - O
. - - O

Ovulation - - O
was - - O
induced - - O
in - - O
8 - - O
( - - O
56 - - O
. - - O
7% - - O
) - - O
patients - - O
who - - O
conceived - - O
. - - O

In - - O
contrast - - O
, - - O
despite - - O
external - - O
radiation - - O
therapy - - O
, - - O
brain - - O
metastases - - O
proved - - O
fatal - - O
. - - O

As - - O
determined - - O
in - - O
a - - O
modified - - O
yeast - - O
two-hybrid - - O
system - - O
, - - O
mIRS3 - - O
bound - - O
strongly - - O
to - - O
the - - O
p85 - - O
subunit - - O
of - - O
phosphatidylinositol - - O
3-kinase - - O
. - - O

Analysis - - O
of - - O
liver - - O
biopsy - - O
specimens - - O
from - - O
patients - - O
with - - O
hepatitis - - O
showed - - O
a - - O
large - - O
variation - - O
in - - O
the - - O
mean - - O
iron - - O
content - - O
of - - O
the - - O
liver - - O
ferritin - - O
molecules - - O
. - - O

Electrical - - O
activity - - O
was - - O
evaluated - - O
by - - O
monitoring - - O
the - - O
general - - O
electrocorticogram - - O
( - - O
ECoG - - O
) - - O
as - - O
well - - O
as - - O
local - - O
DC - - O
steady - - O
potential - - O
( - - O
two - - O
sites - - O
) - - O
. - - O

The - - O
antigen-specific - - O
IgG4 - - O
antibody - - O
seems - - O
to - - O
be - - O
an - - O
index - - O
in - - O
evaluating - - O
immunotherapy - - O
objectively - - O
. - - O

BACKGROUND - - O
: - - O
The - - O
c-myc - - O
proto-oncogene - - O
has - - O
been - - O
suggested - - O
to - - O
play - - O
key - - O
roles - - O
in - - O
cell - - O
proliferation - - O
, - - O
differentiation - - O
, - - O
transformation - - O
and - - O
apoptosis - - O
. - - O

Simultaneous - - O
, - - O
bilateral - - O
and - - O
permanent - - O
ventilation - - O
with - - O
a - - O
diaphragm - - O
pacing - - O
in - - O
childhood - - O
: - - O
the - - O
implantation - - O
technique - - O
and - - O
indications - - O
. - - O

T7 - - O
transcription - - O
could - - O
be - - O
manipulated - - O
to - - O
achieve - - O
different - - O
levels - - O
of - - O
constitutive - - O
expression - - O
, - - O
through - - O
the - - O
use - - O
of - - O
promoter - - O
mutations - - O
. - - O

Interferon - - O
beta - - O
therapy - - O
was - - O
discontinued - - O
for - - O
4 - - O
weeks - - O
. - - O

Deletion - - O
analysis - - O
indicates - - O
that - - O
TBP - - O
and - - O
hTAFII18 - - O
bind - - O
to - - O
distinct - - O
domains - - O
of - - O
hTAFII28 - - O
. - - O
hTAFII18 - - O
also - - O
interacts - - O
with - - O
TBP - - O
, - - O
but - - O
it - - O
interacts - - O
more - - O
strongly - - O
with - - O
hTAFII28 - - O
and - - O
hTAFII30 - - O
. - - O

The - - O
coding - - O
region - - O
of - - O
mkh1 - - O
is - - O
contained - - O
within - - O
a - - O
single - - O
exon - - O
encoding - - O
a - - O
1 - - O
, - - O
116-amino-acid - - O
protein - - O
. - - O

The - - O
outer - - O
diameter - - O
and - - O
the - - O
thickness - - O
of - - O
the - - O
rotor - - O
are - - O
60 - - O
mm - - O
and - - O
8 - - O
mm - - O
, - - O
respectively - - O
. - - O

Clinical - - O
research - - O
of - - O
non-A - - O
, - - O
non-B - - O
post-transfusion - - O
hepatitis - - O
. - - O

The - - O
highest - - O
postoperative - - O
CK-MB - - O
level - - O
was - - O
less - - O
after - - O
BC - - O
( - - O
BC - - O
, - - O
31 - - O
+ - - O
- - - O
17 - - O
U - - O
L - - O
; - - O
CC - - O
, - - O
56 - - O
+ - - O
- - - O
13 - - O
U - - O
L - - O
; - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

The - - O
current - - O
study - - O
defines - - O
the - - O
vinculin- - - O
and - - O
FAK-interaction - - O
domains - - O
on - - O
paxillin - - O
and - - O
identifies - - O
the - - O
principal - - O
paxillin - - O
focal - - O
adhesion - - O
targeting - - O
motif - - O
. - - O

In - - O
44 - - O
evaluable - - O
patients - - O
the - - O
response - - O
rate - - O
was - - O
50% - - O
, - - O
with - - O
one - - O
complete - - O
response - - O
. - - O

The - - O
effect - - O
of - - O
treatment - - O
may - - O
thus - - O
be - - O
divided - - O
into - - O
two - - O
main - - O
phases--an - - O
initial - - O
phase - - O
with - - O
a - - O
reduction - - O
in - - O
LV - - O
mass - - O
and - - O
a - - O
reduction - - O
in - - O
cardiac - - O
output - - O
and - - O
no - - O
change - - O
in - - O
total - - O
peripheral - - O
resistance--and - - O
a - - O
second - - O
phase - - O
with - - O
a - - O
constant - - O
LV - - O
mass - - O
but - - O
an - - O
increase - - O
in - - O
cardiac - - O
output - - O
to - - O
the - - O
pretreatment - - O
level - - O
again - - O
and - - O
a - - O
concomitant - - O
decrease - - O
in - - O
total - - O
peripheral - - O
resistance - - O
. - - O

NF-kappaB - - O
, - - O
which - - O
is - - O
probably - - O
important - - O
for - - O
basal - - O
activity - - O
of - - O
the - - O
human - - O
NOS - - O
II - - O
promoter - - O
, - - O
is - - O
unlikely - - O
to - - O
function - - O
as - - O
a - - O
major - - O
effector - - O
of - - O
CM - - O
in - - O
DLD-1 - - O
cells - - O
. - - O

A - - O
false - - O
positive - - O
marker - - O
screen - - O
was - - O
associated - - O
with - - O
the - - O
occurrence - - O
of - - O
hand-foot - - O
syndrome - - O
even - - O
when - - O
the - - O
effect - - O
of - - O
regimen - - O
was - - O
accounted - - O
for - - O
by - - O
stratification - - O
( - - O
p - - O
= - - O
. - - O
01 - - O
) - - O
. - - O

With - - O
the - - O
exception - - O
of - - O
virus - - O
assay - - O
and - - O
quantitation - - O
, - - O
these - - O
methods - - O
are - - O
simple - - O
and - - O
inexpensive - - O
enough - - O
to - - O
be - - O
done - - O
in - - O
typical - - O
shellfish - - O
microbiology - - O
laboratories - - O
. - - O

Pulmonary - - O
vascular - - O
resistance - - O
was - - O
not - - O
altered - - O
, - - O
ejection - - O
fraction - - O
remained - - O
unchanged - - O
and - - O
isovolumic - - O
relaxation - - O
period - - O
was - - O
lengthened - - O
( - - O
119 - - O
+ - - O
- - - O
20 - - O
. - - O
1 - - O
to - - O
147 - - O
. - - O
39 - - O
+ - - O
- - - O
21 - - O
. - - O
15 - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

Presently - - O
four - - O
unique - - O
variants - - O
carrying - - O
distinct - - O
GAF - - O
sequences - - O
in - - O
the - - O
N-terminal - - O
region - - O
have - - O
been - - O
identified - - O
. - - O

Through - - O
a - - O
stretch - - O
of - - O
56 - - O
amino - - O
acids - - O
, - - O
constituting - - O
the - - O
MADS - - O
domain - - O
, - - O
the - - O
two - - O
proteins - - O
are - - O
identical - - O
except - - O
for - - O
two - - O
conservative - - O
amino - - O
acid - - O
substitutions - - O
. - - O

The - - O
ability - - O
of - - O
SMRT - - O
to - - O
associate - - O
with - - O
these - - O
transcription - - O
factors - - O
and - - O
thereby - - O
to - - O
mediate - - O
repression - - O
is - - O
strongly - - O
inhibited - - O
by - - O
activation - - O
of - - O
tyrosine - - O
kinase - - O
signaling - - O
pathways - - O
, - - O
such - - O
as - - O
that - - O
represented - - O
by - - O
the - - O
epidermal - - O
growth - - O
factor - - O
receptor - - O
. - - O

Finally - - O
, - - O
we - - O
determined - - O
that - - O
the - - O
P68 - - O
amino - - O
terminus - - O
was - - O
both - - O
necessary - - O
and - - O
sufficient - - O
for - - O
binding - - O
dsRNA - - O
as - - O
we - - O
were - - O
able - - O
to - - O
transfer - - O
dsRNA-binding - - O
properties - - O
to - - O
a - - O
reporter - - O
gene - - O
product - - O
previously - - O
unable - - O
to - - O
bind - - O
RNA - - O
. - - O

METHODS - - O
: - - O
A - - O
total - - O
of - - O
15 - - O
pigs - - O
were - - O
randomised - - O
to - - O
ligation - - O
of - - O
left - - O
marginal - - O
arteries - - O
( - - O
infarction - - O
group - - O
, - - O
n - - O
= - - O
5 - - O
) - - O
, - - O
to - - O
TMLR - - O
of - - O
the - - O
left - - O
lateral - - O
wall - - O
using - - O
a - - O
holmium - - O
: - - O
yttrium-aluminium - - O
garnet - - O
( - - O
Ho - - O
: - - O
YAG - - O
) - - O
laser - - O
( - - O
laser - - O
group - - O
, - - O
n - - O
= - - O
5 - - O
) - - O
, - - O
and - - O
to - - O
both - - O
( - - O
laser-infarction - - O
group - - O
, - - O
n - - O
= - - O
5 - - O
) - - O
. - - O

Moreover - - O
, - - O
promoters - - O
containing - - O
a - - O
TATA - - O
box - - O
in - - O
the - - O
absence - - O
of - - O
Sp1 - - O
sites - - O
or - - O
Sp1 - - O
sites - - O
in - - O
the - - O
absence - - O
of - - O
a - - O
TATA - - O
box - - O
were - - O
equally - - O
inducible - - O
in - - O
vitro - - O
, - - O
as - - O
was - - O
an - - O
RNA - - O
polymerase - - O
III - - O
promoter - - O
. - - O

Further - - O
research - - O
is - - O
recommended - - O
to - - O
identify - - O
the - - O
coping - - O
styles - - O
associated - - O
with - - O
the - - O
high - - O
EE - - O
low - - O
EE - - O
research - - O
classification - - O
. - - O

Curiously - - O
, - - O
testololactone - - O
was - - O
earlier - - O
and - - O
more - - O
widely - - O
used - - O
than - - O
aminoglutethimide - - O
in - - O
treating - - O
advanced - - O
breast - - O
carcinoma - - O
. - - O

Responses - - O
to - - O
the - - O
Plowright - - O
Rinderpest - - O
vaccine - - O
by - - O
43 - - O
calves - - O
and - - O
70 - - O
adult - - O
cattle - - O
in - - O
Uganda - - O
in - - O
1990 - - O
, - - O
through - - O
the - - O
production - - O
of - - O
IgG - - O
antibodies - - O
, - - O
were - - O
monitored - - O
for - - O
4 - - O
weeks - - O
using - - O
the - - O
ELISA - - O
assay - - O
. - - O

Fifty-one - - O
patients - - O
with - - O
primary - - O
refractory - - O
or - - O
relapsed - - O
malignant - - O
lymphoma - - O
( - - O
47 - - O
non-Hodgkin's - - O
lymphoma - - O
and - - O
four - - O
Hodgkin's - - O
disease - - O
) - - O
were - - O
treated - - O
with - - O
a - - O
new - - O
chemotherapeutic - - O
regimen - - O
( - - O
cisplatinum - - O
, - - O
methyl - - O
GAG - - O
, - - O
bleomocyin - - O
, - - O
methyl - - O
prednisolon - - O
) - - O
. - - O

In - - O
addition - - O
, - - O
marked - - O
hypertension - - O
accompanied - - O
this - - O
disorder - - O
and - - O
all - - O
abnormalities - - O
, - - O
including - - O
the - - O
hypertension - - O
, - - O
responded - - O
to - - O
1-desamino-8-D-arginine - - O
vasopressin - - O
therapy - - O
. - - O

These - - O
two - - O
contigs - - O
contain - - O
a - - O
total - - O
of - - O
163 - - O
open - - O
reading - - O
frames - - O
( - - O
ORFs - - O
) - - O
in - - O
26-29 - - O
putative - - O
operons - - O
; - - O
56 - - O
ORFs - - O
could - - O
be - - O
identified - - O
with - - O
reasonable - - O
certainty - - O
. - - O

Toxicity - - O
was - - O
significant - - O
in - - O
selected - - O
cases - - O
; - - O
three - - O
patients - - O
developed - - O
WBC - - O
counts - - O
less - - O
than - - O
1 - - O
, - - O
000 - - O
mm3 - - O
and - - O
one - - O
of - - O
these - - O
patients - - O
died - - O
with - - O
sepsis - - O
. - - O

Over-expression - - O
of - - O
the - - O
cofactor - - O
p300 - - O
, - - O
which - - O
functions - - O
as - - O
a - - O
coactivator - - O
of - - O
myoD-mediated - - O
transcription - - O
, - - O
alleviated - - O
repression - - O
by - - O
COUP-TF - - O
II - - O
. - - O

Interaction - - O
of - - O
the - - O
Fur - - O
repressor - - O
with - - O
a - - O
150-bp - - O
fragment - - O
encompassing - - O
the - - O
pvdS - - O
promoter - - O
was - - O
demonstrated - - O
in - - O
vivo - - O
by - - O
the - - O
Fur - - O
titration - - O
assay - - O
and - - O
confirmed - - O
in - - O
vitro - - O
by - - O
gel - - O
retardation - - O
experiments - - O
with - - O
a - - O
partially - - O
purified - - O
Fur - - O
preparation - - O
. - - O

The - - O
selective - - O
5-HT3 - - O
receptor - - O
antagonists - - O
ramosetron - - O
( - - O
YM060 - - O
) - - O
, - - O
YM114 - - O
( - - O
KAE-393 - - O
) - - O
, - - O
granisetron - - O
and - - O
ondansetron - - O
, - - O
and - - O
the - - O
substituted - - O
benzamides - - O
( - - O
5-HT4 - - O
receptor - - O
agonist - - O
5-HT3 - - O
receptor - - O
antagonists - - O
) - - O
cisapride - - O
mosapride - - O
and - - O
SC-53116 - - O
dose-dependently - - O
enhanced - - O
gastric - - O
emptying - - O
in - - O
normal - - O
rats - - O
. - - O

IFN - - O
alpha - - O
and - - O
IFN - - O
gamma - - O
inducibility - - O
is - - O
mediated - - O
by - - O
a - - O
single - - O
element - - O
: - - O
a - - O
high - - O
affinity - - O
, - - O
nearly - - O
palindromic - - O
version - - O
of - - O
the - - O
IFN - - O
gamma - - O
activation - - O
site - - O
( - - O
GAS - - O
) - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
we - - O
characterized - - O
cis-elements - - O
of - - O
the - - O
human - - O
PCI - - O
gene - - O
required - - O
for - - O
expression - - O
in - - O
the - - O
hepatoma-derived - - O
cell - - O
line - - O
, - - O
HepG2 - - O
cells - - O
, - - O
and - - O
also - - O
evaluated - - O
rat - - O
PCI - - O
mRNA - - O
expression - - O
, - - O
particularly - - O
on - - O
the - - O
effect - - O
of - - O
androgen - - O
in - - O
rat - - O
reproductive - - O
tissues - - O
. - - O

The - - O
transcription - - O
factor - - O
CHOP - - O
( - - O
C - - O
EBP - - O
homologous - - O
protein - - O
10 - - O
) - - O
is - - O
a - - O
bZIP - - O
protein - - O
induced - - O
by - - O
a - - O
variety - - O
of - - O
stimuli - - O
that - - O
evoke - - O
cellular - - O
stress - - O
responses - - O
and - - O
has - - O
been - - O
shown - - O
to - - O
arrest - - O
cell - - O
growth - - O
and - - O
to - - O
promote - - O
programmed - - O
cell - - O
death - - O
. - - O

All - - O
ribosomal - - O
protein - - O
( - - O
rp - - O
) - - O
gene - - O
promoters - - O
from - - O
Saccharomyces - - O
cerevisiae - - O
studied - - O
so - - O
far - - O
contain - - O
either - - O
( - - O
usually - - O
two - - O
) - - O
binding - - O
sites - - O
for - - O
the - - O
global - - O
gene - - O
regulator - - O
Rap1p - - O
or - - O
one - - O
binding - - O
site - - O
for - - O
another - - O
global - - O
factor - - O
, - - O
Abf1p - - O
. - - O

Therefore - - O
, - - O
this - - O
study - - O
has - - O
demonstrated - - O
that - - O
prenatal - - O
disturbance - - O
can - - O
induce - - O
a - - O
lasting - - O
change - - O
in - - O
cytokine - - O
biology - - O
, - - O
which - - O
persists - - O
well - - O
beyond - - O
the - - O
fetal - - O
and - - O
infant - - O
stage - - O
. - - O

Seventeen - - O
of - - O
them - - O
were - - O
on - - O
treatment - - O
with - - O
systemic - - O
steroids - - O
. - - O

In - - O
contrast - - O
, - - O
c-Src - - O
activated - - O
by - - O
isoproterenol - - O
led - - O
to - - O
tyrosine - - O
phosphorylation - - O
of - - O
Shc - - O
and - - O
subsequent - - O
Erk - - O
activation - - O
, - - O
but - - O
not - - O
tyrosine - - O
phosphorylation - - O
of - - O
cortactin - - O
or - - O
Stat3 - - O
. - - O

Identity - - O
of - - O
GABP - - O
with - - O
NRF-2 - - O
, - - O
a - - O
multisubunit - - O
activator - - O
of - - O
cytochrome - - O
oxidase - - O
expression - - O
, - - O
reveals - - O
a - - O
cellular - - O
role - - O
for - - O
an - - O
ETS - - O
domain - - O
activator - - O
of - - O
viral - - O
promoters - - O
. - - O

Thus - - O
it - - O
appears - - O
that - - O
the - - O
management - - O
of - - O
blood - - O
, - - O
including - - O
washing - - O
is - - O
of - - O
great - - O
importance - - O
. - - O

In - - O
order - - O
to - - O
investigate - - O
the - - O
blood - - O
compatibility - - O
of - - O
autogenous - - O
vein - - O
graft - - O
( - - O
AVG - - O
) - - O
, - - O
changes - - O
in - - O
prostacyclin - - O
( - - O
PGI2 - - O
) - - O
production - - O
following - - O
harvesting - - O
and - - O
arterial - - O
implantation - - O
were - - O
studied - - O
experimentally - - O
. - - O

MAIN - - O
OUTCOME - - O
MEASURES - - O
: - - O
Associations - - O
of - - O
factor - - O
analysis-derived - - O
syndromes - - O
with - - O
risk - - O
factors - - O
for - - O
chemical - - O
interactions - - O
that - - O
inhibit - - O
butyrylcholinesterase - - O
and - - O
neuropathy - - O
target - - O
esterase - - O
. - - O

State - - O
of - - O
the - - O
body - - O
in - - O
disorders - - O
of - - O
diurnal - - O
physiological - - O
rhythms - - O
and - - O
long-term - - O
hypokinesia - - O
. - - O

OsBBPI - - O
was - - O
found - - O
to - - O
be - - O
rapidly - - O
induced - - O
in - - O
rice - - O
seedling - - O
leaf - - O
in - - O
response - - O
to - - O
cut - - O
, - - O
exogenous - - O
jasmonic - - O
acid - - O
( - - O
JA - - O
) - - O
, - - O
and - - O
two - - O
potent - - O
protein - - O
phosphatase - - O
2A - - O
( - - O
PP2A - - O
) - - O
inhibitors - - O
, - - O
cantharidin - - O
( - - O
CN - - O
) - - O
and - - O
endothall - - O
( - - O
EN - - O
) - - O
, - - O
in - - O
a - - O
light - - O
dark- - - O
, - - O
time- - - O
and - - O
dose-dependent - - O
manner - - O
; - - O
this - - O
induction - - O
was - - O
completely - - O
inhibited - - O
by - - O
cycloheximide - - O
( - - O
CHX - - O
) - - O
, - - O
indicating - - O
a - - O
requirement - - O
for - - O
de - - O
novo - - O
protein - - O
synthesis - - O
in - - O
its - - O
induction - - O
. - - O

Moreover - - O
, - - O
a - - O
high - - O
proportion - - O
of - - O
blood - - O
samples - - O
from - - O
a - - O
random - - O
sample - - O
of - - O
the - - O
rest - - O
of - - O
the - - O
suspects - - O
tested - - O
positive - - O
for - - O
trypanosome-specific - - O
DNA - - O
by - - O
PCR - - O
( - - O
79 - - O
. - - O
9% - - O
for - - O
T - - O
. - - O
b - - O
. - - O
gambiense - - O
and - - O
13 - - O
. - - O
9% - - O
for - - O
T - - O
. - - O
b - - O
. - - O
rhodesiense - - O
) - - O
. - - O

Mutations - - O
in - - O
the - - O
small - - O
subunit - - O
of - - O
ribulosebisphosphate - - O
carboxylase - - O
affect - - O
subunit - - O
binding - - O
and - - O
catalysis - - O
. - - O

Increased - - O
dietary - - O
energy - - O
decreased - - O
PAB - - O
and - - O
the - - O
use - - O
of - - O
added - - O
dietary - - O
CO - - O
rather - - O
than - - O
PF - - O
decreased - - O
PSHL - - O
in - - O
broiler - - O
breeders - - O
between - - O
26 - - O
and - - O
47 - - O
wk - - O
of - - O
age - - O
. - - O

Our - - O
data - - O
showed - - O
that - - O
activation - - O
of - - O
the - - O
raf-ERK - - O
pathway - - O
led - - O
to - - O
activation - - O
of - - O
TF - - O
expression - - O
in - - O
breast - - O
carcinoma - - O
cells - - O
and - - O
suggested - - O
that - - O
constitutive - - O
activation - - O
of - - O
this - - O
pathway - - O
leads - - O
to - - O
high - - O
TF - - O
expression - - O
in - - O
MDA-MB-231 - - O
cells - - O
. - - O

As - - O
expected - - O
, - - O
homologous - - O
loxP - - O
sequences - - O
efficiently - - O
underwent - - O
Cre-mediated - - O
recombination - - O
. - - O

IL-1beta - - O
was - - O
significantly - - O
higher - - O
in - - O
endometrioma - - O
than - - O
in - - O
lesions - - O
of - - O
other - - O
localizations - - O
. - - O

Evolution - - O
of - - O
lesions - - O
did - - O
not - - O
necessarily - - O
follow - - O
a - - O
regular - - O
progression - - O
through - - O
the - - O
later - - O
stages - - O
of - - O
the - - O
vitelliform - - O
classification - - O
. - - O

To - - O
get - - O
further - - O
insights - - O
into - - O
the - - O
molecular - - O
mechanisms - - O
that - - O
control - - O
tal-1 - - O
expression - - O
, - - O
we - - O
have - - O
isolated - - O
5' - - O
sequences - - O
of - - O
the - - O
murine - - O
gene - - O
and - - O
compared - - O
them - - O
to - - O
their - - O
human - - O
counterparts - - O
. - - O

Serum - - O
antibody - - O
titre - - O
was - - O
not - - O
significantly - - O
associated - - O
with - - O
the - - O
recurrence - - O
rate - - O
or - - O
the - - O
duration - - O
of - - O
infection - - O
. - - O

A - - O
series - - O
of - - O
5'-deletions - - O
revealed - - O
that - - O
the - - O
fragment - - O
-218 - - O
to - - O
+4 - - O
from - - O
the - - O
TSS - - O
had - - O
the - - O
highest - - O
promoter - - O
activity - - O
, - - O
nearly - - O
1000-fold - - O
greater - - O
than - - O
the - - O
promoterless - - O
chloramphenicol - - O
acetyltransferase - - O
construct - - O
. - - O

Areas - - O
with - - O
significantly - - O
greater - - O
rCBF - - O
for - - O
targeting - - O
were - - O
the - - O
left - - O
motor - - O
cortex - - O
, - - O
left - - O
intraparietal - - O
sulcus - - O
, - - O
and - - O
left - - O
caudate - - O
. - - O

A - - O
v-erbB-related - - O
protooncogene - - O
, - - O
c-erbB-2 - - O
, - - O
is - - O
distinct - - O
from - - O
the - - O
c-erbB-1 - - O
epidermal - - O
growth - - O
factor-receptor - - O
gene - - O
and - - O
is - - O
amplified - - O
in - - O
a - - O
human - - O
salivary - - O
gland - - O
adenocarcinoma - - O
. - - O

Finally - - O
, - - O
using - - O
in - - O
vitro - - O
binding - - O
studies - - O
, - - O
we - - O
showed - - O
that - - O
SREBP2 - - O
was - - O
able - - O
to - - O
displace - - O
ADD1 - - O
SREBP1 - - O
binding - - O
from - - O
the - - O
sterol - - O
regulatory - - O
element - - O
( - - O
SRE - - O
) - - O
site - - O
. - - O

Chronic - - O
nutritional - - O
diseases - - O
of - - O
infectious - - O
origin - - O
: - - O
an - - O
assessment - - O
of - - O
a - - O
nascent - - O
field - - O
. - - O

Isolation - - O
and - - O
characterization - - O
of - - O
the - - O
rat - - O
chromosomal - - O
gene - - O
for - - O
a - - O
polypeptide - - O
( - - O
pS1 - - O
) - - O
antigenically - - O
related - - O
to - - O
statin - - O
. - - O

Deformities - - O
of - - O
the - - O
tip - - O
of - - O
the - - O
olecranon - - O
and - - O
of - - O
the - - O
coronoid - - O
process - - O
are - - O
also - - O
described - - O
( - - O
De - - O
Palma - - O
1956 - - O
, - - O
Jordan - - O
1958 - - O
, - - O
Ahlberg - - O
1965 - - O
, - - O
Weseloh - - O
1973 - - O
) - - O
. - - O

Deletion - - O
of - - O
both - - O
prfA - - O
and - - O
ponA - - O
resulted - - O
in - - O
extremely - - O
slow - - O
growth - - O
and - - O
a - - O
reduction - - O
in - - O
sporulation - - O
efficiency - - O
. - - O

Secretion - - O
of - - O
interleukin-8 - - O
, - - O
RANTES - - O
, - - O
macrophage - - O
inflammatory - - O
protein - - O
1alpha - - O
, - - O
and - - O
10-kappaDa - - O
IFN-gamma-inducible - - O
protein - - O
were - - O
increased - - O
in - - O
differentiating - - O
keratinocytes - - O
by - - O
E6 - - O
. - - O

Stimulation - - O
of - - O
the - - O
caudate - - O
nucleus' - - O
dophamine-reactive - - O
system - - O
in - - O
dogs - - O
by - - O
means - - O
of - - O
administration - - O
of - - O
dophamine - - O
( - - O
60 - - O
micrograms - - O
) - - O
and - - O
phenamine - - O
led - - O
to - - O
deterioration - - O
of - - O
conditioned - - O
and - - O
unconditioned - - O
components - - O
of - - O
feeding - - O
behaviour - - O
. - - O

Binding - - O
to - - O
sulphatides - - O
and - - O
the - - O
alpha-dystroglycan - - O
receptor - - O
was - - O
much - - O
stronger - - O
and - - O
required - - O
at - - O
least - - O
two - - O
LG - - O
modules - - O
. - - O

The - - O
immune - - O
response - - O
of - - O
past-infection - - O
of - - O
cytomegalovirus - - O
in - - O
the - - O
patients - - O
of - - O
RTID - - O
is - - O
rather - - O
remarkable - - O
. - - O

The - - O
effect - - O
of - - O
CBZ - - O
and - - O
DPH - - O
can - - O
be - - O
explained - - O
by - - O
interference - - O
with - - O
thyroid - - O
hormone - - O
binding - - O
to - - O
TBG - - O
combined - - O
with - - O
enzyme-induced - - O
increased - - O
metabolic - - O
clearance - - O
rate - - O
of - - O
thyroid - - O
hormones - - O
without - - O
homeostatic - - O
maintenance - - O
of - - O
premedication - - O
levels - - O
of - - O
FT4 - - O
and - - O
FT3 - - O
. - - O

Reverse - - O
transcriptase - - O
and - - O
protease - - O
activities - - O
of - - O
avian - - O
leukosis - - O
virus - - O
Gag-Pol - - O
fusion - - O
proteins - - O
expressed - - O
in - - O
insect - - O
cells - - O
. - - O

Erythrocytic - - O
stages - - O
of - - O
mammalian - - O
malarial - - O
parasites - - O
contain - - O
acristate - - O
mitochondria - - O
whose - - O
functions - - O
are - - O
not - - O
well - - O
understood - - O
. - - O

New - - O
techniques - - O
for - - O
the - - O
mass - - O
spectrometry - - O
of - - O
natural - - O
products - - O
. - - O

Thromboxane - - O
B2 - - O
increased - - O
( - - O
97 - - O
+ - - O
- - - O
105 - - O
versus - - O
40 - - O
+ - - O
- - - O
26 - - O
pg - - O
ml - - O
) - - O
and - - O
was - - O
significantly - - O
higher - - O
during - - O
heparin - - O
free - - O
hemodialysis - - O
than - - O
during - - O
hemodialysis - - O
with - - O
heparin - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
01 - - O
, - - O
Wilcoxon - - O
matched - - O
pairs - - O
signed - - O
rank - - O
test - - O
) - - O
. - - O

None - - O
were - - O
restricted - - O
from - - O
clinical - - O
duties - - O
, - - O
were - - O
given - - O
varicella-zoster - - O
immune - - O
globulin - - O
, - - O
or - - O
developed - - O
disease - - O
. - - O

D - - O
. - - O

This - - O
0 - - O
. - - O
74 - - O
kb - - O
cDNA - - O
contains - - O
an - - O
open - - O
reading - - O
frame - - O
( - - O
ORF - - O
) - - O
of - - O
477 - - O
bp - - O
encoding - - O
a - - O
polypeptide - - O
of - - O
159 - - O
amino - - O
acids - - O
( - - O
aa - - O
) - - O
which - - O
differs - - O
at - - O
only - - O
one - - O
position - - O
( - - O
position - - O
65 - - O
) - - O
from - - O
the - - O
human - - O
U1-C - - O
protein - - O
. - - O

Our - - O
results - - O
demonstrated - - O
that - - O
50% - - O
of - - O
the - - O
hepatic - - O
artery-alone - - O
ALT - - O
graft - - O
showed - - O
almost - - O
normal - - O
structure - - O
histologically - - O
at - - O
1 - - O
month - - O
after - - O
grafting - - O
, - - O
with - - O
bile - - O
secretion - - O
preserved - - O
. - - O

Human - - O
bcl3 - - O
protein - - O
specifically - - O
displaces - - O
( - - O
p50 - - O
) - - O
2-DNA - - O
complexes - - O
. - - O

Observations - - O
on - - O
saccules - - O
of - - O
rats - - O
exposed - - O
to - - O
long-term - - O
hypergravity - - O
. - - O

Videonystagmoscopy - - O
has - - O
been - - O
used - - O
to - - O
subjectively - - O
observe - - O
the - - O
responses - - O
of - - O
the - - O
vestibular - - O
system - - O
in - - O
a - - O
population - - O
of - - O
patients - - O
with - - O
vestibular - - O
deficits - - O
. - - O

In - - O
conclusion - - O
, - - O
these - - O
studies - - O
indicate - - O
that - - O
LiCl - - O
( - - O
1 - - O
) - - O
decreases - - O
histamine-stimulated - - O
gastric - - O
acid - - O
secretion - - O
, - - O
and - - O
( - - O
2 - - O
) - - O
diminishes - - O
bile-induced - - O
disruption - - O
of - - O
the - - O
gastric - - O
mucosal - - O
barrier - - O
in - - O
the - - O
canine - - O
Heidenhain - - O
pouch - - O
. - - O

We - - O
have - - O
previously - - O
reported - - O
that - - O
high - - O
level - - O
human - - O
desmin - - O
expression - - O
depends - - O
on - - O
a - - O
280-base - - O
pair - - O
muscle-specific - - O
enhancer - - O
which - - O
can - - O
function - - O
not - - O
only - - O
in - - O
myotubes - - O
, - - O
but - - O
can - - O
also - - O
activate - - O
gene - - O
expression - - O
in - - O
myoblasts - - O
. - - O

Treatment - - O
of - - O
human - - O
myeloid - - O
cell - - O
lines - - O
HL-60 - - O
and - - O
U937 - - O
with - - O
phorbol - - O
12-myristate - - O
13-acetate - - O
( - - O
PMA - - O
) - - O
increased - - O
within - - O
2 - - O
h - - O
cellular - - O
levels - - O
of - - O
the - - O
RNA - - O
hybridizable - - O
to - - O
LD78 - - O
cDNA - - O
. - - O

Analysis - - O
of - - O
intron - - O
exon - - O
boundaries - - O
of - - O
the - - O
genomic - - O
BAC - - O
clones - - O
demonstrate - - O
that - - O
junctin - - O
, - - O
junctate - - O
, - - O
and - - O
aspartyl - - O
beta-hydroxylase - - O
result - - O
from - - O
alternative - - O
splicing - - O
of - - O
the - - O
same - - O
gene - - O
. - - O

We - - O
have - - O
examined - - O
the - - O
regulation - - O
of - - O
the - - O
FGFR-1 - - O
gene - - O
( - - O
cek-1 - - O
) - - O
in - - O
avian - - O
myogenic - - O
cultures - - O
by - - O
immunocytochemistry - - O
and - - O
Northern - - O
blot - - O
analysis - - O
. - - O

A - - O
low - - O
aspirin - - O
esterase - - O
activity - - O
may - - O
be - - O
a - - O
contributory - - O
factor - - O
in - - O
precipitating - - O
these - - O
aspirin - - O
sensitive - - O
reactions - - O
. - - O

On - - O
the - - O
character - - O
of - - O
changes - - O
in - - O
the - - O
enzyme - - O
activity - - O
in - - O
the - - O
brain - - O
tissue - - O
during - - O
reflex - - O
epilepsy - - O
. - - O

Localized - - O
fluorescence - - O
was - - O
detectable - - O
only - - O
in - - O
cells - - O
containing - - O
a - - O
visible - - O
midcell - - O
constriction - - O
, - - O
suggesting - - O
that - - O
FtsK - - O
targeting - - O
normally - - O
occurs - - O
only - - O
at - - O
a - - O
late - - O
stage - - O
of - - O
septation - - O
. - - O

The - - O
NarX - - O
and - - O
NarQ - - O
proteins - - O
with - - O
amino - - O
acid - - O
substitutions - - O
at - - O
the - - O
first - - O
conserved - - O
histidine - - O
position - - O
were - - O
also - - O
unable - - O
to - - O
dephosphorylate - - O
NarL-phosphate - - O
in - - O
vitro - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Chloramphenicol - - O
acetyltransferase - - O
assays - - O
examining - - O
the - - O
ability - - O
of - - O
IE86 - - O
to - - O
repress - - O
activity - - O
from - - O
the - - O
HCMV - - O
major - - O
IE - - O
promoter - - O
or - - O
activate - - O
the - - O
HCMV - - O
early - - O
promoter - - O
for - - O
the - - O
2 - - O
. - - O
2-kb - - O
class - - O
of - - O
RNAs - - O
demonstrated - - O
the - - O
functional - - O
integrity - - O
of - - O
the - - O
IE86 - - O
protein - - O
. - - O

Piroximone - - O
is - - O
a - - O
new - - O
phosphodiesterase - - O
III - - O
inhibitor - - O
that - - O
combines - - O
inotropic - - O
and - - O
vasodilator - - O
properties - - O
. - - O

This - - O
enzyme - - O
is - - O
designated - - O
( - - O
1-- - - O
> - - O
4 - - O
) - - O
-beta-xylan - - O
endohydrolase - - O
isoenzyme - - O
X-I - - O
. - - O

Because - - O
the - - O
number - - O
of - - O
parameters - - O
required - - O
by - - O
a - - O
Volterra - - O
series - - O
grows - - O
rapidly - - O
with - - O
both - - O
the - - O
length - - O
of - - O
its - - O
memory - - O
and - - O
the - - O
order - - O
of - - O
its - - O
nonlinearity - - O
, - - O
methods - - O
for - - O
identifying - - O
these - - O
models - - O
from - - O
measurements - - O
of - - O
input - - O
output - - O
data - - O
are - - O
limited - - O
to - - O
low-order - - O
systems - - O
with - - O
relatively - - O
short - - O
memories - - O
. - - O

In - - O
macrophages - - O
, - - O
LPS-inducible - - O
HIV-1 - - O
gene - - O
expression - - O
is - - O
mediated - - O
in - - O
part - - O
by - - O
binding - - O
of - - O
NF-kappa - - O
B - - O
to - - O
identical - - O
tandem - - O
binding - - O
sites - - O
located - - O
within - - O
the - - O
long - - O
terminal - - O
repeat - - O
( - - O
LTR - - O
) - - O
. - - O

Both - - O
normal - - O
and - - O
transforming - - O
PCPH - - O
proteins - - O
have - - O
guanosine - - O
diphosphatase - - O
activity - - O
but - - O
only - - O
the - - O
oncoprotein - - O
cooperates - - O
with - - O
Ras - - O
in - - O
activating - - O
extracellular - - O
signal-regulated - - O
kinase - - O
ERK1 - - O
. - - O

New - - O
Langevin - - O
equations - - O
for - - O
a - - O
translating - - O
and - - O
simultaneously - - O
rotating - - O
asymmetric - - O
top - - O
. - - O

The - - O
early - - O
dg - - O
. - - O
of - - O
rejection - - O
and - - O
especially - - O
acute - - O
rejection - - O
, - - O
it's - - O
adequate - - O
management - - O
, - - O
decreased - - O
risk - - O
for - - O
the - - O
future - - O
chronic - - O
rejection - - O
nephropathy - - O
. - - O

Improvement - - O
of - - O
the - - O
CRT - - O
display - - O
of - - O
an - - O
averager - - O
. - - O

The - - O
half-life - - O
of - - O
the - - O
serum-induced - - O
CBP - - O
tk - - O
binding - - O
activity - - O
was - - O
estimated - - O
to - - O
be - - O
less - - O
than - - O
1 - - O
h - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
400 - - O
WORDS - - O
) - - O

Seventy-two - - O
of - - O
73 - - O
negative - - O
controls - - O
and - - O
all - - O
positive - - O
blocks - - O
as - - O
seen - - O
on - - O
soft - - O
tissue - - O
radiographs - - O
( - - O
STRs - - O
) - - O
were - - O
correctly - - O
coded - - O
( - - O
specificity - - O
98 - - O
. - - O
6% - - O
, - - O
sensitivity - - O
100% - - O
) - - O
. - - O

The - - O
method - - O
requires - - O
a - - O
reversed-phase - - O
column - - O
and - - O
a - - O
paired-ion - - O
technique - - O
to - - O
separate - - O
docusate - - O
sodium - - O
from - - O
other - - O
components - - O
. - - O

This - - O
study - - O
was - - O
aimed - - O
at - - O
assessing - - O
whether - - O
c-DDP - - O
administration - - O
immediately - - O
before - - O
radiotherapy - - O
could - - O
increase - - O
frequency - - O
and - - O
duration - - O
of - - O
objective - - O
responses - - O
, - - O
as - - O
well - - O
as - - O
survival - - O
, - - O
in - - O
patients - - O
affected - - O
with - - O
locally - - O
advanced - - O
stages - - O
of - - O
squamous - - O
carcinomas - - O
of - - O
the - - O
head - - O
and - - O
neck - - O
. - - O

Chem - - O
. - - O

In - - O
contrast - - O
, - - O
in - - O
LL - - O
patients - - O
during - - O
ENL - - O
the - - O
ConA-induced - - O
suppressor - - O
response - - O
was - - O
markedly - - O
reduced - - O
. - - O

In - - O
contrast - - O
, - - O
cotransfection - - O
of - - O
TFIIB - - O
and - - O
IRF-1 - - O
into - - O
NIH - - O
3T3 - - O
cells - - O
resulted - - O
in - - O
a - - O
dose-dependent - - O
repression - - O
of - - O
promoter - - O
activation - - O
which - - O
occurred - - O
in - - O
a - - O
TATA-dependent - - O
manner - - O
. - - O

Fetal - - O
lung - - O
volume - - O
: - - O
estimation - - O
at - - O
MR - - O
imaging-initial - - O
results - - O
. - - O

It - - O
contains - - O
three - - O
putative - - O
binding - - O
sites - - O
for - - O
transcription - - O
factor - - O
Sp1 - - O
as - - O
well - - O
as - - O
several - - O
short - - O
sequences - - O
that - - O
are - - O
similar - - O
to - - O
known - - O
cis-acting - - O
enhancers - - O
or - - O
binding - - O
sites - - O
for - - O
transcription - - O
factors - - O
. - - O

Thus - - O
, - - O
the - - O
system - - O
can - - O
be - - O
used - - O
to - - O
detect - - O
and - - O
study - - O
dynamic - - O
perfusion - - O
changes - - O
from - - O
the - - O
brain - - O
surface - - O
with - - O
minimal - - O
tissue - - O
damage - - O
. - - O

No - - O
'TATA' - - O
motif - - O
was - - O
identified - - O
near - - O
either - - O
the - - O
GABPalpha - - O
or - - O
ATPsynCF6 - - O
transcription - - O
start - - O
sites - - O
. - - O

Addition - - O
of - - O
soluble - - O
recombinant - - O
human - - O
SLF - - O
to - - O
SI4-h220 - - O
cultures - - O
enhanced - - O
reduction - - O
of - - O
cell-surface - - O
c-kit - - O
expression - - O
and - - O
its - - O
protein - - O
degradation - - O
. - - O

Transcription - - O
factors - - O
containing - - O
a - - O
basic - - O
helix-loop-helix - - O
( - - O
bHLH - - O
) - - O
motif - - O
regulate - - O
the - - O
expression - - O
of - - O
tissue-specific - - O
genes - - O
in - - O
a - - O
number - - O
of - - O
mammalian - - O
and - - O
insect - - O
systems - - O
. - - O

Also - - O
, - - O
transient - - O
overexpression - - O
of - - O
this - - O
protein - - O
in - - O
C2C12 - - O
cells - - O
reduced - - O
the - - O
transcription - - O
of - - O
a - - O
CAT-reporter - - O
regulated - - O
by - - O
an - - O
E12 - - O
MyoD - - O
driven - - O
enhancer - - O
. - - O

Two - - O
patients - - O
were - - O
treated - - O
with - - O
both - - O
regimens - - O
. - - O

271 - - O
: - - O
31290-31295 - - O
, - - O
1996 - - O
) - - O
. - - O

A - - O
1 - - O
. - - O
8-kb - - O
cDNA - - O
clone - - O
( - - O
designed - - O
hKID - - O
, - - O
gene - - O
symbol - - O
AQP2L - - O
) - - O
with - - O
homology - - O
to - - O
the - - O
aquaporins - - O
was - - O
isolated - - O
from - - O
a - - O
human - - O
kidney - - O
cDNA - - O
library - - O
. - - O

The - - O
Lm - - O
increased - - O
and - - O
the - - O
alveoli - - O
mm2 - - O
and - - O
elastic - - O
recoil - - O
pressure - - O
decreased - - O
. - - O

Serum-ferritin - - O
in - - O
diagnosis - - O
of - - O
haemochromatosis - - O
. - - O

Comparison - - O
of - - O
1 - - O
. - - O
5 - - O
Tesla - - O
and - - O
0 - - O
. - - O
35 - - O
Tesla - - O
field - - O
strength - - O
magnetic - - O
resonance - - O
imaging - - O
scans - - O
in - - O
the - - O
morphometric - - O
evaluation - - O
of - - O
the - - O
lumbar - - O
intervertebral - - O
foramina - - O
. - - O

Plasmid - - O
pAL618 - - O
contains - - O
the - - O
genetic - - O
determinants - - O
for - - O
H2 - - O
uptake - - O
( - - O
hup - - O
) - - O
from - - O
Rhizobium - - O
leguminosarum - - O
bv - - O
. - - O
viciae - - O
, - - O
including - - O
a - - O
cluster - - O
of - - O
17 - - O
genes - - O
named - - O
hupSLCDEFGHIJK-hypABFCDE - - O
. - - O

Chronic - - O
endotoxemia - - O
appears - - O
to - - O
be - - O
associated - - O
with - - O
an - - O
elevated - - O
pulmonary - - O
microvascular - - O
permeability - - O
and - - O
a - - O
tendency - - O
toward - - O
a - - O
hyperdynamic - - O
circulation - - O
but - - O
with - - O
an - - O
appreciable - - O
degree - - O
of - - O
refractoriness - - O
associated - - O
with - - O
regional - - O
hemodynamics - - O
and - - O
eicosanoid - - O
biosynthesis - - O
. - - O

These - - O
rearrangements - - O
result - - O
in - - O
the - - O
formation - - O
of - - O
chimeric - - O
genes - - O
showing - - O
the - - O
tyrosine - - O
kinase - - O
domain - - O
of - - O
ret - - O
fused - - O
with - - O
the - - O
5' - - O
end - - O
sequences - - O
of - - O
different - - O
genes - - O
. - - O

The - - O
TATA - - O
box-binding - - O
protein - - O
( - - O
TBP - - O
) - - O
plays - - O
an - - O
essential - - O
role - - O
in - - O
transcription - - O
by - - O
all - - O
three - - O
eukaryotic - - O
nuclear - - O
RNA - - O
polymerases - - O
, - - O
polymerases - - O
( - - O
Pol - - O
) - - O
I - - O
, - - O
II - - O
, - - O
and - - O
III - - O
. - - O

Mutation - - O
of - - O
nucleotides - - O
adjacent - - O
to - - O
the - - O
AP-1 - - O
cis-response - - O
elements - - O
had - - O
no - - O
effect - - O
on - - O
trans-activation - - O
. - - O

Endurance - - O
training - - O
resulted - - O
in - - O
an - - O
increase - - O
of - - O
stiffness - - O
associated - - O
with - - O
a - - O
decrease - - O
of - - O
type - - O
II - - O
fibers - - O
. - - O

Dual - - O
innervation - - O
of - - O
fast - - O
fibers - - O
in - - O
trunk - - O
muscles - - O
of - - O
lamprey - - O
larvae - - O
. - - O

Mucolipidosis - - O
type - - O
IV - - O
: - - O
clinical - - O
spectrum - - O
and - - O
natural - - O
history - - O
. - - O

At - - O
necropsy - - O
28 - - O
days - - O
post-inoculation - - O
, - - O
F344 - - O
rats - - O
had - - O
no - - O
gross - - O
lung - - O
lesions - - O
, - - O
even - - O
those - - O
given - - O
the - - O
maximum - - O
dose - - O
of - - O
1 - - O
. - - O
4 - - O
X - - O
10 - - O
( - - O
9 - - O
) - - O
colony-forming - - O
units - - O
of - - O
M - - O
. - - O
pulmonis - - O
. - - O

The - - O
Epstein-Barr - - O
virus - - O
transactivator - - O
Zta - - O
triggers - - O
lytic - - O
gene - - O
expression - - O
and - - O
is - - O
essential - - O
for - - O
replication - - O
of - - O
the - - O
lytic - - O
origin - - O
, - - O
oriLyt - - O
. - - O

Simple - - O
reaction - - O
time - - O
( - - O
RT - - O
) - - O
to - - O
a - - O
peripheral - - O
visual - - O
target - - O
( - - O
S2 - - O
) - - O
is - - O
shortened - - O
when - - O
a - - O
non-informative - - O
cue - - O
( - - O
S1 - - O
) - - O
is - - O
flashed - - O
at - - O
the - - O
S2 - - O
location - - O
100-150 - - O
ms - - O
before - - O
target - - O
onset - - O
( - - O
early - - O
facilitation - - O
) - - O
. - - O

We - - O
have - - O
determined - - O
the - - O
molecular - - O
lesions - - O
of - - O
nine - - O
Scm - - O
mutant - - O
alleles - - O
, - - O
which - - O
identify - - O
functional - - O
requirements - - O
for - - O
specific - - O
domains - - O
. - - O

MATERIAL - - O
AND - - O
METHODS - - O
: - - O
Of - - O
the - - O
17 - - O
men - - O
and - - O
17 - - O
women - - O
, - - O
who - - O
were - - O
21 - - O
to - - O
80 - - O
years - - O
of - - O
age - - O
, - - O
27 - - O
had - - O
hereditary - - O
motor - - O
and - - O
sensory - - O
neuropathy - - O
type - - O
I - - O
and - - O
7 - - O
had - - O
acquired - - O
demyelinating - - O
polyneuropathy - - O
. - - O

Anti-B - - O
. - - O
burgdorferi - - O
, - - O
anti-B - - O
. - - O
turicatae - - O
and - - O
anti-B - - O
. - - O
parkeri - - O
antibodies - - O
, - - O
tested - - O
by - - O
the - - O
indirect - - O
immunofluorescent - - O
assay - - O
( - - O
IFA - - O
) - - O
, - - O
were - - O
detected - - O
in - - O
10 - - O
. - - O
8 - - O
, - - O
16 - - O
. - - O
1 - - O
and - - O
8 - - O
. - - O
2% - - O
of - - O
the - - O
serum - - O
samples - - O
tested - - O
, - - O
and - - O
confirmed - - O
by - - O
IFA-ABS - - O
in - - O
1 - - O
. - - O
3 - - O
, - - O
1 - - O
. - - O
3 - - O
and - - O
1 - - O
. - - O
0% - - O
, - - O
respectively - - O
. - - O

Tobramycin - - O
60 - - O
mg - - O
did - - O
not - - O
show - - O
any - - O
remarkable - - O
effect - - O
, - - O
but - - O
dibecacin - - O
100 - - O
mg - - O
produced - - O
a - - O
slight - - O
potentiating - - O
effect - - O
on - - O
the - - O
action - - O
of - - O
d-tubocurarine - - O
. - - O

Ventricular - - O
volume - - O
stiffness - - O
vs - - O
. - - O
the - - O
mean - - O
wall - - O
stress - - O
relationship - - O
of - - O
LVH - - O
shifted - - O
upward - - O
, - - O
whereas - - O
the - - O
normalized - - O
wall - - O
muscle - - O
stiffness - - O
vs - - O
. - - O
the - - O
mean - - O
wall - - O
stress - - O
relationship - - O
of - - O
LVH - - O
showed - - O
a - - O
smaller - - O
slope - - O
. - - O

OBJECTIVE - - O
: - - O
1998 - - O
Surveillance - - O
, - - O
Epidemiology - - O
, - - O
and - - O
End - - O
Results - - O
( - - O
SEER - - O
) - - O
data - - O
estimate - - O
an - - O
83 - - O
. - - O
1% - - O
5-year - - O
survival - - O
rate - - O
for - - O
corpus - - O
uteri - - O
adenocarcinoma - - O
FIGO - - O
stage - - O
II - - O
. - - O

Intron - - O
K1 - - O
cox1 - - O
. - - O
2 - - O
is - - O
not - - O
found - - O
in - - O
S - - O
. - - O
cerevisiae - - O
and - - O
appears - - O
at - - O
an - - O
unique - - O
location - - O
in - - O
K - - O
. - - O
lactis - - O
. - - O

In - - O
B - - O
cells - - O
, - - O
HEF1 - - O
is - - O
phosphorylated - - O
by - - O
a - - O
cytoskeleton-dependent - - O
mechanism - - O
that - - O
is - - O
triggered - - O
by - - O
integrin - - O
ligation - - O
. - - O

Attenuation - - O
from - - O
the - - O
vit - - O
A2 - - O
consensus - - O
ERE - - O
is - - O
not - - O
necessarily - - O
dependent - - O
on - - O
DNA - - O
binding - - O
as - - O
the - - O
TR - - O
alpha - - O
DNA - - O
binding - - O
mutant - - O
was - - O
still - - O
able - - O
to - - O
inhibit - - O
E-dependent - - O
transactivation - - O
. - - O

We - - O
conclude - - O
that - - O
this - - O
new - - O
measurement - - O
technique - - O
provides - - O
an - - O
easy - - O
and - - O
accurate - - O
P0 - - O
. - - O
1 - - O
measurement - - O
using - - O
standard - - O
respiratory - - O
equipment - - O
when - - O
tested - - O
in - - O
a - - O
lung - - O
model - - O
. - - O

The - - O
data - - O
indicate - - O
that - - O
the - - O
minimal - - O
catalytic - - O
domain - - O
of - - O
Nmt1p - - O
is - - O
located - - O
between - - O
Ile59-- - - O
> - - O
Phe96 - - O
and - - O
Gly451-- - - O
> - - O
Leu455 - - O
. - - O

This - - O
family - - O
of - - O
proteins - - O
binds - - O
GC-rich - - O
motifs - - O
widely - - O
distributed - - O
in - - O
gene - - O
promoters - - O
, - - O
resulting - - O
in - - O
distinct - - O
activation - - O
or - - O
repression - - O
of - - O
transcriptional - - O
activities - - O
. - - O

Rare - - O
neurogenic - - O
tumor - - O
with - - O
metastasis - - O
to - - O
mouth - - O
, - - O
jaw - - O
and - - O
face - - O
regions - - O
. - - O

Studies - - O
using - - O
an - - O
inhibitor - - O
or - - O
a - - O
mutant - - O
Lb - - O
proteinase - - O
indicated - - O
that - - O
stimulation - - O
of - - O
IRES-driven - - O
translation - - O
is - - O
mediated - - O
via - - O
proteolysis - - O
of - - O
some - - O
cellular - - O
component - - O
( - - O
s - - O
) - - O
. - - O

The - - O
subjects - - O
were - - O
diagnosed - - O
on - - O
the - - O
basis - - O
of - - O
DSM-IV - - O
pathological - - O
gambling - - O
criteria - - O
and - - O
completed - - O
the - - O
Turkish - - O
Version - - O
of - - O
South - - O
Oaks - - O
Gambling - - O
Screen - - O
( - - O
SOGS - - O
) - - O
. - - O

The - - O
newly - - O
defined - - O
region - - O
contains - - O
an - - O
intron - - O
that - - O
may - - O
be - - O
alternatively - - O
spliced - - O
and - - O
seven - - O
polyadenylation - - O
signal - - O
sequences - - O
. - - O

The - - O
psaD - - O
, - - O
psaF - - O
, - - O
psaH - - O
, - - O
and - - O
psaL - - O
products - - O
have - - O
two - - O
isoforms - - O
each - - O
that - - O
are - - O
distinguished - - O
by - - O
different - - O
mobilities - - O
in - - O
polyacrylamide - - O
gel - - O
electrophoresis - - O
, - - O
and - - O
the - - O
psaE - - O
product - - O
has - - O
four - - O
isoforms - - O
. - - O

Fans - - O
in - - O
tunnels - - O
and - - O
open - - O
windows - - O
at - - O
aboveground - - O
locations - - O
appeared - - O
to - - O
greatly - - O
reduce - - O
the - - O
likelihood - - O
of - - O
high - - O
PH3 - - O
concentrations - - O
in - - O
enclosed - - O
areas - - O
. - - O

These - - O
well-characterized - - O
brain - - O
regions - - O
may - - O
provide - - O
a - - O
basis - - O
for - - O
future - - O
studies - - O
of - - O
RPTP-kappa - - O
function - - O
. - - O

The - - O
crystal - - O
structure - - O
of - - O
the - - O
VP16 - - O
core - - O
has - - O
been - - O
determined - - O
at - - O
2 - - O
. - - O
1 - - O
A - - O
resolution - - O
. - - O

A - - O
sequence - - O
representing - - O
about - - O
50% - - O
of - - O
the - - O
expected - - O
complete - - O
sequence - - O
was - - O
obtained - - O
by - - O
translation - - O
of - - O
the - - O
two - - O
open - - O
reading - - O
frames - - O
present - - O
on - - O
a - - O
1 - - O
. - - O
6 - - O
kb - - O
DNA - - O
genomic - - O
fragment - - O
. - - O

Drosophila - - O
UbcD1 - - O
encodes - - O
a - - O
highly - - O
conserved - - O
ubiquitin-conjugating - - O
enzyme - - O
involved - - O
in - - O
selective - - O
protein - - O
degradation - - O
. - - O

In - - O
vitro - - O
expression - - O
of - - O
four - - O
different - - O
naturally - - O
occurring - - O
nonsense - - O
and - - O
missense - - O
mutations - - O
revealed - - O
a - - O
dramatically - - O
altered - - O
subcellular - - O
location - - O
of - - O
the - - O
protein - - O
in - - O
cultured - - O
cells - - O
. - - O

Five - - O
of - - O
these - - O
eight - - O
patients - - O
in - - O
group - - O
II - - O
also - - O
received - - O
8-in-1 - - O
chemotherapy - - O
. - - O

What - - O
young - - O
people - - O
think - - O
and - - O
do - - O
when - - O
the - - O
option - - O
for - - O
cystic - - O
fibrosis - - O
carrier - - O
testing - - O
is - - O
available - - O
. - - O

The - - O
controversy - - O
of - - O
significance - - O
testing - - O
: - - O
misconceptions - - O
and - - O
alternatives - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
the - - O
p33 - - O
subunit - - O
of - - O
eIF3 - - O
plays - - O
an - - O
important - - O
role - - O
in - - O
the - - O
initiation - - O
phase - - O
of - - O
protein - - O
synthesis - - O
and - - O
that - - O
its - - O
RNA-binding - - O
domain - - O
is - - O
required - - O
for - - O
optimal - - O
activity - - O
. - - O

It - - O
has - - O
been - - O
shown - - O
in - - O
experiments - - O
in - - O
vitro - - O
that - - O
the - - O
hepatotrophic - - O
organic - - O
anions - - O
, - - O
the - - O
radiographic - - O
contrast - - O
agent - - O
( - - O
RCA - - O
) - - O
bilignost - - O
used - - O
in - - O
cholecystography - - O
and - - O
Bengal - - O
pink - - O
, - - O
have - - O
an - - O
affinity - - O
, - - O
unlike - - O
the - - O
urographic - - O
RCA - - O
triombrin - - O
and - - O
renotrophic - - O
dye - - O
indigo-carmine - - O
, - - O
for - - O
the - - O
plasmatic - - O
membranes - - O
( - - O
PM - - O
) - - O
of - - O
liver - - O
cells - - O
. - - O

The - - O
alpha - - O
7A - - O
form - - O
RNA - - O
contains - - O
an - - O
additional - - O
113 - - O
nucleotides - - O
compared - - O
to - - O
the - - O
B - - O
form - - O
, - - O
and - - O
a - - O
common - - O
coding - - O
region - - O
in - - O
the - - O
A - - O
and - - O
B - - O
form - - O
RNAs - - O
is - - O
used - - O
in - - O
alternate - - O
reading - - O
frames - - O
. - - O

The - - O
across-fiber - - O
pattern - - O
of - - O
the - - O
responses - - O
to - - O
hypotonic - - O
NaCl - - O
solutions - - O
correlated - - O
strongly - - O
to - - O
that - - O
elicited - - O
by - - O
distilled - - O
H2O - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
400 - - O
WORDS - - O
) - - O

A - - O
Bub2p-dependent - - O
spindle - - O
checkpoint - - O
pathway - - O
regulates - - O
the - - O
Dbf2p - - O
kinase - - O
in - - O
budding - - O
yeast - - O
. - - O

All - - O
six - - O
ARF - - O
cDNAs - - O
are - - O
more - - O
similar - - O
to - - O
each - - O
other - - O
than - - O
to - - O
other - - O
approximately - - O
20-kDa - - O
guanine - - O
nucleotide-binding - - O
proteins - - O
. - - O

We - - O
have - - O
subcloned - - O
into - - O
pBR322 - - O
deoxyribonucleic - - O
acid - - O
( - - O
DNA - - O
) - - O
sequences - - O
mapping - - O
either - - O
in - - O
the - - O
coding - - O
region - - O
, - - O
the - - O
5' - - O
spacer - - O
, - - O
or - - O
the - - O
3' - - O
spacer - - O
of - - O
the - - O
H2B - - O
histone - - O
gene - - O
. - - O

The - - O
rrd1 - - O
, - - O
2delta - - O
mutant - - O
was - - O
partially - - O
rescued - - O
by - - O
inactivation - - O
of - - O
HOG1 - - O
or - - O
PBS2 - - O
, - - O
suggesting - - O
an - - O
interaction - - O
between - - O
the - - O
RRD - - O
genes - - O
and - - O
the - - O
Hog1p - - O
signal - - O
transduction - - O
pathway - - O
. - - O

Oscilloscope - - O
triggering - - O
circuit - - O
for - - O
recording - - O
long - - O
transients - - O
at - - O
fast - - O
sweep - - O
speeds - - O
. - - O

The - - O
negative - - O
predictive - - O
value - - O
is - - O
92% - - O
, - - O
vs - - O
80% - - O
for - - O
the - - O
NCEP - - O
I - - O
. - - O

The - - O
matrix - - O
surrounding - - O
the - - O
clusters - - O
either - - O
showed - - O
a - - O
normal - - O
morphology - - O
or - - O
a - - O
homogeneous - - O
appearance - - O
, - - O
within - - O
which - - O
faint - - O
cross - - O
striations - - O
but - - O
no - - O
distinctly - - O
fibrillar - - O
outlines - - O
could - - O
be - - O
identified - - O
. - - O

The - - O
muskox - - O
is - - O
a - - O
new - - O
host - - O
record - - O
for - - O
T - - O
. - - O
gondii - - O
. - - O

The - - O
patient's - - O
role - - O
, - - O
organized - - O
by - - O
the - - O
prerequisites - - O
of - - O
expressive - - O
freedom - - O
, - - O
is - - O
counter - - O
posed - - O
with - - O
the - - O
psychoanalyst's - - O
, - - O
which - - O
is - - O
structured - - O
to - - O
empower - - O
listening - - O
and - - O
understanding - - O
. - - O

Fas-resistant - - O
DT-40 - - O
lymphoma - - O
B-cells - - O
rendered - - O
BTK-deficient - - O
through - - O
targeted - - O
disruption - - O
of - - O
the - - O
btk - - O
gene - - O
by - - O
homologous - - O
recombination - - O
knockout - - O
underwent - - O
apoptosis - - O
after - - O
Fas - - O
ligation - - O
, - - O
but - - O
wild-type - - O
DT-40 - - O
cells - - O
or - - O
BTK-deficient - - O
DT-40 - - O
cells - - O
reconstituted - - O
with - - O
wild-type - - O
human - - O
btk - - O
gene - - O
did - - O
not - - O
. - - O

Immunoreactive - - O
AR - - O
content - - O
in - - O
transfected - - O
COS-1 - - O
cells - - O
was - - O
not - - O
influenced - - O
by - - O
exposure - - O
to - - O
8-Br-cAMP - - O
. - - O

Erythrocyte - - O
protoporphyrin - - O
concentration - - O
increased - - O
significantly - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
05 - - O
) - - O
by - - O
14 - - O
days - - O
in - - O
dogs - - O
fed - - O
the - - O
basal - - O
diet - - O
, - - O
and - - O
remained - - O
significantly - - O
high - - O
relative - - O
to - - O
that - - O
in - - O
dogs - - O
of - - O
the - - O
other - - O
dietary - - O
groups - - O
for - - O
the - - O
remainder - - O
of - - O
the - - O
study - - O
. - - O

A - - O
case - - O
of - - O
Goodpasture's - - O
syndrome - - O
. - - O

RXR-gamma - - O
expression - - O
produced - - O
significant - - O
reduction - - O
in - - O
levels - - O
of - - O
RA-responsive - - O
genes - - O
including - - O
the - - O
cyclin-dependent - - O
kinase - - O
inhibitors - - O
p21Cip1 - - O
WAF1 - - O
and - - O
p27Kip1 - - O
, - - O
resulting - - O
in - - O
increased - - O
cdc2 - - O
and - - O
cdk2 - - O
kinase - - O
activity - - O
and - - O
RB - - O
phosphorylation - - O
. - - O

Lower - - O
limits - - O
( - - O
to - - O
10 - - O
micrograms - - O
kg - - O
) - - O
were - - O
detectable - - O
, - - O
but - - O
with - - O
lower - - O
reliability - - O
( - - O
60% - - O
) - - O
. - - O

Insulin-like - - O
growth - - O
factor - - O
II - - O
( - - O
IGFII - - O
) - - O
is - - O
a - - O
mitogenic - - O
polypeptide - - O
, - - O
the - - O
mRNAs - - O
of - - O
which - - O
are - - O
present - - O
in - - O
multiple - - O
forms - - O
, - - O
despite - - O
derivation - - O
from - - O
a - - O
single - - O
gene - - O
. - - O

The - - O
more - - O
traditional - - O
SERMS - - O
, - - O
clomiphene - - O
citrate - - O
and - - O
tamoxifen - - O
, - - O
will - - O
be - - O
reviewed - - O
along - - O
with - - O
such - - O
modern - - O
drugs - - O
as - - O
raloxifene - - O
and - - O
faslodex - - O
, - - O
with - - O
emphasis - - O
upon - - O
their - - O
actions - - O
on - - O
breast - - O
, - - O
uterus - - O
, - - O
bone - - O
and - - O
lipids - - O
. - - O

We - - O
have - - O
cloned - - O
cDNA - - O
and - - O
genomic - - O
DNA - - O
for - - O
a - - O
mouse - - O
gene - - O
encoding - - O
a - - O
protein - - O
with - - O
significant - - O
sequence - - O
similarity - - O
to - - O
conserved - - O
domains - - O
found - - O
in - - O
proteins - - O
of - - O
the - - O
Spo11p - - O
family - - O
. - - O

If - - O
E - - O
. - - O
coli - - O
is - - O
present - - O
in - - O
any - - O
source - - O
water - - O
sample - - O
, - - O
the - - O
borehole - - O
and - - O
any - - O
directly - - O
connected - - O
borehole - - O
should - - O
be - - O
embargoed - - O
. - - O

One - - O
of - - O
these - - O
is - - O
surrounded - - O
by - - O
an - - O
adenine-uridine - - O
rich - - O
region - - O
that - - O
can - - O
form - - O
an - - O
11-base - - O
pair - - O
stem - - O
structure - - O
. - - O

An - - O
important - - O
mechanism - - O
by - - O
which - - O
the - - O
tumor - - O
suppressor - - O
p53 - - O
maintains - - O
genomic - - O
stability - - O
is - - O
to - - O
induce - - O
cell - - O
cycle - - O
arrest - - O
through - - O
activation - - O
of - - O
the - - O
cyclin-dependent - - O
kinase - - O
inhibitor - - O
p21 - - O
( - - O
WAF1 - - O
Cip1 - - O
) - - O
gene - - O
. - - O

However - - O
, - - O
the - - O
mouse - - O
has - - O
previously - - O
been - - O
shown - - O
to - - O
possess - - O
only - - O
three - - O
forms - - O
of - - O
ADH - - O
. - - O

The - - O
effect - - O
of - - O
antilymphocyte - - O
sera - - O
on - - O
formation - - O
of - - O
transplantation - - O
and - - O
anti-infection - - O
immunity - - O
in - - O
mice - - O
. - - O

The - - O
quantity - - O
of - - O
each - - O
population - - O
( - - O
L - - O
. - - O
bulgaricus - - O
, - - O
S - - O
. - - O
thermophilus - - O
) - - O
was - - O
then - - O
estimated - - O
in - - O
the - - O
pellet - - O
by - - O
PyMS - - O
, - - O
and - - O
the - - O
data - - O
were - - O
analysed - - O
by - - O
artificial - - O
neural - - O
networks - - O
( - - O
ANNs - - O
) - - O
. - - O

LysR - - O
proteins - - O
have - - O
been - - O
shown - - O
to - - O
regulate - - O
urease - - O
in - - O
Klebsiella - - O
aerogenes - - O
( - - O
NAC - - O
) - - O
, - - O
and - - O
catalase - - O
in - - O
Escherichia - - O
coli - - O
( - - O
OxyR - - O
) - - O
, - - O
which - - O
offers - - O
the - - O
intracellular - - O
bacterium - - O
protection - - O
from - - O
phagolysosome - - O
damage - - O
. - - O

Experiments - - O
on - - O
narcotized - - O
cats - - O
demonstrated - - O
that - - O
the - - O
derivatives - - O
of - - O
2-mercaptobenzimidazole - - O
possessing - - O
the - - O
properties - - O
of - - O
specific - - O
bradycardic - - O
agents - - O
and - - O
coded - - O
as - - O
CM-251 - - O
, - - O
CM-266 - - O
, - - O
and - - O
CM-345 - - O
, - - O
reduce - - O
the - - O
mean - - O
rise - - O
of - - O
segment - - O
ST - - O
on - - O
numerous - - O
leads - - O
of - - O
the - - O
epicardial - - O
electrogram - - O
during - - O
5-min - - O
occlusion - - O
of - - O
the - - O
anterior - - O
descending - - O
branch - - O
of - - O
the - - O
left - - O
coronary - - O
artery - - O
. - - O

Ten - - O
weeks - - O
after - - O
reconstruction - - O
, - - O
the - - O
regenerating - - O
nerves - - O
already - - O
resembled - - O
normal - - O
nerves - - O
. - - O

Franz - - O
Schubert--his - - O
life - - O
, - - O
music - - O
and - - O
diseases - - O
. - - O

The - - O
emerging - - O
view - - O
based - - O
on - - O
studies - - O
in - - O
yeast - - O
is - - O
that - - O
each - - O
class - - O
of - - O
snoRNPs - - O
is - - O
composed - - O
of - - O
a - - O
unique - - O
set - - O
of - - O
proteins - - O
. - - O

Conclusion - - O
: - - O
inlet - - O
type - - O
VSD - - O
and - - O
perimembranous - - O
type - - O
TOF - - O
have - - O
anatomic - - O
features - - O
in - - O
which - - O
the - - O
proximal - - O
His - - O
bundle - - O
tends - - O
to - - O
be - - O
jeopardized - - O
by - - O
suturing - - O
for - - O
VSD - - O
closure - - O
. - - O

Svensson - - O
et - - O
al - - O
. - - O

This - - O
study - - O
suggests - - O
that - - O
BSPMs - - O
are - - O
useful - - O
in - - O
the - - O
assessment - - O
of - - O
AMI - - O
in - - O
terms - - O
of - - O
diagnosis - - O
, - - O
location - - O
and - - O
extent - - O
of - - O
myocardial - - O
infarct - - O
. - - O

Erratum - - O
: - - O
Absence - - O
of - - O
precursor - - O
effects - - O
above - - O
the - - O
martensitic - - O
transformation - - O
in - - O
a - - O
virgin - - O
crystal - - O
of - - O
Li - - O
metal - - O
[ - - O
Phys - - O
. - - O

B-myb - - O
is - - O
essential - - O
for - - O
G1 - - O
S - - O
transition - - O
and - - O
has - - O
been - - O
shown - - O
to - - O
be - - O
phosphorylated - - O
by - - O
the - - O
cyclin - - O
A2 - - O
cdk2 - - O
complex - - O
. - - O

Movement - - O
programming - - O
depends - - O
on - - O
understanding - - O
of - - O
behavioral - - O
requirements - - O
. - - O

Its - - O
neuromuscular - - O
effects - - O
are - - O
similar - - O
to - - O
a - - O
single - - O
ED90 - - O
dose - - O
of - - O
vecuronium - - O
. - - O

The - - O
hp55 - - O
gamma - - O
protein - - O
interacts - - O
strongly - - O
with - - O
the - - O
activated - - O
IGFIR - - O
but - - O
not - - O
with - - O
the - - O
kinase-negative - - O
mutant - - O
receptor - - O
. - - O
hp55 - - O
gamma - - O
also - - O
interacts - - O
with - - O
the - - O
insulin - - O
receptor - - O
( - - O
IR - - O
) - - O
in - - O
the - - O
yeast - - O
two-hybrid - - O
system - - O
. - - O

In - - O
humans - - O
, - - O
four - - O
AMP - - O
deaminase - - O
variants - - O
, - - O
termed - - O
M - - O
( - - O
muscle - - O
) - - O
, - - O
L - - O
( - - O
liver - - O
) - - O
, - - O
E1 - - O
, - - O
and - - O
E2 - - O
( - - O
erythrocyte - - O
) - - O
can - - O
be - - O
distinguished - - O
by - - O
a - - O
variety - - O
of - - O
biochemical - - O
and - - O
immunological - - O
criteria - - O
. - - O

In - - O
a - - O
longitudinal - - O
study - - O
, - - O
14 - - O
low-risk - - O
fetuses - - O
were - - O
studied - - O
at - - O
2-week - - O
intervals - - O
from - - O
32 - - O
weeks - - O
of - - O
gestation - - O
onward - - O
. - - O

However - - O
the - - O
sequence - - O
surrounding - - O
the - - O
transcription - - O
start - - O
site - - O
CTCA - - O
( - - O
+1 - - O
) - - O
TTCC - - O
was - - O
similar - - O
to - - O
the - - O
consensus - - O
CTCA - - O
( - - O
+1 - - O
) - - O
NTCT - - O
( - - O
N - - O
is - - O
any - - O
nucleoside - - O
) - - O
for - - O
an - - O
initiator - - O
element - - O
found - - O
in - - O
terminal - - O
deoxynucleotidyltransferase - - O
and - - O
a - - O
number - - O
of - - O
other - - O
highly - - O
regulated - - O
genes - - O
. - - O

C - - O
. - - O
elegans - - O
KLP-11 - - O
OSM-3 - - O
KAP-1 - - O
: - - O
orthologs - - O
of - - O
the - - O
sea - - O
urchin - - O
kinesin-II - - O
, - - O
and - - O
mouse - - O
KIF3A - - O
KIFB - - O
KAP3 - - O
kinesin - - O
complexes - - O
. - - O

Increase - - O
in - - O
blood - - O
NEFA - - O
was - - O
further - - O
augmented - - O
by - - O
fat - - O
plus - - O
AA - - O
supplementation - - O
, - - O
but - - O
no - - O
changes - - O
in - - O
concentrations - - O
of - - O
Lys - - O
or - - O
Met - - O
in - - O
blood - - O
were - - O
found - - O
. - - O

Most - - O
eukaryotic - - O
mRNAs - - O
are - - O
translated - - O
by - - O
a - - O
"scanning - - O
ribosome" - - O
mechanism - - O
. - - O

According - - O
to - - O
the - - O
biochemical - - O
tests - - O
, - - O
high - - O
activity - - O
( - - O
over - - O
200 - - O
U - - O
l - - O
) - - O
of - - O
alkaline - - O
phosphatase - - O
was - - O
recorded - - O
exclusively - - O
in - - O
patients - - O
with - - O
the - - O
lymphogranulomatosis-induced - - O
liver - - O
damage - - O
. - - O

During - - O
sub-maximal - - O
exercise - - O
, - - O
DCR - - O
in - - O
the - - O
UT - - O
dogs - - O
decreased - - O
from - - O
a - - O
resting - - O
value - - O
of - - O
4 - - O
. - - O
08 - - O
+ - - O
- - - O
0 - - O
. - - O
18 - - O
mm - - O
Hg - - O
X - - O
ml-1 - - O
X - - O
min-1 - - O
to - - O
1 - - O
. - - O
91 - - O
+ - - O
- - - O
0 - - O
. - - O
17 - - O
mm - - O
Hg - - O
X - - O
ml-1 - - O
X - - O
min-1 - - O
at - - O
a - - O
workload - - O
of - - O
6 - - O
. - - O
4 - - O
kph - - O
( - - O
speed - - O
) - - O
16% - - O
( - - O
grade - - O
) - - O
. - - O

The - - O
incidence - - O
of - - O
HSV-2 - - O
positive - - O
subjects - - O
( - - O
HSV-2 - - O
HSV-1 - - O
antibody - - O
ratio - - O
> - - O
or - - O
= - - O
1 - - O
) - - O
was - - O
low - - O
in - - O
the - - O
Jewish - - O
Israeli - - O
population - - O
, - - O
compared - - O
to - - O
other - - O
demographic - - O
areas - - O
. - - O

The - - O
sorption - - O
mechanisms - - O
changed - - O
from - - O
adsorption - - O
to - - O
partition - - O
in - - O
the - - O
process - - O
of - - O
repetitious - - O
sorption - - O
. - - O

According - - O
to - - O
their - - O
staining - - O
affinity - - O
for - - O
anti-T - - O
antibodies - - O
, - - O
the - - O
glandular - - O
tissue - - O
cells - - O
were - - O
classified - - O
as - - O
T- - - O
, - - O
T+ - - O
, - - O
T++ - - O
, - - O
and - - O
T - - O
and - - O
the - - O
annual - - O
changes - - O
in - - O
the - - O
numbers - - O
of - - O
these - - O
cell - - O
populations - - O
, - - O
as - - O
well - - O
as - - O
in - - O
the - - O
volume - - O
occupied - - O
by - - O
the - - O
glandular - - O
tissue - - O
, - - O
were - - O
calculated - - O
. - - O

Cardiac - - O
preservation - - O
. - - O

A - - O
new - - O
method - - O
for - - O
the - - O
in - - O
vitro - - O
transfer - - O
of - - O
delayed - - O
hypersensitivity - - O
by - - O
dialysed - - O
transfer - - O
factor - - O
. - - O

Karger - - O
AG - - O
, - - O
Basel - - O

The - - O
cloned - - O
alcR - - O
gene - - O
provided - - O
in - - O
trans - - O
restored - - O
these - - O
siderophore - - O
system - - O
activities - - O
to - - O
the - - O
mutants - - O
. - - O

Study - - O
of - - O
bacterial - - O
motility - - O
and - - O
rate - - O
of - - O
movement - - O
using - - O
a - - O
closed - - O
circuit - - O
television - - O
. - - O

Analysis - - O
of - - O
lacZ - - O
transcriptional - - O
fusions - - O
shows - - O
that - - O
the - - O
KdgR-binding - - O
sites - - O
negatively - - O
affect - - O
the - - O
expression - - O
of - - O
rsmB - - O
. - - O

Extramedullary - - O
plasmacytoma - - O
of - - O
the - - O
parotid - - O
gland - - O
. - - O

In - - O
addition - - O
, - - O
a - - O
21-mer - - O
subrepeat - - O
structure - - O
is - - O
also - - O
present - - O
in - - O
each - - O
unit - - O
. - - O

Intravenous - - O
glucose - - O
tolerance - - O
tests - - O
were - - O
performed - - O
before - - O
operation - - O
, - - O
before - - O
starting - - O
CyA - - O
and - - O
after - - O
3 - - O
weeks - - O
. - - O

Modulation - - O
of - - O
AUUUA - - O
response - - O
element - - O
binding - - O
by - - O
heterogeneous - - O
nuclear - - O
ribonucleoprotein - - O
A1 - - O
in - - O
human - - O
T - - O
lymphocytes - - O
. - - O

The - - O
data - - O
provide - - O
strong - - O
evidence - - O
that - - O
ThlA - - O
is - - O
involved - - O
in - - O
the - - O
metabolism - - O
of - - O
both - - O
acid - - O
and - - O
solvent - - O
formation - - O
, - - O
whereas - - O
the - - O
physiological - - O
function - - O
of - - O
ThlB - - O
has - - O
yet - - O
to - - O
be - - O
elucidated - - O
. - - O

Selection - - O
of - - O
the - - O
22 - - O
items - - O
of - - O
the - - O
Clinical - - O
Institute - - O
Withdrawal - - O
Assessment-Benzodiazepines - - O
( - - O
CIWA-B - - O
) - - O
was - - O
based - - O
on - - O
statistically - - O
significant - - O
differences - - O
between - - O
baseline - - O
and - - O
critical - - O
withdrawal - - O
periods - - O
in - - O
high-dose - - O
subjects - - O
and - - O
between - - O
symptoms - - O
associated - - O
with - - O
placebo - - O
and - - O
diazepam - - O
in - - O
low-dose - - O
subjects - - O
, - - O
using - - O
contingency - - O
tables - - O
and - - O
logistic - - O
regression - - O
analysis - - O
. - - O

We - - O
also - - O
observed - - O
that - - O
cell - - O
surface - - O
CD4 - - O
( - - O
- - - O
) - - O
CD8 - - O
( - - O
- - - O
) - - O
CD3 - - O
( - - O
- - - O
) - - O
cells - - O
with - - O
rearranged - - O
TCR - - O
genes - - O
developed - - O
from - - O
Id3-transduced - - O
but - - O
not - - O
from - - O
control-transduced - - O
pre-T - - O
cells - - O
in - - O
an - - O
FTOC - - O
. - - O

In - - O
order - - O
to - - O
define - - O
potential - - O
candidate - - O
genes - - O
for - - O
inherited - - O
disorders - - O
characterized - - O
by - - O
aberrant - - O
gene - - O
expression - - O
, - - O
we - - O
utilized - - O
Kruppel-related - - O
sequences - - O
to - - O
isolate - - O
zinc - - O
finger-containing - - O
cDNAs - - O
. - - O

Praziquantel - - O
and - - O
Albendazole - - O
were - - O
found - - O
effective - - O
in - - O
the - - O
treatment - - O
of - - O
neurocysticercosis - - O
, - - O
but - - O
because - - O
of - - O
serious - - O
side - - O
effects - - O
encountered - - O
in - - O
some - - O
cases - - O
, - - O
the - - O
drugs - - O
should - - O
be - - O
used - - O
cautiously - - O
in - - O
selected - - O
cases - - O
only - - O
. - - O

The - - O
results - - O
raise - - O
the - - O
possibility - - O
that - - O
pH - - O
induced - - O
post-translational - - O
modifications - - O
of - - O
DdRPA - - O
are - - O
involved - - O
in - - O
events - - O
that - - O
halt - - O
cell - - O
proliferation - - O
and - - O
induce - - O
differentiation - - O
in - - O
Dictyostelium - - O
. - - O

However - - O
, - - O
activation - - O
of - - O
the - - O
cAMP - - O
pathway - - O
, - - O
which - - O
is - - O
known - - O
to - - O
regulate - - O
inhibin - - O
alpha - - O
expression - - O
, - - O
greatly - - O
enhanced - - O
the - - O
actions - - O
of - - O
SF-1 - - O
. - - O

At - - O
different - - O
times - - O
of - - O
the - - O
surgical - - O
procedures - - O
( - - O
thorax - - O
opening - - O
and - - O
closure - - O
, - - O
period - - O
of - - O
cardiopulmonary - - O
bypass - - O
) - - O
67 - - O
to - - O
100% - - O
of - - O
the - - O
patients - - O
in - - O
group - - O
1 - - O
had - - O
vancomycin - - O
concentrations - - O
in - - O
the - - O
studied - - O
tissues - - O
above - - O
the - - O
MIC - - O
90 - - O
for - - O
Staphylococcus - - O
aureus - - O
( - - O
1 - - O
microgram - - O
g - - O
) - - O
and - - O
Staphylococcus - - O
epidermidis - - O
( - - O
2 - - O
micrograms - - O
g - - O
) - - O
. - - O

Ent-kaurene - - O
synthase - - O
from - - O
the - - O
fungus - - O
Phaeosphaeria - - O
sp - - O
. - - O

Data - - O
Management - - O
in - - O
Practice-based - - O
Research - - O
. - - O

The - - O
incidence - - O
of - - O
cardiac - - O
death - - O
( - - O
one - - O
per - - O
group - - O
) - - O
, - - O
Q - - O
wave - - O
MI - - O
( - - O
propofol - - O
, - - O
n - - O
= - - O
7 - - O
; - - O
midazolam - - O
, - - O
n - - O
= - - O
3 - - O
; - - O
P - - O
= - - O
0 - - O
. - - O
27 - - O
) - - O
, - - O
or - - O
non - - O
Q - - O
wave - - O
MI - - O
( - - O
propofol - - O
, - - O
n - - O
= - - O
16 - - O
; - - O
midazolam - - O
, - - O
n - - O
= - - O
18 - - O
; - - O
P - - O
= - - O
0 - - O
. - - O
81 - - O
) - - O
did - - O
not - - O
differ - - O
between - - O
treatment - - O
groups - - O
. - - O

Evidence - - O
is - - O
presented - - O
that - - O
Leber's - - O
military - - O
aneurysm - - O
retinitis - - O
is - - O
not - - O
a - - O
separate - - O
entity - - O
but - - O
a - - O
special - - O
form - - O
of - - O
Coats' - - O
disease - - O
. - - O

Here - - O
, - - O
we - - O
alter - - O
the - - O
dimerization - - O
specificity - - O
of - - O
Fos - - O
by - - O
precisely - - O
replacing - - O
its - - O
leucine - - O
zipper - - O
with - - O
that - - O
from - - O
GCN4 - - O
. - - O

We - - O
confirmed - - O
the - - O
interaction - - O
between - - O
TLS - - O
and - - O
p65 - - O
by - - O
the - - O
pull-down - - O
assay - - O
in - - O
vitro - - O
and - - O
by - - O
a - - O
coimmunoprecipitation - - O
experiment - - O
followed - - O
by - - O
Western - - O
blot - - O
of - - O
the - - O
cultured - - O
cell - - O
in - - O
vivo - - O
. - - O

The - - O
cycle - - O
length - - O
of - - O
induced - - O
VT - - O
( - - O
n - - O
= - - O
10 - - O
VTs - - O
) - - O
was - - O
380 - - O
+ - - O
- - - O
41 - - O
msec - - O
. - - O

Nucleotide - - O
sequence - - O
, - - O
genome - - O
organization - - O
and - - O
phylogenetic - - O
analysis - - O
of - - O
pineapple - - O
mealybug - - O
wilt-associated - - O
virus-2 - - O
. - - O

Observations - - O
on - - O
the - - O
flight - - O
activities - - O
of - - O
Chrysops - - O
caecutiens - - O
L - - O
. - - O

Stimulation - - O
of - - O
[ - - O
3H - - O
] - - O
PA - - O
production - - O
upon - - O
CD3 - - O
cross-linking - - O
was - - O
77% - - O
lower - - O
in - - O
permeabilized - - O
CD45- - - O
cells - - O
than - - O
in - - O
CD45+ - - O
cells - - O
, - - O
consistent - - O
with - - O
the - - O
reduced - - O
activity - - O
of - - O
p59fyn - - O
in - - O
CD45- - - O
cells - - O
. - - O

In - - O
a - - O
series - - O
of - - O
402 - - O
consecutive - - O
autopsies - - O
, - - O
parietal - - O
pleural - - O
plaques - - O
( - - O
PP - - O
) - - O
were - - O
found - - O
in - - O
68 - - O
individuals - - O
above - - O
40 - - O
years - - O
of - - O
age - - O
. - - O

In - - O
contrast - - O
, - - O
high - - O
COUP-TFI - - O
expression - - O
impeded - - O
the - - O
neuronal - - O
differentiation - - O
of - - O
P19 - - O
cells - - O
induced - - O
with - - O
RA - - O
, - - O
resulting - - O
in - - O
cell - - O
cultures - - O
lacking - - O
neurons - - O
. - - O

We - - O
show - - O
that - - O
several - - O
heme-responsive - - O
mechanisms - - O
combine - - O
to - - O
regulate - - O
DAN - - O
TIR - - O
gene - - O
expression - - O
. - - O

NGF - - O
, - - O
but - - O
not - - O
EGF - - O
, - - O
enhances - - O
the - - O
upper - - O
bands - - O
, - - O
corresponding - - O
to - - O
phosphorylated - - O
Fra-2 - - O
. - - O

The - - O
FFA - - O
levels - - O
were - - O
not - - O
affected - - O
( - - O
P - - O
greater - - O
than - - O
. - - O
1 - - O
) - - O
by - - O
meal - - O
interval - - O
. - - O

A - - O
survey - - O
is - - O
given - - O
of - - O
the - - O
pharmacological - - O
backgrounds - - O
that - - O
are - - O
relevant - - O
for - - O
the - - O
drug - - O
treatment - - O
of - - O
essential - - O
hypertension - - O
in - - O
the - - O
elderly - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
the - - O
minimal - - O
requirements - - O
for - - O
induction - - O
of - - O
PEPCK - - O
by - - O
PKA - - O
and - - O
inhibition - - O
by - - O
insulin - - O
include - - O
: - - O
1 - - O
) - - O
the - - O
CREB - - O
activation - - O
domain - - O
, - - O
2 - - O
) - - O
the - - O
PEPCK - - O
TATA - - O
sequence - - O
, - - O
and - - O
3 - - O
) - - O
insulin-responsive - - O
hepatoma - - O
cells - - O
. - - O

The - - O
Drosophila - - O
melanogaster - - O
Gart - - O
gene - - O
encodes - - O
three - - O
enzymatic - - O
activities - - O
in - - O
the - - O
pathway - - O
for - - O
purine - - O
de - - O
novo - - O
synthesis - - O
. - - O

In - - O
contrast - - O
, - - O
we - - O
did - - O
not - - O
detect - - O
a - - O
significant - - O
correlation - - O
between - - O
plasma - - O
TNFalpha - - O
and - - O
radiation - - O
pneumonitis - - O
. - - O

Unlike - - O
the - - O
mammalian - - O
proteins - - O
, - - O
XFGF3 - - O
is - - O
efficiently - - O
secreted - - O
as - - O
a - - O
Mr - - O
31 - - O
, - - O
000 - - O
glycoprotein - - O
, - - O
gp31 - - O
, - - O
which - - O
undergoes - - O
proteolytic - - O
cleavage - - O
to - - O
produce - - O
an - - O
NH2-terminally - - O
truncated - - O
product - - O
, - - O
gp27 - - O
. - - O

Enhancement - - O
of - - O
the - - O
immune - - O
response - - O
by - - O
aspecific - - O
action - - O
of - - O
vaccine - - O
additives - - O
in - - O
the - - O
aerogenic - - O
immunization - - O
of - - O
swine - - O
against - - O
swine - - O
plague - - O
. - - O

The - - O
effect - - O
of - - O
six - - O
arginine - - O
mutations - - O
of - - O
oxidative - - O
phosphorylation - - O
and - - O
AAC - - O
expression - - O
. - - O

Neuregulin - - O
stimulates - - O
ErbB2 - - O
, - - O
ErbB3 - - O
, - - O
and - - O
ErbB4 - - O
, - - O
members - - O
of - - O
the - - O
ErbB - - O
family - - O
of - - O
receptor - - O
tyrosine - - O
kinases - - O
. - - O

Previous - - O
studies - - O
have - - O
demonstrated - - O
that - - O
the - - O
TATA - - O
element - - O
is - - O
critical - - O
for - - O
basal - - O
and - - O
Tat-induced - - O
HIV-1 - - O
gene - - O
expression - - O
. - - O

Furthermore - - O
, - - O
cpxA* - - O
mutations - - O
suppress - - O
the - - O
toxicity - - O
conferred - - O
by - - O
the - - O
LamB-LacZ - - O
hybrid - - O
protein - - O
, - - O
which - - O
exerts - - O
its - - O
effects - - O
in - - O
the - - O
cytoplasm - - O
, - - O
sequestered - - O
from - - O
DegP - - O
. - - O

They - - O
include - - O
genes - - O
encoding - - O
three - - O
subunits - - O
of - - O
the - - O
cytochrome - - O
oxidase - - O
( - - O
cox1 - - O
to - - O
3 - - O
) - - O
, - - O
apocytochrome - - O
b - - O
( - - O
cob - - O
) - - O
, - - O
seven - - O
subunits - - O
of - - O
the - - O
NADH - - O
dehydrogenase - - O
complex - - O
( - - O
nad1 - - O
to - - O
6 - - O
, - - O
nad4L - - O
) - - O
, - - O
two - - O
ATPase - - O
subunits - - O
( - - O
atp6 - - O
and - - O
atp9 - - O
) - - O
, - - O
three - - O
ribosomal - - O
RNAs - - O
( - - O
rrn5 - - O
, - - O
srn - - O
and - - O
lrn - - O
) - - O
, - - O
23 - - O
tRNAs - - O
and - - O
four - - O
ribosomal - - O
proteins - - O
( - - O
rps3 - - O
, - - O
rps11 - - O
, - - O
rps12 - - O
and - - O
rpl16 - - O
) - - O
. - - O

OUTCOME - - O
: - - O
Acetylcholine - - O
receptor - - O
antibodies - - O
and - - O
single-fibre - - O
electromyogram - - O
were - - O
useful - - O
in - - O
the - - O
diagnosis - - O
of - - O
myasthenia - - O
gravis - - O
. - - O

In - - O
the - - O
PMR - - O
target - - O
area - - O
but - - O
not - - O
in - - O
the - - O
nontreated - - O
area - - O
an - - O
improvement - - O
in - - O
regional - - O
myocardial - - O
flow - - O
reserve - - O
occurs - - O
in - - O
wall - - O
segments - - O
with - - O
initially - - O
severely - - O
or - - O
moderately - - O
reduced - - O
stress - - O
perfusion - - O
. - - O

Therefore - - O
, - - O
ICSBP - - O
may - - O
be - - O
involved - - O
in - - O
maintaining - - O
submaximal - - O
transcriptional - - O
activity - - O
of - - O
IFN-inducible - - O
genes - - O
in - - O
hematopoietic - - O
cells - - O
. - - O

Blood - - O
eosinophils - - O
in - - O
patients - - O
with - - O
Taenia - - O
saginata - - O
taeniasis - - O
. - - O

Our - - O
results - - O
suggest - - O
that - - O
WASP - - O
activates - - O
transcription - - O
following - - O
TCR - - O
stimulation - - O
in - - O
a - - O
manner - - O
that - - O
is - - O
independent - - O
of - - O
its - - O
role - - O
in - - O
Arp2 - - O
3-directed - - O
actin - - O
polymerization - - O
. - - O

O2 - - O
and - - O
CO2 - - O
in - - O
the - - O
tracheostomy - - O
tube - - O
were - - O
continuously - - O
monitored - - O
by - - O
mass - - O
spectrometry - - O
using - - O
a - - O
special - - O
sample-hold - - O
phase-locked - - O
sampling - - O
technique - - O
. - - O

Removal - - O
of - - O
the - - O
carboxyl - - O
region - - O
severely - - O
reduced - - O
transcriptional - - O
activation - - O
. - - O

Aortic - - O
diameters - - O
in - - O
infants - - O
and - - O
young - - O
children - - O
: - - O
normative - - O
angiographic - - O
data - - O
. - - O

Using - - O
a - - O
3'-rapid - - O
amplification - - O
of - - O
cDNA - - O
ends - - O
strategy - - O
, - - O
we - - O
have - - O
cloned - - O
cDNAs - - O
representing - - O
the - - O
3'-termini - - O
of - - O
both - - O
the - - O
native - - O
and - - O
mutant - - O
transcripts - - O
from - - O
both - - O
P388 - - O
ADR - - O
3 - - O
and - - O
P388 - - O
ADR - - O
7 - - O
cells - - O
. - - O

Mutations - - O
at - - O
three - - O
sites - - O
have - - O
larger - - O
effects - - O
in - - O
muscle - - O
than - - O
nonmuscle - - O
cells - - O
; - - O
an - - O
A - - O
T-rich - - O
site - - O
mutation - - O
has - - O
a - - O
pronounced - - O
effect - - O
in - - O
both - - O
striated - - O
muscle - - O
types - - O
, - - O
mutations - - O
at - - O
the - - O
MEF1 - - O
( - - O
Right - - O
E-box - - O
) - - O
site - - O
are - - O
relatively - - O
specific - - O
to - - O
expression - - O
in - - O
skeletal - - O
muscle - - O
, - - O
and - - O
mutations - - O
at - - O
the - - O
CArG - - O
site - - O
are - - O
relatively - - O
specific - - O
to - - O
expression - - O
in - - O
cardiac - - O
muscle - - O
. - - O

Therefore - - O
, - - O
in - - O
our - - O
in - - O
vitro - - O
model - - O
, - - O
the - - O
localization - - O
of - - O
the - - O
mutation - - O
in - - O
the - - O
K-ras - - O
gene - - O
predisposes - - O
to - - O
a - - O
different - - O
level - - O
of - - O
aggressiveness - - O
in - - O
the - - O
transforming - - O
phenotype - - O
. - - O

Induction - - O
of - - O
anaesthesia - - O
was - - O
standardised - - O
: - - O
fentanyl - - O
( - - O
3 - - O
micrograms - - O
kg - - O
) - - O
, - - O
thiopentone - - O
( - - O
5 - - O
mg - - O
kg - - O
) - - O
, - - O
atracurium - - O
( - - O
0 - - O
. - - O
4 - - O
mg - - O
kg - - O
) - - O
. - - O

Moreover - - O
, - - O
Western - - O
blots - - O
demonstrated - - O
at - - O
least - - O
six - - O
types - - O
of - - O
Ypt - - O
in - - O
both - - O
Cr - - O
and - - O
Vc - - O
, - - O
suggesting - - O
that - - O
these - - O
Ypt - - O
are - - O
used - - O
for - - O
household - - O
functions - - O
responsible - - O
for - - O
vesicle - - O
transport - - O
rather - - O
than - - O
for - - O
cellular - - O
differentiation - - O
. - - O

In - - O
on-going - - O
screening - - O
programmes - - O
, - - O
the - - O
Haemoccult - - O
test - - O
consists - - O
of - - O
six - - O
slides - - O
and - - O
a - - O
test - - O
is - - O
considered - - O
positive - - O
if - - O
at - - O
least - - O
one - - O
slide - - O
is - - O
coloured - - O
. - - O

The - - O
results - - O
obtained - - O
were - - O
as - - O
follows - - O
: - - O
The - - O
mitral - - O
valve - - O
orifice - - O
area - - O
( - - O
MVA - - O
) - - O
was - - O
significantly - - O
smaller - - O
in - - O
patients - - O
with - - O
type - - O
III - - O
of - - O
the - - O
LVIT - - O
flow - - O
velocity - - O
pattern - - O
than - - O
in - - O
patients - - O
with - - O
type - - O
I - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Our - - O
data - - O
indicate - - O
that - - O
SIP1 - - O
is - - O
required - - O
to - - O
confine - - O
XBra - - O
gene - - O
expression - - O
to - - O
the - - O
mesoderm - - O
. - - O

Menstrual-cycle - - O
phase - - O
did - - O
not - - O
significantly - - O
affect - - O
personality - - O
variables - - O
in - - O
either - - O
group - - O
. - - O

Here - - O
we - - O
show - - O
that - - O
these - - O
synthetic - - O
binding - - O
sites - - O
have - - O
a - - O
more - - O
restricted - - O
and - - O
specific - - O
ability - - O
to - - O
enhance - - O
transcription - - O
when - - O
assayed - - O
in - - O
transformed - - O
embryos - - O
. - - O

Administration - - O
of - - O
anticoagulants - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
heparin - - O
, - - O
prostaglandin - - O
E1 - - O
and - - O
ticlopidine - - O
seems - - O
to - - O
be - - O
effective - - O
in - - O
alleviating - - O
symptoms - - O
and - - O
might - - O
prevent - - O
further - - O
deterioration - - O
. - - O

Both - - O
tear - - O
volume - - O
and - - O
tear - - O
flow - - O
were - - O
found - - O
to - - O
be - - O
significantly - - O
( - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
decreased - - O
up - - O
to - - O
6 - - O
h - - O
after - - O
instillation - - O
, - - O
reaching - - O
a - - O
minimum - - O
90 - - O
min - - O
after - - O
application - - O
( - - O
tear - - O
volume - - O
: - - O
-63% - - O
; - - O
tear - - O
flow - - O
: - - O
-71% - - O
) - - O
. - - O

Experimental - - O
reproduction - - O
of - - O
malignant - - O
catarrhal - - O
fever - - O
in - - O
Bali - - O
cattle - - O
. - - O

Deletion - - O
analysis - - O
was - - O
carried - - O
out - - O
within - - O
a - - O
part - - O
of - - O
the - - O
5'-flanking - - O
region - - O
showing - - O
homology - - O
to - - O
the - - O
upstream - - O
region - - O
of - - O
the - - O
yeast - - O
CYC1 - - O
gene - - O
. - - O

The - - O
fusion - - O
proteins - - O
were - - O
tested - - O
by - - O
ELISA - - O
for - - O
reactivity - - O
with - - O
a - - O
panel - - O
of - - O
human - - O
anti-La - - O
sera - - O
in - - O
order - - O
to - - O
define - - O
the - - O
nature - - O
of - - O
the - - O
epitopes - - O
. - - O

Class - - O
I - - O
alpha1 - - O
, - - O
2-mannosidases - - O
play - - O
an - - O
essential - - O
role - - O
in - - O
the - - O
elaboration - - O
of - - O
complex - - O
and - - O
hybrid - - O
N - - O
-glycans - - O
in - - O
mammalian - - O
cells - - O
. - - O

Recent - - O
developments - - O
in - - O
drugs - - O
antagonistic - - O
to - - O
factors - - O
causing - - O
peptic - - O
ulcer--clinical - - O
efficacy - - O
and - - O
problems - - O
; - - O
gastrin - - O
receptor - - O
blockaders - - O
. - - O

SCOB - - O
testing - - O
of - - O
food-restricted - - O
animals - - O
, - - O
using - - O
a - - O
multiple - - O
fixed - - O
ratio - - O
( - - O
FR - - O
) - - O
fixed - - O
interval - - O
( - - O
FI - - O
) - - O
schedule - - O
( - - O
FR20 - - O
: - - O
FI120 - - O
) - - O
, - - O
was - - O
conducted - - O
prior - - O
to - - O
each - - O
exposure - - O
to - - O
maintain - - O
the - - O
operant - - O
behavior - - O
; - - O
the - - O
data - - O
from - - O
Weeks - - O
-1 - - O
, - - O
4 - - O
, - - O
8 - - O
, - - O
and - - O
13 - - O
were - - O
evaluated - - O
for - - O
evidence - - O
of - - O
neurotoxicity - - O
. - - O

Two - - O
overlapping - - O
clones - - O
contained - - O
the - - O
complete - - O
Adh-2 - - O
gene - - O
composed - - O
of - - O
nine - - O
exons - - O
in - - O
a - - O
12-kb - - O
region - - O
, - - O
with - - O
the - - O
placement - - O
of - - O
introns - - O
matching - - O
that - - O
observed - - O
in - - O
other - - O
mammalian - - O
ADH - - O
genes - - O
. - - O

The - - O
imprinted - - O
expression - - O
of - - O
the - - O
endogenous - - O
gene - - O
can - - O
be - - O
recapitulated - - O
in - - O
mice - - O
by - - O
using - - O
a - - O
14-kb - - O
transgene - - O
encompassing - - O
4 - - O
kb - - O
of - - O
5'-flanking - - O
sequence - - O
, - - O
8 - - O
kb - - O
of - - O
3'-flanking - - O
sequence - - O
, - - O
which - - O
includes - - O
the - - O
two - - O
endoderm-specific - - O
enhancers - - O
, - - O
and - - O
an - - O
internally - - O
deleted - - O
structural - - O
gene - - O
. - - O

The - - O
strong - - O
conservation - - O
of - - O
the - - O
inverted - - O
terminal - - O
repeat - - O
sequence - - O
may - - O
reflect - - O
a - - O
common - - O
integration - - O
mechanism - - O
for - - O
VL30 - - O
elements - - O
and - - O
MuLV - - O
proviruses - - O
. - - O

A - - O
method - - O
of - - O
three-station - - O
three-dimensional - - O
magnetic - - O
resonance - - O
( - - O
MR - - O
) - - O
angiography - - O
of - - O
the - - O
lower - - O
extremities - - O
with - - O
segmented - - O
volume - - O
acquisition - - O
is - - O
presented - - O
. - - O

The - - O
presence - - O
of - - O
unidentified - - O
macroscopic - - O
or - - O
microscopic - - O
clusters - - O
of - - O
neoplastic - - O
cells - - O
, - - O
lying - - O
around - - O
, - - O
more - - O
or - - O
less - - O
close - - O
to - - O
, - - O
the - - O
line - - O
of - - O
insertion - - O
of - - O
lesion - - O
, - - O
could - - O
render - - O
any - - O
attempt - - O
to - - O
gain - - O
a - - O
"radical" - - O
excision - - O
useless - - O
. - - O

Psychological - - O
examinations - - O
in - - O
patients - - O
with - - O
chronic - - O
kidney - - O
insufficiency - - O
. - - O

Pathological - - O
processes - - O
in - - O
the - - O
cervix - - O
uteri - - O
. - - O

After - - O
the - - O
first - - O
cycle - - O
, - - O
18 - - O
cases - - O
were - - O
treated - - O
at - - O
dose - - O
level - - O
1 - - O
, - - O
after - - O
a - - O
second - - O
cycle - - O
, - - O
13 - - O
cases - - O
were - - O
treated - - O
at - - O
dose - - O
level - - O
2 - - O
. - - O

Their - - O
hydropathic - - O
plots - - O
are - - O
very - - O
similar - - O
and - - O
both - - O
possess - - O
three - - O
hydrophobic - - O
segments - - O
that - - O
are - - O
likely - - O
alpha-helical - - O
transmembrane - - O
segments - - O
. - - O

We - - O
propose - - O
that - - O
Mnt - - O
: - - O
Max - - O
: - - O
Sin3 - - O
complexes - - O
normally - - O
function - - O
to - - O
restrict - - O
Myc - - O
: - - O
Max - - O
activities - - O
associated - - O
with - - O
cell - - O
proliferation - - O
. - - O

We - - O
recently - - O
characterized - - O
a - - O
single - - O
yeast - - O
hnRNP - - O
methyltransferase - - O
( - - O
HMT1 - - O
) - - O
. - - O

The - - O
factor - - O
which - - O
binds - - O
to - - O
the - - O
TR - - O
promoter - - O
co-sedimented - - O
with - - O
SV40 - - O
chromosomes - - O
extracted - - O
late - - O
in - - O
infection - - O
. - - O

Complexes - - O
of - - O
qTBP42 - - O
with - - O
each - - O
complementary - - O
strand - - O
of - - O
telomeric - - O
DNA - - O
and - - O
with - - O
quadruplex - - O
forms - - O
of - - O
the - - O
guanine-rich - - O
strand - - O
had - - O
3 - - O
. - - O
7-14 - - O
. - - O
6 - - O
nM - - O
dissociation - - O
constants - - O
, - - O
Kd - - O
, - - O
whereas - - O
complexes - - O
with - - O
double-stranded - - O
telomeric - - O
DNA - - O
had - - O
up - - O
to - - O
100-fold - - O
higher - - O
Kd - - O
values - - O
. - - O

Between - - O
the - - O
subgroups - - O
of - - O
dementia - - O
disorders - - O
there - - O
were - - O
no - - O
significant - - O
differences - - O
in - - O
basal - - O
cortisol - - O
levels - - O
. - - O

Certain - - O
characteristics - - O
of - - O
eye - - O
changes - - O
in - - O
patients - - O
with - - O
pheochromocytoma - - O
including - - O
Sipple's - - O
syndrome - - O
. - - O

Proteomic - - O
patterns - - O
of - - O
nipple - - O
aspirate - - O
fluids - - O
obtained - - O
by - - O
SELDI-TOF - - O
: - - O
potential - - O
for - - O
new - - O
biomarkers - - O
to - - O
aid - - O
in - - O
the - - O
diagnosis - - O
of - - O
breast - - O
cancer - - O
. - - O

Correlation - - O
of - - O
skin - - O
disorders - - O
with - - O
CD4 - - O
lymphocyte - - O
counts - - O
in - - O
patients - - O
with - - O
HIV - - O
AIDS - - O
. - - O

An - - O
intact - - O
5 - - O
. - - O
7-kb - - O
provirus - - O
of - - O
the - - O
avian - - O
erythroblastosis - - O
virus - - O
E26 - - O
has - - O
been - - O
molecularly - - O
cloned - - O
for - - O
comparisons - - O
with - - O
avian - - O
myeloblastosis - - O
virus - - O
( - - O
AMV - - O
) - - O
and - - O
other - - O
avian - - O
tumor - - O
viruses - - O
. - - O

RESULTS - - O
: - - O
For - - O
E1 - - O
, - - O
itraconazole - - O
plasma - - O
drug - - O
concentration - - O
extrapolated - - O
to - - O
time - - O
zero - - O
( - - O
IV - - O
dose - - O
) - - O
was - - O
5 - - O
. - - O
2 - - O
+ - - O
- - - O
1 - - O
. - - O
4 - - O
micrograms - - O
ml - - O
, - - O
and - - O
mean - - O
residence - - O
time - - O
( - - O
MRT - - O
) - - O
was - - O
37 - - O
+ - - O
- - - O
16 - - O
hours - - O
. - - O

It - - O
was - - O
shown - - O
that - - O
administration - - O
of - - O
immunomodulator - - O
neurotropin - - O
( - - O
NSP - - O
) - - O
results - - O
in - - O
more - - O
steady - - O
consolidation - - O
and - - O
retention - - O
of - - O
feeding - - O
and - - O
avoidance - - O
behavior - - O
, - - O
and - - O
some - - O
neurophysiological - - O
mechanisms - - O
of - - O
that - - O
phenomena - - O
were - - O
revealed - - O
. - - O

Intriguingly - - O
, - - O
three - - O
hypomorphic - - O
Scm - - O
mutations - - O
, - - O
which - - O
map - - O
within - - O
an - - O
mbt - - O
repeat - - O
, - - O
interact - - O
with - - O
PcG - - O
mutations - - O
more - - O
strongly - - O
than - - O
do - - O
Scm - - O
null - - O
alleles - - O
. - - O

Serial - - O
measurements - - O
of - - O
total - - O
serum - - O
IgE - - O
appears - - O
to - - O
be - - O
a - - O
useful - - O
index - - O
of - - O
disease - - O
activity - - O
in - - O
ABPA - - O
. - - O

Dynamic - - O
decision - - O
making - - O
: - - O
human - - O
control - - O
of - - O
complex - - O
systems - - O
. - - O

Autopsy - - O
demonstrated - - O
good - - O
survival - - O
of - - O
the - - O
transplanted - - O
cells - - O
with - - O
good - - O
integration - - O
with - - O
the - - O
brain - - O
of - - O
the - - O
recipient - - O
and - - O
traces - - O
of - - O
positive - - O
immunocytochemical - - O
reaction - - O
for - - O
tyrosine - - O
hydroxylase - - O
. - - O

After - - O
profound - - O
normovolemic - - O
hemodilution - - O
( - - O
Hct - - O
9% - - O
) - - O
superiority - - O
of - - O
LV - - O
MC - - O
and - - O
LV - - O
diastolic - - O
properties - - O
was - - O
found - - O
, - - O
when - - O
myocardial - - O
oxygenation - - O
was - - O
supported - - O
by - - O
i - - O
. - - O
v - - O
. - - O
perflubron - - O
emulsion - - O
, - - O
a - - O
temporary - - O
O2 - - O
carrier - - O
. - - O

The - - O
inner - - O
ears - - O
were - - O
exposed - - O
by - - O
microdissection - - O
, - - O
and - - O
the - - O
vestibular - - O
sensory - - O
regions - - O
were - - O
either - - O
sectioned - - O
and - - O
studied - - O
with - - O
light - - O
or - - O
electron - - O
microscopy - - O
, - - O
or - - O
prepared - - O
and - - O
studied - - O
with - - O
the - - O
surface - - O
specimen - - O
technique - - O
. - - O

One - - O
of - - O
these - - O
fragments - - O
shows - - O
the - - O
highest - - O
amino - - O
acid - - O
sequence - - O
homology - - O
to - - O
the - - O
insect - - O
ecdysone - - O
inducible - - O
gene - - O
E75 - - O
. - - O

The - - O
domain - - O
structure - - O
of - - O
bovine - - O
LTBP-2 - - O
is - - O
very - - O
similar - - O
to - - O
that - - O
of - - O
the - - O
human - - O
LTBP-2 - - O
, - - O
containing - - O
20 - - O
examples - - O
of - - O
6-cysteine - - O
epidermal - - O
growth - - O
factor-like - - O
repeats - - O
, - - O
16 - - O
of - - O
which - - O
have - - O
the - - O
consensus - - O
sequence - - O
for - - O
calcium - - O
binding - - O
, - - O
together - - O
with - - O
4 - - O
examples - - O
of - - O
8-cysteine - - O
motifs - - O
characteristic - - O
of - - O
fibrillins - - O
and - - O
LTBP-1 - - O
. - - O

Stat - - O
activation - - O
in - - O
response - - O
to - - O
GH - - O
and - - O
IL-6 - - O
was - - O
determined - - O
by - - O
reporter - - O
gene - - O
induction - - O
. - - O

During - - O
early - - O
neurogenesis - - O
, - - O
Vnd - - O
protein - - O
is - - O
restricted - - O
to - - O
ventral - - O
column - - O
neuroectoderm - - O
and - - O
neuroblasts - - O
; - - O
later - - O
it - - O
is - - O
detected - - O
in - - O
a - - O
complex - - O
pattern - - O
of - - O
neurons - - O
. - - O

The - - O
median - - O
post-treatment - - O
, - - O
pre-operative - - O
serum - - O
PSA - - O
was - - O
0 - - O
. - - O
4 - - O
ng - - O
ml - - O
. - - O

The - - O
growth - - O
factor - - O
receptor-bound - - O
protein - - O
2 - - O
( - - O
Grb2 - - O
) - - O
adaptor - - O
when - - O
complexed - - O
with - - O
Sos - - O
( - - O
Son - - O
of - - O
sevenless - - O
) - - O
, - - O
the - - O
exchange - - O
factor - - O
of - - O
Ras - - O
, - - O
conveys - - O
the - - O
signal - - O
induced - - O
by - - O
tyrosine - - O
kinase-activated - - O
receptor - - O
to - - O
Ras - - O
by - - O
recruiting - - O
Sos - - O
to - - O
the - - O
membrane - - O
, - - O
allowing - - O
activation - - O
of - - O
Ras - - O
. - - O

Thus - - O
, - - O
despite - - O
the - - O
potential - - O
for - - O
common - - O
regulatory - - O
mechanisms - - O
, - - O
the - - O
available - - O
evidence - - O
indicates - - O
that - - O
the - - O
Mtx - - O
minimal - - O
promoter - - O
does - - O
not - - O
significantly - - O
affect - - O
Thbs3 - - O
gene - - O
expression - - O
. - - O

Phosphatidylinositol - - O
3-kinase - - O
potentiates - - O
, - - O
but - - O
does - - O
not - - O
trigger - - O
, - - O
T - - O
cell - - O
proliferation - - O
mediated - - O
by - - O
the - - O
IL-2 - - O
receptor - - O
. - - O

Value - - O
of - - O
the - - O
EMG - - O
in - - O
the - - O
diagnosis - - O
of - - O
a - - O
cardiomyopathy - - O
associated - - O
with - - O
a - - O
myotonic - - O
myopathy - - O
. - - O

As - - O
a - - O
result - - O
of - - O
alternative - - O
splicing - - O
, - - O
the - - O
BGP - - O
gene - - O
is - - O
transcribed - - O
into - - O
at - - O
least - - O
seven - - O
distinct - - O
mRNA - - O
species - - O
. - - O

Finally - - O
, - - O
some - - O
point - - O
mutations - - O
in - - O
the - - O
Gag-Pol - - O
PR - - O
domain - - O
inhibited - - O
activation - - O
of - - O
RT - - O
in - - O
trans - - O
by - - O
a - - O
wild-type - - O
PR - - O
, - - O
suggesting - - O
that - - O
the - - O
correct - - O
conformation - - O
of - - O
the - - O
PR - - O
domain - - O
in - - O
Gag-Pol - - O
is - - O
prerequisite - - O
for - - O
activation - - O
of - - O
RT - - O
. - - O

Three - - O
different - - O
site-directed - - O
mutations - - O
of - - O
the - - O
cyclic - - O
AMP - - O
response - - O
element - - O
each - - O
reduced - - O
the - - O
nerve - - O
growth - - O
factor - - O
effect - - O
by - - O
> - - O
90% - - O
. - - O

Significant - - O
GMBF - - O
reductions - - O
occurred - - O
in - - O
early - - O
shock - - O
in - - O
both - - O
treatment - - O
groups - - O
. - - O

HBB - - O
concentration - - O
in - - O
the - - O
fetuses - - O
indicated - - O
little - - O
, - - O
if - - O
any - - O
accumulation - - O
. - - O

SPP - - O
also - - O
induced - - O
transient - - O
tyrosine - - O
phosphorylation - - O
of - - O
focal - - O
adhesion - - O
kinase - - O
( - - O
p125 - - O
( - - O
FAK - - O
) - - O
) - - O
, - - O
a - - O
cytosolic - - O
tyrosine - - O
kinase - - O
that - - O
localizes - - O
in - - O
focal - - O
adhesions - - O
, - - O
and - - O
of - - O
the - - O
cytoskeleton-associated - - O
protein - - O
paxillin - - O
. - - O

Unlike - - O
the - - O
introns - - O
of - - O
other - - O
duplicated - - O
ribosomal - - O
protein - - O
genes - - O
which - - O
are - - O
highly - - O
diverged - - O
, - - O
the - - O
duplicated - - O
S13 - - O
genes - - O
have - - O
two - - O
nearly - - O
identical - - O
DNA - - O
sequences - - O
of - - O
25 - - O
and - - O
31 - - O
bp - - O
in - - O
length - - O
within - - O
their - - O
introns - - O
. - - O

Changes - - O
induced - - O
in - - O
the - - O
gills - - O
of - - O
milkfish - - O
( - - O
Chanos - - O
chanos - - O
Forsskal - - O
) - - O
fingerlings - - O
after - - O
acute - - O
exposure - - O
to - - O
nifurpirinol - - O
( - - O
Furanace - - O
; - - O
P-7138 - - O
) - - O
. - - O

In - - O
agreement - - O
with - - O
these - - O
data - - O
, - - O
western - - O
blot - - O
experiments - - O
using - - O
an - - O
antibody - - O
directed - - O
against - - O
the - - O
carboxy-terminal - - O
portion - - O
of - - O
the - - O
mouse - - O
c-kit - - O
protein - - O
showed - - O
that - - O
a - - O
polypeptide - - O
, - - O
of - - O
the - - O
size - - O
predicted - - O
by - - O
the - - O
open - - O
reading - - O
frame - - O
of - - O
the - - O
spermatid-specific - - O
c-kit - - O
cDNA - - O
, - - O
accumulates - - O
in - - O
the - - O
latest - - O
stages - - O
of - - O
spermatogenesis - - O
and - - O
in - - O
epididymal - - O
spermatozoa - - O
. - - O

Both - - O
the - - O
presence - - O
of - - O
arginine - - O
and - - O
anaerobiosis - - O
are - - O
needed - - O
to - - O
trigger - - O
induction - - O
of - - O
the - - O
pathway - - O
. - - O

The - - O
relatively - - O
mild - - O
defects - - O
observed - - O
in - - O
Rpd3 - - O
mutants - - O
suggest - - O
that - - O
the - - O
recently - - O
identified - - O
Groucho - - O
and - - O
dCtBP - - O
corepressor - - O
proteins - - O
do - - O
not - - O
function - - O
solely - - O
through - - O
the - - O
recruitment - - O
of - - O
histone - - O
deacetylases - - O
. - - O

Since - - O
September - - O
1980 - - O
to - - O
June - - O
1983 - - O
we - - O
have - - O
treated - - O
32 - - O
patients - - O
with - - O
ovarian - - O
cancer - - O
. - - O

Nonreturn - - O
rates - - O
can - - O
be - - O
used - - O
to - - O
derive - - O
more - - O
elementary - - O
biological - - O
measures - - O
for - - O
reproductive - - O
efficiency - - O
, - - O
such - - O
as - - O
conception - - O
rate - - O
and - - O
calving - - O
rate - - O
, - - O
which - - O
separately - - O
might - - O
be - - O
more - - O
reliable - - O
than - - O
nonreturn - - O
rate - - O
itself - - O
to - - O
evaluate - - O
the - - O
fertility - - O
of - - O
a - - O
bull - - O
or - - O
the - - O
performance - - O
of - - O
an - - O
AI - - O
technician - - O
. - - O

Waves - - O
N1 - - O
, - - O
P3 - - O
and - - O
CNV - - O
were - - O
recorded - - O
during - - O
a - - O
CNV - - O
paradigm - - O
in - - O
a - - O
simple - - O
reaction - - O
time - - O
task - - O
with - - O
a - - O
constant - - O
interstimulus - - O
interval - - O
( - - O
ISI - - O
) - - O
of - - O
1 - - O
sec - - O
. - - O

In - - O
the - - O
B6-derived - - O
Db - - O
mutant - - O
B6 - - O
. - - O
CH-2bm13 - - O
( - - O
bm13 - - O
) - - O
strain - - O
, - - O
part - - O
of - - O
the - - O
class - - O
I - - O
Db - - O
antigen-presenting - - O
groove - - O
is - - O
shaped - - O
by - - O
a - - O
class - - O
I - - O
Kb-encoded - - O
sequence - - O
. - - O

The - - O
stability - - O
of - - O
isoniazid - - O
solutions - - O
increases - - O
markedly - - O
with - - O
increasing - - O
NTA - - O
or - - O
EDTA - - O
concentration - - O
up - - O
to - - O
1 - - O
mmol - - O
l - - O
. - - O

Prolonged - - O
suspension - - O
induced - - O
a - - O
significant - - O
change - - O
in - - O
the - - O
geometric - - O
configuration - - O
of - - O
the - - O
femur - - O
middiaphysis - - O
by - - O
increasing - - O
the - - O
minimum - - O
diameter - - O
( - - O
12% - - O
) - - O
without - - O
any - - O
significant - - O
alterations - - O
in - - O
cortical - - O
area - - O
, - - O
density - - O
, - - O
mineral - - O
, - - O
and - - O
collagen - - O
concentrations - - O
. - - O

The - - O
dynamic - - O
properties - - O
of - - O
this - - O
protein - - O
fragment - - O
were - - O
measured - - O
and - - O
analyzed - - O
using - - O
both - - O
isotropic - - O
and - - O
anisotropic - - O
models - - O
of - - O
molecular - - O
motion - - O
. - - O

The - - O
original - - O
technique - - O
was - - O
developed - - O
in - - O
the - - O
1960's - - O
to - - O
analyze - - O
the - - O
inner - - O
ear - - O
fluid - - O
as - - O
a - - O
diagnostic - - O
procedure - - O
( - - O
i - - O
. - - O
e - - O
. - - O
, - - O
diagnostic - - O
labyrinthotomy - - O
) - - O
in - - O
acoustic - - O
neuroma - - O
suspects - - O
. - - O

This - - O
study - - O
utilizes - - O
the - - O
mammalian - - O
two-hybrid - - O
system - - O
to - - O
examine - - O
the - - O
role - - O
of - - O
ligand - - O
in - - O
the - - O
dimerization - - O
of - - O
human - - O
progesterone - - O
receptor - - O
( - - O
hPR - - O
) - - O
. - - O

No - - O
mutation - - O
of - - O
the - - O
NRL - - O
gene - - O
was - - O
found - - O
in - - O
any - - O
of - - O
the - - O
two - - O
families - - O
. - - O

The - - O
Nmd3 - - O
protein - - O
sequence - - O
does - - O
not - - O
contain - - O
readily - - O
recognizable - - O
motifs - - O
of - - O
known - - O
function - - O
. - - O

Several - - O
distinct - - O
apoptotic - - O
stimuli - - O
induce - - O
the - - O
expression - - O
and - - O
caspase-dependent - - O
cleavage - - O
of - - O
hTAF - - O
( - - O
II - - O
) - - O
80 - - O
delta - - O
. - - O
hTAF - - O
( - - O
II - - O
) - - O
80 - - O
delta - - O
, - - O
unlike - - O
hTAF - - O
( - - O
II - - O
) - - O
80 - - O
, - - O
forms - - O
a - - O
TFIID-like - - O
complex - - O
lacking - - O
hTAF - - O
( - - O
II - - O
) - - O
31 - - O
. - - O

A - - O
computed - - O
tomographic - - O
scan - - O
obtained - - O
after - - O
EOE-13 - - O
infusion - - O
accurately - - O
showed - - O
the - - O
perfusion - - O
pattern - - O
of - - O
the - - O
implanted - - O
catheter - - O
. - - O

Therefore - - O
, - - O
in - - O
conjunction - - O
with - - O
a - - O
positive - - O
pregnancy - - O
test - - O
and - - O
the - - O
patient's - - O
clinical - - O
history - - O
, - - O
a - - O
severely - - O
depressed - - O
or - - O
absent - - O
serum - - O
PAPP-A - - O
level - - O
may - - O
aid - - O
in - - O
the - - O
diagnosis - - O
of - - O
extrauterine - - O
pregnancy - - O
. - - O

Aneurysmal - - O
bone - - O
cyst - - O
of - - O
the - - O
jaws - - O
: - - O
analysis - - O
of - - O
11 - - O
cases - - O
. - - O

An - - O
8-bp - - O
sequence - - O
( - - O
ATTTCAAA - - O
) - - O
within - - O
the - - O
protected - - O
region - - O
shares - - O
significant - - O
homology - - O
with - - O
promoter - - O
sequences - - O
required - - O
for - - O
ethylene - - O
responsiveness - - O
from - - O
the - - O
tomato - - O
fruit-ripening - - O
E4 - - O
gene - - O
. - - O

However - - O
, - - O
the - - O
a1 - - O
isoform - - O
is - - O
expressed - - O
most - - O
heavily - - O
in - - O
brain - - O
and - - O
heart - - O
, - - O
a2 - - O
in - - O
liver - - O
and - - O
kidney - - O
, - - O
and - - O
a3 - - O
in - - O
liver - - O
, - - O
lung - - O
, - - O
heart - - O
, - - O
brain - - O
, - - O
spleen - - O
, - - O
and - - O
kidney - - O
. - - O

The - - O
R2 - - O
region - - O
within - - O
the - - O
class - - O
I - - O
enhancer - - O
acts - - O
as - - O
a - - O
negative - - O
element - - O
in - - O
Ad12-transformed - - O
cells - - O
and - - O
exhibits - - O
a - - O
stronger - - O
binding - - O
activity - - O
than - - O
is - - O
observed - - O
in - - O
nontumorigenic - - O
Ad5-transformed - - O
cells - - O
, - - O
which - - O
are - - O
not - - O
reduced - - O
in - - O
class - - O
I - - O
expression - - O
. - - O

Diverse - - O
endogenous - - O
light - - O
chains - - O
contribute - - O
to - - O
basement - - O
membrane - - O
reactivity - - O
in - - O
nonautoimmune - - O
mice - - O
transgenic - - O
for - - O
an - - O
anti-laminin - - O
Ig - - O
heavy - - O
chain - - O
. - - O

UF-021 - - O
ophthalmic - - O
solution - - O
( - - O
0 - - O
. - - O
03 - - O
to - - O
0 - - O
. - - O
24% - - O
) - - O
, - - O
when - - O
topically - - O
applied - - O
to - - O
the - - O
eyes - - O
of - - O
rabbits - - O
, - - O
caused - - O
dose-dependent - - O
IOP - - O
reduction - - O
( - - O
2 - - O
. - - O
8 - - O
to - - O
5 - - O
. - - O
2 - - O
mmHg - - O
) - - O
, - - O
without - - O
transient - - O
IOP - - O
rise - - O
. - - O

All - - O
9 - - O
untreated - - O
patients - - O
underwent - - O
laparoscopy - - O
, - - O
which - - O
identified - - O
3 - - O
intra-abdominal - - O
, - - O
3 - - O
vanished - - O
and - - O
2 - - O
peeping - - O
testes - - O
, - - O
and - - O
1 - - O
atrophic - - O
testis - - O
in - - O
the - - O
inguinal - - O
canal - - O
. - - O

This - - O
slope - - O
tended - - O
to - - O
be - - O
higher - - O
( - - O
approximately - - O
1 - - O
. - - O
6 - - O
dB - - O
dB - - O
) - - O
for - - O
L1 - - O
= - - O
L2 - - O
greater - - O
than - - O
80 - - O
dB - - O
. - - O

Another - - O
stem-loop - - O
called - - O
structure - - O
III - - O
near - - O
the - - O
3'-end - - O
of - - O
repY - - O
sequesters - - O
both - - O
the - - O
5'-rCGCC-3' - - O
sequence - - O
and - - O
the - - O
repZ - - O
ribosome-binding - - O
site - - O
. - - O

We - - O
further - - O
studied - - O
the - - O
effects - - O
of - - O
SIE-1 - - O
hypermethylation - - O
on - - O
p21WAF1 - - O
induction - - O
by - - O
STAT - - O
activation - - O
. - - O

Tumor - - O
necrosis - - O
factor-alpha - - O
( - - O
TNF - - O
alpha - - O
) - - O
, - - O
a - - O
proinflammatory - - O
cytokine - - O
, - - O
inhibits - - O
cAMP-stimulated - - O
testosterone - - O
production - - O
in - - O
mouse - - O
Leydig - - O
cells - - O
. - - O

Positive - - O
shifts - - O
of - - O
basal - - O
skin - - O
potentials - - O
during - - O
human - - O
sleep - - O
. - - O

To - - O
explore - - O
the - - O
functional - - O
properties - - O
of - - O
the - - O
protein - - O
encoded - - O
by - - O
neu - - O
, - - O
we - - O
created - - O
a - - O
fusion - - O
gene - - O
that - - O
joins - - O
the - - O
cytoplasmic - - O
domain - - O
of - - O
neu - - O
to - - O
the - - O
extracellular - - O
portion - - O
of - - O
an - - O
immunoglobulin - - O
heavy - - O
chain - - O
. - - O

Dermal - - O
toxicity - - O
and - - O
carcinogenicity - - O
of - - O
4-vinyl-1-cyclohexene - - O
diepoxide - - O
in - - O
Fischer - - O
rats - - O
and - - O
B6C3F1 - - O
mice - - O
. - - O

Radiogallium - - O
imaging - - O
is - - O
thus - - O
of - - O
limited - - O
use - - O
in - - O
evaluation - - O
of - - O
suspected - - O
giant - - O
cell - - O
tumors - - O
of - - O
bone - - O
. - - O

In - - O
vivo - - O
epiluminescence - - O
microscopy - - O
of - - O
pigmented - - O
skin - - O
lesions - - O
. - - O

In - - O
invertebrates - - O
, - - O
Fhit - - O
is - - O
encoded - - O
as - - O
a - - O
fusion - - O
protein - - O
with - - O
Nit - - O
, - - O
a - - O
member - - O
of - - O
the - - O
nitrilase - - O
superfamily - - O
. - - O

Here - - O
we - - O
localize - - O
a - - O
transferable - - O
40-amino - - O
acid - - O
region - - O
within - - O
the - - O
LBDs - - O
of - - O
RXR - - O
, - - O
RAR - - O
, - - O
TR - - O
, - - O
and - - O
chicken - - O
ovalbumin - - O
upstream - - O
promoter - - O
transcription - - O
factor - - O
that - - O
is - - O
critical - - O
for - - O
determining - - O
identity - - O
in - - O
the - - O
heterodimeric - - O
interaction - - O
and - - O
for - - O
high-affinity - - O
DNA - - O
binding - - O
. - - O

Recently - - O
, - - O
the - - O
3 - - O
. - - O
6-kb - - O
full-length - - O
alpha-GalNAc - - O
cDNA - - O
sequence - - O
was - - O
isolated - - O
and - - O
found - - O
to - - O
have - - O
remarkable - - O
nucleotide - - O
and - - O
predicted - - O
amino - - O
acid - - O
homology - - O
( - - O
55 - - O
. - - O
8 - - O
and - - O
46 - - O
. - - O
9% - - O
, - - O
respectively - - O
) - - O
with - - O
the - - O
human - - O
alpha-galactosidase - - O
A - - O
( - - O
alpha-Gal - - O
A - - O
) - - O
cDNA - - O
. - - O

Re-examination - - O
of - - O
the - - O
ED01 - - O
study - - O
. - - O

In - - O
the - - O
treatment - - O
of - - O
opioid - - O
naive - - O
patients - - O
who - - O
underwent - - O
surgery - - O
and - - O
received - - O
opioids - - O
for - - O
acute - - O
pain - - O
, - - O
oral - - O
ADL - - O
8-2698 - - O
( - - O
6 - - O
. - - O
0 - - O
mg - - O
) - - O
improved - - O
the - - O
management - - O
of - - O
postoperative - - O
ileus - - O
( - - O
POI - - O
) - - O
by - - O
shortening - - O
the - - O
time - - O
to - - O
achieve - - O
normal - - O
bowel - - O
function - - O
and - - O
, - - O
ultimately - - O
, - - O
hospital - - O
stay - - O
. - - O

The - - O
CPK-MB - - O
isoenzyme - - O
showed - - O
no - - O
percentage - - O
increase - - O
of - - O
total - - O
CPK - - O
higher - - O
than - - O
5% - - O
, - - O
measured - - O
at - - O
6 - - O
, - - O
12 - - O
, - - O
and - - O
24 - - O
h - - O
after - - O
the - - O
shock - - O
, - - O
independent - - O
of - - O
the - - O
number - - O
of - - O
attempts - - O
of - - O
cardioversion - - O
. - - O

Latanoprost - - O
produces - - O
an - - O
additional - - O
reduction - - O
of - - O
intraocular - - O
pressure - - O
( - - O
IOP - - O
) - - O
when - - O
used - - O
in - - O
combination - - O
with - - O
timolol - - O
, - - O
pilocarpine - - O
, - - O
acetazolamide - - O
and - - O
dipivefrin - - O
. - - O

The - - O
inhibitory - - O
response - - O
to - - O
taps - - O
is - - O
essentially - - O
a - - O
protective - - O
reflex - - O
which - - O
probably - - O
serves - - O
to - - O
reduce - - O
the - - O
activity - - O
of - - O
the - - O
jaw-closing - - O
muscles - - O
when - - O
one - - O
bites - - O
unexpectedly - - O
on - - O
hard - - O
objects - - O
. - - O

A - - O
flow - - O
rate - - O
of - - O
at - - O
least - - O
5 - - O
mL - - O
h - - O
is - - O
required - - O
through - - O
the - - O
receptor - - O
( - - O
volume - - O
, - - O
0 - - O
. - - O
4 - - O
mL - - O
) - - O
for - - O
accurate - - O
results - - O
. - - O

We - - O
conclude - - O
that - - O
Hansel's - - O
stain - - O
substantially - - O
improves - - O
the - - O
recognition - - O
of - - O
eosinophiluria - - O
as - - O
compared - - O
with - - O
Wright's - - O
stain - - O
. - - O

Histopathologically - - O
, - - O
a - - O
cystic - - O
lymphangioma - - O
was - - O
diagnosed - - O
because - - O
of - - O
the - - O
morphological - - O
features - - O
and - - O
the - - O
immunohistochemical - - O
stainings - - O
of - - O
CD34 - - O
and - - O
Factor - - O
VIII - - O
related - - O
antigen - - O
which - - O
were - - O
observed - - O
positive - - O
reactions - - O
in - - O
endothelial - - O
cells - - O
of - - O
the - - O
cysts - - O
. - - O

These - - O
changes - - O
in - - O
virus - - O
entry - - O
features - - O
may - - O
result - - O
in - - O
coronaviruses - - O
with - - O
novel - - O
pathogenic - - O
properties - - O
. - - O

Allelic - - O
variation - - O
in - - O
HLA-B - - O
and - - O
HLA-C - - O
sequences - - O
and - - O
the - - O
evolution - - O
of - - O
the - - O
HLA-B - - O
alleles - - O
. - - O

Nephrectomy - - O
applied - - O
to - - O
cattle - - O
. - - O

Structure - - O
and - - O
localization - - O
of - - O
the - - O
human - - O
gene - - O
encoding - - O
SR-BI - - O
CLA-1 - - O
. - - O

Rhesus - - O
macaques - - O
and - - O
BALB - - O
c - - O
mice - - O
inoculated - - O
with - - O
the - - O
Mengo - - O
virus - - O
SIV - - O
recombinants - - O
failed - - O
to - - O
develop - - O
CTL - - O
responses - - O
against - - O
the - - O
SIV - - O
gene - - O
products - - O
, - - O
while - - O
one - - O
of - - O
the - - O
HIV-Nef - - O
recombinants - - O
induced - - O
a - - O
weak - - O
CTL - - O
response - - O
in - - O
mice - - O
directed - - O
to - - O
an - - O
HIV1 - - O
Nef - - O
peptide - - O
spanning - - O
positions - - O
182-198 - - O
. - - O

We - - O
cloned - - O
and - - O
sequenced - - O
the - - O
cDNAs - - O
against - - O
genomic - - O
RNA - - O
and - - O
mRNA - - O
for - - O
phosphoprotein - - O
( - - O
P - - O
) - - O
of - - O
human - - O
parainfluenza - - O
type - - O
2 - - O
virus - - O
( - - O
PIV-2 - - O
) - - O
. - - O
cDNA - - O
clone - - O
from - - O
genomic - - O
RNA - - O
was - - O
1439 - - O
nucleotides - - O
in - - O
length - - O
excluding - - O
poly - - O
( - - O
A - - O
) - - O
and - - O
was - - O
found - - O
to - - O
have - - O
two - - O
small - - O
open - - O
reading - - O
frames - - O
encoding - - O
proteins - - O
of - - O
233 - - O
and - - O
249 - - O
amino - - O
acids - - O
. - - O

Also - - O
, - - O
samples - - O
of - - O
serum - - O
were - - O
absorbed - - O
with - - O
the - - O
various - - O
solid-phase - - O
allergens - - O
and - - O
the - - O
reactivity - - O
of - - O
the - - O
remaining - - O
IgE - - O
antibodies - - O
was - - O
determined - - O
. - - O

This - - O
study - - O
demonstrates - - O
that - - O
alteration - - O
of - - O
CDKN2 - - O
is - - O
one - - O
of - - O
the - - O
most - - O
frequent - - O
genetic - - O
abnormalities - - O
in - - O
prostate - - O
cancer - - O
and - - O
may - - O
contribute - - O
to - - O
prostate - - O
carcinogenesis - - O
. - - O

The - - O
chick - - O
axon-associated - - O
surface - - O
glycoprotein - - O
neurofascin - - O
is - - O
implicated - - O
in - - O
axonal - - O
growth - - O
and - - O
fasciculation - - O
as - - O
revealed - - O
by - - O
antibody - - O
perturbation - - O
experiments - - O
. - - O

In - - O
contrast - - O
, - - O
overproduction - - O
of - - O
Der3p - - O
is - - O
lethal - - O
in - - O
a - - O
sec61-2 - - O
strain - - O
at - - O
the - - O
permissive - - O
temperature - - O
of - - O
25 - - O
degrees - - O
C - - O
. - - O

The - - O
unilateral - - O
vestibular - - O
hypofunction - - O
. - - O

The - - O
lysozyme - - O
FEF - - O
site - - O
is - - O
immediately - - O
5' - - O
to - - O
a - - O
PU - - O
. - - O

The - - O
authors - - O
have - - O
tested - - O
the - - O
interference - - O
of - - O
the - - O
hemoglobin - - O
by - - O
two - - O
routine - - O
methods - - O
( - - O
Berthelot - - O
classic - - O
and - - O
Berthelot - - O
modified - - O
) - - O
for - - O
the - - O
determination - - O
of - - O
plasmatic - - O
urea - - O
. - - O

The - - O
nit-3 - - O
gene - - O
of - - O
the - - O
filamentous - - O
fungus - - O
Neurospora - - O
crassa - - O
encodes - - O
nitrate - - O
reductase - - O
, - - O
the - - O
enzyme - - O
which - - O
catalyzes - - O
the - - O
first - - O
step - - O
in - - O
nitrate - - O
assimilation - - O
. - - O

IgG - - O
and - - O
IgM - - O
antibody - - O
activity - - O
was - - O
determined - - O
by - - O
adding - - O
a - - O
1 - - O
: - - O
100 - - O
dilution - - O
of - - O
serum - - O
to - - O
plates - - O
coated - - O
with - - O
A60 - - O
antigen - - O
. - - O

GAL4-VP16-mediated - - O
antirepression - - O
required - - O
an - - O
auxiliary - - O
factor - - O
, - - O
denoted - - O
as - - O
a - - O
co-antirepressor - - O
, - - O
which - - O
was - - O
partially - - O
purified - - O
from - - O
Drosophila - - O
embryos - - O
. - - O

A - - O
consensus - - O
binding - - O
site - - O
for - - O
the - - O
transcription - - O
factor - - O
SP1 - - O
was - - O
identified - - O
in - - O
intron - - O
As - - O
downstream - - O
of - - O
the - - O
proenkephalin - - O
germ - - O
cell - - O
cap - - O
site - - O
region - - O
. - - O

The - - O
isolation - - O
of - - O
this - - O
gene - - O
was - - O
based - - O
on - - O
the - - O
identification - - O
of - - O
the - - O
Y-231 - - O
cosmid - - O
that - - O
contains - - O
CpG - - O
rich - - O
sequences - - O
( - - O
HTF - - O
islands - - O
) - - O
in - - O
its - - O
human - - O
insert - - O
. - - O

Sulfuric - - O
acid - - O
concentration - - O
in - - O
the - - O
catalyzed - - O
breathalyzer - - O
ampules - - O
. - - O

Additionally - - O
, - - O
a - - O
CaCO3-CO2 - - O
N2 - - O
buffered - - O
solution - - O
was - - O
necessary - - O
to - - O
maintain - - O
a - - O
pH - - O
of - - O
8 - - O
. - - O

For - - O
this - - O
reason - - O
, - - O
the - - O
particle - - O
forming - - O
capacity - - O
of - - O
derivatives - - O
of - - O
the - - O
HIV-1 - - O
group - - O
specific - - O
core - - O
antigen - - O
p55 - - O
gag - - O
was - - O
assayed - - O
and - - O
compared - - O
dependent - - O
on - - O
various - - O
expression - - O
systems - - O
: - - O
recombinant - - O
bacteria - - O
, - - O
vaccinia- - - O
and - - O
baculoviruses - - O
were - - O
established - - O
encoding - - O
the - - O
entire - - O
core - - O
protein - - O
p55 - - O
either - - O
in - - O
its - - O
authentic - - O
sequence - - O
or - - O
lacking - - O
the - - O
myristylation - - O
consensus - - O
signal - - O
. - - O

Ketanserin - - O
, - - O
a - - O
hypotensive - - O
drug - - O
with - - O
5-HT2 - - O
receptor - - O
antagonism - - O
, - - O
when - - O
administered - - O
by - - O
topical - - O
infusion - - O
of - - O
a - - O
0 - - O
. - - O
25% - - O
w - - O
v - - O
solution - - O
by - - O
corneal - - O
and - - O
scleral - - O
applications - - O
, - - O
was - - O
found - - O
to - - O
lower - - O
intraocular - - O
pressure - - O
with - - O
four - - O
times - - O
more - - O
activity - - O
than - - O
its - - O
metabolite - - O
, - - O
ketanserinol - - O
. - - O

The - - O
starting - - O
point - - O
is - - O
the - - O
consideration - - O
that - - O
the - - O
conceptions - - O
underlying - - O
the - - O
ICIDH - - O
are - - O
not - - O
suitable - - O
to - - O
serve - - O
as - - O
a - - O
mainstay - - O
of - - O
a - - O
model - - O
for - - O
diagnostics - - O
in - - O
rehabilitation - - O
because - - O
they - - O
do - - O
not - - O
reflect - - O
essential - - O
characteristics - - O
of - - O
the - - O
diagnostic - - O
process - - O
which - - O
is - - O
the - - O
basis - - O
for - - O
intervention - - O
. - - O

Analysis - - O
of - - O
the - - O
entire - - O
16 - - O
. - - O
7-kb - - O
mt - - O
genome - - O
determined - - O
that - - O
a - - O
MDP1 - - O
mediates - - O
cleavage - - O
of - - O
chick - - O
mtDNA - - O
in - - O
vitro - - O
at - - O
three - - O
H- - - O
and - - O
two - - O
L-strand - - O
sequence-specific - - O
target - - O
sites - - O
located - - O
within - - O
a - - O
90-bp - - O
A - - O
+ - - O
T-rich - - O
genomic - - O
tract - - O
, - - O
theoretically - - O
capable - - O
of - - O
forming - - O
stable - - O
secondary - - O
structures - - O
, - - O
approximately - - O
200 - - O
bases - - O
upstream - - O
from - - O
the - - O
H-strand - - O
origin - - O
( - - O
OH - - O
) - - O
of - - O
replication - - O
. - - O

Utility - - O
of - - O
OAE - - O
screener - - O
( - - O
GSI - - O
70 - - O
) - - O
for - - O
the - - O
evaluation - - O
of - - O
distortion - - O
product - - O
otoacoustic - - O
emissions - - O
The - - O
purpose - - O
of - - O
this - - O
study - - O
was - - O
to - - O
investigate - - O
the - - O
ability - - O
of - - O
the - - O
OAE - - O
screener - - O
GSI - - O
70 - - O
to - - O
evaluate - - O
of - - O
cochlea - - O
function - - O
in - - O
neonates - - O
, - - O
infants - - O
and - - O
adults - - O
. - - O

The - - O
3' - - O
UTR - - O
has - - O
several - - O
stable - - O
hairpins - - O
that - - O
are - - O
flanked - - O
by - - O
single-stranded - - O
( - - O
A - - O
U - - O
) - - O
UGC - - O
sequences - - O
. - - O

Terazosin - - O
, - - O
a - - O
structural - - O
analog - - O
of - - O
prazosin - - O
, - - O
also - - O
inhibits - - O
alpha - - O
1 - - O
adrenoceptors - - O
and - - O
is - - O
recommended - - O
as - - O
once - - O
or - - O
twice-daily - - O
therapy - - O
. - - O

The - - O
extraction - - O
measurements - - O
were - - O
used - - O
to - - O
test - - O
for - - O
extracerebral - - O
contamination - - O
of - - O
venous - - O
outflow - - O
. - - O

The - - O
patients - - O
are - - O
two - - O
healthy - - O
adult - - O
males - - O
. - - O

Supplementation - - O
was - - O
stopped - - O
when - - O
pl-ALB - - O
reached - - O
2 - - O
. - - O
0 - - O
g - - O
dL - - O
. - - O

Treatment - - O
of - - O
recurrent - - O
FSGS - - O
has - - O
included - - O
high-dose - - O
steroids - - O
, - - O
high-dose - - O
cyclosporine - - O
( - - O
CSA - - O
) - - O
, - - O
plasmapheresis - - O
, - - O
and - - O
ACE - - O
inhibitors - - O
with - - O
mixed - - O
results - - O
. - - O

Effect - - O
of - - O
proteolytic - - O
enzymes - - O
and - - O
polypeptides - - O
on - - O
the - - O
antacid - - O
activity - - O
of - - O
almagate - - O
and - - O
other - - O
antacids - - O
. - - O

We - - O
propose - - O
that - - O
the - - O
ambiguous - - O
discrimination - - O
required - - O
a - - O
greater - - O
time - - O
for - - O
simulus - - O
evaluation - - O
and - - O
that - - O
this - - O
was - - O
reflected - - O
in - - O
the - - O
delayed - - O
P3 - - O
latencies - - O
. - - O

The - - O
median - - O
preoperative - - O
best-corrected - - O
visual - - O
acuity - - O
of - - O
0 - - O
. - - O
08 - - O
( - - O
range - - O
hand - - O
motions - - O
0 - - O
. - - O
003 - - O
to - - O
0 - - O
. - - O
4 - - O
) - - O
, - - O
improved - - O
by - - O
5 - - O
lines - - O
to - - O
a - - O
median - - O
final - - O
postoperative - - O
best-corrected - - O
visual - - O
acuity - - O
of - - O
0 - - O
. - - O
25 - - O
( - - O
range - - O
0 - - O
. - - O
025-0 - - O
. - - O
5 - - O
) - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

In - - O
the - - O
second - - O
case - - O
, - - O
an - - O
epidermal - - O
cyst - - O
was - - O
diagnosed - - O
. - - O

The - - O
colony-stimulating - - O
factors - - O
( - - O
CSFs - - O
) - - O
principally - - O
involved - - O
in - - O
the - - O
production - - O
of - - O
neutrophils - - O
and - - O
monocytes - - O
are - - O
granulocyte - - O
CSF - - O
, - - O
granulocyte-macrophage - - O
CSF - - O
, - - O
macrophage - - O
CSF - - O
, - - O
and - - O
interleukin - - O
3 - - O
( - - O
sometimes - - O
called - - O
multi-CSF - - O
) - - O
. - - O

By - - O
treating - - O
monkey - - O
COS - - O
cells - - O
with - - O
oligonucleotides - - O
linked - - O
to - - O
psoralen - - O
, - - O
we - - O
have - - O
generated - - O
targeted - - O
mutations - - O
in - - O
a - - O
simian - - O
virus - - O
40 - - O
( - - O
SV40 - - O
) - - O
vector - - O
contained - - O
within - - O
the - - O
cells - - O
via - - O
intracellular - - O
triple - - O
helix - - O
formation - - O
. - - O

Deltamethrin - - O
was - - O
most - - O
effective - - O
on - - O
the - - O
thatched - - O
surface - - O
and - - O
produced - - O
100% - - O
mortality - - O
of - - O
An - - O
. - - O
culicifacies - - O
adults - - O
up - - O
to - - O
12 - - O
weeks - - O
, - - O
even - - O
when - - O
exposed - - O
at - - O
the - - O
lowest - - O
dose - - O
12 - - O
. - - O
5 - - O
mg - - O
m2 - - O
. - - O

The - - O
DNA - - O
sequence - - O
adjacent - - O
to - - O
the - - O
lacZ - - O
gene - - O
has - - O
been - - O
determined - - O
for - - O
91 - - O
vegetative - - O
fusion - - O
genes - - O
whose - - O
products - - O
have - - O
been - - O
localized - - O
and - - O
for - - O
43 - - O
meiotically - - O
induced - - O
fusions - - O
. - - O

This - - O
study - - O
proposes - - O
an - - O
estimator - - O
for - - O
such - - O
global - - O
synchronizing - - O
effects - - O
upon - - O
unit-pair - - O
correlations - - O
based - - O
on - - O
local - - O
field - - O
potentials - - O
( - - O
LFPs - - O
) - - O
. - - O

RESULTS - - O
: - - O
Neither - - O
basal - - O
FSH - - O
level - - O
nor - - O
stimulated - - O
FSH - - O
level - - O
alone - - O
were - - O
statistically - - O
significant - - O
predictors - - O
of - - O
IVF - - O
success - - O
; - - O
however - - O
, - - O
no - - O
patient - - O
with - - O
a - - O
day - - O
3 - - O
FSH - - O
level - - O
> - - O
11 - - O
. - - O
1 - - O
mIU - - O
ml - - O
or - - O
a - - O
stimulated - - O
day - - O
10 - - O
FSH - - O
level - - O
> - - O
13 - - O
. - - O
5 - - O
mIU - - O
ml - - O
conceived - - O
and - - O
carried - - O
a - - O
pregnancy - - O
. - - O

The - - O
serum - - O
insulin - - O
response - - O
cannot - - O
. - - O

Significant - - O
correlations - - O
were - - O
obtained - - O
between - - O
changes - - O
in - - O
SSEP - - O
in - - O
response - - O
to - - O
AS - - O
and - - O
the - - O
presence - - O
of - - O
not - - O
deep - - O
residual-organic - - O
disturbances - - O
, - - O
so-called - - O
"ground" - - O
in - - O
psychogenic - - O
disorders - - O
. - - O

In - - O
rats - - O
, - - O
we - - O
examined - - O
the - - O
effect - - O
of - - O
an - - O
omentum - - O
wrapping - - O
on - - O
the - - O
vascularization - - O
of - - O
the - - O
trachea - - O
and - - O
on - - O
regeneration - - O
of - - O
the - - O
mucosal - - O
epithelium - - O
in - - O
the - - O
very - - O
early - - O
stage - - O
after - - O
free - - O
tracheal - - O
grafting - - O
. - - O

To - - O
evaluate - - O
the - - O
hepatic - - O
regenerative - - O
response - - O
in - - O
patients - - O
with - - O
alcoholic - - O
liver - - O
disease - - O
, - - O
sera - - O
from - - O
263 - - O
patients - - O
with - - O
severe - - O
alcoholic - - O
hepatitis - - O
and - - O
or - - O
cirrhosis - - O
were - - O
analyzed - - O
for - - O
hepatocyte - - O
growth - - O
factor - - O
( - - O
HGF - - O
) - - O
and - - O
alpha-fetoprotein - - O
( - - O
AFP - - O
) - - O
. - - O

Composites - - O
as - - O
restoration - - O
materials - - O
. - - O

The - - O
high - - O
selectivity - - O
of - - O
arrestins - - O
for - - O
this - - O
particular - - O
functional - - O
form - - O
of - - O
receptor - - O
ensures - - O
their - - O
timely - - O
binding - - O
and - - O
dissociation - - O
. - - O

Primary - - O
invasive - - O
Haemophilus - - O
influenzae - - O
type - - O
b - - O
disease - - O
: - - O
a - - O
population-based - - O
assessment - - O
of - - O
risk - - O
factors - - O
. - - O

However - - O
, - - O
while - - O
the - - O
sequence - - O
similarity - - O
between - - O
the - - O
membrane - - O
exons - - O
of - - O
avian - - O
mIgY - - O
and - - O
mammalian - - O
mIgG - - O
and - - O
IgE - - O
is - - O
striking - - O
, - - O
the - - O
overall - - O
similarity - - O
with - - O
Xenopus - - O
mIgY - - O
is - - O
very - - O
low - - O
. - - O

The - - O
same-sized - - O
EBNA - - O
protein - - O
( - - O
approximately - - O
78 - - O
, - - O
000 - - O
) - - O
was - - O
made - - O
after - - O
transfection - - O
with - - O
BamHI-K - - O
( - - O
5 - - O
. - - O
2 - - O
kilobase - - O
pairs - - O
[ - - O
kbp - - O
] - - O
) - - O
or - - O
the - - O
I1f - - O
subfragment - - O
( - - O
2 - - O
. - - O
9 - - O
kbp - - O
) - - O
. - - O

VP5 - - O
, - - O
which - - O
encodes - - O
the - - O
major - - O
capsid - - O
protein - - O
, - - O
each - - O
fused - - O
to - - O
the - - O
chloramphenicol - - O
acetyltransferase - - O
gene - - O
. - - O

Alternative - - O
splicing - - O
of - - O
RNA - - O
transcripts - - O
encoded - - O
by - - O
the - - O
murine - - O
p105 - - O
NF-kappa - - O
B - - O
gene - - O
generates - - O
I - - O
kappa - - O
B - - O
gamma - - O
isoforms - - O
with - - O
different - - O
inhibitory - - O
activities - - O
. - - O

Elevation - - O
of - - O
the - - O
tissues - - O
of - - O
the - - O
face - - O
is - - O
essentially - - O
vertical - - O
and - - O
acts - - O
on - - O
the - - O
forehead - - O
, - - O
temporal - - O
region - - O
, - - O
gaze - - O
and - - O
cheekbones - - O
. - - O

If - - O
facilities - - O
for - - O
measurements - - O
of - - O
O2 - - O
consumption - - O
and - - O
hence - - O
metabolic - - O
rate - - O
are - - O
available - - O
, - - O
these - - O
should - - O
be - - O
utilized - - O
. - - O

The - - O
P165 - - O
component - - O
, - - O
however - - O
, - - O
could - - O
be - - O
differentiated - - O
from - - O
the - - O
two - - O
later - - O
components - - O
since - - O
it - - O
increased - - O
in - - O
amplitude - - O
with - - O
increased - - O
task - - O
demands - - O
while - - O
the - - O
N2 - - O
and - - O
P3 - - O
amplitudes - - O
remained - - O
constant - - O
. - - O

Patients - - O
with - - O
moderate - - O
PDDAT - - O
were - - O
impaired - - O
on - - O
all - - O
serial - - O
positions - - O
for - - O
both - - O
spatial - - O
order - - O
and - - O
spatial - - O
recognition - - O
memory - - O
. - - O

At - - O
the - - O
time - - O
of - - O
the - - O
13 - - O
latest - - O
BPVs - - O
, - - O
age - - O
ranged - - O
from - - O
three - - O
days - - O
to - - O
13 - - O
. - - O
1 - - O
years - - O
( - - O
mean - - O
5 - - O
. - - O
7 - - O
+ - - O
- - - O
SD - - O
4 - - O
. - - O
8 - - O
years - - O
) - - O
. - - O

Stably - - O
transfected - - O
human - - O
kidney - - O
293 - - O
cells - - O
expressing - - O
the - - O
wild - - O
type - - O
rat - - O
LH - - O
CG - - O
receptor - - O
( - - O
rLHR - - O
) - - O
or - - O
receptors - - O
with - - O
C-terminal - - O
tails - - O
truncated - - O
at - - O
residues - - O
653 - - O
, - - O
631 - - O
, - - O
or - - O
628 - - O
( - - O
designated - - O
rLHR-t653 - - O
, - - O
rLHR-t631 - - O
, - - O
and - - O
rLHR-t628 - - O
) - - O
were - - O
used - - O
to - - O
probe - - O
the - - O
importance - - O
of - - O
this - - O
region - - O
on - - O
the - - O
regulation - - O
of - - O
hormonal - - O
responsiveness - - O
. - - O

We - - O
examined - - O
the - - O
hypothesis - - O
that - - O
the - - O
coronary - - O
vasomotor - - O
responses - - O
to - - O
etomidate - - O
( - - O
ETO - - O
) - - O
, - - O
propofol - - O
( - - O
PRO - - O
) - - O
, - - O
and - - O
sodium - - O
thiopental - - O
( - - O
STP - - O
) - - O
are - - O
mediated - - O
through - - O
contrasting - - O
effects - - O
on - - O
the - - O
resting - - O
nitric - - O
oxide - - O
( - - O
NO - - O
) - - O
-dependent - - O
vasodilator - - O
tone - - O
that - - O
opposes - - O
adrenergic - - O
vasoconstrictor - - O
activity - - O
in - - O
the - - O
intact - - O
dog - - O
. - - O

Here - - O
we - - O
have - - O
examined - - O
the - - O
ability - - O
of - - O
the - - O
cellular - - O
protein - - O
YB-1 - - O
to - - O
modulate - - O
transcription - - O
of - - O
the - - O
HIV-1 - - O
promoter - - O
in - - O
a - - O
human - - O
astrocytic - - O
cell - - O
line - - O
( - - O
U-87MG - - O
) - - O
, - - O
a - - O
neuronal - - O
cell - - O
line - - O
( - - O
SK-N-MC - - O
) - - O
and - - O
lymphoid - - O
cells - - O
( - - O
Jurkat - - O
) - - O
by - - O
transfection - - O
assay - - O
. - - O

In - - O
this - - O
study - - O
we - - O
examined - - O
hepatic - - O
stellate - - O
cell - - O
regulation - - O
of - - O
M6P - - O
IGFIIR - - O
expression - - O
and - - O
found - - O
that - - O
M6P - - O
IGFIIR - - O
mRNA - - O
transcript - - O
levels - - O
increased - - O
in - - O
stellate - - O
cells - - O
from - - O
rats - - O
exposed - - O
to - - O
carbon - - O
tetrachloride - - O
( - - O
CCl4 - - O
) - - O
, - - O
a - - O
potent - - O
fibrogenic - - O
stimulant - - O
. - - O

However - - O
, - - O
other - - O
regions - - O
of - - O
the - - O
plasmid - - O
are - - O
also - - O
efficiently - - O
repaired - - O
. - - O

Lack - - O
of - - O
effect - - O
of - - O
the - - O
appetite - - O
stimulant - - O
pizotifen - - O
( - - O
BC - - O
105 - - O
) - - O
on - - O
the - - O
absorption - - O
of - - O
isonicotinylhydrazine - - O
. - - O

We - - O
have - - O
improved - - O
our - - O
system - - O
for - - O
nuclear - - O
contour - - O
digitization - - O
and - - O
determined - - O
its - - O
theoretical - - O
limitations - - O
by - - O
digitizing - - O
standardized - - O
objects - - O
. - - O

To - - O
evaluate - - O
the - - O
comparative - - O
safety - - O
of - - O
U-P - - O
and - - O
D&E - - O
, - - O
we - - O
analyzed - - O
2 - - O
, - - O
805 - - O
U-P - - O
and - - O
9 - - O
, - - O
572 - - O
D&E - - O
abortions - - O
at - - O
13 - - O
to - - O
24 - - O
menstrual - - O
weeks' - - O
gestation - - O
. - - O

2 - - O
. - - O

These - - O
corrections - - O
do - - O
not - - O
involve - - O
sequences - - O
predicted - - O
to - - O
function - - O
as - - O
transcription - - O
factor - - O
binding - - O
sites - - O
. - - O

Our - - O
results - - O
showed - - O
that - - O
compared - - O
to - - O
the - - O
primary - - O
photon - - O
fluence - - O
, - - O
the - - O
extra-focal - - O
photon - - O
fluence - - O
from - - O
the - - O
primary - - O
collimator - - O
and - - O
the - - O
flattening - - O
filter - - O
was - - O
11%-16% - - O
at - - O
the - - O
isocenter - - O
, - - O
among - - O
which - - O
70% - - O
was - - O
contributed - - O
by - - O
the - - O
flattening - - O
filter - - O
. - - O

In - - O
men - - O
with - - O
BMI - - O
< - - O
30 - - O
, - - O
the - - O
OR - - O
was - - O
1 - - O
. - - O
83 - - O
for - - O
postprandial - - O
TG - - O
( - - O
P - - O
= - - O
. - - O
041 - - O
) - - O
and - - O
2 - - O
. - - O
77 - - O
for - - O
postprandial - - O
RP - - O
( - - O
P - - O
= - - O
. - - O
032 - - O
) - - O
in - - O
models - - O
that - - O
included - - O
fasting - - O
TG - - O
, - - O
LDL-C - - O
, - - O
and - - O
hypertension - - O
. - - O

The - - O
kinase - - O
inhibitor - - O
staurosporine - - O
( - - O
1 - - O
microM - - O
) - - O
blocks - - O
LPA-induced - - O
, - - O
but - - O
not - - O
epidermal - - O
growth - - O
factor-induced - - O
, - - O
activation - - O
of - - O
p21ras - - O
and - - O
MAP - - O
kinase - - O
, - - O
consistent - - O
with - - O
an - - O
intermediate - - O
protein - - O
kinase - - O
linking - - O
the - - O
LPA - - O
receptor - - O
to - - O
p21ras - - O
activation - - O
. - - O

The - - O
histochemistry - - O
and - - O
ultrastructure - - O
of - - O
calcified - - O
cerebellar - - O
deposits - - O
described - - O
by - - O
Tonge - - O
et - - O
al - - O
. - - O

Three - - O
of - - O
these - - O
subunits - - O
are - - O
also - - O
homologous - - O
to - - O
the - - O
dimeric - - O
POR - - O
from - - O
a - - O
mesophilic - - O
archaeon - - O
, - - O
Halobacterium - - O
halobium - - O
( - - O
21% - - O
identity - - O
) - - O
. - - O

The - - O
RNA - - O
transcripts - - O
structurally - - O
equivalent - - O
to - - O
I - - O
( - - O
2 - - O
) - - O
sgRNAs - - O
of - - O
TMV - - O
U1 - - O
and - - O
crTMV - - O
, - - O
but - - O
containing - - O
a - - O
hairpin - - O
structure - - O
( - - O
H - - O
) - - O
immediately - - O
upstream - - O
of - - O
IRES - - O
( - - O
MP - - O
, - - O
75 - - O
) - - O
( - - O
HIRES - - O
( - - O
MP - - O
) - - O
, - - O
( - - O
75 - - O
) - - O
( - - O
CR - - O
) - - O
-MP-CP-3'UTR - - O
; - - O
HIRES - - O
( - - O
MP - - O
, - - O
75 - - O
) - - O
( - - O
U1 - - O
) - - O
-MP-CP-3'UTR - - O
) - - O
, - - O
were - - O
able - - O
to - - O
express - - O
the - - O
MP - - O
gene - - O
in - - O
vitro - - O
. - - O

In - - O
addition - - O
a - - O
greater - - O
proportion - - O
of - - O
women - - O
in - - O
the - - O
sweeping - - O
group - - O
had - - O
a - - O
cervical - - O
dilatation - - O
of - - O
4 - - O
cm - - O
or - - O
more - - O
at - - O
the - - O
first - - O
vaginal - - O
examination - - O
in - - O
the - - O
labour - - O
ward - - O
( - - O
16 - - O
33 - - O
( - - O
49% - - O
) - - O
vs - - O
5 - - O
32 - - O
( - - O
16% - - O
) - - O
; - - O
OR - - O
4 - - O
. - - O
39 - - O
; - - O
95% - - O
CI - - O
1 - - O
. - - O
56 - - O
to - - O
12 - - O
. - - O
32 - - O
; - - O
P - - O
= - - O
0 - - O
. - - O
005 - - O
) - - O
. - - O

Exposure - - O
of - - O
endothelium - - O
to - - O
pulsatile - - O
shear - - O
stresses - - O
that - - O
followed - - O
a - - O
tape - - O
recording - - O
of - - O
physiological - - O
flow - - O
waveforms - - O
( - - O
electromagnetic - - O
flowmeter - - O
) - - O
did - - O
not - - O
cause - - O
gross - - O
injury - - O
or - - O
denudation - - O
even - - O
when - - O
peak - - O
shear - - O
exceeded - - O
1500 - - O
dyne - - O
cm2 - - O
. - - O

We - - O
report - - O
the - - O
preliminary - - O
biochemical - - O
characterization - - O
of - - O
the - - O
T - - O
antigens - - O
encoded - - O
by - - O
three - - O
SV40 - - O
mutants - - O
, - - O
5030 - - O
, - - O
5031 - - O
, - - O
and - - O
5061 - - O
, - - O
each - - O
of - - O
which - - O
have - - O
altered - - O
residues - - O
within - - O
or - - O
near - - O
the - - O
ATP - - O
binding - - O
pocket - - O
. - - O

Site-directed - - O
mutagenesis - - O
showed - - O
that - - O
two - - O
adjacent - - O
SP1 - - O
sites - - O
proximal - - O
to - - O
exon - - O
1 - - O
were - - O
equally - - O
important - - O
in - - O
sustaining - - O
basal - - O
promoter - - O
activity - - O
. - - O

Taken - - O
together - - O
, - - O
these - - O
results - - O
are - - O
consistent - - O
with - - O
the - - O
possibility - - O
that - - O
p202 - - O
protein - - O
contributes - - O
to - - O
the - - O
cell - - O
growth - - O
retardation - - O
activity - - O
of - - O
the - - O
IFNs - - O
, - - O
at - - O
least - - O
in - - O
part - - O
, - - O
by - - O
modulating - - O
p21 - - O
protein - - O
levels - - O
. - - O

Genomic - - O
organization - - O
of - - O
the - - O
human - - O
phosphodiesterase - - O
PDE11A - - O
gene - - O
. - - O

To - - O
modulate - - O
transcription - - O
, - - O
regulatory - - O
factors - - O
communicate - - O
with - - O
basal - - O
transcription - - O
factors - - O
and - - O
or - - O
RNA - - O
polymerases - - O
in - - O
a - - O
variety - - O
of - - O
ways - - O
. - - O

In - - O
Mv1Lu - - O
lung - - O
epithelial - - O
cells - - O
, - - O
ActR-IB - - O
and - - O
T - - O
beta - - O
R-I - - O
signal - - O
a - - O
common - - O
set - - O
of - - O
growth-inhibitory - - O
and - - O
transcriptional - - O
responses - - O
in - - O
association - - O
with - - O
their - - O
corresponding - - O
ligands - - O
and - - O
type - - O
II - - O
receptors - - O
. - - O

The - - O
observed - - O
phenotypes - - O
may - - O
be - - O
explained - - O
by - - O
( - - O
i - - O
) - - O
a - - O
selective - - O
disruption - - O
of - - O
very-low-density - - O
lipoprotein - - O
secretion - - O
due - - O
to - - O
decreased - - O
expression - - O
of - - O
genes - - O
encoding - - O
apolipoprotein - - O
B - - O
and - - O
microsomal - - O
triglyceride - - O
transfer - - O
protein - - O
, - - O
( - - O
ii - - O
) - - O
an - - O
increase - - O
in - - O
hepatic - - O
cholesterol - - O
uptake - - O
due - - O
to - - O
increased - - O
expression - - O
of - - O
the - - O
major - - O
high-density - - O
lipoprotein - - O
receptor - - O
, - - O
scavenger - - O
receptor - - O
BI - - O
, - - O
and - - O
( - - O
iii - - O
) - - O
a - - O
decrease - - O
in - - O
bile - - O
acid - - O
uptake - - O
to - - O
the - - O
liver - - O
due - - O
to - - O
down-regulation - - O
of - - O
the - - O
major - - O
basolateral - - O
bile - - O
acid - - O
transporters - - O
sodium - - O
taurocholate - - O
cotransporter - - O
protein - - O
and - - O
organic - - O
anion - - O
transporter - - O
protein - - O
1 - - O
. - - O

Two - - O
estrogen - - O
receptor - - O
( - - O
ER - - O
) - - O
isoforms - - O
with - - O
different - - O
estrogen - - O
dependencies - - O
are - - O
generated - - O
from - - O
the - - O
trout - - O
ER - - O
gene - - O
. - - O

In - - O
the - - O
context - - O
of - - O
the - - O
ADH2 - - O
upstream - - O
regulatory - - O
region - - O
, - - O
including - - O
UAS1 - - O
, - - O
working - - O
in - - O
concert - - O
with - - O
the - - O
ADH2 - - O
basal - - O
promoter - - O
elements - - O
, - - O
UAS2-dependent - - O
gene - - O
activation - - O
was - - O
dependent - - O
on - - O
orientation - - O
, - - O
copy - - O
number - - O
, - - O
and - - O
helix - - O
phase - - O
. - - O

Measurements - - O
were - - O
done - - O
with - - O
a - - O
commercial - - O
haematofluorometer - - O
Buchler - - O
ZF - - O
which - - O
was - - O
calibrated - - O
to - - O
the - - O
average - - O
haematocrit - - O
value - - O
of - - O
0 - - O
. - - O
42 - - O
. - - O

Paracrine - - O
activation - - O
of - - O
the - - O
HIV-1 - - O
LTR - - O
promoter - - O
by - - O
the - - O
viral - - O
Tat - - O
protein - - O
is - - O
mechanistically - - O
similar - - O
to - - O
trans-activation - - O
within - - O
a - - O
cell - - O
. - - O

Furthermore - - O
, - - O
binding - - O
of - - O
recombinant - - O
Myb - - O
and - - O
Ets-2 - - O
protein - - O
to - - O
these - - O
fragments - - O
could - - O
be - - O
competed - - O
with - - O
an - - O
excess - - O
of - - O
double - - O
stranded - - O
oligodeoxynucleotides - - O
containing - - O
canonical - - O
, - - O
but - - O
not - - O
mutated - - O
, - - O
Myb- - - O
or - - O
Ets-binding - - O
sites - - O
. - - O

A - - O
total - - O
of - - O
117 - - O
EVS - - O
treatments - - O
were - - O
performed - - O
on - - O
34 - - O
patients - - O
. - - O

O - - O
. - - O
novo-ulmi - - O
RNA-7 - - O
, - - O
previously - - O
believed - - O
to - - O
be - - O
a - - O
satellite-like - - O
RNA - - O
, - - O
is - - O
shown - - O
to - - O
be - - O
a - - O
defective - - O
RNA - - O
, - - O
derived - - O
from - - O
OnuMV4-Ld - - O
RNA - - O
by - - O
multiple - - O
internal - - O
deletions - - O
. - - O

Diffuse - - O
myalgias - - O
were - - O
more - - O
frequent - - O
in - - O
patients - - O
with - - O
than - - O
without - - O
an - - O
MMF - - O
lesion - - O
at - - O
deltoid - - O
muscle - - O
biopsy - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
0001 - - O
) - - O
. - - O

Successful - - O
treatment - - O
with - - O
nasal - - O
continuous - - O
positive - - O
airway - - O
pressure - - O
( - - O
8 - - O
. - - O
3 - - O
+ - - O
- - - O
1 - - O
. - - O
5 - - O
cmH2O - - O
) - - O
for - - O
3 - - O
days - - O
caused - - O
a - - O
significant - - O
decrease - - O
in - - O
mean - - O
blood - - O
pressure - - O
in - - O
OSAS - - O
. - - O

DNA - - O
binding - - O
assays - - O
confirmed - - O
the - - O
interference - - O
of - - O
p30 - - O
( - - O
II - - O
) - - O
with - - O
the - - O
assembly - - O
of - - O
CREB-Tax-p300 - - O
CBP - - O
multiprotein - - O
complexes - - O
on - - O
21-bp - - O
repeat - - O
oligonucleotides - - O
in - - O
vitro - - O
. - - O

Full-length - - O
AT-PHH1 - - O
, - - O
and - - O
both - - O
AT-PHH1 - - O
and - - O
AT-PHH1 - - O
delta - - O
C-513 - - O
( - - O
truncated - - O
to - - O
be - - O
approximately - - O
the - - O
size - - O
of - - O
microbial - - O
photolyase - - O
genes - - O
) - - O
cDNAs - - O
, - - O
were - - O
overexpressed - - O
, - - O
respectively - - O
, - - O
in - - O
yeast - - O
and - - O
Escherichia - - O
coli - - O
mutants - - O
hypersensitive - - O
to - - O
ultraviolet - - O
light - - O
. - - O

GAP-N - - O
bound - - O
constitutively - - O
to - - O
p190 - - O
in - - O
both - - O
serum-deprived - - O
and - - O
growth - - O
factor-stimulated - - O
cells - - O
. - - O

Binding - - O
activity - - O
in - - O
rat - - O
liver - - O
nuclear - - O
extracts - - O
includes - - O
these - - O
orphan - - O
receptors - - O
as - - O
judged - - O
from - - O
electromobility - - O
supershift - - O
experiments - - O
and - - O
from - - O
results - - O
obtained - - O
with - - O
expressed - - O
receptors - - O
, - - O
although - - O
the - - O
element - - O
in - - O
CYP2C11 - - O
did - - O
not - - O
bind - - O
HNF-4 - - O
. - - O

Muscular - - O
pathology - - O
. - - O

Further - - O
, - - O
the - - O
ORFs - - O
of - - O
components - - O
3 - - O
and - - O
5 - - O
potentially - - O
encoded - - O
proteins - - O
of - - O
about - - O
20 - - O
kDa - - O
, - - O
the - - O
size - - O
of - - O
the - - O
BBTV - - O
coat - - O
protein - - O
. - - O

This - - O
computation - - O
is - - O
performed - - O
by - - O
a - - O
parallel - - O
network - - O
of - - O
locally - - O
connected - - O
neuron-like - - O
elements - - O
. - - O

SFP - - O
was - - O
significantly - - O
elevated - - O
in - - O
Hn - - O
( - - O
s - - O
) - - O
. - - O

Neither - - O
the - - O
p42 - - O
44 - - O
nor - - O
the - - O
JNK - - O
pathway - - O
was - - O
involved - - O
in - - O
the - - O
action - - O
of - - O
IL-1beta - - O
. - - O

Linkage - - O
studies - - O
have - - O
shown - - O
locus - - O
heterogeneity - - O
with - - O
one - - O
TSC - - O
gene - - O
mapped - - O
to - - O
chromosome - - O
9q34 - - O
and - - O
a - - O
second - - O
to - - O
16p13 - - O
. - - O
3 - - O
. - - O

These - - O
results - - O
suggest - - O
KCC3 - - O
is - - O
a - - O
new - - O
member - - O
of - - O
the - - O
KCC - - O
family - - O
that - - O
is - - O
under - - O
distinct - - O
regulation - - O
from - - O
KCC1 - - O
. - - O

The - - O
primary - - O
structure - - O
of - - O
a - - O
2671 - - O
bp - - O
DNA - - O
fragment - - O
between - - O
the - - O
pla - - O
gene - - O
( - - O
encoding - - O
plasminogen - - O
activator - - O
) - - O
and - - O
the - - O
origin - - O
of - - O
replication - - O
of - - O
the - - O
wild-type - - O
Yersinia - - O
pestis - - O
plasmid - - O
pYP358 - - O
was - - O
determined - - O
. - - O

A - - O
single - - O
amino - - O
acid - - O
difference - - O
in - - O
the - - O
C-terminal - - O
region - - O
influences - - O
dominant - - O
negative - - O
activity - - O
and - - O
receptor - - O
dimer - - O
formation - - O
. - - O

Progressive - - O
study - - O
and - - O
robustness - - O
test - - O
of - - O
QSAR - - O
model - - O
based - - O
on - - O
quantum - - O
chemical - - O
parameters - - O
for - - O
predicting - - O
BCF - - O
of - - O
selected - - O
polychlorinated - - O
organic - - O
compounds - - O
( - - O
PCOCs - - O
) - - O
. - - O

EEA1 - - O
is - - O
a - - O
conserved - - O
alpha-helical - - O
peripheral - - O
membrane - - O
protein - - O
flanked - - O
by - - O
cysteine - - O
"fingers" - - O
and - - O
contains - - O
a - - O
calmodulin-binding - - O
IQ - - O
motif - - O
. - - O

In - - O
a - - O
series - - O
of - - O
16 - - O
full-scale - - O
fire - - O
tests - - O
, - - O
investigators - - O
at - - O
the - - O
IIT - - O
Research - - O
Institute - - O
have - - O
concluded - - O
that - - O
automatic - - O
door - - O
control - - O
in - - O
the - - O
room - - O
of - - O
fire - - O
origin - - O
can - - O
significantly - - O
reduce - - O
the - - O
spread - - O
of - - O
toxic - - O
smoke - - O
and - - O
gases - - O
. - - O

Two - - O
studies - - O
on - - O
the - - O
relationship - - O
between - - O
taking - - O
a - - O
commercial - - O
coaching - - O
course - - O
and - - O
performance - - O
on - - O
the - - O
Medical - - O
College - - O
Admission - - O
Test - - O
( - - O
MCAT - - O
) - - O
are - - O
reported - - O
. - - O

However - - O
, - - O
in - - O
some - - O
of - - O
them - - O
either - - O
pattern - - O
may - - O
predominate - - O
or - - O
be - - O
exclusively - - O
present - - O
. - - O

The - - O
consensus - - O
gene - - O
order - - O
deduced - - O
by - - O
combining - - O
data - - O
from - - O
both - - O
crosses - - O
is - - O
D2Mit1- - - O
( - - O
Dbh - - O
, - - O
Notch1 - - O
) - - O
- - - O
( - - O
Col5a1 - - O
, - - O
Rxra - - O
) - - O
-Spna2-Ab - - O
l- - - O
( - - O
Ak1 - - O
, - - O
Fpgs - - O
) - - O
- - - O
( - - O
Grp78 - - O
, - - O
Pbx3 - - O
) - - O
- - - O
( - - O
Epb7 - - O
. - - O
2 - - O
, - - O
Hc - - O
, - - O
Gsn - - O
) - - O
-Acra - - O
. - - O

One - - O
form - - O
of - - O
the - - O
SBEI - - O
gene - - O
transcript - - O
in - - O
12-day - - O
old - - O
kernels - - O
contained - - O
the - - O
exon - - O
I+II+III - - O
combination - - O
at - - O
the - - O
5' - - O
end - - O
, - - O
whereas - - O
other - - O
forms - - O
differed - - O
by - - O
inclusion - - O
of - - O
intron - - O
1 - - O
or - - O
exclusion - - O
of - - O
exon - - O
II - - O
sequences - - O
. - - O

CHAP - - O
and - - O
the - - O
Department - - O
of - - O
Veterans - - O
Affairs - - O
. - - O

The - - O
remainder - - O
( - - O
18 - - O
. - - O
4% - - O
) - - O
was - - O
with - - O
IgA - - O
nephropathy - - O
, - - O
which - - O
was - - O
histologically - - O
mild - - O
. - - O

Cardiac - - O
output - - O
( - - O
CO - - O
) - - O
was - - O
significantly - - O
higher - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
0005 - - O
) - - O
in - - O
the - - O
MBBF - - O
group - - O
. - - O

The - - O
presence - - O
of - - O
AS-oligo - - O
had - - O
no - - O
further - - O
effect - - O
on - - O
the - - O
FSH-mediated - - O
activation - - O
of - - O
the - - O
EB*-mTf-CAT - - O
construct - - O
but - - O
reduced - - O
cAMP-mediated - - O
activation - - O
. - - O

Among - - O
eight - - O
graminaceous - - O
species - - O
tested - - O
, - - O
Ids3 - - O
expression - - O
was - - O
observed - - O
only - - O
in - - O
Fe-deficient - - O
roots - - O
of - - O
H - - O
. - - O
vulgare - - O
and - - O
Secale - - O
cereale - - O
. - - O
which - - O
not - - O
only - - O
secrete - - O
2'-deoxymugineic - - O
acid - - O
( - - O
DMA - - O
) - - O
, - - O
but - - O
also - - O
mugineic - - O
acid - - O
( - - O
MA - - O
) - - O
and - - O
3-epihydroxymugineic - - O
acid - - O
( - - O
epiHMA - - O
, - - O
H - - O
. - - O
vulgare - - O
) - - O
, - - O
and - - O
3-hydroxymugineic - - O
acid - - O
( - - O
HMA - - O
, - - O
S - - O
. - - O
cereale - - O
) - - O
. - - O

We - - O
also - - O
found - - O
that - - O
environmental - - O
conditions - - O
for - - O
meiosis - - O
finely - - O
regulate - - O
the - - O
transcript - - O
levels - - O
of - - O
KIN28 - - O
and - - O
CCL1 - - O
, - - O
such - - O
that - - O
nitrogen - - O
starvation - - O
first - - O
elevates - - O
them - - O
but - - O
subsequent - - O
alkalization - - O
of - - O
medium - - O
decreases - - O
them - - O
. - - O

PURPOSE - - O
: - - O
To - - O
determine - - O
the - - O
effects - - O
of - - O
hypercholesterolemia - - O
and - - O
atherosclerosis-induced - - O
chronic - - O
cavernosal - - O
arterial - - O
insufficiency - - O
on - - O
cavernosal - - O
smooth - - O
muscle - - O
tone - - O
, - - O
nitric - - O
oxide - - O
synthase - - O
( - - O
NOS - - O
) - - O
activity - - O
and - - O
cavernosal - - O
tissue - - O
synthesis - - O
of - - O
constrictor - - O
eicosanoids - - O
. - - O

The - - O
multiple - - O
factors - - O
affecting - - O
plasma - - O
renin - - O
activity - - O
in - - O
essential - - O
hypertension - - O
. - - O

Transient - - O
co-transfection - - O
assays - - O
involving - - O
NFKB2 - - O
expression - - O
vectors - - O
and - - O
kappa - - O
B-driven - - O
reporter - - O
plasmids - - O
indicate - - O
that - - O
NFKB2 - - O
p85 - - O
has - - O
lost - - O
the - - O
transcriptional - - O
repressor - - O
functions - - O
typical - - O
of - - O
normal - - O
NFKB2 - - O
p52 - - O
. - - O

We - - O
suggest - - O
that - - O
ventriculopleural - - O
shunting - - O
should - - O
be - - O
considered - - O
as - - O
the - - O
preferred - - O
alternative - - O
to - - O
peritoneal - - O
drainage - - O
in - - O
children - - O
with - - O
intra-abdominal - - O
adhesions - - O
or - - O
with - - O
a - - O
history - - O
of - - O
recent - - O
peritoneal - - O
infection - - O
. - - O

We - - O
have - - O
obtained - - O
the - - O
human - - O
EP4 - - O
receptor - - O
gene - - O
sequence - - O
and - - O
determined - - O
its - - O
structure - - O
relative - - O
to - - O
EP4R - - O
cDNA - - O
synthesized - - O
from - - O
peripheral - - O
blood - - O
lymphocytes - - O
. - - O

Model - - O
IV - - O
: - - O
primary - - O
abutments - - O
with - - O
the - - O
lateral - - O
incisor - - O
and - - O
the - - O
second - - O
molar - - O
as - - O
secondary - - O
abutments - - O
. - - O

Skeletal - - O
muscle - - O
metaboreceptor - - O
exercise - - O
responses - - O
are - - O
attenuated - - O
in - - O
heart - - O
failure - - O
. - - O

We - - O
use - - O
the - - O
term - - O
corticosteroid-dependent - - O
IA - - O
to - - O
refer - - O
to - - O
the - - O
serious - - O
problem - - O
of - - O
chronic - - O
IA - - O
requiring - - O
maintenance - - O
prednisone - - O
therapy - - O
. - - O

The - - O
maximum - - O
amplitude - - O
of - - O
evoked - - O
responses - - O
in - - O
the - - O
cervical - - O
sympathetic - - O
trunk - - O
was - - O
obtained - - O
when - - O
the - - O
T2 - - O
white - - O
ramus - - O
was - - O
stimulated - - O
and - - O
decreased - - O
gradually - - O
when - - O
followed - - O
by - - O
the - - O
stimulation - - O
of - - O
T1 - - O
, - - O
T3 - - O
, - - O
T4 - - O
and - - O
T5 - - O
white - - O
rami - - O
. - - O

CONCLUSION - - O
: - - O
Local - - O
control - - O
was - - O
highest - - O
with - - O
Preop - - O
in - - O
patients - - O
presenting - - O
primarily - - O
with - - O
gross - - O
disease - - O
, - - O
and - - O
with - - O
Postop - - O
in - - O
patients - - O
presenting - - O
primarily - - O
following - - O
gross - - O
total - - O
excision - - O
. - - O

Studies - - O
of - - O
lipoprotein-X - - O
( - - O
LP-X - - O
) - - O
and - - O
bile - - O
acids - - O
in - - O
familial - - O
LCAT - - O
deficiency - - O
. - - O

Oligonucleotide - - O
mutagenesis - - O
of - - O
these - - O
binding - - O
domains - - O
indicated - - O
their - - O
importance - - O
in - - O
the - - O
transcriptional - - O
regulation - - O
of - - O
the - - O
E3 - - O
promoter - - O
in - - O
yeast - - O
cells - - O
. - - O

Residual - - O
amphotericin - - O
B - - O
was - - O
detected - - O
in - - O
the - - O
feces - - O
of - - O
the - - O
mice - - O
only - - O
while - - O
they - - O
were - - O
receiving - - O
the - - O
0 - - O
. - - O
3 - - O
mg - - O
ml - - O
dose - - O
level - - O
. - - O

Neither - - O
Ha-Ras - - O
( - - O
G12V - - O
, - - O
T35S - - O
) - - O
( - - O
Ha-RasV12S35 - - O
) - - O
, - - O
which - - O
activates - - O
the - - O
Rafl - - O
signaling - - O
pathway - - O
, - - O
nor - - O
Ha-Ras - - O
( - - O
G12V - - O
, - - O
E37G - - O
) - - O
( - - O
Ha-RasV12G37 - - O
) - - O
, - - O
which - - O
stimulates - - O
the - - O
RalGDS - - O
pathway - - O
, - - O
did - - O
not - - O
have - - O
significant - - O
effects - - O
on - - O
factor-withdrawal - - O
apoptosis - - O
of - - O
myeloid - - O
cells - - O
. - - O

Effects - - O
of - - O
ionizing - - O
radiation - - O
in - - O
the - - O
human - - O
oral - - O
cavity - - O
and - - O
oropharynx - - O
: - - O
results - - O
of - - O
a - - O
survey - - O
. - - O

This - - O
report - - O
describes - - O
the - - O
identification - - O
of - - O
a - - O
gene - - O
of - - O
related - - O
function - - O
, - - O
SMD1 - - O
, - - O
located - - O
immediately - - O
3' - - O
to - - O
PRP38 - - O
. - - O

Preventive - - O
effect - - O
of - - O
ONO-3708 - - O
on - - O
thrombosis - - O
and - - O
vasospasms - - O
in - - O
vitro - - O
and - - O
in - - O
vivo - - O
. - - O

CONCLUSION - - O
: - - O
Rheumatic - - O
fever - - O
in - - O
the - - O
Nazareth - - O
area - - O
is - - O
still - - O
manifest - - O
. - - O

Water - - O
content - - O
and - - O
equilibrium - - O
water - - O
partition - - O
in - - O
immature - - O
cartilage - - O
. - - O

A - - O
novel - - O
cDNA - - O
clone - - O
termed - - O
R2 - - O
was - - O
isolated - - O
by - - O
subtractive - - O
hybridization - - O
of - - O
a - - O
cDNA - - O
library - - O
of - - O
phytohemagglutinin - - O
( - - O
PHA - - O
) - - O
phorbol - - O
myristate - - O
acetate-stimulated - - O
Jurkat - - O
cells - - O
and - - O
by - - O
rescreening - - O
a - - O
cDNA - - O
library - - O
of - - O
PHA-stimulated - - O
peripheral - - O
blood - - O
lymphocytes - - O
. - - O

Diltiazem - - O
decreased - - O
the - - O
total - - O
body - - O
clearance - - O
from - - O
34 - - O
. - - O
0 - - O
+ - - O
- - - O
8 - - O
. - - O
0 - - O
to - - O
28 - - O
. - - O
6 - - O
+ - - O
- - - O
6 - - O
. - - O
1 - - O
mL - - O
min - - O
( - - O
P - - O
less - - O
than - - O
. - - O
01 - - O
) - - O
, - - O
and - - O
prolonged - - O
the - - O
elimination - - O
half-life - - O
from - - O
12 - - O
. - - O
6 - - O
+ - - O
- - - O
3 - - O
. - - O
0 - - O
to - - O
14 - - O
. - - O
3 - - O
+ - - O
- - - O
2 - - O
. - - O
5 - - O
hours - - O
( - - O
P - - O
less - - O
than - - O
. - - O
01 - - O
) - - O
of - - O
antipyrine - - O
without - - O
any - - O
changes - - O
in - - O
volume - - O
of - - O
distribution - - O
. - - O

The - - O
yeast - - O
RER2 - - O
gene - - O
, - - O
identified - - O
by - - O
endoplasmic - - O
reticulum - - O
protein - - O
localization - - O
mutations - - O
, - - O
encodes - - O
cis-prenyltransferase - - O
, - - O
a - - O
key - - O
enzyme - - O
in - - O
dolichol - - O
synthesis - - O
. - - O

In - - O
electromobility - - O
shift - - O
assays - - O
, - - O
EWS-FLI-1 - - O
binding - - O
to - - O
the - - O
SRE - - O
is - - O
detectable - - O
in - - O
the - - O
absence - - O
of - - O
SRF - - O
whereas - - O
the - - O
binding - - O
of - - O
FLI-1 - - O
is - - O
not - - O
, - - O
suggesting - - O
that - - O
the - - O
interaction - - O
with - - O
DNA - - O
is - - O
the - - O
step - - O
which - - O
limits - - O
ternary - - O
complex - - O
formation - - O
by - - O
FLI-1 - - O
. - - O

We - - O
characterized - - O
three - - O
Arabidopsis - - O
thaliana - - O
cDNA - - O
clones - - O
that - - O
could - - O
rescue - - O
the - - O
sterile - - O
phenotype - - O
of - - O
the - - O
Schizosaccharomyces - - O
pombe - - O
pde1 - - O
mutant - - O
, - - O
which - - O
is - - O
defective - - O
in - - O
cAMP - - O
phosphodiesterase - - O
. - - O

Cortical - - O
afferents - - O
to - - O
the - - O
entorhinal - - O
cortex - - O
of - - O
the - - O
Rhesus - - O
monkey - - O
. - - O

In - - O
this - - O
study - - O
, - - O
we - - O
report - - O
the - - O
isolation - - O
and - - O
characterization - - O
of - - O
the - - O
entire - - O
rat - - O
GSTA3 - - O
( - - O
rGST - - O
Yc1 - - O
) - - O
subunit - - O
gene - - O
. - - O

Ras2p - - O
activates - - O
invasive - - O
growth - - O
using - - O
either - - O
of - - O
two - - O
downstream - - O
signaling - - O
pathways - - O
, - - O
the - - O
filamentation - - O
MAPK - - O
( - - O
Cdc42p - - O
Ste20p - - O
MAPK - - O
) - - O
cascade - - O
or - - O
the - - O
cAMP-dependent - - O
protein - - O
kinase - - O
( - - O
Cyr1p - - O
cAMP - - O
PKA - - O
) - - O
pathway - - O
. - - O

Gamma - - O
glutamyl - - O
transpeptidase - - O
activity - - O
was - - O
increased - - O
up - - O
to - - O
15 - - O
times - - O
above - - O
the - - O
upper - - O
normal - - O
limit - - O
in - - O
children - - O
, - - O
who - - O
received - - O
aminopyrine - - O
for - - O
two - - O
weeks - - O
or - - O
longer - - O
. - - O

CONCLUSIONS - - O
: - - O
Use - - O
of - - O
the - - O
first - - O
method - - O
was - - O
associated - - O
with - - O
a - - O
reduction - - O
in - - O
the - - O
time - - O
patients - - O
remained - - O
in - - O
the - - O
ICU - - O
before - - O
transfer - - O
to - - O
another - - O
unit - - O
and - - O
savings - - O
in - - O
nursing - - O
time - - O
, - - O
but - - O
the - - O
two - - O
methods - - O
did - - O
not - - O
differ - - O
according - - O
to - - O
clinical - - O
outcomes - - O
. - - O

In - - O
part - - O
as - - O
a - - O
result - - O
of - - O
its - - O
inability - - O
to - - O
sustain - - O
radiative - - O
loses - - O
, - - O
the - - O
BB - - O
resonator - - O
has - - O
extremely - - O
low - - O
RF - - O
power - - O
requirements - - O
. - - O

Hypoxic - - O
ventilatory - - O
responses - - O
were - - O
-1 - - O
. - - O
99 - - O
+ - - O
- - - O
0 - - O
. - - O
37 - - O
L - - O
min - - O
% - - O
SaO2 - - O
in - - O
the - - O
relatives - - O
and - - O
-1 - - O
. - - O
54 - - O
+ - - O
- - - O
0 - - O
. - - O
25 - - O
L - - O
min - - O
% - - O
SaO2 - - O
in - - O
the - - O
control - - O
subjects - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

They - - O
also - - O
discuss - - O
the - - O
existing - - O
nomenclature - - O
. - - O

These - - O
data - - O
indicate - - O
that - - O
the - - O
interaction - - O
of - - O
eIF4A - - O
with - - O
the - - O
middle - - O
region - - O
of - - O
eIF4GI - - O
is - - O
necessary - - O
for - - O
translation - - O
, - - O
whereas - - O
the - - O
interaction - - O
of - - O
eIF4A - - O
with - - O
the - - O
C-terminal - - O
region - - O
plays - - O
a - - O
modulatory - - O
role - - O
. - - O

In - - O
this - - O
report - - O
, - - O
we - - O
demonstrate - - O
that - - O
hGCN5 - - O
is - - O
also - - O
an - - O
HAT - - O
and - - O
has - - O
the - - O
same - - O
substrate - - O
specificity - - O
as - - O
yGCN5 - - O
. - - O

Instead - - O
, - - O
some - - O
small - - O
negative - - O
effects - - O
are - - O
observed - - O
, - - O
particularly - - O
involving - - O
effects - - O
of - - O
husbands' - - O
retirement - - O
on - - O
the - - O
marital - - O
satisfaction - - O
of - - O
employed - - O
wives - - O
. - - O

We - - O
previously - - O
described - - O
two - - O
alanine - - O
cluster - - O
mutations - - O
, - - O
R77 - - O
to - - O
A - - O
( - - O
R77A - - O
) - - O
-K79A - - O
and - - O
E192A-E194A - - O
, - - O
which - - O
selectively - - O
inactivated - - O
the - - O
triphosphatase - - O
component - - O
. - - O

CKII - - O
as - - O
a - - O
CD44-associated - - O
serine - - O
kinase - - O
therefore - - O
may - - O
serve - - O
as - - O
an - - O
important - - O
molecule - - O
in - - O
a - - O
signaling - - O
cascade - - O
that - - O
produces - - O
a - - O
variety - - O
of - - O
cellular - - O
responses - - O
in - - O
MDA231 - - O
breast - - O
cancer - - O
cells - - O
. - - O

This - - O
is - - O
the - - O
first - - O
example - - O
of - - O
a - - O
eukaryotic - - O
transcription - - O
factor - - O
complex - - O
containing - - O
both - - O
a - - O
MADS-box - - O
and - - O
a - - O
forkhead - - O
protein - - O
, - - O
and - - O
it - - O
has - - O
important - - O
implications - - O
for - - O
the - - O
regulation - - O
of - - O
mammalian - - O
gene - - O
expression - - O
. - - O

To - - O
investigate - - O
the - - O
requirements - - O
for - - O
CBF2 - - O
binding - - O
, - - O
we - - O
synthesized - - O
a - - O
series - - O
of - - O
oligonucleotides - - O
carrying - - O
double - - O
transversion - - O
mutations - - O
spanning - - O
both - - O
the - - O
conserved - - O
core - - O
sequence - - O
and - - O
outside - - O
flanking - - O
sequences - - O
. - - O

Biol - - O
. - - O

Replacement - - O
of - - O
the - - O
wild-type - - O
5'-regulatory - - O
region - - O
with - - O
either - - O
of - - O
the - - O
mutants' - - O
cis-acting - - O
regulatory - - O
element - - O
resulted - - O
in - - O
the - - O
anaerobic - - O
expression - - O
of - - O
active - - O
Mn-superoxide - - O
dismutase - - O
. - - O

To - - O
study - - O
the - - O
functional - - O
differences - - O
between - - O
cutaneous - - O
HPV5 - - O
and - - O
HPV8 - - O
E7s - - O
and - - O
genital - - O
HPV16 - - O
E7 - - O
, - - O
we - - O
cloned - - O
each - - O
of - - O
the - - O
E7 - - O
open - - O
reading - - O
frames - - O
and - - O
tested - - O
their - - O
immortalizing - - O
and - - O
transforming - - O
activities - - O
, - - O
the - - O
binding - - O
ability - - O
of - - O
their - - O
products - - O
with - - O
retinoblastoma - - O
protein - - O
( - - O
RB - - O
) - - O
and - - O
their - - O
complementation - - O
activity - - O
of - - O
a - - O
RB-nonbinding - - O
adenovirus - - O
E1A - - O
mutant - - O
. - - O

Immunohistochemical - - O
staining - - O
was - - O
positive - - O
for - - O
S-100 - - O
in - - O
all - - O
9 - - O
cases - - O
stained - - O
, - - O
positive - - O
for - - O
HMB-45 - - O
in - - O
9 - - O
( - - O
90% - - O
) - - O
of - - O
10 - - O
, - - O
and - - O
negative - - O
for - - O
cytokeratin - - O
in - - O
all - - O
9 - - O
cases - - O
in - - O
which - - O
myxoid - - O
melanoma - - O
remained - - O
in - - O
the - - O
block - - O
after - - O
previous - - O
sections - - O
. - - O

Pneumothorax - - O
complicated - - O
by - - O
chronic - - O
steroid - - O
treatment - - O
. - - O

The - - O
response - - O
of - - O
the - - O
plasma - - O
fibrinogen - - O
level - - O
to - - O
the - - O
subucutaneous - - O
injection - - O
of - - O
turpentine - - O
and - - O
to - - O
the - - O
intravenous - - O
injection - - O
of - - O
endotoxin - - O
was - - O
measured - - O
in - - O
normal - - O
rabbits - - O
and - - O
in - - O
rabbits - - O
made - - O
granulocytopenic - - O
and - - O
thrombocytopenic - - O
with - - O
busulfan - - O
. - - O

The - - O
spleen - - O
rate - - O
of - - O
about - - O
600 - - O
villagers - - O
of - - O
RK - - O
I - - O
examined - - O
was - - O
54 - - O
. - - O
3% - - O
and - - O
the - - O
parasite - - O
rate - - O
13 - - O
. - - O
2% - - O
before - - O
the - - O
drug - - O
intervention - - O
. - - O

A - - O
thermal - - O
Kubo-Martin-Schwinger - - O
condition - - O
arises - - O
due - - O
to - - O
the - - O
coupling - - O
of - - O
a - - O
computer - - O
to - - O
a - - O
strong - - O
periodic - - O
source - - O
, - - O
namely - - O
, - - O
the - - O
daily - - O
and - - O
weekly - - O
usage - - O
patterns - - O
of - - O
the - - O
system - - O
. - - O

This - - O
region - - O
binds - - O
two - - O
ubiquitous - - O
nuclear - - O
factors - - O
, - - O
USF - - O
MLTF - - O
and - - O
the - - O
CAAT-binding - - O
transcription - - O
factor - - O
nuclear - - O
factor - - O
1 - - O
( - - O
CTF - - O
NF1 - - O
) - - O
. - - O

Among - - O
the - - O
LE6 - - O
deletions - - O
, - - O
only - - O
one - - O
had - - O
a - - O
reduced - - O
transformation - - O
efficiency - - O
, - - O
while - - O
seven - - O
transformed - - O
cells - - O
at - - O
least - - O
as - - O
efficiently - - O
as - - O
wild-type - - O
LE6 - - O
. - - O

Changes - - O
of - - O
plasma - - O
cortisol - - O
level - - O
in - - O
late - - O
asthmatic - - O
responses - - O
. - - O

All - - O
patients - - O
with - - O
deterioriation - - O
in - - O
mental - - O
status - - O
showed - - O
a - - O
marked - - O
increase - - O
in - - O
liver - - O
enzymes - - O
( - - O
aspartate - - O
and - - O
alanine - - O
aminotransaminases - - O
) - - O
and - - O
severe - - O
coagulopathy - - O
. - - O

The - - O
results - - O
also - - O
showed - - O
that - - O
although - - O
oyster - - O
shell - - O
supplementation - - O
generally - - O
increased - - O
alkaline - - O
phosphatase - - O
activity - - O
, - - O
bone - - O
mineralization - - O
was - - O
relatively - - O
uninfluenced - - O
as - - O
judged - - O
by - - O
the - - O
low - - O
coefficients - - O
of - - O
variation - - O
( - - O
CV - - O
) - - O
of - - O
3 - - O
. - - O
14-3 - - O
. - - O
51% - - O
and - - O
3 - - O
. - - O
39-4 - - O
. - - O
82% - - O
for - - O
calcium - - O
and - - O
phosphorus - - O
content - - O
in - - O
the - - O
femur - - O
and - - O
tibia - - O
respectively - - O
. - - O

1 - - O
A - - O
colonic - - O
delivery - - O
system - - O
is - - O
described - - O
to - - O
deliver - - O
orally - - O
ingested - - O
drugs - - O
to - - O
the - - O
colon - - O
and - - O
release - - O
them - - O
at - - O
that - - O
site - - O
by - - O
coating - - O
with - - O
an - - O
acrylic - - O
based - - O
resin - - O
( - - O
Eudragit - - O
S - - O
) - - O
. - - O

Treating - - O
renal - - O
anaemia - - O
with - - O
recombinant - - O
human - - O
erythropoietin - - O
. - - O

The - - O
resulting - - O
clone - - O
pKB11 - - O
, - - O
which - - O
has - - O
a - - O
1369-base - - O
pair - - O
( - - O
bp - - O
) - - O
cDNA - - O
insert - - O
, - - O
overlapping - - O
pCAD142 - - O
by - - O
781 - - O
bp - - O
, - - O
was - - O
identified - - O
by - - O
hybridization - - O
methods - - O
and - - O
sequence - - O
analysis - - O
and - - O
found - - O
to - - O
contain - - O
the - - O
entire - - O
cDNA - - O
sequence - - O
for - - O
the - - O
amino - - O
end - - O
of - - O
the - - O
CAD - - O
polypeptide - - O
. - - O

Treatment - - O
of - - O
unstable - - O
angina - - O
: - - O
role - - O
of - - O
antithrombotic - - O
therapy - - O
. - - O

Acad - - O
. - - O

Biochemical - - O
studies - - O
revealed - - O
the - - O
expected - - O
loss - - O
of - - O
ChAT - - O
activity - - O
in - - O
the - - O
dorsal - - O
and - - O
ventral - - O
hippocampi - - O
of - - O
lesioned - - O
animals - - O
along - - O
with - - O
elevated - - O
levels - - O
of - - O
norepinephrine - - O
( - - O
NE - - O
) - - O
in - - O
the - - O
dorsal - - O
hippocampus - - O
of - - O
MS - - O
HSI - - O
animals - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Recognition - - O
of - - O
emphysema - - O
was - - O
poor - - O
when - - O
radiographs - - O
of - - O
inadequate - - O
quality - - O
were - - O
included - - O
( - - O
anteroposterior - - O
films - - O
or - - O
films - - O
from - - O
patients - - O
with - - O
acute - - O
or - - O
chronic - - O
lung - - O
disease - - O
) - - O
. - - O

Vasopressin - - O
( - - O
AVP - - O
) - - O
, - - O
the - - O
antidiuretic - - O
hormone - - O
, - - O
is - - O
a - - O
cyclic - - O
nonapeptide - - O
that - - O
acts - - O
through - - O
binding - - O
to - - O
G - - O
protein-coupled - - O
specific - - O
membrane - - O
receptors - - O
pharmacologically - - O
divided - - O
into - - O
three - - O
subtypes - - O
( - - O
V1a - - O
, - - O
V1b - - O
, - - O
and - - O
V2 - - O
) - - O
linked - - O
to - - O
distinct - - O
second - - O
messengers - - O
. - - O

Immunofluorescence - - O
studies - - O
in - - O
C2C12 - - O
myotubes - - O
show - - O
that - - O
Smad2 - - O
and - - O
MEF2A - - O
co-localise - - O
in - - O
the - - O
nucleus - - O
of - - O
multinuclear - - O
myotubes - - O
during - - O
differentiation - - O
. - - O

Homozygous - - O
mutation - - O
in - - O
two - - O
children - - O
led - - O
to - - O
amputation - - O
of - - O
legs - - O
due - - O
to - - O
purpura - - O
fulminans - - O
. - - O

The - - O
effect - - O
of - - O
salmon - - O
calcitonin - - O
nasal - - O
spray - - O
in - - O
women - - O
with - - O
established - - O
osteoporosis - - O
has - - O
also - - O
been - - O
studied - - O
. - - O

Studies - - O
in - - O
mammalian - - O
cells - - O
have - - O
correlated - - O
induction - - O
of - - O
inhibitory - - O
tyrosine - - O
15 - - O
( - - O
Y15 - - O
) - - O
phosphorylation - - O
on - - O
p34cdc2 - - O
with - - O
the - - O
response - - O
to - - O
DNA - - O
damage - - O
. - - O

Altogether - - O
46 - - O
phase - - O
III - - O
activities - - O
were - - O
recorded - - O
. - - O

Using - - O
a - - O
battery - - O
of - - O
I - - O
kappa - - O
B - - O
alpha - - O
mutants - - O
, - - O
we - - O
show - - O
that - - O
( - - O
i - - O
) - - O
a - - O
dimer - - O
binds - - O
a - - O
single - - O
I - - O
kappa - - O
B - - O
alpha - - O
molecule - - O
, - - O
( - - O
ii - - O
) - - O
the - - O
acidic - - O
C-terminal - - O
region - - O
of - - O
I - - O
kappa - - O
B - - O
alpha - - O
is - - O
not - - O
required - - O
for - - O
protein-protein - - O
binding - - O
and - - O
does - - O
not - - O
mask - - O
the - - O
nuclear - - O
localization - - O
signal - - O
of - - O
the - - O
dimer - - O
, - - O
( - - O
iii - - O
) - - O
the - - O
same - - O
C-terminal - - O
region - - O
is - - O
required - - O
for - - O
inhibition - - O
of - - O
DNA - - O
binding - - O
, - - O
and - - O
( - - O
iv - - O
) - - O
this - - O
inhibition - - O
may - - O
be - - O
accomplished - - O
by - - O
direct - - O
interaction - - O
between - - O
the - - O
PEST-like - - O
region - - O
and - - O
the - - O
DNA-binding - - O
region - - O
of - - O
one - - O
of - - O
the - - O
subunits - - O
of - - O
the - - O
dimer - - O
. - - O

Activation - - O
mediated - - O
by - - O
Cat8p - - O
was - - O
no - - O
longer - - O
detectable - - O
in - - O
a - - O
cat1 - - O
mutant - - O
. - - O

EGF - - O
acts - - O
primarily - - O
by - - O
means - - O
of - - O
transactivation - - O
domain - - O
AF-1 - - O
, - - O
whereas - - O
cAMP - - O
acts - - O
via - - O
transactivation - - O
domain - - O
AF-2 - - O
of - - O
the - - O
ER - - O
. - - O

Of - - O
those - - O
injuries - - O
, - - O
143 - - O
cases - - O
were - - O
snowboard - - O
related - - O
and - - O
158 - - O
cases - - O
were - - O
ski - - O
related - - O
. - - O

Diacylglycerol - - O
kinase - - O
( - - O
DGK - - O
) - - O
attenuates - - O
levels - - O
of - - O
second - - O
messenger - - O
diacylglycerol - - O
in - - O
cells - - O
and - - O
produces - - O
another - - O
( - - O
putative - - O
) - - O
messenger - - O
, - - O
phosphatidic - - O
acid - - O
. - - O

Unusual - - O
course - - O
of - - O
plasmocytosis - - O
. - - O

4 - - O
) - - O
PU - - O
and - - O
PD - - O
lacked - - O
the - - O
canonical - - O
TATA - - O
or - - O
CAAT - - O
motifs - - O
, - - O
and - - O
are - - O
AT-rich - - O
. - - O

Their - - O
use - - O
established - - O
that - - O
the - - O
BrAAP - - O
activity - - O
catalyzed - - O
both - - O
a - - O
postproline - - O
and - - O
a - - O
postglutamate - - O
cleavage - - O
and - - O
therefore - - O
has - - O
a - - O
broader - - O
specificity - - O
than - - O
previously - - O
recognized - - O
. - - O

We - - O
have - - O
found - - O
that - - O
PEA2 - - O
is - - O
also - - O
required - - O
for - - O
the - - O
bipolar - - O
budding - - O
pattern - - O
and - - O
that - - O
it - - O
encodes - - O
a - - O
novel - - O
protein - - O
with - - O
a - - O
predicted - - O
coiled-coil - - O
domain - - O
. - - O

The - - O
most - - O
important - - O
finding - - O
, - - O
however - - O
, - - O
was - - O
that - - O
IMT - - O
values - - O
were - - O
related - - O
with - - O
24 - - O
h - - O
SBP - - O
or - - O
PP - - O
standard - - O
deviation - - O
( - - O
P - - O
< - - O
0 - - O
. - - O
001 - - O
) - - O
, - - O
a - - O
measure - - O
of - - O
overall - - O
SBP - - O
or - - O
PP - - O
variability - - O
. - - O

We - - O
recently - - O
found - - O
that - - O
the - - O
p72syk - - O
protein - - O
tyrosine - - O
kinase - - O
is - - O
physically - - O
associated - - O
with - - O
the - - O
TCR - - O
CD3 - - O
complex - - O
and - - O
is - - O
rapidly - - O
tyrosine - - O
phosphorylated - - O
and - - O
activated - - O
by - - O
receptor - - O
triggering - - O
also - - O
in - - O
T - - O
cells - - O
lacking - - O
p56lck - - O
. - - O

Similar - - O
synergistic - - O
activation - - O
was - - O
observed - - O
in - - O
the - - O
IL-8 - - O
promoter - - O
, - - O
which - - O
also - - O
contains - - O
both - - O
NF-IL6 - - O
and - - O
NF-kappa - - O
B - - O
binding - - O
sites - - O
. - - O

To - - O
identify - - O
the - - O
DNA - - O
sequences - - O
that - - O
cis-regulate - - O
the - - O
expression - - O
of - - O
the - - O
rat - - O
liver - - O
pyruvate - - O
kinase - - O
( - - O
L-PK - - O
) - - O
genes - - O
, - - O
a - - O
series - - O
of - - O
constructs - - O
in - - O
which - - O
the - - O
chloramphenicol - - O
acetyltransferase - - O
reporter - - O
genes - - O
is - - O
driven - - O
by - - O
various - - O
deleted - - O
fragments - - O
of - - O
the - - O
3200 - - O
base - - O
pairs - - O
( - - O
bp - - O
) - - O
upstream - - O
of - - O
the - - O
L-PK - - O
gene - - O
cap - - O
site - - O
have - - O
been - - O
assayed - - O
for - - O
transient - - O
expression - - O
after - - O
introduction - - O
into - - O
hepatoma - - O
HepG2 - - O
cells - - O
, - - O
rat - - O
hepatocytes - - O
in - - O
primary - - O
culture - - O
, - - O
fibroblast - - O
LTK- - - O
cells - - O
, - - O
myogenic - - O
C2C12 - - O
cells - - O
, - - O
and - - O
CHO - - O
cells - - O
. - - O

Stable - - O
transfection - - O
of - - O
the - - O
truncated - - O
reduced - - O
folate - - O
carrier - - O
cDNA - - O
into - - O
mouse - - O
L1210 - - O
leukemia - - O
cells - - O
: - - O
increased - - O
folate - - O
accumulation - - O
, - - O
decreased - - O
their - - O
leucovorin - - O
and - - O
folic - - O
acid - - O
growth - - O
requirements - - O
, - - O
and - - O
increased - - O
their - - O
sensitivity - - O
to - - O
methotrexate - - O
. - - O

Instead - - O
, - - O
TRPS1 - - O
potently - - O
and - - O
specifically - - O
represses - - O
transcriptional - - O
activation - - O
mediated - - O
by - - O
other - - O
GATA - - O
factors - - O
. - - O

Hyaluronan - - O
treatment - - O
stimulated - - O
collagen - - O
remodeling - - O
in - - O
the - - O
peripheral - - O
region - - O
and - - O
inhibited - - O
swelling - - O
of - - O
the - - O
meniscus - - O
repaired - - O
in - - O
the - - O
inner - - O
region - - O
. - - O

Recombinant - - O
human - - O
TFIID - - O
supported - - O
weak - - O
basal - - O
transcription - - O
in - - O
heat-treated - - O
nuclear - - O
extracts - - O
whereas - - O
a - - O
partially - - O
purified - - O
TFIID - - O
fraction - - O
from - - O
HeLa - - O
cells - - O
reconstituted - - O
a - - O
maximal - - O
level - - O
of - - O
transcription - - O
. - - O

We - - O
can - - O
classify - - O
antibiotics - - O
into - - O
two - - O
groups - - O
based - - O
on - - O
initial - - O
bactericidal - - O
activity - - O
against - - O
P - - O
. - - O
aeruginosa - - O
; - - O
one - - O
class - - O
is - - O
antibiotics - - O
having - - O
rapid - - O
initial - - O
killing - - O
such - - O
as - - O
AMK - - O
, - - O
IPM - - O
and - - O
PAPM - - O
, - - O
the - - O
other - - O
is - - O
CAZ - - O
, - - O
MEPM - - O
showing - - O
slow - - O
initial - - O
killing - - O
. - - O

X-ray - - O
crystallographic - - O
data - - O
show - - O
that - - O
the - - O
PLZF - - O
BTB - - O
POZ - - O
domain - - O
forms - - O
an - - O
obligate - - O
homodimer - - O
via - - O
an - - O
extensive - - O
interface - - O
. - - O

We - - O
have - - O
previously - - O
identified - - O
mouse - - O
and - - O
human - - O
cDNAs - - O
encoding - - O
UNC-51-like - - O
kinase - - O
( - - O
ULK1 - - O
) - - O
. - - O

Sequencing - - O
of - - O
zebrafish - - O
( - - O
Danio - - O
rerio - - O
) - - O
bacterial - - O
artificial - - O
chromosome - - O
and - - O
P1 - - O
artificial - - O
chromosome - - O
genomic - - O
clone - - O
fragments - - O
and - - O
of - - O
cDNA - - O
clones - - O
has - - O
led - - O
to - - O
the - - O
identification - - O
of - - O
five - - O
new - - O
loci - - O
coding - - O
for - - O
beta - - O
subunits - - O
of - - O
proteasomes - - O
( - - O
PSMB - - O
) - - O
. - - O

Penicillin - - O
acylase - - O
( - - O
PA - - O
) - - O
from - - O
Escherichia - - O
coli - - O
ATCC11105 - - O
is - - O
a - - O
periplasmic - - O
heterodimer - - O
consisting - - O
of - - O
a - - O
24 - - O
kDa - - O
small - - O
subunit - - O
and - - O
a - - O
65 - - O
kDa - - O
large - - O
subunit - - O
. - - O

Hepatocellular - - O
injury - - O
during - - O
preservation - - O
of - - O
human - - O
livers - - O
with - - O
UW - - O
and - - O
HTK - - O
solution - - O
. - - O

There - - O
was - - O
a - - O
significant - - O
but - - O
similar - - O
elevation - - O
of - - O
mean - - O
O2 - - O
uptake - - O
during - - O
40 - - O
min - - O
postexercise - - O
by - - O
13 - - O
. - - O
6% - - O
in - - O
both - - O
the - - O
fasted - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
and - - O
fed - - O
state - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
001 - - O
) - - O
. - - O

Intracellular - - O
localization - - O
studies - - O
using - - O
the - - O
mDAP-3 - - O
EGFP - - O
fusion - - O
protein - - O
, - - O
cell - - O
fractionation - - O
and - - O
protease - - O
protection - - O
experiments - - O
localized - - O
mDAP-3 - - O
to - - O
the - - O
mitochondrial - - O
matrix - - O
. - - O

CONCLUSION - - O
: - - O
The - - O
study - - O
demonstrates - - O
that - - O
transvaginal - - O
ultrasonography - - O
has - - O
an - - O
efficiency - - O
of - - O
88% - - O
in - - O
differentiating - - O
endometriomas - - O
from - - O
other - - O
ovarian - - O
masses - - O
with - - O
a - - O
specificity - - O
of - - O
90% - - O
. - - O

Two - - O
polyadenylation - - O
sites - - O
were - - O
used - - O
, - - O
one - - O
at - - O
the - - O
end - - O
of - - O
the - - O
early - - O
( - - O
E - - O
) - - O
region - - O
of - - O
the - - O
viral - - O
DNA - - O
, - - O
the - - O
other - - O
at - - O
the - - O
end - - O
of - - O
the - - O
late - - O
( - - O
L - - O
) - - O
region - - O
. - - O

We - - O
concluded - - O
that - - O
Ga-fbg - - O
scintigraphy - - O
is - - O
a - - O
very - - O
simple - - O
method - - O
and - - O
sufficiently - - O
useful - - O
for - - O
detecting - - O
active - - O
left - - O
ventricular - - O
thrombi - - O
and - - O
for - - O
monitoring - - O
the - - O
effect - - O
of - - O
anticoagulant - - O
therapy - - O
. - - O

The - - O
carcass - - O
of - - O
a - - O
great - - O
horned - - O
owl - - O
( - - O
Bubo - - O
virginianus - - O
) - - O
, - - O
which - - O
had - - O
been - - O
found - - O
moribund - - O
in - - O
southern - - O
Ontario - - O
, - - O
was - - O
presented - - O
for - - O
necropsy - - O
. - - O

NGF - - O
elicits - - O
a - - O
more - - O
delayed - - O
and - - O
sustained - - O
ERK - - O
phosphorylation - - O
than - - O
EGF - - O
, - - O
consistent - - O
with - - O
previous - - O
reports - - O
. - - O

Compound - - O
1 - - O
is - - O
either - - O
21-O-angeloyl - - O
, - - O
22-O-tigloyl - - O
R1-barrigenol - - O
, - - O
or - - O
21-O-tigloyl - - O
, - - O
22-O-angeloyl - - O
R1-barrigenol - - O
. - - O

The - - O
enhancer - - O
region - - O
of - - O
Akv - - O
murine - - O
leukemia - - O
virus - - O
contains - - O
the - - O
sequence - - O
motif - - O
ACAGATGG - - O
. - - O

We - - O
show - - O
that - - O
in - - O
contrast - - O
to - - O
SRC1 - - O
, - - O
direct - - O
binding - - O
of - - O
CBP - - O
to - - O
the - - O
estrogen - - O
receptor - - O
is - - O
weak - - O
, - - O
suggesting - - O
that - - O
SRC1 - - O
functions - - O
primarily - - O
as - - O
an - - O
adaptor - - O
to - - O
recruit - - O
CBP - - O
and - - O
p300 - - O
. - - O

Immuno-cytochemistry - - O
, - - O
using - - O
antisera - - O
against - - O
Campylobacter - - O
jejuni - - O
, - - O
showed - - O
that - - O
the - - O
positive - - O
staining - - O
in - - O
altered - - O
epithelial - - O
cells - - O
were - - O
restricted - - O
to - - O
intracellular - - O
organisms - - O
having - - O
a - - O
structure - - O
resembling - - O
Campylobacter - - O
spp - - O
. - - O

The - - O
translation - - O
products - - O
of - - O
both - - O
clones - - O
are - - O
highly - - O
homologous - - O
to - - O
APS1 - - O
( - - O
66 - - O
and - - O
86% - - O
identity - - O
, - - O
respectively - - O
) - - O
over - - O
their - - O
entire - - O
lengths - - O
, - - O
including - - O
amino - - O
terminal - - O
sequences - - O
resembling - - O
transit - - O
peptides - - O
for - - O
plastid - - O
localization - - O
. - - O

Organization - - O
of - - O
the - - O
human - - O
LU - - O
gene - - O
and - - O
molecular - - O
basis - - O
of - - O
the - - O
Lu - - O
( - - O
a - - O
) - - O
Lu - - O
( - - O
b - - O
) - - O
blood - - O
group - - O
polymorphism - - O
. - - O

The - - O
MCA - - O
and - - O
UA - - O
PI - - O
values - - O
showed - - O
the - - O
greatest - - O
deviation - - O
for - - O
any - - O
single-vessel - - O
parameter - - O
. - - O

A - - O
decrease - - O
of - - O
erythrocyte - - O
Mn - - O
with - - O
age - - O
, - - O
expressed - - O
in - - O
nmol - - O
L - - O
, - - O
was - - O
noted - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
02 - - O
) - - O
. - - O

Progressive - - O
100-mmHg - - O
stepwise - - O
decreases - - O
in - - O
superfusate - - O
oxygen - - O
partial - - O
pressure - - O
( - - O
PO2 - - O
) - - O
from - - O
control - - O
( - - O
95% - - O
O2 - - O
aeration - - O
, - - O
PO2 - - O
, - - O
620-650 - - O
mmHg - - O
) - - O
were - - O
produced - - O
, - - O
and - - O
subsequent - - O
changes - - O
in - - O
isometric - - O
active - - O
and - - O
resting - - O
tension - - O
were - - O
measured - - O
. - - O

Results - - O
of - - O
the - - O
long-term - - O
observation - - O
and - - O
treatment - - O
of - - O
patients - - O
with - - O
arterial - - O
hypertension - - O
. - - O

Jean - - O
Klig - - O
reviews - - O
recent - - O
literature - - O
about - - O
lower - - O
respiratory - - O
tract - - O
infection - - O
in - - O
children - - O
. - - O

In - - O
particular - - O
, - - O
the - - O
highly - - O
expressed - - O
ADH1 - - O
gene - - O
is - - O
represented - - O
in - - O
this - - O
database - - O
by - - O
no - - O
less - - O
than - - O
20 - - O
EST - - O
sequences - - O
. - - O

Transient - - O
expression - - O
of - - O
human - - O
and - - O
chicken - - O
progesterone - - O
receptors - - O
does - - O
not - - O
support - - O
alternative - - O
translational - - O
initiation - - O
from - - O
a - - O
single - - O
mRNA - - O
as - - O
the - - O
mechanism - - O
generating - - O
two - - O
receptor - - O
isoforms - - O
. - - O

In - - O
some - - O
cases - - O
, - - O
factor-induced - - O
Rac - - O
activation - - O
results - - O
in - - O
Rho - - O
activation - - O
, - - O
and - - O
factor-induced - - O
Cdc42 - - O
activation - - O
leads - - O
to - - O
Rac - - O
activation - - O
, - - O
as - - O
determined - - O
by - - O
specific - - O
morphological - - O
changes - - O
. - - O

A - - O
sequence - - O
comparison - - O
reveals - - O
two - - O
CCAAT - - O
enhancer - - O
binding - - O
protein - - O
( - - O
C - - O
EBP - - O
) - - O
consensus - - O
sequences - - O
, - - O
basic - - O
DNA - - O
binding - - O
region - - O
and - - O
leucine - - O
zippers - - O
1 - - O
and - - O
2 - - O
( - - O
bZIP1 - - O
and - - O
bZIP2 - - O
) - - O
, - - O
within - - O
this - - O
region - - O
. - - O

In - - O
the - - O
lattice - - O
, - - O
23% - - O
of - - O
the - - O
sites - - O
are - - O
occupied - - O
, - - O
95% - - O
of - - O
the - - O
atoms - - O
are - - O
in - - O
the - - O
lowest - - O
energy - - O
magnetic - - O
sublevel - - O
, - - O
and - - O
37% - - O
are - - O
in - - O
the - - O
lowest - - O
3D - - O
vibrational - - O
state - - O
. - - O

Arsenic - - O
contents - - O
in - - O
native - - O
copper - - O
. - - O

Complexes - - O
containing - - O
wild-type - - O
and - - O
either - - O
his175 - - O
or - - O
his273 - - O
mutant - - O
p53 - - O
proteins - - O
are - - O
completely - - O
unable - - O
to - - O
bind - - O
to - - O
the - - O
RGC - - O
DNA - - O
sequence - - O
. - - O

Analysis - - O
of - - O
human - - O
genomic - - O
DNA - - O
reveals - - O
an - - O
intronless - - O
sequence - - O
with - - O
strong - - O
homology - - O
to - - O
human - - O
G - - O
alpha - - O
q - - O
cDNA - - O
. - - O

The - - O
risk - - O
factors - - O
studied - - O
were - - O
male - - O
sex - - O
, - - O
hypertension - - O
, - - O
diabetes - - O
mellitus - - O
, - - O
hypercholesterolemia - - O
, - - O
cigarette - - O
smoking - - O
, - - O
sedentary - - O
life-style - - O
, - - O
and - - O
family - - O
history - - O
. - - O

CONCLUSIONS - - O
: - - O
Pretreatment - - O
with - - O
OCs - - O
prior - - O
to - - O
pituitary - - O
suppression - - O
in - - O
the - - O
early - - O
follicular - - O
phase - - O
decreases - - O
ovarian - - O
cyst - - O
formation - - O
, - - O
without - - O
an - - O
apparent - - O
effect - - O
on - - O
subsequent - - O
follicular - - O
recruitment - - O
or - - O
pregnancy - - O
rates - - O
. - - O

SV1 - - O
has - - O
a - - O
33-amino - - O
acid - - O
insert - - O
in - - O
the - - O
S1 - - O
transmembrane - - O
domain - - O
that - - O
does - - O
not - - O
alter - - O
S1 - - O
overall - - O
hydrophobicity - - O
, - - O
but - - O
makes - - O
the - - O
S0-S1 - - O
linker - - O
longer - - O
. - - O

Four - - O
transcription - - O
initiation - - O
sites - - O
have - - O
been - - O
identified - - O
by - - O
full-length - - O
RNA - - O
ligase-mediated - - O
rapid - - O
amplification - - O
of - - O
cDNA - - O
ends - - O
( - - O
RLM-RACE - - O
) - - O
between - - O
-61 - - O
and - - O
-32 - - O
bp - - O
from - - O
the - - O
translation - - O
initiation - - O
codon - - O
. - - O
Reverse - - O
transcription-PCR - - O
analysis - - O
revealed - - O
that - - O
PFK-A - - O
, - - O
PFK-B - - O
and - - O
PFK-C - - O
genes - - O
were - - O
expressed - - O
, - - O
in - - O
all - - O
mouse - - O
tissues - - O
tested - - O
, - - O
at - - O
varying - - O
levels - - O
. - - O

The - - O
small - - O
size - - O
and - - O
placement - - O
of - - O
the - - O
mutagenesis - - O
marker - - O
( - - O
the - - O
supF - - O
suppressor - - O
tRNA - - O
gene - - O
from - - O
Escherichia - - O
coli - - O
) - - O
within - - O
the - - O
vector - - O
substantially - - O
reduced - - O
the - - O
frequency - - O
of - - O
spontaneous - - O
mutations - - O
normally - - O
observed - - O
after - - O
transfection - - O
of - - O
mammalian - - O
cells - - O
with - - O
plasmid - - O
DNA - - O
; - - O
hence - - O
, - - O
UV-induced - - O
mutations - - O
were - - O
easily - - O
identified - - O
above - - O
the - - O
spontaneous - - O
background - - O
. - - O

Although - - O
not - - O
consistently - - O
identified - - O
in - - O
all - - O
samples - - O
, - - O
secondary - - O
Academic - - O
, - - O
Personal - - O
Responsibility - - O
, - - O
and - - O
Community - - O
Vocational - - O
dimensions - - O
were - - O
also - - O
identified - - O
. - - O

It - - O
can - - O
be - - O
concluded - - O
that - - O
in - - O
normotensive - - O
subjects - - O
, - - O
uric - - O
acid - - O
and - - O
xanthine - - O
oxidase - - O
have - - O
significant - - O
association - - O
with - - O
blood - - O
pressure - - O
and - - O
thus - - O
are - - O
one - - O
of - - O
the - - O
many - - O
factors - - O
which - - O
are - - O
involved - - O
in - - O
the - - O
cause - - O
or - - O
effect - - O
of - - O
hypertension - - O
. - - O

Hybridization - - O
analysis - - O
showed - - O
that - - O
the - - O
size - - O
of - - O
the - - O
mRNA - - O
is - - O
about - - O
1 - - O
. - - O
4 - - O
kilobases - - O
. - - O

The - - O
heterogeneous - - O
nuclear - - O
ribonucleoprotein - - O
C - - O
protein - - O
tetramer - - O
binds - - O
U1 - - O
, - - O
U2 - - O
, - - O
and - - O
U6 - - O
snRNAs - - O
through - - O
its - - O
high - - O
affinity - - O
RNA - - O
binding - - O
domain - - O
( - - O
the - - O
bZIP-like - - O
motif - - O
) - - O
. - - O

Canadian - - O
survey - - O
reveals - - O
widespread - - O
dissatisfaction - - O
among - - O
physicians - - O
. - - O

Topoisomerase - - O
II - - O
is - - O
a - - O
major - - O
target - - O
of - - O
the - - O
protein - - O
kinase - - O
casein - - O
kinase - - O
2 - - O
( - - O
PK - - O
CK2 - - O
) - - O
in - - O
vivo - - O
. - - O

Its - - O
transcription - - O
product - - O
, - - O
a - - O
1 - - O
. - - O
3 - - O
kb - - O
mRNA - - O
, - - O
is - - O
polyadenylated - - O
at - - O
a - - O
site - - O
containing - - O
consensus - - O
eukaryotic - - O
polyadenylation - - O
signals - - O
and - - O
mapping - - O
87 - - O
bp - - O
downstream - - O
of - - O
the - - O
translation - - O
termination - - O
codon - - O
for - - O
CG30 - - O
. - - O

The - - O
AL-R8 - - O
SI - - O
: - - O
the - - O
next - - O
generation - - O
staging - - O
container - - O
for - - O
plutonium - - O
pits - - O
at - - O
the - - O
USDOE - - O
Pantex - - O
Plant - - O
. - - O

The - - O
rad9 - - O
. - - O
192 - - O
DNA - - O
repair - - O
mutant - - O
from - - O
the - - O
fission - - O
yeast - - O
, - - O
Schizosaccharomyces - - O
pombe - - O
, - - O
is - - O
sensitive - - O
to - - O
both - - O
UV - - O
and - - O
ionising - - O
radiation - - O
. - - O

Seven - - O
patients - - O
( - - O
8 - - O
. - - O
3 - - O
percent - - O
) - - O
had - - O
latent - - O
hypothyroidism - - O
only - - O
discovered - - O
by - - O
hormonal - - O
determinations - - O
. - - O

In - - O
contrast - - O
to - - O
other - - O
known - - O
retroviruses - - O
, - - O
the - - O
FV - - O
pol - - O
genes - - O
are - - O
expressed - - O
via - - O
spliced - - O
transcripts - - O
. - - O

Two - - O
basic - - O
patterns - - O
of - - O
locomotor - - O
behavior - - O
and - - O
corresponding - - O
torso - - O
morphology - - O
exist - - O
among - - O
extant - - O
anthropoids - - O
. - - O

Collagen - - O
was - - O
extracted - - O
from - - O
the - - O
skin - - O
, - - O
and - - O
the - - O
lack - - O
of - - O
type - - O
III - - O
collagen - - O
was - - O
determined - - O
by - - O
means - - O
of - - O
sodium - - O
dodecyl - - O
sulfate-polyacrylamide - - O
gel - - O
electrophoresis - - O
( - - O
SDS-PAGE - - O
) - - O
. - - O

High - - O
fibrinogen - - O
levels - - O
could - - O
thus - - O
be - - O
a - - O
risk - - O
for - - O
perioperative - - O
thrombosis - - O
. - - O

Cooperative - - O
roles - - O
of - - O
Bozozok - - O
Dharma - - O
and - - O
Nodal-related - - O
proteins - - O
in - - O
the - - O
formation - - O
of - - O
the - - O
dorsal - - O
organizer - - O
in - - O
zebrafish - - O
. - - O

Newcastle - - O
disease - - O
virus - - O
surveillance - - O
in - - O
Hong - - O
Kong - - O
on - - O
local - - O
and - - O
imported - - O
poultry - - O
. - - O

RESULTS - - O
: - - O
Auditory - - O
thresholds - - O
collected - - O
during - - O
audiometric - - O
tests - - O
increased - - O
gradually - - O
in - - O
proportion - - O
with - - O
age - - O
, - - O
especially - - O
in - - O
the - - O
hypertensive - - O
group - - O
( - - O
p - - O
< - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

In - - O
this - - O
case - - O
the - - O
degree - - O
of - - O
promoter - - O
methylation - - O
, - - O
which - - O
could - - O
extend - - O
beyond - - O
the - - O
T-DNA - - O
borders - - O
, - - O
was - - O
not - - O
correlated - - O
with - - O
the - - O
reduction - - O
in - - O
steady-state - - O
poly - - O
( - - O
A - - O
) - - O
+ - - O
mRNA - - O
levels - - O
, - - O
the - - O
silenced - - O
state - - O
was - - O
transmitted - - O
through - - O
meiosis - - O
and - - O
reactivation - - O
lasted - - O
several - - O
generations - - O
. - - O

Specimens - - O
were - - O
assayed - - O
for - - O
alpha-fetoprotein - - O
, - - O
unconjugated - - O
estriol - - O
, - - O
free - - O
alpha - - O
hCG - - O
, - - O
and - - O
total - - O
hCG - - O
. - - O

We - - O
report - - O
the - - O
use - - O
of - - O
a - - O
new - - O
technetium-99m-albumin - - O
colloid - - O
white - - O
blood - - O
cell - - O
( - - O
TAC-WBC - - O
) - - O
scan - - O
in - - O
the - - O
evaluation - - O
of - - O
appendicitis - - O
. - - O

Thus - - O
, - - O
SOX8 - - O
is - - O
a - - O
good - - O
candidate - - O
gene - - O
contributing - - O
to - - O
the - - O
mental - - O
retardation - - O
phenotype - - O
seen - - O
in - - O
ATR-16 - - O
patients - - O
. - - O

The - - O
concentrations - - O
of - - O
C4 - - O
and - - O
C1-INH - - O
increased - - O
with - - O
advancing - - O
stage - - O
of - - O
disease - - O
and - - O
were - - O
above - - O
normal - - O
mean - - O
values - - O
in - - O
all - - O
stages - - O
. - - O

We - - O
measured - - O
serum - - O
hepatocyte - - O
growth - - O
factor - - O
( - - O
HGF - - O
) - - O
in - - O
patients - - O
with - - O
acute - - O
myocardial - - O
infarction - - O
, - - O
angina - - O
pectoris - - O
, - - O
and - - O
other - - O
heart - - O
diseases - - O
. - - O

The - - O
Man9-mannosidase - - O
specificity - - O
of - - O
the - - O
cDNA - - O
construct - - O
was - - O
verified - - O
by - - O
the - - O
observation - - O
that - - O
all - - O
peptide - - O
sequences - - O
derived - - O
from - - O
a - - O
previously - - O
purified - - O
, - - O
catalytically - - O
active - - O
49-kDa - - O
fragment - - O
were - - O
found - - O
within - - O
the - - O
coding - - O
region - - O
. - - O

Cranio-caudal - - O
differences - - O
in - - O
granulation - - O
tissue - - O
formation - - O
: - - O
an - - O
experimental - - O
study - - O
in - - O
the - - O
rat - - O
. - - O

Here - - O
we - - O
show - - O
that - - O
for - - O
expression - - O
of - - O
snRNA - - O
genes - - O
in - - O
maize - - O
, - - O
a - - O
monocotyledonous - - O
plant - - O
, - - O
the - - O
USE - - O
and - - O
TATA - - O
elements - - O
are - - O
essential - - O
, - - O
but - - O
not - - O
sufficient - - O
, - - O
for - - O
transcription - - O
. - - O

The - - O
PETCO2 - - O
measurement - - O
during - - O
precordial - - O
compression - - O
predicted - - O
the - - O
success - - O
of - - O
defibrillation - - O
with - - O
return - - O
of - - O
spontaneous - - O
circulation - - O
. - - O

RESULTS - - O
: - - O
The - - O
binding - - O
of - - O
99mTc - - O
d - - O
, - - O
1-HMPAO - - O
to - - O
human - - O
placenta - - O
ranged - - O
from - - O
2 - - O
. - - O
95% - - O
+ - - O
- - - O
1 - - O
. - - O
5% - - O
to - - O
5 - - O
. - - O
82% - - O
+ - - O
- - - O
0 - - O
. - - O
3% - - O
per - - O
1 - - O
ml - - O
standard - - O
solution - - O
. - - O

Low - - O
NA - - O
and - - O
A - - O
may - - O
participate - - O
in - - O
lowering - - O
the - - O
plasma - - O
renin - - O
activity - - O
which - - O
in - - O
PA - - O
in - - O
suppressed - - O
, - - O
sometimes - - O
disproportionately - - O
to - - O
the - - O
actual - - O
body - - O
sodium - - O
content - - O
. - - O

These - - O
results - - O
suggest - - O
that - - O
indoramin - - O
may - - O
have - - O
Class - - O
III - - O
antiarrhythmic - - O
activity - - O
. - - O

A - - O
9 - - O
. - - O
5-kb - - O
KpnI-SalI - - O
fragment - - O
, - - O
where - - O
all - - O
the - - O
DNA - - O
changes - - O
associated - - O
with - - O
su - - O
( - - O
Hw - - O
) - - O
mutations - - O
were - - O
mapped - - O
, - - O
was - - O
able - - O
to - - O
rescue - - O
the - - O
su - - O
( - - O
Hw - - O
) - - O
mutant - - O
phenotype - - O
after - - O
P-element-mediated - - O
germ-line - - O
transformation - - O
. - - O

A - - O
panel - - O
of - - O
pharmacologic - - O
inhibitors - - O
was - - O
used - - O
to - - O
investigate - - O
the - - O
signal - - O
transduction - - O
pathways - - O
involved - - O
in - - O
TRAIL - - O
gene - - O
induction - - O
following - - O
T - - O
lymphocyte - - O
activation - - O
. - - O

Scanning - - O
electron - - O
microscopic - - O
investigations - - O
on - - O
the - - O
formation - - O
of - - O
Reissner's - - O
fiber - - O
in - - O
Rattus - - O
rattus - - O
. - - O

Changes - - O
in - - O
dopamine - - O
receptor - - O
sensitivity - - O
in - - O
humans - - O
after - - O
heavy - - O
alcohol - - O
intake - - O
. - - O

The - - O
sample - - O
is - - O
deproteinized - - O
and - - O
after - - O
centrifugation - - O
valproic - - O
acid - - O
in - - O
the - - O
supernatant - - O
is - - O
measured - - O
in - - O
the - - O
free - - O
form - - O
by - - O
direct - - O
injection - - O
into - - O
the - - O
gas - - O
chromatograph - - O
. - - O

Further - - O
, - - O
intracerebroventricular - - O
injections - - O
of - - O
KA - - O
resulted - - O
in - - O
the - - O
substantial - - O
loss - - O
of - - O
pyramidal - - O
cells - - O
in - - O
the - - O
whole - - O
CA3 - - O
field - - O
of - - O
the - - O
hippocampus - - O
. - - O

Gabapentin - - O
for - - O
opiod-related - - O
myoclonus - - O
in - - O
cancer - - O
patients - - O
. - - O

Heterogeneous - - O
electron - - O
transfer - - O
of - - O
cytochrome - - O
c - - O
facilitated - - O
by - - O
polypyrrole - - O
and - - O
methylene - - O
blue - - O
polypyrrole - - O
film - - O
modified - - O
electrodes - - O
. - - O

Sequence - - O
analysis - - O
revealed - - O
: - - O
1 - - O
) - - O
a - - O
kinase - - O
catalytic - - O
domain - - O
most - - O
characteristic - - O
of - - O
serine - - O
threonine - - O
kinases - - O
but - - O
hybrid - - O
between - - O
members - - O
of - - O
the - - O
family - - O
of - - O
microtubule-associated - - O
protein - - O
kinase - - O
kinase - - O
kinases - - O
and - - O
the - - O
fibroblast - - O
growth - - O
factor - - O
receptor - - O
family - - O
; - - O
2 - - O
) - - O
two - - O
putative - - O
alpha-helical - - O
leucine - - O
zipper - - O
motifs - - O
separated - - O
by - - O
a - - O
25-amino - - O
acid - - O
charged - - O
intermediate - - O
segment - - O
but - - O
lacking - - O
an - - O
NH2-terminal - - O
basic - - O
domain - - O
; - - O
and - - O
3 - - O
) - - O
COOH-terminal - - O
and - - O
NH2-terminal - - O
proline-rich - - O
domains - - O
suggestive - - O
of - - O
src - - O
homology - - O
3 - - O
( - - O
SH3 - - O
) - - O
domain - - O
binding - - O
regions - - O
. - - O

Epithelial - - O
damage - - O
was - - O
not - - O
observed - - O
in - - O
any - - O
controls - - O
but - - O
was - - O
in - - O
all - - O
tissues - - O
exposed - - O
to - - O
SO2 - - O
. - - O

Distribution - - O
and - - O
correlations - - O
of - - O
serum - - O
uric-acid - - O
in - - O
two - - O
French - - O
adult - - O
populations - - O
: - - O
13 - - O
, - - O
885 - - O
men - - O
and - - O
6 - - O
, - - O
861 - - O
women - - O
. - - O

Effects - - O
of - - O
cortisone - - O
, - - O
starvation - - O
, - - O
and - - O
rickets - - O
on - - O
oxidative - - O
enzyme - - O
activities - - O
of - - O
epiphyseal - - O
cartilage - - O
from - - O
rats - - O
. - - O

Transient - - O
overexpression - - O
of - - O
mutant - - O
EphB1 - - O
receptors - - O
( - - O
Y594F - - O
) - - O
blocked - - O
Nck - - O
recruitment - - O
to - - O
EphB1 - - O
, - - O
attenuated - - O
downstream - - O
JNK - - O
activation - - O
, - - O
and - - O
blocked - - O
cell - - O
attachment - - O
responses - - O
. - - O

Analysis - - O
of - - O
the - - O
upstream - - O
untranslated - - O
region - - O
of - - O
CHL15 - - O
revealed - - O
the - - O
presence - - O
of - - O
the - - O
hexamer - - O
element - - O
, - - O
ACGCGT - - O
( - - O
an - - O
MluI - - O
restriction - - O
site - - O
) - - O
controlling - - O
both - - O
the - - O
periodic - - O
expression - - O
and - - O
coordinate - - O
regulation - - O
of - - O
the - - O
DNA - - O
synthesis - - O
genes - - O
in - - O
budding - - O
yeast - - O
. - - O

Our - - O
results - - O
indicate - - O
that - - O
the - - O
expression - - O
of - - O
Cktsf1b1 - - O
, - - O
a - - O
gene - - O
associated - - O
with - - O
early - - O
development - - O
and - - O
cell - - O
transformation - - O
, - - O
is - - O
sensitive - - O
to - - O
MKK - - O
levels - - O
and - - O
may - - O
be - - O
regulated - - O
via - - O
multiple - - O
transcription - - O
factor - - O
complexes - - O
. - - O

Drugs - - O
suppressed - - O
> - - O
or - - O
= - - O
75% - - O
of - - O
the - - O
total - - O
premature - - O
ventricular - - O
contractions - - O
in - - O
all - - O
patients - - O
who - - O
had - - O
both - - O
use-dependent - - O
QRS - - O
prolongation - - O
and - - O
reverse - - O
use-dependent - - O
QT - - O
prolongation - - O
, - - O
in - - O
79% - - O
of - - O
patients - - O
with - - O
use-dependent - - O
QRS - - O
prolongation - - O
alone - - O
, - - O
in - - O
70% - - O
with - - O
reverse - - O
use-dependent - - O
QT - - O
prolongation - - O
alone - - O
, - - O
and - - O
in - - O
11% - - O
with - - O
neither - - O
use-dependent - - O
QRS - - O
prolongation - - O
nor - - O
reverse - - O
use-dependent - - O
QT - - O
prolongation - - O
. - - O

CONCLUSION - - O
: - - O
NBP - - O
pre-treatment - - O
or - - O
post-treatment - - O
markedly - - O
enhanced - - O
the - - O
rCBF - - O
to - - O
striatum - - O
in - - O
RMCAO - - O
rats - - O
. - - O

Thioredoxin - - O
( - - O
TR - - O
) - - O
is - - O
a - - O
small - - O
ubiquitous - - O
dithiol-reductase - - O
enzyme - - O
first - - O
identified - - O
in - - O
bacteria - - O
and - - O
plants - - O
. - - O

4 - - O
Five - - O
patients - - O
died - - O
within - - O
one - - O
month - - O
of - - O
captopril - - O
and - - O
five - - O
between - - O
four - - O
and - - O
seven - - O
months - - O
, - - O
three - - O
of - - O
whom - - O
had - - O
improved - - O
to - - O
class - - O
IIM - - O
and - - O
one - - O
to - - O
IIS - - O
before - - O
death - - O
. - - O

We - - O
have - - O
partially - - O
sequenced - - O
the - - O
RAP74 - - O
protein - - O
from - - O
purified - - O
HeLa - - O
cells - - O
, - - O
cloned - - O
its - - O
complementary - - O
DNA - - O
and - - O
shown - - O
that - - O
its - - O
translation - - O
product - - O
can - - O
interact - - O
with - - O
RAP30 - - O
in - - O
vitro - - O
as - - O
well - - O
as - - O
in - - O
vivo - - O
. - - O

Regulation - - O
of - - O
the - - O
human - - O
p21 - - O
WAF1 - - O
Cip1 - - O
promoter - - O
in - - O
hepatic - - O
cells - - O
by - - O
functional - - O
interactions - - O
between - - O
Sp1 - - O
and - - O
Smad - - O
family - - O
members - - O
. - - O

Nonetheless - - O
, - - O
that - - O
ventricular - - O
afferents - - O
, - - O
in - - O
certain - - O
special - - O
settings - - O
, - - O
are - - O
able - - O
to - - O
induce - - O
e - - O
. - - O
g - - O
. - - O
generalised - - O
vasodilation - - O
and - - O
hypotension - - O
cannot - - O
be - - O
excluded - - O
. - - O

A - - O
comparison - - O
of - - O
the - - O
nucleotide - - O
and - - O
deduced - - O
amino - - O
acid - - O
sequences - - O
of - - O
the - - O
core - - O
regions - - O
of - - O
the - - O
RNA-dependent - - O
RNA - - O
polymerase - - O
domains - - O
found - - O
in - - O
these - - O
three - - O
dsRNAs - - O
suggested - - O
that - - O
these - - O
dsRNAs - - O
probably - - O
evolved - - O
independently - - O
within - - O
each - - O
host - - O
plant - - O
from - - O
a - - O
common - - O
ancestor - - O
. - - O

CASE - - O
REPORT - - O
: - - O
We - - O
observed - - O
a - - O
congenital - - O
skin - - O
defect - - O
located - - O
exclusively - - O
on - - O
the - - O
trunk - - O
. - - O

The - - O
small - - O
GTPase - - O
Rho - - O
is - - O
implicated - - O
in - - O
physiological - - O
functions - - O
associated - - O
with - - O
actin-myosin - - O
filaments - - O
such - - O
as - - O
cytokinesis - - O
, - - O
cell - - O
motility - - O
, - - O
and - - O
smooth - - O
muscle - - O
contraction - - O
. - - O

Canine - - O
reproduction - - O
: - - O
effects - - O
of - - O
a - - O
single - - O
injection - - O
of - - O
medroxyprogesterone - - O
acetate - - O
on - - O
the - - O
reproductive - - O
organs - - O
of - - O
the - - O
bitch - - O
. - - O

The - - O
size - - O
of - - O
the - - O
infarct - - O
was - - O
determined - - O
using - - O
the - - O
creatine - - O
kinase - - O
integral - - O
method - - O
. - - O

The - - O
identified - - O
isolates - - O
of - - O
CSF - - O
( - - O
20 - - O
of - - O
29 - - O
) - - O
were - - O
: - - O
ECHO - - O
30 - - O
( - - O
9 - - O
) - - O
, - - O
ECHO - - O
11 - - O
( - - O
7 - - O
) - - O
, - - O
ECHO - - O
9 - - O
( - - O
3 - - O
) - - O
and - - O
ECHO - - O
7 - - O
( - - O
1 - - O
) - - O
. - - O

The - - O
cDNA - - O
clone - - O
was - - O
used - - O
as - - O
a - - O
homologous - - O
probe - - O
to - - O
isolate - - O
a - - O
truncated - - O
genomic - - O
clone - - O
encoding - - O
H2A1 - - O
. - - O

RESULTS - - O
: - - O
Plasma - - O
AVP - - O
responses - - O
to - - O
osmotic - - O
stimulation - - O
, - - O
and - - O
non-osmotic - - O
inhibition - - O
by - - O
drinking - - O
, - - O
were - - O
normal - - O
in - - O
patients - - O
with - - O
compulsive - - O
water - - O
drinking - - O
. - - O

Moreover - - O
, - - O
in - - O
rats - - O
allowed - - O
to - - O
choose - - O
in - - O
a - - O
T-maze - - O
between - - O
immediate-but-small - - O
vs - - O
. - - O
delayed-but-large - - O
reward - - O
, - - O
BZP - - O
significantly - - O
decreased - - O
the - - O
frequency - - O
with - - O
which - - O
the - - O
delayed - - O
reward - - O
was - - O
chosen - - O
, - - O
with - - O
5-HT - - O
uptake - - O
blockers - - O
producing - - O
opposite - - O
effects - - O
. - - O

Both - - O
the - - O
intact - - O
A1 - - O
protein - - O
and - - O
its - - O
proteolytic - - O
fragment - - O
, - - O
the - - O
UP1 - - O
protein - - O
, - - O
can - - O
be - - O
cleaved - - O
by - - O
Staphylococcus - - O
aureus - - O
V-8 - - O
protease - - O
to - - O
produce - - O
two - - O
polypeptides - - O
of - - O
92 - - O
amino - - O
acids - - O
. - - O

The - - O
human - - O
p100 - - O
protein - - O
was - - O
recently - - O
identified - - O
as - - O
a - - O
coactivator - - O
of - - O
the - - O
Epstein-Barr - - O
virus - - O
nuclear - - O
antigen - - O
2 - - O
. - - O

OBJECTIVES - - O
: - - O
To - - O
measure - - O
coagulation - - O
factor - - O
VIII - - O
: - - O
coagulant - - O
( - - O
F - - O
. - - O
VIII - - O
: - - O
C - - O
) - - O
and - - O
C1-esterase - - O
inhibitor - - O
( - - O
C1-INH - - O
) - - O
, - - O
hemostasis-associated - - O
acute-phase - - O
reactant - - O
proteins - - O
and - - O
coagulation - - O
factors - - O
VII - - O
( - - O
F - - O
. - - O
VII - - O
) - - O
, - - O
IX - - O
( - - O
F - - O
. - - O
IX - - O
) - - O
, - - O
and - - O
X - - O
( - - O
F - - O
. - - O
X - - O
) - - O
, - - O
hemostasis - - O
proteins - - O
not - - O
associated - - O
with - - O
an - - O
acute-phase - - O
response - - O
, - - O
in - - O
a - - O
select - - O
population - - O
of - - O
horses - - O
with - - O
colic - - O
and - - O
hemostasis - - O
abnormalities - - O
, - - O
and - - O
presumed - - O
to - - O
have - - O
acute-phase - - O
changes - - O
. - - O

SAM-TR-68-54 - - O
. - - O

Consistent - - O
with - - O
the - - O
hypothesis - - O
that - - O
it - - O
acts - - O
as - - O
transcriptional - - O
regulator - - O
, - - O
wild-type - - O
p53 - - O
protein - - O
binds - - O
DNA - - O
and - - O
activates - - O
transcription - - O
of - - O
several - - O
promoters - - O
. - - O

Critique - - O
of - - O
"Interactive - - O
Effects - - O
of - - O
Test - - O
Anxiety - - O
and - - O
Credit - - O
No - - O
Credit - - O
or - - O
A-F - - O
Grade - - O
Condition - - O
upon - - O
Short-term - - O
and - - O
Long-term - - O
Recall - - O
of - - O
Course - - O
Information - - O
. - - O

The - - O
distribution - - O
of - - O
red - - O
rice - - O
cultivation - - O
in - - O
Sri - - O
Lanka - - O
is - - O
coincident - - O
with - - O
the - - O
HIDD - - O
villages - - O
. - - O

It - - O
was - - O
not - - O
possible - - O
to - - O
study - - O
the - - O
basis - - O
for - - O
tissue-specific - - O
expression - - O
of - - O
this - - O
gene - - O
, - - O
because - - O
the - - O
beta - - O
3 - - O
gene - - O
promoter - - O
had - - O
not - - O
been - - O
isolated - - O
previously - - O
. - - O

The - - O
E1 - - O
replication - - O
protein - - O
of - - O
bovine - - O
papillomavirus - - O
type - - O
1 - - O
contains - - O
an - - O
extended - - O
nuclear - - O
localization - - O
signal - - O
that - - O
includes - - O
a - - O
p34cdc2 - - O
phosphorylation - - O
site - - O
. - - O

Stoichiometric - - O
phosphorylation - - O
of - - O
human - - O
p53 - - O
at - - O
Ser315 - - O
stimulates - - O
p53-dependent - - O
transcription - - O
. - - O
p53 - - O
protein - - O
activity - - O
as - - O
a - - O
transcription - - O
factor - - O
can - - O
be - - O
activated - - O
in - - O
vivo - - O
by - - O
antibodies - - O
that - - O
target - - O
its - - O
C-terminal - - O
negative - - O
regulatory - - O
domain - - O
suggesting - - O
that - - O
cellular - - O
enzymes - - O
that - - O
target - - O
this - - O
domain - - O
may - - O
play - - O
a - - O
role - - O
in - - O
stimulating - - O
p53-dependent - - O
gene - - O
expression - - O
. - - O

Commutative - - O
saccadic - - O
generator - - O
is - - O
sufficient - - O
to - - O
control - - O
a - - O
3-D - - O
ocular - - O
plant - - O
with - - O
pulleys - - O
. - - O

Measurements - - O
in - - O
the - - O
LWS - - O
p - - O
. - - O
a - - O
. - - O
, - - O
LWS - - O
lat - - O
. - - O
and - - O
at - - O
Ward's - - O
triangle - - O
were - - O
made - - O
in - - O
a - - O
total - - O
of - - O
100 - - O
patients - - O
. - - O

This - - O
suggests - - O
that - - O
helicase-like - - O
genes - - O
may - - O
be - - O
involved - - O
in - - O
the - - O
biosynthesis - - O
of - - O
nucleic - - O
acids - - O
and - - O
proteins - - O
, - - O
and - - O
that - - O
the - - O
genes - - O
can - - O
be - - O
transcriptionally - - O
activated - - O
by - - O
heat - - O
shock - - O
to - - O
compensate - - O
for - - O
the - - O
repressed - - O
synthesis - - O
of - - O
mRNA - - O
and - - O
protein - - O
. - - O

Elledge - - O
, - - O
P - - O
. - - O

With - - O
the - - O
modified - - O
fingertip-to-floor - - O
( - - O
MFTF - - O
) - - O
method - - O
, - - O
patients - - O
stand - - O
on - - O
a - - O
stool - - O
and - - O
forward - - O
bend - - O
so - - O
that - - O
measurements - - O
can - - O
be - - O
taken - - O
on - - O
patients - - O
who - - O
are - - O
able - - O
to - - O
touch - - O
the - - O
floor - - O
or - - O
reach - - O
beyond - - O
the - - O
level - - O
of - - O
the - - O
floor - - O
. - - O

Clicking - - O
on - - O
"Examples - - O
and - - O
Explanations - - O
of - - O
APA - - O
Form" - - O
provides - - O
a - - O
help - - O
system - - O
with - - O
examples - - O
of - - O
the - - O
various - - O
sections - - O
of - - O
a - - O
review - - O
article - - O
, - - O
journal - - O
article - - O
that - - O
has - - O
one - - O
experiment - - O
, - - O
or - - O
journal - - O
article - - O
that - - O
has - - O
two - - O
or - - O
more - - O
experiments - - O
. - - O

This - - O
proposed - - O
method - - O
is - - O
similar - - O
in - - O
principle - - O
to - - O
the - - O
sets - - O
technique - - O
but - - O
is - - O
shown - - O
to - - O
have - - O
much - - O
better - - O
expected - - O
time - - O
to - - O
alarm - - O
properties - - O
. - - O

After - - O
phosphorylation - - O
, - - O
STAT - - O
proteins - - O
are - - O
transported - - O
into - - O
the - - O
nucleus - - O
and - - O
exhibit - - O
transcriptional - - O
activity - - O
. - - O

Morphine - - O
produced - - O
a - - O
dose-dependent - - O
bradycardia - - O
followed - - O
by - - O
tachycardia - - O
. - - O

For - - O
the - - O
first - - O
30 - - O
min - - O
following - - O
insulin - - O
administration - - O
, - - O
the - - O
rate - - O
of - - O
change - - O
in - - O
glucose - - O
levels - - O
was - - O
significantly - - O
less - - O
among - - O
the - - O
patients - - O
with - - O
major - - O
depressive - - O
disorder - - O
than - - O
among - - O
either - - O
the - - O
patients - - O
with - - O
dysthymic - - O
disorder - - O
or - - O
the - - O
normal - - O
control - - O
subjects - - O
. - - O

The - - O
expression - - O
of - - O
chloramphenicol - - O
acetyltransferase - - O
was - - O
detected - - O
within - - O
1 - - O
h - - O
after - - O
infection - - O
of - - O
cells - - O
with - - O
recombinant - - O
virus - - O
, - - O
reflecting - - O
the - - O
early - - O
nature - - O
of - - O
the - - O
promoters - - O
used - - O
. - - O

Bioplastique - - O
granuloma - - O
presents - - O
with - - O
irregularly - - O
shaped - - O
cystic - - O
spaces - - O
of - - O
varying - - O
size - - O
containing - - O
jagged - - O
, - - O
translucent - - O
, - - O
nonbirefringent - - O
foreign - - O
bodies - - O
whereas - - O
Artecoll - - O
granuloma - - O
shows - - O
numerous - - O
round - - O
vacuoles - - O
nearly - - O
identical - - O
in - - O
size - - O
and - - O
shape - - O
enclosing - - O
round - - O
and - - O
sharply - - O
circumscribed - - O
, - - O
translucent - - O
, - - O
nonbirefringent - - O
foreign - - O
bodies - - O
. - - O

Pharmacokinetics - - O
of - - O
Carbamazepine - - O
in - - O
man - - O
: - - O
a - - O
review - - O
. - - O

Two - - O
transcripts - - O
of - - O
1 - - O
. - - O
6 - - O
kb - - O
and - - O
5 - - O
. - - O
8 - - O
kb - - O
are - - O
5' - - O
coterminal - - O
and - - O
may - - O
both - - O
encode - - O
the - - O
novel - - O
glycoprotein - - O
gene - - O
EUS4 - - O
. - - O

A - - O
randomised - - O
, - - O
controlled - - O
trial - - O
was - - O
undertaken - - O
in - - O
40 - - O
patients - - O
with - - O
active - - O
Crohn's - - O
disease - - O
to - - O
evaluate - - O
clinical - - O
and - - O
nutritional - - O
outcomes - - O
after - - O
an - - O
amino - - O
acid - - O
based - - O
diet - - O
containing - - O
3% - - O
fat - - O
was - - O
given - - O
by - - O
a - - O
feeding - - O
tube - - O
compared - - O
with - - O
a - - O
peptide - - O
based - - O
diet - - O
containing - - O
33% - - O
fat - - O
. - - O

Recombinant - - O
human - - O
erythropoietin - - O
( - - O
epoetin - - O
) - - O
is - - O
approved - - O
to - - O
be - - O
administered - - O
by - - O
the - - O
intravenous - - O
( - - O
i - - O
. - - O
v - - O
. - - O
) - - O
or - - O
subcutaneous - - O
( - - O
SC - - O
) - - O
route - - O
. - - O

We - - O
speculate - - O
that - - O
mast - - O
cell - - O
degranulation - - O
may - - O
be - - O
involved - - O
in - - O
the - - O
pathogenesis - - O
of - - O
necrobiosis - - O
by - - O
altering - - O
fibroblast - - O
enzyme - - O
activity - - O
and - - O
or - - O
producing - - O
prolonged - - O
inflammatory - - O
reactions - - O
. - - O

Hypomorphic - - O
dSLBP - - O
alleles - - O
support - - O
zygotic - - O
development - - O
but - - O
cause - - O
female - - O
sterility - - O
. - - O

Molecular - - O
cloning - - O
and - - O
characterization - - O
of - - O
a - - O
cDNA - - O
, - - O
CHEMR1 - - O
, - - O
encoding - - O
a - - O
chemokine - - O
receptor - - O
with - - O
a - - O
homology - - O
to - - O
the - - O
human - - O
C-C - - O
chemokine - - O
receptor - - O
, - - O
CCR-4 - - O
. - - O

To - - O
achieve - - O
complete - - O
dissection - - O
of - - O
the - - O
anterior - - O
vitreous - - O
, - - O
we - - O
remove - - O
even - - O
a - - O
clear - - O
lens - - O
during - - O
the - - O
first - - O
surgical - - O
intervention - - O
in - - O
selected - - O
cases - - O
. - - O

Suggestive - - O
evidence - - O
was - - O
obtained - - O
that - - O
cstA - - O
is - - O
involved - - O
in - - O
peptide - - O
utilization - - O
. - - O

QBMDs - - O
for - - O
a - - O
5% - - O
change - - O
in - - O
response - - O
( - - O
QBMD05 - - O
) - - O
were - - O
6-fold - - O
lower - - O
, - - O
on - - O
average - - O
, - - O
than - - O
the - - O
corresponding - - O
NOAEL - - O
. - - O

Recombinant - - O
FVIIa - - O
was - - O
stable - - O
in - - O
the - - O
infusion - - O
pump - - O
for - - O
several - - O
days - - O
at - - O
room - - O
temperature - - O
and - - O
for - - O
24 - - O
h - - O
at - - O
body - - O
temperature - - O
. - - O

Using - - O
the - - O
polymerase - - O
chain - - O
reaction - - O
, - - O
Whipple-specific - - O
DNA - - O
fragments - - O
of - - O
284 - - O
base - - O
pairs - - O
from - - O
the - - O
genome - - O
of - - O
the - - O
Whipple - - O
bacterium - - O
( - - O
Tropheryma - - O
whippelii - - O
) - - O
were - - O
demonstrated - - O
. - - O

We - - O
have - - O
previously - - O
reported - - O
that - - O
depletion - - O
of - - O
protein - - O
kinase - - O
C - - O
by - - O
long-term - - O
treatment - - O
of - - O
B16 - - O
mouse - - O
melanoma - - O
cells - - O
with - - O
phorbol - - O
dibutyrate - - O
( - - O
PDBu - - O
) - - O
prevented - - O
cell - - O
density-dependent - - O
melanogenesis - - O
. - - O

PM - - O
12 - - O
or - - O
18 - - O
mg - - O
kg - - O
daily - - O
plus - - O
a - - O
standard - - O
dose - - O
of - - O
SB - - O
for - - O
21 - - O
days - - O
was - - O
statistically - - O
more - - O
effective - - O
than - - O
SB - - O
in - - O
producing - - O
a - - O
final - - O
cure - - O
for - - O
patients - - O
with - - O
VL - - O
in - - O
Bihar - - O
, - - O
India - - O
. - - O

Visidex - - O
I - - O
is - - O
unsuitable - - O
for - - O
storage - - O
and - - O
re-reading - - O
. - - O

A - - O
pathway - - O
for - - O
regulation - - O
of - - O
B - - O
lymphocyte - - O
antigen - - O
receptor-induced - - O
calcium - - O
flux - - O
. - - O

Silicosis - - O
mortality - - O
. - - O

Rats - - O
with - - O
one - - O
olfactory - - O
bulb - - O
removed - - O
and - - O
the - - O
contralateral - - O
naris - - O
closed - - O
can - - O
detect - - O
odors - - O
. - - O

Specimen - - O
mass - - O
reduction - - O
increased - - O
with - - O
irradiance - - O
from - - O
19 - - O
to - - O
72% - - O
of - - O
the - - O
initial - - O
mass - - O
for - - O
9--31 - - O
W - - O
cm - - O
( - - O
2 - - O
) - - O
, - - O
respectively - - O
. - - O

The - - O
transcription - - O
factor - - O
Jun - - O
( - - O
c-Jun - - O
) - - O
functions - - O
as - - O
a - - O
recipient - - O
of - - O
extracellular - - O
growth - - O
signals - - O
and - - O
converts - - O
them - - O
into - - O
patterns - - O
of - - O
gene - - O
expression - - O
. - - O

The - - O
encoded - - O
polypeptide - - O
is - - O
similar - - O
in - - O
sequence - - O
to - - O
the - - O
ABA-1 - - O
allergen - - O
of - - O
Ascaris - - O
, - - O
the - - O
gp15 - - O
400 - - O
'ladder' - - O
protein - - O
of - - O
Brugia - - O
malayi - - O
, - - O
Brugia - - O
pahangi - - O
and - - O
Wuchereria - - O
bancrofti - - O
, - - O
and - - O
a - - O
15-kDa - - O
antigen - - O
of - - O
Dirofilaria - - O
immitis - - O
. - - O

We - - O
now - - O
describe - - O
the - - O
identification - - O
of - - O
DEK - - O
as - - O
this - - O
43-kDa - - O
pets - - O
factor - - O
. - - O

TH-SH3 - - O
binding - - O
in - - O
vitro - - O
is - - O
abolished - - O
by - - O
specific - - O
, - - O
single - - O
amino - - O
acid - - O
substitutions - - O
within - - O
the - - O
Btk - - O
TH - - O
domain - - O
or - - O
the - - O
Fyn - - O
SH3 - - O
domain - - O
. - - O

Nuclear - - O
extracts - - O
prepared - - O
from - - O
both - - O
neural - - O
and - - O
non-neural - - O
cell - - O
lines - - O
, - - O
mouse - - O
brain - - O
, - - O
and - - O
mouse - - O
liver - - O
contain - - O
proteins - - O
that - - O
recognize - - O
and - - O
bind - - O
to - - O
the - - O
PROX - - O
and - - O
PAL - - O
sequences - - O
indicating - - O
that - - O
proteins - - O
which - - O
bind - - O
to - - O
these - - O
target - - O
sequences - - O
are - - O
widespread - - O
. - - O

The - - O
exon-intron - - O
distribution - - O
of - - O
Cdebp - - O
appears - - O
strikingly - - O
similar - - O
to - - O
that - - O
of - - O
the - - O
App - - O
gene - - O
in - - O
the - - O
regions - - O
encoding - - O
the - - O
conserved - - O
domains - - O
, - - O
with - - O
a - - O
divergent - - O
structure - - O
in - - O
the - - O
other - - O
parts - - O
. - - O

A - - O
region - - O
in - - O
the - - O
C-terminus - - O
of - - O
adenovirus - - O
2 - - O
5 - - O
E1a - - O
protein - - O
is - - O
required - - O
for - - O
association - - O
with - - O
a - - O
cellular - - O
phosphoprotein - - O
and - - O
important - - O
for - - O
the - - O
negative - - O
modulation - - O
of - - O
T24-ras - - O
mediated - - O
transformation - - O
, - - O
tumorigenesis - - O
and - - O
metastasis - - O
. - - O

We - - O
also - - O
review - - O
the - - O
role - - O
of - - O
grains - - O
in - - O
the - - O
formation - - O
of - - O
complex - - O
molecules - - O
in - - O
interstellar - - O
molecular - - O
clouds - - O
. - - O

Identification - - O
of - - O
an - - O
enhancer - - O
and - - O
an - - O
alternative - - O
promoter - - O
in - - O
the - - O
first - - O
intron - - O
of - - O
the - - O
alpha-fetoprotein - - O
gene - - O
. - - O

Spontaneous - - O
burst - - O
firing - - O
in - - O
cat - - O
primary - - O
auditory - - O
cortex - - O
: - - O
age - - O
and - - O
depth - - O
dependence - - O
and - - O
its - - O
effect - - O
on - - O
neural - - O
interaction - - O
measures - - O
. - - O

Second - - O
, - - O
plasmid-derived - - O
transgenes - - O
and - - O
gene - - O
targeting - - O
of - - O
the - - O
endogenous - - O
Hnf3g - - O
gene - - O
locus - - O
were - - O
used - - O
to - - O
demonstrate - - O
that - - O
the - - O
3'-flanking - - O
region - - O
of - - O
the - - O
gene - - O
is - - O
necessary - - O
and - - O
sufficient - - O
to - - O
direct - - O
reporter - - O
gene - - O
expression - - O
in - - O
liver - - O
, - - O
pancreas - - O
, - - O
stomach - - O
and - - O
small - - O
intestine - - O
. - - O

Polysome - - O
analyses - - O
in - - O
a - - O
temperature-sensitive - - O
fal1-1 - - O
mutant - - O
and - - O
a - - O
Fal1p-depleted - - O
strain - - O
reveal - - O
a - - O
decrease - - O
in - - O
the - - O
number - - O
of - - O
40S - - O
ribosomal - - O
subunits - - O
. - - O

Consistent - - O
with - - O
a - - O
possible - - O
role - - O
in - - O
transcription - - O
, - - O
Paf1p - - O
is - - O
localized - - O
to - - O
the - - O
nucleus - - O
. - - O

However - - O
, - - O
if - - O
the - - O
spatial - - O
resolution - - O
is - - O
not - - O
critical - - O
and - - O
interest - - O
is - - O
to - - O
compare - - O
a - - O
pathologic - - O
area - - O
with - - O
a - - O
contralateral - - O
VOI - - O
, - - O
then - - O
the - - O
acquisition - - O
of - - O
two - - O
single-voxel - - O
spectra - - O
may - - O
be - - O
preferred - - O
. - - O

Angiographic - - O
work-up - - O
in - - O
a - - O
patient - - O
with - - O
late - - O
vaginal - - O
metastasis - - O
from - - O
a - - O
renal - - O
carcinoma - - O
. - - O

Adaptation - - O
of - - O
taurocholate - - O
transport - - O
maximum - - O
to - - O
increased - - O
secretory - - O
load - - O
in - - O
the - - O
rat - - O
. - - O

The - - O
molecular - - O
mechanism - - O
of - - O
Tax-mediated - - O
trans-activation - - O
has - - O
been - - O
well - - O
investigated - - O
. - - O

This - - O
suggested - - O
that - - O
delta - - O
6 - - O
and - - O
delta - - O
5 - - O
desaturation - - O
activities - - O
are - - O
normal - - O
in - - O
these - - O
conditions - - O
with - - O
this - - O
C18 - - O
: - - O
2w6 - - O
supply - - O
. - - O

The - - O
mean - - O
values - - O
of - - O
the - - O
first - - O
three - - O
components - - O
were - - O
not - - O
significantly - - O
different - - O
in - - O
ARVD - - O
patients - - O
and - - O
control - - O
subjects - - O
. - - O

Additional - - O
information - - O
including - - O
echocardiographic - - O
sequences - - O
, - - O
perioperative - - O
video - - O
sequences - - O
, - - O
x-ray - - O
analysis - - O
, - - O
angiograms - - O
, - - O
etc - - O
. - - O
is - - O
represented - - O
in - - O
the - - O
program - - O
. - - O

Classification - - O
according - - O
to - - O
the - - O
ILAR - - O
criteria - - O
was - - O
possible - - O
in - - O
321 - - O
patients - - O
; - - O
290 - - O
patients - - O
had - - O
a - - O
disease - - O
duration - - O
> - - O
or - - O
= - - O
3 - - O
months - - O
and - - O
were - - O
classified - - O
according - - O
to - - O
the - - O
EULAR - - O
criteria - - O
. - - O

METHODS - - O
: - - O
109 - - O
suspected - - O
cases - - O
with - - O
SS - - O
underwent - - O
the - - O
biopsies - - O
. - - O

In - - O
order - - O
to - - O
delineate - - O
structural - - O
motifs - - O
regulating - - O
substrate - - O
affinity - - O
and - - O
recognition - - O
for - - O
the - - O
human - - O
dopamine - - O
transporter - - O
( - - O
DAT - - O
) - - O
, - - O
we - - O
assessed - - O
[ - - O
3H - - O
] - - O
dopamine - - O
uptake - - O
kinetics - - O
and - - O
[ - - O
3H - - O
] - - O
CFT - - O
binding - - O
characteristics - - O
of - - O
COS-7 - - O
cells - - O
transiently - - O
expressing - - O
mutant - - O
DATs - - O
in - - O
which - - O
the - - O
COOH - - O
terminus - - O
was - - O
truncated - - O
or - - O
substituted - - O
. - - O

Thus - - O
, - - O
methylation - - O
of - - O
Pph21p - - O
is - - O
important - - O
for - - O
formation - - O
of - - O
PP2A - - O
trimeric - - O
and - - O
dimeric - - O
complexes - - O
, - - O
and - - O
consequently - - O
, - - O
for - - O
PP2A - - O
function - - O
. - - O

157 - - O
+ - - O
- - - O
16 - - O
mg - - O
dl - - O
; - - O
NS - - O
) - - O
, - - O
glucose - - O
levels - - O
, - - O
and - - O
basal - - O
( - - O
17 - - O
+ - - O
- - - O
4 - - O
vs - - O
. - - O

Collectively - - O
, - - O
these - - O
experiments - - O
demonstrate - - O
that - - O
CFTR's - - O
NBF1+R - - O
region - - O
and - - O
its - - O
NBF2 - - O
domain - - O
, - - O
after - - O
folding - - O
separately - - O
as - - O
distinct - - O
units - - O
, - - O
have - - O
a - - O
strong - - O
propensity - - O
to - - O
interact - - O
and - - O
that - - O
this - - O
interaction - - O
is - - O
stable - - O
in - - O
the - - O
absence - - O
of - - O
added - - O
nucleotides - - O
or - - O
exogenously - - O
induced - - O
phosphorylation - - O
. - - O

Recurrent - - O
acute - - O
rhinosinusitis - - O
was - - O
common - - O
in - - O
both - - O
groups - - O
of - - O
patients - - O
, - - O
but - - O
the - - O
development - - O
of - - O
chronic - - O
rhinosinusitis - - O
was - - O
only - - O
found - - O
in - - O
patients - - O
with - - O
CVID - - O
, - - O
indicating - - O
the - - O
more - - O
severe - - O
nature - - O
of - - O
this - - O
condition - - O
compared - - O
with - - O
selective - - O
IgA - - O
deficiency - - O
. - - O

In - - O
patients - - O
who - - O
were - - O
not - - O
vented - - O
, - - O
there - - O
was - - O
overall - - O
significant - - O
depression - - O
of - - O
function - - O
( - - O
67 - - O
+ - - O
- - - O
5% - - O
of - - O
control - - O
; - - O
range - - O
, - - O
91--45% - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Value - - O
of - - O
the - - O
method - - O
of - - O
passive - - O
hemagglutination - - O
with - - O
polysaccharide - - O
C - - O
in - - O
detecting - - O
C-reactive - - O
protein - - O
as - - O
compared - - O
to - - O
precipitation - - O
in - - O
capillaries - - O
and - - O
slide - - O
latex - - O
test - - O
with - - O
anti-CRP - - O
serum - - O
. - - O

2 - - O
new - - O
Algerian - - O
cases - - O
. - - O

Expression - - O
of - - O
the - - O
src - - O
homology - - O
3 - - O
( - - O
SH3 - - O
) - - O
-encoding - - O
, - - O
expressed - - O
in - - O
tumorigenic - - O
astrocytes - - O
( - - O
SETA - - O
) - - O
gene - - O
is - - O
associated - - O
with - - O
astrocyte - - O
transformation - - O
in - - O
culture - - O
and - - O
tumors - - O
in - - O
the - - O
adult - - O
brain - - O
. - - O

AIM - - O
: - - O
To - - O
understand - - O
the - - O
role - - O
of - - O
nutritional - - O
status - - O
in - - O
cirrhotic - - O
patients - - O
without - - O
clinical - - O
porto-systemic - - O
encephalopathy - - O
( - - O
PSE - - O
) - - O
. - - O
METHODS - - O
: - - O
Fifty-one - - O
non-alcoholic - - O
patients - - O
with - - O
cirrhosis - - O
without - - O
PSE - - O
were - - O
studied - - O
prospectively - - O
and - - O
compared - - O
with - - O
20 - - O
healthy - - O
volunteers - - O
. - - O

We - - O
have - - O
recently - - O
detected - - O
high - - O
levels - - O
of - - O
CKB - - O
mRNA - - O
in - - O
HeLa - - O
cells - - O
and - - O
, - - O
in - - O
this - - O
study - - O
, - - O
have - - O
tested - - O
whether - - O
this - - O
may - - O
be - - O
due - - O
to - - O
the - - O
extremely - - O
low - - O
amounts - - O
of - - O
p53 - - O
protein - - O
present - - O
in - - O
HeLa - - O
cells - - O
. - - O

Video - - O
images - - O
of - - O
the - - O
nostrils - - O
were - - O
captured - - O
and - - O
then - - O
analyzed - - O
for - - O
area - - O
, - - O
perimeter - - O
, - - O
centroid - - O
, - - O
principal - - O
axis - - O
, - - O
moments - - O
about - - O
the - - O
major - - O
and - - O
minor - - O
axes - - O
( - - O
I11 - - O
, - - O
I22 - - O
) - - O
, - - O
anisometry - - O
, - - O
bulkiness - - O
, - - O
lateral - - O
offset - - O
, - - O
internostril - - O
angle - - O
, - - O
and - - O
rotational - - O
angle - - O
. - - O

A - - O
randomized - - O
mix - - O
of - - O
180 - - O
sections - - O
( - - O
10 - - O
samples - - O
x - - O
3 - - O
tissues - - O
x - - O
3 - - O
stains - - O
x - - O
2 - - O
) - - O
gave - - O
90 - - O
matched - - O
pairs - - O
. - - O

Four - - O
out - - O
of - - O
10 - - O
patients - - O
showed - - O
clinical - - O
improvement - - O
according - - O
to - - O
Ritchie-Index - - O
, - - O
pain - - O
score - - O
, - - O
ESR - - O
and - - O
CRP - - O
. - - O

The - - O
results - - O
of - - O
these - - O
analyses - - O
indicate - - O
that - - O
the - - O
proteinase - - O
cleaves - - O
at - - O
amino - - O
acid - - O
residues - - O
E960-A961 - - O
, - - O
E1071-S1072 - - O
, - - O
E1345-T1346 - - O
, - - O
and - - O
E1419-G1420 - - O
; - - O
however - - O
, - - O
the - - O
cleavage - - O
efficiency - - O
is - - O
varied - - O
. - - O

Experiments - - O
with - - O
recombinant - - O
proteins - - O
showed - - O
that - - O
p50 - - O
p65 - - O
and - - O
high-mobility-group - - O
I - - O
( - - O
Y - - O
) - - O
protein - - O
cooperatively - - O
facilitated - - O
the - - O
binding - - O
of - - O
IRF-1 - - O
to - - O
the - - O
VCAM1 - - O
IRF - - O
binding - - O
site - - O
and - - O
that - - O
IRF-1 - - O
physically - - O
interacted - - O
with - - O
p50 - - O
and - - O
with - - O
high-mobility-group - - O
I - - O
( - - O
Y - - O
) - - O
protein - - O
. - - O

Control - - O
intact - - O
rats - - O
were - - O
age-matched - - O
to - - O
the - - O
different - - O
treated - - O
groups - - O
. - - O

Platelet - - O
function - - O
and - - O
platelet-polymorphonuclear-neutrophil - - O
interaction - - O
in - - O
patients - - O
with - - O
deficient - - O
platelet - - O
lipoxygenase - - O
activity - - O
. - - O

This - - O
machine - - O
drift - - O
, - - O
which - - O
was - - O
not - - O
associated - - O
with - - O
a - - O
rise - - O
in - - O
water - - O
phantom - - O
temperature - - O
and - - O
did - - O
not - - O
consistently - - O
correlate - - O
with - - O
estimated - - O
x-ray - - O
tube - - O
heat - - O
, - - O
could - - O
result - - O
in - - O
a - - O
significant - - O
overestimation - - O
of - - O
regional - - O
cerebral - - O
blood - - O
flow - - O
( - - O
rCBF - - O
) - - O
for - - O
a - - O
xenon - - O
CT - - O
rCBF - - O
protocol - - O
involving - - O
5-7 - - O
sequential - - O
scans - - O
obtained - - O
at - - O
1-min - - O
interscan - - O
intervals - - O
. - - O

In - - O
addition - - O
, - - O
negatively - - O
regulatory - - O
region - - O
may - - O
exist - - O
from - - O
-1782 - - O
to - - O
-1295 - - O
bp - - O
. - - O

In - - O
this - - O
report - - O
, - - O
we - - O
present - - O
two - - O
lines - - O
of - - O
evidence - - O
that - - O
all - - O
ribosomes - - O
which - - O
synthesize - - O
GCN4 - - O
have - - O
previously - - O
translated - - O
uORF1 - - O
, - - O
resumed - - O
scanning - - O
, - - O
and - - O
reinitiated - - O
at - - O
the - - O
GCN4 - - O
start - - O
site - - O
. - - O

A - - O
36 - - O
year-old - - O
woman - - O
was - - O
given - - O
Ergotamine - - O
Tartrate - - O
4 - - O
. - - O
5 - - O
mg - - O
p - - O
. - - O
d - - O
. - - O
during - - O
seven - - O
days - - O
, - - O
after - - O
an - - O
abortion - - O
( - - O
a - - O
still - - O
birth - - O
) - - O
. - - O

An - - O
economic - - O
analysis - - O
using - - O
West - - O
of - - O
Scotland - - O
Coronary - - O
Prevention - - O
Study - - O
( - - O
WOSCOPS - - O
) - - O
findings - - O
indicates - - O
that - - O
statin - - O
treatment - - O
would - - O
have - - O
prevented - - O
318 - - O
events - - O
per - - O
10 - - O
, - - O
000 - - O
patients - - O
in - - O
a - - O
population - - O
similar - - O
to - - O
that - - O
in - - O
WOSCOPS - - O
( - - O
average - - O
1 - - O
. - - O
5% - - O
annual - - O
risk - - O
of - - O
a - - O
cardiovascular - - O
event - - O
) - - O
at - - O
a - - O
discounted - - O
cost - - O
per - - O
life-year - - O
gained - - O
of - - O
pound20 - - O
, - - O
375 - - O
( - - O
$31 - - O
, - - O
818 - - O
) - - O
. - - O

The - - O
titer - - O
of - - O
TSH - - O
binding - - O
inhibitor - - O
immunoglobulin - - O
( - - O
TBII - - O
) - - O
, - - O
which - - O
had - - O
been - - O
8 - - O
. - - O
6% - - O
at - - O
initial - - O
presentation - - O
, - - O
rose - - O
to - - O
14 - - O
. - - O
9% - - O
in - - O
2 - - O
weeks - - O
. - - O

Y - - O
. - - O

A - - O
possible - - O
decrease - - O
in - - O
theophylline's - - O
volume - - O
of - - O
distribution - - O
at - - O
4 - - O
days - - O
, - - O
but - - O
not - - O
immediately - - O
, - - O
after - - O
administration - - O
of - - O
chloroquine - - O
was - - O
suggested - - O
, - - O
although - - O
this - - O
just - - O
failed - - O
to - - O
achieve - - O
statistical - - O
significance - - O
( - - O
p - - O
= - - O
0 - - O
. - - O
055 - - O
) - - O
. - - O

There - - O
was - - O
no - - O
correlation - - O
between - - O
secretor - - O
status - - O
and - - O
clinical - - O
status - - O
, - - O
spirometry - - O
measurements - - O
, - - O
salivary - - O
and - - O
serum - - O
lysozyme - - O
levels - - O
or - - O
rates - - O
of - - O
respiratory - - O
tract - - O
colonization - - O
with - - O
P - - O
. - - O
aeruginosa - - O
and - - O
S - - O
. - - O
aureus - - O
. - - O

The - - O
results - - O
presented - - O
in - - O
this - - O
report - - O
suggest - - O
that - - O
the - - O
SV40 - - O
G-C-rich - - O
sequences - - O
can - - O
function - - O
as - - O
independent - - O
RNA - - O
polymerase - - O
II - - O
transcriptional-control - - O
elements - - O
. - - O

To - - O
determine - - O
if - - O
signing - - O
, - - O
when - - O
established - - O
, - - O
would - - O
compete - - O
with - - O
SIB - - O
when - - O
both - - O
were - - O
reinforced - - O
, - - O
extinction - - O
was - - O
then - - O
withdrawn - - O
. - - O

The - - O
structure - - O
of - - O
the - - O
calcineurin - - O
A - - O
gene - - O
was - - O
determined - - O
by - - O
comparison - - O
of - - O
the - - O
genomic - - O
and - - O
cDNA - - O
sequences - - O
. - - O

Fructokinase - - O
activity - - O
is - - O
elevated - - O
up - - O
to - - O
twofold - - O
when - - O
Z - - O
. - - O
mobilis - - O
was - - O
grown - - O
on - - O
fructose - - O
instead - - O
of - - O
glucose - - O
, - - O
and - - O
there - - O
was - - O
a - - O
parallel - - O
increase - - O
in - - O
frk - - O
mRNA - - O
levels - - O
. - - O

Mycoplasma - - O
pneumoniae - - O
was - - O
isolated - - O
from - - O
the - - O
pleural - - O
fluid - - O
of - - O
this - - O
patient - - O
. - - O

We - - O
found - - O
that - - O
T3 - - O
( - - O
10 - - O
( - - O
-8 - - O
) - - O
M - - O
) - - O
selectively - - O
stimulates - - O
transcription - - O
from - - O
rGH-TRE- - - O
and - - O
TREpal- - - O
, - - O
but - - O
not - - O
ME-TRE- - - O
and - - O
F2-TRE- - - O
, - - O
containing - - O
templates - - O
in - - O
which - - O
these - - O
TREs - - O
are - - O
linked - - O
in - - O
front - - O
of - - O
the - - O
rGH - - O
minimal - - O
promoter - - O
containing - - O
only - - O
the - - O
TATA - - O
box - - O
binding - - O
protein - - O
, - - O
but - - O
not - - O
any - - O
other - - O
proximal - - O
binding - - O
protein - - O
, - - O
sequence - - O
. - - O

On - - O
the - - O
basis - - O
of - - O
a - - O
patient's - - O
report - - O
of - - O
one - - O
inaccurate - - O
Clinitemp - - O
, - - O
we - - O
undertook - - O
to - - O
investigate - - O
the - - O
accuracy - - O
of - - O
this - - O
thermometer - - O
. - - O

Oligonucleotide-directed - - O
mutagenesis - - O
was - - O
used - - O
to - - O
create - - O
an - - O
NdeI - - O
restriction - - O
site - - O
at - - O
the - - O
natural - - O
ATG - - O
of - - O
the - - O
yeast - - O
R - - O
. - - O

However - - O
, - - O
three - - O
Hm1 - - O
mutants - - O
that - - O
were - - O
moderately - - O
deficient - - O
in - - O
stimulating - - O
PI - - O
turnover - - O
displayed - - O
normal - - O
sequestration - - O
, - - O
suggesting - - O
distinct - - O
mechanisms - - O
. - - O

Therefore - - O
, - - O
it - - O
would - - O
be - - O
advantageous - - O
to - - O
identify - - O
such - - O
persons - - O
and - - O
treat - - O
them - - O
preferentially - - O
. - - O

Large - - O
scale - - O
electronic - - O
structure - - O
calculations - - O
. - - O

Southern - - O
blot - - O
hybridization - - O
experiments - - O
suggest - - O
the - - O
presence - - O
of - - O
one - - O
copy - - O
of - - O
Atcys1 - - O
, - - O
Athyp1 - - O
and - - O
AKin10 - - O
per - - O
haploid - - O
genome - - O
, - - O
and - - O
Northern - - O
blot - - O
analysis - - O
demonstrates - - O
that - - O
the - - O
three - - O
genes - - O
are - - O
differentially - - O
expressed - - O
in - - O
roots - - O
, - - O
shoots - - O
and - - O
leaves - - O
. - - O

The - - O
results - - O
obtained - - O
are - - O
similar - - O
to - - O
those - - O
described - - O
with - - O
the - - O
previous - - O
Cremophor - - O
formulation - - O
although - - O
greater - - O
variability - - O
in - - O
induction - - O
and - - O
recovery - - O
times - - O
was - - O
noted - - O
with - - O
the - - O
emulsion - - O
formulation - - O
. - - O

Indeed - - O
the - - O
predicted - - O
folding - - O
of - - O
the - - O
5' - - O
and - - O
3'-untranslated - - O
regions - - O
revealed - - O
patterns - - O
of - - O
stem - - O
and - - O
loop - - O
structures - - O
conserved - - O
for - - O
all - - O
tick-borne - - O
flaviviruses - - O
suggesting - - O
a - - O
purifying - - O
selection - - O
for - - O
preservation - - O
of - - O
essential - - O
RNA - - O
secondary - - O
structures - - O
which - - O
could - - O
be - - O
involved - - O
in - - O
translational - - O
control - - O
and - - O
replication - - O
. - - O

Taurine - - O
deficiency - - O
significantly - - O
depressed - - O
the - - O
amplitude - - O
of - - O
OP1 - - O
and - - O
OP4 - - O
. - - O

The - - O
promoter - - O
region - - O
showed - - O
no - - O
consensus - - O
TATA - - O
box - - O
but - - O
it - - O
contains - - O
CCAAT - - O
and - - O
CreA - - O
boxes - - O
known - - O
to - - O
be - - O
involved - - O
in - - O
both - - O
stress - - O
and - - O
carbon-catabolite - - O
regulation - - O
of - - O
fungal - - O
promoters - - O
. - - O

We - - O
remain - - O
convinced - - O
that - - O
antilymphocyte - - O
globulin - - O
( - - O
ALG - - O
) - - O
is - - O
a - - O
potent - - O
immunosuppressive - - O
agent - - O
in - - O
humans - - O
. - - O

According - - O
to - - O
out - - O
field - - O
research - - O
, - - O
the - - O
tick - - O
fauna - - O
was - - O
very - - O
rich - - O
throughout - - O
that - - O
area - - O
, - - O
and - - O
it - - O
was - - O
permissible - - O
enough - - O
to - - O
determine - - O
ticks - - O
as - - O
the - - O
vectors - - O
, - - O
based - - O
on - - O
arising - - O
of - - O
anti-SF - - O
group - - O
rickettsiae - - O
( - - O
SFGR - - O
) - - O
antibody - - O
in - - O
mice - - O
inoculated - - O
with - - O
some - - O
tick - - O
emulsions - - O
, - - O
findings - - O
of - - O
rickettsiae - - O
reactive - - O
to - - O
patient - - O
sera - - O
or - - O
a - - O
species-specific - - O
monoclonal - - O
antibody - - O
to - - O
JSFR - - O
in - - O
the - - O
hemolymph - - O
cells - - O
of - - O
some - - O
ticks - - O
, - - O
and - - O
electron - - O
microscopical - - O
observations - - O
of - - O
SFGR - - O
in - - O
various - - O
internal - - O
organs - - O
including - - O
the - - O
salivary - - O
gland - - O
of - - O
ticks - - O
. - - O

An - - O
increase - - O
in - - O
hypothalamic - - O
expression - - O
of - - O
at - - O
least - - O
two - - O
of - - O
the - - O
erbB - - O
receptors - - O
is - - O
initiated - - O
before - - O
the - - O
pubertal - - O
augmentation - - O
of - - O
gonadal - - O
steroid - - O
secretion - - O
and - - O
is - - O
completed - - O
on - - O
the - - O
day - - O
of - - O
the - - O
first - - O
preovulatory - - O
surge - - O
of - - O
gonadotropins - - O
. - - O

These - - O
data - - O
indicate - - O
that - - O
phosphorylation - - O
of - - O
M - - O
protein - - O
at - - O
the - - O
major - - O
in - - O
vivo - - O
sites - - O
is - - O
not - - O
essential - - O
for - - O
virus - - O
assembly - - O
. - - O

Aviators - - O
from - - O
the - - O
Light - - O
Attack - - O
Wing - - O
, - - O
Pacific - - O
were - - O
surveyed - - O
and - - O
the - - O
results - - O
were - - O
categorized - - O
by - - O
aircraft - - O
type - - O
. - - O

Identification - - O
of - - O
mutations - - O
in - - O
the - - O
coding - - O
sequence - - O
of - - O
the - - O
proto-oncogene - - O
c-kit - - O
in - - O
a - - O
human - - O
mast - - O
cell - - O
leukemia - - O
cell - - O
line - - O
causing - - O
ligand-independent - - O
activation - - O
of - - O
c-kit - - O
product - - O
. - - O

Deletion - - O
from - - O
either - - O
the - - O
N- - - O
or - - O
C-terminal - - O
ends - - O
of - - O
repA - - O
( - - O
28 - - O
and - - O
69 - - O
codons - - O
, - - O
respectively - - O
, - - O
out - - O
of - - O
the - - O
286-codon - - O
open - - O
reading - - O
frame - - O
) - - O
affected - - O
the - - O
initiator - - O
but - - O
not - - O
the - - O
inhibitory - - O
activity - - O
. - - O

73 - - O
: - - O
658-666 - - O
, - - O
1999 - - O
) - - O
. - - O

A - - O
patient - - O
is - - O
described - - O
with - - O
skin - - O
lesions - - O
resembling - - O
Kaposi's - - O
sarcoma - - O
( - - O
KS - - O
) - - O
. - - O

Such - - O
mutations - - O
are - - O
thought - - O
to - - O
exert - - O
their - - O
dominant - - O
phenotype - - O
by - - O
sequestration - - O
of - - O
the - - O
guanine - - O
nucleotide - - O
exchange - - O
factor - - O
( - - O
GNEF - - O
) - - O
. - - O

Induction - - O
of - - O
AtP5CS1 - - O
mRNA - - O
accumulation - - O
in - - O
salt-treated - - O
seedlings - - O
involves - - O
an - - O
immediate - - O
early - - O
transcriptional - - O
response - - O
regulated - - O
by - - O
ABA - - O
signalling - - O
that - - O
is - - O
not - - O
inhibited - - O
by - - O
cycloheximide - - O
, - - O
but - - O
abolished - - O
by - - O
the - - O
deficiency - - O
of - - O
ABA - - O
biosynthesis - - O
in - - O
the - - O
aba1 - - O
Arabidopsis - - O
mutant - - O
. - - O

NF-kappaB - - O
pathway - - O
activation - - O
occurs - - O
during - - O
transformation - - O
induced - - O
by - - O
a - - O
number - - O
of - - O
classical - - O
oncogenes - - O
, - - O
including - - O
Bcr - - O
Abl - - O
, - - O
Ras - - O
and - - O
Rac - - O
, - - O
and - - O
is - - O
necessary - - O
for - - O
full - - O
transforming - - O
potential - - O
. - - O

L-canavanine - - O
, - - O
a - - O
selective - - O
inhibitor - - O
of - - O
the - - O
inducible - - O
nitric - - O
oxide - - O
synthase - - O
, - - O
increases - - O
the - - O
mean - - O
systemic - - O
filling - - O
pressure - - O
, - - O
thereby - - O
improving - - O
venous - - O
return - - O
, - - O
under - - O
these - - O
conditions - - O
. - - O

One - - O
of - - O
these - - O
SEBPs - - O
, - - O
SEBP2 - - O
, - - O
was - - O
shown - - O
to - - O
be - - O
the - - O
product - - O
of - - O
the - - O
homeotic - - O
gene - - O
fork - - O
head - - O
. - - O

Electrophoretic - - O
mobility - - O
shift - - O
assays - - O
( - - O
EMSAs - - O
) - - O
using - - O
purified - - O
glucocorticoid - - O
receptor - - O
DNA - - O
binding - - O
domain - - O
( - - O
DBD - - O
) - - O
demonstrated - - O
that - - O
both - - O
GRE-2 - - O
and - - O
-3 - - O
motifs - - O
interact - - O
with - - O
DBD - - O
and - - O
oligonucleotide - - O
competition - - O
experiments - - O
established - - O
that - - O
these - - O
have - - O
different - - O
affinities - - O
for - - O
DBD - - O
. - - O

Human - - O
T-cell - - O
leukemia - - O
virus - - O
type - - O
I - - O
( - - O
HTLV-I - - O
) - - O
Tax - - O
is - - O
a - - O
potent - - O
transcriptional - - O
regulator - - O
that - - O
can - - O
activate - - O
or - - O
repress - - O
specific - - O
cellular - - O
genes - - O
and - - O
that - - O
has - - O
been - - O
proposed - - O
to - - O
contribute - - O
to - - O
leukemogenesis - - O
in - - O
adult - - O
T-cell - - O
leukemia - - O
. - - O

The - - O
major - - O
inserted - - O
DNA - - O
has - - O
no - - O
significant - - O
homology - - O
to - - O
published - - O
human - - O
nucleic - - O
acid - - O
sequences - - O
. - - O

CONCLUSION - - O
: - - O
Presence - - O
of - - O
APOE - - O
epsilon4 - - O
* - - O
seems - - O
to - - O
increase - - O
the - - O
risk - - O
for - - O
dementia - - O
and - - O
AD - - O
independently - - O
of - - O
its - - O
effect - - O
on - - O
dyslipidemia - - O
and - - O
atherogenesis - - O
. - - O

Experimental - - O
pancreatitis - - O
in - - O
pigs - - O
. - - O

These - - O
IgG - - O
antibodies - - O
in - - O
the - - O
babies - - O
diminished - - O
rapidly - - O
after - - O
delivery - - O
, - - O
and - - O
were - - O
detectable - - O
only - - O
in - - O
3 - - O
cases - - O
at - - O
2 - - O
, - - O
3 - - O
, - - O
and - - O
5 - - O
months - - O
of - - O
ages - - O
out - - O
of - - O
38 - - O
babies - - O
up - - O
to - - O
21 - - O
months - - O
. - - O

PATIENTS - - O
AND - - O
METHODS - - O
: - - O
One - - O
hundred - - O
eighty-four - - O
chemotherapy-naive - - O
patients - - O
receiving - - O
high-dose - - O
cisplatin - - O
( - - O
81 - - O
to - - O
120 - - O
mg - - O
m2 - - O
) - - O
were - - O
randomized - - O
to - - O
receive - - O
one - - O
of - - O
four - - O
granisetron - - O
doses - - O
( - - O
5 - - O
, - - O
10 - - O
, - - O
20 - - O
, - - O
or - - O
40 - - O
micrograms - - O
kg - - O
) - - O
administered - - O
before - - O
chemotherapy - - O
. - - O

The - - O
O2 - - O
deficit - - O
was - - O
not - - O
related - - O
to - - O
blood - - O
lactate - - O
during - - O
submaximal - - O
exercise - - O
, - - O
muscle - - O
enzyme - - O
activity - - O
( - - O
citrate - - O
synthase - - O
, - - O
3-hydroxyacyl-CoA-dehydrogenase - - O
, - - O
lactate - - O
dehydrogenase - - O
) - - O
, - - O
number - - O
of - - O
muscle - - O
capillaries - - O
, - - O
%ST - - O
fibres - - O
or - - O
muscle - - O
buffer - - O
capacity - - O
. - - O

Subtraction - - O
hybridization - - O
identified - - O
melanoma - - O
differentiation - - O
associated - - O
gene-7 - - O
( - - O
mda-7 - - O
) - - O
, - - O
as - - O
a - - O
gene - - O
induced - - O
during - - O
these - - O
physiological - - O
changes - - O
in - - O
human - - O
melanoma - - O
cells - - O
. - - O

The - - O
euglobulin - - O
clot - - O
lysis - - O
time - - O
was - - O
slightly - - O
longer - - O
in - - O
the - - O
smokers - - O
than - - O
in - - O
the - - O
non-smokers - - O
in - - O
all - - O
three - - O
experimental - - O
situations - - O
, - - O
but - - O
the - - O
differences - - O
were - - O
not - - O
significant - - O
. - - O

The - - O
two - - O
IL6 - - O
mRNA - - O
species - - O
are - - O
generated - - O
by - - O
alternative - - O
polyadenylation - - O
at - - O
sites - - O
separated - - O
by - - O
a - - O
distance - - O
of - - O
1 - - O
. - - O
2 - - O
kilobases - - O
. - - O

We - - O
previously - - O
reported - - O
that - - O
Tax - - O
induced - - O
cell - - O
cycle - - O
progression - - O
from - - O
G0 - - O
G1 - - O
phase - - O
to - - O
S - - O
and - - O
G2 - - O
M - - O
phases - - O
in - - O
human - - O
T-cell - - O
line - - O
Kit - - O
225 - - O
cells - - O
. - - O

The - - O
variations - - O
were - - O
caused - - O
by - - O
opposite - - O
shifts - - O
in - - O
TSH - - O
frequency - - O
distribution - - O
in - - O
mothers - - O
and - - O
neonates - - O
. - - O

In - - O
the - - O
last - - O
20 - - O
years - - O
, - - O
the - - O
therapeutic - - O
uses - - O
of - - O
botulinum - - O
toxin - - O
, - - O
a - - O
potent - - O
neurotoxin - - O
, - - O
have - - O
been - - O
investigated - - O
. - - O

Obstruction - - O
of - - O
the - - O
ERF - - O
repressor - - O
function - - O
by - - O
the - - O
transactivating - - O
members - - O
of - - O
the - - O
ets - - O
family - - O
of - - O
genes - - O
( - - O
i - - O
. - - O
e - - O
. - - O
gag-myb-ets - - O
) - - O
may - - O
be - - O
essential - - O
for - - O
the - - O
control - - O
of - - O
genes - - O
involved - - O
in - - O
cell - - O
proliferation - - O
and - - O
may - - O
also - - O
underlie - - O
their - - O
tumorigenic - - O
effects - - O
. - - O

Intraventricular - - O
injection - - O
of - - O
( - - O
2S - - O
, - - O
1'R - - O
, - - O
2'R - - O
, - - O
3'R - - O
) - - O
-2- - - O
( - - O
2 - - O
, - - O
3-dicarboxycyclopropyl - - O
) - - O
glycine - - O
( - - O
DCG-IV - - O
) - - O
, - - O
a - - O
potent - - O
agonist - - O
for - - O
metabotropic - - O
glutamate - - O
receptors - - O
, - - O
to - - O
rats - - O
retarded - - O
dose-dependently - - O
the - - O
recovery - - O
from - - O
halothane - - O
anesthesia - - O
at - - O
a - - O
dose - - O
range - - O
from - - O
30 - - O
to - - O
300 - - O
pmol - - O
rat - - O
. - - O

The - - O
single - - O
most - - O
important - - O
element - - O
, - - O
by - - O
linker-scanning - - O
analysis - - O
, - - O
is - - O
a - - O
10-bp - - O
region - - O
that - - O
contains - - O
a - - O
CCAAT - - O
motif - - O
. - - O

An - - O
FP - - O
mutant - - O
, - - O
AcFP875-2 - - O
, - - O
had - - O
a - - O
1 - - O
. - - O
6-kbp - - O
insertion - - O
of - - O
S - - O
. - - O
frugiperda - - O
DNA - - O
near - - O
the - - O
5' - - O
end - - O
of - - O
these - - O
transcripts - - O
which - - O
by - - O
S1 - - O
analysis - - O
were - - O
shown - - O
to - - O
initiate - - O
within - - O
the - - O
host - - O
cell - - O
sequence - - O
. - - O

We - - O
took - - O
advantage - - O
of - - O
the - - O
high - - O
degree - - O
of - - O
aa - - O
sequence - - O
homology - - O
between - - O
DAHPSs - - O
from - - O
several - - O
species - - O
to - - O
isolate - - O
ARO3 - - O
homologues - - O
from - - O
the - - O
pathogenic - - O
yeast - - O
Candida - - O
albicans - - O
. - - O

The - - O
serum - - O
levels - - O
of - - O
beta-human - - O
chorionic - - O
gonadotropin - - O
( - - O
HCG - - O
) - - O
and - - O
placental - - O
alkaline - - O
phosphatase - - O
( - - O
PLAP - - O
) - - O
were - - O
not - - O
elevated - - O
. - - O

Effects - - O
of - - O
aging - - O
and - - O
beta-adrenergic-blockade - - O
on - - O
standing-induced - - O
QT - - O
QS2 - - O
changes - - O
. - - O

Several - - O
nuclear - - O
factors - - O
that - - O
interact - - O
with - - O
sequences - - O
in - - O
the - - O
5' - - O
flanking - - O
region - - O
of - - O
the - - O
mouse - - O
tyrosinase - - O
gene - - O
were - - O
identified - - O
using - - O
band - - O
shift - - O
and - - O
methylation - - O
interference - - O
assays - - O
. - - O

Only - - O
one - - O
of - - O
these - - O
bands - - O
was - - O
supershifted - - O
by - - O
antibody - - O
to - - O
p50 - - O
, - - O
whereas - - O
antibodies - - O
to - - O
p65 - - O
or - - O
other - - O
NF-kappaB - - O
proteins - - O
had - - O
no - - O
effect - - O
. - - O

All - - O
corneal - - O
buttons - - O
were - - O
processed - - O
for - - O
histopathologic - - O
and - - O
electron - - O
microscopic - - O
studies - - O
. - - O

In - - O
gel - - O
mobility - - O
shift - - O
assays - - O
, - - O
we - - O
found - - O
no - - O
evidence - - O
for - - O
VDR-TR - - O
heterodimer - - O
interaction - - O
with - - O
any - - O
tested - - O
element - - O
. - - O

A - - O
combined - - O
series - - O
of - - O
patients - - O
experienced - - O
a - - O
TOL - - O
after - - O
two - - O
or - - O
more - - O
previous - - O
cesarean - - O
deliveries - - O
; - - O
the - - O
rate - - O
of - - O
vaginal - - O
delivery - - O
was - - O
66% - - O
, - - O
and - - O
there - - O
was - - O
virtually - - O
no - - O
morbidity - - O
. - - O

The - - O
two - - O
drugs - - O
increase - - O
the - - O
rate - - O
of - - O
early - - O
diastolic - - O
filling - - O
. - - O

Furthermore - - O
, - - O
p150 - - O
suppresses - - O
actin - - O
gelation - - O
, - - O
which - - O
is - - O
induced - - O
by - - O
smooth - - O
muscle - - O
alpha-actinin - - O
. - - O

3--It - - O
is - - O
necessary - - O
to - - O
think - - O
about - - O
cosmetic - - O
consequences - - O
of - - O
the - - O
chinese - - O
flap - - O
and - - O
consider - - O
other - - O
possibilities - - O
of - - O
the - - O
flap - - O
choice - - O
. - - O

The - - O
HPLC - - O
method - - O
involves - - O
an - - O
octadecylsilane - - O
column - - O
at - - O
55 - - O
degrees - - O
C - - O
, - - O
a - - O
mixture - - O
of - - O
water-acetonitrile-orthophosphoric - - O
acid - - O
( - - O
779 - - O
: - - O
220 - - O
: - - O
1 - - O
, - - O
v - - O
v - - O
) - - O
as - - O
mobile - - O
phase - - O
and - - O
detection - - O
at - - O
226 - - O
nm - - O
. - - O

The - - O
results - - O
indicate - - O
that - - O
hrpRS - - O
and - - O
hrpL - - O
are - - O
part - - O
of - - O
a - - O
regulatory - - O
cascade - - O
in - - O
which - - O
HrpR - - O
and - - O
HrpS - - O
activate - - O
expression - - O
of - - O
hrpL - - O
and - - O
HrpL - - O
, - - O
a - - O
putative - - O
sigma - - O
factor - - O
, - - O
induces - - O
expression - - O
of - - O
HrpL-responsive - - O
genes - - O
. - - O

In - - O
Xenopus - - O
embryos - - O
, - - O
the - - O
engineered - - O
PDGF - - O
receptor - - O
protein - - O
induced - - O
the - - O
formation - - O
of - - O
mesoderm - - O
from - - O
animal-pole - - O
explants - - O
in - - O
an - - O
FK1012-dependent - - O
manner - - O
. - - O

Mutations - - O
within - - O
human - - O
UTR1 - - O
modulate - - O
NRF-1 - - O
expression - - O
by - - O
interfering - - O
with - - O
mRNA - - O
translational - - O
efficiency - - O
in - - O
transfected - - O
cells - - O
and - - O
in - - O
an - - O
in - - O
vitro - - O
translation - - O
system - - O
. - - O

In - - O
particular - - O
, - - O
Western - - O
, - - O
supershift - - O
, - - O
and - - O
promoter - - O
deletion - - O
analyses - - O
suggested - - O
a - - O
role - - O
for - - O
CCAAT - - O
enhancer-binding - - O
protein-beta - - O
( - - O
C - - O
EBP-beta - - O
) - - O
binding - - O
site - - O
between - - O
-2010 - - O
and - - O
-1954 - - O
in - - O
regulating - - O
transcription - - O
of - - O
collagenase-1 - - O
in - - O
monocytic - - O
cells - - O
. - - O

Mus81p - - O
also - - O
shares - - O
homology - - O
with - - O
motifs - - O
found - - O
in - - O
the - - O
XPF - - O
endonuclease - - O
superfamily - - O
. - - O

In - - O
the - - O
Rett - - O
syndrome - - O
we - - O
, - - O
therefore - - O
, - - O
suspect - - O
there - - O
are - - O
disturbances - - O
in - - O
the - - O
brain - - O
stem - - O
functions - - O
especially - - O
in - - O
the - - O
ascending - - O
reticular - - O
activating - - O
system - - O
which - - O
is - - O
related - - O
to - - O
elevation - - O
of - - O
the - - O
conscious - - O
level - - O
. - - O

Multistep - - O
transformation - - O
by - - O
defined - - O
fragments - - O
of - - O
herpes - - O
simplex - - O
virus - - O
type - - O
2 - - O
DNA - - O
: - - O
oncogenic - - O
region - - O
and - - O
its - - O
gene - - O
product - - O
. - - O

The - - O
gcd2-503 - - O
mutation - - O
also - - O
results - - O
in - - O
polysome - - O
runoff - - O
, - - O
accumulation - - O
of - - O
inactive - - O
80S - - O
ribosomal - - O
couples - - O
, - - O
and - - O
accumulation - - O
of - - O
at - - O
least - - O
one - - O
of - - O
the - - O
subunits - - O
of - - O
the - - O
general - - O
translation - - O
initiation - - O
factor - - O
2 - - O
( - - O
eIF-2 - - O
alpha - - O
) - - O
in - - O
43S-48S - - O
particles - - O
following - - O
a - - O
shift - - O
to - - O
the - - O
restrictive - - O
temperature - - O
. - - O

Similarly - - O
, - - O
the - - O
DNA-binding - - O
activity - - O
of - - O
activator - - O
protein - - O
1 - - O
( - - O
AP-1 - - O
) - - O
is - - O
modified - - O
by - - O
a - - O
DNA - - O
repair - - O
enzyme - - O
, - - O
redox - - O
factor - - O
1 - - O
( - - O
Ref-1 - - O
) - - O
, - - O
which - - O
is - - O
identical - - O
to - - O
a - - O
DNA - - O
repair - - O
enzyme - - O
, - - O
AP - - O
endonuclease - - O
. - - O

Stereotactic - - O
radiofrequency - - O
lesioning - - O
of - - O
the - - O
hamartoma - - O
resulted - - O
in - - O
seizure - - O
remission - - O
without - - O
complications - - O
20 - - O
months - - O
after - - O
surgery - - O
. - - O

Gastric - - O
CO2 - - O
HCO3 - - O
was - - O
determined - - O
in - - O
absence - - O
of - - O
simultaneous - - O
inhibition - - O
of - - O
acid - - O
secretion - - O
by - - O
intra- - - O
and - - O
extragastric - - O
pCO2 - - O
pH - - O
measurements - - O
in - - O
23 - - O
persons - - O
and - - O
calculated - - O
using - - O
the - - O
equation - - O
of - - O
Henderson-Hasselbalch - - O
. - - O
pCO2 - - O
was - - O
measured - - O
with - - O
use - - O
of - - O
a - - O
new - - O
electrode - - O
. - - O

The - - O
microdensitometric - - O
scores - - O
and - - O
their - - O
side-to-side - - O
differences - - O
in - - O
patients - - O
correlated - - O
negatively - - O
with - - O
the - - O
serum - - O
25-OHD - - O
concentration - - O
and - - O
positively - - O
with - - O
the - - O
degree - - O
of - - O
paralysis - - O
. - - O

The - - O
investigation - - O
was - - O
thereafter - - O
continued - - O
in - - O
an - - O
open - - O
fashion - - O
by - - O
administering - - O
a - - O
single - - O
10 - - O
mg - - O
dose - - O
of - - O
the - - O
MAO-B - - O
inhibitor - - O
deprenyl - - O
to - - O
the - - O
same - - O
subjects - - O
. - - O

Immunofluoresence - - O
data - - O
indicated - - O
that - - O
once - - O
bound - - O
to - - O
the - - O
mutant - - O
receptor - - O
, - - O
fluorescent-labeled - - O
RAP - - O
co-localized - - O
with - - O
markers - - O
of - - O
the - - O
endosomal - - O
pathway - - O
, - - O
whereas - - O
, - - O
in - - O
cells - - O
expressing - - O
the - - O
wild-type - - O
receptor - - O
, - - O
RAP - - O
fluorescence - - O
co-localized - - O
with - - O
lysosomal - - O
markers - - O
. - - O

In - - O
14 - - O
patients - - O
whose - - O
PaCO2 - - O
was - - O
greater - - O
than - - O
or - - O
equal - - O
to - - O
39 - - O
torr - - O
( - - O
range - - O
39 - - O
to - - O
58 - - O
torr - - O
) - - O
and - - O
clinical - - O
asthma - - O
score - - O
was - - O
6 - - O
or - - O
greater - - O
, - - O
PaCO2 - - O
decreased - - O
a - - O
mean - - O
of - - O
11 - - O
. - - O
7 - - O
torr - - O
during - - O
a - - O
mean - - O
of - - O
8 - - O
. - - O
1 - - O
hours - - O
. - - O

Deletion - - O
analysis - - O
revealed - - O
that - - O
the - - O
essential - - O
domain - - O
of - - O
this - - O
promoter - - O
, - - O
termed - - O
the - - O
ORF5 - - O
deltaX - - O
transcript - - O
promoter - - O
, - - O
mapped - - O
to - - O
nucleotides - - O
1525-1625 - - O
. - - O

The - - O
need - - O
for - - O
including - - O
forensic - - O
medical - - O
expertise - - O
in - - O
the - - O
list - - O
of - - O
urgent - - O
criminal - - O
investigative - - O
actions - - O
. - - O

Expression - - O
of - - O
thymidine - - O
kinase - - O
gene - - O
in - - O
normal - - O
human - - O
diploid - - O
cells - - O
is - - O
both - - O
cell - - O
cycle- - - O
and - - O
age-dependent - - O
and - - O
appears - - O
to - - O
be - - O
transcriptionally - - O
regulated - - O
. - - O

By - - O
using - - O
interleukin-3-dependent - - O
cells - - O
that - - O
ectopically - - O
express - - O
the - - O
three - - O
ErbB - - O
proteins - - O
or - - O
their - - O
combinations - - O
, - - O
we - - O
found - - O
that - - O
ErbB-3 - - O
is - - O
devoid - - O
of - - O
any - - O
biological - - O
activity - - O
but - - O
both - - O
ErbB-1 - - O
and - - O
ErbB-2 - - O
can - - O
reconstitute - - O
its - - O
extremely - - O
potent - - O
mitogenic - - O
activity - - O
. - - O

This - - O
suggests - - O
that - - O
while - - O
underpredictions - - O
of - - O
pain - - O
do - - O
not - - O
hurt - - O
more - - O
, - - O
disruption - - O
on - - O
primary - - O
tasks - - O
and - - O
physiological - - O
impact - - O
are - - O
higher - - O
. - - O

Marine - - O
oils - - O
and - - O
cardiovascular - - O
reactivity - - O
. - - O

Psychiatry - - O
and - - O
the - - O
skin - - O
. - - O

The - - O
entire - - O
human - - O
teneurin-1 - - O
( - - O
TEN1 - - O
) - - O
gene - - O
is - - O
contained - - O
in - - O
eight - - O
PAC - - O
clones - - O
representing - - O
part - - O
of - - O
the - - O
chromosomal - - O
locus - - O
Xq25 - - O
. - - O

In - - O
the - - O
present - - O
study - - O
, - - O
we - - O
identified - - O
a - - O
strong - - O
positive - - O
cis-regulatory - - O
element - - O
at - - O
-70 - - O
bp - - O
to - - O
-75 - - O
bp - - O
in - - O
the - - O
LpS1 - - O
beta - - O
promoter - - O
with - - O
the - - O
sequence - - O
( - - O
G - - O
) - - O
6 - - O
and - - O
a - - O
similar - - O
, - - O
more - - O
distal - - O
cis-element - - O
at - - O
-721 - - O
bp - - O
to - - O
-726 - - O
bp - - O
. - - O

Several - - O
artifacts - - O
occurred - - O
that - - O
interfered - - O
with - - O
visualization - - O
of - - O
the - - O
diaphragm - - O
. - - O

Developmental - - O
follow-up - - O
at - - O
age - - O
2 - - O
years - - O
was - - O
performed - - O
. - - O

On - - O
the - - O
third - - O
occasion - - O
water - - O
( - - O
W - - O
) - - O
was - - O
ingested - - O
throughout - - O
the - - O
run - - O
. - - O

The - - O
JS78 - - O
mutation - - O
changes - - O
Gln243 - - O
in - - O
gp0 - - O
. - - O
7 - - O
to - - O
an - - O
amber - - O
codon - - O
, - - O
which - - O
explains - - O
the - - O
production - - O
of - - O
the - - O
truncated - - O
, - - O
30-kDa - - O
gp0 - - O
. - - O
7-related - - O
polypeptide - - O
, - - O
and - - O
implicates - - O
the - - O
11-kDa - - O
C-terminal - - O
domain - - O
in - - O
host - - O
transcription - - O
shut-off - - O
. - - O

Both - - O
pancreatic - - O
and - - O
intestinal - - O
cell - - O
lines - - O
were - - O
found - - O
to - - O
express - - O
a - - O
number - - O
of - - O
POU - - O
( - - O
OCT - - O
binding - - O
) - - O
homeodomain - - O
proteins - - O
examined - - O
by - - O
electrophoretic - - O
mobility - - O
shift - - O
assay - - O
. - - O

Sequencing - - O
of - - O
the - - O
16p - - O
11 - - O
. - - O
1 - - O
Xq28 - - O
duplication - - O
breakpoints - - O
has - - O
revealed - - O
the - - O
presence - - O
of - - O
repetitive - - O
immunoglobulin-like - - O
CAGGG - - O
pentamer - - O
sequences - - O
at - - O
or - - O
near - - O
the - - O
paralogy - - O
boundaries - - O
. - - O

Thus - - O
, - - O
the - - O
synergistic - - O
effects - - O
of - - O
HNF-1beta - - O
and - - O
the - - O
GR - - O
on - - O
dexamethasone-stimulated - - O
promoter - - O
activity - - O
require - - O
that - - O
they - - O
are - - O
bound - - O
to - - O
the - - O
HNF-1 - - O
site - - O
and - - O
the - - O
GRE - - O
, - - O
respectively - - O
, - - O
and - - O
may - - O
involve - - O
protein-protein - - O
interactions - - O
between - - O
the - - O
transcription - - O
factors - - O
, - - O
or - - O
between - - O
them - - O
and - - O
the - - O
basal - - O
transcription - - O
machinery - - O
or - - O
a - - O
steroid - - O
receptor - - O
coactivator - - O
. - - O

In - - O
the - - O
control - - O
preparation - - O
before - - O
weight - - O
was - - O
allowed - - O
to - - O
increase - - O
, - - O
isogravimetric - - O
capillary - - O
pressure - - O
( - - O
Pci - - O
) - - O
averaged - - O
8 - - O
mmHg - - O
lower - - O
than - - O
colloid - - O
osmotic - - O
pressure - - O
of - - O
the - - O
plasma - - O
( - - O
IIp - - O
) - - O
. - - O

Construction - - O
of - - O
human - - O
cell - - O
lines - - O
which - - O
contain - - O
and - - O
express - - O
the - - O
adenovirus - - O
DNA - - O
binding - - O
protein - - O
gene - - O
by - - O
cotransformation - - O
with - - O
the - - O
HSV-1 - - O
tk - - O
gene - - O
. - - O

The - - O
occurrence - - O
, - - O
maintenance - - O
and - - O
possible - - O
involvement - - O
of - - O
these - - O
repeated - - O
sequences - - O
, - - O
capable - - O
of - - O
forming - - O
stable - - O
secondary - - O
structures - - O
, - - O
are - - O
discussed - - O
in - - O
relation - - O
to - - O
their - - O
location - - O
in - - O
the - - O
region - - O
of - - O
control - - O
signals - - O
. - - O

This - - O
subfamily - - O
of - - O
genes - - O
all - - O
have - - O
a - - O
single - - O
ATP-binding - - O
domain - - O
at - - O
the - - O
N-terminus - - O
and - - O
a - - O
single - - O
C-terminal - - O
set - - O
of - - O
transmembrane - - O
segments - - O
. - - O

Approximately - - O
65% - - O
of - - O
the - - O
total - - O
cAMP-dependent - - O
phosphotransferase - - O
activity - - O
is - - O
recovered - - O
in - - O
particulate - - O
fractions - - O
of - - O
homogenates - - O
prepared - - O
from - - O
asynchronous - - O
populations - - O
of - - O
C - - O
. - - O
elegans - - O
. - - O

The - - O
various - - O
available - - O
data - - O
strongly - - O
suggesting - - O
an - - O
environmental - - O
toxic - - O
origin - - O
for - - O
the - - O
"sperm - - O
fall" - - O
will - - O
be - - O
presented - - O
as - - O
well - - O
as - - O
the - - O
most - - O
frequently - - O
suspected - - O
class - - O
of - - O
substances - - O
, - - O
the - - O
xenoestrogens - - O
. - - O

The - - O
predicted - - O
Pay4p - - O
sequence - - O
contains - - O
two - - O
putative - - O
ATP-binding - - O
domains - - O
and - - O
shows - - O
structural - - O
relationships - - O
to - - O
other - - O
potential - - O
ATP-binding - - O
proteins - - O
involved - - O
in - - O
biological - - O
processes - - O
as - - O
diverse - - O
as - - O
peroxisome - - O
biogenesis - - O
, - - O
vesicle-mediated - - O
protein - - O
transport - - O
, - - O
cell - - O
cycle - - O
control - - O
, - - O
and - - O
transcriptional - - O
regulation - - O
. - - O

DNA - - O
recognition - - O
by - - O
F - - O
factor - - O
TraI36 - - O
: - - O
highly - - O
sequence-specific - - O
binding - - O
of - - O
single-stranded - - O
DNA - - O
. - - O

We - - O
have - - O
followed - - O
37 - - O
phenytoin-treated - - O
patients - - O
with - - O
reduced - - O
serum - - O
IgA - - O
concentrations - - O
for - - O
2-7 - - O
years - - O
. - - O

Erythema - - O
exsudativum - - O
multiforme - - O
induced - - O
by - - O
granulocyte - - O
colony-stimulating - - O
factor - - O
in - - O
an - - O
allogeneic - - O
peripheral - - O
blood - - O
stem - - O
cell - - O
donor - - O
. - - O

The - - O
expression - - O
of - - O
the - - O
first - - O
two - - O
genes - - O
located - - O
in - - O
this - - O
unit - - O
( - - O
c-gvpD - - O
and - - O
c-gvpE - - O
) - - O
was - - O
also - - O
monitored - - O
by - - O
Western - - O
blot - - O
( - - O
immunoblot - - O
) - - O
analyses - - O
using - - O
antisera - - O
raised - - O
against - - O
these - - O
proteins - - O
synthesized - - O
in - - O
Escherichia - - O
coli - - O
. - - O

This - - O
region - - O
also - - O
contains - - O
a - - O
gene - - O
specifying - - O
a - - O
Leu-tRNA - - O
precursor - - O
and - - O
a - - O
remnant - - O
of - - O
a - - O
tau - - O
element - - O
. - - O

In - - O
summary - - O
, - - O
at - - O
equianesthetic - - O
concentrations - - O
, - - O
desflurane - - O
and - - O
isoflurane - - O
produced - - O
similar - - O
hemodynamic - - O
effects - - O
; - - O
however - - O
, - - O
in - - O
the - - O
absence - - O
of - - O
drugs - - O
that - - O
inhibit - - O
autonomic - - O
reflexes - - O
, - - O
desflurane - - O
had - - O
less - - O
negative - - O
inotropic - - O
activity - - O
and - - O
produced - - O
less - - O
decrease - - O
in - - O
arterial - - O
pressure - - O
. - - O

Sparfloxacin - - O
and - - O
clinafloxacin - - O
were - - O
evaluated - - O
against - - O
Enterococcus - - O
faecium - - O
SF2149 - - O
and - - O
Enterococcus - - O
faecalis - - O
WH245 - - O
, - - O
respectively - - O
. - - O

A - - O
330-kb - - O
YAC - - O
, - - O
A148A7 - - O
, - - O
spanned - - O
from - - O
the - - O
HLA-DQA1 - - O
locus - - O
through - - O
the - - O
Y3 - - O
Ring - - O
4 - - O
locus - - O
and - - O
extended - - O
at - - O
least - - O
130 - - O
kb - - O
centromeric - - O
of - - O
YAC - - O
B1D12 - - O
. - - O

Modification - - O
of - - O
dopamine - - O
D2 - - O
receptor - - O
activity - - O
by - - O
pergolide - - O
in - - O
Parkinson's - - O
disease - - O
: - - O
an - - O
in - - O
vivo - - O
study - - O
by - - O
PET - - O
. - - O

The - - O
highest - - O
doses - - O
were - - O
found - - O
for - - O
drivers - - O
who - - O
transported - - O
large - - O
numbers - - O
of - - O
99Mo - - O
generators - - O
. - - O

National - - O
certification - - O
: - - O
a - - O
vital - - O
component - - O
of - - O
quality - - O
assurance - - O
. - - O

Effects - - O
of - - O
dopamine - - O
and - - O
of - - O
a - - O
dopaminergic - - O
blocker - - O
, - - O
haloperidol - - O
, - - O
on - - O
the - - O
responses - - O
of - - O
carotid - - O
body - - O
chemoreceptors - - O
to - - O
hypoxia - - O
and - - O
hypercapnia - - O
were - - O
investigated - - O
in - - O
16 - - O
anesthetized - - O
cats - - O
. - - O

Mutational - - O
analysis - - O
of - - O
a - - O
DNA - - O
sequence - - O
involved - - O
in - - O
linking - - O
gene - - O
expression - - O
to - - O
the - - O
cell - - O
cycle - - O
. - - O

PCR - - O
Southern - - O
blot - - O
analysis - - O
of - - O
human - - O
kidney - - O
cDNA - - O
using - - O
primers - - O
flanking - - O
the - - O
hKID - - O
coding - - O
sequence - - O
revealed - - O
expression - - O
of - - O
a - - O
full-length - - O
mRNA - - O
and - - O
short - - O
transcripts - - O
with - - O
partial - - O
exon - - O
1 - - O
and - - O
partial - - O
exon - - O
4 - - O
deletions - - O
. - - O

E - - O
. - - O
, - - O
Hession - - O
, - - O
C - - O
. - - O
, - - O
Goff - - O
, - - O
D - - O
. - - O
, - - O
Griffiths - - O
, - - O
B - - O
. - - O
, - - O
Tizard - - O
, - - O
R - - O
. - - O
, - - O
Newman - - O
, - - O
B - - O
. - - O
, - - O
Chi-Rosso - - O
, - - O
G - - O
. - - O
, - - O
and - - O
Lobb - - O
, - - O
R - - O
. - - O
, - - O
( - - O
1990 - - O
) - - O
Cell - - O
63 - - O
, - - O
1349-1356 - - O
) - - O
. - - O

The - - O
NF-kappaB - - O
responsive - - O
reporter - - O
construct - - O
, - - O
( - - O
PRDII - - O
) - - O
( - - O
4 - - O
) - - O
-CAT - - O
, - - O
was - - O
used - - O
to - - O
explore - - O
transcription - - O
resulting - - O
from - - O
NF-kappaB - - O
activated - - O
by - - O
Tat - - O
. - - O

Transcriptional - - O
regulation - - O
of - - O
fbp1 - - O
promoter - - O
constructs - - O
containing - - O
only - - O
UAS1 - - O
or - - O
UAS2 - - O
confirms - - O
that - - O
the - - O
PKA - - O
and - - O
MAPK - - O
regulation - - O
is - - O
targeted - - O
to - - O
both - - O
sites - - O
. - - O

Furthermore - - O
, - - O
formation - - O
of - - O
foci - - O
of - - O
transformed - - O
RECs - - O
by - - O
the - - O
c-jun - - O
ras - - O
combination - - O
was - - O
augmented - - O
3-fold - - O
by - - O
the - - O
tumor - - O
promoter - - O
phorbol - - O
12-tetradecanoate - - O
13-acetate - - O
. - - O

Commonly - - O
used - - O
stressors - - O
are - - O
mental - - O
arithmetics - - O
, - - O
speech - - O
tasks - - O
, - - O
the - - O
Stroop - - O
test - - O
, - - O
videogame - - O
playing - - O
, - - O
films - - O
or - - O
videotapes - - O
and - - O
interviews - - O
. - - O

The - - O
highly - - O
restrained - - O
girls - - O
had - - O
a - - O
significantly - - O
higher - - O
EAT - - O
score - - O
than - - O
the - - O
low-restrained - - O
girls - - O
, - - O
and - - O
shared - - O
with - - O
their - - O
mothers - - O
a - - O
susceptibility - - O
to - - O
the - - O
disinhibitory - - O
effects - - O
of - - O
negative - - O
mood - - O
states - - O
on - - O
their - - O
eating - - O
behaviour - - O
. - - O

It - - O
was - - O
proposed - - O
that - - O
the - - O
synthetase-related - - O
sequences - - O
of - - O
GCN2 - - O
stimulate - - O
the - - O
activity - - O
of - - O
the - - O
kinase - - O
by - - O
interacting - - O
directly - - O
with - - O
uncharged - - O
tRNA - - O
that - - O
accumulates - - O
during - - O
amino - - O
acid - - O
limitation - - O
. - - O

99mTc - - O
phytate - - O
, - - O
198Au - - O
colloid - - O
, - - O
and - - O
99mTc - - O
antimony - - O
sulfide - - O
have - - O
been - - O
used - - O
; - - O
the - - O
last - - O
appears - - O
to - - O
have - - O
been - - O
the - - O
most - - O
satisfactory - - O
. - - O

Invited - - O
editorial - - O
on - - O
"Acute - - O
and - - O
chronic - - O
effects - - O
of - - O
exercise - - O
on - - O
leptin - - O
levels - - O
in - - O
humans" - - O
. - - O

Pharmacologic - - O
properties - - O
of - - O
serotonergic - - O
agents - - O
and - - O
antidepressant - - O
drugs - - O
. - - O

LCBF - - O
in - - O
normal - - O
and - - O
hypoxic - - O
puppies - - O
was - - O
correlated - - O
with - - O
local - - O
cerebral - - O
glucose - - O
utilization - - O
( - - O
LCGU - - O
) - - O
obtained - - O
under - - O
the - - O
same - - O
experimental - - O
conditions - - O
( - - O
Duffy - - O
et - - O
al - - O
, - - O
1982 - - O
) - - O
. - - O

Retinoids - - O
participate - - O
in - - O
the - - O
onset - - O
of - - O
differentiation - - O
, - - O
apoptosis - - O
and - - O
the - - O
inhibition - - O
of - - O
growth - - O
in - - O
a - - O
wide - - O
variety - - O
of - - O
normal - - O
and - - O
cancerous - - O
cells - - O
. - - O

The - - O
results - - O
revealed - - O
a - - O
hierarchy - - O
of - - O
ligand - - O
affinities - - O
that - - O
mirrored - - O
their - - O
adhesive - - O
activity - - O
( - - O
rsVCAM-1 - - O
> - - O
fibronectin - - O
variants - - O
containing - - O
CS1 - - O
> - - O
> - - O
other - - O
fibronectin - - O
variants - - O
) - - O
. - - O

The - - O
diagnosis - - O
of - - O
miliary - - O
tuberculosis - - O
should - - O
be - - O
systematically - - O
considered - - O
in - - O
ARDS - - O
of - - O
unknown - - O
origin - - O
. - - O

After - - O
giving - - O
a - - O
survey - - O
on - - O
the - - O
situation - - O
of - - O
antibiotic - - O
resistance - - O
in - - O
the - - O
region - - O
of - - O
Northern - - O
Bavaria - - O
during - - O
1973 - - O
74 - - O
and - - O
comparing - - O
the - - O
activity - - O
of - - O
a - - O
sulfamethoxazole - - O
( - - O
SMZ - - O
) - - O
trimethoprim - - O
( - - O
TMP - - O
) - - O
combination - - O
to - - O
other - - O
commonly - - O
used - - O
antibiotics - - O
and - - O
chemotherapeutic - - O
agents - - O
, - - O
the - - O
results - - O
of - - O
tests - - O
with - - O
the - - O
new - - O
combination - - O
of - - O
N1- - - O
( - - O
4 - - O
, - - O
5-dimethyl-2-oxazolyl - - O
) - - O
-sulfanilamide - - O
) - - O
( - - O
sulfamoxole - - O
) - - O
and - - O
2 - - O
, - - O
4-diamino-5- - - O
( - - O
3 - - O
, - - O
4 - - O
, - - O
5-trimethoxy-benzyl - - O
) - - O
-pyrimidine - - O
( - - O
trimethoprim - - O
) - - O
at - - O
a - - O
ratio - - O
of - - O
5 - - O
: - - O
1 - - O
( - - O
CN - - O
3123 - - O
; - - O
Nevin - - O
, - - O
Supristol - - O
) - - O
are - - O
compared - - O
to - - O
those - - O
of - - O
tests - - O
with - - O
TMP - - O
SMZ - - O
. - - O

The - - O
psychological - - O
tests - - O
consisted - - O
of - - O
a - - O
free-recall - - O
task - - O
, - - O
a - - O
test - - O
for - - O
visuomotor - - O
coordination - - O
and - - O
a - - O
recognition - - O
task - - O
. - - O

Coronary - - O
vasoconstriction - - O
caused - - O
by - - O
endothelin-1 - - O
is - - O
enhanced - - O
by - - O
ischemia-reperfusion - - O
and - - O
by - - O
norepinephrine - - O
present - - O
in - - O
concentrations - - O
typically - - O
observed - - O
after - - O
neonatal - - O
cardiopulmonary - - O
bypass - - O
. - - O

The - - O
plasmid - - O
shuffle - - O
technique - - O
was - - O
used - - O
to - - O
replace - - O
the - - O
wild-type - - O
gene - - O
with - - O
the - - O
mutant - - O
form - - O
, - - O
resulting - - O
in - - O
failure - - O
of - - O
the - - O
yeast - - O
cells - - O
to - - O
grow - - O
. - - O

Late - - O
mRNA - - O
selected - - O
by - - O
a - - O
cDNA - - O
homologous - - O
to - - O
the - - O
HindIII-P - - O
EcoRI-B - - O
region - - O
of - - O
the - - O
AcNPV - - O
map - - O
directed - - O
the - - O
synthesis - - O
of - - O
31K - - O
and - - O
30K - - O
proteins - - O
which - - O
comigrated - - O
with - - O
the - - O
31K - - O
and - - O
30K - - O
proteins - - O
translated - - O
from - - O
RNA - - O
selected - - O
by - - O
the - - O
HindIII-A - - O
EcoRI-C - - O
SstI-G - - O
cDNA - - O
. - - O

To - - O
determine - - O
whether - - O
the - - O
NTP-binding - - O
motif - - O
is - - O
important - - O
for - - O
Rad24 - - O
function - - O
, - - O
we - - O
mutated - - O
the - - O
conserved - - O
lysine - - O
( - - O
115 - - O
) - - O
residue - - O
in - - O
this - - O
motif - - O
. - - O

Copper - - O
and - - O
ceruloplasmin - - O
content - - O
in - - O
pregnant - - O
women - - O
and - - O
in - - O
women - - O
with - - O
certain - - O
gynecological - - O
diseases - - O
. - - O

Constitutive - - O
activation - - O
of - - O
Rac1 - - O
and - - O
RhoA - - O
causes - - O
tumorigenic - - O
transformation - - O
of - - O
NIH - - O
3T3 - - O
cells - - O
, - - O
and - - O
their - - O
functions - - O
may - - O
be - - O
required - - O
for - - O
full - - O
Ras - - O
transformation - - O
. - - O

Proposals - - O
on - - O
authorization - - O
; - - O
by - - O
a - - O
group - - O
of - - O
nurses - - O
from - - O
psychiatric - - O
hospitals - - O
. - - O

RESULTS - - O
: - - O
The - - O
cardiac - - O
index - - O
significantly - - O
changed - - O
with - - O
varying - - O
PaCO2 - - O
levels - - O
( - - O
hypocapnia - - O
, - - O
- - - O
9% - - O
; - - O
hypercapnia - - O
, - - O
13% - - O
) - - O
. - - O

The - - O
DNA - - O
sequence - - O
of - - O
the - - O
sulfate - - O
activation - - O
locus - - O
from - - O
Escherichia - - O
coli - - O
K-12 - - O
has - - O
been - - O
determined - - O
. - - O

Transforming - - O
growth - - O
factor-beta - - O
( - - O
TGF-beta - - O
) - - O
induced - - O
growth - - O
arrest - - O
of - - O
cells - - O
involves - - O
regulation - - O
of - - O
the - - O
activities - - O
of - - O
both - - O
D- - - O
and - - O
E-type - - O
cyclin - - O
kinase - - O
complexes - - O
thought - - O
to - - O
be - - O
mediated - - O
primarily - - O
by - - O
the - - O
regulation - - O
of - - O
p15 - - O
( - - O
Ink4b - - O
) - - O
and - - O
p27 - - O
( - - O
Kip1 - - O
) - - O
cyclin - - O
kinase - - O
inhibitors - - O
. - - O

Epstein-Barr - - O
virus-encoded - - O
latent - - O
membrane - - O
protein - - O
1 - - O
activates - - O
the - - O
JNK - - O
pathway - - O
through - - O
its - - O
extreme - - O
C - - O
terminus - - O
via - - O
a - - O
mechanism - - O
involving - - O
TRADD - - O
and - - O
TRAF2 - - O
. - - O

WA - - O
constructs - - O
afforded - - O
relaxed - - O
and - - O
positive - - O
topoisomers - - O
, - - O
and - - O
cyclization - - O
kinetics - - O
indicated - - O
slow - - O
interconversion - - O
of - - O
precursors - - O
to - - O
the - - O
two - - O
topoisomers - - O
. - - O

These - - O
changes - - O
may - - O
be - - O
the - - O
result - - O
of - - O
, - - O
on - - O
the - - O
one - - O
hand - - O
, - - O
an - - O
increased - - O
sensitivity - - O
of - - O
the - - O
neuromuscular - - O
transmission - - O
and - - O
or - - O
decreased - - O
muscle - - O
contractility - - O
and - - O
, - - O
on - - O
the - - O
other - - O
hand - - O
, - - O
the - - O
result - - O
of - - O
a - - O
reduced - - O
plasma - - O
clearance - - O
during - - O
hypothermia - - O
. - - O

G-box-directed - - O
expression - - O
in - - O
leaves - - O
required - - O
the - - O
presence - - O
of - - O
an - - O
enhancer - - O
region - - O
from - - O
the - - O
cauliflower - - O
mosaic - - O
virus - - O
( - - O
CaMV - - O
) - - O
35S - - O
promoter - - O
. - - O

Binding - - O
specificity - - O
and - - O
modulation - - O
of - - O
the - - O
ApoA-I - - O
promoter - - O
activity - - O
by - - O
homo- - - O
and - - O
heterodimers - - O
of - - O
nuclear - - O
receptors - - O
. - - O

Different - - O
thermoluminescent - - O
detectors - - O
( - - O
TLD - - O
) - - O
have - - O
been - - O
used - - O
to - - O
measure - - O
the - - O
contribution - - O
of - - O
the - - O
low - - O
linear - - O
energy - - O
transfer - - O
component - - O
( - - O
LET - - O
< - - O
10 - - O
keV - - O
micrometer - - O
) - - O
and - - O
plastic - - O
nuclear - - O
track - - O
detectors - - O
( - - O
PNTD - - O
) - - O
for - - O
the - - O
high - - O
linear - - O
energy - - O
tranfer - - O
( - - O
LET - - O
) - - O
component - - O
. - - O

Deletion - - O
mapping - - O
experiments - - O
determined - - O
that - - O
the - - O
sequences - - O
required - - O
for - - O
full - - O
activity - - O
in - - O
MSC-1 - - O
cells - - O
were - - O
included - - O
within - - O
619 - - O
bp - - O
of - - O
the - - O
start - - O
site - - O
and - - O
identified - - O
several - - O
regions - - O
that - - O
demonstrated - - O
increased - - O
luciferase - - O
activity - - O
: - - O
the - - O
-583 - - O
bp - - O
to - - O
-564 - - O
bp - - O
, - - O
-503 - - O
bp - - O
to - - O
-484 - - O
bp - - O
, - - O
and - - O
-114 - - O
bp - - O
to - - O
-65 - - O
regions - - O
. - - O

Like - - O
the - - O
p190-B - - O
exon - - O
, - - O
the - - O
first - - O
exon - - O
of - - O
p190-A - - O
is - - O
extremely - - O
large - - O
( - - O
3 - - O
. - - O
7 - - O
kb - - O
in - - O
length - - O
) - - O
, - - O
encoding - - O
both - - O
the - - O
GTPase - - O
and - - O
middle - - O
domains - - O
( - - O
residues - - O
1-1228 - - O
) - - O
, - - O
but - - O
not - - O
the - - O
remaining - - O
GAP - - O
domain - - O
, - - O
suggesting - - O
a - - O
high - - O
conservation - - O
of - - O
genomic - - O
structure - - O
between - - O
two - - O
p190 - - O
genes - - O
. - - O

We - - O
have - - O
cloned - - O
a - - O
novel - - O
mouse - - O
protein - - O
, - - O
TAF - - O
( - - O
II - - O
) - - O
140 - - O
, - - O
containing - - O
an - - O
HFD - - O
and - - O
a - - O
plant - - O
homeodomain - - O
( - - O
PHD - - O
) - - O
finger - - O
, - - O
which - - O
we - - O
demonstrated - - O
by - - O
immunoprecipitation - - O
to - - O
be - - O
a - - O
mammalian - - O
TFIID - - O
component - - O
. - - O

The - - O
eukaryotic - - O
cell - - O
cycle - - O
is - - O
governed - - O
in - - O
part - - O
by - - O
the - - O
periodic - - O
transcription - - O
of - - O
cyclin - - O
genes - - O
, - - O
whose - - O
protein - - O
products - - O
associate - - O
with - - O
and - - O
positively - - O
regulate - - O
the - - O
cyclin-dependent - - O
kinases - - O
. - - O

Dopamine - - O
beta-hydroxylase - - O
( - - O
DBH - - O
) - - O
catalyzes - - O
the - - O
conversion - - O
of - - O
dopamine - - O
to - - O
noradrenaline - - O
and - - O
is - - O
selectively - - O
expressed - - O
in - - O
noradrenergic - - O
and - - O
adrenergic - - O
neurons - - O
and - - O
neuroendocrine - - O
cells - - O
. - - O

Cooperative - - O
dimerization - - O
of - - O
paired - - O
class - - O
homeo - - O
domains - - O
on - - O
DNA - - O
. - - O

G - - O
. - - O
, - - O
and - - O
Hyde - - O
, - - O
C - - O
. - - O

The - - O
cellular - - O
part - - O
of - - O
the - - O
third - - O
chimeric - - O
clone - - O
shows - - O
significant - - O
homology - - O
to - - O
an - - O
exon - - O
of - - O
the - - O
human - - O
tyrosine - - O
phosphatase - - O
1 - - O
gene - - O
, - - O
although - - O
oriented - - O
in - - O
the - - O
antisense - - O
direction - - O
compared - - O
to - - O
the - - O
adjacent - - O
LTR - - O
. - - O

Mobilization - - O
with - - O
cyclophosphamide - - O
and - - O
granulocyte-colony - - O
stimulating - - O
factor - - O
was - - O
effective - - O
in - - O
terms - - O
of - - O
CD34+ - - O
cell - - O
shift - - O
to - - O
peripheral - - O
blood - - O
and - - O
the - - O
good - - O
quality - - O
autograft - - O
reliaebly - - O
led - - O
to - - O
haematopoetic - - O
recovery - - O
after - - O
megachemotherapy - - O
. - - O

Both - - O
parents - - O
are - - O
clinically - - O
normal - - O
and - - O
unrelated - - O
. - - O

The - - O
results - - O
show - - O
that - - O
the - - O
structure - - O
of - - O
the - - O
decorin - - O
gene - - O
promoter - - O
is - - O
different - - O
from - - O
that - - O
of - - O
any - - O
other - - O
proteoglycan - - O
promoter - - O
characterized - - O
so - - O
far - - O
and - - O
indicate - - O
that - - O
the - - O
pur - - O
pyr - - O
segment - - O
plays - - O
a - - O
role - - O
in - - O
the - - O
regulation - - O
of - - O
gene - - O
transcription - - O
. - - O

Ammonia - - O
concentration - - O
dropped - - O
significantly - - O
in - - O
all - - O
treatments - - O
, - - O
a - - O
finding - - O
which - - O
suggests - - O
a - - O
protective - - O
effect - - O
on - - O
protein - - O
nitrogen - - O
degradation - - O
to - - O
non-protein - - O
nitrogen - - O
( - - O
NH3 - - O
) - - O
. - - O

Thus - - O
, - - O
IRF-7 - - O
exhibits - - O
functional - - O
similarity - - O
to - - O
IRF-3 - - O
; - - O
however - - O
, - - O
the - - O
preferential - - O
expression - - O
of - - O
IRF-7 - - O
in - - O
lymphoid - - O
cells - - O
( - - O
the - - O
cell - - O
type - - O
that - - O
expresses - - O
IFNA - - O
) - - O
suggests - - O
that - - O
IRF-7 - - O
may - - O
play - - O
a - - O
critical - - O
role - - O
in - - O
regulating - - O
the - - O
IFNA - - O
gene - - O
expression - - O
. - - O

Rather - - O
, - - O
complete - - O
skipping - - O
of - - O
exon - - O
V - - O
and - - O
subsequent - - O
joining - - O
of - - O
exon - - O
IV - - O
to - - O
exon - - O
VI - - O
caused - - O
a - - O
shift - - O
in - - O
the - - O
open - - O
reading - - O
frame - - O
, - - O
which - - O
remodeled - - O
GPHe - - O
( - - O
P2 - - O
) - - O
with - - O
an - - O
elongated - - O
new - - O
hydrophobic - - O
sequence - - O
for - - O
membrane - - O
anchoring - - O
. - - O

All - - O
stimulations - - O
were - - O
down-regulated - - O
with - - O
GnRH-a - - O
commenced - - O
on - - O
day - - O
21 - - O
in - - O
a - - O
long - - O
protocol - - O
before - - O
gonadotropin - - O
stimulation - - O
. - - O

The - - O
consensus - - O
highlights - - O
the - - O
importance - - O
of - - O
residues - - O
other - - O
than - - O
the - - O
eight - - O
motifs - - O
that - - O
are - - O
often - - O
associated - - O
with - - O
DEAD-box - - O
RNA - - O
helicases - - O
, - - O
as - - O
well - - O
as - - O
de-emphasising - - O
the - - O
importance - - O
of - - O
the - - O
"A" - - O
residue - - O
within - - O
the - - O
"DEAD" - - O
motif - - O
. - - O

Fortunately - - O
DDT- - - O
, - - O
HCH- - - O
and - - O
HCB-levels - - O
decreased - - O
in - - O
breast - - O
milk - - O
during - - O
the - - O
last - - O
years - - O
. - - O

Two - - O
other - - O
peptides - - O
, - - O
either - - O
partially - - O
or - - O
totally - - O
lacking - - O
the - - O
basic - - O
region - - O
, - - O
but - - O
containing - - O
the - - O
intact - - O
leucine - - O
zipper - - O
domain - - O
, - - O
readily - - O
form - - O
dimers - - O
but - - O
do - - O
not - - O
bind - - O
to - - O
the - - O
CRE - - O
. - - O

The - - O
duration - - O
of - - O
diabetes - - O
mellitus - - O
in - - O
these - - O
patients - - O
was - - O
from - - O
5 - - O
months - - O
to - - O
6 - - O
years - - O
, - - O
and - - O
in - - O
all - - O
patients - - O
this - - O
was - - O
the - - O
first - - O
myocardial - - O
infarction - - O
. - - O

We - - O
detected - - O
mos - - O
transcripts - - O
by - - O
Northern - - O
( - - O
RNA - - O
) - - O
analyses - - O
in - - O
RNA - - O
prepared - - O
from - - O
chicken - - O
and - - O
quail - - O
ovaries - - O
and - - O
testes - - O
. - - O

Nursing - - O
home - - O
discharges - - O
in - - O
clinical - - O
practice - - O
. - - O

Seven - - O
clones - - O
encoding - - O
interferon - - O
response - - O
element - - O
binding - - O
factors - - O
have - - O
been - - O
isolated - - O
from - - O
a - - O
mouse - - O
fibroblast - - O
lambda - - O
gt11 - - O
cDNA - - O
library - - O
by - - O
using - - O
a - - O
32P - - O
end-labeled - - O
tandem - - O
trimer - - O
of - - O
the - - O
mouse - - O
( - - O
2'-5' - - O
) - - O
oligoadenylate - - O
synthetase - - O
gene - - O
interferon - - O
response - - O
element - - O
as - - O
a - - O
probe - - O
. - - O

The - - O
patient - - O
initially - - O
attained - - O
complete - - O
remission - - O
( - - O
CR1 - - O
) - - O
with - - O
conventional - - O
chemotherapy - - O
and - - O
then - - O
relapsed - - O
14 - - O
months - - O
later - - O
. - - O

Truncation - - O
variants - - O
of - - O
peptides - - O
isolated - - O
from - - O
MHC - - O
class - - O
II - - O
molecules - - O
suggest - - O
sequence - - O
motifs - - O
. - - O

Recombinant - - O
I-kappa - - O
B - - O
alpha - - O
inhibited - - O
kappa - - O
B - - O
motif - - O
binding - - O
by - - O
nuclear - - O
factor-kappa - - O
B1 - - O
, - - O
RelA - - O
, - - O
and - - O
c-Rel - - O
as - - O
indicated - - O
by - - O
studies - - O
using - - O
UV - - O
radiation-induced - - O
covalent - - O
cross-linking - - O
to - - O
a - - O
bromodeoxyuridine-substituted - - O
kappa - - O
B - - O
oligonucleotide - - O
. - - O

Cells - - O
lacking - - O
p116 - - O
exhibit - - O
a - - O
striking - - O
defect - - O
in - - O
the - - O
formation - - O
of - - O
these - - O
macropinocytic - - O
structures - - O
, - - O
a - - O
concomitant - - O
reduction - - O
in - - O
the - - O
rate - - O
of - - O
fluid - - O
phase - - O
pinocytosis - - O
, - - O
a - - O
significant - - O
decrease - - O
in - - O
the - - O
efficiency - - O
of - - O
chemotactic - - O
aggregation - - O
, - - O
and - - O
a - - O
decrease - - O
in - - O
cellular - - O
F-actin - - O
content - - O
. - - O

Promoter - - O
region - - O
of - - O
the - - O
transcriptional - - O
unit - - O
for - - O
human - - O
alpha - - O
1-chimaerin - - O
, - - O
a - - O
neuron-specific - - O
GTPase-activating - - O
protein - - O
for - - O
p21rac - - O
. - - O
alpha - - O
1-chimaerin - - O
is - - O
a - - O
neuron-specific - - O
GTPase-activating - - O
protein - - O
for - - O
p21rac - - O
, - - O
a - - O
protein - - O
involved - - O
in - - O
morphological - - O
events - - O
. - - O

Surprisingly - - O
, - - O
the - - O
COOH-terminal - - O
domain - - O
of - - O
RanGAP1 - - O
was - - O
also - - O
found - - O
to - - O
harbor - - O
a - - O
nuclear - - O
localization - - O
signal - - O
. - - O

Thus - - O
, - - O
the - - O
anti-interferon - - O
functions - - O
of - - O
vIRF-2 - - O
may - - O
contribute - - O
to - - O
the - - O
establishment - - O
of - - O
a - - O
chronic - - O
or - - O
latent - - O
infection - - O
. - - O

For - - O
EPV - - O
3 - - O
, - - O
10 - - O
, - - O
or - - O
40 - - O
, - - O
the - - O
bias - - O
exceeded - - O
25% - - O
for - - O
7 - - O
, - - O
3 - - O
, - - O
and - - O
1 - - O
in - - O
the - - O
8-predictor - - O
model - - O
respectively - - O
, - - O
when - - O
a - - O
conventional - - O
selection - - O
criterion - - O
was - - O
used - - O
( - - O
alpha - - O
= - - O
0 - - O
. - - O
05 - - O
) - - O
. - - O

Position - - O
22 - - O
is - - O
an - - O
isoleucine - - O
in - - O
the - - O
complete - - O
SsoL12 - - O
protein - - O
sequence - - O
, - - O
coded - - O
by - - O
an - - O
AUA - - O
codon - - O
. - - O

Plasma - - O
concentrations - - O
of - - O
ANF - - O
( - - O
pANF - - O
) - - O
, - - O
aldosterone - - O
( - - O
PAC - - O
) - - O
and - - O
renin - - O
( - - O
PRC - - O
) - - O
were - - O
measured - - O
daily - - O
, - - O
as - - O
were - - O
hemodynamic - - O
parameters - - O
. - - O

Immunochemical - - O
studies - - O
with - - O
filarial - - O
antigens - - O
. - - O

RPM - - O
RGL3 - - O
resembled - - O
AF-6 - - O
and - - O
Nore1 - - O
in - - O
interacting - - O
strongly - - O
with - - O
constitutively - - O
active - - O
M-Ras - - O
and - - O
p21 - - O
Ras - - O
. - - O

To - - O
our - - O
knowledge - - O
this - - O
is - - O
the - - O
first - - O
case - - O
in - - O
which - - O
a - - O
probable - - O
association - - O
between - - O
cholelithiasis - - O
and - - O
Wildervanck's - - O
syndrome - - O
has - - O
been - - O
recorded - - O
. - - O

The - - O
results - - O
are - - O
discussed - - O
in - - O
relation - - O
to - - O
acoustical - - O
models - - O
of - - O
sound - - O
propagation - - O
and - - O
physiology - - O
, - - O
and - - O
it - - O
is - - O
suggested - - O
that - - O
height-dependent - - O
degradation - - O
within - - O
a - - O
forest - - O
is - - O
an - - O
important - - O
selection - - O
pressure - - O
for - - O
transmissibility - - O
in - - O
avian - - O
communication - - O
. - - O

To - - O
identify - - O
the - - O
important - - O
cis-DNA - - O
regulatory - - O
element - - O
( - - O
s - - O
) - - O
involved - - O
in - - O
the - - O
tissue- - - O
, - - O
region- - - O
, - - O
and - - O
cell-specific - - O
expression - - O
of - - O
the - - O
mE-RABP - - O
gene - - O
, - - O
the - - O
5-kb - - O
DNA - - O
fragment - - O
was - - O
sequenced - - O
. - - O

The - - O
two - - O
larger - - O
peptides - - O
, - - O
one - - O
containing - - O
amino - - O
acids - - O
1-228 - - O
and - - O
the - - O
other - - O
containing - - O
amino - - O
acids - - O
85-228 - - O
, - - O
formed - - O
dimers - - O
in - - O
solution - - O
and - - O
bound - - O
DNA - - O
specifically - - O
as - - O
a - - O
dimer - - O
. - - O

Here - - O
the - - O
cloning - - O
and - - O
molecular - - O
analysis - - O
of - - O
the - - O
Zm-ERabp1 - - O
, - - O
Zm-ERabp4 - - O
, - - O
and - - O
Zm-ERabp5 - - O
genes - - O
is - - O
presented - - O
. - - O

Mechanism - - O
of - - O
enhancement - - O
of - - O
DNA - - O
expression - - O
consequent - - O
to - - O
cointernalization - - O
of - - O
a - - O
replication-deficient - - O
adenovirus - - O
and - - O
unmodified - - O
plasmid - - O
DNA - - O
. - - O

Using - - O
this - - O
method - - O
, - - O
VLPs - - O
were - - O
obtained - - O
in - - O
quantities - - O
sufficient - - O
for - - O
further - - O
characterization - - O
. - - O

Lactate - - O
accumulation - - O
peak - - O
was - - O
unaffected - - O
by - - O
supplementation - - O
( - - O
HMB - - O
, - - O
8 - - O
. - - O
1 - - O
+ - - O
- - - O
1 - - O
. - - O
1 - - O
mM - - O
; - - O
LEU - - O
, - - O
6 - - O
. - - O
2 - - O
+ - - O
- - - O
0 - - O
. - - O
8 - - O
mM - - O
; - - O
CON - - O
, - - O
7 - - O
. - - O
5 - - O
+ - - O
- - - O
1 - - O
. - - O
3 - - O
mM - - O
) - - O
. - - O

W - - O
. - - O

Tissue - - O
pressure - - O
, - - O
rCBF - - O
, - - O
and - - O
water - - O
content - - O
were - - O
measured - - O
from - - O
gray - - O
matter - - O
in - - O
the - - O
central - - O
core - - O
and - - O
the - - O
peripheral - - O
margin - - O
of - - O
the - - O
MCA - - O
territory - - O
over - - O
6 - - O
h - - O
after - - O
MCAO - - O
. - - O

Exons - - O
III - - O
to - - O
VIII - - O
, - - O
which - - O
cover - - O
the - - O
coding - - O
region - - O
and - - O
the - - O
3' - - O
untranslated - - O
region - - O
, - - O
are - - O
almost - - O
identical - - O
in - - O
all - - O
types - - O
of - - O
PST - - O
or - - O
AST - - O
cDNAs - - O
. - - O

Alena - - O
is - - O
a - - O
nurse - - O
in - - O
Prague--she - - O
dreams - - O
of - - O
higher - - O
wages - - O
and - - O
a - - O
trip - - O
across - - O
the - - O
ocean - - O
. - - O

An - - O
experiment - - O
examined - - O
the - - O
effects - - O
of - - O
treatment - - O
with - - O
gonadotrophin - - O
releasing - - O
hormone - - O
( - - O
100 - - O
micrograms - - O
GnRH - - O
injected - - O
24 - - O
h - - O
after - - O
progestagen - - O
sponge - - O
removal - - O
) - - O
, - - O
season - - O
of - - O
treatment - - O
( - - O
autumn - - O
v - - O
. - - O
spring - - O
) - - O
, - - O
the - - O
effect - - O
of - - O
supplementary - - O
feeding - - O
with - - O
lupin - - O
grain - - O
( - - O
in - - O
autumn - - O
only - - O
, - - O
from - - O
12 - - O
days - - O
before - - O
until - - O
8 - - O
days - - O
after - - O
sponge - - O
removal - - O
) - - O
on - - O
the - - O
time - - O
of - - O
ovulation - - O
in - - O
182 - - O
mature - - O
Merino - - O
ewes - - O
superovulated - - O
with - - O
a - - O
combination - - O
of - - O
400 - - O
I - - O
. - - O
U - - O
. - - O
pregnant - - O
mare - - O
serum - - O
gonadotrophin - - O
( - - O
PMSG - - O
) - - O
and - - O
12 - - O
mg - - O
follicle - - O
stimulating - - O
hormone - - O
( - - O
FSH-P - - O
) - - O
. - - O

The - - O
early - - O
lethality - - O
of - - O
the - - O
left-sided - - O
resectio - - O
was - - O
0% - - O
and - - O
the - - O
postoperative - - O
survival--5-10 - - O
months - - O
. - - O

EIAV - - O
LTR - - O
sequence - - O
variability - - O
is - - O
confined - - O
mostly - - O
to - - O
a - - O
small - - O
portion - - O
of - - O
the - - O
enhancer - - O
within - - O
the - - O
U3 - - O
segment - - O
of - - O
the - - O
LTR - - O
. - - O

In - - O
the - - O
context - - O
of - - O
liver - - O
allograft - - O
shortage - - O
, - - O
our - - O
results - - O
suggest - - O
that - - O
an - - O
ELT - - O
should - - O
not - - O
be - - O
performed - - O
in - - O
patients - - O
with - - O
cardiac - - O
failure - - O
, - - O
more - - O
than - - O
two - - O
OSF - - O
, - - O
or - - O
an - - O
APACHE - - O
II - - O
score - - O
higher - - O
than - - O
30 - - O
. - - O

If - - O
no - - O
alloantibodies - - O
are - - O
detected - - O
, - - O
further - - O
analysis - - O
to - - O
define - - O
a - - O
role - - O
of - - O
drug- - - O
related - - O
or - - O
autoantibodies - - O
is - - O
required - - O
. - - O

The - - O
protein - - O
mixtures - - O
of - - O
sesame - - O
flour - - O
and - - O
soybean - - O
flour - - O
were - - O
well - - O
accepted - - O
. - - O

The - - O
site - - O
of - - O
autophosphorylation - - O
is - - O
Tyr397 - - O
which - - O
corresponds - - O
to - - O
the - - O
consensus - - O
autophosphorylation - - O
site - - O
of - - O
other - - O
Src - - O
family - - O
tyrosine - - O
kinases - - O
. - - O

Our - - O
results - - O
favor - - O
the - - O
possibility - - O
that - - O
the - - O
Drosophila - - O
EGF - - O
receptor - - O
DER - - O
Egfr - - O
expressed - - O
by - - O
the - - O
EMA - - O
cells - - O
functions - - O
as - - O
a - - O
receptor - - O
for - - O
Vein - - O
. - - O

Infrared - - O
measurements - - O
of - - O
temperature - - O
changes - - O
and - - O
estimates - - O
of - - O
the - - O
heating - - O
produced - - O
at - - O
the - - O
mical - - O
. - - O

Northern - - O
blot - - O
and - - O
reverse - - O
transcription-PCR - - O
analyses - - O
of - - O
human - - O
mRNA - - O
samples - - O
demonstrate - - O
that - - O
RNR - - O
is - - O
expressed - - O
exclusively - - O
in - - O
the - - O
retina - - O
, - - O
with - - O
transcripts - - O
of - - O
approximately - - O
7 - - O
. - - O
5 - - O
kb - - O
, - - O
approximately - - O
3 - - O
. - - O
0 - - O
kb - - O
, - - O
and - - O
approximately - - O
2 - - O
. - - O
3 - - O
kb - - O
by - - O
Northern - - O
blot - - O
analysis - - O
. - - O

One - - O
group - - O
of - - O
six - - O
cDNA - - O
clones - - O
was - - O
derived - - O
from - - O
a - - O
2 - - O
. - - O
9-kilobase - - O
early - - O
transcript - - O
encoded - - O
by - - O
the - - O
IR2 - - O
repeat - - O
element - - O
and - - O
showed - - O
restriction - - O
site - - O
polymorphism - - O
for - - O
the - - O
enzyme - - O
SmaI - - O
. - - O

Compared - - O
to - - O
controls - - O
, - - O
both - - O
UB - - O
and - - O
OCS - - O
rats - - O
showed - - O
a - - O
small - - O
but - - O
significant - - O
post-operative - - O
reduction - - O
in - - O
the - - O
nocturnality - - O
of - - O
drinking - - O
. - - O

Recombinant - - O
human - - O
serum - - O
albumin - - O
( - - O
rHSA - - O
) - - O
produced - - O
by - - O
cultured - - O
fermentation - - O
has - - O
been - - O
prepared - - O
in - - O
the - - O
form - - O
of - - O
microcapsules - - O
nominally - - O
3-5 - - O
microns - - O
in - - O
diameter - - O
and - - O
radiolabelled - - O
with - - O
technetium-99m - - O
following - - O
reduction - - O
with - - O
stannous - - O
chloride - - O
. - - O

These - - O
data - - O
suggest - - O
that - - O
proper - - O
direct - - O
binding - - O
of - - O
Nhp2p - - O
to - - O
H - - O
ACA - - O
snoRNAs - - O
is - - O
required - - O
for - - O
the - - O
assembly - - O
of - - O
H - - O
ACA - - O
snoRNPs - - O
and - - O
hence - - O
for - - O
the - - O
stability - - O
of - - O
some - - O
of - - O
their - - O
components - - O
. - - O

This - - O
mode - - O
of - - O
ternary - - O
complex - - O
formation - - O
is - - O
in - - O
contrast - - O
to - - O
the - - O
one - - O
seen - - O
in - - O
the - - O
promoter - - O
of - - O
the - - O
c-fos - - O
protooncogene - - O
, - - O
where - - O
formation - - O
of - - O
the - - O
ternary - - O
complex - - O
is - - O
dependent - - O
on - - O
the - - O
prior - - O
assembly - - O
of - - O
the - - O
serum - - O
response - - O
factor-DNA - - O
binary - - O
complex - - O
. - - O

Bile - - O
bilirubin - - O
did - - O
not - - O
rise - - O
within - - O
12 - - O
h - - O
after - - O
haem - - O
infusion - - O
a - - O
finding - - O
which - - O
warrants - - O
further - - O
investigation - - O
. - - O

Following - - O
intravenous - - O
administration - - O
, - - O
the - - O
myocardial - - O
concentration - - O
of - - O
tracer - - O
thallium-201 - - O
, - - O
potassium-43 - - O
, - - O
and - - O
rubidium-81 - - O
were - - O
determined - - O
in - - O
mice - - O
; - - O
thallium - - O
was - - O
present - - O
in - - O
the - - O
greatest - - O
concentration - - O
in - - O
the - - O
myocardium - - O
( - - O
2 - - O
. - - O
08% - - O
compared - - O
1 - - O
. - - O
25% - - O
for - - O
potassium - - O
and - - O
1 - - O
. - - O
15% - - O
for - - O
rubidium - - O
at - - O
10 - - O
minutes - - O
) - - O
. - - O

It - - O
acts - - O
on - - O
Cdks - - O
in - - O
the - - O
G1 - - O
and - - O
S - - O
phases - - O
of - - O
the - - O
cell - - O
cycle - - O
, - - O
and - - O
also - - O
binds - - O
to - - O
proliferating - - O
cell - - O
nuclear - - O
antigen - - O
( - - O
PCNA - - O
) - - O
, - - O
blocking - - O
DNA - - O
replication - - O
in - - O
vitro - - O
. - - O

The - - O
mutation - - O
within - - O
the - - O
asgB480 - - O
allele - - O
was - - O
identified - - O
as - - O
an - - O
A-to-G - - O
transition - - O
that - - O
results - - O
in - - O
a - - O
threonine-to-alanine - - O
substitution - - O
in - - O
the - - O
predicted - - O
protein - - O
product - - O
. - - O

Nucleotide - - O
sequence - - O
and - - O
transcriptional - - O
analysis - - O
of - - O
the - - O
polyhedrin - - O
gene - - O
of - - O
Spodoptera - - O
exigua - - O
nuclear - - O
polyhedrosis - - O
virus - - O
. - - O

In - - O
12 - - O
cases - - O
( - - O
3 - - O
. - - O
1% - - O
) - - O
, - - O
a - - O
change - - O
in - - O
stage - - O
resulted - - O
. - - O

Inherent - - O
hematology - - O
of - - O
old - - O
age - - O
. - - O

We - - O
couldn't - - O
detect - - O
any - - O
effect - - O
of - - O
n-3 - - O
FA - - O
supplementation - - O
on - - O
total - - O
cholesterol - - O
, - - O
HDL - - O
cholesterol - - O
, - - O
LDL - - O
cholesterol - - O
, - - O
apo - - O
A1 - - O
, - - O
Lp - - O
( - - O
a - - O
) - - O
, - - O
HbA1C - - O
, - - O
glucose - - O
, - - O
fibrinogen - - O
, - - O
factor - - O
VIII - - O
, - - O
antithrombin - - O
III - - O
, - - O
plasminogen - - O
activator - - O
inhibitor - - O
, - - O
tissue - - O
plasminogen - - O
activator - - O
and - - O
von - - O
Willebrand - - O
factor - - O
concentration - - O
, - - O
on - - O
bleeding - - O
time - - O
or - - O
on - - O
systolic - - O
or - - O
diastolic - - O
blood - - O
pressure - - O
. - - O

A - - O
multi-centre - - O
evaluation - - O
of - - O
the - - O
card - - O
indirect - - O
agglutination - - O
test - - O
for - - O
trypanosomiasis - - O
( - - O
TrypTect - - O
CIATT - - O
) - - O
. - - O

Indeed - - O
, - - O
A-MuLV - - O
pseudotyped - - O
with - - O
some - - O
viruses - - O
, - - O
such - - O
as - - O
the - - O
Moloney - - O
MuLV - - O
, - - O
has - - O
been - - O
shown - - O
to - - O
be - - O
highly - - O
lymphogenic - - O
, - - O
whereas - - O
A-MuLV - - O
pseudotyped - - O
with - - O
other - - O
viruses - - O
, - - O
such - - O
as - - O
the - - O
BALB - - O
c - - O
endogenous - - O
N-tropic - - O
MuLV - - O
, - - O
has - - O
been - - O
shown - - O
to - - O
be - - O
devoid - - O
of - - O
lymphogenic - - O
potential - - O
( - - O
N - - O
. - - O

Whole-mount - - O
in - - O
situ - - O
hybridization - - O
to - - O
early - - O
mouse - - O
embryos - - O
of - - O
9 - - O
. - - O
5-10 - - O
. - - O
5 - - O
days - - O
indicated - - O
a - - O
complex - - O
pattern - - O
of - - O
Arp1 - - O
expression - - O
spatially - - O
overlapping - - O
with - - O
the - - O
expression - - O
of - - O
All1 - - O
. - - O

Conjugated - - O
estrogens - - O
shorten - - O
bleeding - - O
time - - O
in - - O
uraemia - - O
: - - O
a - - O
possible - - O
role - - O
of - - O
serotonin - - O
? - - O

The - - O
subunit-a - - O
gene - - O
is - - O
preceded - - O
by - - O
a - - O
gene - - O
coding - - O
for - - O
a - - O
small - - O
hydrophobic - - O
protein - - O
, - - O
as - - O
has - - O
been - - O
observed - - O
previously - - O
in - - O
the - - O
atp - - O
operons - - O
in - - O
E - - O
. - - O
coli - - O
, - - O
bacterium - - O
PS3 - - O
and - - O
cyanobacteria - - O
. - - O

US-Doppler - - O
has - - O
recently - - O
gained - - O
attention - - O
as - - O
a - - O
noninvasive - - O
method - - O
for - - O
the - - O
functional - - O
evaluation - - O
of - - O
arteriovenous - - O
fistulas - - O
( - - O
FAV - - O
) - - O
. - - O

The - - O
physical - - O
and - - O
chemical - - O
stability - - O
of - - O
a - - O
combination - - O
of - - O
drugs - - O
commonly - - O
administered - - O
into - - O
the - - O
epidural - - O
or - - O
intrathecal - - O
space - - O
for - - O
the - - O
treatment - - O
of - - O
chronic - - O
pain - - O
was - - O
investigated - - O
. - - O

Are - - O
low - - O
P300 - - O
amplitudes - - O
a - - O
marker - - O
for - - O
schizophrenia - - O
. - - O

The - - O
human - - O
pathogenic - - O
bacterium - - O
group - - O
A - - O
Streptococcus - - O
produces - - O
an - - O
extracellular - - O
cysteine - - O
protease - - O
[ - - O
streptococcal - - O
pyrogenic - - O
exotoxin - - O
B - - O
( - - O
SpeB - - O
) - - O
] - - O
that - - O
is - - O
a - - O
critical - - O
virulence - - O
factor - - O
for - - O
invasive - - O
disease - - O
episodes - - O
. - - O

Restriction - - O
analysis - - O
and - - O
Southern - - O
hybridization - - O
revealed - - O
the - - O
presence - - O
of - - O
Tn5422 - - O
in - - O
all - - O
the - - O
plasmid-mediated - - O
cadmium-resistant - - O
L - - O
. - - O
monocytogenes - - O
strains - - O
tested - - O
but - - O
not - - O
in - - O
strains - - O
encoding - - O
cadmium - - O
resistance - - O
on - - O
the - - O
chromosome - - O
. - - O

Another - - O
full - - O
ORF - - O
was - - O
found - - O
on - - O
the - - O
opposite - - O
strand - - O
downstream - - O
from - - O
the - - O
nspC - - O
gene - - O
. - - O

These - - O
two - - O
mAbs - - O
used - - O
the - - O
same - - O
V - - O
( - - O
H - - O
) - - O
and - - O
J - - O
( - - O
H - - O
) - - O
gene - - O
segments - - O
, - - O
but - - O
different - - O
D - - O
, - - O
Vkappa - - O
, - - O
and - - O
Jkappa - - O
genes - - O
. - - O

Similarity - - O
is - - O
most - - O
striking - - O
in - - O
the - - O
zinc - - O
knuckle - - O
region - - O
, - - O
a - - O
region - - O
characteristic - - O
of - - O
gag - - O
genes - - O
of - - O
most - - O
replication-competent - - O
retroelements - - O
. - - O

The - - O
up-regulation - - O
of - - O
E-selectin - - O
, - - O
one - - O
of - - O
the - - O
adhesion - - O
molecules - - O
on - - O
the - - O
endothelium - - O
, - - O
is - - O
an - - O
important - - O
event - - O
in - - O
the - - O
mediation - - O
of - - O
the - - O
inflammatory - - O
response - - O
. - - O

IGF - - O
I - - O
and - - O
insulin - - O
receptors - - O
are - - O
homologous - - O
proteins - - O
that - - O
function - - O
in - - O
distinct - - O
physiological - - O
pathways - - O
. - - O

Side - - O
effect - - O
including - - O
subjective - - O
and - - O
objective - - O
symptoms - - O
were - - O
strictly - - O
evaluated - - O
in - - O
163 - - O
cases - - O
( - - O
KS-R1 - - O
group - - O
in - - O
83 - - O
cases - - O
, - - O
oral - - O
group - - O
in - - O
80 - - O
cases - - O
) - - O
, - - O
but - - O
the - - O
incidence - - O
rate - - O
which - - O
was - - O
22 - - O
. - - O
9% - - O
for - - O
the - - O
KS-R1 - - O
group - - O
and - - O
23 - - O
. - - O
8% - - O
for - - O
the - - O
oral - - O
group - - O
showed - - O
no - - O
significant - - O
difference - - O
. - - O

Increased - - O
plasma - - O
IgE - - O
was - - O
also - - O
confirmed - - O
in - - O
the - - O
NC - - O
mice - - O
, - - O
and - - O
treatment - - O
with - - O
FK506 - - O
ointment - - O
reduced - - O
the - - O
plasma - - O
IgE - - O
level - - O
. - - O

We - - O
found - - O
that - - O
the - - O
amplitude - - O
of - - O
the - - O
cortical - - O
evoked - - O
potentials - - O
( - - O
amplitude - - O
of - - O
the - - O
N2 - - O
P2 - - O
peak - - O
) - - O
increased - - O
from - - O
5 - - O
. - - O
1 - - O
+ - - O
- - - O
0 - - O
. - - O
7 - - O
microV - - O
at - - O
5 - - O
mA - - O
to - - O
16 - - O
. - - O
3 - - O
+ - - O
- - - O
1 - - O
. - - O
1 - - O
microV - - O
at - - O
20 - - O
mA - - O
. - - O

Disruption - - O
of - - O
RB - - O
E2F-1 - - O
interaction - - O
by - - O
single - - O
point - - O
mutations - - O
in - - O
E2F-1 - - O
enhances - - O
S-phase - - O
entry - - O
and - - O
apoptosis - - O
. - - O

Ventilatory - - O
management - - O
casebook - - O
. - - O

Plots - - O
of - - O
RV - - O
, - - O
LV - - O
+ - - O
S - - O
and - - O
2A - - O
weight - - O
vs - - O
real - - O
hematocrit - - O
showed - - O
sharp - - O
upward - - O
inflections - - O
at - - O
real - - O
hematocrit - - O
65% - - O
, - - O
suggesting - - O
a - - O
possible - - O
role - - O
of - - O
increased - - O
viscosity - - O
in - - O
CO - - O
cardiomegaly - - O
at - - O
the - - O
higher - - O
hematocrit - - O
. - - O

We - - O
conclude - - O
that - - O
DNA - - O
ploidy - - O
is - - O
a - - O
major - - O
objective - - O
prognostic - - O
factor - - O
and - - O
therapeutic - - O
determinant - - O
for - - O
endometrial - - O
carcinoma - - O
. - - O

When - - O
phosphorylation - - O
of - - O
exogenous - - O
peptide - - O
substrates - - O
was - - O
measured - - O
as - - O
a - - O
function - - O
of - - O
receptor - - O
self-phosphorylation - - O
, - - O
tyrosine - - O
kinase - - O
activity - - O
was - - O
found - - O
to - - O
be - - O
enhanced - - O
two - - O
to - - O
threefold - - O
at - - O
1-2 - - O
mol - - O
of - - O
phosphate - - O
per - - O
mol - - O
of - - O
receptor - - O
. - - O

It - - O
is - - O
exclusively - - O
observed - - O
in - - O
smooth - - O
muscle - - O
cells - - O
by - - O
Northern - - O
blotting - - O
and - - O
immunohistochemical - - O
analysis - - O
and - - O
therefore - - O
designated - - O
"smoothelin - - O
. - - O
" - - O
A - - O
human - - O
smooth - - O
muscle - - O
cDNA - - O
library - - O
was - - O
screened - - O
with - - O
the - - O
monoclonal - - O
antibody - - O
R4A - - O
, - - O
and - - O
a - - O
full-size - - O
cDNA - - O
of - - O
the - - O
protein - - O
was - - O
selected - - O
. - - O

The - - O
native - - O
enzyme - - O
purified - - O
from - - O
protease-B-deficient - - O
URA2-transformed - - O
cells - - O
, - - O
was - - O
phosphorylated - - O
in - - O
vitro - - O
using - - O
catalytic - - O
subunits - - O
of - - O
pure - - O
cAMP-dependent - - O
protein - - O
kinase - - O
. - - O

Sodium - - O
polystyrene - - O
sulfonate - - O
treatment - - O
for - - O
lithium - - O
toxicity - - O
: - - O
effects - - O
on - - O
serum - - O
potassium - - O
concentrations - - O
. - - O

BACKGROUND - - O
: - - O
We - - O
conducted - - O
a - - O
phase - - O
I - - O
study - - O
with - - O
MDL - - O
73 - - O
, - - O
147EF - - O
, - - O
a - - O
new - - O
5 - - O
hydroxytryptamine - - O
3 - - O
( - - O
5-HT3 - - O
) - - O
receptor - - O
antagonist - - O
, - - O
in - - O
25 - - O
patients - - O
requiring - - O
emetogenic - - O
chemotherapy - - O
. - - O

We - - O
examined - - O
Akt - - O
activation - - O
in - - O
Lyn- - - O
, - - O
Syk- - - O
and - - O
Btk-deficient - - O
DT40 - - O
cells - - O
and - - O
B - - O
cells - - O
from - - O
Lyn - - O
( - - O
- - - O
- - - O
) - - O
mice - - O
. - - O

Large - - O
strain - - O
differences - - O
were - - O
found - - O
for - - O
all - - O
variables - - O
recorded - - O
, - - O
i - - O
. - - O
e - - O
. - - O
, - - O
the - - O
proportion - - O
of - - O
attacking - - O
males - - O
, - - O
the - - O
time - - O
spent - - O
in - - O
the - - O
brightly - - O
lit - - O
box - - O
, - - O
and - - O
the - - O
number - - O
of - - O
transitions - - O
between - - O
the - - O
lit - - O
and - - O
the - - O
dark - - O
boxes - - O
. - - O

During - - O
ISO+AT - - O
infusion - - O
, - - O
abdominal - - O
fat - - O
blood - - O
flow - - O
was - - O
still - - O
significantly - - O
increased - - O
as - - O
compared - - O
with - - O
control - - O
values - - O
in - - O
lean - - O
and - - O
obese - - O
subjects - - O
. - - O

Twenty-two - - O
of - - O
the - - O
24 - - O
patients - - O
had - - O
a - - O
rise - - O
in - - O
the - - O
total - - O
serum - - O
amylase - - O
following - - O
ERCP - - O
. - - O

MCh - - O
infusion - - O
caused - - O
a - - O
concentration-dependent - - O
increase - - O
in - - O
airway - - O
resistance - - O
at - - O
constant - - O
QBA - - O
. - - O

We - - O
obtained - - O
the - - O
prevalence - - O
of - - O
IgG - - O
antibodies - - O
against - - O
Trypanosoma - - O
cruzi - - O
among - - O
1076 - - O
blood - - O
donors - - O
at - - O
the - - O
Instituto - - O
Nacional - - O
de - - O
Cardiologia - - O
"Ignacio - - O
Chavez" - - O
in - - O
Mexico - - O
City - - O
. - - O

In - - O
particular - - O
, - - O
the - - O
potential - - O
for - - O
prostate - - O
cancer - - O
chemoprevention - - O
using - - O
nonsteroidal - - O
anti-inflammatory - - O
drugs - - O
( - - O
cyclo-oxygenase - - O
inhibitors - - O
; - - O
NSAIDs - - O
) - - O
has - - O
received - - O
little - - O
attention - - O
. - - O

Both - - O
TRE-like - - O
elements - - O
were - - O
capable - - O
of - - O
binding - - O
AP1 - - O
. - - O

Anamnestic - - O
data - - O
were - - O
obtained - - O
from - - O
case - - O
history - - O
, - - O
smoking - - O
habits - - O
were - - O
not - - O
known - - O
in - - O
collective - - O
A - - O
and - - O
C - - O
. - - O

Using - - O
a - - O
conditional-lethal - - O
mutant - - O
allele - - O
of - - O
SUP45 - - O
( - - O
sup45-2 - - O
) - - O
and - - O
a - - O
combination - - O
of - - O
in - - O
vivo - - O
and - - O
in - - O
vitro - - O
approaches - - O
, - - O
we - - O
demonstrate - - O
that - - O
the - - O
product - - O
of - - O
the - - O
SUP45 - - O
gene - - O
( - - O
Sup45p - - O
or - - O
eRF1 - - O
) - - O
is - - O
a - - O
factor - - O
required - - O
for - - O
translation - - O
termination - - O
in - - O
yeast - - O
. - - O

Large - - O
differences - - O
between - - O
the - - O
groups - - O
were - - O
not - - O
observed - - O
in - - O
HA-synthesizing - - O
enzyme - - O
activity - - O
, - - O
but - - O
degradative - - O
enzyme - - O
activity - - O
was - - O
much - - O
higher - - O
in - - O
aspirin-induced - - O
asthma-related - - O
polyps - - O
than - - O
in - - O
other - - O
types - - O
of - - O
nasal - - O
polyps - - O
tested - - O
. - - O

The - - O
progression - - O
of - - O
non-A - - O
, - - O
non-B - - O
hepatitis - - O
to - - O
chronic - - O
diseases - - O
, - - O
and - - O
the - - O
transformation - - O
to - - O
hepatocellular - - O
carcinoma - - O
. - - O

This - - O
study - - O
investigated - - O
the - - O
degree - - O
to - - O
which - - O
racial - - O
identity - - O
influences - - O
Mexican-Americans' - - O
performance - - O
on - - O
the - - O
L - - O
, - - O
K - - O
, - - O
and - - O
MF - - O
scales - - O
of - - O
the - - O
MMPI-2 - - O
. - - O

The - - O
results - - O
show - - O
that - - O
both - - O
the - - O
amino - - O
and - - O
carboxy - - O
termini - - O
of - - O
the - - O
NS1 - - O
protein - - O
molecule - - O
and - - O
the - - O
cysteines - - O
at - - O
residues - - O
337 - - O
and - - O
340 - - O
are - - O
essential - - O
for - - O
tubule - - O
formation - - O
. - - O

Several - - O
cytokines - - O
exhibit - - O
a - - O
high - - O
degree - - O
of - - O
temporal - - O
regulation - - O
as - - O
well - - O
as - - O
somnogenic - - O
potency - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
interleukin-1 - - O
[ - - O
IL-1 - - O
] - - O
, - - O
tumor - - O
necrosis - - O
factor-alpha - - O
[ - - O
TNF-alpha - - O
] - - O
) - - O
. - - O

Effects - - O
of - - O
single - - O
and - - O
combined - - O
maltose - - O
tetrapalmitate - - O
immunotherapy - - O
, - - O
cyclophosphamide - - O
chemotherapy - - O
and - - O
radiotherapy - - O
on - - O
ethyl - - O
carbamate - - O
accelerated - - O
primary - - O
lung - - O
cancer - - O
in - - O
A - - O
J - - O
mice - - O
. - - O

The - - O
authors - - O
evaluate - - O
the - - O
clinical - - O
efficacy - - O
of - - O
EMB - - O
AZS - - O
in - - O
recurrent - - O
ulcer - - O
after - - O
operation - - O
on - - O
the - - O
stomach - - O
caused - - O
by - - O
a - - O
high - - O
level - - O
of - - O
acid - - O
production - - O
and - - O
ulcerative - - O
gastroduodenal - - O
bleeding - - O
. - - O

Vacuum - - O
Rabi - - O
splitting - - O
as - - O
a - - O
feature - - O
of - - O
linear-dispersion - - O
theory - - O
: - - O
Analysis - - O
and - - O
experimental - - O
observations - - O
. - - O

Successive - - O
abdominal - - O
scintillation - - O
with - - O
131-I-tagged - - O
BSP--description - - O
of - - O
the - - O
thyroid - - O
gland - - O
, - - O
kidney - - O
and - - O
spleen - - O
( - - O
comparison - - O
with - - O
131-I-RB - - O
) - - O
. - - O

The - - O
operation - - O
recommended - - O
is - - O
excision - - O
of - - O
3 - - O
mm - - O
of - - O
central - - O
slip - - O
followed - - O
by - - O
end-to-end - - O
repair - - O
of - - O
the - - O
tendon - - O
. - - O

The - - O
Scales - - O
of - - O
Cognitive - - O
Impairment - - O
Rated - - O
From - - O
Institutional - - O
Records - - O
( - - O
SCIRFIR - - O
) - - O
, - - O
a - - O
battery - - O
based - - O
on - - O
commonly - - O
used - - O
dementia - - O
rating - - O
instruments - - O
, - - O
was - - O
tested - - O
on - - O
the - - O
records - - O
of - - O
26 - - O
chronically - - O
institutionalized - - O
, - - O
elderly - - O
schizophrenia - - O
patients - - O
, - - O
for - - O
the - - O
purpose - - O
of - - O
retrospectively - - O
evaluating - - O
the - - O
long-term - - O
course - - O
of - - O
cognitive - - O
change - - O
in - - O
schizophrenia - - O
and - - O
relating - - O
it - - O
to - - O
available - - O
autopsy - - O
materials - - O
. - - O

We - - O
report - - O
an - - O
odd - - O
case - - O
of - - O
marked - - O
enlargement - - O
of - - O
suprapineal - - O
recess - - O
in - - O
a - - O
patient - - O
with - - O
triventricular - - O
hydrocephalus - - O
. - - O

Molecular - - O
cloning - - O
and - - O
characterization - - O
of - - O
OsPSK - - O
, - - O
a - - O
gene - - O
encoding - - O
a - - O
precursor - - O
for - - O
phytosulfokine-alpha - - O
, - - O
required - - O
for - - O
rice - - O
cell - - O
proliferation - - O
. - - O

Cross-talking - - O
among - - O
Drosophila - - O
nuclear - - O
receptors - - O
at - - O
the - - O
promiscuous - - O
response - - O
element - - O
of - - O
the - - O
ng-1 - - O
and - - O
ng-2 - - O
intermolt - - O
genes - - O
. - - O

The - - O
results - - O
of - - O
supershift - - O
analysis - - O
using - - O
specific - - O
antibodies - - O
against - - O
transcription - - O
factors - - O
suggested - - O
that - - O
both - - O
binding - - O
complexes - - O
contained - - O
the - - O
NF-kappaB - - O
components - - O
p50 - - O
and - - O
p65 - - O
, - - O
and - - O
did - - O
not - - O
contain - - O
other - - O
NF-kappaB - - O
proteins - - O
( - - O
p52 - - O
, - - O
c-Rel - - O
, - - O
Rel - - O
B - - O
) - - O
, - - O
AP-1 - - O
proteins - - O
( - - O
c-Fos - - O
, - - O
C-Jun - - O
) - - O
, - - O
CREB - - O
or - - O
C - - O
EBPbeta - - O
( - - O
NF-IL6 - - O
) - - O
. - - O

The - - O
COOH-terminal - - O
46 - - O
codons - - O
of - - O
slyD - - O
encode - - O
a - - O
remarkable - - O
histidine-rich - - O
peptide - - O
sequence - - O
which - - O
is - - O
at - - O
least - - O
partly - - O
dispensable - - O
for - - O
slyD - - O
function - - O
in - - O
E-mediated - - O
lysis - - O
. - - O

These - - O
results - - O
confirmed - - O
that - - O
cleavage - - O
of - - O
the - - O
leader - - O
peptide - - O
is - - O
the - - O
last - - O
step - - O
in - - O
nisin - - O
maturation - - O
and - - O
is - - O
necessary - - O
to - - O
generate - - O
a - - O
biologically - - O
active - - O
peptide - - O
. - - O

It - - O
is - - O
concluded - - O
that - - O
axillo-axillary - - O
by-pass - - O
is - - O
a - - O
simple - - O
solution - - O
for - - O
a - - O
complex - - O
haemodynamic - - O
, - - O
clinical - - O
and - - O
therapeutic - - O
problem - - O
. - - O

Under - - O
these - - O
conditions - - O
, - - O
transfections - - O
with - - O
cDNAs - - O
of - - O
the - - O
NF-kappa - - O
B - - O
p50 - - O
and - - O
serum - - O
response - - O
factor - - O
( - - O
SRF - - O
) - - O
produced - - O
a - - O
factor - - O
( - - O
s - - O
) - - O
that - - O
mediated - - O
Tax - - O
binding - - O
to - - O
the - - O
NF-kappa - - O
B - - O
site - - O
and - - O
the - - O
CArG - - O
box - - O
respectively - - O
. - - O

Here - - O
we - - O
report - - O
that - - O
Dbp5p - - O
and - - O
Rat7p - - O
interact - - O
through - - O
their - - O
Nterminal - - O
domains - - O
. - - O

Comparisons - - O
with - - O
the - - O
available - - O
amino - - O
acid - - O
residue - - O
( - - O
aa - - O
) - - O
sequence - - O
information - - O
from - - O
the - - O
complete - - O
CPMV - - O
RNA - - O
1 - - O
sequence - - O
and - - O
the - - O
partial - - O
sequence - - O
of - - O
red - - O
clover - - O
mottle - - O
virus - - O
RNA - - O
1 - - O
suggest - - O
that - - O
CPSMV - - O
RNA - - O
1 - - O
specifies - - O
the - - O
expected - - O
set - - O
of - - O
five - - O
mature - - O
proteins - - O
: - - O
32K - - O
proteinase - - O
cofactor - - O
, - - O
58K - - O
presumed - - O
helicase - - O
, - - O
VPg - - O
5'-linked - - O
protein - - O
of - - O
the - - O
genomic - - O
RNAs - - O
, - - O
24K - - O
proteinase - - O
, - - O
and - - O
87K - - O
presumed - - O
polymerase - - O
, - - O
separated - - O
by - - O
four - - O
cleavage - - O
sites - - O
. - - O

Reverse - - O
transcriptase-polymerase - - O
chain - - O
reaction - - O
assays - - O
showed - - O
that - - O
PKRDeltaE7 - - O
is - - O
expressed - - O
in - - O
a - - O
broad - - O
range - - O
of - - O
human - - O
tissues - - O
at - - O
variable - - O
levels - - O
. - - O

Two - - O
mammalian - - O
enzymes - - O
, - - O
the - - O
haem-controlled - - O
repressor - - O
( - - O
HCR - - O
) - - O
and - - O
the - - O
double-stranded - - O
RNA-activated - - O
inhibitor - - O
( - - O
dsI - - O
) - - O
, - - O
phosphorylate - - O
Ser-51 - - O
of - - O
the - - O
alpha - - O
subunit - - O
, - - O
thereby - - O
inhibiting - - O
the - - O
exchange - - O
of - - O
bound - - O
nucleotides - - O
on - - O
, - - O
and - - O
thus - - O
the - - O
recycling - - O
of - - O
, - - O
eIF-2 - - O
. - - O

The - - O
mean - - O
serum - - O
creatinine - - O
levels - - O
were - - O
similar - - O
at - - O
one - - O
year - - O
( - - O
SPK - - O
1 - - O
. - - O
8 - - O
, - - O
KTA - - O
1 - - O
. - - O
9 - - O
mg - - O
d - - O
) - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

Urinary - - O
excretion - - O
of - - O
oestrone - - O
, - - O
oestradiol-17 - - O
beta - - O
and - - O
oestriol - - O
in - - O
pregnancies - - O
complicated - - O
by - - O
steroid - - O
sulphatase - - O
deficiency - - O
. - - O

Although - - O
a - - O
great - - O
deal - - O
is - - O
understood - - O
about - - O
how - - O
bHLH - - O
factors - - O
activate - - O
gene - - O
transcription - - O
via - - O
E-box - - O
DNA - - O
consensus - - O
sequences - - O
, - - O
studies - - O
of - - O
bHLH - - O
factor - - O
function - - O
in - - O
higher - - O
eukaryotes - - O
often - - O
have - - O
been - - O
hindered - - O
by - - O
the - - O
presence - - O
of - - O
multiple - - O
family - - O
members - - O
. - - O

However - - O
these - - O
search - - O
engines - - O
respond - - O
with - - O
such - - O
cumbersome - - O
results - - O
that - - O
domain - - O
specific - - O
experts - - O
can - - O
not - - O
tolerate - - O
. - - O

Previous - - O
genetic - - O
studies - - O
led - - O
to - - O
the - - O
conclusion - - O
that - - O
nitrate - - O
and - - O
nitrite - - O
induction - - O
of - - O
nasF - - O
operon - - O
expression - - O
is - - O
determined - - O
by - - O
a - - O
transcriptional - - O
antitermination - - O
mechanism - - O
. - - O

According - - O
to - - O
symptoms - - O
, - - O
signs - - O
, - - O
imaging - - O
features - - O
, - - O
operation - - O
findings - - O
, - - O
the - - O
original - - O
places - - O
and - - O
the - - O
expansive - - O
directions - - O
of - - O
the - - O
tumor - - O
, - - O
they - - O
were - - O
divided - - O
into - - O
four - - O
clinical - - O
types - - O
: - - O
sellar - - O
, - - O
clival - - O
, - - O
occipito-temporal - - O
and - - O
extent - - O
. - - O

ID-PaGIA - - O
diphtheria - - O
toxin - - O
polymer - - O
particle - - O
diagnostic - - O
agent - - O
manufactured - - O
by - - O
DiaMed - - O
AG - - O
, - - O
Switzerland - - O
, - - O
was - - O
tried - - O
at - - O
bacteriological - - O
laboratory - - O
of - - O
Institute - - O
of - - O
Childhood - - O
Infections - - O
in - - O
St - - O
. - - O

The - - O
localization - - O
of - - O
ZAP-70 - - O
to - - O
the - - O
cell - - O
cortex - - O
is - - O
, - - O
therefore - - O
, - - O
regulated - - O
by - - O
the - - O
activity - - O
of - - O
SRC-family - - O
kinases - - O
, - - O
independently - - O
of - - O
their - - O
ability - - O
to - - O
phosphorylate - - O
immunoreceptor - - O
tyrosine-based - - O
activation - - O
motifs - - O
of - - O
the - - O
TCR - - O
. - - O

Revascularization - - O
after - - O
anterior - - O
maxillary - - O
and - - O
mandibular - - O
osteotomy - - O
. - - O

Short-course - - O
amphotericin - - O
B - - O
therapy - - O
for - - O
candidemia - - O
in - - O
pediatric - - O
patients - - O
. - - O

RESULTS - - O
: - - O
Fournier's - - O
gangrene - - O
occurs - - O
worldwide - - O
. - - O

Kindling - - O
of - - O
the - - O
primary - - O
visual - - O
cortex - - O
( - - O
VC - - O
) - - O
was - - O
compared - - O
with - - O
that - - O
of - - O
the - - O
amygdala - - O
in - - O
cats - - O
. - - O

To - - O
study - - O
the - - O
regulation - - O
of - - O
its - - O
expression - - O
, - - O
the - - O
human - - O
aldehyde - - O
reductase - - O
gene - - O
and - - O
promoter - - O
were - - O
cloned - - O
and - - O
characterized - - O
. - - O

Serodiagnosis - - O
of - - O
trypanosomiasis - - O
in - - O
dromedary - - O
camels - - O
using - - O
a - - O
card - - O
agglutination - - O
test - - O
set - - O
( - - O
Testryp - - O
CATT - - O
) - - O
. - - O

The - - O
impact - - O
of - - O
social - - O
support - - O
on - - O
the - - O
relationships - - O
of - - O
gay - - O
male - - O
couples - - O
is - - O
examined - - O
. - - O

RESULTS - - O
: - - O
The - - O
bilinear - - O
model - - O
provided - - O
a - - O
significantly - - O
better - - O
fit - - O
to - - O
the - - O
acuity - - O
outcome - - O
data - - O
. - - O

Atherosclerosis - - O
. - - O

Tobacco - - O
mosaic - - O
virus-infected - - O
tobacco - - O
( - - O
Nicotiana - - O
tabacum - - O
var - - O
. - - O

The - - O
long-term - - O
prediction - - O
is - - O
based - - O
on - - O
an - - O
algorithm - - O
for - - O
R-R - - O
interval - - O
estimation - - O
. - - O

Despite - - O
these - - O
limitations - - O
the - - O
CHIME - - O
monitor - - O
provides - - O
an - - O
opportunity - - O
to - - O
record - - O
physiological - - O
data - - O
previously - - O
unavailable - - O
in - - O
the - - O
home - - O
. - - O

Diffuse - - O
white - - O
matter - - O
injury - - O
can - - O
be - - O
attributed - - O
to - - O
radiation - - O
and - - O
associated - - O
with - - O
neurological - - O
deficits - - O
, - - O
but - - O
leukoencephalopathy - - O
is - - O
rarely - - O
observed - - O
in - - O
the - - O
absence - - O
of - - O
chemotherapy - - O
. - - O

The - - O
biology - - O
of - - O
Hyostrongylus - - O
ruidus - - O
. - - O

This - - O
observation - - O
cannot - - O
be - - O
explained - - O
by - - O
the - - O
scanning - - O
model - - O
for - - O
ribosomal - - O
initiation - - O
and - - O
suggests - - O
that - - O
ribosomes - - O
may - - O
be - - O
binding - - O
directly - - O
at - - O
an - - O
internal - - O
mRNA - - O
site - - O
at - - O
or - - O
near - - O
the - - O
initiator - - O
AUG - - O
codon - - O
for - - O
the - - O
C - - O
protein - - O
. - - O

Several - - O
new - - O
techniques - - O
are - - O
available - - O
for - - O
monitoring - - O
control - - O
of - - O
diabetes - - O
. - - O

Static - - O
and - - O
dynamic - - O
compliance - - O
was - - O
measured - - O
after - - O
induction - - O
of - - O
anesthesia - - O
, - - O
before - - O
and - - O
immediately - - O
after - - O
filtration - - O
in - - O
the - - O
operating - - O
theater - - O
, - - O
1 - - O
hour - - O
after - - O
return - - O
to - - O
the - - O
pediatric - - O
intensive - - O
care - - O
unit - - O
, - - O
and - - O
24 - - O
hours - - O
after - - O
the - - O
operation - - O
. - - O

Large - - O
ones - - O
were - - O
similar - - O
in - - O
size - - O
to - - O
the - - O
main - - O
lobe - - O
and - - O
small - - O
ones - - O
were - - O
approximately - - O
1 - - O
4 - - O
of - - O
the - - O
length - - O
of - - O
the - - O
main - - O
lobe - - O
. - - O

Two - - O
families - - O
with - - O
concordant - - O
inheritance - - O
of - - O
DNAH9 - - O
alleles - - O
in - - O
affected - - O
individuals - - O
were - - O
observed - - O
. - - O

Serum - - O
IgM - - O
and - - O
IgE - - O
concentrations - - O
, - - O
allergen-specific - - O
IgE - - O
scores - - O
, - - O
and - - O
the - - O
tumor - - O
E2R - - O
status - - O
were - - O
combined - - O
to - - O
construct - - O
a - - O
three-level - - O
risk - - O
classification - - O
that - - O
was - - O
more - - O
prognostic - - O
than - - O
any - - O
of - - O
the - - O
individual - - O
components - - O
. - - O

Hyperprolactinaemia - - O
, - - O
moderate - - O
hypogonadism - - O
, - - O
infraclinical - - O
neuropathies - - O
, - - O
arterial - - O
stenoses - - O
and - - O
moderate - - O
venous - - O
leakages - - O
seem - - O
to - - O
play - - O
a - - O
partial - - O
role - - O
of - - O
organic - - O
starter - - O
or - - O
cofactor - - O
, - - O
the - - O
sexual - - O
consequences - - O
of - - O
which - - O
are - - O
amplified - - O
by - - O
psychological - - O
factors - - O
, - - O
partly - - O
secondary - - O
to - - O
the - - O
initial - - O
sexual - - O
failures - - O
. - - O

The - - O
resurgence - - O
of - - O
drug-resistant - - O
malaria - - O
makes - - O
urgent - - O
the - - O
evaluation - - O
of - - O
new - - O
antimalarial - - O
agents - - O
. - - O

The - - O
spectrum - - O
of - - O
phenotypes - - O
caused - - O
by - - O
these - - O
mutations - - O
was - - O
strikingly - - O
different - - O
than - - O
mutations - - O
in - - O
the - - O
adaptor - - O
for - - O
the - - O
VP16 - - O
activation - - O
domain - - O
. - - O

CONCLUSIONS - - O
: - - O
Congenital - - O
horizontal - - O
tarsal - - O
kink - - O
is - - O
rare - - O
and - - O
its - - O
cause - - O
is - - O
unknown - - O
. - - O

The - - O
transforming - - O
gene - - O
of - - O
the - - O
avian - - O
sarcoma - - O
virus - - O
CT10 - - O
encodes - - O
a - - O
fusion - - O
protein - - O
( - - O
p47gag-crk - - O
or - - O
v-Crk - - O
) - - O
containing - - O
viral - - O
Gag - - O
sequences - - O
fused - - O
to - - O
cellular - - O
sequences - - O
consisting - - O
primarily - - O
of - - O
Src - - O
homology - - O
regions - - O
2 - - O
and - - O
3 - - O
( - - O
SH2 - - O
and - - O
SH3 - - O
sequences - - O
) - - O
. - - O

It - - O
is - - O
likely - - O
that - - O
other - - O
pathways - - O
involve - - O
alternate - - O
signal - - O
transduction - - O
events - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
calcium - - O
mobilization - - O
) - - O
and - - O
promoter - - O
response - - O
elements - - O
( - - O
e - - O
. - - O
g - - O
. - - O
, - - O
SRE - - O
) - - O
. - - O

Their - - O
studies - - O
have - - O
revealed - - O
a - - O
considerable - - O
increase - - O
of - - O
CSF - - O
AP - - O
activity - - O
in - - O
purulent - - O
meningitides - - O
whereas - - O
in - - O
serous - - O
meningitides - - O
it - - O
grows - - O
negligibly - - O
. - - O

The - - O
ORF3 - - O
probe - - O
also - - O
hybridized - - O
to - - O
a - - O
540 - - O
bp - - O
transcript - - O
consistent - - O
with - - O
the - - O
size - - O
of - - O
ORF3 - - O
alone - - O
and - - O
supportive - - O
of - - O
the - - O
mutagenesis - - O
data - - O
of - - O
non-linkage - - O
. - - O

In - - O
these - - O
cases - - O
, - - O
greatly - - O
increased - - O
human - - O
chorionic - - O
gonadotropin - - O
( - - O
hCG - - O
) - - O
levels - - O
and - - O
suppressed - - O
TSH - - O
levels - - O
suggest - - O
that - - O
hCG - - O
has - - O
thyrotropic - - O
activity - - O
. - - O

Disturbance - - O
of - - O
regeneration - - O
in - - O
the - - O
above - - O
pathological - - O
condition - - O
results - - O
from - - O
the - - O
damage - - O
to - - O
tunica - - O
propria - - O
and - - O
loss - - O
of - - O
its - - O
function - - O
for - - O
the - - O
support - - O
of - - O
structural - - O
homeostasis - - O
. - - O

However - - O
, - - O
a - - O
correlation - - O
was - - O
observed - - O
between - - O
SF - - O
levels - - O
of - - O
IL-8 - - O
with - - O
those - - O
of - - O
lactate - - O
, - - O
LDH - - O
, - - O
beta - - O
2-microglobulin - - O
and - - O
glucose - - O
. - - O

The - - O
recently - - O
developed - - O
gamma-interferon - - O
( - - O
IFN-gamma - - O
) - - O
assay - - O
system - - O
for - - O
the - - O
diagnosis - - O
of - - O
bovine - - O
tuberculosis - - O
in - - O
cattle - - O
has - - O
been - - O
accredited - - O
by - - O
the - - O
Standing - - O
Committee - - O
on - - O
Agriculture - - O
for - - O
use - - O
in - - O
Australia - - O
. - - O

Substrates - - O
for - - O
p210 - - O
( - - O
bcr-abl - - O
) - - O
are - - O
likely - - O
to - - O
be - - O
involved - - O
in - - O
the - - O
pathogenesis - - O
of - - O
CML - - O
. - - O

Comparison - - O
of - - O
cDNA - - O
sequences - - O
revealed - - O
that - - O
the - - O
two - - O
mRNA - - O
species - - O
arise - - O
as - - O
a - - O
result - - O
of - - O
alternate - - O
use - - O
of - - O
poly - - O
( - - O
A - - O
) - - O
-addition - - O
sites - - O
. - - O

Polyprotein - - O
processing - - O
in - - O
Southampton - - O
virus - - O
: - - O
identification - - O
of - - O
3C-like - - O
protease - - O
cleavage - - O
sites - - O
by - - O
in - - O
vitro - - O
mutagenesis - - O
. - - O

Assay - - O
of - - O
serum - - O
immunoreactive - - O
trypsin - - O
in - - O
dried - - O
blood - - O
spots - - O
and - - O
the - - O
early - - O
detection - - O
of - - O
cystic - - O
fibrosis - - O
. - - O

Reliability - - O
of - - O
cervical - - O
range - - O
of - - O
motion - - O
using - - O
the - - O
OSI - - O
CA - - O
6000 - - O
spine - - O
motion - - O
analyser - - O
on - - O
asymptomatic - - O
and - - O
symptomatic - - O
subjects - - O
. - - O

Implications - - O
of - - O
this - - O
observation - - O
for - - O
pediatrics - - O
are - - O
discussed - - O
. - - O

At - - O
some - - O
sites - - O
, - - O
%T - - O
is - - O
greatly - - O
increased - - O
by - - O
Cl- - - O
concentrations - - O
up - - O
to - - O
1 - - O
M - - O
, - - O
while - - O
at - - O
other - - O
sites - - O
%T - - O
is - - O
reduced - - O
or - - O
unaffected - - O
by - - O
these - - O
conditions - - O
. - - O

Northern - - O
blot - - O
analysis - - O
demonstrated - - O
the - - O
ubiquitous - - O
expression - - O
of - - O
2 - - O
. - - O
9 - - O
kb - - O
and - - O
3 - - O
. - - O

Objective - - O
responses - - O
also - - O
occurred - - O
in - - O
studies - - O
that - - O
explored - - O
sequential - - O
use - - O
of - - O
exemestane - - O
after - - O
failure - - O
of - - O
aminoglutethimide - - O
( - - O
26% - - O
with - - O
exemestane - - O
200 - - O
mg - - O
day - - O
) - - O
or - - O
other - - O
nonsteroidal - - O
aromatase - - O
inhibitors - - O
( - - O
6 - - O
. - - O
6% - - O
with - - O
exemestane - - O
25 - - O
mg - - O
day - - O
) - - O
. - - O

Thus - - O
, - - O
sgRNA2 - - O
has - - O
the - - O
3'TE - - O
in - - O
its - - O
5' - - O
UTR - - O
. - - O

Such - - O
a - - O
concept - - O
is - - O
crucial - - O
to - - O
our - - O
understanding - - O
of - - O
the - - O
pathology - - O
of - - O
ageing - - O
in - - O
general - - O
. - - O

After - - O
the - - O
application - - O
of - - O
RS - - O
86 - - O
, - - O
REM - - O
latency - - O
was - - O
shortened - - O
in - - O
all - - O
groups - - O
under - - O
investigation - - O
. - - O

Two - - O
additional - - O
cis-acting - - O
sequences - - O
, - - O
conserved - - O
in - - O
both - - O
the - - O
region - - O
1 - - O
and - - O
3 - - O
promoters - - O
, - - O
were - - O
identified - - O
, - - O
suggesting - - O
a - - O
role - - O
for - - O
these - - O
sequences - - O
in - - O
the - - O
coordinate - - O
regulation - - O
of - - O
transcription - - O
from - - O
these - - O
promoters - - O
. - - O

BRCA1 - - O
, - - O
a - - O
familial - - O
breast - - O
and - - O
ovarian - - O
cancer - - O
susceptibility - - O
gene - - O
encodes - - O
nuclear - - O
phosphoproteins - - O
that - - O
function - - O
as - - O
tumor - - O
suppressors - - O
in - - O
human - - O
breast - - O
cancer - - O
cells - - O
. - - O

A - - O
high - - O
efficacy - - O
of - - O
the - - O
combined - - O
use - - O
of - - O
nontoxic - - O
doses - - O
of - - O
two - - O
pharmaceuticals - - O
: - - O
cystamine - - O
( - - O
50 - - O
mg - - O
kg - - O
) - - O
and - - O
mexamine - - O
( - - O
25 - - O
mg - - O
kg - - O
) - - O
under - - O
the - - O
conditions - - O
of - - O
short-term - - O
exogenous - - O
hypoxia - - O
( - - O
7 - - O
. - - O
5% - - O
O2 - - O
) - - O
was - - O
found - - O
in - - O
( - - O
CBA - - O
X - - O
C57Bl - - O
) - - O
F1 - - O
mice - - O
. - - O

In - - O
contrast - - O
, - - O
both - - O
Sp1 - - O
and - - O
ETS - - O
proteins - - O
are - - O
required - - O
to - - O
bring - - O
about - - O
full - - O
promoter - - O
activity - - O
in - - O
the - - O
Surf-1 - - O
direction - - O
. - - O

The - - O
epidemic - - O
occurred - - O
in - - O
a - - O
group - - O
of - - O
26 - - O
community - - O
members - - O
( - - O
23 - - O
men - - O
and - - O
3 - - O
women - - O
, - - O
mean - - O
age - - O
, - - O
28 - - O
. - - O
9--3 - - O
years - - O
) - - O
living - - O
and - - O
working - - O
together - - O
, - - O
who - - O
underwent - - O
acute - - O
and - - O
convalescent - - O
serologic - - O
tests - - O
for - - O
Mycoplasma - - O
pneumoniae - - O
, - - O
Legionella - - O
pneumophila - - O
, - - O
cytomegalovirus - - O
, - - O
adenovirus - - O
, - - O
Coxiella - - O
burnetii - - O
, - - O
and - - O
Chlamydia - - O
pneumoniae - - O
. - - O

We - - O
found - - O
strand - - O
selective - - O
repair - - O
in - - O
DNA - - O
fragments - - O
within - - O
two - - O
active - - O
genes - - O
, - - O
DHFR - - O
and - - O
an - - O
unknown - - O
gene - - O
adjacent - - O
to - - O
DHFR - - O
. - - O

Six - - O
( - - O
four - - O
FAP - - O
; - - O
two - - O
primary - - O
amyloidosis - - O
) - - O
also - - O
had - - O
diffusely - - O
positive - - O
myocardial - - O
uptakes - - O
, - - O
but - - O
the - - O
intensity - - O
was - - O
less - - O
than - - O
that - - O
of - - O
the - - O
sternum - - O
. - - O

The - - O
minimum - - O
inhibitory - - O
concentrations - - O
( - - O
MICs - - O
) - - O
of - - O
ketoconazole - - O
, - - O
miconazole - - O
, - - O
itraconazole - - O
, - - O
fluconazole - - O
, - - O
and - - O
amphotericin - - O
B - - O
were - - O
significantly - - O
influenced - - O
by - - O
the - - O
inoculum - - O
size - - O
, - - O
regardless - - O
of - - O
the - - O
techniques - - O
used - - O
. - - O

The - - O
major - - O
phenotypes - - O
resulting - - O
from - - O
Fab1p - - O
kinase - - O
inactivation - - O
include - - O
temperature-sensitive - - O
growth - - O
, - - O
vacuolar - - O
acidification - - O
defects - - O
, - - O
and - - O
dramatic - - O
increases - - O
in - - O
vacuolar - - O
size - - O
. - - O

These - - O
results - - O
demonstrate - - O
Ras- - - O
and - - O
Raf-independent - - O
ERK - - O
MAPK - - O
activation - - O
maintains - - O
cell - - O
viability - - O
following - - O
heat - - O
shock - - O
. - - O

Initial - - O
control - - O
of - - O
bleeding - - O
is - - O
similar - - O
, - - O
but - - O
eradication - - O
is - - O
achieved - - O
in - - O
fewer - - O
sessions - - O
with - - O
EVL - - O
. - - O

Naloxone - - O
( - - O
2 - - O
mg - - O
kg - - O
bolus - - O
+ - - O
2 - - O
mg - - O
X - - O
kg-1 - - O
X - - O
h-1 - - O
) - - O
was - - O
given - - O
with - - O
one - - O
of - - O
the - - O
two - - O
doses - - O
of - - O
the - - O
lipopolysaccharide - - O
. - - O

Moreover - - O
, - - O
a - - O
complex - - O
containing - - O
PTP - - O
phi - - O
, - - O
paxillin - - O
, - - O
and - - O
a - - O
paxillin-associated - - O
tyrosine - - O
kinase - - O
, - - O
Pyk2 - - O
, - - O
can - - O
be - - O
immunoprecipitated - - O
from - - O
macrophage - - O
lysates - - O
, - - O
and - - O
the - - O
catalytic - - O
domain - - O
of - - O
PTP - - O
phi - - O
selectively - - O
binds - - O
paxillin - - O
and - - O
Pyk2 - - O
in - - O
vitro - - O
. - - O

Action - - O
of - - O
strontium-90 - - O
and - - O
metaphos - - O
on - - O
Cyprinus - - O
carpio - - O
. - - O

In - - O
the - - O
pRb - - O
( - - O
- - - O
) - - O
SAOS-2 - - O
cell - - O
line - - O
transiently - - O
transfected - - O
with - - O
a - - O
reporter - - O
plasmid - - O
containing - - O
six - - O
tal-1 - - O
binding - - O
site - - O
, - - O
pRb - - O
enhances - - O
the - - O
transcriptional - - O
activity - - O
of - - O
tal-1-E12-Lmo2 - - O
and - - O
tal-1-E12-Lmo2-Ldb1 - - O
complexes - - O
but - - O
not - - O
that - - O
of - - O
a - - O
tal-1-E12 - - O
heterodimer - - O
. - - O

The - - O
flux - - O
rates - - O
of - - O
p-toluidine - - O
decreased - - O
as - - O
the - - O
pH - - O
value - - O
in - - O
the - - O
donor - - O
solution - - O
increased - - O
. - - O

Using - - O
immunochemical - - O
co-precipitation - - O
methods - - O
, - - O
we - - O
also - - O
found - - O
that - - O
the - - O
two - - O
proteins - - O
are - - O
bound - - O
in - - O
vivo - - O
. - - O

Transcription - - O
start - - O
site - - O
mapping - - O
identified - - O
the - - O
presence - - O
of - - O
an - - O
aphidicolin-sensitive - - O
late - - O
transcript - - O
arising - - O
from - - O
a - - O
TAAG - - O
motif - - O
located - - O
at - - O
-352 - - O
nucleotides - - O
and - - O
an - - O
aphidicolin-insensitive - - O
early - - O
transcript - - O
originating - - O
from - - O
a - - O
TTGT - - O
motif - - O
located - - O
35 - - O
nucleotides - - O
downstream - - O
to - - O
a - - O
TATA - - O
box - - O
at - - O
-312 - - O
nucleotides - - O
, - - O
with - - O
respect - - O
to - - O
the - - O
+1 - - O
ATG - - O
of - - O
lef2 - - O
. - - O

Anesthesiologists - - O
often - - O
use - - O
more - - O
than - - O
one - - O
drug - - O
in - - O
a - - O
patient - - O
to - - O
achieve - - O
a - - O
target - - O
response - - O
, - - O
such - - O
as - - O
a - - O
desired - - O
blood - - O
pressure - - O
. - - O

Aneurysmectomy - - O
and - - O
the - - O
performance - - O
of - - O
CABG - - O
were - - O
not - - O
significantly - - O
associated - - O
with - - O
postoperative - - O
ECG - - O
changes - - O
, - - O
but - - O
more - - O
bypass - - O
grafts - - O
per - - O
patient - - O
grafted - - O
appeared - - O
in - - O
the - - O
group - - O
with - - O
postoperative - - O
ECG - - O
changes - - O
, - - O
suggesting - - O
that - - O
coronary - - O
artery - - O
disease - - O
may - - O
be - - O
more - - O
severe - - O
in - - O
that - - O
group - - O
. - - O

The - - O
average - - O
values - - O
were - - O
199 - - O
and - - O
424 - - O
revertants - - O
g - - O
for - - O
the - - O
hamburgers - - O
and - - O
hot - - O
dogs - - O
, - - O
respectively - - O
. - - O

Of - - O
208 - - O
eligible - - O
subjects - - O
, - - O
82 - - O
received - - O
supervised - - O
IPT - - O
at - - O
a - - O
dose - - O
of - - O
900 - - O
mg - - O
twice - - O
weekly - - O
for - - O
6 - - O
mo - - O
( - - O
Regimen - - O
A - - O
) - - O
, - - O
73 - - O
received - - O
unsupervised - - O
IPT - - O
900 - - O
mg - - O
twice - - O
weekly - - O
for - - O
6 - - O
mo - - O
( - - O
Regimen - - O
B - - O
) - - O
, - - O
and - - O
53 - - O
received - - O
unsupervised - - O
IPT - - O
300 - - O
mg - - O
daily - - O
for - - O
6 - - O
mo - - O
( - - O
Regimen - - O
C - - O
) - - O
. - - O

We - - O
demonstrate - - O
that - - O
a - - O
VT+ - - O
peptide - - O
was - - O
specifically - - O
phosphorylated - - O
by - - O
protein - - O
kinase - - O
C - - O
( - - O
PKC - - O
) - - O
in - - O
vitro - - O
, - - O
but - - O
not - - O
by - - O
protein - - O
kinase - - O
A - - O
( - - O
PKA - - O
) - - O
. - - O

Plasma - - O
and - - O
erthrocyte - - O
lipid - - O
profile - - O
and - - O
lipoprotein - - O
lipase - - O
activity - - O
in - - O
postheparin - - O
plasma - - O
on - - O
vasectomized - - O
rabbits - - O
were - - O
studied - - O
and - - O
also - - O
the - - O
incidence - - O
of - - O
atherosclerosis - - O
in - - O
different - - O
arterial - - O
beds - - O
. - - O

Treatment - - O
of - - O
meat - - O
muscle - - O
800 - - O
V - - O
for - - O
45 - - O
s - - O
reduced - - O
weeping - - O
but - - O
increased - - O
slightly - - O
the - - O
rate - - O
of - - O
autoxidation - - O
of - - O
lipids - - O
. - - O

The - - O
single-stranded - - O
DNA - - O
Pur - - O
alpha - - O
recognition - - O
element - - O
disrupts - - O
these - - O
complexes - - O
. - - O

Our - - O
data - - O
provide - - O
a - - O
biochemical - - O
explanation - - O
for - - O
the - - O
similarity - - O
in - - O
phenotype - - O
between - - O
A-T - - O
and - - O
NBS - - O
. - - O

The - - O
role - - O
of - - O
calcitonin - - O
, - - O
and - - O
other - - O
agonists - - O
which - - O
activate - - O
the - - O
cAMP - - O
pathway - - O
, - - O
in - - O
regulating - - O
transcription - - O
of - - O
the - - O
human - - O
parathyroid - - O
hormone-related - - O
protein - - O
( - - O
PTHrP - - O
) - - O
gene - - O
was - - O
investigated - - O
in - - O
a - - O
human - - O
lung - - O
cancer - - O
cell - - O
line - - O
( - - O
BEN - - O
) - - O
. - - O

The - - O
extended - - O
rat - - O
SP-A - - O
isoforms - - O
were - - O
enriched - - O
in - - O
the - - O
more - - O
fully - - O
glycosylated - - O
and - - O
multimeric - - O
SP-A - - O
species - - O
separated - - O
on - - O
SDS-PAGE - - O
gels - - O
. - - O

PATIENTS - - O
AND - - O
METHODS - - O
: - - O
We - - O
report - - O
our - - O
experience - - O
with - - O
seven - - O
children - - O
with - - O
active - - O
small - - O
bowel - - O
Crohn's - - O
disease - - O
given - - O
a - - O
casein-based - - O
, - - O
polymeric - - O
feed - - O
rich - - O
in - - O
TGF-beta - - O
2 - - O
( - - O
Specific - - O
Polymeric - - O
Diet - - O
; - - O
Nestle-Clintec - - O
; - - O
Vevey - - O
, - - O
Switzerland - - O
) - - O
as - - O
complete - - O
nutrition - - O
for - - O
8 - - O
weeks - - O
. - - O

The - - O
action - - O
of - - O
nef - - O
was - - O
specific - - O
to - - O
the - - O
LTR - - O
, - - O
as - - O
expression - - O
of - - O
nef - - O
had - - O
no - - O
effect - - O
on - - O
the - - O
activity - - O
of - - O
the - - O
simian - - O
virus - - O
40 - - O
, - - O
c-fms - - O
, - - O
urokinase - - O
plasminogen - - O
activator - - O
, - - O
or - - O
type - - O
5 - - O
acid - - O
phosphatase - - O
promoter - - O
. - - O
trans-activating - - O
activity - - O
was - - O
also - - O
manifested - - O
by - - O
a - - O
frameshift - - O
mutant - - O
expressing - - O
only - - O
the - - O
first - - O
35 - - O
amino - - O
acids - - O
of - - O
the - - O
protein - - O
. - - O

Kf - - O
, - - O
c - - O
and - - O
CT - - O
( - - O
referenced - - O
to - - O
the - - O
initial - - O
lung - - O
mass - - O
) - - O
decreased - - O
linearly - - O
with - - O
reductions - - O
in - - O
lung - - O
mass - - O
% - - O
delta - - O
Kf - - O
, - - O
c - - O
= - - O
1 - - O
. - - O
26-0 - - O
. - - O
98% - - O
mass - - O
removed - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
90 - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
and - - O
% - - O
delta - - O
CT - - O
= - - O
-3 - - O
. - - O
99-0 - - O
. - - O
98% - - O
mass - - O
removed - - O
( - - O
r - - O
= - - O
0 - - O
. - - O
82 - - O
, - - O
P - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
relationships - - O
that - - O
were - - O
not - - O
altered - - O
by - - O
blocker - - O
pretreatment - - O
. - - O
( - - O
ABSTRACT - - O
TRUNCATED - - O
AT - - O
250 - - O
WORDS - - O
) - - O

During - - O
1985 - - O
, - - O
1990 - - O
, - - O
and - - O
1995 - - O
, - - O
respectively - - O
, - - O
11 - - O
. - - O
7 - - O
, - - O
11 - - O
. - - O
3 - - O
, - - O
and - - O
11 - - O
. - - O
4 - - O
infants - - O
per - - O
100 - - O
, - - O
000 - - O
live - - O
births - - O
had - - O
a - - O
diagnosis - - O
of - - O
HSV - - O
( - - O
P - - O
= - - O
. - - O
98 - - O
) - - O
. - - O

The - - O
Wilms' - - O
tumour - - O
suppressor - - O
protein - - O
( - - O
WT1 - - O
) - - O
is - - O
a - - O
putative - - O
transcriptional - - O
regulatory - - O
protein - - O
with - - O
four - - O
zinc - - O
fingers - - O
, - - O
the - - O
last - - O
three - - O
of - - O
which - - O
have - - O
extensive - - O
sequence - - O
homology - - O
to - - O
the - - O
early - - O
growth - - O
response-1 - - O
( - - O
EGR-1 - - O
) - - O
protein - - O
. - - O

This - - O
study - - O
demonstrates - - O
secretion - - O
of - - O
bicarbonate - - O
by - - O
the - - O
human - - O
stomach - - O
in - - O
vivo - - O
at - - O
a - - O
rate - - O
equivalent - - O
to - - O
10--20% - - O
of - - O
basal - - O
acid - - O
secretion - - O
. - - O

Commonly - - O
observed - - O
systemic - - O
toxic - - O
effects - - O
( - - O
bone - - O
marrow - - O
, - - O
gastrointestinal - - O
tract - - O
, - - O
and - - O
heart - - O
) - - O
were - - O
not - - O
seen - - O
in - - O
this - - O
study - - O
. - - O

Correlating - - O
with - - O
the - - O
previous - - O
observation - - O
that - - O
CBF - - O
binding - - O
to - - O
the - - O
78C1 - - O
site - - O
is - - O
enhanced - - O
by - - O
EGTA - - O
and - - O
EDTA - - O
, - - O
these - - O
divalent - - O
cation - - O
chelators - - O
specifically - - O
stimulate - - O
78C1-directed - - O
transcription - - O
. - - O

At - - O
pH - - O
6 - - O
. - - O
9 - - O
, - - O
the - - O
same - - O
lidocaine - - O
concentrations - - O
significantly - - O
reduced - - O
resting - - O
potential - - O
( - - O
3-10% - - O
) - - O
, - - O
action - - O
potential - - O
amplitude - - O
( - - O
3-8% - - O
) - - O
and - - O
Vmax - - O
( - - O
14-22% - - O
) - - O
. - - O

The - - O
methylation - - O
of - - O
nuclear - - O
and - - O
chloroplast - - O
DNAs - - O
has - - O
been - - O
examined - - O
in - - O
relation - - O
to - - O
the - - O
known - - O
differential - - O
expression - - O
of - - O
C4 - - O
photosynthesis - - O
genes - - O
in - - O
the - - O
bundle - - O
sheath - - O
and - - O
mesophyll - - O
cells - - O
of - - O
etiolated - - O
, - - O
greening - - O
, - - O
and - - O
fully - - O
green - - O
maize - - O
leaves - - O
. - - O

Marinol - - O
marijuana - - O
usage - - O
was - - O
associated - - O
with - - O
depressed - - O
CD4+ - - O
counts - - O
and - - O
elevated - - O
amylase - - O
levels - - O
within - - O
the - - O
DDI - - O
subgroup - - O
. - - O

Two - - O
Pax2 - - O
5 - - O
8-binding - - O
sites - - O
in - - O
Engrailed2 - - O
are - - O
required - - O
for - - O
proper - - O
initiation - - O
of - - O
endogenous - - O
mid-hindbrain - - O
expression - - O
. - - O

The - - O
SH3 - - O
domains - - O
of - - O
Grb2 - - O
bound - - O
in - - O
vitro - - O
to - - O
specific - - O
proline-rich - - O
motifs - - O
in - - O
the - - O
HPK1 - - O
tail - - O
and - - O
functioned - - O
synergistically - - O
to - - O
direct - - O
the - - O
stable - - O
binding - - O
of - - O
Grb2 - - O
to - - O
HPK1 - - O
in - - O
transfected - - O
Cos1 - - O
cells - - O
. - - O

An - - O
approximately - - O
37-kDa - - O
cytoplasmic - - O
protein - - O
is - - O
rapidly - - O
tyrosine-phosphorylated - - O
in - - O
the - - O
response - - O
of - - O
mouse - - O
BAC1 - - O
. - - O
2F5 - - O
macrophages - - O
to - - O
colony - - O
stimulating - - O
factor-1 - - O
( - - O
CSF-1 - - O
) - - O
. - - O
pp37 - - O
was - - O
purified - - O
from - - O
the - - O
cytosolic - - O
fraction - - O
by - - O
anti-Tyr - - O
( - - O
P - - O
) - - O
affinity - - O
chromatography - - O
, - - O
size - - O
exclusion - - O
chromatography - - O
, - - O
and - - O
C4 - - O
reverse - - O
phase - - O
high - - O
pressure - - O
liquid - - O
chromatography - - O
. - - O

The - - O
immunophilin - - O
, - - O
which - - O
can - - O
be - - O
of - - O
the - - O
FK506- - - O
or - - O
cyclosporin - - O
A-binding - - O
class - - O
, - - O
binds - - O
to - - O
hsp90 - - O
via - - O
its - - O
tetratricopeptide - - O
repeat - - O
( - - O
TPR - - O
) - - O
domain - - O
, - - O
and - - O
different - - O
receptor - - O
heterocomplexes - - O
exist - - O
depending - - O
upon - - O
which - - O
immunophilin - - O
occupies - - O
the - - O
TPR-binding - - O
region - - O
of - - O
hsp90 - - O
. - - O

Cocaine-treated - - O
rats - - O
acquired - - O
a - - O
preference - - O
for - - O
cocaine-associated - - O
contextual - - O
stimuli - - O
( - - O
CS - - O
) - - O
relative - - O
to - - O
saline-injected - - O
control - - O
rats - - O
. - - O

Primer - - O
extension - - O
and - - O
S1 - - O
nuclease - - O
mapping - - O
experiments - - O
were - - O
used - - O
to - - O
locate - - O
the - - O
transcription - - O
initiation - - O
site - - O
of - - O
Nramp1 - - O
and - - O
revealed - - O
the - - O
presence - - O
of - - O
one - - O
major - - O
and - - O
several - - O
minor - - O
initiation - - O
sites - - O
. - - O

Feeding - - O
behavior - - O
, - - O
circannual - - O
body - - O
weight - - O
and - - O
hibernation - - O
rhythms - - O
in - - O
European - - O
hamsters - - O
lesioned - - O
in - - O
the - - O
noradrenergic - - O
ascending - - O
bundles - - O
. - - O

Double-blind - - O
, - - O
placebo-controlled - - O
trial - - O
. - - O

We - - O
have - - O
identified - - O
two - - O
overlapping - - O
expressed - - O
sequence - - O
tag - - O
clones - - O
, - - O
which - - O
contain - - O
the - - O
missing - - O
4 - - O
. - - O
4-kb - - O
3'-UTR - - O
of - - O
the - - O
human - - O
D2 - - O
( - - O
hD2 - - O
) - - O
cDNA - - O
. - - O

Eight - - O
induced - - O
cDNA - - O
sequences - - O
were - - O
identified - - O
and - - O
designated - - O
message - - O
up-regulated - - O
during - - O
death - - O
( - - O
mud - - O
) - - O
-1-8 - - O
. - - O

Several - - O
highly - - O
conserved - - O
regions - - O
were - - O
identified - - O
at - - O
the - - O
near - - O
N - - O
terminus - - O
, - - O
middle - - O
and - - O
C - - O
terminus - - O
. - - O

S - - O
. - - O
, - - O
K - - O
. - - O

Aryl - - O
hydrocarbon - - O
receptor - - O
nuclear - - O
translocator - - O
( - - O
ARNT - - O
) - - O
is - - O
a - - O
component - - O
of - - O
the - - O
transcription - - O
factors - - O
, - - O
aryl - - O
hydrocarbon - - O
receptor - - O
( - - O
AhR - - O
) - - O
and - - O
hypoxia-inducible - - O
factor - - O
1 - - O
, - - O
which - - O
transactivate - - O
their - - O
target - - O
genes - - O
, - - O
such - - O
as - - O
CYP1A1 - - O
and - - O
erythropoietin - - O
, - - O
in - - O
response - - O
to - - O
xenobiotic - - O
aromatic - - O
hydrocarbons - - O
and - - O
to - - O
low - - O
O2 - - O
concentration - - O
, - - O
respectively - - O
. - - O

Deletion - - O
and - - O
mutational - - O
analyses - - O
revealed - - O
two - - O
positive - - O
cis-regulatory - - O
elements - - O
in - - O
this - - O
region - - O
that - - O
are - - O
essential - - O
for - - O
CSX1 - - O
expression - - O
in - - O
cardiomyocytes - - O
. - - O

This - - O
mechanism - - O
is - - O
in - - O
contrast - - O
to - - O
other - - O
cases - - O
of - - O
splicing - - O
regulation - - O
by - - O
PTB - - O
, - - O
in - - O
which - - O
the - - O
protein - - O
represses - - O
the - - O
splice - - O
site - - O
to - - O
which - - O
it - - O
binds - - O
. - - O

Time - - O
shifts - - O
increase - - O
growth - - O
hormone - - O
release - - O
. - - O

The - - O
pharmacological - - O
effects - - O
of - - O
the - - O
novel - - O
compound - - O
WEB - - O
1881 - - O
FU - - O
( - - O
4-amino-methyl-1-benzyl-pyrrolidine-2-one-fumarate - - O
) - - O
were - - O
investigated - - O
. - - O

Phenazone - - O
potentiates - - O
the - - O
local - - O
anaesthetic - - O
effect - - O
of - - O
lidocaine - - O
in - - O
mice - - O
. - - O

Salzburg - - O
, - - O
9-12 - - O
September - - O
1987 - - O
. - - O

There - - O
was - - O
a - - O
trend - - O
in - - O
all - - O
studies - - O
favouring - - O
PVI - - O
. - - O

Estimation - - O
of - - O
L-alanine - - O
in - - O
serum - - O
or - - O
plasma - - O
using - - O
the - - O
LKB - - O
reaction - - O
rate - - O
analyser - - O
. - - O

We - - O
have - - O
carried - - O
out - - O
a - - O
comprehensive - - O
and - - O
systematic - - O
mutagenesis - - O
of - - O
the - - O
Cse4p - - O
N - - O
terminus - - O
to - - O
analyze - - O
its - - O
function - - O
. - - O

On - - O
the - - O
diagnosis - - O
of - - O
bovine - - O
leucosis - - O
and - - O
its - - O
control - - O
in - - O
southern - - O
Lower - - O
Saxony - - O
. - - O

HL-A - - O
antibodies - - O
in - - O
polytransfused - - O
patients - - O
. - - O

Analysis - - O
of - - O
cell - - O
cycle - - O
regulation - - O
in - - O
the - - O
budding - - O
yeast - - O
Saccharomyces - - O
cerevisiae - - O
has - - O
shown - - O
that - - O
a - - O
central - - O
regulatory - - O
protein - - O
kinase - - O
, - - O
Cdc28 - - O
, - - O
undergoes - - O
changes - - O
in - - O
activity - - O
through - - O
the - - O
cell - - O
cycle - - O
by - - O
associating - - O
with - - O
distinct - - O
groups - - O
of - - O
cyclins - - O
that - - O
accumulate - - O
at - - O
different - - O
times - - O
. - - O

Ischaemia - - O
was - - O
induced - - O
by - - O
a - - O
low - - O
flow - - O
rate - - O
of - - O
0 - - O
. - - O
8 - - O
mL - - O
min-1 - - O
for - - O
30 - - O
min - - O
, - - O
and - - O
was - - O
followed - - O
by - - O
a - - O
40-minute - - O
reperfusion - - O
. - - O

They - - O
also - - O
indicate - - O
that - - O
direct - - O
interactions - - O
between - - O
C - - O
EBPs - - O
and - - O
specific - - O
Ets - - O
family - - O
members - - O
, - - O
together - - O
with - - O
GATA-1 - - O
, - - O
are - - O
important - - O
for - - O
eosinophil - - O
lineage - - O
determination - - O
. - - O

To - - O
understand - - O
the - - O
molecular - - O
regulation - - O
of - - O
these - - O
genes - - O
in - - O
thyroid - - O
cells - - O
, - - O
the - - O
effect - - O
of - - O
thyroid - - O
transcription - - O
factor - - O
1 - - O
( - - O
TTF-1 - - O
) - - O
and - - O
the - - O
paired - - O
domain-containing - - O
protein - - O
8 - - O
( - - O
Pax-8 - - O
) - - O
on - - O
the - - O
transcriptional - - O
activity - - O
of - - O
the - - O
deiodinase - - O
promoters - - O
were - - O
studied - - O
. - - O

To - - O
begin - - O
to - - O
understand - - O
this - - O
role - - O
, - - O
we - - O
overexpressed - - O
ATF-2 - - O
in - - O
a - - O
human - - O
cancer - - O
cell - - O
line - - O
. - - O

CD - - O
was - - O
determined - - O
using - - O
the - - O
Farnsworth - - O
D-15 - - O
method - - O
. - - O

During - - O
insulin - - O
infusion - - O
, - - O
a - - O
20% - - O
dextrose - - O
solution - - O
was - - O
infused - - O
by - - O
a - - O
Biostator - - O
in - - O
order - - O
to - - O
maintain - - O
the - - O
patient's - - O
glycemia - - O
at - - O
90 - - O
mg - - O
dl - - O
. - - O

An - - O
approximately - - O
2-kilobase - - O
B2 - - O
transcript - - O
was - - O
expressed - - O
in - - O
all - - O
alfalfa - - O
organs - - O
tested - - O
. - - O

Doxorubicin - - O
, - - O
dacarbazine - - O
, - - O
vincristine - - O
, - - O
and - - O
cyclophosphamide - - O
in - - O
the - - O
treatment - - O
of - - O
advanced - - O
gastrointestinal - - O
leiomyosarcoma - - O
. - - O

A - - O
cohort - - O
of - - O
Swedish - - O
children - - O
was - - O
monitored - - O
from - - O
6 - - O
months - - O
to - - O
11 - - O
years - - O
of - - O
age - - O
. - - O

We - - O
provide - - O
community - - O
metabolic - - O
data - - O
that - - O
indicate - - O
that - - O
large - - O
changes - - O
in - - O
CO2 - - O
concentration - - O
can - - O
occur - - O
in - - O
coral - - O
reef - - O
waters - - O
via - - O
biogeochemical - - O
processes - - O
not - - O
directly - - O
associated - - O
with - - O
photosynthesis - - O
, - - O
respiration - - O
, - - O
calcification - - O
, - - O
and - - O
CaCO3 - - O
dissolution - - O
. - - O

Effect - - O
of - - O
aging - - O
on - - O
respiratory - - O
skeletal - - O
muscles - - O
. - - O

Mutational - - O
analysis - - O
of - - O
yeast - - O
CEG1 - - O
demonstrated - - O
that - - O
four - - O
of - - O
the - - O
five - - O
conserved - - O
motifs - - O
are - - O
essential - - O
for - - O
capping - - O
enzyme - - O
function - - O
in - - O
vivo - - O
. - - O

Chronic - - O
hypophosphatemia - - O
is - - O
the - - O
most - - O
common - - O
type - - O
of - - O
"resistant" - - O
rickets - - O
. - - O

Abbreviations - - O
: - - O
CAS - - O
, - - O
CRK-associated - - O
substrate - - O
; - - O
CH - - O
, - - O
calponin-homology - - O
domain - - O
; - - O
CSK - - O
, - - O
C-terminal - - O
SRC - - O
kinase - - O
; - - O
E6 - - O
, - - O
Papillomavirus - - O
E6 - - O
protein - - O
; - - O
FAK - - O
, - - O
focal - - O
adhesion - - O
kinase - - O
; - - O
GIT - - O
, - - O
GRK - - O
interacter - - O
; - - O
GPCR - - O
, - - O
heterotrimeric-G-protein-coupled - - O
receptor - - O
; - - O
GRK - - O
, - - O
G-protein-coupled-receptor - - O
kinase - - O
; - - O
MAPK - - O
, - - O
mitogen-activated - - O
protein - - O
kinase - - O
( - - O
ERK - - O
, - - O
p38 - - O
, - - O
JNK - - O
) - - O
; - - O
PAK - - O
, - - O
p21-activated - - O
kinase - - O
; - - O
PBS - - O
, - - O
paxillin-binding - - O
subdomain - - O
; - - O
PIX - - O
, - - O
PAK-interacting - - O
exchange - - O
factor - - O
; - - O
PKL - - O
, - - O
paxillin - - O
kinase - - O
linker - - O
; - - O
POR1 - - O
, - - O
partner - - O
of - - O
Rac - - O
; - - O
PS - - O
, - - O
phosphoserine - - O
; - - O
PT - - O
, - - O
phosphothreonine - - O
; - - O
PY - - O
, - - O
phosphotyrosine - - O
; - - O
RTK - - O
, - - O
growth - - O
factor - - O
receptor - - O
tyrosine - - O
kinase - - O
; - - O
SH - - O
, - - O
SRC-homology - - O
domain - - O
. - - O

We - - O
have - - O
identified - - O
SWI5's - - O
nuclear - - O
localization - - O
signal - - O
( - - O
NLS - - O
) - - O
and - - O
show - - O
that - - O
it - - O
can - - O
confer - - O
cell - - O
cycle-dependent - - O
nuclear - - O
entry - - O
to - - O
a - - O
heterologous - - O
protein - - O
. - - O

We - - O
found - - O
that - - O
PML - - O
was - - O
expressed - - O
at - - O
a - - O
lower - - O
level - - O
in - - O
S - - O
, - - O
G2 - - O
, - - O
and - - O
M - - O
phases - - O
and - - O
at - - O
a - - O
significantly - - O
higher - - O
level - - O
in - - O
G1 - - O
phase - - O
. - - O

Electroglottography - - O
is - - O
a - - O
useful - - O
, - - O
non-invasive - - O
technique - - O
that - - O
can - - O
assist - - O
in - - O
the - - O
assessment - - O
of - - O
vocal - - O
fold - - O
dysfunction - - O
. - - O

The - - O
three-dimensional - - O
structure - - O
of - - O
RT - - O
shows - - O
that - - O
it - - O
is - - O
a - - O
strikingly - - O
asymmetric - - O
heterodimer - - O
consisting - - O
of - - O
two - - O
differently - - O
folded - - O
subunits - - O
( - - O
molecular - - O
weights - - O
66 - - O
kDa - - O
and - - O
51 - - O
kDa - - O
) - - O
with - - O
identical - - O
amino-terminal - - O
amino - - O
acid - - O
sequences - - O
( - - O
residues - - O
1-428 - - O
) - - O
. - - O

Metformin - - O
plasma - - O
concentrations - - O
remained - - O
unchanged - - O
except - - O
for - - O
patients - - O
transferred - - O
from - - O
1 - - O
. - - O
5 - - O
to - - O
2 - - O
. - - O
0 - - O
g - - O
daily - - O
to - - O
850 - - O
mg - - O
twice - - O
daily - - O
; - - O
in - - O
these - - O
patients - - O
plasma - - O
concentrations - - O
increased - - O
from - - O
1 - - O
. - - O
83 - - O
+ - - O
- - - O
0 - - O
. - - O
87 - - O
to - - O
2 - - O
. - - O
50 - - O
+ - - O
- - - O
0 - - O
. - - O
89 - - O
micrograms - - O
l - - O
( - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

From - - O
the - - O
National - - O
Institutes - - O
of - - O
Health - - O
. - - O

The - - O
TYAC - - O
P1 - - O
resource - - O
, - - O
derivative - - O
STSs - - O
, - - O
and - - O
polymorphisms - - O
constitute - - O
an - - O
enabling - - O
resource - - O
to - - O
further - - O
studies - - O
of - - O
telomere - - O
structure - - O
and - - O
function - - O
and - - O
a - - O
means - - O
for - - O
physical - - O
and - - O
genetic - - O
map - - O
integration - - O
and - - O
closure - - O
. - - O

One - - O
complex - - O
most - - O
likely - - O
contained - - O
Sp1 - - O
, - - O
and - - O
another - - O
complex - - O
showed - - O
S-phase-specific - - O
binding - - O
, - - O
suggesting - - O
a - - O
direct - - O
role - - O
in - - O
the - - O
cell-cycle-dependent - - O
R1 - - O
gene - - O
expression - - O
. - - O

This - - O
points - - O
to - - O
a - - O
specific - - O
interference - - O
with - - O
HSV-induced - - O
DNA - - O
amplification - - O
. - - O

The - - O
cell - - O
cycle-regulated - - O
transcription - - O
factor - - O
E2F - - O
is - - O
also - - O
known - - O
to - - O
bend - - O
DNA - - O
upon - - O
binding - - O
. - - O

In - - O
11 - - O
patients - - O
with - - O
Horton's - - O
headache - - O
morphological - - O
investigations - - O
( - - O
differential - - O
white - - O
blood - - O
cell - - O
count - - O
) - - O
, - - O
cytoenzymatic - - O
determinations - - O
( - - O
alkaline - - O
and - - O
acid - - O
phosphatase - - O
, - - O
non-specific - - O
esterase - - O
) - - O
and - - O
cytoimmunological - - O
tests - - O
( - - O
IgM - - O
and - - O
IgG - - O
binding - - O
) - - O
were - - O
carried - - O
out - - O
on - - O
capillary - - O
blood - - O
neutrophils - - O
obtained - - O
from - - O
the - - O
area - - O
of - - O
pain - - O
, - - O
non-painful - - O
area - - O
of - - O
the - - O
skin - - O
on - - O
the - - O
head - - O
on - - O
the - - O
contralateral - - O
side - - O
, - - O
and - - O
from - - O
the - - O
finger - - O
. - - O

The - - O
oxygen - - O
uptake - - O
( - - O
VO2 - - O
) - - O
, - - O
carbon - - O
dioxide - - O
output - - O
( - - O
VCO2 - - O
) - - O
, - - O
respiratory - - O
rate - - O
( - - O
fR - - O
) - - O
, - - O
minute - - O
ventilation - - O
( - - O
VE - - O
) - - O
, - - O
alveolar - - O
ventilation - - O
( - - O
VA - - O
) - - O
, - - O
alveolar - - O
oxygen - - O
pressure - - O
( - - O
PAO2 - - O
) - - O
, - - O
and - - O
VE - - O
VO2 - - O
ratio - - O
were - - O
higher - - O
in - - O
the - - O
cows - - O
, - - O
while - - O
the - - O
tidal - - O
volume - - O
( - - O
VT - - O
) - - O
and - - O
physiological - - O
dead - - O
space - - O
( - - O
VD - - O
) - - O
were - - O
larger - - O
in - - O
the - - O
horses - - O
. - - O

Two - - O
cDNAs - - O
encoding - - O
casein - - O
kinase-1 - - O
have - - O
been - - O
isolated - - O
from - - O
a - - O
yeast - - O
cDNA - - O
library - - O
and - - O
termed - - O
CKI1 - - O
and - - O
CKI2 - - O
. - - O

The - - O
RAP74 - - O
subunit - - O
of - - O
TFIIF - - O
alone - - O
contained - - O
the - - O
stimulatory - - O
activity - - O
and - - O
the - - O
minimal - - O
region - - O
sufficient - - O
for - - O
stimulation - - O
corresponds - - O
to - - O
COOH-terminal - - O
residues - - O
358-517 - - O
. - - O

These - - O
observations - - O
of - - O
elevated - - O
serum - - O
lipase - - O
and - - O
serum - - O
CA - - O
19-9 - - O
in - - O
Sjogren's - - O
syndrome - - O
without - - O
evidence - - O
of - - O
malignancy - - O
may - - O
reflect - - O
pancreatic - - O
involvement - - O
in - - O
this - - O
disorder - - O
. - - O

These - - O
results - - O
confirming - - O
the - - O
high - - O
validity - - O
of - - O
NOM - - O
inhibiting - - O
test - - O
in - - O
the - - O
diagnosis - - O
of - - O
tumoural - - O
hyperprolactinemic - - O
states - - O
, - - O
reveal - - O
contradictory - - O
responses - - O
to - - O
CD - - O
LD - - O
, - - O
LD - - O
and - - O
DOM - - O
, - - O
with - - O
sustain - - O
the - - O
existence - - O
of - - O
2 - - O
sub-group - - O
of - - O
Prolactinomas - - O
: - - O
with - - O
or - - O
without - - O
a - - O
maintained - - O
DA - - O
central - - O
tonus - - O
supporting - - O
the - - O
possibility - - O
of - - O
different - - O
etiopathogenetical - - O
factors - - O
in - - O
inducing - - O
a - - O
tumoural - - O
hyperprolactinemic - - O
states - - O
. - - O

Efficacy - - O
of - - O
first-generation - - O
Cavermap - - O
to - - O
verify - - O
location - - O
and - - O
function - - O
of - - O
cavernous - - O
nerves - - O
during - - O
radical - - O
prostatectomy - - O
: - - O
a - - O
multi-institutional - - O
evaluation - - O
by - - O
experienced - - O
surgeons - - O
. - - O

In - - O
order - - O
to - - O
characterize - - O
the - - O
functional - - O
elements - - O
of - - O
the - - O
promoter - - O
that - - O
in - - O
some - - O
way - - O
must - - O
respond - - O
to - - O
these - - O
regulatory - - O
signals - - O
, - - O
a - - O
number - - O
of - - O
promoter - - O
mutations - - O
were - - O
constructed - - O
, - - O
including - - O
a - - O
set - - O
of - - O
linker-scanning - - O
mutations - - O
across - - O
the - - O
entire - - O
promoter - - O
region - - O
. - - O

Skn-1a - - O
lacking - - O
the - - O
C-terminal - - O
region - - O
completely - - O
lost - - O
transactivation - - O
ability - - O
, - - O
irrespective - - O
of - - O
the - - O
promoter - - O
tested - - O
, - - O
and - - O
was - - O
able - - O
to - - O
block - - O
transactivation - - O
by - - O
normal - - O
Skn-1a - - O
in - - O
competition - - O
assays - - O
. - - O

Structural - - O
basis - - O
for - - O
activation - - O
of - - O
human - - O
lymphocyte - - O
kinase - - O
Lck - - O
upon - - O
tyrosine - - O
phosphorylation - - O
. - - O

Among - - O
them - - O
, - - O
26 - - O
cases - - O
were - - O
benign - - O
and - - O
34 - - O
malignant - - O
. - - O

Such - - O
transgenic - - O
plants - - O
should - - O
enable - - O
not - - O
only - - O
the - - O
mutational - - O
analysis - - O
of - - O
sequence - - O
elements - - O
within - - O
the - - O
replication - - O
origin - - O
region - - O
, - - O
but - - O
also - - O
the - - O
construction - - O
of - - O
a - - O
new - - O
generation - - O
of - - O
vectors - - O
for - - O
gene - - O
amplification - - O
in - - O
plants - - O
, - - O
based - - O
on - - O
a - - O
minimal - - O
virus - - O
replicon - - O
. - - O

Site-directed - - O
mutagenesis - - O
revealed - - O
that - - O
two - - O
clusters - - O
of - - O
basic - - O
amino - - O
acids - - O
within - - O
a - - O
conserved - - O
basic - - O
region - - O
and - - O
two - - O
amphipathic - - O
helices - - O
within - - O
the - - O
adjacent - - O
HLH - - O
domain - - O
are - - O
essential - - O
for - - O
sequence-specific - - O
DNA - - O
binding - - O
and - - O
hetero-oligomerization - - O
, - - O
respectively - - O
. - - O

OBJECTIVE - - O
: - - O
To - - O
determine - - O
the - - O
impact - - O
of - - O
the - - O
introduction - - O
of - - O
clarithromycin - - O
and - - O
azithromycin - - O
on - - O
the - - O
treatment - - O
and - - O
survival - - O
of - - O
patients - - O
with - - O
AIDS - - O
and - - O
disseminated - - O
Mycobacterium - - O
avium - - O
complex - - O
( - - O
DMAC - - O
) - - O
. - - O

At - - O
this - - O
stage - - O
, - - O
the - - O
eventual - - O
high - - O
mortality - - O
of - - O
acute - - O
ischemia - - O
is - - O
established - - O
whatever - - O
the - - O
urgency - - O
of - - O
the - - O
operation - - O
or - - O
the - - O
skill - - O
with - - O
which - - O
it - - O
is - - O
performed - - O
. - - O

The - - O
relation - - O
between - - O
VE - - O
VO2 - - O
and - - O
Q - - O
VO2 - - O
showed - - O
a - - O
significant - - O
negative - - O
correlation - - O
( - - O
r - - O
= - - O
-0 - - O
. - - O
93 - - O
, - - O
p - - O
less - - O
than - - O
0 - - O
. - - O
01 - - O
) - - O
. - - O

Indoor - - O
concentrations - - O
were - - O
only - - O
weakly - - O
correlated - - O
with - - O
outdoor - - O
concentrations - - O
, - - O
however - - O
, - - O
and - - O
personal - - O
exposures - - O
were - - O
even - - O
more - - O
poorly - - O
correlated - - O
with - - O
outdoor - - O
concentrations - - O
. - - O

However - - O
, - - O
when - - O
a - - O
second - - O
, - - O
upstream - - O
IRE-like - - O
sequence - - O
was - - O
evaluated - - O
by - - O
EMSA - - O
, - - O
a - - O
DNA - - O
binding - - O
pattern - - O
distinct - - O
from - - O
that - - O
seen - - O
following - - O
exposure - - O
to - - O
IFN-gamma - - O
alone - - O
was - - O
observed - - O
after - - O
prolonged - - O
stimulation - - O
with - - O
both - - O
IFN-alpha - - O
and - - O
IFN-gamma - - O
. - - O

Growth - - O
factor - - O
allows - - O
effective - - O
dose-intensive - - O
regimen - - O
in - - O
advanced - - O
breast - - O
cancer - - O
patients - - O
. - - O

Clone - - O
4c - - O
( - - O
2681 - - O
bp - - O
) - - O
had - - O
a - - O
coding - - O
region - - O
identical - - O
to - - O
that - - O
of - - O
clone - - O
22c - - O
but - - O
it - - O
included - - O
a - - O
putative - - O
intron - - O
of - - O
959 - - O
bp - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
an - - O
internal - - O
short - - O
element - - O
located - - O
at - - O
the - - O
very - - O
5' - - O
terminal - - O
of - - O
L1 - - O
sequence - - O
and - - O
the - - O
nuclear - - O
factor - - O
binding - - O
to - - O
the - - O
element - - O
play - - O
a - - O
crucial - - O
role - - O
in - - O
the - - O
transcription - - O
of - - O
human - - O
L1 - - O
. - - O

E47 - - O
protein - - O
levels - - O
remain - - O
high - - O
until - - O
the - - O
double - - O
positive - - O
developmental - - O
stage - - O
, - - O
at - - O
which - - O
point - - O
they - - O
drop - - O
to - - O
relatively - - O
moderate - - O
levels - - O
, - - O
and - - O
are - - O
further - - O
downregulated - - O
upon - - O
transition - - O
to - - O
the - - O
single - - O
positive - - O
stage - - O
. - - O

Laboratory - - O
aspects - - O
with - - O
particular - - O
reference - - O
to - - O
chemotherapy - - O
and - - O
control - - O
. - - O

The - - O
transcriptional - - O
unit - - O
spans - - O
a - - O
chromosomal - - O
region - - O
of - - O
about - - O
55 - - O
kilobase - - O
pairs - - O
( - - O
kbp - - O
) - - O
. - - O

The - - O
plant - - O
protein - - O
maintains - - O
all - - O
the - - O
functional - - O
domains - - O
found - - O
in - - O
the - - O
other - - O
proteins - - O
, - - O
including - - O
nuclear - - O
localization - - O
signal - - O
, - - O
DNA-binding - - O
domain - - O
and - - O
helicase - - O
motifs - - O
, - - O
suggesting - - O
that - - O
it - - O
might - - O
also - - O
act - - O
as - - O
part - - O
of - - O
the - - O
RNA - - O
transcription - - O
apparatus - - O
, - - O
as - - O
well - - O
as - - O
nucleotide - - O
excision - - O
repair - - O
in - - O
plant - - O
cells - - O
. - - O

SELECTION - - O
CRITERIA - - O
: - - O
All - - O
controlled - - O
trials - - O
where - - O
adults - - O
with - - O
schizophrenia - - O
or - - O
similar - - O
illnesses - - O
were - - O
randomised - - O
to - - O
quetiapine - - O
, - - O
placebo - - O
or - - O
other - - O
neuroleptic - - O
drugs - - O
and - - O
where - - O
clinically - - O
relevant - - O
outcomes - - O
were - - O
reported - - O
. - - O

Transcriptional - - O
control - - O
signals - - O
of - - O
a - - O
herpes - - O
simplex - - O
virus - - O
type - - O
1 - - O
late - - O
( - - O
gamma - - O
2 - - O
) - - O
gene - - O
lie - - O
within - - O
bases - - O
-34 - - O
to - - O
+124 - - O
relative - - O
to - - O
the - - O
5' - - O
terminus - - O
of - - O
the - - O
mRNA - - O
. - - O

Although - - O
it - - O
has - - O
been - - O
shown - - O
that - - O
it - - O
is - - O
possible - - O
to - - O
use - - O
orally - - O
administered - - O
testosterone - - O
to - - O
maintain - - O
se-T - - O
levels - - O
in - - O
the - - O
normal - - O
male - - O
range - - O
, - - O
the - - O
convenience - - O
to - - O
the - - O
patient - - O
must - - O
be - - O
balanced - - O
against - - O
the - - O
cost - - O
and - - O
possible - - O
side - - O
effects - - O
of - - O
the - - O
large - - O
doses - - O
required - - O
. - - O

The - - O
congenital - - O
forms - - O
( - - O
7 - - O
cases - - O
) - - O
all - - O
occurred - - O
in - - O
female - - O
infants - - O
and - - O
involved - - O
the - - O
mucosa - - O
overlying - - O
either - - O
the - - O
anterior - - O
ridge - - O
of - - O
the - - O
maxilla - - O
or - - O
the - - O
mandible - - O
. - - O

The - - O
recovery - - O
value - - O
of - - O
systolic - - O
pressure - - O
was - - O
higher - - O
than - - O
diastolic - - O
pressure - - O
and - - O
pulse - - O
pressure - - O
increased - - O
. - - O

Human - - O
T-cell - - O
leukemia - - O
virus - - O
type - - O
I - - O
( - - O
HTLV-I - - O
) - - O
encodes - - O
a - - O
40-kDa - - O
nuclear - - O
protein - - O
, - - O
Tax - - O
, - - O
which - - O
stimulates - - O
transcription - - O
from - - O
three - - O
21-base - - O
pair - - O
( - - O
bp - - O
) - - O
repeats - - O
in - - O
its - - O
U3 - - O
region - - O
. - - O

The - - O
effect - - O
of - - O
ligustrazine - - O
hydrochloride - - O
( - - O
LTH - - O
) - - O
on - - O
depressing - - O
pulmonary - - O
artery - - O
hypertension - - O
has - - O
been - - O
proved - - O
in - - O
recent - - O
studies - - O
. - - O

Band-shift - - O
assays - - O
were - - O
performed - - O
using - - O
the - - O
LPS-and - - O
IL-1-responsive - - O
element - - O
( - - O
LILRE - - O
) - - O
oligonucleotide - - O
, - - O
a - - O
gamma - - O
interferon - - O
activation - - O
site-like - - O
site - - O
that - - O
is - - O
present - - O
in - - O
the - - O
human - - O
IL-1beta - - O
promoter - - O
. - - O

Here - - O
we - - O
suggest - - O
that - - O
uvrA - - O
and - - O
the - - O
nucleotide - - O
excision - - O
repair - - O
pathway - - O
are - - O
involved - - O
in - - O
the - - O
repair - - O
of - - O
acid-induced - - O
DNA - - O
damage - - O
and - - O
are - - O
associated - - O
with - - O
successful - - O
adaptation - - O
of - - O
S - - O
. - - O
mutans - - O
to - - O
low - - O
pH - - O
. - - O

A - - O
protein - - O
footprint - - O
also - - O
was - - O
identified - - O
for - - O
a - - O
GC - - O
box - - O
element - - O
at - - O
nucleotides - - O
-59 - - O
to - - O
-45 - - O
. - - O

Thus - - O
, - - O
we - - O
have - - O
identified - - O
a - - O
GRE - - O
sufficient - - O
to - - O
account - - O
for - - O
full - - O
glucocorticoid - - O
inducibility - - O
and - - O
an - - O
HNF-1 - - O
site - - O
close - - O
to - - O
the - - O
promoter - - O
that - - O
are - - O
major - - O
determinants - - O
of - - O
transcriptional - - O
control - - O
of - - O
the - - O
Xenopus - - O
fibrinogen - - O
B - - O
beta - - O
subunit - - O
gene - - O
in - - O
cells - - O
from - - O
normal - - O
liver - - O
tissue - - O
. - - O

Here - - O
we - - O
present - - O
genetic - - O
evidence - - O
suggesting - - O
that - - O
PP2A - - O
functions - - O
downstream - - O
of - - O
Ras1 - - O
in - - O
the - - O
Sevenless - - O
receptor - - O
tyrosine - - O
kinase - - O
( - - O
RTK - - O
) - - O
signal - - O
transduction - - O
pathway - - O
that - - O
specifies - - O
R7 - - O
photoreceptor - - O
cell - - O
fate - - O
in - - O
the - - O
developing - - O
Drosophila - - O
eye - - O
. - - O

CONCLUSION - - O
: - - O
In - - O
our - - O
animal - - O
model - - O
, - - O
blood-brain - - O
barrier - - O
disruption - - O
was - - O
a - - O
reproducible - - O
, - - O
integral - - O
finding - - O
of - - O
single-fraction - - O
, - - O
high-dose - - O
irradiation - - O
injury - - O
. - - O

Three - - O
radiologists - - O
without - - O
knowledge - - O
of - - O
patients' - - O
data - - O
and - - O
treatment - - O
analyzed - - O
30 - - O
angiograms - - O
with - - O
and - - O
30 - - O
examinations - - O
without - - O
PGF - - O
. - - O

Mean - - O
Hg - - O
concentrations - - O
in - - O
the - - O
livers - - O
of - - O
mice - - O
at - - O
some - - O
sites - - O
in - - O
Isle - - O
Royale - - O
are - - O
not - - O
significantly - - O
lower - - O
( - - O
P - - O
= - - O
0 - - O
. - - O
62 - - O
) - - O
than - - O
Hg - - O
concentrations - - O
considered - - O
by - - O
some - - O
government - - O
agencies - - O
to - - O
be - - O
unhealthy - - O
for - - O
human - - O
consumption - - O
. - - O

axl - - O
, - - O
a - - O
transforming - - O
gene - - O
isolated - - O
from - - O
primary - - O
human - - O
myeloid - - O
leukemia - - O
cells - - O
, - - O
encodes - - O
a - - O
novel - - O
receptor - - O
tyrosine - - O
kinase - - O
. - - O

In - - O
E - - O
. - - O
coli - - O
, - - O
CheW - - O
mediates - - O
the - - O
physical - - O
coupling - - O
of - - O
the - - O
receptors - - O
to - - O
the - - O
kinase - - O
CheA - - O
. - - O

We - - O
argue - - O
that - - O
this - - O
is - - O
the - - O
general - - O
property - - O
of - - O
QSAR - - O
models - - O
developed - - O
using - - O
LOO - - O
cross-validation - - O
. - - O

Expression - - O
in - - O
established - - O
LCLs - - O
, - - O
occurring - - O
irrespective - - O
of - - O
virus - - O
producer - - O
status - - O
, - - O
was - - O
not - - O
a - - O
consequence - - O
of - - O
continued - - O
in - - O
vitro - - O
passage - - O
; - - O
thus - - O
, - - O
appropriately - - O
spliced - - O
BamHI-A - - O
transcripts - - O
could - - O
be - - O
amplified - - O
from - - O
normal - - O
B - - O
cells - - O
within - - O
1 - - O
day - - O
of - - O
their - - O
experimental - - O
infection - - O
in - - O
vitro - - O
, - - O
along - - O
with - - O
BamHI-C - - O
W - - O
promoter-initiated - - O
but - - O
not - - O
BamHI-F - - O
promoter-initiated - - O
mRNAs - - O
. - - O

The - - O
equivalent - - O
of - - O
the - - O
third - - O
ligand - - O
, - - O
H-87 - - O
, - - O
is - - O
T-47 - - O
in - - O
the - - O
PSTAIRE - - O
sequence - - O
motif - - O
. - - O

In - - O
all - - O
eight - - O
cases - - O
, - - O
neither - - O
FL - - O
nor - - O
DLL - - O
cells - - O
showed - - O
alterations - - O
of - - O
bcl-2 - - O
gene - - O
sequences - - O
in - - O
the - - O
breakpoint - - O
region - - O
, - - O
suggesting - - O
high - - O
conservation - - O
of - - O
the - - O
bcl-2 - - O
gene - - O
during - - O
both - - O
t - - O
( - - O
14 - - O
; - - O
18 - - O
) - - O
translocation - - O
and - - O
morphologic - - O
transformation - - O
of - - O
the - - O
FL - - O
cells - - O
. - - O

The - - O
transcriptional - - O
activity - - O
of - - O
PPARgamma - - O
is - - O
positively - - O
modulated - - O
by - - O
ligand - - O
binding - - O
and - - O
negatively - - O
regulated - - O
by - - O
phosphorylation - - O
mediated - - O
by - - O
the - - O
MEK - - O
ERK - - O
signaling - - O
pathway - - O
. - - O

Furthermore - - O
, - - O
the - - O
insertion - - O
of - - O
the - - O
ColE1 - - O
cer - - O
site - - O
into - - O
the - - O
RK2 - - O
plasmid - - O
deleted - - O
for - - O
the - - O
par - - O
region - - O
failed - - O
to - - O
stabilize - - O
the - - O
plasmid - - O
in - - O
the - - O
MC1061K - - O
strain - - O
, - - O
indicating - - O
that - - O
the - - O
multimer - - O
resolution - - O
activity - - O
encoded - - O
by - - O
parCBA - - O
is - - O
not - - O
by - - O
itself - - O
responsible - - O
for - - O
the - - O
stabilization - - O
activity - - O
observed - - O
for - - O
this - - O
operon - - O
. - - O

19F - - O
NMR - - O
studies - - O
in - - O
ABF4-type - - O
layered - - O
antiferromagnets - - O
. - - O

No - - O
local - - O
destruction - - O
by - - O
tumor - - O
or - - O
infection - - O
could - - O
be - - O
demonstrated - - O
apart - - O
from - - O
HIV - - O
infection - - O
. - - O

We - - O
have - - O
identified - - O
three - - O
binding - - O
sites - - O
for - - O
protein - - O
complexes - - O
: - - O
a - - O
palindrome - - O
, - - O
a - - O
direct - - O
repeat - - O
, - - O
and - - O
a - - O
C+T - - O
sequence - - O
that - - O
corresponds - - O
to - - O
seven - - O
GAGA - - O
motifs - - O
on - - O
the - - O
transcribed - - O
strand - - O
. - - O

These - - O
results - - O
indicate - - O
that - - O
the - - O
sulfhydryl - - O
group - - O
of - - O
certain - - O
angiotensin - - O
converting - - O
enzyme - - O
inhibitors - - O
can - - O
potentiate - - O
their - - O
effect - - O
on - - O
the - - O
endogenous - - O
nitrovasodilator - - O
EDRF - - O
. - - O

Selenium - - O
, - - O
as - - O
a - - O
constituent - - O
of - - O
glutathione - - O
peroxidase - - O
, - - O
plays - - O
a - - O
role - - O
in - - O
the - - O
antioxidant - - O
defense - - O
systems - - O
of - - O
the - - O
body - - O
, - - O
but - - O
other - - O
metabolic - - O
roles - - O
for - - O
selenium - - O
may - - O
yet - - O
be - - O
discovered - - O
. - - O

Since - - O
the - - O
UfAP - - O
and - - O
UTMP - - O
share - - O
many - - O
biosynthetic - - O
and - - O
structural - - O
features - - O
that - - O
include - - O
site - - O
of - - O
biosynthesis - - O
in - - O
the - - O
endometrium - - O
, - - O
P4-responsiveness - - O
, - - O
the - - O
presence - - O
of - - O
the - - O
mannose - - O
6-phosphate - - O
lysosomal - - O
recognition - - O
marker - - O
, - - O
and - - O
considerable - - O
sequence - - O
similarity - - O
, - - O
the - - O
UfAP - - O
and - - O
the - - O
UTMP - - O
may - - O
have - - O
homologous - - O
function - - O
which - - O
for - - O
both - - O
still - - O
remains - - O
obscure - - O
. - - O

HVH2 - - O
mRNA - - O
showed - - O
an - - O
expression - - O
pattern - - O
distinct - - O
from - - O
CL100 - - O
( - - O
human - - O
homologue - - O
of - - O
mouse - - O
MKP1 - - O
) - - O
and - - O
PAC1 - - O
, - - O
two - - O
previously - - O
identified - - O
MAP - - O
kinase - - O
phosphatases - - O
. - - O

In - - O
ciliates - - O
, - - O
both - - O
mechanisms - - O
are - - O
readily - - O
observed - - O
. - - O

We - - O
have - - O
studied - - O
the - - O
biokinetics - - O
of - - O
BLM - - O
labeled - - O
with - - O
indium-111 - - O
( - - O
In-111 - - O
) - - O
. - - O

Exon - - O
A - - O
is - - O
located - - O
approximately - - O
7 - - O
kb - - O
5' - - O
to - - O
the - - O
HSL - - O
translation - - O
start - - O
site - - O
. - - O

In - - O
contrast - - O
, - - O
transiently - - O
transfected - - O
cells - - O
expressing - - O
EBNA-3 - - O
revealed - - O
a - - O
sixfold - - O
increase - - O
in - - O
EBNA-3 - - O
protein - - O
expression - - O
from - - O
the - - O
genomic - - O
EBNA-3 - - O
gene - - O
compared - - O
to - - O
EBNA-3 - - O
cDNA - - O
. - - O

SETTING - - O
: - - O
A - - O
division - - O
of - - O
a - - O
large - - O
tea - - O
plantation - - O
in - - O
Kandy - - O
. - - O

Imaging - - O
features - - O
of - - O
splenic - - O
epidermoid - - O
cyst - - O
with - - O
pathologic - - O
correlation - - O
. - - O

One - - O
of - - O
these - - O
genes - - O
, - - O
REC114 - - O
, - - O
is - - O
described - - O
here - - O
, - - O
and - - O
the - - O
data - - O
confirm - - O
that - - O
REC114 - - O
is - - O
a - - O
meiosis-specific - - O
recombination - - O
gene - - O
with - - O
no - - O
detectable - - O
function - - O
in - - O
mitosis - - O
. - - O

2 - - O
) - - O
The - - O
time-sharing - - O
principle - - O
was - - O
applied - - O
to - - O
gain - - O
high - - O
stability - - O
. - - O

The - - O
corresponding - - O
genotype - - O
was - - O
determined - - O
with - - O
a - - O
restriction - - O
enzyme-based - - O
assay - - O
. - - O

In - - O
patients - - O
with - - O
limited - - O
disease - - O
, - - O
the - - O
survival - - O
in - - O
the - - O
alternating - - O
arm - - O
was - - O
significantly - - O
superior - - O
to - - O
the - - O
survival - - O
in - - O
the - - O
CAV - - O
arm - - O
( - - O
P - - O
= - - O
. - - O
014 - - O
) - - O
or - - O
the - - O
survival - - O
in - - O
the - - O
PE - - O
arm - - O
( - - O
P - - O
= - - O
. - - O
023 - - O
) - - O
. - - O

Analysis - - O
of - - O
disassociation - - O
rates - - O
indicates - - O
that - - O
the - - O
Grf10-Swi5-DNA - - O
complex - - O
has - - O
a - - O
longer - - O
half-life - - O
than - - O
protein-DNA - - O
complexes - - O
that - - O
contain - - O
only - - O
Swi5 - - O
or - - O
Grf10 - - O
. - - O

Constructs - - O
were - - O
made - - O
in - - O
which - - O
an - - O
AATAAA - - O
and - - O
the - - O
GT-rich - - O
region - - O
were - - O
separated - - O
by - - O
various - - O
distances - - O
ranging - - O
from - - O
7 - - O
to - - O
43 - - O
bp - - O
. - - O

The - - O
prevalence - - O
of - - O
hepatitis - - O
B - - O
surface - - O
antigen - - O
( - - O
HBsAg - - O
) - - O
and - - O
anti-HBs - - O
was - - O
determined - - O
by - - O
a - - O
sensitive - - O
double-antibody - - O
radio-immunoassay - - O
technique - - O
in - - O
a - - O
series - - O
of - - O
patients - - O
with - - O
chronic - - O
liver - - O
diseases - - O
. - - O

GCD10 - - O
binds - - O
RNA - - O
in - - O
vitro - - O
and - - O
we - - O
present - - O
strong - - O
biochemical - - O
evidence - - O
that - - O
it - - O
is - - O
identical - - O
to - - O
the - - O
RNA-binding - - O
subunit - - O
of - - O
yeast - - O
initiation - - O
factor-3 - - O
( - - O
eIF-3 - - O
) - - O
. - - O
eIF-3 - - O
is - - O
a - - O
multisubunit - - O
complex - - O
that - - O
stimulates - - O
translation - - O
initiation - - O
in - - O
vitro - - O
at - - O
several - - O
different - - O
steps - - O
. - - O

Based - - O
on - - O
these - - O
results - - O
the - - O
minimal - - O
control - - O
element - - O
( - - O
AX - - O
470 - - O
) - - O
specifying - - O
the - - O
anterior - - O
boundary - - O
of - - O
Hox - - O
expression - - O
was - - O
designated - - O
as - - O
Hoxa-7 - - O
enhancer - - O
. - - O

There - - O
have - - O
been - - O
five - - O
problems - - O
( - - O
extravasation - - O
2 - - O
, - - O
suspected - - O
sepsis - - O
1 - - O
, - - O
and - - O
hematoma - - O
2 - - O
) - - O
during - - O
a - - O
total - - O
of - - O
2 - - O
, - - O
927 - - O
days - - O
of - - O
exposure - - O
. - - O

Plasma - - O
lipid - - O
and - - O
lipoprotein - - O
profiles - - O
were - - O
compared - - O
in - - O
elderly - - O
female - - O
runners - - O
( - - O
RU - - O
: - - O
n - - O
= - - O
15 - - O
, - - O
aged - - O
66 - - O
+ - - O
- - - O
5 - - O
years - - O
, - - O
body - - O
fat - - O
20 - - O
+ - - O
- - - O
4% - - O
, - - O
training - - O
distance - - O
35 - - O
+ - - O
- - - O
15 - - O
km - - O
week-1 - - O
, - - O
VO2max - - O
36 - - O
+ - - O
- - - O
4 - - O
ml - - O
kg-1 - - O
min-1 - - O
, - - O
mean - - O
+ - - O
- - - O
SD - - O
) - - O
and - - O
age-matched - - O
untrained - - O
women - - O
( - - O
UT - - O
: - - O
n - - O
= - - O
28 - - O
, - - O
66 - - O
+ - - O
- - - O
4 - - O
years - - O
, - - O
body - - O
fat - - O
26 - - O
+ - - O
- - - O
6% - - O
, - - O
VO2max - - O
26 - - O
+ - - O
- - - O
3 - - O
ml - - O
kg-1 - - O
min-1 - - O
) - - O
. - - O

Dementia - - O
is - - O
being - - O
avoided - - O
in - - O
NHS - - O
and - - O
social - - O
care - - O
. - - O

The - - O
cDNA - - O
has - - O
an - - O
open - - O
reading - - O
frame - - O
of - - O
900 - - O
amino - - O
acids - - O
capable - - O
of - - O
encoding - - O
a - - O
97-kDa - - O
protein - - O
. - - O

Two - - O
independent - - O
transgenic - - O
lines - - O
were - - O
produced - - O
, - - O
and - - O
both - - O
showed - - O
expression - - O
of - - O
the - - O
Gus - - O
gene - - O
specifically - - O
in - - O
the - - O
endosperm - - O
during - - O
mid-development - - O
( - - O
first - - O
detected - - O
10-12 - - O
d - - O
after - - O
anthesis - - O
) - - O
. - - O

The - - O
second - - O
complex - - O
, - - O
when - - O
purified - - O
, - - O
contained - - O
four - - O
protein - - O
components - - O
including - - O
the - - O
36-kDa - - O
protein - - O
. - - O

Histopathologic - - O
observations - - O
showed - - O
that - - O
both - - O
somatostatin - - O
and - - O
triamcinolone - - O
acetonide - - O
reduced - - O
the - - O
inflammatory - - O
signs - - O
in - - O
the - - O
joint - - O
structures - - O
, - - O
although - - O
triamcinolone - - O
acetonide - - O
appeared - - O
to - - O
be - - O
more - - O
effective - - O
. - - O

Induction - - O
in - - O
AP-1 - - O
DNA - - O
binding - - O
correlates - - O
with - - O
a - - O
concomitant - - O
GH - - O
trans-activation - - O
of - - O
c-jun - - O
and - - O
c-fos - - O
genes - - O
described - - O
previously - - O
. - - O

HDL-cholesterol - - O
( - - O
+6% - - O
, - - O
P - - O
less - - O
than - - O
. - - O
01 - - O
) - - O
and - - O
apolipoprotein - - O
A-I - - O
( - - O
+6% - - O
, - - O
P - - O
less - - O
than - - O
. - - O
01 - - O
) - - O
concentrations - - O
increased - - O
significantly - - O
only - - O
in - - O
the - - O
young - - O
. - - O

We - - O
have - - O
generated - - O
a - - O
computer - - O
model - - O
of - - O
the - - O
C-terminal - - O
domain - - O
of - - O
the - - O
434 - - O
repressor - - O
based - - O
on - - O
the - - O
crystal - - O
structure - - O
of - - O
the - - O
homologous - - O
UmuD' - - O
protein - - O
. - - O

Activation - - O
of - - O
a - - O
CRE-dependent - - O
junB - - O
promoter - - O
chloramphenicol - - O
acetyltransferase - - O
( - - O
CAT - - O
) - - O
reporter - - O
gene - - O
by - - O
the - - O
BCR - - O
was - - O
also - - O
blocked - - O
by - - O
SB203580 - - O
. - - O

Oxygen - - O
delivery - - O
and - - O
consumption - - O
and - - O
P50 - - O
in - - O
patients - - O
with - - O
acute - - O
myocardial - - O
infarction - - O
. - - O

The - - O
tyrosine - - O
hydroxylase - - O
gene - - O
( - - O
TH - - O
) - - O
contains - - O
a - - O
single - - O
copy - - O
of - - O
a - - O
consensus - - O
CRE - - O
at - - O
-45 - - O
to - - O
-38 - - O
base - - O
pair - - O
( - - O
bp - - O
) - - O
upstream - - O
of - - O
the - - O
transcription - - O
initiation - - O
site - - O
. - - O

Adrenergic - - O
system - - O
activation - - O
, - - O
indicated - - O
by - - O
metanephrine - - O
epinephrine - - O
ratio - - O
, - - O
increased - - O
with - - O
time - - O
in - - O
losing - - O
males - - O
, - - O
except - - O
that - - O
after - - O
one - - O
month - - O
of - - O
cohabitation - - O
, - - O
turnover - - O
returned - - O
to - - O
levels - - O
that - - O
equaled - - O
those - - O
of - - O
control - - O
animals - - O
. - - O

In - - O
C - - O
. - - O
albicans - - O
, - - O
HST6 - - O
is - - O
expressed - - O
constitutively - - O
at - - O
high - - O
levels - - O
in - - O
the - - O
different - - O
cell - - O
types - - O
analysed - - O
( - - O
yeast - - O
, - - O
hyphae - - O
, - - O
white - - O
and - - O
opaque - - O
) - - O
, - - O
demonstrating - - O
that - - O
HST6 - - O
transcription - - O
is - - O
not - - O
repressed - - O
in - - O
this - - O
diploid - - O
yeast - - O
, - - O
unlike - - O
in - - O
diploid - - O
S - - O
. - - O
cerevisiae - - O
, - - O
and - - O
suggesting - - O
a - - O
basic - - O
biological - - O
function - - O
for - - O
the - - O
Hst6p - - O
transporter - - O
in - - O
C - - O
. - - O
albicans - - O
. - - O

Ketamine - - O
in - - O
the - - O
treatment - - O
of - - O
bronchospasm - - O
during - - O
mechanical - - O
ventilation - - O
. - - O

It - - O
is - - O
concluded - - O
that - - O
the - - O
plasma - - O
prolactin - - O
response - - O
to - - O
12 - - O
. - - O
5 - - O
micrograms - - O
i - - O
. - - O
v - - O
. - - O

But - - O
no - - O
influence - - O
was - - O
observed - - O
at - - O
lower - - O
concentrations - - O
than - - O
1 - - O
4 - - O
MIC - - O
of - - O
AMK - - O
. - - O

Three - - O
patients - - O
with - - O
four - - O
renoureteral - - O
units - - O
have - - O
undergone - - O
single-stage - - O
reconstruction - - O
involving - - O
ureteroureterostomy - - O
and - - O
ipsilateral - - O
ureteroneocystostomy - - O
following - - O
temporary - - O
loop - - O
cutaneous - - O
ureterostomy - - O
. - - O

Oxygen - - O
tension - - O
of - - O
the - - O
small - - O
lymph - - O
vessels - - O
( - - O
PLO2 - - O
) - - O
of - - O
the - - O
rabbit - - O
hind - - O
limb - - O
was - - O
measured - - O
with - - O
both - - O
a - - O
flow-through - - O
micro - - O
chamber - - O
and - - O
a - - O
polarographic - - O
catheter-tip - - O
oxygen - - O
electrode - - O
to - - O
obtain - - O
experimental - - O
data - - O
on - - O
the - - O
source - - O
of - - O
oxygen - - O
in - - O
the - - O
lymph - - O
. - - O

The - - O
smaller - - O
uptake - - O
rate - - O
and - - O
faster - - O
clearance - - O
rate - - O
resulted - - O
in - - O
the - - O
lower - - O
BCF - - O
for - - O
SWA - - O
killifish - - O
. - - O

The - - O
second - - O
functional - - O
pair - - O
of - - O
CreA - - O
sites - - O
is - - O
located - - O
between - - O
the - - O
two - - O
transcription - - O
initiation - - O
sites - - O
. - - O

Six - - O
out - - O
of - - O
ten - - O
hearts - - O
from - - O
macerated - - O
stillborn - - O
infants - - O
showed - - O
varying - - O
degrees - - O
of - - O
positive - - O
staining - - O
. - - O

The - - O
proliferation-specific - - O
HNF-3 - - O
fork - - O
head - - O
homolog-11B - - O
protein - - O
( - - O
HFH-11B - - O
; - - O
also - - O
known - - O
as - - O
Trident - - O
and - - O
Win - - O
) - - O
is - - O
a - - O
family - - O
member - - O
of - - O
the - - O
winged - - O
helix - - O
fork - - O
head - - O
transcription - - O
factors - - O
and - - O
in - - O
regenerating - - O
liver - - O
its - - O
expression - - O
is - - O
reactivated - - O
prior - - O
to - - O
hepatocyte - - O
entry - - O
into - - O
DNA - - O
replication - - O
( - - O
S - - O
phase - - O
) - - O
. - - O

In - - O
vitro - - O
transcription - - O
results - - O
indicate - - O
that - - O
this - - O
5' - - O
structure - - O
functions - - O
in - - O
the - - O
attenuation - - O
mechanism - - O
, - - O
since - - O
deletion - - O
of - - O
the - - O
stem-loop - - O
caused - - O
an - - O
increase - - O
in - - O
transcription - - O
readthrough - - O
. - - O

Northern - - O
blotting - - O
showed - - O
that - - O
MDMX - - O
, - - O
like - - O
MDM2 - - O
, - - O
is - - O
expressed - - O
in - - O
all - - O
tissues - - O
tested - - O
, - - O
and - - O
that - - O
several - - O
mRNAs - - O
for - - O
MDMX - - O
can - - O
be - - O
detected - - O
. - - O

The - - O
mean - - O
serum - - O
creatinine - - O
level - - O
did - - O
not - - O
change - - O
during - - O
the - - O
first - - O
6 - - O
months - - O
after - - O
withdrawal - - O
of - - O
MMF - - O
. - - O

Control - - O
subjects' - - O
evoked - - O
potentials - - O
( - - O
EPs - - O
) - - O
were - - O
characterized - - O
by - - O
an - - O
initial - - O
positivity - - O
in - - O
the - - O
90-140 - - O
ms - - O
range - - O
( - - O
P1 - - O
) - - O
at - - O
the - - O
temporo-occipital - - O
site - - O
. - - O

The - - O
diagnostic - - O
value - - O
of - - O
blood - - O
serum - - O
and - - O
urinary - - O
amylase - - O
, - - O
lipase - - O
, - - O
and - - O
trypsin - - O
in - - O
exacerbations - - O
of - - O
chronic - - O
relapsing - - O
pancreatitis - - O
is - - O
discussed - - O
. - - O

Gel - - O
filtration - - O
, - - O
sedimentation - - O
velocity - - O
, - - O
and - - O
immunoprecipitation - - O
experiments - - O
revealed - - O
that - - O
beta4 - - O
is - - O
a - - O
component - - O
of - - O
a - - O
multisubunit - - O
complex - - O
( - - O
AP-4 - - O
) - - O
that - - O
also - - O
contains - - O
the - - O
sigma4 - - O
polypeptide - - O
and - - O
two - - O
additional - - O
adaptor - - O
subunit - - O
homologs - - O
named - - O
mu4 - - O
( - - O
mu-ARP2 - - O
) - - O
and - - O
epsilon - - O
. - - O

Hexsyn - - O
is - - O
the - - O
Goodyear - - O
Tire - - O
and - - O
Rubber - - O
Company - - O
tradename - - O
for - - O
a - - O
polyolefin - - O
rubber - - O
synthesized - - O
from - - O
1-hexene - - O
with - - O
3-5% - - O
methylhexadiene - - O
as - - O
the - - O
source - - O
of - - O
residual - - O
double - - O
bonds - - O
for - - O
vulcanization - - O
. - - O

The - - O
recessive - - O
hos1 - - O
mutation - - O
causes - - O
enhanced - - O
induction - - O
of - - O
the - - O
CBF - - O
transcription - - O
factors - - O
by - - O
low - - O
temperature - - O
as - - O
well - - O
as - - O
of - - O
their - - O
downstream - - O
cold-responsive - - O
genes - - O
. - - O

This - - O
mutant - - O
was - - O
identified - - O
by - - O
screening - - O
with - - O
a - - O
TGF-beta-inducible - - O
vector - - O
a - - O
series - - O
of - - O
mink - - O
lung - - O
epithelial - - O
cell - - O
clones - - O
that - - O
have - - O
normal - - O
TGF-beta - - O
binding - - O
activity - - O
but - - O
have - - O
lost - - O
antiproliferative - - O
and - - O
transcriptional - - O
responses - - O
to - - O
TGF-beta - - O
. - - O

Regulation - - O
of - - O
ASN1 - - O
and - - O
ASN2 - - O
expression - - O
was - - O
studied - - O
using - - O
lacZ - - O
fusions - - O
and - - O
both - - O
genes - - O
were - - O
found - - O
to - - O
be - - O
several - - O
times - - O
less - - O
expressed - - O
in - - O
the - - O
absence - - O
of - - O
the - - O
transcription - - O
activator - - O
Gcn4p - - O
. - - O

GlcNAc- - - O
and - - O
GlcNAc2-PP-Dolichol - - O
biosynthesis - - O
could - - O
be - - O
shown - - O
with - - O
isolated - - O
S - - O
. - - O
cerevisiae - - O
membranes - - O
from - - O
cells - - O
harboring - - O
the - - O
recombinant - - O
plasmid - - O
and - - O
grown - - O
on - - O
glucose - - O
thus - - O
suppressing - - O
transcription - - O
of - - O
the - - O
endogenous - - O
gene - - O
. - - O

The - - O
predicted - - O
domain - - O
structures - - O
of - - O
FkbB - - O
and - - O
FkbC - - O
are - - O
analogous - - O
to - - O
that - - O
of - - O
FkbA - - O
and - - O
comprise - - O
30 - - O
fatty-acid-synthase - - O
( - - O
FAS - - O
) - - O
-like - - O
domains - - O
arranged - - O
in - - O
6 - - O
modules - - O
. - - O

The - - O
observation - - O
that - - O
beta - - O
2m - - O
with - - O
covalently - - O
attached - - O
peptide - - O
can - - O
effectively - - O
create - - O
CTL - - O
target - - O
structures - - O
in - - O
vitro - - O
offers - - O
new - - O
possibilities - - O
for - - O
the - - O
in - - O
vivo - - O
induction - - O
of - - O
epitope-specific - - O
CTL - - O
responses - - O
by - - O
either - - O
DNA - - O
immunization - - O
or - - O
injection - - O
of - - O
the - - O
purified - - O
epitope-linked - - O
beta - - O
2m - - O
. - - O

The - - O
mechanistic - - O
implications - - O
of - - O
aromatic - - O
non-responsiveness - - O
of - - O
autonomously - - O
expressed - - O
A-domain - - O
, - - O
despite - - O
its - - O
demonstrated - - O
ability - - O
to - - O
bind - - O
phenol - - O
, - - O
are - - O
discussed - - O
. - - O

No - - O
systematic - - O
L-R - - O
differences - - O
were - - O
observed - - O
. - - O

Computerized - - O
detection - - O
of - - O
abnormal - - O
asymmetry - - O
in - - O
digital - - O
chest - - O
radiographs - - O
. - - O

When - - O
pollen - - O
allergen - - O
from - - O
three - - O
grass - - O
species - - O
were - - O
used - - O
, - - O
The - - O
RAST-test - - O
results - - O
did - - O
not - - O
differ - - O
from - - O
duplicate - - O
values - - O
either - - O
. - - O

In - - O
1990 - - O
, - - O
an - - O
International - - O
Commission - - O
for - - O
the - - O
Certification - - O
of - - O
Eradication - - O
of - - O
Poliomyelitis - - O
Eradication - - O
( - - O
ICCPE - - O
) - - O
was - - O
established - - O
by - - O
the - - O
Pan - - O
American - - O
Health - - O
Organization - - O
to - - O
eventually - - O
determine - - O
if - - O
transmission - - O
was - - O
interrupted - - O
. - - O

New - - O
diagnostic - - O
strategies - - O
for - - O
lupus - - O
anticoagulants - - O
and - - O
antiphospholipid - - O
antibodies - - O
. - - O

A - - O
genetic - - O
and - - O
molecular - - O
analysis - - O
of - - O
non-inducible - - O
qutA - - O
mutants - - O
showed - - O
that - - O
all - - O
23 - - O
mutations - - O
analysed - - O
map - - O
within - - O
the - - O
N-terminal - - O
half - - O
of - - O
the - - O
encoded - - O
QUTA - - O
protein - - O
. - - O

To - - O
the - - O
best - - O
of - - O
our - - O
knowledge - - O
, - - O
SNTCS - - O
is - - O
highly - - O
malignant - - O
. - - O

Motile - - O
nocardoid - - O
Actinomycetales - - O
. - - O

Our - - O
data - - O
complement - - O
other - - O
studies - - O
of - - O
circumpolar - - O
populations - - O
and - - O
reinforce - - O
the - - O
reported - - O
high - - O
prevalences - - O
of - - O
SPA - - O
and - - O
HLA-B27 - - O
among - - O
those - - O
populations - - O
. - - O

Here - - O
, - - O
we - - O
report - - O
that - - O
a - - O
transfected - - O
Chinese - - O
hamster - - O
ovary - - O
( - - O
CHO - - O
) - - O
cell - - O
line - - O
expressing - - O
a - - O
murine - - O
CD4 - - O
fragment - - O
containing - - O
the - - O
first - - O
two - - O
N-terminal - - O
domains - - O
secretes - - O
both - - O
monomeric - - O
molecules - - O
and - - O
disulfide-linked - - O
multimers - - O
. - - O

